{"meta":{"query_hash":"9648b529e30c","filters":{"venue":"European Journal of Cancer"},"cohort_total":655,"direct_labels_cover":1,"predictions_cover":655,"exported":655,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/9648b529e30c","api":"https://metacan.xera.ac/api/v1/cohort?venue=European+Journal+of+Cancer"},"results":[{"id":"W122940189","doi":"10.1016/s0959-8049(01)00156-3","title":"Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Immunotherapy; Lectin; Medicine; Biology; Cancer research; Immunology; Immune system","score_opus":0.016157919466205345,"score_gpt":0.23872688065353034,"score_spread":0.222568961187325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W122940189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957804,0.028621348,0.0071029123,0.0009140578,0.0015076721,0.00017240334,0.000009938947,0.000025349074,0.0038422702],"genre_scores_gemma":[0.989252,0.002253479,0.00036715102,0.00027307618,0.00007356666,0.0000019245488,0.0000035840078,0.00004025167,0.00773499],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863905,0.00041910922,0.0005213146,0.0001339459,0.000068443645,0.00021812448],"domain_scores_gemma":[0.9987976,0.000053076812,0.0006352414,0.00023433035,0.00025652346,0.000023206687],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052296557,0.0001771549,0.0003372458,0.00015374165,0.00008428429,0.000020986623,0.0004364579,0.000049135277,0.001252906],"category_scores_gemma":[0.000021662532,0.00011100137,0.00012399076,0.0001701139,0.00011107321,0.0001762999,0.00004022652,0.00036322218,0.000025770125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043805274,0.00027121842,0.0028267156,0.000019612065,0.0007573262,0.00021369614,0.002008053,0.000014931171,0.8318533,0.00030754856,0.0038867844,0.15346034],"study_design_scores_gemma":[0.013154933,0.008166287,0.11181959,0.00069213216,0.00011324715,0.0030196256,0.0011552066,0.0000052527903,0.45022583,0.0001604095,0.41099387,0.0004936014],"about_ca_topic_score_codex":0.000023778051,"about_ca_topic_score_gemma":0.000016695933,"teacher_disagreement_score":0.40710708,"about_ca_system_score_codex":0.000062585335,"about_ca_system_score_gemma":0.00013179316,"threshold_uncertainty_score":0.9996601},"labels":[],"label_agreement":null},{"id":"W1239915614","doi":"10.1016/j.ejca.2015.08.004","title":"Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Juravinski Hospital; Queen's University","funders":"","keywords":"Clinical endpoint; Medicine; Clinical trial; Internal medicine; Sample size determination; Outcome (game theory); Phases of clinical research; Phase (matter); Clinical study design; Oncology; Statistics","score_opus":0.6506362328123789,"score_gpt":0.5936434193847209,"score_spread":0.05699281342765805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1239915614","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4800731,0.0001833138,0.48871705,0.00059624115,0.011952172,0.0010369971,0.00013937498,0.000033042776,0.017268725],"genre_scores_gemma":[0.707226,0.000039096023,0.28926334,0.00010878091,0.0030230933,0.0000058515157,0.0000019479212,0.000076638804,0.00025528524],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947437,0.0023107375,0.0021023636,0.0001341606,0.000535071,0.00017396006],"domain_scores_gemma":[0.983208,0.01270119,0.0028428056,0.0002070213,0.00076957815,0.00027142774],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007554365,0.00016043491,0.0010404298,0.000087899054,0.000025025705,0.000020484626,0.00023030792,0.000051910207,0.00031275398],"category_scores_gemma":[0.06541654,0.00011158369,0.0001743562,0.00012799278,0.00017380177,0.00008262678,0.000031238716,0.0003637791,0.000009554413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81265986,0.0035778026,0.000035570163,0.000039427425,0.00033463322,0.00030436428,0.00046874286,0.000022632463,0.00060931087,0.0007568404,0.002141326,0.17904946],"study_design_scores_gemma":[0.94387627,0.036324624,0.000028358918,0.00016623843,0.0009824423,0.000023640998,0.000105026746,0.00016043396,0.00066213805,0.005025919,0.012456845,0.00018806399],"about_ca_topic_score_codex":0.0000010180139,"about_ca_topic_score_gemma":9.857716e-7,"teacher_disagreement_score":0.22715288,"about_ca_system_score_codex":0.00016518382,"about_ca_system_score_gemma":0.00028933372,"threshold_uncertainty_score":0.9424558},"labels":[],"label_agreement":null},{"id":"W1241485355","doi":"10.1016/j.ejca.2015.08.017","title":"Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Unicancer; Fondation de France; Dana-Farber/Harvard Cancer Center","keywords":"Renal cell carcinoma; Blockade; PD-L1; Medicine; Oncology; Cancer research; Internal medicine; Immunotherapy; Receptor; Cancer","score_opus":0.03496179729988725,"score_gpt":0.27880808328509454,"score_spread":0.2438462859852073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1241485355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633051,0.03192097,0.00003613791,0.0005843304,0.0002178097,0.00019938288,0.000008047325,0.0000065534314,0.0037216563],"genre_scores_gemma":[0.9967526,0.00016532298,0.0015939509,0.00016716919,0.00032961223,0.000003871515,0.000002390439,0.000055197317,0.0009298449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976955,0.0004644905,0.00079692266,0.00017134495,0.00060975226,0.0002619822],"domain_scores_gemma":[0.99849796,0.000063409585,0.0004974381,0.00025975434,0.00037218985,0.00030925896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007892896,0.0002200077,0.00055955845,0.00028859315,0.00001380809,0.0000139427075,0.00016803994,0.00001992182,0.00028198148],"category_scores_gemma":[0.00007230017,0.00015249552,0.00022632476,0.00024165542,0.00009047356,0.00009186753,0.000039938706,0.00032317982,0.000025331847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048078403,0.0037044082,0.5329585,0.000747815,0.0021070603,0.043690924,0.03880989,0.0031069824,0.2668995,0.000014519463,0.014299774,0.045582194],"study_design_scores_gemma":[0.014145291,0.0025386263,0.8815739,0.00036632214,0.0005421798,0.00028233236,0.00046997872,0.000024889481,0.09072217,0.000015966063,0.0091233635,0.0001949636],"about_ca_topic_score_codex":0.000052019215,"about_ca_topic_score_gemma":0.000012571634,"teacher_disagreement_score":0.34861538,"about_ca_system_score_codex":0.00022678546,"about_ca_system_score_gemma":0.0003595847,"threshold_uncertainty_score":0.62185866},"labels":[],"label_agreement":null},{"id":"W1478180867","doi":"10.1016/j.ejca.2015.06.072","title":"P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Monoclonal antibody; Melanoma; Antibody; Monoclonal; Oncology; Internal medicine; Cancer research; Immunotherapy; Immunology; Cancer","score_opus":0.031577964653606364,"score_gpt":0.33412338809626674,"score_spread":0.3025454234426604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1478180867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437153,0.0015278639,0.000018527691,0.00086729525,0.0007172403,0.00020087587,0.000014272655,0.000006174835,0.0022761885],"genre_scores_gemma":[0.99857056,0.00025757775,0.00013790501,0.00047770984,0.00031762794,3.833382e-7,0.000006318032,0.000035898516,0.00019604545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765027,0.00045154453,0.0009360085,0.00015585532,0.00060302933,0.00020329106],"domain_scores_gemma":[0.99828595,0.00004514381,0.0007541881,0.00027197693,0.00048002272,0.00016270461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011551043,0.00015843575,0.00047986113,0.00011439326,0.000028041723,0.000013824519,0.0002901382,0.000036339006,0.00013733859],"category_scores_gemma":[0.00010598187,0.0000871303,0.00021048314,0.00032423777,0.00020943541,0.00010060258,0.00004805033,0.0004123819,0.0000059793156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017365336,0.0005211893,0.9549696,0.000015886499,0.0003644721,0.00013751817,0.00038676118,0.000050205348,0.00092282676,0.0000035597293,0.004933164,0.020329496],"study_design_scores_gemma":[0.02446861,0.0015863768,0.94523245,0.00048571525,0.00012240814,0.000053823653,0.000056009743,0.000012463666,0.00052690227,0.0000017210679,0.027348494,0.000105047104],"about_ca_topic_score_codex":0.00004697473,"about_ca_topic_score_gemma":0.00001624589,"teacher_disagreement_score":0.022415329,"about_ca_system_score_codex":0.000117424584,"about_ca_system_score_gemma":0.00056044216,"threshold_uncertainty_score":0.35530704},"labels":[],"label_agreement":null},{"id":"W151374958","doi":"10.1016/s0959-8049(02)00138-7","title":"Use of hair colouring products and breast cancer risk","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Skin Protection and Aging","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; National Institutes of Health; Yale Cancer Center","keywords":"Hair dyes; Breast cancer; Medicine; Dermatology; Cancer; Internal medicine; Chemistry","score_opus":0.04053418063415085,"score_gpt":0.2629014485926657,"score_spread":0.22236726795851483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W151374958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98789454,0.006148265,0.000054658958,0.004546486,0.00037872704,0.000089158,0.000008872808,0.000010183811,0.0008690947],"genre_scores_gemma":[0.99302185,0.0037785813,0.00043371483,0.00024663715,0.00065812236,7.131821e-7,5.0021654e-8,0.00001992611,0.0018404108],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992763,0.00010159523,0.00026120438,0.00008555662,0.00017710592,0.00009826483],"domain_scores_gemma":[0.99920064,0.000016504779,0.00033686231,0.0000831731,0.0002705295,0.00009228138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002825475,0.00007048869,0.0001702181,0.000088265944,0.000041565854,0.00001549877,0.000038992188,0.000008987639,0.00041010382],"category_scores_gemma":[0.00010255768,0.00005246527,0.000041634416,0.00012035061,0.00004914999,0.000119417484,0.000018131133,0.00023470694,0.000003331945],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057139294,0.00014985364,0.29682544,0.00022348676,0.000410044,0.0004959578,0.002110702,0.00056622137,0.033202413,0.000007878467,0.02550088,0.63993573],"study_design_scores_gemma":[0.0022244728,0.00024314472,0.87002677,0.0013426638,0.0002368877,0.0013437618,0.0000883151,0.00032165952,0.011877564,0.0000026725043,0.11216466,0.00012741887],"about_ca_topic_score_codex":0.00005358798,"about_ca_topic_score_gemma":0.0000051423194,"teacher_disagreement_score":0.6398083,"about_ca_system_score_codex":0.000038379258,"about_ca_system_score_gemma":0.0000289312,"threshold_uncertainty_score":0.44903493},"labels":[],"label_agreement":null},{"id":"W1576469977","doi":"10.1016/j.ejca.2012.12.016","title":"Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis","year":2013,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Cancer Research UK","keywords":"Medicine; Hazard ratio; Meta-analysis; Internal medicine; Chemotherapy; Confidence interval; Oncology; Cancer; Randomized controlled trial; Clinical trial; Progression-free survival","score_opus":0.16443906223011737,"score_gpt":0.4027531655647888,"score_spread":0.23831410333467143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1576469977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006334772,0.99659455,0.0002510467,0.00023697306,0.000434324,0.0012052254,0.000894596,0.000012837474,0.00030712583],"genre_scores_gemma":[0.00009496667,0.9941077,0.003627464,0.00022531603,0.0007945978,0.00008059601,0.00023570862,0.0001252473,0.0007083582],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959058,0.0003400959,0.0019705743,0.00050965743,0.00088839186,0.0003854724],"domain_scores_gemma":[0.9940021,0.00009605856,0.0039430293,0.0010497253,0.0006131139,0.00029597824],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010561546,0.00056851294,0.004946854,0.0010238778,0.000048700887,0.00005940684,0.0012121128,0.000060525177,0.0017728232],"category_scores_gemma":[0.000062471554,0.00036928683,0.0032753474,0.0011116257,0.00006164782,0.000319322,0.00020021065,0.00045741792,0.0000064724895],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007610397,0.0001115398,0.000050122915,0.0019954783,0.13636987,0.000010085421,0.00009846601,0.00004233354,0.0000013456065,0.0000026959217,0.0067365416,0.8545054],"study_design_scores_gemma":[0.0008066404,0.00057397835,0.00011776471,0.0006088319,0.35217378,0.000011002569,0.00004749925,0.000010965172,0.000002828282,0.000002380169,0.64546514,0.00017922587],"about_ca_topic_score_codex":0.00003591252,"about_ca_topic_score_gemma":0.000029965973,"teacher_disagreement_score":0.8543262,"about_ca_system_score_codex":0.00016729542,"about_ca_system_score_gemma":0.00048286153,"threshold_uncertainty_score":0.9998759},"labels":[],"label_agreement":null},{"id":"W1586634518","doi":"10.1016/j.ejca.2015.04.027","title":"Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis","year":2015,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Canada Research Chairs","funders":"","keywords":"Nasopharyngeal carcinoma; Medicine; Regimen; Chemoradiotherapy; Oncology; Internal medicine; Hazard ratio; Meta-analysis; Radiation therapy; Randomized controlled trial; Confidence interval","score_opus":0.17239712514871328,"score_gpt":0.40687404610641315,"score_spread":0.23447692095769987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1586634518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000264069,0.99381256,0.0008325389,0.0011770589,0.00057901716,0.000867247,0.00012969205,0.000019531364,0.0025797053],"genre_scores_gemma":[0.000046458685,0.9852585,0.004539419,0.0008870956,0.0042407773,0.00008753674,0.000037737147,0.0001934047,0.004709061],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99612635,0.0005230401,0.0016298181,0.00046636254,0.00073555723,0.00051889714],"domain_scores_gemma":[0.99560094,0.00017942226,0.0020805346,0.0005144791,0.001119381,0.0005052456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019983025,0.00067384134,0.009404252,0.00038804807,0.00010858376,0.000034022938,0.0004169578,0.00009223522,0.0002909735],"category_scores_gemma":[0.00006624782,0.0004253983,0.006754223,0.00090982736,0.00010817723,0.00009089299,0.000048858255,0.00063146406,0.000007760735],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005175022,0.00007301227,0.000017163233,0.0032391185,0.25670624,0.0006416736,0.0001838869,0.00010839793,5.0072117e-7,0.0000174037,0.11913056,0.61936456],"study_design_scores_gemma":[0.0014139792,0.000633387,0.000019337956,0.0009465195,0.31587747,0.00015271101,0.000008784614,0.0000053754293,3.2042712e-7,0.0000062507493,0.6806891,0.00024675325],"about_ca_topic_score_codex":0.000005541148,"about_ca_topic_score_gemma":0.000017754835,"teacher_disagreement_score":0.6191178,"about_ca_system_score_codex":0.00047433347,"about_ca_system_score_gemma":0.0015317169,"threshold_uncertainty_score":0.99981976},"labels":[],"label_agreement":null},{"id":"W1617009213","doi":"10.1016/j.ejca.2015.04.011","title":"Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bile duct cancer; Medicine; Internal medicine; Chemotherapy; Oncology; Bile duct; CA19-9; Cancer; Gastroenterology; Pancreatic cancer","score_opus":0.024743778441791608,"score_gpt":0.2690086053385916,"score_spread":0.2442648268968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1617009213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914161,0.0057671554,0.0000062349586,0.0007595067,0.00044786182,0.00024055954,0.000013285464,0.000005994591,0.0013433106],"genre_scores_gemma":[0.997663,0.0013270277,0.00007943746,0.00021961416,0.0003837664,0.0000066417447,0.0000016550384,0.000043247583,0.00027560248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981201,0.000139166,0.0006179908,0.00018177765,0.00068347063,0.00025746328],"domain_scores_gemma":[0.9987605,0.00001861457,0.000358738,0.00016208345,0.0005276693,0.00017237164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006503801,0.00017531474,0.0005656261,0.00023741584,0.000019644323,0.000011594271,0.00014217429,0.000025268944,0.000081821905],"category_scores_gemma":[0.00005580856,0.0001256397,0.000066121116,0.0003093122,0.00005894771,0.0001505535,0.00006022132,0.00033545904,0.0000012248115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026712075,0.00018321989,0.9895034,0.00007167282,0.00016513208,0.00042582102,0.0019834363,0.00086835906,0.00022242527,4.8023463e-7,0.0005745244,0.0033303194],"study_design_scores_gemma":[0.015392722,0.00059160934,0.9799566,0.0007367767,0.000058262383,0.000020426647,0.00021054453,0.000008635051,0.00095788756,0.0000023760992,0.0019397722,0.00012434534],"about_ca_topic_score_codex":0.0007705661,"about_ca_topic_score_gemma":0.0024391052,"teacher_disagreement_score":0.012721514,"about_ca_system_score_codex":0.0003522583,"about_ca_system_score_gemma":0.00039828592,"threshold_uncertainty_score":0.51234376},"labels":[],"label_agreement":null},{"id":"W1664877704","doi":"10.1016/j.ejca.2015.06.004","title":"Duration of Trastuzumab. In matters of the heart, one size may not fit all?","year":2015,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Clinical trial; Oncology; Internal medicine; Intensive care medicine; Cancer","score_opus":0.11603175485353937,"score_gpt":0.3744749291052125,"score_spread":0.2584431742516732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1664877704","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036215786,0.0016645166,0.000008156344,0.9574599,0.0008803785,0.00041129248,0.00007054384,0.0000047467993,0.0032846797],"genre_scores_gemma":[0.38905448,0.0010888668,0.00063434464,0.5887656,0.0077681663,0.000009746588,0.000009375131,0.00025447225,0.012414902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538743,0.00094470946,0.0013065045,0.00019228534,0.0018470228,0.0003220452],"domain_scores_gemma":[0.9974143,0.00019428736,0.001095986,0.0004565102,0.0007216663,0.00011724046],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002246763,0.00022332616,0.00081737497,0.0002428796,0.000016681885,0.00001733442,0.0005045048,0.000117033655,0.0009085109],"category_scores_gemma":[0.00040953548,0.00014743257,0.00028889885,0.0002672008,0.00021543588,0.00007775448,0.000083956664,0.0023861513,0.000014579993],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042297563,0.00005808806,0.0013865308,0.0005717453,0.00020583368,0.00043442068,0.00068727735,0.00006661216,0.008526036,5.9778426e-7,0.9848778,0.002762048],"study_design_scores_gemma":[0.0019598692,0.00059027475,0.03366721,0.0030820156,0.00017242284,0.00014520633,0.000048155158,0.000005615471,0.0046370067,0.000005284716,0.9555556,0.00013133376],"about_ca_topic_score_codex":0.0001402405,"about_ca_topic_score_gemma":0.000034441415,"teacher_disagreement_score":0.36869425,"about_ca_system_score_codex":0.0005930795,"about_ca_system_score_gemma":0.0011314949,"threshold_uncertainty_score":0.99991536},"labels":[],"label_agreement":null},{"id":"W1702502468","doi":"10.1016/j.ejca.2015.07.035","title":"A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":272,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"National Cancer Institute; Small Business Innovation Research","keywords":"Medicine; Vaccine therapy; Lung cancer; Maintenance therapy; Cell; Cancer; Cell therapy; Cancer research; Oncology; Immunology; Immunotherapy; Internal medicine; Biology; Chemotherapy","score_opus":0.02318868574445882,"score_gpt":0.3017719594808618,"score_spread":0.27858327373640296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1702502468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9177476,0.07903288,0.0004027734,0.00011187156,0.0013976576,0.0007065296,0.000034278222,0.000014708782,0.00055165286],"genre_scores_gemma":[0.9892273,0.0045525883,0.00010852423,0.00034030154,0.000198509,0.000033016284,0.0000061881187,0.000088025176,0.005445571],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972453,0.0009716963,0.0009602821,0.00027038695,0.00010359779,0.00044871413],"domain_scores_gemma":[0.99764997,0.00009167907,0.0011421068,0.00035620126,0.0006783466,0.00008167312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001492289,0.00032281486,0.00066016533,0.0002025835,0.0001504437,0.000026764896,0.00072952214,0.00007385589,0.0003401404],"category_scores_gemma":[0.00003242205,0.000244918,0.00023069966,0.00016442548,0.00006426767,0.00019388604,0.000054298114,0.0003900249,0.000015490692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025643298,0.0033400403,0.0011580706,0.000035016234,0.0006827232,0.000067157554,0.011346747,0.0002456353,0.92791384,0.0000024452186,0.0110071525,0.018557854],"study_design_scores_gemma":[0.115969285,0.024026431,0.005350961,0.00023678801,0.00035814033,0.000120775476,0.006282587,0.000020780717,0.7357297,0.000008122938,0.11133552,0.0005608803],"about_ca_topic_score_codex":0.00024036787,"about_ca_topic_score_gemma":0.000048543647,"teacher_disagreement_score":0.19218414,"about_ca_system_score_codex":0.000090494854,"about_ca_system_score_gemma":0.0005488262,"threshold_uncertainty_score":0.99874663},"labels":[],"label_agreement":null},{"id":"W174022502","doi":"10.1016/j.ejca.2003.11.011","title":"Knowledge of and attitudes toward complementary and alternative therapies","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Erna and Olav Aakre Foundation for Cancer Research; Cancer Research Society","keywords":"Reflexology; Homeopathy; Medicine; Massage; Aromatherapy; Alternative medicine; Complementary therapy; Meditation; Acupuncture; Family medicine; Naturopathy; Complementary medicine; Traditional medicine; Therapeutic touch; Internal medicine; Pathology","score_opus":0.08223511672166475,"score_gpt":0.38484227434949214,"score_spread":0.3026071576278274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W174022502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656319,0.03007653,0.00034656018,0.0021823177,0.00016852953,0.00007777212,0.000010668346,0.0000028583352,0.001502891],"genre_scores_gemma":[0.9930132,0.0052448916,0.0009848691,0.00018084435,0.00050686643,4.968123e-7,7.3086403e-7,0.000009574459,0.000058494275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993469,0.000065769746,0.00029030576,0.00007943554,0.00013356024,0.000084017454],"domain_scores_gemma":[0.99948156,0.000042613472,0.00018929875,0.000045337947,0.00017105797,0.00007016072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027573787,0.000092424554,0.00026751755,0.000081372214,0.00003782009,0.0000048036927,0.00005575398,0.0000017270817,0.000106489286],"category_scores_gemma":[0.000015330774,0.00006215356,0.000040075396,0.000043991226,0.00020539289,0.00006152105,0.00006810591,0.00010836069,6.003065e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010061673,0.00042112637,0.6440514,0.0005129219,0.0031818356,0.00043843023,0.05431957,0.00007211842,0.009196769,0.0011795277,0.001086963,0.2845332],"study_design_scores_gemma":[0.008712906,0.0031836263,0.93684626,0.0013428613,0.0002668203,0.00017928837,0.004442545,0.0000063901366,0.0029690193,0.00027583062,0.041657496,0.00011698391],"about_ca_topic_score_codex":0.00005501743,"about_ca_topic_score_gemma":0.000022943788,"teacher_disagreement_score":0.29279485,"about_ca_system_score_codex":0.000028522785,"about_ca_system_score_gemma":0.00003067413,"threshold_uncertainty_score":0.25345486},"labels":[],"label_agreement":null},{"id":"W1789162631","doi":"10.1016/j.ejca.2015.07.019","title":"A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer","year":2015,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; Kelowna General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; External beam radiotherapy; Radiation therapy; Management of prostate cancer; Brachytherapy; Cryotherapy; Randomized controlled trial; Sexual function; Adverse effect; Watchful waiting; Urology; Cancer; Oncology; Internal medicine; Surgery","score_opus":0.0884566545512611,"score_gpt":0.42182832694479155,"score_spread":0.33337167239353044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1789162631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000023539098,0.978645,0.00009606494,0.00037655825,0.00063605746,0.01944473,0.0006147609,0.0000063714033,0.00017806757],"genre_scores_gemma":[0.0000054904194,0.9962785,0.0002735439,0.00033951394,0.000629439,0.0018088289,0.00002743024,0.00013867798,0.0004985764],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.986921,0.0036737253,0.008119229,0.00024964256,0.0007780637,0.00025830683],"domain_scores_gemma":[0.97833645,0.0016212631,0.016937008,0.00043939584,0.0023880284,0.00027787266],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.016827395,0.00056607573,0.023712019,0.0002931832,0.000020580164,0.000016555767,0.00029725046,0.00006729202,0.0002114523],"category_scores_gemma":[0.003495515,0.00027993947,0.005083534,0.00027172448,0.00009135921,0.00005995913,0.000017560082,0.0002496208,0.0000013344536],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077754017,0.00016063325,0.0000013477022,0.769175,0.014325225,0.000058472928,0.000117781456,0.000003602432,0.0000036191989,0.000003193573,0.009678427,0.19869728],"study_design_scores_gemma":[0.07892861,0.0008894775,2.7573623e-7,0.57599956,0.041850444,0.000036808073,0.0000076065157,0.0000017529262,0.000015252079,0.0000014807853,0.30214107,0.00012766318],"about_ca_topic_score_codex":0.000008748609,"about_ca_topic_score_gemma":9.221252e-7,"teacher_disagreement_score":0.29246265,"about_ca_system_score_codex":0.00063755777,"about_ca_system_score_gemma":0.0030128534,"threshold_uncertainty_score":0.99996525},"labels":[],"label_agreement":null},{"id":"W1799482054","doi":"10.1016/j.ejca.2015.03.015","title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":337,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University Health Network; University of Toronto; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Cetuximab; Medicine; KRAS; Internal medicine; Colorectal cancer; Oncology; Hazard ratio; Proportional hazards model; Epidermal growth factor receptor; Refractory (planetary science); Splenic flexure; Cancer; Gastroenterology; Confidence interval; Colonoscopy; Biology","score_opus":0.040185961049699744,"score_gpt":0.32087468650912954,"score_spread":0.2806887254594298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1799482054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96752566,0.029538246,0.000008683612,0.00044183907,0.0003992159,0.00027480294,0.00007278815,0.000006205964,0.001732562],"genre_scores_gemma":[0.997896,0.001401184,0.00011259676,0.000056333563,0.00024528994,0.0000075771172,0.000004390321,0.0000236839,0.00025295073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860454,0.00008731088,0.0005655431,0.00015962488,0.00042521712,0.00015776059],"domain_scores_gemma":[0.9982871,0.00014210821,0.00054043916,0.00011737518,0.00075129705,0.0001616779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020256483,0.00015987597,0.0005381946,0.00013471584,0.000023203178,0.000009475396,0.00008585541,0.000028688477,0.00016011165],"category_scores_gemma":[0.00034955767,0.00011689428,0.000062999636,0.00016727136,0.00010867257,0.00010162917,0.000034827193,0.00016129202,0.0000019173779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02975624,0.0008111629,0.8912815,0.00038446064,0.0021209563,0.0006064733,0.018371962,0.00035450552,0.006963641,0.000026786653,0.0045895325,0.044732798],"study_design_scores_gemma":[0.01772936,0.004977703,0.9645892,0.0025691267,0.0005740181,0.000023959085,0.0007037734,0.00006579794,0.005689068,0.000049190887,0.0028789798,0.0001498452],"about_ca_topic_score_codex":0.00093810406,"about_ca_topic_score_gemma":0.0015385111,"teacher_disagreement_score":0.07330769,"about_ca_system_score_codex":0.00032952172,"about_ca_system_score_gemma":0.00055710925,"threshold_uncertainty_score":0.47668105},"labels":[],"label_agreement":null},{"id":"W1820078379","doi":"10.1016/j.ejca.2015.07.010","title":"The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"Novartis Pharmaceuticals Corporation","keywords":"GiST; Medicine; Imatinib; Stromal tumor; Observational study; Imatinib mesylate; Internal medicine; Cancer registry; Clinical trial; Surgery; Cancer; Stromal cell","score_opus":0.08429501739544203,"score_gpt":0.3399838208740723,"score_spread":0.25568880347863027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1820078379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259347,0.00057743123,0.0003195441,0.0024172703,0.00007989108,0.00034673102,0.000096189826,0.000016045244,0.0035534594],"genre_scores_gemma":[0.99100745,0.000020972726,0.008175878,0.000071838214,0.00026550153,0.0000040438936,0.000022749371,0.000027029599,0.00040456696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788207,0.00016295878,0.00036422993,0.0002890723,0.00095941947,0.00034225822],"domain_scores_gemma":[0.9973947,0.00010463042,0.0005094959,0.000393955,0.0011139687,0.00048329457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006842922,0.0001983905,0.00025177066,0.000038229275,0.00014978669,0.00010497689,0.00032243776,0.0000068331283,0.000006872558],"category_scores_gemma":[0.0015212415,0.00011549401,0.000041005223,0.0002338119,0.00024272563,0.00018820899,0.0001239979,0.00040292193,0.000003107123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008312687,0.00021327581,0.97771615,0.000018007913,0.000090205176,0.0015843179,0.000016407506,0.00015192293,0.000015098274,0.00004789585,0.008357928,0.0034760989],"study_design_scores_gemma":[0.0077700973,0.0081163775,0.97846144,0.0011693874,0.00009629179,0.0023246726,0.00019146025,0.00011932976,0.000013470181,0.000023043225,0.0016197461,0.0000946733],"about_ca_topic_score_codex":0.000023267003,"about_ca_topic_score_gemma":0.000036759564,"teacher_disagreement_score":0.007903102,"about_ca_system_score_codex":0.00041687602,"about_ca_system_score_gemma":0.0007543297,"threshold_uncertainty_score":0.4709709},"labels":[],"label_agreement":null},{"id":"W1959093538","doi":"10.1016/j.ejca.2007.04.015","title":"Long term survivors of childhood cancer: Cure and care","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; McMaster University Medical Centre","funders":"","keywords":"Childhood cancer; Medicine; Family medicine; Pediatrics; Cancer; Statement (logic)","score_opus":0.01844803390161643,"score_gpt":0.31443311859773215,"score_spread":0.29598508469611573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1959093538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9310958,0.061359804,0.00019197434,0.0018954484,0.00091826374,0.0001737577,0.000030134333,0.000018326085,0.004316497],"genre_scores_gemma":[0.99170595,0.005039139,0.00033706293,0.00075468834,0.0018541844,5.880967e-7,0.0000028101058,0.00006890647,0.00023669262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753267,0.00020711707,0.0009946477,0.00021835657,0.00072834163,0.00031884716],"domain_scores_gemma":[0.997805,0.00008686576,0.000861274,0.00027020145,0.00059426716,0.00038239773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015102329,0.0002291075,0.0006296837,0.00022298982,0.000059023092,0.000019609271,0.00022063477,0.00004425377,0.00021093198],"category_scores_gemma":[0.00010464854,0.00019291679,0.00021094817,0.00024132626,0.00016024723,0.00014307996,0.00006848242,0.00050369266,0.0000037156503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005970025,0.00014993768,0.76057386,0.00062657805,0.0004873047,0.0004876038,0.02044272,0.00002356077,0.0014508001,0.000019440553,0.0016928595,0.2134483],"study_design_scores_gemma":[0.0028989902,0.00055015285,0.9732937,0.0019091637,0.00028926277,0.00021070859,0.0018087549,4.6498238e-7,0.004245471,0.0000042697543,0.014593624,0.00019540176],"about_ca_topic_score_codex":0.00034245834,"about_ca_topic_score_gemma":0.001501174,"teacher_disagreement_score":0.2132529,"about_ca_system_score_codex":0.00013142217,"about_ca_system_score_gemma":0.00033286956,"threshold_uncertainty_score":0.7866919},"labels":[],"label_agreement":null},{"id":"W1964288741","doi":"10.1016/j.ejca.2014.08.001","title":"Reply to Verlingue, Koscielny and Ferté","year":2014,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Geology; Philosophy","score_opus":0.04507503816458584,"score_gpt":0.35600218406495954,"score_spread":0.3109271459003737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964288741","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014223516,0.0031861686,0.0002666983,0.9364591,0.00065143243,0.00019027184,0.0000055629503,0.000010600423,0.04500665],"genre_scores_gemma":[0.0035565114,0.0011412915,0.0013462297,0.94679826,0.012635273,0.0000023441953,0.000003315212,0.000070988994,0.034445763],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980242,0.0003902355,0.000513415,0.00020601452,0.0005685056,0.00029758105],"domain_scores_gemma":[0.99854296,0.00016002671,0.0003235371,0.00026694025,0.00043530343,0.0002712052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013654131,0.00017901223,0.0007418347,0.0002475977,0.00005300165,0.000031622007,0.0002076033,0.0000917555,0.00039256294],"category_scores_gemma":[0.00048761952,0.00012761694,0.00012197428,0.0000990715,0.00010974363,0.000028076554,0.00006730678,0.0016734165,0.00009696054],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021208322,0.000010363449,0.0051707304,0.00012461634,0.00019492481,0.0048085754,0.00017372875,6.4592933e-7,0.00010520341,0.00000147632,0.97818035,0.011017284],"study_design_scores_gemma":[0.0011211849,0.0011327385,0.017720671,0.0008433934,0.00035091708,0.00092314085,0.000010778388,0.000007165203,0.000019934401,0.00000908478,0.9777437,0.00011728706],"about_ca_topic_score_codex":0.000030440364,"about_ca_topic_score_gemma":0.0000014640351,"teacher_disagreement_score":0.012549941,"about_ca_system_score_codex":0.00011480716,"about_ca_system_score_gemma":0.00039154527,"threshold_uncertainty_score":0.7270255},"labels":[],"label_agreement":null},{"id":"W1965752049","doi":"10.1016/s0959-8049(01)00423-3","title":"Contacts with animals and humans as risk factors for adult brain tumours. An international case–control study","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Human-Animal Interaction Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba","funders":"","keywords":"Medicine; Oncology; Neuroscience; Physiology; Pathology; Internal medicine; Biology","score_opus":0.023427894541205856,"score_gpt":0.34071996158880646,"score_spread":0.3172920670476006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965752049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972852,0.00067482976,0.00022938296,0.00029848993,0.00017495306,0.00017061991,0.000076928496,0.0000041444127,0.0010854406],"genre_scores_gemma":[0.99820936,0.0001833356,0.00008802992,0.00037254448,0.00058920425,0.0000042853403,0.0000011622009,0.000028979128,0.00052308623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990819,0.00020654754,0.0002710383,0.0001785072,0.00013944955,0.00012255345],"domain_scores_gemma":[0.99879867,0.000040622937,0.00036245698,0.000095954056,0.0006084849,0.00009380646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029787672,0.00013361164,0.0001683898,0.000052104482,0.000117372125,0.00006414444,0.00012624767,0.0000142944145,0.00013729496],"category_scores_gemma":[0.00028426282,0.00009816764,0.000060040893,0.000020173662,0.000044821845,0.000021220847,0.00002571002,0.00011962452,0.0000024173141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053834375,0.001115968,0.82104254,0.000025175677,0.0057710693,0.0032027955,0.01607242,0.00046787353,0.108238816,0.00009666885,0.019705823,0.018877394],"study_design_scores_gemma":[0.01597314,0.030339882,0.83351105,0.00010560887,0.0007544256,0.0022588382,0.019288436,0.00015350644,0.010276907,0.000010397928,0.08657063,0.0007572033],"about_ca_topic_score_codex":0.000034506047,"about_ca_topic_score_gemma":0.00044756816,"teacher_disagreement_score":0.09796191,"about_ca_system_score_codex":0.000019293457,"about_ca_system_score_gemma":0.00001294664,"threshold_uncertainty_score":0.400316},"labels":[],"label_agreement":null},{"id":"W1967092678","doi":"10.1016/j.ejca.2014.03.014","title":"The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"EORTC Charitable Trust","keywords":"Medicine; Hazard ratio; Lesion; Target lesion; Proportional hazards model; Response Evaluation Criteria in Solid Tumors; Covariate; Database; Oncology; Internal medicine; Cancer; Progressive disease; Disease; Confidence interval; Pathology; Statistics","score_opus":0.0334883995005282,"score_gpt":0.36352809194079105,"score_spread":0.3300396924402629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967092678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506444,0.0029290854,0.00011632011,0.001074755,0.00031115717,0.00018352033,0.000023531735,7.740207e-7,0.0002964444],"genre_scores_gemma":[0.9991596,0.00030572707,0.0001338603,0.00012489811,0.00021618008,0.00001750519,0.0000148119925,0.00001220304,0.00001525981],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976709,0.001559463,0.0002970981,0.00010273786,0.00024824904,0.00012156551],"domain_scores_gemma":[0.9992187,0.00014543827,0.00027166537,0.00016406465,0.0001787649,0.000021388323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046938392,0.00008382985,0.00012204714,0.00004501601,0.000057967,0.000015162422,0.00022243209,0.000013240149,0.0000050437893],"category_scores_gemma":[0.00042555138,0.000047938196,0.00004545653,0.000048650272,0.00005742439,0.000008077183,0.000045888148,0.000068666675,3.953991e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047781575,0.0007431043,0.07164068,0.0001054998,0.00045023914,0.000058233778,0.0038977328,0.0017154256,0.79118717,0.00038524595,0.014686494,0.0673486],"study_design_scores_gemma":[0.0076578595,0.00094669184,0.9169152,0.00051963975,0.00011022599,0.000029644785,0.0006383309,0.00031017035,0.024549821,0.00020543794,0.04793772,0.00017927603],"about_ca_topic_score_codex":0.00002068944,"about_ca_topic_score_gemma":0.00006290938,"teacher_disagreement_score":0.8452745,"about_ca_system_score_codex":0.000035365585,"about_ca_system_score_gemma":0.0000921963,"threshold_uncertainty_score":0.19548628},"labels":[],"label_agreement":null},{"id":"W1968449590","doi":"10.1016/j.ejca.2011.06.018","title":"Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Sanofi; F. Hoffmann-La Roche; Amgen","keywords":"Docetaxel; Bevacizumab; Medicine; Metastatic breast cancer; Neutropenia; Internal medicine; Hazard ratio; Febrile neutropenia; Adverse effect; Oncology; Breast cancer; Placebo; Population; Chemotherapy; Cancer; Confidence interval; Surgery; Pathology","score_opus":0.03946862490249079,"score_gpt":0.3032199038091107,"score_spread":0.26375127890661987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968449590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932863,0.0035279002,0.00023352994,0.0012495192,0.00015161606,0.0009072513,0.0005165437,0.0000030382398,0.00012426925],"genre_scores_gemma":[0.9955264,0.0037369998,0.0004777394,0.000046692232,0.00007390961,0.000016615617,0.000017388993,0.000022068418,0.000082188315],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99888617,0.00008935797,0.0005535306,0.00013725301,0.00021060205,0.00012311008],"domain_scores_gemma":[0.99852437,0.0001901574,0.00069792656,0.00011794232,0.00039768175,0.00007192184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018201688,0.00015117906,0.0004218364,0.00008316914,0.00003372782,0.0000040855243,0.00007416131,0.000011497507,0.00010292675],"category_scores_gemma":[0.000014355164,0.00007062708,0.0000515133,0.00012516249,0.000103469814,0.00006190329,0.000009097179,0.000081229075,2.3445224e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34312075,0.0036273014,0.057867907,0.00011077196,0.0019560475,0.000084297695,0.0064909114,0.0003043066,0.000042420303,0.000006959403,0.00025578632,0.5861325],"study_design_scores_gemma":[0.12512246,0.031740833,0.83585864,0.0010561363,0.001970265,0.000025881234,0.00011039218,0.00007550027,0.0006684512,0.0000074134355,0.0032605464,0.00010346315],"about_ca_topic_score_codex":0.0005451495,"about_ca_topic_score_gemma":0.001608377,"teacher_disagreement_score":0.77799076,"about_ca_system_score_codex":0.0001651432,"about_ca_system_score_gemma":0.00021490261,"threshold_uncertainty_score":0.28800887},"labels":[],"label_agreement":null},{"id":"W1968544498","doi":"10.1016/j.ejca.2015.03.017","title":"Efficacy-effectiveness gap as an obstacle to translating clinical trials to clinical practice","year":2015,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Scopus; Medicine; Clinical trial; Randomized controlled trial; External validity; MEDLINE; Population; Internal medicine; Medical physics; Oncology; Psychology","score_opus":0.8658882959528195,"score_gpt":0.714443397102945,"score_spread":0.15144489884987444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968544498","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00633178,0.0012458726,0.26990783,0.6507092,0.044659253,0.0057252888,0.0005566979,0.00023088747,0.020633174],"genre_scores_gemma":[0.00045905713,0.00013070022,0.6402708,0.29145792,0.066763535,0.00002237685,0.0000033106537,0.00040410654,0.00048816184],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.77643067,0.20204876,0.015691502,0.0014626303,0.0033168085,0.0010496468],"domain_scores_gemma":[0.6233532,0.36377376,0.00684659,0.0012890712,0.0030474106,0.0016899826],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.32581937,0.00081254344,0.006013779,0.00031216207,0.00011547884,0.00031443918,0.0020311202,0.00083660166,0.0006056674],"category_scores_gemma":[0.84881777,0.00062290125,0.0019359504,0.00051468227,0.00025507552,0.00030240172,0.00028827082,0.00811081,0.0004991945],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005401312,0.00048161478,0.000052447034,0.00015166982,0.001014626,0.0032303338,0.00030386512,0.000033036467,0.0000139637705,0.00020166789,0.6379749,0.35114053],"study_design_scores_gemma":[0.007276193,0.0068211635,0.0006107866,0.0023535271,0.002662593,0.00016130196,0.0000801084,0.0000075842077,0.000030623498,0.03552574,0.94364095,0.0008294518],"about_ca_topic_score_codex":0.000012045462,"about_ca_topic_score_gemma":0.0000035872868,"teacher_disagreement_score":0.5229984,"about_ca_system_score_codex":0.00027708084,"about_ca_system_score_gemma":0.0013514678,"threshold_uncertainty_score":0.9996222},"labels":[],"label_agreement":null},{"id":"W1968620853","doi":"10.1016/j.ejca.2012.12.011","title":"Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Bevacizumab; Irinotecan; Medicine; FOLFIRI; Capecitabine; Internal medicine; Colorectal cancer; Neutropenia; Fluorouracil; Clinical endpoint; Oncology; Gastroenterology; Chemotherapy; Cancer; Randomized controlled trial","score_opus":0.027177173802597644,"score_gpt":0.29489772493370203,"score_spread":0.2677205511311044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968620853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901508,0.0021659003,0.0000243785,0.00029322307,0.00039468115,0.0063087298,0.00035807633,0.000035939713,0.00026824177],"genre_scores_gemma":[0.99881333,0.00035700045,0.0001614303,0.00002750139,0.00011855344,0.0001949892,0.00009199661,0.000108171036,0.00012701658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9935816,0.0010072946,0.0024922325,0.00079156045,0.0014849977,0.0006423323],"domain_scores_gemma":[0.9944405,0.0005922644,0.0024307475,0.0005526776,0.001595188,0.00038863413],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082736224,0.0007953635,0.002521482,0.0005944567,0.0002902372,0.000058339512,0.00039078796,0.00006808743,0.00016524292],"category_scores_gemma":[0.00043103754,0.0005925202,0.00022962638,0.0008243247,0.00028389302,0.0003579804,0.00021675452,0.0006555338,0.0000024138817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8376657,0.011460247,0.01698826,0.00017516638,0.004816965,0.00067376764,0.027821584,0.008160579,0.0002353429,0.00000123729,0.00018908607,0.09181211],"study_design_scores_gemma":[0.58587027,0.07925923,0.32665598,0.0008586289,0.0025833522,0.000009469165,0.0031432942,0.0007542117,0.00035894112,0.0000013859038,0.0000919191,0.00041333586],"about_ca_topic_score_codex":0.010393495,"about_ca_topic_score_gemma":0.008767957,"teacher_disagreement_score":0.3096677,"about_ca_system_score_codex":0.0030808747,"about_ca_system_score_gemma":0.001561497,"threshold_uncertainty_score":0.9996526},"labels":[],"label_agreement":null},{"id":"W1968832277","doi":"10.1016/j.ejca.2010.09.035","title":"Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Biopsy; Intraepithelial neoplasia; Incidence (geometry); Prostate; Gynecology; Cancer screening; Cancer detection; Oncology; Internal medicine","score_opus":0.03333045962821706,"score_gpt":0.3410103970834474,"score_spread":0.3076799374552303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968832277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808449,0.012794525,0.0002920908,0.0025565715,0.00064957625,0.0026582493,0.00016309862,0.000007183777,0.000033815366],"genre_scores_gemma":[0.98935634,0.008889598,0.00035617524,0.00016896447,0.00063323724,0.0004580786,0.0000030337703,0.000062824554,0.00007176105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975843,0.0006008357,0.00097501173,0.00024958493,0.00031648626,0.00027380465],"domain_scores_gemma":[0.99774796,0.00043372702,0.0009437279,0.00019328175,0.0005604531,0.00012084526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021319753,0.00023255509,0.0008594652,0.00017222659,0.00011440388,0.000026308606,0.00017591073,0.00002777412,0.000032697553],"category_scores_gemma":[0.00019972082,0.00014051591,0.00021570417,0.00020213606,0.00017776522,0.0000962688,0.000036606296,0.00035840864,1.223121e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11990497,0.001610929,0.14829513,0.00056900765,0.0019393951,0.00011528885,0.011605209,0.0020482412,0.03222866,0.000058139045,0.0008910486,0.680734],"study_design_scores_gemma":[0.24420829,0.00408171,0.71354175,0.001795178,0.0023342685,0.000026710339,0.001810483,0.00036385172,0.02576182,0.000078172474,0.0056932624,0.00030452694],"about_ca_topic_score_codex":0.0017797586,"about_ca_topic_score_gemma":0.007271573,"teacher_disagreement_score":0.68042946,"about_ca_system_score_codex":0.00009085696,"about_ca_system_score_gemma":0.00019361699,"threshold_uncertainty_score":0.5730073},"labels":[],"label_agreement":null},{"id":"W1968901807","doi":"10.1016/s0959-8049(11)70152-6","title":"Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer","year":2011,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Debulking; Medicine; Ovarian cancer; Surgery; Chemotherapy; Stage (stratigraphy); Cancer; Oncology; Internal medicine","score_opus":0.07258835780814786,"score_gpt":0.3448472579200515,"score_spread":0.2722589001119036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968901807","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005231108,0.99393487,0.000026113992,0.0007231312,0.0028407592,0.00062552356,0.00008728671,0.000028078732,0.0012111368],"genre_scores_gemma":[0.00042060943,0.9948211,0.00028776794,0.0011675886,0.0014474974,0.00009640506,0.000040647225,0.00032303965,0.0013953452],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99495584,0.00071221543,0.0025522849,0.0005827595,0.0005450499,0.00065184914],"domain_scores_gemma":[0.99558645,0.00071040046,0.0025385476,0.0005015167,0.00024808172,0.00041502572],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017207653,0.0008108419,0.0047158953,0.0007008871,0.00005631508,0.00005992772,0.00034277703,0.00014967429,0.0018295106],"category_scores_gemma":[0.00015670716,0.0005355001,0.0018158655,0.0006116547,0.0000791222,0.00022672956,0.00007102774,0.0009379371,0.000025087813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094233,0.00037356632,0.0024651922,0.004698827,0.001478751,0.004506579,0.0001599227,0.0000010278054,0.0000036283316,0.0000010981456,0.0544948,0.9308743],"study_design_scores_gemma":[0.0022772863,0.00022146225,0.00417062,0.094419904,0.0015067515,0.00037888312,0.000011417377,2.4677067e-7,0.000018684837,9.262221e-7,0.89652115,0.00047269682],"about_ca_topic_score_codex":0.0001536883,"about_ca_topic_score_gemma":0.00010733807,"teacher_disagreement_score":0.93040156,"about_ca_system_score_codex":0.0016184825,"about_ca_system_score_gemma":0.0039128894,"threshold_uncertainty_score":0.99970967},"labels":[],"label_agreement":null},{"id":"W1971381741","doi":"10.1016/j.ejca.2008.10.021","title":"Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Coalition for Research in Women's Health","funders":"","keywords":"Breast cancer; Odds ratio; Single-nucleotide polymorphism; Genotype; Internal medicine; Oncology; Medicine; Confidence interval; Case-control study; Cancer; Biology; Genetics; Gene","score_opus":0.011410865564529969,"score_gpt":0.27209010089332775,"score_spread":0.2606792353287978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971381741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985304,0.010917029,0.00061194296,0.0005956766,0.0005950307,0.0001095822,0.00011420021,0.0000018932999,0.0017506283],"genre_scores_gemma":[0.9891625,0.009450263,0.00015762751,0.00018515054,0.00072673,0.000006222776,0.0000016829478,0.000036093043,0.00027372356],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986153,0.0003548512,0.0004109129,0.00017435246,0.00024967006,0.00019487056],"domain_scores_gemma":[0.9988335,0.000021435244,0.00050638913,0.00029105527,0.00027069228,0.0000769494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007371538,0.0001432177,0.00020082228,0.00007817256,0.00008109981,0.000011966508,0.00040352947,0.00003915163,0.00012844069],"category_scores_gemma":[0.000060019214,0.00010125698,0.00017246505,0.00019261453,0.0002233145,0.000009287886,0.000065848755,0.00026098755,0.0000029982832],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013360115,0.00014835932,0.34332457,0.00006177674,0.001389592,0.00020501002,0.004970647,0.13915819,0.35132784,0.00001179284,0.04824134,0.10982486],"study_design_scores_gemma":[0.002604587,0.0003022388,0.9098535,0.00018875636,0.00015205918,0.0003258523,0.0005012472,0.00013131715,0.04899024,0.000017898303,0.03662471,0.0003075731],"about_ca_topic_score_codex":0.00010628419,"about_ca_topic_score_gemma":0.000110860514,"teacher_disagreement_score":0.5665289,"about_ca_system_score_codex":0.00010366787,"about_ca_system_score_gemma":0.00041037178,"threshold_uncertainty_score":0.41291398},"labels":[],"label_agreement":null},{"id":"W1971785038","doi":"10.1016/s0959-8049(01)81200-4","title":"A phase II trial of zd0473 in patients with metastatic breast cancer. A National Cancer Institute of Canada clinical trials group study (NCIC CTG-IND 129)","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Oncology; Internal medicine; Metastatic breast cancer; Cancer; Gynecology","score_opus":0.13632156723767389,"score_gpt":0.47071870049918757,"score_spread":0.33439713326151366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971785038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961106,0.0005505224,0.00003676976,0.0012418986,0.0004381208,0.00076135434,0.00029080527,0.0000030522215,0.0005668718],"genre_scores_gemma":[0.9983085,0.0002845351,0.000094709365,0.00023942832,0.00084423507,0.0000313476,0.0000069331218,0.000022107559,0.0001682137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99611473,0.00052684254,0.0019792733,0.00020112643,0.00097528566,0.00020276693],"domain_scores_gemma":[0.9971991,0.00017984539,0.0014103014,0.00015492912,0.0007677744,0.00028801037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029621723,0.00017457375,0.0009487725,0.00009552656,0.000055758843,0.000007058195,0.00019958022,0.000021246446,0.00041483963],"category_scores_gemma":[0.0004427538,0.00012302793,0.00015326307,0.0004193121,0.00014074634,0.00012273116,0.000027416016,0.00042256195,2.9730217e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45899218,0.04895456,0.2538748,0.00042877358,0.0060973857,0.000879134,0.0010280398,0.0030611956,0.004000637,0.000053427786,0.0112310145,0.21139884],"study_design_scores_gemma":[0.6239674,0.010590506,0.32490566,0.0013801466,0.0028472543,0.000079699494,0.00024320543,0.00015907854,0.0010226388,0.000016696162,0.03437416,0.0004135607],"about_ca_topic_score_codex":0.0049660634,"about_ca_topic_score_gemma":0.010480347,"teacher_disagreement_score":0.21098527,"about_ca_system_score_codex":0.00033335955,"about_ca_system_score_gemma":0.002670032,"threshold_uncertainty_score":0.75072354},"labels":[],"label_agreement":null},{"id":"W1972453208","doi":"10.1016/j.ejca.2007.06.006","title":"PSA and other tissue kallikreins for prostate cancer detection","year":2007,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"Berliner Sparkassenstiftung Medizin; Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft","keywords":"Prostate cancer; Medicine; Cancer; Kallikrein; Oncology; Internal medicine; Biology; Biochemistry","score_opus":0.10554676152379036,"score_gpt":0.4453220908145876,"score_spread":0.33977532929079723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972453208","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007880909,0.9962655,0.00022571278,0.00020760213,0.0005694632,0.0011164125,0.000115439914,0.000013567562,0.0014075399],"genre_scores_gemma":[0.000069905036,0.98662555,0.0002220268,0.00015319292,0.002214985,0.00005128117,0.0000058947685,0.00014866499,0.010508479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981773,0.00016380892,0.00070297875,0.00024690432,0.00035828864,0.00035074263],"domain_scores_gemma":[0.99845576,0.00007616251,0.000664699,0.00015720386,0.00037300415,0.00027316966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009096974,0.0003160504,0.0010877068,0.0003299829,0.000084355604,0.00004589386,0.00012691689,0.000077186414,0.000156477],"category_scores_gemma":[0.000040274936,0.00019753014,0.00030898093,0.00021465242,0.00009968407,0.00006959946,0.00003367358,0.0005292337,0.00001157674],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039305372,0.000033863158,0.000040706374,0.0068206335,0.00066059845,0.00026561093,0.0001497087,9.20328e-7,0.00004140488,0.0000018739142,0.0016350314,0.9899566],"study_design_scores_gemma":[0.0018894037,0.00094781315,0.000056722256,0.014406815,0.0015978429,0.00029197632,0.000016138556,0.0000013437942,0.00020841238,0.0000036647534,0.9803955,0.00018439683],"about_ca_topic_score_codex":0.000032561304,"about_ca_topic_score_gemma":0.00004614197,"teacher_disagreement_score":0.9897722,"about_ca_system_score_codex":0.00039305977,"about_ca_system_score_gemma":0.0005893235,"threshold_uncertainty_score":0.80550456},"labels":[],"label_agreement":null},{"id":"W1973167936","doi":"10.1016/j.ejca.2013.05.012","title":"Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nordion (Canada)","funders":"","keywords":"Medicine; Prospective cohort study; Progression-free survival; Internal medicine; Phases of clinical research; Clinical endpoint; Gastroenterology; Adverse effect; Neuroendocrine tumors; Ascites; Refractory (planetary science); Survival rate; Vomiting; Surgery; Chemotherapy; Clinical trial","score_opus":0.08484389951560253,"score_gpt":0.30411373841783773,"score_spread":0.2192698389022352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973167936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928995,0.0025711274,0.0016697327,0.00037949707,0.00030409577,0.0015723656,0.00023732762,0.000013383512,0.000353006],"genre_scores_gemma":[0.99307376,0.00006360724,0.005815669,0.00013623557,0.00058204884,0.000058278594,0.000053244286,0.000023643595,0.00019352947],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99860406,0.00020382115,0.0005398509,0.0001890064,0.0003177701,0.00014550917],"domain_scores_gemma":[0.99865514,0.000057711146,0.00036940724,0.00013409754,0.00061471004,0.00016890425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038666982,0.00015841948,0.00030641246,0.00010340431,0.00014400674,0.00003310468,0.00007284836,0.000015183879,0.000271369],"category_scores_gemma":[0.00017311594,0.000105453706,0.00018943324,0.00009030479,0.000041706076,0.00022251824,0.000024713905,0.00013503064,0.00002866876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009290064,0.011884857,0.124968894,0.00004451622,0.0032243638,0.002383046,0.029194038,0.00007793717,0.0059997765,0.000024137707,0.011417741,0.8014906],"study_design_scores_gemma":[0.2249367,0.06082282,0.58498794,0.0007417102,0.0061348327,0.00023318788,0.0045220125,0.011596968,0.024005743,0.000058789676,0.08108616,0.00087315234],"about_ca_topic_score_codex":0.00016888171,"about_ca_topic_score_gemma":0.000013493746,"teacher_disagreement_score":0.80061746,"about_ca_system_score_codex":0.0001690948,"about_ca_system_score_gemma":0.00016025435,"threshold_uncertainty_score":0.43002772},"labels":[],"label_agreement":null},{"id":"W1973604174","doi":"10.1016/j.ejca.2010.02.052","title":"The prognostic value of erythrocyte polyamines in the preoperative evaluation of patients with renal cell carcinoma","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Polyamine Metabolism and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Spermidine; Spermine; Nephrectomy; Polyamine; Renal cell carcinoma; Medicine; Internal medicine; Stage (stratigraphy); Gastroenterology; Oncology; Urology; Biology; Kidney; Biochemistry","score_opus":0.007707414319314905,"score_gpt":0.25123092641335426,"score_spread":0.24352351209403936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973604174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692595,0.0018690407,0.00007472401,0.00011936388,0.00007451459,0.0001876749,0.000016541204,3.1291168e-7,0.0007318969],"genre_scores_gemma":[0.99953806,0.000069233596,0.00013215121,0.000028246688,0.00016790828,0.0000071768104,0.000005277939,0.000008176068,0.00004376555],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99905664,0.00028277852,0.00025060456,0.00006804923,0.00026708248,0.00007484846],"domain_scores_gemma":[0.99895793,0.000025119909,0.00033009675,0.00016612181,0.00050090865,0.000019824836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082036556,0.000063356434,0.0000797748,0.000021533664,0.000039560728,0.000008509236,0.00023387666,0.000012098781,0.0000049277473],"category_scores_gemma":[0.00009661817,0.00003097025,0.00003562272,0.000078955694,0.00010324025,0.000005212007,0.000023123757,0.00010362353,2.7420987e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043226927,0.00035339582,0.29290488,0.000021519469,0.00007546927,0.000001699898,0.0013512842,0.0008350045,0.67447734,0.00016305433,0.0008483024,0.028535806],"study_design_scores_gemma":[0.0009592633,0.00027130282,0.86572105,0.000012034061,0.00007926221,0.0000021965739,0.00008453627,0.000030184472,0.12957348,0.000009466915,0.0032150194,0.00004219886],"about_ca_topic_score_codex":0.0000084675585,"about_ca_topic_score_gemma":0.000052420837,"teacher_disagreement_score":0.5728162,"about_ca_system_score_codex":0.0000033720896,"about_ca_system_score_gemma":0.00013859633,"threshold_uncertainty_score":0.126293},"labels":[],"label_agreement":null},{"id":"W1973942156","doi":"10.1016/j.ejca.2008.10.027","title":"Individual patient data analysis to assess modifications to the RECIST criteria","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":201,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Medical physics","score_opus":0.1216553627625872,"score_gpt":0.3557272994793777,"score_spread":0.2340719367167905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973942156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96997887,0.004331404,0.011656924,0.010051328,0.0006026877,0.00017984048,0.0008785541,0.0000060755447,0.002314318],"genre_scores_gemma":[0.9953755,0.0003992433,0.0022639567,0.0011169966,0.00057121273,0.0000062463273,0.000048671915,0.000015668395,0.00020249707],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990045,0.00017825922,0.00026484355,0.0002005371,0.0002259835,0.00012589665],"domain_scores_gemma":[0.9989045,0.0000118037915,0.00015389221,0.0005828111,0.00024044274,0.000106527084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003006827,0.00009797892,0.00013789404,0.00007519517,0.0001504897,0.000028806378,0.00062772,0.000010005724,0.000036362537],"category_scores_gemma":[0.00008453991,0.0000657509,0.00007703512,0.0002909188,0.00003680336,0.0000064257088,0.0003253233,0.00006303751,0.000014342276],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005725996,0.00031771068,0.0304403,0.000005769251,0.008294967,0.00014068195,0.00554414,0.009515224,0.01568255,0.000014964855,0.75851226,0.17095882],"study_design_scores_gemma":[0.0003275825,0.00022743834,0.39643085,0.000014733274,0.00064532587,0.00006361471,0.00023232907,0.000008308667,0.0038475175,0.0000010811095,0.59805286,0.00014832514],"about_ca_topic_score_codex":0.000032701184,"about_ca_topic_score_gemma":0.00013530948,"teacher_disagreement_score":0.36599055,"about_ca_system_score_codex":0.000024819077,"about_ca_system_score_gemma":0.000079064324,"threshold_uncertainty_score":0.2681244},"labels":[],"label_agreement":null},{"id":"W1974459875","doi":"10.1016/j.ejca.2006.09.002","title":"Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours","year":2006,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Breast Cancer Alliance; Cancer Research Institute","keywords":"DNMT3B; CTCF; Epigenetics; Biology; DNA methylation; Methylation; Methyltransferase; Cancer research; Molecular biology; Gene expression; Gene; Genetics","score_opus":0.007271324155511971,"score_gpt":0.22995325070154618,"score_spread":0.22268192654603422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974459875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905709,0.008177488,0.0008106779,0.00010324291,0.000045394434,0.00006973792,0.000026491372,0.0000010965116,0.00019499012],"genre_scores_gemma":[0.9984789,0.0010978212,0.00022047113,0.000021493672,0.00010328707,7.03644e-7,0.000011373478,0.000022063332,0.000043901902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888957,0.00020492474,0.0004605488,0.00013038517,0.00020216133,0.00011238866],"domain_scores_gemma":[0.9991415,0.000016127817,0.000482155,0.00010254609,0.0002112768,0.000046409543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050772924,0.00010955699,0.00021782586,0.00010642903,0.000019076868,0.0000069844295,0.000086787746,0.000038852,0.000011834494],"category_scores_gemma":[0.000025342237,0.00008858167,0.000052371426,0.00011132204,0.00007082367,0.000011666608,0.000014844499,0.00009166218,9.725702e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022625156,0.00008468207,0.032883458,0.000017902017,0.000029502398,0.000011051051,0.00012727806,0.00089717424,0.96299356,0.00000536609,0.000042723488,0.002681063],"study_design_scores_gemma":[0.0010018796,0.00030590908,0.3456983,0.00017699279,0.00003088798,0.0000052513747,0.000027510632,0.000012050643,0.652511,0.000049038674,0.00011044537,0.00007071971],"about_ca_topic_score_codex":0.00005984995,"about_ca_topic_score_gemma":0.000037378577,"teacher_disagreement_score":0.31281486,"about_ca_system_score_codex":0.00001969953,"about_ca_system_score_gemma":0.000072574614,"threshold_uncertainty_score":0.36122558},"labels":[],"label_agreement":null},{"id":"W1974833358","doi":"10.1016/s0959-8049(00)00186-6","title":"A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients","year":2000,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":805,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Head and neck cancer; Cancer; Head and neck; Reliability (semiconductor); Physical therapy; Surgery; Internal medicine","score_opus":0.02182268262219785,"score_gpt":0.28512797624648173,"score_spread":0.2633052936242839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974833358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713459,0.019862322,8.6743603e-7,0.002248644,0.00033704672,0.00042155493,0.000015642645,0.0000046020086,0.005763416],"genre_scores_gemma":[0.9729574,0.024719365,0.000022719909,0.0010714218,0.00031289397,0.000005353852,5.481307e-7,0.000025489904,0.00088482647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826056,0.0002699949,0.00056135247,0.00022194488,0.000451961,0.00023416238],"domain_scores_gemma":[0.99915075,0.00008864058,0.00026251326,0.00022910502,0.00014508473,0.00012390265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005078647,0.000197343,0.00054457237,0.000071919836,0.00016417346,0.000029157436,0.00013536577,0.00003020463,0.00020202757],"category_scores_gemma":[0.00004238053,0.00010909551,0.00006230824,0.0001590009,0.00020139565,0.00011598319,0.0000928113,0.00042920763,0.0000017079402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042934795,0.00036727614,0.84584916,0.00009482779,0.00019991418,0.000057204998,0.01154128,0.000058655467,0.0000853846,0.0000049731143,0.012802106,0.12464572],"study_design_scores_gemma":[0.013226013,0.0011881893,0.84565496,0.0010581841,0.00011972002,0.000026063917,0.00061240606,0.000017368002,0.000041522395,0.0000091536685,0.13793094,0.00011545586],"about_ca_topic_score_codex":0.0007128309,"about_ca_topic_score_gemma":0.0024333147,"teacher_disagreement_score":0.12512884,"about_ca_system_score_codex":0.00007813204,"about_ca_system_score_gemma":0.000079452744,"threshold_uncertainty_score":0.44487858},"labels":[],"label_agreement":null},{"id":"W1974952755","doi":"10.1016/j.ejca.2006.03.015","title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","year":2006,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Temsirolimus; Medicine; Discontinuation; Pulmonary toxicity; Pneumonitis; Toxicity; Lung; Sirolimus; Hypersensitivity pneumonitis; Internal medicine; Surgery; Pharmacology; Pathology; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway; Biology","score_opus":0.004441667544535384,"score_gpt":0.21636057750824822,"score_spread":0.21191890996371285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974952755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944289,0.0023402914,0.00011788086,0.00024115831,0.00075103145,0.00007074391,0.000022378921,0.0000012838033,0.0020263626],"genre_scores_gemma":[0.9982337,0.000085389525,0.000043331762,0.00014191835,0.0010544637,7.340303e-7,9.339435e-7,0.000019275822,0.0004202527],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896604,0.000219487,0.00039282395,0.0000888385,0.00023072383,0.00010209684],"domain_scores_gemma":[0.99876165,0.000008575186,0.00077112933,0.00023470506,0.00020034275,0.0000235878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036866963,0.00008586286,0.00012049931,0.000018270359,0.0000415037,0.000008038117,0.00034204146,0.000028840344,0.000025912761],"category_scores_gemma":[0.000031741958,0.000051749696,0.00016742197,0.00007909652,0.000092980365,0.0000054884426,0.00007990592,0.00012326379,5.5249797e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006110395,0.000036235022,0.01196684,0.000020957326,0.000023222523,9.538584e-7,0.00006324893,0.0011937849,0.98140305,0.0000031091824,0.0043940367,0.0008334322],"study_design_scores_gemma":[0.00040304853,0.000085479354,0.09700924,0.00007902796,0.000031597374,0.0000059431422,0.000012093902,0.000017041657,0.8886622,0.000007723447,0.013630356,0.000056226054],"about_ca_topic_score_codex":0.000017161577,"about_ca_topic_score_gemma":0.000009724168,"teacher_disagreement_score":0.092740856,"about_ca_system_score_codex":0.000031022257,"about_ca_system_score_gemma":0.000113352085,"threshold_uncertainty_score":0.21102914},"labels":[],"label_agreement":null},{"id":"W1975046069","doi":"10.1016/j.ejca.2005.03.028","title":"Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ","year":2005,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Ductal carcinoma; Radiation therapy; Salvage therapy; Stage (stratigraphy); Wide local excision; Carcinoma; Surgery; Radiology; Breast cancer; Internal medicine; Cancer; Chemotherapy","score_opus":0.023203099127971596,"score_gpt":0.290139820715627,"score_spread":0.2669367215876554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975046069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96547264,0.0058223484,0.023186654,0.004293443,0.00021085674,0.0006059145,0.00028770964,0.000005499634,0.00011492766],"genre_scores_gemma":[0.996221,0.0005785245,0.0013176823,0.00029716812,0.0012176553,0.00014969491,0.00006996633,0.00003266474,0.00011564607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99905944,0.00007879983,0.00031430088,0.00022419049,0.00011667909,0.00020660005],"domain_scores_gemma":[0.999353,0.000032458625,0.00022631354,0.00010709104,0.00020687739,0.0000742463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009560167,0.00020851077,0.00021923076,0.000059768103,0.000054934153,0.000016280921,0.00007034547,0.00003030659,0.000012997184],"category_scores_gemma":[0.0000067995406,0.00013837707,0.000116706564,0.000057941194,0.00010521532,0.000019354015,0.000011354235,0.000035688125,0.0000013263141],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03232436,0.00067048246,0.03126268,0.000034638648,0.00065366743,0.00015998611,0.0011351404,0.0016782915,0.0025307252,0.000014059082,0.0019625025,0.92757344],"study_design_scores_gemma":[0.05651047,0.02247391,0.53360623,0.00043311372,0.0008831873,0.0017243918,0.0009405714,0.0006188918,0.062846854,0.000019075702,0.31895468,0.0009886578],"about_ca_topic_score_codex":0.00005428025,"about_ca_topic_score_gemma":0.0019567772,"teacher_disagreement_score":0.92658484,"about_ca_system_score_codex":0.00045217387,"about_ca_system_score_gemma":0.00032383006,"threshold_uncertainty_score":0.56428534},"labels":[],"label_agreement":null},{"id":"W1975712049","doi":"10.1016/j.ejca.2004.02.006","title":"Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dartmouth General Hospital; Dalhousie University; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Lymphoma; Asymptomatic; Immunophenotyping; Rituximab; Marginal zone B-cell lymphoma; Biopsy; Lung; Bone marrow; Mucosa-associated lymphoid tissue; Internal medicine; MALT lymphoma; Pathology; Marginal zone; B cell; Antigen; Antibody; Immunology","score_opus":0.031006899039304696,"score_gpt":0.3474808403479048,"score_spread":0.31647394130860007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975712049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922877,0.004849906,0.000010531689,0.00088213716,0.0005176022,0.00030116455,0.000021685568,0.000014574165,0.0011146739],"genre_scores_gemma":[0.99793065,0.00071650825,0.000089167144,0.00038803928,0.0005682723,0.0000047513545,0.0000030700746,0.00003873362,0.00026080533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774015,0.00034256387,0.0009941917,0.00018709342,0.0005403859,0.00019564302],"domain_scores_gemma":[0.9981188,0.0000619876,0.000738241,0.00025094528,0.00038842962,0.00044158252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006130401,0.00017489669,0.0005936058,0.00009850555,0.000050755894,0.000016963282,0.00015498477,0.00002321274,0.00011046206],"category_scores_gemma":[0.00028969123,0.00012444885,0.00023818013,0.00019827245,0.000065652544,0.00007627202,0.000048334467,0.00008653294,0.000022434726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022733808,0.017331889,0.8344523,0.000040155104,0.0014882535,0.0099327965,0.0013794646,0.00019821785,0.0001206955,0.00001787446,0.0034703754,0.12929465],"study_design_scores_gemma":[0.041100226,0.00450931,0.94404805,0.0005617032,0.0010650578,0.0001094006,0.00025946676,0.000001795777,0.00028978358,0.00001248742,0.007930635,0.000112103444],"about_ca_topic_score_codex":0.000112922986,"about_ca_topic_score_gemma":0.000038773473,"teacher_disagreement_score":0.12918253,"about_ca_system_score_codex":0.0004423153,"about_ca_system_score_gemma":0.00085413485,"threshold_uncertainty_score":0.50748765},"labels":[],"label_agreement":null},{"id":"W1976093835","doi":"10.1016/s0959-8049(11)70809-7","title":"1166 POSTER Triple-negative Breast Cancer Cells May Transfer Phenotypic Characteristics via Exosomes","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Circular RNAs in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Trinity College Dublin; Science Foundation Ireland","keywords":"Microvesicles; Phenotype; Triple-negative breast cancer; Breast cancer; Cancer research; Cancer; Medicine; Biology; microRNA; Internal medicine; Genetics; Gene","score_opus":0.015453452099895097,"score_gpt":0.24279027968790162,"score_spread":0.22733682758800652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976093835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895331,0.0038251441,0.0016954904,0.00023305969,0.0014242727,0.00015651224,0.0002958151,0.000009149554,0.0028274313],"genre_scores_gemma":[0.9957749,0.0013890712,0.00014107976,0.00067614217,0.0012935238,0.000004484714,0.000006810575,0.00007216647,0.0006418137],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99855816,0.00026080493,0.00046054693,0.0002298966,0.00022882666,0.0002617538],"domain_scores_gemma":[0.99893916,0.000008427716,0.00023566934,0.0002559578,0.0003584193,0.00020237354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023441677,0.00022446354,0.00025340205,0.000065171735,0.00005649681,0.000034056255,0.00038052627,0.000045335375,0.0010829298],"category_scores_gemma":[0.000023680908,0.00019015804,0.00023767572,0.00007772985,0.0001270519,0.00002026332,0.000056044053,0.00018688221,0.000025115247],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020131818,0.00030042254,0.022546148,0.00007428721,0.00087331474,0.0003327069,0.001178937,0.000023740793,0.87944996,0.000013924523,0.004502642,0.08869072],"study_design_scores_gemma":[0.0027385887,0.000516864,0.53009206,0.00021764472,0.00039703722,0.00023120662,0.00012774633,0.000005501433,0.4459158,0.000028317052,0.019143535,0.0005856945],"about_ca_topic_score_codex":0.000025891142,"about_ca_topic_score_gemma":0.000018187013,"teacher_disagreement_score":0.50754595,"about_ca_system_score_codex":0.000040964638,"about_ca_system_score_gemma":0.00015150387,"threshold_uncertainty_score":0.9998302},"labels":[],"label_agreement":null},{"id":"W1976122187","doi":"10.1016/s0959-8049(01)00085-5","title":"Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"XIAP; TUNEL assay; Apoptosis; Cervical cancer; Inhibitor of apoptosis; Carcinoma; Pathology; Terminal deoxynucleotidyl transferase; Immunohistochemistry; Cervix; Cancer research; Cervical carcinoma; Medicine; Stage (stratigraphy); Biology; Cancer; Oncology; Internal medicine; Programmed cell death; Caspase","score_opus":0.01186314078261819,"score_gpt":0.2297074569808054,"score_spread":0.21784431619818723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976122187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931052,0.0046687857,0.0014735919,0.00029356,0.00008092988,0.00024730843,0.0000023618759,0.0000021928067,0.00012612237],"genre_scores_gemma":[0.99762946,0.001330149,0.0006493461,0.000093992465,0.00017174149,0.0000049888836,0.0000022610582,0.000019146411,0.000098910576],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991477,0.00018625554,0.00025266164,0.00017576336,0.000087342596,0.00015026655],"domain_scores_gemma":[0.99957985,0.000011785119,0.00015344576,0.00008274315,0.00008349406,0.00008870484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030281124,0.00012466351,0.00016632953,0.00005284388,0.000039566396,0.00003234608,0.00007275188,0.000031949025,0.000006287947],"category_scores_gemma":[0.00004204208,0.000089725276,0.00003587065,0.000067821944,0.000070598566,0.000009172419,0.000037760823,0.00011762691,4.9854725e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033350493,0.00009549347,0.09184334,0.00007634875,0.00007335465,0.00013400284,0.00071931526,0.000806333,0.85874474,0.000035502522,0.000051349216,0.047086723],"study_design_scores_gemma":[0.002300954,0.0015927192,0.88493603,0.00026592202,0.000051123647,0.00038701258,0.00033324046,0.0007352382,0.1049307,0.00012882255,0.003980128,0.00035810826],"about_ca_topic_score_codex":0.000007256554,"about_ca_topic_score_gemma":0.000014945012,"teacher_disagreement_score":0.79309267,"about_ca_system_score_codex":0.0000133017,"about_ca_system_score_gemma":0.000049651517,"threshold_uncertainty_score":0.36588904},"labels":[],"label_agreement":null},{"id":"W1977428762","doi":"10.1016/j.ejca.2014.06.004","title":"Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole","year":2014,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Prostate Cancer Canada; Princess Margaret Hospital Foundation","keywords":"Medicine; Ketoconazole; Abiraterone acetate; Prostate cancer; Urology; Docetaxel; Internal medicine; Log-rank test; Cancer; Retrospective cohort study; Androgen deprivation therapy; Proportional hazards model","score_opus":0.04270691158083056,"score_gpt":0.3753689660803812,"score_spread":0.3326620544995506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977428762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017881852,0.9788395,0.0000025836334,0.00044045877,0.0002359151,0.0022590978,0.0001517356,0.00000455708,0.00018426677],"genre_scores_gemma":[0.013170631,0.9855391,0.00011029251,0.00007393627,0.00012035239,0.00014564724,0.0000074482505,0.00007332983,0.00075926795],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9954054,0.0009872532,0.0020228133,0.00037346355,0.00084961584,0.00036150022],"domain_scores_gemma":[0.99577314,0.00008416652,0.0027723762,0.0004426432,0.0007436308,0.00018403225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016557747,0.0004458138,0.0026599246,0.00022892912,0.00008046124,0.0000271592,0.00042686233,0.00004426272,0.00014279172],"category_scores_gemma":[0.00017107617,0.00024277909,0.00036875246,0.00060279394,0.0004551559,0.00016626772,0.0001756386,0.00067538157,0.0000013849717],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012761138,0.00033474257,0.0017111728,0.25149974,0.0012399446,0.000551912,0.0039159264,0.000009607335,0.0010229461,0.000017702296,0.00049396657,0.7379262],"study_design_scores_gemma":[0.007112449,0.0018815353,0.019680835,0.7088994,0.0026307288,0.00025735993,0.00018793026,0.0000059282943,0.0013516762,0.0000131774805,0.25745395,0.0005250344],"about_ca_topic_score_codex":0.000059163856,"about_ca_topic_score_gemma":0.000092002985,"teacher_disagreement_score":0.7374012,"about_ca_system_score_codex":0.00049258606,"about_ca_system_score_gemma":0.0015386346,"threshold_uncertainty_score":0.9900244},"labels":[],"label_agreement":null},{"id":"W1978080370","doi":"10.1016/j.ejca.2009.05.024","title":"Patients’ and health care professionals’ evaluation of health-related quality of life issues in bone metastases","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Deutsche Krebshilfe","keywords":"Psychosocial; Medicine; Worry; Quality of life (healthcare); Disease; Affect (linguistics); Health professionals; Physical therapy; Cancer; Health care; Family medicine; Nursing; Internal medicine; Psychiatry; Psychology; Anxiety","score_opus":0.10587592843718753,"score_gpt":0.43909355529402044,"score_spread":0.3332176268568329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978080370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89309055,0.09288117,0.000017309369,0.013074537,0.00010206387,0.00044054847,0.000024533796,0.0000032245123,0.00036603952],"genre_scores_gemma":[0.9971671,0.0006079471,0.00066706084,0.0014526836,0.000028612596,0.0000010630174,0.000016905708,0.000010611057,0.0000479773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948884,0.0021569622,0.0016650296,0.000111241294,0.0010504184,0.00012794335],"domain_scores_gemma":[0.9969697,0.00002975958,0.0019142082,0.00013112924,0.00078962586,0.00016556676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008051302,0.00009724598,0.0006561523,0.00021398903,0.000023547562,0.000003667457,0.00005889934,0.00000914691,0.00015749101],"category_scores_gemma":[0.0006377942,0.0000755091,0.00007370543,0.00017396196,0.000037740323,0.00008882298,0.000019004032,0.0001361331,6.4176743e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017540801,0.0017804622,0.10519103,0.0020300986,0.00032578857,0.000020526135,0.0125953695,0.0002116572,0.00010728285,0.00016936523,0.015505462,0.8603089],"study_design_scores_gemma":[0.00686772,0.0010547047,0.9878632,0.0010738233,0.00013265022,9.732737e-7,0.0022791598,0.000025193685,0.00004055506,0.00003983528,0.000566372,0.000055832505],"about_ca_topic_score_codex":0.00011547255,"about_ca_topic_score_gemma":0.000016273305,"teacher_disagreement_score":0.88267213,"about_ca_system_score_codex":0.00011458982,"about_ca_system_score_gemma":0.0006245056,"threshold_uncertainty_score":0.30791718},"labels":[],"label_agreement":null},{"id":"W1979321534","doi":"10.1016/j.ejca.2011.09.005","title":"Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":214,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec; Saskatchewan Cancer Agency; CancerCare Manitoba; Montreal Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; British Columbia Children's Hospital; Children's Hospital of Eastern Ontario; Children's Hospital of Western Ontario; McGill University; Alberta Children's Hospital; Stollery Children's Hospital; Hospital for Sick Children; McMaster University","funders":"","keywords":"Central nervous system; Medicine; Pathology; Oncology; Internal medicine","score_opus":0.01645005950500219,"score_gpt":0.23631339101673543,"score_spread":0.21986333151173323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979321534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854798,0.0066764504,0.00059927773,0.00072582497,0.0010261615,0.00009245817,0.000016382895,0.000009157219,0.0053745355],"genre_scores_gemma":[0.9968919,0.00019323338,0.00022001182,0.00081599195,0.0015374596,0.000003232027,0.0000021856138,0.000032759017,0.000303201],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985342,0.00029545615,0.00040942928,0.00017887258,0.0002168809,0.00036515822],"domain_scores_gemma":[0.9989724,0.000009467034,0.00027228234,0.00022165994,0.00020709398,0.00031707456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048074432,0.00015382668,0.00015640499,0.00004894947,0.00017581301,0.000053444637,0.00045210362,0.000040115832,0.000075721786],"category_scores_gemma":[0.00007242884,0.000105896,0.00014649938,0.000093757575,0.00011244919,0.000007974934,0.000046020963,0.00022505182,0.000009784982],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003058335,0.0003524647,0.13453296,0.00031912283,0.0009990819,0.003977447,0.026998973,0.006883279,0.35719532,0.00091132446,0.30071792,0.16405378],"study_design_scores_gemma":[0.004234597,0.0017526996,0.45287448,0.0006767664,0.00032081033,0.0035290034,0.006032348,0.0010590153,0.12867746,0.000032049807,0.39918396,0.0016267891],"about_ca_topic_score_codex":0.0018024438,"about_ca_topic_score_gemma":0.004982022,"teacher_disagreement_score":0.31834155,"about_ca_system_score_codex":0.0001127068,"about_ca_system_score_gemma":0.0005852743,"threshold_uncertainty_score":0.43183136},"labels":[],"label_agreement":null},{"id":"W1980041456","doi":"10.1016/s0959-8049(99)00259-2","title":"Chemotherapy dose reduction and delay in clinical practice","year":2000,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Chemotherapy; Neutropenia; Febrile neutropenia; Breast cancer; Incidence (geometry); Complication; Internal medicine; Clinical trial; Cancer; Surgery; Oncology","score_opus":0.07621194248936429,"score_gpt":0.4565783842083961,"score_spread":0.3803664417190318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980041456","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026935825,0.9828621,0.0000055048667,0.0008013157,0.0009025012,0.0002462267,0.0000028928137,0.000007401518,0.014902671],"genre_scores_gemma":[0.00006265974,0.9950968,0.0003191431,0.00046512825,0.0028992298,0.0000041963,0.0000014549894,0.000064807864,0.00108659],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745375,0.0007488291,0.0012451353,0.00019483925,0.00021812884,0.00013932002],"domain_scores_gemma":[0.9985039,0.000090940965,0.0009096924,0.00017507393,0.0001553723,0.0001649989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014214311,0.00019707864,0.0010886235,0.00020431244,0.00003027124,0.000029225901,0.00009356831,0.000068934256,0.0003480019],"category_scores_gemma":[0.00008987887,0.00014116772,0.00035518705,0.00024565653,0.000074219584,0.00015527761,0.000013934817,0.0011564819,0.000029707693],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027596066,0.00010845124,0.000032044998,0.0005891201,0.00024303596,0.0005906063,0.000056518802,0.0000012572126,6.633748e-7,0.0000034002217,0.0062795156,0.99181944],"study_design_scores_gemma":[0.0015028159,0.0004695401,0.000561164,0.009253597,0.0012562948,0.0074498197,0.000014629905,1.2352973e-7,4.2866978e-7,0.0000015955377,0.97937155,0.00011847007],"about_ca_topic_score_codex":0.000009153356,"about_ca_topic_score_gemma":0.0000028791994,"teacher_disagreement_score":0.99170095,"about_ca_system_score_codex":0.0001540876,"about_ca_system_score_gemma":0.00058349845,"threshold_uncertainty_score":0.57566524},"labels":[],"label_agreement":null},{"id":"W1981355076","doi":"10.1016/j.ejca.2013.09.015","title":"Sorting out measures and definitions of screening participation to improve comparability: The example of colorectal cancer","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer","funders":"U.S. National Library of Medicine; Instituto de Salud Carlos III","keywords":"Comparability; Medicine; Psychological intervention; Population; Terminology; Colorectal cancer; Family medicine; Cancer; Environmental health; Nursing","score_opus":0.10139549852618378,"score_gpt":0.32471894982033056,"score_spread":0.22332345129414677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981355076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932094,0.0012465494,0.0030035141,0.00093038665,0.00020397967,0.00022870657,0.0000072957096,0.000007204584,0.0011629628],"genre_scores_gemma":[0.99840796,0.00012629431,0.0010869959,0.00012629089,0.00019714813,0.000018566965,5.576879e-7,0.000014334916,0.000021832466],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987455,0.00017513314,0.00054574,0.00010768272,0.00029393836,0.00013200728],"domain_scores_gemma":[0.9985067,0.00012213385,0.000502207,0.00010181613,0.00065312634,0.000113997296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077692,0.00008679816,0.00027300772,0.000081663,0.00007006152,0.000016807759,0.00006824229,0.000015075726,0.0000937398],"category_scores_gemma":[0.0002897755,0.000059060523,0.00008562566,0.00014603115,0.00009590639,0.00009315974,0.00003346644,0.00017996306,0.0000012745239],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038654949,0.00015267111,0.17101526,0.00015902703,0.00039059043,0.000006298459,0.008845023,0.0030138185,0.23647432,0.00006635611,0.0012522027,0.57475895],"study_design_scores_gemma":[0.0012940976,0.002937982,0.93188393,0.00047927783,0.00027985446,0.000020296671,0.0005782716,0.0008842898,0.06017081,0.00006973397,0.0012984375,0.00010303711],"about_ca_topic_score_codex":0.0016011522,"about_ca_topic_score_gemma":0.00047266108,"teacher_disagreement_score":0.76086867,"about_ca_system_score_codex":0.000045016513,"about_ca_system_score_gemma":0.00008799152,"threshold_uncertainty_score":0.2420474},"labels":[],"label_agreement":null},{"id":"W1981924536","doi":"10.1016/j.ejca.2007.01.029","title":"Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"MLH1; Colorectal cancer; Internal medicine; Medicine; Oncology; Stage (stratigraphy); Cancer; Pathological; DNA mismatch repair; Biology","score_opus":0.015099728127443836,"score_gpt":0.2970255265432505,"score_spread":0.28192579841580667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981924536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944501,0.0034825685,0.000026710784,0.00034008984,0.00024788413,0.00031018292,0.000011777216,0.00000975048,0.0011209319],"genre_scores_gemma":[0.99831283,0.0005336125,0.00070932246,0.00011931156,0.00018162219,0.0000066123794,9.915158e-7,0.000045813016,0.00008989166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814063,0.00014495265,0.0006085519,0.00019426155,0.00063032366,0.0002812681],"domain_scores_gemma":[0.9984502,0.00007346464,0.00072232826,0.00007440402,0.00048070133,0.00019890911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010068729,0.0001822869,0.00042998407,0.00020865393,0.000033679597,0.0000076290958,0.00011621658,0.000052334046,0.00019627967],"category_scores_gemma":[0.00014238653,0.00012412842,0.00007488633,0.0003348524,0.00017472912,0.00009480814,0.000051707582,0.00038713496,8.225441e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037060352,0.00020379583,0.79559857,0.000088277746,0.00011538103,0.0007838819,0.0019146742,0.000049740593,0.1732152,5.4215656e-7,0.0006789625,0.023644928],"study_design_scores_gemma":[0.0031877107,0.0015136118,0.6799923,0.0031066255,0.00010010578,0.00009535296,0.00018368977,0.000013556617,0.3111885,0.0000019718648,0.00050175877,0.00011481261],"about_ca_topic_score_codex":0.000020592026,"about_ca_topic_score_gemma":0.0001247257,"teacher_disagreement_score":0.13797328,"about_ca_system_score_codex":0.00024956328,"about_ca_system_score_gemma":0.00026235162,"threshold_uncertainty_score":0.506181},"labels":[],"label_agreement":null},{"id":"W1983280008","doi":"10.1016/j.ejca.2014.08.006","title":"Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Prostate cancer; Hazard ratio; Internal medicine; Proportional hazards model; Confidence interval; Cancer; Standardized mortality ratio; Cohort; Cohort study; Population; Oncology","score_opus":0.007582800881759445,"score_gpt":0.22573571271365933,"score_spread":0.2181529118318999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983280008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236107,0.006212967,0.000008092414,0.0009519227,0.00010338444,0.00025441704,0.000029066887,0.0000023338278,0.00007677531],"genre_scores_gemma":[0.9928461,0.006478254,0.00013742004,0.0001999211,0.00013230286,0.0000032874887,0.0000010592909,0.000029277002,0.00017239248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837714,0.00052536273,0.0005101989,0.00010294134,0.00033397067,0.00015040881],"domain_scores_gemma":[0.99804664,0.00044170723,0.0007642017,0.00018396982,0.00048377633,0.00007969182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072019425,0.00013050428,0.00046147656,0.0001237928,0.000029753157,0.0000120987215,0.00009773337,0.000015046686,0.000029355058],"category_scores_gemma":[0.00053982995,0.000070564216,0.000090892434,0.00011987159,0.00025860945,0.00010363046,0.00002163166,0.0002338224,5.3648614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01763487,0.000090050235,0.9450125,0.000081701095,0.00022295845,0.000021385971,0.0016073426,0.00037465966,0.00006823576,0.0000058420474,0.0004149489,0.034465488],"study_design_scores_gemma":[0.010325332,0.001262269,0.97459507,0.0011168903,0.00041932886,0.000016842878,0.000085847336,0.000025439838,0.0004646782,0.0000022883037,0.011607817,0.00007822306],"about_ca_topic_score_codex":0.0007677228,"about_ca_topic_score_gemma":0.00012519442,"teacher_disagreement_score":0.034387264,"about_ca_system_score_codex":0.00004503715,"about_ca_system_score_gemma":0.00017377308,"threshold_uncertainty_score":0.2877525},"labels":[],"label_agreement":null},{"id":"W1983467262","doi":"10.1016/j.ejca.2008.02.012","title":"Risk of second malignant neoplasms after childhood central nervous system malignant tumours: An international study","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Saskatchewan Cancer Agency; CancerCare Manitoba; BC Cancer Agency","funders":"National Cancer Institute; Compagnia di San Paolo","keywords":"Medicine; Central nervous system; Pathology; Childhood cancer; Oncology; Internal medicine; Cancer","score_opus":0.011340170411508806,"score_gpt":0.24536452393738756,"score_spread":0.23402435352587875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983467262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958105,0.0016352261,0.000012200164,0.00012982367,0.00092034444,0.0002656494,0.00008145184,0.000012868957,0.0011319],"genre_scores_gemma":[0.9983614,0.0003772541,0.00022178557,0.000076553115,0.00079134974,0.000006730428,0.000003216885,0.000043524695,0.00011815717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795437,0.00030913574,0.00072689936,0.00019767968,0.000569584,0.00024233865],"domain_scores_gemma":[0.9984434,0.000022770058,0.0006717143,0.00024362838,0.0003303058,0.0002881671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040880084,0.0001929197,0.0004384231,0.0001778703,0.000056410612,0.000021657404,0.00019628192,0.000017702925,0.00043104385],"category_scores_gemma":[0.000025459818,0.00012971177,0.00022314327,0.0000995555,0.00004709417,0.00016589198,0.00004003638,0.00020039555,0.000016069233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006416716,0.002185778,0.97039354,0.000027499405,0.0010048823,0.01600482,0.0039649727,0.00021954856,0.00053598825,0.000007972907,0.0006742462,0.004339082],"study_design_scores_gemma":[0.0050178077,0.0021672912,0.9845604,0.0004973104,0.0005089893,0.0026587697,0.0010127004,0.000020499992,0.0022242377,6.784632e-7,0.0012156087,0.00011574919],"about_ca_topic_score_codex":0.00005580532,"about_ca_topic_score_gemma":0.000047567086,"teacher_disagreement_score":0.014166819,"about_ca_system_score_codex":0.00016049256,"about_ca_system_score_gemma":0.00014213701,"threshold_uncertainty_score":0.52894926},"labels":[],"label_agreement":null},{"id":"W1983518614","doi":"10.1016/j.ejca.2010.12.005","title":"Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation","year":2011,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Cancer Care Ontario","keywords":"Interim; Interim analysis; Medicine; Accrual; Clinical trial; Sample size determination; Interpretation (philosophy); Closure (psychology); Medical physics; Oncology; Internal medicine; Statistics; Computer science","score_opus":0.827093014633824,"score_gpt":0.6594701102687771,"score_spread":0.1676229043650469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983518614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022612252,0.94201815,0.050258208,0.00012459233,0.0019233914,0.0023263686,0.0001927842,0.000008886933,0.0031249984],"genre_scores_gemma":[0.000013063784,0.6479322,0.35103396,0.00004493132,0.000660792,0.000077684716,0.0000018058582,0.00006647974,0.00016909071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9100717,0.072813936,0.015815524,0.000528528,0.00031193346,0.0004583871],"domain_scores_gemma":[0.6737049,0.31751606,0.008198753,0.00019730392,0.0002565962,0.00012639684],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.21610527,0.0004324719,0.014269473,0.001175973,0.000020547734,0.00003489561,0.0004359218,0.00033311752,0.00010755638],"category_scores_gemma":[0.49654838,0.0002706212,0.0017695344,0.00032013134,0.00014961681,0.000064523214,0.000065487024,0.0010805855,0.0000016550445],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059240747,0.000088675995,7.3528025e-7,0.0010425372,0.00071666663,0.000081526225,0.00047344464,6.154103e-7,0.0000010313444,0.0020446964,0.00038596833,0.93592334],"study_design_scores_gemma":[0.34321162,0.0027889984,0.000085529675,0.023278527,0.008773712,0.000049414397,0.000050395807,0.000026372325,0.0000039703846,0.14402896,0.4771149,0.00058761524],"about_ca_topic_score_codex":0.000009467576,"about_ca_topic_score_gemma":0.00005045923,"teacher_disagreement_score":0.93533576,"about_ca_system_score_codex":0.00022880702,"about_ca_system_score_gemma":0.00024358164,"threshold_uncertainty_score":0.9999746},"labels":[],"label_agreement":null},{"id":"W1983992309","doi":"10.1016/j.ejca.2007.07.026","title":"Health-related quality of life of long-term childhood cancer survivors: A population-based study from the Childhood Cancer Registry of Piedmont, Italy","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Regione Piemonte; Università degli Studi di Torino; Università degli Studi di Milano-Bicocca; Compagnia di San Paolo","keywords":"Medicine; Quality of life (healthcare); Cancer registry; Childhood cancer; Cancer; Population; Cohort; Retinoblastoma; Pediatrics; Physical therapy; Gerontology; Internal medicine; Environmental health","score_opus":0.04078568431165279,"score_gpt":0.35118461276627383,"score_spread":0.310398928454621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983992309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593817,0.031127071,0.00023261388,0.0063309628,0.0011342139,0.0009881508,0.0005333863,0.00003079147,0.00024108985],"genre_scores_gemma":[0.9960042,0.0008120324,0.00015401607,0.0015457209,0.0012430842,0.000008484055,0.00003460342,0.00012796318,0.000069853835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895533,0.0019730346,0.0052377833,0.0005139406,0.0021678149,0.0005541815],"domain_scores_gemma":[0.98824924,0.00085551146,0.008013637,0.0011435047,0.0011932126,0.0005448674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0072352155,0.00050511747,0.0022731358,0.0002904308,0.00014124447,0.000023405828,0.0008704437,0.00010601516,0.0005296515],"category_scores_gemma":[0.0010684045,0.00038447187,0.0007106122,0.0008464486,0.00025688813,0.0001938069,0.00010508971,0.0010093132,0.0000020257787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018326065,0.0020497441,0.96423966,0.0004085752,0.0019760716,0.00003909336,0.012978328,0.0007621088,0.00029064118,0.000008792311,0.00055111264,0.014863266],"study_design_scores_gemma":[0.00836784,0.00103476,0.9837409,0.0034269032,0.000543634,0.0000090379435,0.0017533868,0.0000043446394,0.0006978113,0.000013401059,0.00009261343,0.00031536614],"about_ca_topic_score_codex":0.10380975,"about_ca_topic_score_gemma":0.067824185,"teacher_disagreement_score":0.03662252,"about_ca_system_score_codex":0.00040167882,"about_ca_system_score_gemma":0.0024717837,"threshold_uncertainty_score":0.9998607},"labels":[],"label_agreement":null},{"id":"W1984533574","doi":"10.1016/s0959-8049(01)00313-6","title":"Inhibition of tumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; BioPhage Pharma (Canada); Institut National de la Recherche Scientifique","funders":"Deutsches Elektronen-Synchrotron","keywords":"Antibody-dependent cell-mediated cytotoxicity; Monoclonal antibody; Fibrosarcoma; Biology; Cytotoxicity; Cancer research; Nude mouse; Cell culture; Antibody; In vivo; Epitope; In vitro; Immunotherapy; Immunology; Molecular biology; Immune system","score_opus":0.024038395143785033,"score_gpt":0.325752380525386,"score_spread":0.301713985381601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984533574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98673767,0.0067592496,0.00007191002,0.0012655946,0.00008390349,0.00010317244,0.00009751889,0.0000049373316,0.004876029],"genre_scores_gemma":[0.993076,0.0047071343,0.0005110907,0.00012717942,0.00035356852,5.384304e-7,0.000015763973,0.000031982945,0.0011766895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978888,0.0002570323,0.0007671056,0.00016013107,0.0006774738,0.00024946337],"domain_scores_gemma":[0.99861145,0.000068003654,0.0005357172,0.000108149456,0.00042878228,0.00024786982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006449997,0.00017525768,0.00053206633,0.00022451463,0.00006665449,0.000015571377,0.00013649398,0.000027205704,0.0004274724],"category_scores_gemma":[0.000037365928,0.00013213759,0.00020690817,0.00021814354,0.00024543135,0.00013935378,0.000079617515,0.00033173285,0.0000051452594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007752343,0.00019097888,0.020659685,0.00026902658,0.00021674253,0.0004295242,0.000243626,0.0000040477426,0.96665186,0.000082039216,0.0053119743,0.005165273],"study_design_scores_gemma":[0.0030859227,0.0025593282,0.13782181,0.00087363925,0.00024129717,0.0005020596,0.00016799809,0.000018354076,0.8410794,0.000089268426,0.013360586,0.00020029339],"about_ca_topic_score_codex":0.00014846379,"about_ca_topic_score_gemma":0.0000054117713,"teacher_disagreement_score":0.12557241,"about_ca_system_score_codex":0.000025083998,"about_ca_system_score_gemma":0.00008693244,"threshold_uncertainty_score":0.5388414},"labels":[],"label_agreement":null},{"id":"W1985011852","doi":"10.1016/j.ejca.2012.07.019","title":"Single domain antibody against carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits proliferation, migration, invasion and angiogenesis of pancreatic cancer cells","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute for Biological Sciences","funders":"Ministry of Education, India; Ministry of Earth Sciences","keywords":"Carcinoembryonic antigen; Angiogenesis; Cell adhesion molecule; Cancer research; Antibody; Pancreatic cancer; Chemistry; Cell adhesion; Cancer; Medicine; Cell; Immunology; Internal medicine; Biochemistry","score_opus":0.02099342858801562,"score_gpt":0.2887257683723866,"score_spread":0.267732339784371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985011852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97485846,0.022717545,0.00016819248,0.00067996414,0.00011906251,0.00022353773,0.000012638848,0.000011488456,0.001209119],"genre_scores_gemma":[0.9929214,0.0056931665,0.00049549376,0.00023141531,0.00040682734,0.000004380503,0.000013562717,0.00003572075,0.00019802839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985383,0.00016337856,0.00063779036,0.00015042724,0.00029036982,0.00021971905],"domain_scores_gemma":[0.99871373,0.000034543038,0.00047201986,0.0001560192,0.00032863996,0.00029505434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042215502,0.00016341498,0.00031211425,0.00008854126,0.000086639346,0.00001600133,0.000084691215,0.000047248825,0.000101131795],"category_scores_gemma":[0.000028930903,0.00013283562,0.00011114669,0.00027041818,0.00008735406,0.0001637786,0.000025832298,0.00018721794,0.0000055821956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010783238,0.0002307141,0.045140643,0.00016742107,0.00007316561,0.000013523907,0.00078723294,0.000093545925,0.9511476,0.0000058309106,0.0008026713,0.001429804],"study_design_scores_gemma":[0.0012938814,0.00013426285,0.067253545,0.00031409456,0.00024606424,0.00004215674,0.000111455054,0.000055661534,0.9266109,0.0000034200452,0.0038104057,0.00012418324],"about_ca_topic_score_codex":0.0000073058122,"about_ca_topic_score_gemma":0.0000013106886,"teacher_disagreement_score":0.024536744,"about_ca_system_score_codex":0.000076245386,"about_ca_system_score_gemma":0.00010984767,"threshold_uncertainty_score":0.54168797},"labels":[],"label_agreement":null},{"id":"W1985037561","doi":"10.1016/j.ejca.2005.12.009","title":"“The Art of Successful Publication” ECCO 13 Workshop Report","year":2006,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Academic Writing and Publishing","field":"Arts and Humanities","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Research Society; European Association for Cancer Research","keywords":"Competition (biology); Relevance (law); Engineering ethics; Element (criminal law); Key (lock); Computer science; Political science; Engineering; Law","score_opus":0.02212797853565503,"score_gpt":0.25349867469243026,"score_spread":0.23137069615677522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985037561","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.056585338,0.0049616946,0.00018467092,0.03627951,0.0015360842,0.00004768798,0.000007860457,0.000024339588,0.9003728],"genre_scores_gemma":[0.88437605,0.00016061604,0.000051249233,0.0004525884,0.0063836835,9.175494e-7,0.0000036419806,0.000022839538,0.10854839],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859047,0.00013365297,0.00072546996,0.00007650102,0.00032914424,0.00014478728],"domain_scores_gemma":[0.99780077,0.00014880412,0.0010216548,0.00014535474,0.00083771686,0.000045721103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020399245,0.000073804025,0.00012824874,0.00006935787,0.00023066127,0.00040406236,0.00037573423,0.0000134243055,0.0007201393],"category_scores_gemma":[0.00041123747,0.000048176506,0.00009371268,0.000053930922,0.00013183273,0.00049175567,0.00003184198,0.00033188917,0.000018719558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018162124,0.000014182217,0.0029733155,0.0000072709036,0.00002793143,0.00004333511,0.0011261735,0.000048398007,0.000023678453,0.01272187,0.9658724,0.017123282],"study_design_scores_gemma":[0.00014852016,0.000020109486,0.0021470957,0.00008921487,0.000019984795,0.000055206026,0.0006897577,0.0000067385818,0.00006225927,0.00029352846,0.9964074,0.000060205126],"about_ca_topic_score_codex":0.00008813164,"about_ca_topic_score_gemma":0.00018522135,"teacher_disagreement_score":0.82779074,"about_ca_system_score_codex":0.000024068731,"about_ca_system_score_gemma":0.00008106221,"threshold_uncertainty_score":0.78850204},"labels":[],"label_agreement":null},{"id":"W1985217654","doi":"10.1016/j.ejca.2005.01.024","title":"The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials","year":2005,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Nausea and vomiting management","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aprepitant; Nausea; Vomiting; Medicine; Ondansetron; Placebo; Regimen; NK1 receptor antagonist; Anesthesia; Chemotherapy-induced nausea and vomiting; Chemotherapy; Internal medicine; Antiemetic","score_opus":0.19879246891617874,"score_gpt":0.4422483639553335,"score_spread":0.24345589503915477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985217654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024743213,0.988173,0.0006395275,0.0015894022,0.00049733074,0.006167293,0.00021000544,0.00001033794,0.00023880054],"genre_scores_gemma":[0.0030706576,0.99326706,0.00034740815,0.000132755,0.002114647,0.00007290981,0.000065759494,0.00009240982,0.0008364177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99447256,0.0017068834,0.0027371582,0.00035538984,0.0004630684,0.0002649447],"domain_scores_gemma":[0.9905592,0.0035931617,0.0047718734,0.00065201154,0.00028163195,0.00014210661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015902275,0.00041813092,0.0037963055,0.00012667246,0.00023819227,0.00020595465,0.0006133104,0.00007779789,0.000043298303],"category_scores_gemma":[0.0009139063,0.00018787102,0.0008665994,0.000110325636,0.00012114502,0.000114487615,0.00016675734,0.0004777243,0.0000011929347],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21000624,0.00006180712,0.0000024244757,0.00059460645,0.01817846,0.000028510542,0.00007722404,5.9744957e-7,0.00009180432,0.000014538801,0.0030266554,0.76791716],"study_design_scores_gemma":[0.33032683,0.00049882743,0.000013859556,0.0049942005,0.040258005,0.00006391176,0.00006196084,0.00008948705,0.000041772968,0.000010437131,0.62346107,0.00017965087],"about_ca_topic_score_codex":0.0000127125095,"about_ca_topic_score_gemma":0.000019258183,"teacher_disagreement_score":0.7677375,"about_ca_system_score_codex":0.00007158108,"about_ca_system_score_gemma":0.0003797543,"threshold_uncertainty_score":0.7661158},"labels":[],"label_agreement":null},{"id":"W1985579585","doi":"10.1016/s0959-8049(01)81533-1","title":"Risk factors in malignant extracranial germ cell tumours (MGCTs) of childhood: Analysis of UKCCSG's GCII study","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Carboplatin; Etoposide; Bleomycin; Regimen; Medicine; Cisplatin; Nephrotoxicity; Oncology; Chemotherapy; Internal medicine; Pediatrics; Toxicity","score_opus":0.011787353467339251,"score_gpt":0.27829387547772616,"score_spread":0.26650652201038694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985579585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591064,0.0030713754,0.000034109875,0.000030578365,0.0001060047,0.00017560346,0.00004646583,0.000004352463,0.0006208825],"genre_scores_gemma":[0.9989408,0.000745369,0.00008197923,0.000016024864,0.000094649644,6.9005677e-7,0.0000037976413,0.000026736809,0.00008994859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981332,0.00029491878,0.00076563214,0.00015088884,0.00048199852,0.00017339605],"domain_scores_gemma":[0.9983344,0.000051486953,0.0010108872,0.00021569098,0.00019898528,0.00018854321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004179547,0.00016134372,0.00065054145,0.00045518158,0.000023089482,0.000007660122,0.00013329192,0.000014836774,0.00033575532],"category_scores_gemma":[0.000094661424,0.000111129215,0.00041049946,0.0006160681,0.000038690567,0.000059983322,0.000025025478,0.00017668006,0.0000023475384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033019288,0.0025991385,0.984596,0.000012180842,0.0014258398,0.0019376874,0.0014788017,0.0016718084,0.00045118565,5.0005883e-7,0.000027935399,0.0054687066],"study_design_scores_gemma":[0.0042135934,0.0011510745,0.9860256,0.00012728086,0.0070650815,0.00001887024,0.000744593,0.00004188903,0.00043280446,0.000001909023,0.00009247362,0.0000848569],"about_ca_topic_score_codex":0.00037221605,"about_ca_topic_score_gemma":0.0001099705,"teacher_disagreement_score":0.0056392415,"about_ca_system_score_codex":0.00006592223,"about_ca_system_score_gemma":0.00012496665,"threshold_uncertainty_score":0.4531718},"labels":[],"label_agreement":null},{"id":"W1986333146","doi":"10.1016/j.ejca.2010.07.001","title":"Predictors of outcome and methodological issues in children with acute lymphoblastic leukaemia in El Salvador","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Canadian Institutes of Health Research; American Lebanese Syrian Associated Charities","keywords":"Medicine; Socioeconomic status; Hazard ratio; Confidence interval; Demography; Proportional hazards model; Pediatrics; Internal medicine; Population; Environmental health","score_opus":0.029178198809660542,"score_gpt":0.35406290103373206,"score_spread":0.3248847022240715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986333146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746263,0.00057079375,0.0002795661,0.0008547238,0.00013832009,0.00018109463,0.000008471273,0.000007497313,0.000496896],"genre_scores_gemma":[0.99362874,0.0004697474,0.005200676,0.00013417797,0.00034239673,0.000002037516,0.0000010837873,0.000036660927,0.00018448412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979038,0.0003870337,0.0007142324,0.00019138386,0.00052343303,0.00028009608],"domain_scores_gemma":[0.99885947,0.00025399,0.0003139627,0.00018279703,0.00017456076,0.0002152247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001567128,0.00016857323,0.0006135163,0.0003462648,0.000015752259,0.000012961537,0.00022142952,0.0000572598,0.000113319016],"category_scores_gemma":[0.0007617801,0.00010439349,0.00006351934,0.0002886962,0.00031313475,0.00010823203,0.00008697991,0.0007501419,0.0000035454357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012829439,0.00007688485,0.9812274,0.000029372139,0.00022702344,0.001009479,0.00031956163,0.00005248571,0.011356394,0.000020561294,0.0002482652,0.0041496605],"study_design_scores_gemma":[0.0069012055,0.0009418128,0.98769015,0.0002480205,0.00014918049,0.0019714301,0.000042603962,0.0000913311,0.0015150015,0.000015407268,0.00033289136,0.00010095946],"about_ca_topic_score_codex":0.000095282245,"about_ca_topic_score_gemma":0.00006985352,"teacher_disagreement_score":0.009841392,"about_ca_system_score_codex":0.00020658885,"about_ca_system_score_gemma":0.00041029585,"threshold_uncertainty_score":0.4257043},"labels":[],"label_agreement":null},{"id":"W1987118233","doi":"10.1016/j.ejca.2007.02.001","title":"Serial controlled N-of-1 trials of topical vitamin E as prophylaxis for chemotherapy-induced oral mucositis in paediatric patients","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation; Institute for Clinical Evaluative Sciences; Hospital for Sick Children","funders":"Hospital for Sick Children; Canada Research Chairs; Canadian Child Health Clinician Scientist Program","keywords":"Mucositis; Medicine; Placebo; Chemotherapy; Internal medicine; Meta-analysis; Vitamin; Doxorubicin; Gastroenterology; Surgery; Pathology","score_opus":0.047641300742310835,"score_gpt":0.389716983766142,"score_spread":0.3420756830238312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987118233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539274,0.0009858792,0.00014052488,0.00053234666,0.0012195661,0.0012923304,0.000023538863,0.0000039627266,0.0004091316],"genre_scores_gemma":[0.99626195,0.00021955758,0.0019244626,0.00022498946,0.0012363844,0.000010412468,0.0000022657698,0.000029148656,0.00009085192],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99671215,0.0004305555,0.0020106747,0.00013466699,0.00044180985,0.0002701227],"domain_scores_gemma":[0.9973517,0.00033012344,0.0014841049,0.00013100705,0.00051723566,0.000185848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003955256,0.0001515087,0.001238564,0.00024746306,0.000018620367,0.0000046894434,0.00010988317,0.000053646072,0.00012417907],"category_scores_gemma":[0.000791253,0.000105719446,0.00034516823,0.00021701076,0.000037815735,0.000054465836,0.0000138401765,0.00018799445,0.0000015112811],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07454816,0.0011188844,0.13738722,0.00036096247,0.00035450107,0.00016007178,0.0011435708,0.000013279372,0.012455071,0.000016925724,0.00058784784,0.7718535],"study_design_scores_gemma":[0.2011348,0.033428315,0.6815662,0.0008289164,0.0005053088,0.000023255052,0.00016863103,0.000013046001,0.075081214,0.000048624028,0.0069646593,0.00023705528],"about_ca_topic_score_codex":0.00007954501,"about_ca_topic_score_gemma":0.00004495777,"teacher_disagreement_score":0.77161646,"about_ca_system_score_codex":0.00037958493,"about_ca_system_score_gemma":0.00045614305,"threshold_uncertainty_score":0.43111137},"labels":[],"label_agreement":null},{"id":"W1987301448","doi":"10.1016/j.ejca.2007.07.031","title":"Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Adaptive design; Clinical study design; Task force; Medicine; Task (project management); Clinical trial; Discontinuation; Research design; Clinical endpoint; Multinomial distribution; Medical physics; Risk analysis (engineering); Computer science; Internal medicine; Systems engineering; Engineering; Mathematics; Econometrics; Statistics","score_opus":0.8120928075972004,"score_gpt":0.629842277343655,"score_spread":0.18225053025354532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987301448","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17382424,0.011271841,0.81055826,0.0026246873,0.0008102654,0.00067615823,0.00018447296,0.000004650168,0.00004545955],"genre_scores_gemma":[0.19731078,0.0038516463,0.7981173,0.0003977517,0.00023463723,0.000017628157,4.8282317e-7,0.00003128317,0.000038539605],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950578,0.002539527,0.0017930409,0.0001465686,0.00029505425,0.00016797097],"domain_scores_gemma":[0.9083727,0.087925516,0.0021472098,0.00019481483,0.0013251838,0.00003457667],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.017176319,0.00016695172,0.0007983472,0.00007212537,0.00014649729,0.0000056465533,0.00033118232,0.00003261177,0.0001298278],"category_scores_gemma":[0.01761553,0.00008193304,0.00009556004,0.00026838522,0.00059198984,0.000043597018,0.000065753135,0.0002459439,8.407054e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051503736,0.00035929887,0.00017636074,0.00007280311,0.0051561934,0.0000019300892,0.032578096,0.000055708446,0.096079186,0.0049285246,0.0044863396,0.8509552],"study_design_scores_gemma":[0.014567308,0.00522569,0.005777494,0.0014996378,0.0007929642,0.0000027244803,0.011358751,0.000068546855,0.76083016,0.18225497,0.017246509,0.00037522768],"about_ca_topic_score_codex":0.0000082930355,"about_ca_topic_score_gemma":0.000013584984,"teacher_disagreement_score":0.85058,"about_ca_system_score_codex":0.000046670044,"about_ca_system_score_gemma":0.00022516794,"threshold_uncertainty_score":0.99065953},"labels":[],"label_agreement":null},{"id":"W1987945639","doi":"10.1016/j.ejca.2011.10.035","title":"Comorbidity, age and overall survival in patients with advanced pancreatic cancer – Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dr. H. Bliss Murphy Cancer Centre; Ottawa Hospital; Alberta Health Services","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Erlotinib; Internal medicine; Comorbidity; Gemcitabine; Hazard ratio; Erlotinib Hydrochloride; Proportional hazards model; Pancreatic cancer; Placebo; Oncology; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","score_opus":0.0716409338928136,"score_gpt":0.3556097789209846,"score_spread":0.283968845028171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987945639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411684,0.0007016988,0.000046285437,0.000150942,0.00032163213,0.0008638304,0.0001322398,0.000008013461,0.003658494],"genre_scores_gemma":[0.99604416,0.0016159301,0.0009578575,0.00009492284,0.00034350468,0.000013847337,0.000016275992,0.000042627846,0.00087087956],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9971805,0.000553935,0.0010401289,0.0002538369,0.0006468451,0.0003247037],"domain_scores_gemma":[0.99796283,0.00032317117,0.0007927097,0.00026061718,0.00037835236,0.00028231394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011915673,0.00022254538,0.0011431102,0.0001826876,0.000041794945,0.000010734258,0.0001868507,0.0000473967,0.0004912073],"category_scores_gemma":[0.0004711538,0.00014145531,0.000075604265,0.00017941525,0.00023112679,0.0001427118,0.000069009424,0.00045549817,0.0000025981408],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8552665,0.0011011652,0.12269947,0.00007498229,0.0005468721,0.0016862671,0.0037061505,0.000015970121,0.0002389266,0.000007314997,0.00041971673,0.014236657],"study_design_scores_gemma":[0.45127034,0.009352754,0.53684455,0.0010040313,0.00045176188,0.000010355323,0.00015811228,0.000052433228,0.0000920338,0.000014590032,0.0006021816,0.00014684479],"about_ca_topic_score_codex":0.0012274799,"about_ca_topic_score_gemma":0.0007566581,"teacher_disagreement_score":0.41414508,"about_ca_system_score_codex":0.0001946414,"about_ca_system_score_gemma":0.00069694006,"threshold_uncertainty_score":0.576838},"labels":[],"label_agreement":null},{"id":"W1988231505","doi":"10.1016/j.ejca.2011.06.027","title":"Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Breast cancer; Chemotherapy; Internal medicine; Epirubicin; Oncology; Cancer; Stage (stratigraphy); Cyclophosphamide; Doxorubicin; Multivariate analysis; Biology","score_opus":0.013624157696232138,"score_gpt":0.23892093363356615,"score_spread":0.22529677593733402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988231505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976912,0.0014578841,0.000019063793,0.00011498354,0.0001588494,0.000103270955,0.00013478409,0.0000020767181,0.00031786558],"genre_scores_gemma":[0.9972037,0.0021796618,0.00014724914,0.00011639088,0.00014445117,0.000006793596,0.000002357586,0.000030212283,0.00016917313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989001,0.000108830514,0.00039814936,0.00017146682,0.00021012544,0.00021128895],"domain_scores_gemma":[0.9992385,0.000006167294,0.00038985276,0.00012869925,0.00018118856,0.000055580364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012650232,0.00018694463,0.00034894157,0.000094565665,0.00002223713,0.000007767891,0.00021066287,0.000027958853,0.00015874204],"category_scores_gemma":[0.0000059237896,0.00011817759,0.00006324741,0.0001146467,0.00013043557,0.000016456157,0.000048296013,0.000114777176,6.4290464e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007345306,0.00023441885,0.96401715,0.000013131727,0.00031863034,0.00006061312,0.0028435844,0.000012874566,0.00095624017,0.0000020541424,0.00007308918,0.024122907],"study_design_scores_gemma":[0.004852377,0.0009475958,0.9874608,0.00023521269,0.00003610844,0.000005805573,0.00019917752,5.9928874e-7,0.005793038,0.0000019500526,0.00031901163,0.00014832089],"about_ca_topic_score_codex":0.0003635047,"about_ca_topic_score_gemma":0.0010919507,"teacher_disagreement_score":0.023974586,"about_ca_system_score_codex":0.00005353345,"about_ca_system_score_gemma":0.00013225093,"threshold_uncertainty_score":0.48191422},"labels":[],"label_agreement":null},{"id":"W1989290263","doi":"10.1016/j.ejca.2004.08.026","title":"Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Osteosarcoma; Medicine; Sarcoma; Doxorubicin; Chemotherapy; Cisplatin; Bone Sarcoma; Oncology; Internal medicine; Surgery; Pathology","score_opus":0.017876621643998288,"score_gpt":0.26904021318340365,"score_spread":0.2511635915394054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989290263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864311,0.009045287,0.000020449128,0.002316478,0.00026064613,0.0007151984,0.000016448532,0.000016306405,0.0011780726],"genre_scores_gemma":[0.9975117,0.00038052828,0.00073282456,0.0005738705,0.0002635691,0.000007672969,0.0000010515026,0.00012059152,0.00040818847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99692756,0.00070266885,0.0011050584,0.00033306202,0.00057212706,0.00035950565],"domain_scores_gemma":[0.9982995,0.00008420853,0.0008083019,0.00048207215,0.00013213993,0.00019380805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009044986,0.00036873313,0.0007429384,0.0002540681,0.00007863183,0.00004162198,0.00034056304,0.000032639302,0.00010421585],"category_scores_gemma":[0.000044100438,0.00021144861,0.00023538353,0.00036271306,0.0001551145,0.00010576447,0.00014021435,0.00039999286,0.000010447614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003905536,0.007567202,0.86035526,0.0001978196,0.0005929147,0.011175468,0.009725326,0.00011671339,0.03247914,0.00010907694,0.00060792296,0.07316763],"study_design_scores_gemma":[0.026057303,0.004659668,0.9381135,0.0015536933,0.00029257714,0.00091839256,0.0010976613,0.000003667338,0.023657521,0.00002875336,0.0033688503,0.00024838452],"about_ca_topic_score_codex":0.00045345674,"about_ca_topic_score_gemma":0.00051124586,"teacher_disagreement_score":0.07775828,"about_ca_system_score_codex":0.00027583653,"about_ca_system_score_gemma":0.0001594428,"threshold_uncertainty_score":0.8622624},"labels":[],"label_agreement":null},{"id":"W1989839502","doi":"10.1016/j.ejca.2007.10.021","title":"Adipogenic, osteogenic and myofibrogenic differentiations of a rat malignant fibrous histiocytoma (MFH)-derived cell line, and a relationship of MFH cells with embryonal mesenchymal, perivascular and bone marrow stem cells","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Ministry of Education, Culture, Sports, Science and Technology","keywords":"Mesenchymal stem cell; Histogenesis; Pathology; Biology; Osteocalcin; Vimentin; Bone marrow; Stem cell; Undifferentiated Pleomorphic Sarcoma; Adipogenesis; Progenitor cell; Lineage markers; Sarcoma; Immunohistochemistry; Cell biology; Alkaline phosphatase; Medicine","score_opus":0.016118537774641697,"score_gpt":0.23515955224981908,"score_spread":0.21904101447517738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989839502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9318647,0.067242146,0.0002477818,0.00015323186,0.000088538894,0.00027493233,0.000024729377,0.000006222539,0.00009776554],"genre_scores_gemma":[0.9945903,0.0032097828,0.0017008568,0.000037232356,0.00008926875,0.000003070278,0.0000031164593,0.00004407241,0.00032230304],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982449,0.00018319381,0.00074204116,0.00023011719,0.00038356116,0.00021618766],"domain_scores_gemma":[0.9983808,0.00018450084,0.00066817243,0.00020593243,0.00028433514,0.00027625836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045981052,0.00022814078,0.000560658,0.00021555119,0.000080148915,0.000021648702,0.00006537052,0.00004316026,0.000050220548],"category_scores_gemma":[0.000013592518,0.00016488749,0.00015947549,0.00015909945,0.00018207663,0.00008884306,0.000049763563,0.00017287506,0.0000012760396],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020721704,0.0006511296,0.22321822,0.0006890644,0.0012234163,0.0013191241,0.0023424707,0.00008431751,0.7527261,0.00003632367,0.00032964093,0.015308058],"study_design_scores_gemma":[0.008150837,0.0022542852,0.54215896,0.0009502249,0.0020967296,0.001083819,0.00046038657,0.00005403439,0.4420194,0.000008333671,0.00052292756,0.00024004623],"about_ca_topic_score_codex":0.000015480566,"about_ca_topic_score_gemma":0.000019639858,"teacher_disagreement_score":0.31894076,"about_ca_system_score_codex":0.00006217349,"about_ca_system_score_gemma":0.00014736736,"threshold_uncertainty_score":0.67239165},"labels":[],"label_agreement":null},{"id":"W1990256102","doi":"10.1016/j.ejca.2008.02.030","title":"Predicting survival in patients with advanced disease","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia","funders":"","keywords":"Medicine; Disease; Cancer; Intensive care medicine; Malignancy; Palliative care; Anorexia; Performance status; Internal medicine","score_opus":0.0595708918678473,"score_gpt":0.3516866171460519,"score_spread":0.2921157252782046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990256102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936139,0.0031176186,0.000052549854,0.00014159488,0.00017852282,0.000058032132,0.000006873173,0.0000045277707,0.0028263954],"genre_scores_gemma":[0.998074,0.0009431026,0.0005162434,0.0000938805,0.00020840367,3.8737184e-7,0.0000017047169,0.000017861381,0.0001444348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999134,0.00008506897,0.00028189737,0.00006841228,0.0003254966,0.00010513948],"domain_scores_gemma":[0.999227,0.000029406141,0.00023330534,0.000078130804,0.00029382764,0.00013833582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015404553,0.000073184274,0.0002107463,0.00007375361,0.000017689843,0.0000018154907,0.00006035197,0.000005610071,0.000037325957],"category_scores_gemma":[0.0001635194,0.000050324128,0.000048287086,0.000110090674,0.00004781464,0.000091723276,0.000011853353,0.00014329335,0.0000019826477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015653875,0.00007877288,0.9896914,0.00002613156,0.00004261547,0.0004127744,0.0009465399,0.00022756342,0.000034218578,0.0000011132593,0.0001504314,0.006823099],"study_design_scores_gemma":[0.0041254447,0.00049214094,0.9859242,0.0014154372,0.000040599945,0.0000028771528,0.00009025347,0.0000070593082,0.00012625073,8.7514553e-7,0.0077228663,0.00005199646],"about_ca_topic_score_codex":0.0000068961012,"about_ca_topic_score_gemma":0.000005213471,"teacher_disagreement_score":0.007572435,"about_ca_system_score_codex":0.000047024,"about_ca_system_score_gemma":0.00011077958,"threshold_uncertainty_score":0.20521584},"labels":[],"label_agreement":null},{"id":"W1991029809","doi":"10.1016/j.ejca.2014.04.030","title":"Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Toxicity; Medicine; Limiting; Maximum tolerated dose; Clinical trial; Internal medicine; Oncology","score_opus":0.5609379012588367,"score_gpt":0.5792507951494835,"score_spread":0.01831289389064683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991029809","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13877371,0.0003676481,0.8519902,0.0004267048,0.0023965205,0.0004223422,0.00230893,0.000015763733,0.003298162],"genre_scores_gemma":[0.45326832,0.000048791848,0.54594475,0.00011898156,0.00053123874,0.0000026367122,0.000006073649,0.000041864867,0.000037378737],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.986312,0.007922799,0.0046259947,0.00021798028,0.0006970039,0.00022427502],"domain_scores_gemma":[0.9414331,0.050981656,0.005704941,0.00025284005,0.0014890176,0.00013849398],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.059867166,0.00017474945,0.0013025024,0.0001508471,0.000035648514,0.000028734574,0.00053087965,0.00005000938,0.00018465646],"category_scores_gemma":[0.5323244,0.00013892211,0.00048077357,0.00015976008,0.00010772903,0.00009173802,0.000078006546,0.00026451162,0.000001651814],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053446215,0.0034415605,0.0033575539,0.0011326104,0.00604329,0.00013863886,0.0025332593,0.0008112402,0.15260191,0.05526656,0.048279673,0.67294747],"study_design_scores_gemma":[0.15929498,0.011883856,0.029993001,0.0065797474,0.0027628178,0.000040691037,0.00033265812,0.007061787,0.35081133,0.40196234,0.02759565,0.0016811221],"about_ca_topic_score_codex":0.000010408209,"about_ca_topic_score_gemma":0.0000043988503,"teacher_disagreement_score":0.6712664,"about_ca_system_score_codex":0.000046860387,"about_ca_system_score_gemma":0.00011230356,"threshold_uncertainty_score":0.9680646},"labels":[],"label_agreement":null},{"id":"W1991403331","doi":"10.1016/s0959-8049(03)00358-7","title":"Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract","year":2003,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Doxorubicin; Metastatic Urothelial Carcinoma; Transitional cell carcinoma; Oncology; Chemotherapy; Urology; Internal medicine; Urothelial carcinoma; Cancer; Bladder cancer","score_opus":0.032301144339876756,"score_gpt":0.3161568543341923,"score_spread":0.2838557099943156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991403331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192375,0.00313002,0.00007111977,0.00032833434,0.00033137994,0.00080807525,0.00012822688,0.000001800731,0.0032773076],"genre_scores_gemma":[0.99846417,0.00050063874,0.00023613841,0.00009859554,0.0001627722,0.000011007071,0.0000019284257,0.000030740586,0.00049400877],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99739176,0.0007020456,0.0009474443,0.0001393551,0.0006149509,0.00020445706],"domain_scores_gemma":[0.998678,0.00012379845,0.00063374994,0.00025177584,0.0002331366,0.00007950851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005117862,0.0002033785,0.0006062252,0.000118153315,0.00005299433,0.000005075005,0.00019550502,0.000022511358,0.0004435774],"category_scores_gemma":[0.000042542695,0.00009742483,0.00037343745,0.0003090705,0.00013560528,0.000078851146,0.0000061240553,0.0001790797,9.318839e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51800704,0.07062119,0.006769623,0.00064842653,0.0018221668,0.002044135,0.030167013,0.003623775,0.26393655,0.00016835202,0.0005811063,0.10161061],"study_design_scores_gemma":[0.4738279,0.09489501,0.011571352,0.00057969254,0.0020091573,0.00030230422,0.0012264224,0.000030935276,0.40728018,0.000048470105,0.008013758,0.0002148137],"about_ca_topic_score_codex":0.00009444365,"about_ca_topic_score_gemma":0.000050812752,"teacher_disagreement_score":0.14334361,"about_ca_system_score_codex":0.00011224402,"about_ca_system_score_gemma":0.00088798057,"threshold_uncertainty_score":0.48568612},"labels":[],"label_agreement":null},{"id":"W1991411712","doi":"10.1016/s0959-8049(11)70168-x","title":"Paediatric outcomes following in utero exposure to the diagnosis and treatment of maternal malignancy","year":2011,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"In utero; Medicine; Malignancy; Obstetrics; Pregnancy; Pediatrics; Internal medicine; Fetus; Biology","score_opus":0.07969738128975337,"score_gpt":0.3562667623046198,"score_spread":0.2765693810148664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991411712","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03604958,0.9624234,0.0000035458652,0.00011303251,0.0008169066,0.0003800204,0.000033741304,0.000003209696,0.00017655574],"genre_scores_gemma":[0.017003195,0.9819773,0.000061893516,0.00006183081,0.0004946798,0.000022380604,8.910045e-7,0.00005342671,0.00032440902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998344,0.0002130431,0.0008902933,0.00015338452,0.000224183,0.00017506968],"domain_scores_gemma":[0.99886763,0.00006927723,0.0006538251,0.00021238225,0.00005137096,0.00014549422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000355338,0.0002702334,0.0014518569,0.00027596529,0.000020752008,0.000017622888,0.00016731588,0.000036596462,0.00009938815],"category_scores_gemma":[0.000027284099,0.00013161097,0.000653159,0.00018166451,0.000019111281,0.000042830514,0.00003984254,0.00018518117,0.0000062086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023135506,0.00004594274,0.19380488,0.00052447134,0.00034472664,0.0005570498,0.0004960441,6.8307395e-7,1.0258704e-7,8.001136e-7,0.00020974438,0.80399245],"study_design_scores_gemma":[0.0008759972,0.00090113754,0.1596221,0.008057071,0.0014892495,0.00008555796,0.000019714053,1.9299664e-8,0.0000017867466,5.454075e-7,0.8288418,0.000105023835],"about_ca_topic_score_codex":0.00016638385,"about_ca_topic_score_gemma":0.00009330377,"teacher_disagreement_score":0.82863206,"about_ca_system_score_codex":0.00018800706,"about_ca_system_score_gemma":0.0001630769,"threshold_uncertainty_score":0.53669393},"labels":[],"label_agreement":null},{"id":"W1993227536","doi":"10.1016/j.ejca.2013.03.024","title":"The magnitude and predictors of abandonment of therapy in paediatric acute leukaemia in middle-income countries: A systematic review and meta-analysis","year":2013,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; Hospital for Sick Children","funders":"Australian Government","keywords":"Medicine; Abandonment (legal); Psychological intervention; Confidence interval; Meta-analysis; Demography; Pediatrics; Internal medicine; Psychiatry","score_opus":0.05037368658212883,"score_gpt":0.3428595605107525,"score_spread":0.2924858739286237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993227536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007417924,0.9967031,0.000007749788,0.0002195233,0.000038138714,0.0021730128,0.000055235396,0.0000018566986,0.000059627524],"genre_scores_gemma":[0.00063888094,0.9986592,0.000068518355,0.00009303077,0.00006131115,0.000084937616,0.0000021093438,0.000047626025,0.00034441735],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99353456,0.0018803545,0.003114781,0.00023487731,0.00097251293,0.00026293242],"domain_scores_gemma":[0.9950634,0.0009876397,0.0029155682,0.0004536838,0.0004126358,0.00016703755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050693103,0.0003803542,0.0072106686,0.000731373,0.00002327995,0.000028905515,0.00042218794,0.000067062356,0.00011840216],"category_scores_gemma":[0.00040006908,0.00017259429,0.0010634421,0.0010350143,0.00021171889,0.00008094976,0.00012172424,0.0005820868,0.0000024642563],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112879396,0.00005709396,0.000662615,0.83881915,0.15334134,0.00036383327,0.00039765096,0.000004637871,4.016242e-7,0.0000035234066,0.00027327225,0.0059636007],"study_design_scores_gemma":[0.002655671,0.0006215364,0.0008787549,0.15931353,0.8160451,0.0003349045,0.0000349963,0.000009871553,0.0000013386352,0.0000018637824,0.019870596,0.00023184631],"about_ca_topic_score_codex":0.000047933223,"about_ca_topic_score_gemma":0.000017754572,"teacher_disagreement_score":0.67950565,"about_ca_system_score_codex":0.00049493404,"about_ca_system_score_gemma":0.0008075141,"threshold_uncertainty_score":0.7038191},"labels":[],"label_agreement":null},{"id":"W1995038009","doi":"10.1016/s0959-8049(01)00150-2","title":"Symptom response after palliative radiotherapy for patients with brain metastases","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Palliative care; Oncology; Internal medicine; Nursing","score_opus":0.01812556118880881,"score_gpt":0.28499137269717967,"score_spread":0.26686581150837085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995038009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790799,0.010774803,0.0020619226,0.007147475,0.00016876496,0.00042461485,0.00014536745,0.000009871347,0.00018729133],"genre_scores_gemma":[0.98405325,0.00039959123,0.010638362,0.0028960633,0.00032770293,0.000014656026,0.000004326411,0.000060786828,0.0016052698],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99872446,0.00038800942,0.00029582257,0.0001251696,0.00029426947,0.00017229],"domain_scores_gemma":[0.99891514,0.00021925264,0.0002685858,0.00014201578,0.0002975334,0.00015744692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005621527,0.0001480993,0.00029260255,0.000096018055,0.000039239487,0.00002067093,0.000064009044,0.000009861095,0.0009130758],"category_scores_gemma":[0.00010901201,0.000087496825,0.00016146962,0.00009359335,0.000049487484,0.00008052338,0.0000067777805,0.00010279386,0.0000076151105],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13510555,0.0036200248,0.23664579,0.00017652822,0.0089217285,0.0035280476,0.0059603653,0.00029643698,0.00060993485,0.00005072422,0.1387496,0.46633527],"study_design_scores_gemma":[0.019892551,0.009915475,0.483888,0.00038847406,0.0005690522,0.000039216477,0.000055305438,0.000032858035,0.00021709503,0.0000042729257,0.48482707,0.00017060881],"about_ca_topic_score_codex":0.0000012515675,"about_ca_topic_score_gemma":0.0000014122502,"teacher_disagreement_score":0.46616468,"about_ca_system_score_codex":0.000112289315,"about_ca_system_score_gemma":0.000039782102,"threshold_uncertainty_score":0.999754},"labels":[],"label_agreement":null},{"id":"W1995662976","doi":"10.1016/s0959-8049(03)00630-0","title":"An open randomised trial of second-line endocrine therapy in advanced breast cancer","year":2003,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Oncology; Cancer; Breast cancer; Endocrine system; Internal medicine; Gynecology; Hormone","score_opus":0.010860708174992132,"score_gpt":0.30362075137022604,"score_spread":0.2927600431952339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995662976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98809206,0.008509598,0.000025925852,0.00011005017,0.00041275844,0.0003527429,0.00001729574,0.0000016310147,0.0024779388],"genre_scores_gemma":[0.9920033,0.006938235,0.00015824477,0.00014821975,0.00032199678,0.000009039447,0.000003831257,0.000032790627,0.0003842961],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984951,0.0005920885,0.00046916067,0.00015296722,0.00012458299,0.0001660802],"domain_scores_gemma":[0.9991568,0.000011946342,0.00038850395,0.00018458691,0.00015629789,0.00010190964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000739167,0.00013322751,0.00029431432,0.00005538852,0.000023466237,0.00001836679,0.00034199876,0.000032597054,0.0002547486],"category_scores_gemma":[0.00003387563,0.00009853771,0.00010387149,0.00009383247,0.00004149266,0.00001619123,0.000028061944,0.00017834191,9.28868e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11353107,0.0002569345,0.0005824881,0.0000073618744,0.00016883732,0.00005878567,0.00006407257,0.0010625242,0.8369538,0.000008380974,0.00037295368,0.046932798],"study_design_scores_gemma":[0.37256393,0.004807879,0.0036323592,0.000112341084,0.000038594597,0.00011716209,0.000045221102,0.000008212193,0.5885508,0.000012319003,0.029880218,0.00023096132],"about_ca_topic_score_codex":0.000013000007,"about_ca_topic_score_gemma":0.000024199917,"teacher_disagreement_score":0.25903285,"about_ca_system_score_codex":0.000018016577,"about_ca_system_score_gemma":0.00020514449,"threshold_uncertainty_score":0.40182513},"labels":[],"label_agreement":null},{"id":"W1996283150","doi":"10.1016/j.ejca.2005.11.014","title":"Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?","year":2006,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"Bayer Corporation","keywords":"Sorafenib; Rash; Medicine; Toxicity; Internal medicine; Adverse effect; Pharmacology; Gastroenterology; Oncology; Surgery; Hepatocellular carcinoma","score_opus":0.024249938160825043,"score_gpt":0.335736719819994,"score_spread":0.31148678165916893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996283150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04476461,0.952136,0.00001555359,0.00010220536,0.000120474804,0.00094481715,0.00047464285,0.000013217258,0.0014285088],"genre_scores_gemma":[0.04384193,0.95432544,0.000122021585,0.000094617615,0.00010978303,0.000025314386,0.00014576557,0.00013201669,0.001203134],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99641764,0.00039432387,0.0017234695,0.00038450156,0.0007195881,0.00036045973],"domain_scores_gemma":[0.99607694,0.00010911885,0.002723591,0.0003192522,0.0006268165,0.00014429439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033369623,0.00067459577,0.0046663373,0.0007956956,0.000060770693,0.000020047204,0.00018084214,0.00006386199,0.00017092185],"category_scores_gemma":[0.000028585535,0.00035801285,0.00096753077,0.0013848065,0.00009492663,0.00008661801,0.00002436329,0.00033828715,0.0000018967434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029493452,0.0011871007,0.29732537,0.0003886969,0.03129982,0.00033576495,0.00041806477,0.00035224084,2.3223608e-7,4.117614e-7,0.0001651591,0.66557777],"study_design_scores_gemma":[0.019602202,0.0068462924,0.6598191,0.012305735,0.048851665,0.0000068624554,0.000044544944,0.000004262347,0.0000038990183,3.404021e-7,0.2520128,0.000502288],"about_ca_topic_score_codex":0.00008406512,"about_ca_topic_score_gemma":0.000856549,"teacher_disagreement_score":0.6650755,"about_ca_system_score_codex":0.0018533457,"about_ca_system_score_gemma":0.00045974183,"threshold_uncertainty_score":0.99988717},"labels":[],"label_agreement":null},{"id":"W1996586387","doi":"10.1016/j.ejca.2011.01.021","title":"Time for paediatric febrile neutropenia guidelines – children are not little adults","year":2011,"lang":"en","type":"editorial","venue":"European Journal of Cancer","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; Institute for Clinical Evaluative Sciences","funders":"Canadian Institutes of Health Research","keywords":"Psychosocial; Medicine; Clinical Practice; Health care; Family medicine; Febrile neutropenia; Health professionals; Nursing; Neutropenia; Psychiatry; Internal medicine; Political science","score_opus":0.0220405406582734,"score_gpt":0.3042389361661354,"score_spread":0.282198395507862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996586387","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011208287,0.0210868,0.00007506453,0.0018616818,0.95726883,0.001221955,0.0016031379,0.00009547004,0.0055787954],"genre_scores_gemma":[0.00171977,0.0066515976,0.00055635953,0.00055671483,0.9744132,0.000027688506,0.00011646523,0.0002803206,0.015677856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967891,0.00019987549,0.0013304857,0.0004232716,0.00083222555,0.00042506985],"domain_scores_gemma":[0.99350315,0.00016346024,0.0019093913,0.00044737445,0.0035954653,0.00038118204],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008916177,0.00047110295,0.0010968863,0.00033852982,0.00013998692,0.00006876904,0.00051596423,0.00019999329,0.001006609],"category_scores_gemma":[0.0008142483,0.0003693721,0.0007758293,0.00024120566,0.000089465044,0.00016792832,0.00010190702,0.0011380895,0.00027162294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002138237,0.00009543795,0.00041696694,0.00015015746,0.0004872648,0.00011526933,0.0000785894,0.000025949363,0.00013738756,9.642881e-7,0.9846385,0.011715281],"study_design_scores_gemma":[0.0054589817,0.0013284284,0.006545368,0.0014059448,0.0015344345,0.000108232685,0.000012391524,0.0000024873023,0.00022508479,0.0000030335684,0.9830045,0.00037111336],"about_ca_topic_score_codex":0.000067262416,"about_ca_topic_score_gemma":0.00002488575,"teacher_disagreement_score":0.01714442,"about_ca_system_score_codex":0.00023245117,"about_ca_system_score_gemma":0.0010734223,"threshold_uncertainty_score":0.9999066},"labels":[],"label_agreement":null},{"id":"W1996698172","doi":"10.1016/s0959-8049(03)00456-8","title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","year":2003,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Amgen","keywords":"Darbepoetin alfa; Placebo; Medicine; Chemotherapy; Internal medicine; Surgery; Gastroenterology","score_opus":0.020501349813226922,"score_gpt":0.29562936777237964,"score_spread":0.2751280179591527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996698172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862105,0.0009103914,0.0000076170263,0.00068781554,0.00017837933,0.001539817,0.0000061213514,0.000009480158,0.01044987],"genre_scores_gemma":[0.9979311,0.00028121044,0.00047330506,0.00014832099,0.0001265031,0.000015936945,0.0000042064607,0.000063478146,0.00095593045],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99684185,0.00066518027,0.001323196,0.0002633068,0.0006135912,0.00029285924],"domain_scores_gemma":[0.9977225,0.00015628811,0.0012387879,0.00027788087,0.0004068459,0.00019770087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019507197,0.00029148412,0.0010656754,0.00023263798,0.00004912873,0.000025735635,0.0001501071,0.000033421835,0.00012308951],"category_scores_gemma":[0.00023525501,0.00018740771,0.00020049595,0.00022126568,0.000075628406,0.00008962383,0.000016815238,0.00035783686,0.0000036129725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7977556,0.0022902999,0.19077417,0.000046691308,0.0009177264,0.00042103333,0.0030340569,0.00015068031,0.00020802405,7.91457e-7,0.0013307023,0.0030702522],"study_design_scores_gemma":[0.8686652,0.006260397,0.11929963,0.0012325711,0.00044389264,0.00003174499,0.001213127,0.0000038356698,0.0015982551,0.0000010824722,0.0010529165,0.00019731761],"about_ca_topic_score_codex":0.000024342391,"about_ca_topic_score_gemma":0.00005210719,"teacher_disagreement_score":0.07147454,"about_ca_system_score_codex":0.00017123854,"about_ca_system_score_gemma":0.00032207154,"threshold_uncertainty_score":0.76422644},"labels":[],"label_agreement":null},{"id":"W1997274895","doi":"10.1016/j.ejca.2003.06.001","title":"Melanoma in children and adolescents","year":2003,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":203,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Melanoma; Medicine; CDKN2A; Natural history; Disease; Epidemiology; Cancer; Pediatrics; Xeroderma pigmentosum; Dermatology; Oncology; Internal medicine; Genetics; Cancer research; Gene","score_opus":0.020331535581572382,"score_gpt":0.29961943740610125,"score_spread":0.2792879018245289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997274895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041201335,0.99510574,0.000007937474,0.000030797648,0.00037477163,0.000276889,0.0000031156953,0.000005010337,0.0037837438],"genre_scores_gemma":[0.0006330168,0.99700946,0.000048144455,0.00015772555,0.00038003744,0.0000011539918,0.0000011112745,0.000046882244,0.0017224823],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987018,0.00026601146,0.00057382265,0.00013565026,0.00019348267,0.0001292259],"domain_scores_gemma":[0.99925256,0.0000064003607,0.00044405813,0.00012180667,0.000045395722,0.00012975433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039621934,0.0001815562,0.00081174617,0.0003030959,0.000015155174,0.000019186415,0.00008540458,0.000032015592,0.00012074253],"category_scores_gemma":[0.000021106978,0.00013129183,0.00019574071,0.00013743182,0.000023005183,0.000023085262,0.00003110772,0.00044108485,0.000025852385],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022304557,0.000033694225,0.00087777147,0.0013486416,0.00017784702,0.0007887234,0.00001489998,2.1999749e-7,2.1805856e-7,0.0000017064842,0.0014576482,0.99527633],"study_design_scores_gemma":[0.00083695713,0.00017246137,0.0057847123,0.02045784,0.0006818077,0.005140475,0.0000040864984,1.1617294e-7,2.6325745e-7,5.210389e-7,0.9668123,0.00010844507],"about_ca_topic_score_codex":0.0000034288917,"about_ca_topic_score_gemma":0.0000026868443,"teacher_disagreement_score":0.99516785,"about_ca_system_score_codex":0.00012351,"about_ca_system_score_gemma":0.000096394775,"threshold_uncertainty_score":0.5353926},"labels":[],"label_agreement":null},{"id":"W1997854400","doi":"10.1016/j.ejca.2012.08.003","title":"Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Biliary tract cancer; Medicine; Chemotherapy; Biliary tract; Retrospective cohort study; Cancer; Oncology; General surgery; Internal medicine; Gemcitabine","score_opus":0.03675869846357329,"score_gpt":0.3226150694782145,"score_spread":0.28585637101464123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997854400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9182862,0.079731286,0.0000033673937,0.0005158453,0.00029668596,0.00033433494,0.0000434028,0.000006360921,0.00078254344],"genre_scores_gemma":[0.9946551,0.0042559803,0.00007404529,0.00027707822,0.00055818143,0.0000055356422,5.6665823e-7,0.000031733533,0.00014182091],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985466,0.0001517385,0.0005551158,0.00017876446,0.0003008551,0.00026692156],"domain_scores_gemma":[0.9989722,0.000029800316,0.00038866306,0.00018105272,0.0002771889,0.00015109307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010749531,0.00017077188,0.00059948204,0.00013381489,0.000035225177,0.0000064306178,0.00008813206,0.000019994714,0.00023277836],"category_scores_gemma":[0.00006455237,0.00013021452,0.00011044379,0.00022345645,0.000057568024,0.00020395836,0.00003992763,0.00033811913,7.121576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011870695,0.0009047781,0.968192,0.000062230145,0.0001908528,0.00003646786,0.007440842,0.000008099359,0.00081422454,0.0000032983262,0.0002567574,0.020903373],"study_design_scores_gemma":[0.009161537,0.0011590074,0.9854598,0.0002532266,0.00012687533,0.00003758517,0.0013389357,0.0000017392709,0.00085195934,0.000004328038,0.0014924082,0.00011262271],"about_ca_topic_score_codex":0.000043589087,"about_ca_topic_score_gemma":0.00045806775,"teacher_disagreement_score":0.07636888,"about_ca_system_score_codex":0.00023857386,"about_ca_system_score_gemma":0.00009316379,"threshold_uncertainty_score":0.5309994},"labels":[],"label_agreement":null},{"id":"W1997893645","doi":"10.1016/j.ejca.2014.02.015","title":"Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Hazard ratio; Neutrophil to lymphocyte ratio; Gallbladder cancer; Confidence interval; Proportional hazards model; Cohort; Cancer; Biliary tract cancer; Lymphocyte; Gemcitabine","score_opus":0.01642036812848134,"score_gpt":0.2888078571261575,"score_spread":0.2723874889976761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997893645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98636043,0.006445058,0.000070421585,0.0017925856,0.000801848,0.0003070064,0.000013037623,0.00002660608,0.00418302],"genre_scores_gemma":[0.99595165,0.00096810336,0.0002717457,0.0011985988,0.001224643,0.00001581958,0.000001594381,0.00007023912,0.0002976112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776185,0.00047012715,0.0007376526,0.00021679998,0.0005019181,0.0003116319],"domain_scores_gemma":[0.99855727,0.0000957318,0.00047432352,0.00022986317,0.00032029845,0.00032250222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071615604,0.00022097869,0.00040846562,0.00027496333,0.000047567177,0.00003952015,0.00022316322,0.000038856913,0.00081875967],"category_scores_gemma":[0.00040714678,0.00017335331,0.00020750093,0.00024781172,0.000091515736,0.00019690742,0.000038445443,0.0003553389,0.00006289855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016627901,0.00029996922,0.80364275,0.00022824883,0.00026399211,0.0022690652,0.000712132,0.00016998684,0.01209746,0.000024597224,0.003029665,0.17559934],"study_design_scores_gemma":[0.004336538,0.0005003998,0.93915915,0.0011521521,0.0002435153,0.00020425781,0.00004381125,0.00023930274,0.0037325148,0.00002041193,0.050147574,0.00022034883],"about_ca_topic_score_codex":0.000027445269,"about_ca_topic_score_gemma":0.000014075676,"teacher_disagreement_score":0.17537898,"about_ca_system_score_codex":0.000369982,"about_ca_system_score_gemma":0.0006696856,"threshold_uncertainty_score":0.8964844},"labels":[],"label_agreement":null},{"id":"W1998077412","doi":"10.1016/j.ejca.2013.03.018","title":"Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre","funders":"National Cancer Institute","keywords":"Zoledronic acid; Osteosarcoma; Medicine; Chemotherapy; Oncology; Internal medicine; Cancer research","score_opus":0.02956655096597526,"score_gpt":0.33081412033396945,"score_spread":0.3012475693679942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998077412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800257,0.017084371,0.000043729313,0.0020570864,0.000049314483,0.000640336,0.000033644268,0.0000016758281,0.00006412985],"genre_scores_gemma":[0.99493086,0.0044632573,0.00017769386,0.00032253674,0.000044566437,0.000017152739,0.000015252966,0.000012049716,0.000016640271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982156,0.00053801714,0.00068113435,0.00014956984,0.00026883767,0.00014680032],"domain_scores_gemma":[0.9984448,0.00024713043,0.0008217048,0.00029270057,0.00010188965,0.00009176323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005007762,0.00013977778,0.00065495545,0.00008364874,0.000028257735,0.000012231318,0.00009356642,0.00001275813,0.000065161505],"category_scores_gemma":[0.000030310386,0.000058011778,0.0001683745,0.00025118067,0.00015269483,0.00008639881,0.000008623264,0.00013169821,5.5539925e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087176904,0.0014898784,0.87534446,0.000011912141,0.0025918535,0.00042645112,0.003076285,0.000013335569,0.000103685714,0.0000024220283,0.00007324561,0.115994714],"study_design_scores_gemma":[0.01200901,0.0033755593,0.9808117,0.00008399706,0.0025712338,0.00013422658,0.00034584236,0.000014317236,0.0001258538,0.000008044755,0.00047573258,0.000044482935],"about_ca_topic_score_codex":0.002834208,"about_ca_topic_score_gemma":0.0020152659,"teacher_disagreement_score":0.115950234,"about_ca_system_score_codex":0.00020188643,"about_ca_system_score_gemma":0.00023425343,"threshold_uncertainty_score":0.42844936},"labels":[],"label_agreement":null},{"id":"W2000529260","doi":"10.1016/j.ejca.2012.02.032","title":"AOS15 Assessment of cognitive function in patients with breast and colon cancers undergoing chemotherapy: Results from an exploratory pilot study","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Cognition; Chemotherapy; Montreal Cognitive Assessment; Cancer; Internal medicine; Adjuvant chemotherapy; Oncology; Physical therapy; Cognitive impairment; Psychiatry","score_opus":0.024737032838185655,"score_gpt":0.3008706282481424,"score_spread":0.27613359540995674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000529260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975152,0.00065445795,0.00008237692,0.00016715859,0.00029510068,0.0004938006,0.00007551327,0.000008146263,0.0007082548],"genre_scores_gemma":[0.99906397,0.00022460148,0.0000494751,0.00026415472,0.00032053413,0.0000070784386,0.000009421217,0.000039223156,0.000021555112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983547,0.0003517317,0.0004861287,0.00016895807,0.0004449847,0.00019352914],"domain_scores_gemma":[0.99847466,0.00012208315,0.0006099585,0.00009040996,0.0005508882,0.00015200429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068008585,0.00016523224,0.00035928402,0.0001587995,0.000049379792,0.000010834171,0.0000437565,0.000011861108,0.00004080273],"category_scores_gemma":[0.000056522036,0.0001266428,0.000024210096,0.00018116475,0.00009262718,0.00037866586,0.00002707386,0.00027423998,7.4396416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022406533,0.0015783862,0.95450145,0.000017862549,0.0008222826,0.000019011048,0.0060313893,0.000046329144,0.00015041986,3.8518826e-7,0.00014131854,0.014284644],"study_design_scores_gemma":[0.029010585,0.018169051,0.9440303,0.0012766555,0.0005054472,0.0000043495224,0.0067707584,0.000005869381,0.00005097571,0.0000010001398,0.000055295317,0.00011974535],"about_ca_topic_score_codex":0.00015488215,"about_ca_topic_score_gemma":0.00054344063,"teacher_disagreement_score":0.016590666,"about_ca_system_score_codex":0.00040979264,"about_ca_system_score_gemma":0.00026886316,"threshold_uncertainty_score":0.5164344},"labels":[],"label_agreement":null},{"id":"W2002569247","doi":"10.1016/j.ejca.2006.01.046","title":"Neural stem cells as novel cancer therapeutic vehicles","year":2006,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neurogenesis and neuroplasticity mechanisms","field":"Neuroscience","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Neural stem cell; Stem cell; Progenitor cell; Neuroscience; Cancer stem cell; Biology; Cancer research; Cell biology","score_opus":0.12788277590015704,"score_gpt":0.34510349293864634,"score_spread":0.2172207170384893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002569247","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012760729,0.99265426,0.00011104275,0.00007776146,0.0044914032,0.00034481392,0.00015114578,0.000044964025,0.0008485399],"genre_scores_gemma":[0.0018545025,0.9923273,0.000016173577,0.0011904127,0.0016275238,0.000011423167,4.5427325e-7,0.00029903685,0.0026732003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994921,0.0014292818,0.0014688994,0.000641281,0.0009668806,0.0005726395],"domain_scores_gemma":[0.996514,0.00043981711,0.0022186826,0.00039729217,0.00015971572,0.00027045573],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004808222,0.000713816,0.001588044,0.00033007827,0.00018216265,0.00021990106,0.0013238754,0.00008211269,0.00018797547],"category_scores_gemma":[0.000035276877,0.00051540724,0.00095811964,0.0005003556,0.00012292917,0.0001987928,0.00017253906,0.0010375018,0.00016456687],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035688437,0.000120580444,8.474326e-7,0.0012437523,0.000066259025,0.0012389467,0.000025554698,0.0002284656,0.058835287,0.00010750068,0.0012604386,0.93683666],"study_design_scores_gemma":[0.00043634194,0.00027772828,0.0000041020576,0.0031595374,0.00076762546,0.0006325659,0.000002709816,0.000019465011,0.058876865,0.0000026878047,0.93536466,0.00045571785],"about_ca_topic_score_codex":0.000011240539,"about_ca_topic_score_gemma":0.0000032589703,"teacher_disagreement_score":0.936381,"about_ca_system_score_codex":0.00014200101,"about_ca_system_score_gemma":0.0004733553,"threshold_uncertainty_score":0.99972975},"labels":[],"label_agreement":null},{"id":"W2003697347","doi":"10.1016/j.ejca.2014.07.011","title":"Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)","year":2014,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Ligue Contre le Cancer; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Pancreatic cancer; Event (particle physics); Randomized controlled trial; Clinical endpoint; Clinical trial; Delphi method; End point; Surrogate endpoint; Time point; Delphi; Medical physics; Cancer; Computer science; Internal medicine; Artificial intelligence","score_opus":0.48846869401526455,"score_gpt":0.5447201828328915,"score_spread":0.05625148881762693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003697347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000576295,0.9040046,0.0145961745,0.02756691,0.0015289475,0.029899407,0.018469078,0.000016499982,0.0033421083],"genre_scores_gemma":[0.000779718,0.9816501,0.0076161567,0.001118124,0.0021482557,0.0048730765,0.00019173234,0.00016666364,0.0014561719],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9858807,0.0048839385,0.0072942604,0.0004840875,0.0008721695,0.0005848704],"domain_scores_gemma":[0.9778193,0.012953029,0.0060314713,0.0005930779,0.002381691,0.00022143198],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.037048683,0.00053478807,0.006420433,0.0006999985,0.00012918716,0.000025957957,0.00072445587,0.0001575798,0.00091102015],"category_scores_gemma":[0.02611384,0.0002883691,0.0016973646,0.00062625646,0.0001759597,0.00006849114,0.00014288047,0.0006098862,0.000011463119],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006714756,0.0006153184,0.00014155102,0.009504578,0.0037960578,0.000015079388,0.0007412597,0.0011514871,0.00012988594,0.0001884919,0.09920326,0.87779826],"study_design_scores_gemma":[0.016813144,0.0032679841,0.0011605507,0.07177584,0.010008909,0.000024930952,0.00015879975,0.0009908186,0.00008773598,0.00033361284,0.89498,0.00039766874],"about_ca_topic_score_codex":0.00022596747,"about_ca_topic_score_gemma":0.00038277113,"teacher_disagreement_score":0.87740064,"about_ca_system_score_codex":0.0011965438,"about_ca_system_score_gemma":0.005563607,"threshold_uncertainty_score":0.99995685},"labels":[],"label_agreement":null},{"id":"W2003859804","doi":"10.1016/j.ejca.2010.06.126","title":"Interconversion of three measures of performance status: An empirical analysis","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Performance status; Medicine; Palliative care; Internal medicine; Scale (ratio); Karnofsky Performance Status; Cancer; Oncology; Physical therapy; Nursing","score_opus":0.04457647345240062,"score_gpt":0.321629670671136,"score_spread":0.2770531972187354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003859804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947203,0.00097354443,0.0007289286,0.00021994954,0.0005483293,0.000036366964,0.000009637197,0.0000045345496,0.0027584175],"genre_scores_gemma":[0.9988686,0.0003792521,0.00024550184,0.00011248697,0.00029642697,2.3754096e-7,0.0000017854513,0.000015615185,0.00008009894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987319,0.000101674996,0.00047482157,0.00009626151,0.00046708883,0.00012826509],"domain_scores_gemma":[0.99845487,0.000020754664,0.00042196712,0.00023308214,0.00069100753,0.00017833557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007290477,0.000091294,0.0003870079,0.00026774313,0.000018197736,0.0000060599777,0.0001608901,0.000024056053,0.0005967009],"category_scores_gemma":[0.000051161212,0.00006657293,0.00025319395,0.00036111262,0.00010319963,0.00013301807,0.000027381719,0.00034820515,0.0000020558998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000971592,0.00008997546,0.8481744,0.00008144817,0.00061003905,0.000027401278,0.0026552747,0.00008717515,0.024668902,0.0000044562416,0.0003377849,0.12229158],"study_design_scores_gemma":[0.0012364247,0.0012075523,0.93979836,0.00019924506,0.0012746705,0.000022680499,0.00062006025,0.00025533888,0.019028274,0.0000038033008,0.036253326,0.00010028483],"about_ca_topic_score_codex":0.000120085744,"about_ca_topic_score_gemma":0.0017064713,"teacher_disagreement_score":0.122191295,"about_ca_system_score_codex":0.000033039414,"about_ca_system_score_gemma":0.00016809502,"threshold_uncertainty_score":0.65334564},"labels":[],"label_agreement":null},{"id":"W2004973733","doi":"10.1016/j.ejca.2009.11.007","title":"The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Docetaxel; Oncology; Internal medicine; Cohort; Prednisone; Mitoxantrone; Enzalutamide; Chemotherapy; Cancer; Androgen receptor","score_opus":0.03458361840161109,"score_gpt":0.3294753051642432,"score_spread":0.2948916867626321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004973733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949806,0.0025854844,0.0002983746,0.00121801,0.00006035771,0.0004696739,0.0000794964,0.0000035543655,0.00030448992],"genre_scores_gemma":[0.9958601,0.0020874674,0.0017651971,0.0000340313,0.0000647095,0.000010863624,0.0000057408097,0.000020173986,0.00015170833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984571,0.00023675099,0.0005065515,0.000132639,0.00045149832,0.00021549303],"domain_scores_gemma":[0.9987061,0.00029278445,0.00047870394,0.000103525184,0.0002963541,0.00012252083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013793326,0.0001444615,0.00029201506,0.00011661811,0.0001360329,0.000027921918,0.000085506035,0.000009634389,0.000013200099],"category_scores_gemma":[0.00011786145,0.00007061288,0.000052725998,0.00015514312,0.00007596551,0.000058939728,0.000009096752,0.00022212381,2.1857741e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053040434,0.0007070221,0.5642995,0.00023643747,0.0011903946,0.00031965345,0.011955692,0.006259535,0.00533453,0.000040040297,0.00058958295,0.35602716],"study_design_scores_gemma":[0.010414774,0.0024092323,0.97641134,0.00050919823,0.0002465037,0.0000028954498,0.0010465475,0.00045250423,0.0062919254,0.000042064483,0.0020570557,0.00011596995],"about_ca_topic_score_codex":0.00006648948,"about_ca_topic_score_gemma":0.00086308474,"teacher_disagreement_score":0.41211182,"about_ca_system_score_codex":0.00016819032,"about_ca_system_score_gemma":0.00059760234,"threshold_uncertainty_score":0.28795096},"labels":[],"label_agreement":null},{"id":"W2005040756","doi":"10.1016/j.ejca.2014.02.021","title":"The risk of traumatic lumbar punctures in children with acute lymphoblastic leukaemia","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Traumatic Brain Injury and Neurovascular Disturbances","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Institute for Clinical Evaluative Sciences; SickKids Foundation; University of Toronto","funders":"","keywords":"Medicine; Odds ratio; Lumbar; Confidence interval; Logistic regression; Percentile; Body mass index; Cohort; Internal medicine; Retrospective cohort study; Surgery; Pediatrics","score_opus":0.0077990826936231985,"score_gpt":0.2365618574461943,"score_spread":0.2287627747525711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005040756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944581,0.002778424,0.00048628272,0.0003043101,0.00013235716,0.00013556717,0.0000037523362,0.000006038176,0.0016952059],"genre_scores_gemma":[0.99790514,0.001296897,0.00028525593,0.00016846039,0.00020869124,0.0000017158732,4.6909236e-7,0.000024994724,0.00010837047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984116,0.00044682028,0.0005011452,0.00010439841,0.0003795679,0.00015649508],"domain_scores_gemma":[0.99892426,0.00012245418,0.000536802,0.00023437318,0.000099341036,0.000082754064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010748119,0.000131901,0.00034287813,0.00006928824,0.000061407656,0.000018450366,0.000217121,0.000014568323,0.000030553936],"category_scores_gemma":[0.00019511391,0.000063458734,0.00014991037,0.00014691797,0.00016340932,0.00006135114,0.000013989655,0.0002803669,0.000003928771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021008875,0.00029678844,0.6011966,0.00019113999,0.00458331,0.00020442402,0.0028947114,0.0023513583,0.0020974572,0.0002860971,0.0041154535,0.37968177],"study_design_scores_gemma":[0.002833042,0.0007662449,0.9922264,0.00044613806,0.0006328572,0.0004376331,0.000055414464,0.000054325432,0.0008122843,0.00005029831,0.0016103779,0.00007498399],"about_ca_topic_score_codex":0.00001208298,"about_ca_topic_score_gemma":0.00003403268,"teacher_disagreement_score":0.3910298,"about_ca_system_score_codex":0.000031718828,"about_ca_system_score_gemma":0.00009512615,"threshold_uncertainty_score":0.2587772},"labels":[],"label_agreement":null},{"id":"W2005399143","doi":"10.1016/s0959-8049(03)00315-0","title":"Assessing the evidence for organised cancer screening programmes","year":2003,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto","funders":"","keywords":"Cancer screening; Cancer; Medicine; Family medicine; Breast cancer screening; MEDLINE; Breast cancer; Political science; Mammography","score_opus":0.4622656887967518,"score_gpt":0.534426221554781,"score_spread":0.07216053275802925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005399143","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027757198,0.9928086,0.0035453711,0.0008515659,0.0010134403,0.000946132,0.0000128105385,0.000020838334,0.00077351957],"genre_scores_gemma":[0.00015300656,0.9900069,0.0048962208,0.00094435137,0.0029633788,0.00005666992,0.0000032167038,0.00014762396,0.00082858006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625367,0.0007022567,0.0013650225,0.0003463134,0.0008244658,0.000508302],"domain_scores_gemma":[0.99577206,0.0004452891,0.0021359262,0.00038458026,0.0009995025,0.00026262086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00324893,0.00046739329,0.0016724077,0.00016109305,0.00025566877,0.00033948867,0.00063365244,0.00008678314,0.0002229049],"category_scores_gemma":[0.0007961094,0.00026277246,0.0010689921,0.0005471727,0.00013276013,0.0004379376,0.0000663389,0.0010040875,0.000008225999],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061590465,0.000014184831,0.0001733082,0.0033353372,0.00054303766,0.0001907506,0.00009026014,0.00001315964,0.000004112753,0.000007313473,0.009587442,0.9859795],"study_design_scores_gemma":[0.0005994653,0.0002692645,0.0001592282,0.10315862,0.0040962365,0.0005350175,0.000147516,0.000004738216,0.0000066346897,0.0000030152132,0.8907714,0.00024888976],"about_ca_topic_score_codex":0.000031483123,"about_ca_topic_score_gemma":0.000009806145,"teacher_disagreement_score":0.9857306,"about_ca_system_score_codex":0.00041885686,"about_ca_system_score_gemma":0.002277123,"threshold_uncertainty_score":0.9999825},"labels":[],"label_agreement":null},{"id":"W2007064863","doi":"10.1016/j.ejca.2010.06.004","title":"Prognostic impact of adenomatous polyposis coli gene expression in osteosarcoma of the extremities","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Wnt/β-catenin signaling in development and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunohistochemistry; Osteosarcoma; Adenomatous polyposis coli; Internal medicine; Oncology; Pathological; Chemotherapy; Wnt signaling pathway; Cadherin; Colorectal cancer; Beta-catenin; Pathology; Cancer; Gene; Biology","score_opus":0.008496115129854716,"score_gpt":0.25135726068920916,"score_spread":0.24286114555935445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007064863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99519604,0.0037471126,0.000032208744,0.000054760156,0.0003185692,0.00007455288,0.000010843429,0.0000011929706,0.00056471064],"genre_scores_gemma":[0.9987873,0.00025904595,0.00047717732,0.00002372925,0.00021816722,0.000002034259,0.0000013595932,0.00001968103,0.00021149541],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990656,0.00012594208,0.00040307606,0.00009055376,0.00018685118,0.0001280252],"domain_scores_gemma":[0.9991284,0.000014162783,0.000461247,0.00016218942,0.00018922907,0.000044757042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033413153,0.00010191528,0.00016248813,0.000052087198,0.000023809727,0.000008178493,0.00033910212,0.00003582376,0.00007853629],"category_scores_gemma":[0.00007640522,0.00006427125,0.000156678,0.000090025176,0.00010601634,0.000005797314,0.000085183354,0.00015771648,4.8060355e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000125513,0.000028175371,0.18224856,0.000011481347,0.000042112482,0.0000055196447,0.0001846642,0.00010988598,0.81444573,8.1626786e-7,0.0008849007,0.001912648],"study_design_scores_gemma":[0.00044861907,0.00014808594,0.31961158,0.00013691705,0.000016405515,0.000021392962,0.00003072971,0.0000020280063,0.6787398,0.0000054488128,0.0007773415,0.0000616505],"about_ca_topic_score_codex":0.000014714511,"about_ca_topic_score_gemma":0.000015657777,"teacher_disagreement_score":0.137363,"about_ca_system_score_codex":0.000016026856,"about_ca_system_score_gemma":0.00024070196,"threshold_uncertainty_score":0.26209053},"labels":[],"label_agreement":null},{"id":"W2007748703","doi":"10.1016/j.ejca.2006.08.037","title":"Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy","year":2006,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostatectomy; Urology; Biochemical recurrence; Medicine; Body mass index; Index (typography); Internal medicine; Prostate cancer; Computer science; Cancer","score_opus":0.006898182547442744,"score_gpt":0.258767344388843,"score_spread":0.2518691618414003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007748703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827473,0.0028428813,0.00024325454,0.011906498,0.0006821172,0.0006003626,0.000117681295,0.000018216037,0.0008416518],"genre_scores_gemma":[0.996678,0.00034110594,0.0003114135,0.0010526638,0.0012718323,0.000056961188,0.00000262041,0.000030937896,0.00025444845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820954,0.00016157392,0.00057141966,0.00025706342,0.0005053544,0.00029507495],"domain_scores_gemma":[0.9988609,0.00006486063,0.0002366462,0.0002896737,0.00029110644,0.00025681578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064915896,0.00019207831,0.00029919445,0.000059035152,0.00005133803,0.000049014612,0.00018461695,0.00002760782,0.00017660165],"category_scores_gemma":[0.000095896416,0.00009397522,0.00017004758,0.00014212551,0.00017886897,0.000081915096,0.00005455255,0.00039778405,0.000016695412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0088971695,0.00097299437,0.7103466,0.00028575046,0.00040437543,0.0019592887,0.0005162138,0.00007839622,0.1587536,0.000040357165,0.029410174,0.08833512],"study_design_scores_gemma":[0.0033030154,0.0011962269,0.8045888,0.00055344676,0.00022440749,0.00006202651,0.000031514697,0.00002429724,0.12484998,0.00009512993,0.06488592,0.00018520796],"about_ca_topic_score_codex":0.00003345942,"about_ca_topic_score_gemma":0.000004447034,"teacher_disagreement_score":0.09424227,"about_ca_system_score_codex":0.0002931456,"about_ca_system_score_gemma":0.00021679795,"threshold_uncertainty_score":0.38321984},"labels":[],"label_agreement":null},{"id":"W2007861643","doi":"10.1016/s0959-8049(02)00039-4","title":"Regulation Of B16F1 melanoma cell metastasis by inducible functions of the hepatic microvasculature","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Lipopolysaccharide; Cytotoxic T cell; Melanoma; Immunohistochemistry; VCAM-1; Cell adhesion molecule; Flow cytometry; Nitric oxide synthase; Apoptosis; Chemistry; Nitric oxide; Cancer research; Pathology; Molecular biology; Endocrinology; Medicine; Biology; ICAM-1; Immunology; In vitro; Biochemistry","score_opus":0.009618997858106522,"score_gpt":0.20872720777907924,"score_spread":0.19910820992097272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007861643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9339833,0.061208278,0.00037069002,0.00024873164,0.001152251,0.00007904886,0.000056578065,0.0000015087162,0.0028995941],"genre_scores_gemma":[0.99207485,0.0031092921,0.000214193,0.00009511699,0.00067659194,8.4601066e-7,0.0000042662623,0.000020424448,0.0038044334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999046,0.00019548216,0.00035658551,0.00010890817,0.0001905165,0.000102500766],"domain_scores_gemma":[0.9989408,0.0000059899335,0.0005090944,0.000267667,0.00022949443,0.000046928733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029481485,0.000095296804,0.00018173618,0.00004155988,0.000039757313,0.0000069794314,0.00019863312,0.000034795117,0.0001722399],"category_scores_gemma":[0.000032371347,0.000067310735,0.00024603365,0.00013843508,0.000065255575,0.0000070915494,0.000040339182,0.00012087993,0.0000018794592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033829467,0.000051340437,0.00051248714,0.000022253986,0.00013794353,2.772836e-7,0.00011451204,0.00029270625,0.91925794,0.000002245345,0.06690949,0.0126649905],"study_design_scores_gemma":[0.00066381216,0.00011806305,0.01274738,0.00003525563,0.00018757264,0.000013948344,0.000040689538,0.0000073933866,0.5366277,0.0000033522415,0.44948503,0.00006979007],"about_ca_topic_score_codex":0.000015213672,"about_ca_topic_score_gemma":0.00001385158,"teacher_disagreement_score":0.38263023,"about_ca_system_score_codex":0.000011057133,"about_ca_system_score_gemma":0.000043999804,"threshold_uncertainty_score":0.2744852},"labels":[],"label_agreement":null},{"id":"W2009620636","doi":"10.1016/j.ejca.2008.11.013","title":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Psychosocial; Quality of life (healthcare); Medicine; Cancer; Physical therapy; Family medicine; Nursing; Internal medicine; Psychiatry","score_opus":0.10877984842482596,"score_gpt":0.39261326297394533,"score_spread":0.28383341454911937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009620636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868632,0.0066441474,0.0011063296,0.0032548911,0.000120252495,0.0014249013,0.00013636473,0.0000052512037,0.00044464177],"genre_scores_gemma":[0.9965309,0.0018910952,0.00067200075,0.00010516492,0.0002156245,0.000029108978,0.000008336358,0.00003944448,0.000508329],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973612,0.0009492518,0.0007028213,0.0001365804,0.0006722569,0.00017787897],"domain_scores_gemma":[0.9972657,0.00031147982,0.0007865894,0.00025209758,0.0012465145,0.00013759299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033203273,0.00012228619,0.0003322433,0.00008298846,0.00022358379,0.000016224978,0.0001282797,0.0000067854976,0.000028251054],"category_scores_gemma":[0.0005148684,0.000058808222,0.000103113576,0.000120457495,0.0003275248,0.00007534748,0.000027279784,0.00008278867,6.7052963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03166484,0.0036102592,0.4998353,0.001487353,0.0044441684,0.00007888422,0.010837468,0.0002018677,0.0009591053,0.0009904501,0.023648016,0.42224225],"study_design_scores_gemma":[0.012874576,0.005107438,0.9480712,0.000354868,0.00073523086,0.0000043409095,0.0010894465,0.000031678952,0.00036957534,0.00006232688,0.031191586,0.00010775025],"about_ca_topic_score_codex":0.00007023187,"about_ca_topic_score_gemma":0.00006360203,"teacher_disagreement_score":0.44823587,"about_ca_system_score_codex":0.000094133,"about_ca_system_score_gemma":0.0002944541,"threshold_uncertainty_score":0.23981297},"labels":[],"label_agreement":null},{"id":"W2010480908","doi":"10.1016/j.ejca.2013.12.005","title":"Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research; SickKids Foundation; University of Toronto; Public Health Ontario; Hospital for Sick Children; Mount Sinai Hospital","funders":"","keywords":"Medicine; Lynch syndrome; DNA mismatch repair; Asymptomatic; Microsatellite instability; Genetic testing; Cancer; Asymptomatic carrier; Immunohistochemistry; Germline mutation; Germline; Internal medicine; Oncology; Mutation; Gene; Colorectal cancer; Genetics; Microsatellite; Biology; Allele","score_opus":0.02935354911449617,"score_gpt":0.3149319415972027,"score_spread":0.28557839248270656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010480908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98206234,0.008893269,0.0014664131,0.0005094458,0.0020451632,0.00028127234,0.00005076935,0.000039503655,0.0046518133],"genre_scores_gemma":[0.9917815,0.0006775834,0.006281643,0.0005454021,0.00051059603,0.0000037951147,0.0000030033473,0.00002308937,0.00017342775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955903,0.000594347,0.0020924779,0.00044663958,0.0009496001,0.0003266168],"domain_scores_gemma":[0.99639344,0.000661198,0.0013054442,0.0005309916,0.0008080303,0.00030090098],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0027124542,0.0002672002,0.0007219616,0.000090380956,0.00017822348,0.000023554456,0.00030793765,0.0000884653,0.00036142734],"category_scores_gemma":[0.0020314367,0.00018427245,0.00045127468,0.000197253,0.0042218296,0.00007646704,0.0001248425,0.0005369618,0.000015615264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033815953,0.00019183525,0.9844241,0.00007885673,0.00016762523,0.001906657,0.00014407394,0.00012576896,0.0005721456,0.00025631062,0.0062535494,0.0055408822],"study_design_scores_gemma":[0.0021006418,0.00092760223,0.9597978,0.00063949,0.00057473214,0.013874314,0.00009924507,0.00033270367,0.00026451662,0.00011245656,0.021053007,0.0002234827],"about_ca_topic_score_codex":0.00004935926,"about_ca_topic_score_gemma":0.00002350349,"teacher_disagreement_score":0.024626326,"about_ca_system_score_codex":0.00011093802,"about_ca_system_score_gemma":0.0015127079,"threshold_uncertainty_score":0.9984881},"labels":[],"label_agreement":null},{"id":"W2011502763","doi":"10.1016/j.ejca.2009.06.016","title":"Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Urology; Proportional hazards model; Urothelial carcinoma; Cohort; Internal medicine; Population; Stage (stratigraphy); Overall survival; Epidemiology; Gastroenterology; Cancer; Oncology; Surgery; Bladder cancer","score_opus":0.019357697360852136,"score_gpt":0.2859462039685234,"score_spread":0.26658850660767125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011502763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99772507,0.0009320283,0.0000023463847,0.00019890834,0.000104737876,0.0006527386,0.000028621733,0.000002641519,0.00035289425],"genre_scores_gemma":[0.999392,0.000087002714,0.00007082688,0.00025159158,0.00015365986,0.000005349598,0.0000058509663,0.000017778344,0.000015985865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847263,0.0003216363,0.0005510306,0.00013372146,0.0003878965,0.00013310555],"domain_scores_gemma":[0.9991854,0.000063607346,0.00039087763,0.0001525285,0.00013598983,0.00007161602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016527307,0.00017066712,0.00041041136,0.00015954727,0.000030354997,0.000010671429,0.00009279716,0.000018452032,0.00004877045],"category_scores_gemma":[0.000017033517,0.00010120617,0.00012734892,0.00013750716,0.000025711208,0.000073060735,0.0000046082364,0.000105796535,4.4506942e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015592095,0.0033199536,0.9653493,0.00001858646,0.000119809396,0.0001326403,0.007207271,0.000023761522,0.00050594815,5.6608553e-7,0.000031553293,0.021731375],"study_design_scores_gemma":[0.01856026,0.017950812,0.96064985,0.00013584456,0.00034592807,0.000019240353,0.000579058,0.0000041357894,0.0014978581,0.0000040352147,0.00017856661,0.00007439137],"about_ca_topic_score_codex":0.0002837967,"about_ca_topic_score_gemma":0.00006800487,"teacher_disagreement_score":0.021656983,"about_ca_system_score_codex":0.00014840356,"about_ca_system_score_gemma":0.000126735,"threshold_uncertainty_score":0.4127068},"labels":[],"label_agreement":null},{"id":"W2012062001","doi":"10.1016/j.ejca.2005.07.008","title":"Getting there? Salvage therapy for refractory Langerhans cell histiocytosis in children","year":2005,"lang":"en","type":"editorial","venue":"European Journal of Cancer","topic":"Histiocytic Disorders and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Langerhans cell histiocytosis; Histiocyte; Histiocytosis; Medicine; Salvage therapy; Refractory (planetary science); Pediatrics; Natural history; Disease; Quality of life (healthcare); Surgery; Chemotherapy; Internal medicine; Pathology","score_opus":0.010045016844008792,"score_gpt":0.28496198151380564,"score_spread":0.27491696466979687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012062001","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.117478974,0.1968308,0.00019058952,0.0011922432,0.6446109,0.001711418,0.00070469896,0.000063367894,0.03721701],"genre_scores_gemma":[0.05339845,0.020680575,0.00090514537,0.0003078609,0.9127533,0.000018382965,0.000142207,0.0002545452,0.011539562],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813795,0.0001502801,0.00065290736,0.00023742764,0.00054501306,0.00027640775],"domain_scores_gemma":[0.9984135,0.00015348583,0.00078866904,0.00021284213,0.00029925926,0.00013225568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006193683,0.00029495408,0.0006307574,0.00022108947,0.00005327028,0.000028459866,0.00021804163,0.00013483418,0.00019116183],"category_scores_gemma":[0.00015848377,0.00022513197,0.00030656252,0.00008416665,0.000038993854,0.00006787275,0.00001734051,0.00074106525,0.00001910391],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006744423,0.00037728847,0.0021046237,0.000058025344,0.0003726679,0.00017319807,0.00032767918,0.0000147519095,0.00012767017,2.8942432e-7,0.88124067,0.1145287],"study_design_scores_gemma":[0.009386786,0.00086564367,0.006913113,0.0006603218,0.00029685398,0.00000931721,0.00002481347,0.0000022327645,0.00008617559,0.0000026633475,0.98155034,0.00020171625],"about_ca_topic_score_codex":0.00006183115,"about_ca_topic_score_gemma":0.000026056257,"teacher_disagreement_score":0.26814237,"about_ca_system_score_codex":0.000566855,"about_ca_system_score_gemma":0.0006108304,"threshold_uncertainty_score":0.91806155},"labels":[],"label_agreement":null},{"id":"W2013625307","doi":"10.1016/j.ejca.2009.08.015","title":"Expert opinion in melanoma: The sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden","year":2009,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Sentinel node; Melanoma; Expert opinion; Oncology; Metastatic melanoma; Radiology; Internal medicine; Cancer; Cancer research; Intensive care medicine","score_opus":0.1538227929473301,"score_gpt":0.3977626728891432,"score_spread":0.2439398799418131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013625307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007631428,0.98799086,0.0005382726,0.007937214,0.001066106,0.0010807293,0.000020769834,0.0000041745107,0.0005987181],"genre_scores_gemma":[0.031657826,0.9663205,0.0013249791,0.00029076668,0.0002660326,0.000013197557,0.000004357174,0.00004405249,0.00007829377],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99396557,0.0036472704,0.0014666149,0.00019129964,0.00058410846,0.00014514147],"domain_scores_gemma":[0.99617094,0.00042501334,0.002533294,0.0003998851,0.00041827868,0.00005259324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004064658,0.0002449035,0.0011259405,0.00025955169,0.00005643525,0.000011213022,0.00030559668,0.00003610407,0.000047776055],"category_scores_gemma":[0.0007890459,0.00011632159,0.00038578926,0.00045355168,0.00014326209,0.000041338826,0.000105276995,0.00052391813,0.0000010726737],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055770396,0.0004986965,0.000046717298,0.0046502603,0.0021699579,0.000049079154,0.0010040696,0.00010003322,0.0011984521,0.00050998956,0.007843472,0.9813716],"study_design_scores_gemma":[0.0014441805,0.000492719,0.0016251398,0.015368582,0.00271783,0.0011415348,0.0006612635,0.000028579803,0.00061463146,0.000030561077,0.9757147,0.00016029147],"about_ca_topic_score_codex":0.000059212594,"about_ca_topic_score_gemma":0.00004104436,"teacher_disagreement_score":0.9812113,"about_ca_system_score_codex":0.00019616373,"about_ca_system_score_gemma":0.00035397857,"threshold_uncertainty_score":0.47434568},"labels":[],"label_agreement":null},{"id":"W2014323633","doi":"10.1016/j.ejca.2004.03.026","title":"Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Temozolomide; Radiation therapy; Glioblastoma; Clinical trial; Cancer; Quality assurance; Nuclear medicine; Oncology; Internal medicine; Pathology","score_opus":0.04734254800440533,"score_gpt":0.3553929297454607,"score_spread":0.30805038174105537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014323633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97250384,0.014344713,0.00024371243,0.010156635,0.0005358347,0.0020340986,0.00005842987,0.000011398227,0.00011132057],"genre_scores_gemma":[0.99030155,0.004832284,0.0011674905,0.0028012055,0.00069186476,0.000066431356,0.0000013660951,0.0000602403,0.00007758707],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99743146,0.00050455605,0.0009632277,0.00021176456,0.00063720933,0.00025176155],"domain_scores_gemma":[0.9973133,0.0004237774,0.0012993466,0.00046218393,0.00035560332,0.0001457597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017426703,0.00027203013,0.00077493326,0.00007476591,0.00012475802,0.000030817515,0.00031913447,0.000029381075,0.000076083365],"category_scores_gemma":[0.00047329415,0.00010895808,0.0004114541,0.00028257543,0.00016637064,0.00009233878,0.000025079396,0.00031788647,0.000002566355],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40363863,0.0074838134,0.04408409,0.0030364783,0.008187302,0.014464902,0.0068814806,0.002378839,0.0032563864,0.00023374888,0.044147857,0.46220648],"study_design_scores_gemma":[0.6080782,0.05621122,0.102971226,0.046538632,0.004433696,0.014046021,0.0008732536,0.000026482952,0.024053093,0.000033225337,0.14179915,0.00093581475],"about_ca_topic_score_codex":0.00008306512,"about_ca_topic_score_gemma":0.00066042657,"teacher_disagreement_score":0.46127066,"about_ca_system_score_codex":0.0002223699,"about_ca_system_score_gemma":0.00043249392,"threshold_uncertainty_score":0.44431815},"labels":[],"label_agreement":null},{"id":"W2014342837","doi":"10.1016/j.ejca.2007.05.014","title":"Childhood and adolescent cancer survival: A period analysis of data from the Canadian Cancer Registry","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada; Statistics Canada","funders":"","keywords":"Cancer registry; Childhood cancer; Cancer; Period (music); Medicine; Demography; Oncology; Internal medicine","score_opus":0.07994073889819371,"score_gpt":0.361364959598227,"score_spread":0.2814242207000333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014342837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8744517,0.08091216,0.00033462117,0.03842083,0.0013720171,0.00031644502,0.0019943486,0.000019536468,0.0021783551],"genre_scores_gemma":[0.98529655,0.0061345333,0.00031263233,0.0054524536,0.002459557,0.000001708231,0.000045629044,0.000067379806,0.00022956687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652934,0.0004127229,0.0011553295,0.0004239659,0.0010305824,0.0004480564],"domain_scores_gemma":[0.99631584,0.00017746273,0.0011790608,0.0010870487,0.000546622,0.0006939481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034522754,0.00028081407,0.0009070934,0.00033024195,0.00018264387,0.00007053484,0.00089888053,0.000060489525,0.00077014195],"category_scores_gemma":[0.00030691366,0.00020328032,0.00025975436,0.0008493142,0.00028283717,0.00019644061,0.00017751347,0.0007467581,0.0000027830276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064256584,0.00017590093,0.87371194,0.000111784626,0.008104139,0.00038391637,0.007433852,0.00022618272,0.00036365914,0.000016239683,0.036322158,0.07250766],"study_design_scores_gemma":[0.0015518803,0.00007418156,0.8941393,0.0009868185,0.0036262865,0.00002254982,0.0011516423,0.000051938594,0.000096431235,0.000004069137,0.09809737,0.00019755165],"about_ca_topic_score_codex":0.2590122,"about_ca_topic_score_gemma":0.8195907,"teacher_disagreement_score":0.56057847,"about_ca_system_score_codex":0.0004111389,"about_ca_system_score_gemma":0.002127027,"threshold_uncertainty_score":0.84325147},"labels":[],"label_agreement":null},{"id":"W2014930386","doi":"10.1016/j.ejca.2007.09.022","title":"Prostate volume and adverse prostate cancer features: Fact not artifact","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate cancer; Medicine; Finasteride; Prostatectomy; Prostate; Urology; Biopsy; Cancer; Stage (stratigraphy); Prostate biopsy; Oncology; Internal medicine","score_opus":0.01537478493973862,"score_gpt":0.2928504868440632,"score_spread":0.2774757019043246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014930386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707722,0.019572858,0.00003503332,0.0057539376,0.00066253555,0.00046768464,0.0000787697,0.00002645202,0.0026305083],"genre_scores_gemma":[0.97652674,0.015344939,0.0003463712,0.0016411429,0.0006257636,0.000009778182,0.00000448168,0.000066488334,0.005434288],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99818397,0.00008354637,0.00060081214,0.000254213,0.00045079069,0.00042667188],"domain_scores_gemma":[0.9984296,0.000039512877,0.00050262455,0.00018517279,0.00038485043,0.0004582137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080967654,0.0002568977,0.00042624687,0.0001578123,0.00009302269,0.000040217907,0.00009280687,0.000028821147,0.00029265348],"category_scores_gemma":[0.000049861785,0.00018124726,0.00015832209,0.00016063909,0.00011681036,0.000219365,0.000042211657,0.0003912689,0.000024946497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036154124,0.0002316004,0.39243668,0.00017628208,0.00068648305,0.0040718904,0.0036646652,0.00013089701,0.0057571726,0.000012397849,0.017525882,0.5716906],"study_design_scores_gemma":[0.0040372484,0.0011122808,0.7665464,0.0007468326,0.0003108556,0.00022835919,0.000258671,0.0000050027584,0.012801414,0.000007177928,0.21375367,0.00019206134],"about_ca_topic_score_codex":0.00008736377,"about_ca_topic_score_gemma":0.00008262513,"teacher_disagreement_score":0.5714986,"about_ca_system_score_codex":0.00032447677,"about_ca_system_score_gemma":0.00026627487,"threshold_uncertainty_score":0.7391049},"labels":[],"label_agreement":null},{"id":"W2017583298","doi":"10.1016/j.ejca.2010.02.047","title":"Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":146,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Ovarian cancer; Internal medicine; Chemotherapy; Oncology; Gastroenterology; Peripheral blood mononuclear cell; Toxicity; Histone deacetylase inhibitor; Cancer; Histone deacetylase; Histone; Biology; In vitro","score_opus":0.008189622384496985,"score_gpt":0.2791037541101149,"score_spread":0.2709141317256179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017583298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995656,0.0016810443,0.0000133137255,0.0011020357,0.00078569265,0.00031474815,0.00012766957,0.0000030938857,0.0003163793],"genre_scores_gemma":[0.99708146,0.00040524593,0.00028450502,0.00014076912,0.0013470437,0.000012865382,0.000003130374,0.000061990606,0.0006629885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977894,0.00039509684,0.00068808,0.00029208005,0.00045797107,0.0003773599],"domain_scores_gemma":[0.9984807,0.000023843879,0.0005846553,0.00036450257,0.00031969338,0.00022665363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013214189,0.00022741727,0.0003405,0.00013705002,0.0001587937,0.000027368753,0.0003778352,0.000076636716,0.000057590594],"category_scores_gemma":[0.00020550113,0.00015794131,0.00008202027,0.00020689351,0.00041460613,0.00001629569,0.0001918459,0.0006759664,8.932766e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047198564,0.00037269236,0.00014535603,0.000024487508,0.00007413491,0.000127848,0.00085814256,0.000031642532,0.9395157,0.000004821409,0.0018660079,0.009780573],"study_design_scores_gemma":[0.08020679,0.007369648,0.003807264,0.00029602987,0.00005834318,0.00011136899,0.00019475388,0.0000065263616,0.8352955,0.0000063489256,0.072312,0.00033544493],"about_ca_topic_score_codex":0.00014106314,"about_ca_topic_score_gemma":0.00077928253,"teacher_disagreement_score":0.10422024,"about_ca_system_score_codex":0.00012323304,"about_ca_system_score_gemma":0.00082720915,"threshold_uncertainty_score":0.644066},"labels":[],"label_agreement":null},{"id":"W2017845136","doi":"10.1016/j.ejca.2012.08.002","title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","year":2012,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer; Cancer Research UK; Amgen","keywords":"Zoledronic acid; Denosumab; Medicine; Oncology; Internal medicine; Osteoporosis","score_opus":0.12162885291070309,"score_gpt":0.46206584692694547,"score_spread":0.3404369940162424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017845136","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02164805,0.9744331,0.00032536229,0.000043681524,0.00045897285,0.0026637376,0.00033066765,0.000004593647,0.0000918364],"genre_scores_gemma":[0.081053905,0.9178425,0.00035637157,0.000014777932,0.00013924993,0.00004364039,0.00011306584,0.000069298214,0.00036721065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99274975,0.0017626793,0.0044897166,0.00019855883,0.00050981925,0.00028949356],"domain_scores_gemma":[0.9923673,0.00031270363,0.0058799554,0.00035346785,0.00071674894,0.00036980826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040913853,0.0003478859,0.0065810685,0.0008785068,0.00003140728,0.000003956283,0.00020311146,0.000105031555,0.00040803288],"category_scores_gemma":[0.00069409114,0.00023872025,0.0035076973,0.0008417058,0.00005209118,0.00008813456,0.000031415522,0.0002878996,0.0000044237113],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014738075,0.0019750874,0.00028738697,0.01507665,0.027940737,0.000022435504,0.00019197115,0.0000063071534,0.000114495386,0.0000058625815,0.00014354334,0.9394975],"study_design_scores_gemma":[0.2460473,0.0123617435,0.0015968718,0.04375776,0.34185475,0.000093457464,0.000041954456,0.000010863204,0.00041024602,0.000013406784,0.35334083,0.00047081473],"about_ca_topic_score_codex":0.000025593861,"about_ca_topic_score_gemma":0.00001574623,"teacher_disagreement_score":0.93902665,"about_ca_system_score_codex":0.0002424044,"about_ca_system_score_gemma":0.0008769388,"threshold_uncertainty_score":0.9734729},"labels":[],"label_agreement":null},{"id":"W2018014664","doi":"10.1016/j.ejca.2011.11.006","title":"Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gemcitabine; Medicine; Internal medicine; Deoxycytidine; Oncology; Nucleoside analogue; Gastroenterology; Retrospective cohort study; Confidence interval; Chemotherapy; Nucleoside; Biology","score_opus":0.009175890813785097,"score_gpt":0.23604291693834176,"score_spread":0.22686702612455667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018014664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337023,0.00037905356,0.005639547,0.0000678673,0.00007313217,0.0002290087,0.000044241096,0.000002761168,0.00019416434],"genre_scores_gemma":[0.9974252,0.000007219507,0.0018946584,0.0002803917,0.0001955339,0.000008438654,0.000009523089,0.000034367833,0.00014468336],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99909455,0.00012241404,0.0002954437,0.00017909818,0.00014528181,0.00016322854],"domain_scores_gemma":[0.9994014,0.0000045455954,0.00018777623,0.000121950594,0.00020351002,0.000080852165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023716479,0.00012635112,0.00014322667,0.00007451468,0.0000387691,0.000009472228,0.00015956082,0.000024812423,0.00008242899],"category_scores_gemma":[0.000017208169,0.0000957771,0.000078775265,0.000058016103,0.000023880948,0.000021225575,0.000028840788,0.000085970016,8.4019763e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055886764,0.00029759225,0.099573545,0.000020904823,0.00017942859,0.0001064523,0.004003261,0.00095345994,0.8314878,0.0000030583997,0.0051394305,0.0023483299],"study_design_scores_gemma":[0.0057788254,0.00529009,0.8271885,0.00019417758,0.000046085832,0.000003898819,0.000108285436,0.0000043964797,0.15810691,0.0000073502547,0.0030752139,0.00019624899],"about_ca_topic_score_codex":0.0000021281928,"about_ca_topic_score_gemma":0.000001024634,"teacher_disagreement_score":0.727615,"about_ca_system_score_codex":0.00001678559,"about_ca_system_score_gemma":0.00005059182,"threshold_uncertainty_score":0.39056766},"labels":[],"label_agreement":null},{"id":"W2018304470","doi":"10.1016/j.ejca.2012.02.059","title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Taiwan University; National Health and Medical Research Council; Queen's University; University of Bristol; Assistance publique-Hôpitaux de Paris; Queen's University Belfast; University of Nottingham; Universidade de São Paulo; University of Leeds; Cancer Research UK","keywords":"Quality of life (healthcare); Sample size determination; Attrition; Sample (material); Medicine; Core (optical fiber); Cancer; Psychology; Meta-analysis; Statistics; Computer science; Pathology; Mathematics; Psychotherapist; Internal medicine","score_opus":0.5597861126265973,"score_gpt":0.5052095467940746,"score_spread":0.05457656583252268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018304470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6353727,0.30980042,0.0154235205,0.034566525,0.0018200582,0.0027023498,0.0002094531,0.0000138671085,0.00009114385],"genre_scores_gemma":[0.9888351,0.0065059797,0.00029709653,0.00060560496,0.003511061,0.00010297322,0.0000023376892,0.00004257858,0.000097249365],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982302,0.0004199787,0.0006727571,0.00011681359,0.00035371314,0.00020652507],"domain_scores_gemma":[0.995167,0.0014702494,0.0006301379,0.00020510524,0.0024204687,0.00010700598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060820207,0.00012026402,0.00029714504,0.00007227871,0.00015687321,0.000019950823,0.00016258819,0.000017331477,0.000040894138],"category_scores_gemma":[0.0020619973,0.00006213985,0.00017296975,0.000096277465,0.00018825145,0.000112491936,0.000025684662,0.000092181544,3.232764e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061345473,0.00015253924,0.22750776,0.0010647686,0.0005006861,0.0000011805414,0.016407935,0.00009944345,0.005815199,0.00017194614,0.006625794,0.7355182],"study_design_scores_gemma":[0.009062152,0.0069984095,0.8411343,0.011500528,0.001340684,0.00000914914,0.008480393,0.0014724443,0.013928135,0.0000776418,0.105664745,0.00033143017],"about_ca_topic_score_codex":0.0009075374,"about_ca_topic_score_gemma":0.0010416287,"teacher_disagreement_score":0.73518676,"about_ca_system_score_codex":0.00015429842,"about_ca_system_score_gemma":0.0002805166,"threshold_uncertainty_score":0.25339895},"labels":[],"label_agreement":null},{"id":"W2018626410","doi":"10.1016/s0959-8049(02)80597-4","title":"Regulation and targets of receptor tyrosine kinases","year":2002,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Axon Guidance and Neuronal Signaling","field":"Neuroscience","cited_by":262,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Autophosphorylation; Cell biology; Receptor tyrosine kinase; Signal transduction; Phosphorylation; SH2 domain; Phosphotyrosine-binding domain; Receptor Protein-Tyrosine Kinases; Biology; Signal transducing adaptor protein; PDZ domain; Tyrosine phosphorylation; Chemistry; Protein kinase A","score_opus":0.10009625640199764,"score_gpt":0.3337335402007452,"score_spread":0.23363728379874754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018626410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023829566,0.9978516,0.000041685616,0.00006353981,0.00049598457,0.00011473712,0.000026698752,0.0000072800567,0.001160185],"genre_scores_gemma":[0.0014352213,0.9968629,0.000095801995,0.00009494297,0.0006752719,0.000001098204,7.289442e-7,0.000055947523,0.0007780935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766856,0.0006471939,0.0009202607,0.0002197474,0.0003855049,0.0001587014],"domain_scores_gemma":[0.9976981,0.00019226572,0.0017629274,0.00013805101,0.00011025792,0.00009838815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041355492,0.00022540595,0.00082697964,0.00017365313,0.00005861526,0.000028035356,0.0002853542,0.000034753015,0.00041936515],"category_scores_gemma":[0.00030991415,0.00016583042,0.00025283496,0.00023343926,0.00010933075,0.00016103835,0.000057323196,0.00032689655,0.000022990733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020298266,0.000025238633,0.000003546399,0.0013603552,0.000018561486,0.00007421661,0.00004129338,0.00001134131,0.0039544404,0.000040143266,0.0037064739,0.9907441],"study_design_scores_gemma":[0.00018984037,0.00017658169,0.000026922778,0.009088021,0.00016566785,0.000112217764,0.0000017120564,0.0000028208913,0.0027284136,0.000005821129,0.987354,0.0001479977],"about_ca_topic_score_codex":8.714008e-7,"about_ca_topic_score_gemma":1.7441877e-7,"teacher_disagreement_score":0.9905961,"about_ca_system_score_codex":0.000041131585,"about_ca_system_score_gemma":0.000070368435,"threshold_uncertainty_score":0.67623687},"labels":[],"label_agreement":null},{"id":"W2018788117","doi":"10.1016/j.ejca.2012.12.012","title":"Modifying phase I methodology to facilitate enrolment of molecularly selected patients","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Phase (matter); Medicine; Computer science; Chemistry; Organic chemistry","score_opus":0.05293073901550926,"score_gpt":0.30414980339931236,"score_spread":0.2512190643838031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018788117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670924,0.0015844168,0.030061033,0.00019981913,0.00029679484,0.00015118207,0.000039599054,0.0000018462468,0.00057292165],"genre_scores_gemma":[0.9909676,0.00036715763,0.0077507985,0.0005343813,0.00018577096,0.000005196694,0.000009389852,0.000025508698,0.00015421493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988156,0.0002597228,0.0004417394,0.00014786006,0.00015380682,0.00018126267],"domain_scores_gemma":[0.99853057,0.000025638059,0.00029407095,0.00016565008,0.0008300946,0.00015398905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036150246,0.00011670796,0.00020187978,0.00007486488,0.000024585928,0.000017429235,0.00021552375,0.000024969362,0.00007051288],"category_scores_gemma":[0.00033188457,0.00010462669,0.000094849005,0.00010053544,0.000031716714,0.000005425167,0.000084500636,0.000088110435,0.000011167178],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002710853,0.0001314658,0.001967387,0.00001473329,0.00015281294,0.000008238705,0.0003639408,0.0013434417,0.9204579,0.000007308301,0.0074262726,0.067855425],"study_design_scores_gemma":[0.008666721,0.007487189,0.05034011,0.000108806606,0.00014617524,0.000019099218,0.00015399532,0.00008545266,0.7483606,0.00007762471,0.18403147,0.0005228108],"about_ca_topic_score_codex":0.00005028265,"about_ca_topic_score_gemma":0.000007697613,"teacher_disagreement_score":0.1766052,"about_ca_system_score_codex":0.00002946103,"about_ca_system_score_gemma":0.000100276186,"threshold_uncertainty_score":0.42665526},"labels":[],"label_agreement":null},{"id":"W2018838342","doi":"10.1016/s0959-8049(01)00139-3","title":"Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Calcitriol receptor; Colorectal cancer; Oncogene; Genotype; Internal medicine; Cancer research; ErbB; Biology; Epidermal growth factor receptor; Endocrinology; Allele; Epidermal growth factor; Receptor; Gene expression; Vitamin D and neurology; Gene; Cancer; Medicine; Genetics; Cell cycle","score_opus":0.01679902674403124,"score_gpt":0.30176043656197465,"score_spread":0.28496140981794343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018838342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719335,0.024654262,0.0000061615465,0.0018563933,0.00009831928,0.00017152875,0.0000060072625,0.0000037323591,0.0012701057],"genre_scores_gemma":[0.97428596,0.024295663,0.0003564422,0.000079617654,0.00031148503,0.0000025064753,5.8054934e-7,0.000022184908,0.0006455683],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986377,0.00035177058,0.000380987,0.00014263121,0.00030255574,0.00018439892],"domain_scores_gemma":[0.9992553,0.00010912713,0.00023956134,0.00010629862,0.00016014835,0.00012959221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011202133,0.00012201926,0.00035785796,0.0001238652,0.000091179754,0.000017716795,0.00008945936,0.000021236125,0.00009127028],"category_scores_gemma":[0.0002618045,0.000071151204,0.000041947784,0.00012085191,0.0004922194,0.00009092832,0.00010720941,0.00030956915,8.137288e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036955045,0.00009068459,0.20544326,0.00027970748,0.00034170697,0.00028040816,0.01185427,0.000022131439,0.6607478,0.000034681678,0.014176773,0.10303305],"study_design_scores_gemma":[0.025095835,0.0027643414,0.8313081,0.0042565665,0.00026874224,0.00046731086,0.0051666927,0.000027658823,0.066478364,0.00006095341,0.06370638,0.00039900158],"about_ca_topic_score_codex":0.00008696329,"about_ca_topic_score_gemma":0.000058512676,"teacher_disagreement_score":0.62586486,"about_ca_system_score_codex":0.000084245905,"about_ca_system_score_gemma":0.000073538366,"threshold_uncertainty_score":0.2901462},"labels":[],"label_agreement":null},{"id":"W2019607817","doi":"10.1016/j.ejca.2008.10.026","title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":29472,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council","keywords":"Guideline; Response Evaluation Criteria in Solid Tumors; Medicine; Clinical trial; Clinical endpoint; Pathological; Disease; Target lesion; Progressive disease; Medical physics; Radiology; Pathology; Internal medicine","score_opus":0.07009081787729322,"score_gpt":0.4234162029133073,"score_spread":0.3533253850360141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019607817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82296956,0.004322436,0.02335219,0.13905787,0.0005033322,0.00062846823,0.0000074642016,0.000066849905,0.009091849],"genre_scores_gemma":[0.926128,0.0017199174,0.06467466,0.0029535445,0.0012257062,0.0000036500453,0.000007973092,0.00003719671,0.0032493768],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981853,0.0004163523,0.0006670492,0.000112545946,0.00049921486,0.000119532335],"domain_scores_gemma":[0.9987555,0.000040817733,0.00028861838,0.00018967247,0.00051861646,0.00020674798],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033387959,0.00008292982,0.00021466146,0.00015313269,0.000040237184,0.000009398826,0.00013044693,0.00001668993,0.0015077973],"category_scores_gemma":[0.00095445727,0.000065861495,0.00007599971,0.00020491303,0.000041632615,0.00007932893,0.000024727206,0.00025499953,0.000028343222],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012664587,0.000052432766,0.0008516481,0.000007820003,0.0000115541425,0.0003499516,0.00021493294,0.000018464705,0.048340157,0.000002943797,0.891074,0.057809617],"study_design_scores_gemma":[0.0045747026,0.00048578277,0.056700025,0.0013529559,0.00013741622,0.0006913028,0.000041868057,0.0017048573,0.006503518,0.00005528775,0.9276159,0.00013641448],"about_ca_topic_score_codex":0.000023092012,"about_ca_topic_score_gemma":0.0000012247381,"teacher_disagreement_score":0.13610433,"about_ca_system_score_codex":0.00016884443,"about_ca_system_score_gemma":0.0004988068,"threshold_uncertainty_score":0.99940497},"labels":[],"label_agreement":null},{"id":"W2021959782","doi":"10.1016/j.ejca.2011.03.027","title":"A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Cancer; Internal medicine","score_opus":0.04388196135725048,"score_gpt":0.2917438947400604,"score_spread":0.24786193338280993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021959782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891937,0.0058585675,0.000007153314,0.000042373802,0.0014675722,0.00057415775,0.000011634644,0.0000061990236,0.0028386505],"genre_scores_gemma":[0.99923867,0.0003896364,0.00003047074,0.000068266294,0.00012158371,0.00001489312,2.4546114e-7,0.000035073383,0.000101186284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760187,0.00042612734,0.00088652887,0.00016344979,0.0007437001,0.00017834826],"domain_scores_gemma":[0.99751407,0.000017918022,0.0009967582,0.00029117172,0.0010910209,0.00008909125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029524692,0.00016982899,0.0005772822,0.00027195874,0.000031168194,0.000006862309,0.00030013203,0.00002114288,0.000051813004],"category_scores_gemma":[0.000026094196,0.000103280036,0.00015445126,0.00068063324,0.000064490145,0.00010224914,0.00007079795,0.00030040264,6.381421e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014539701,0.0012427473,0.9508804,0.000646597,0.00036240555,0.000031336695,0.017005015,0.00015890275,0.00367318,0.0000067877995,0.0001292393,0.02440939],"study_design_scores_gemma":[0.004894772,0.0018399546,0.9772085,0.0026903485,0.00020780666,0.0000063959005,0.009877026,0.000008559045,0.002258767,5.235685e-7,0.00090420165,0.00010312816],"about_ca_topic_score_codex":0.0013848757,"about_ca_topic_score_gemma":0.0010282468,"teacher_disagreement_score":0.026328089,"about_ca_system_score_codex":0.0003170213,"about_ca_system_score_gemma":0.0002243653,"threshold_uncertainty_score":0.42116377},"labels":[],"label_agreement":null},{"id":"W2022983962","doi":"10.1016/j.ejca.2013.06.032","title":"Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cardiac Fibrosis and Remodeling","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph's Hospital; St. Joseph’s Healthcare Hamilton","funders":"Kidney Foundation of Canada","keywords":"Periostin; Stromal cell; Renal cell carcinoma; Fibroblast; Cancer research; Medicine; Oncology; Cell biology; Cell culture; Biology; Extracellular matrix","score_opus":0.013369808811783528,"score_gpt":0.22889260459702104,"score_spread":0.2155227957852375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022983962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99153954,0.0020136053,0.000020502472,0.0006049702,0.0005226158,0.00014056482,0.000003879649,0.000008396196,0.005145941],"genre_scores_gemma":[0.99617827,0.00017003372,0.0009284599,0.00005612691,0.0013804865,7.058069e-7,0.0000023217724,0.000040279258,0.0012433032],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99859005,0.00014725162,0.00055870524,0.00014444433,0.00037810483,0.00018144042],"domain_scores_gemma":[0.998614,0.00001931521,0.00049859827,0.00015051209,0.0005577836,0.00015980257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003894226,0.00013006963,0.0003240826,0.00012843027,0.00004172934,0.00002170207,0.00009262555,0.000029646282,0.00034027075],"category_scores_gemma":[0.000057537793,0.000094758914,0.00019254889,0.00013236824,0.00006016449,0.00014819314,0.000034452572,0.00033880008,0.00004048677],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025440683,0.000068190326,0.0045239488,0.00011676574,0.000030249226,0.000018894545,0.000599987,0.00070153514,0.98265094,3.0574094e-7,0.007490279,0.003544523],"study_design_scores_gemma":[0.0023768237,0.0021392272,0.5618902,0.0007940804,0.0002129472,0.00013669694,0.0007649973,0.00021506877,0.42445138,0.0000015632426,0.0068119923,0.0002050685],"about_ca_topic_score_codex":0.00004056177,"about_ca_topic_score_gemma":7.3556316e-7,"teacher_disagreement_score":0.5581995,"about_ca_system_score_codex":0.00005207913,"about_ca_system_score_gemma":0.00015634134,"threshold_uncertainty_score":0.38641563},"labels":[],"label_agreement":null},{"id":"W2025363005","doi":"10.1016/j.ejca.2008.10.031","title":"Lessons learned from independent central review","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Ixabepilone; Human services; Food and drug administration; Clinical trial; Lapatinib; Family medicine; Pharmacology; Cancer; Internal medicine; Breast cancer; Political science","score_opus":0.13320688196963348,"score_gpt":0.39239754501226215,"score_spread":0.25919066304262867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025363005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5437597,0.37054634,0.00007299227,0.05955072,0.0017643373,0.0002264503,0.000031906286,0.00002366938,0.024023905],"genre_scores_gemma":[0.70162433,0.2877644,0.00014702951,0.005054915,0.001502892,0.0000013053469,0.0000049918876,0.00002446079,0.0038756372],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989681,0.0001717942,0.0003307945,0.000103641985,0.00025711255,0.00016855905],"domain_scores_gemma":[0.9992901,0.00002289327,0.0002499477,0.00010491787,0.00012841601,0.00020372706],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019285636,0.0000996545,0.00031722215,0.000042602176,0.000037631562,0.0000040377313,0.00009844381,0.000012918588,0.0036515805],"category_scores_gemma":[0.000025975574,0.000073231146,0.00016884113,0.0000783655,0.000045336343,0.000053843905,0.000019726114,0.0002849554,0.0000646666],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014739526,0.00052240584,0.052204695,0.00020669316,0.0012753136,0.012065416,0.0013004384,0.00003582453,0.01137473,0.000016824819,0.55658317,0.36294052],"study_design_scores_gemma":[0.0036027497,0.0003882524,0.22817153,0.0011180363,0.0005771072,0.0004903625,0.000013245605,0.0000016667932,0.0012481721,0.000009823758,0.7642933,0.00008576097],"about_ca_topic_score_codex":0.00004031337,"about_ca_topic_score_gemma":0.0000102223385,"teacher_disagreement_score":0.36285475,"about_ca_system_score_codex":0.00012697325,"about_ca_system_score_gemma":0.0002488672,"threshold_uncertainty_score":0.9972592},"labels":[],"label_agreement":null},{"id":"W2025911470","doi":"10.1016/j.ejca.2011.10.037","title":"Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cohort; Internal medicine; Ganglioneuroblastoma; Medicine; Stage (stratigraphy); Pathological; Oncology; Neuroblastoma; Biology; Ganglioneuroma","score_opus":0.034508027595901644,"score_gpt":0.28314247830532224,"score_spread":0.24863445070942058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025911470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867886,0.0001971137,0.000021985059,0.0001420322,0.00010509886,0.00018432448,0.00003658848,0.000005092628,0.0006288903],"genre_scores_gemma":[0.99908644,0.00011038525,0.00030346768,0.00015889957,0.00011293158,0.0000012237459,0.0000043019077,0.000029863686,0.00019246104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880576,0.00014172161,0.00040779918,0.00011618158,0.00039786592,0.000130641],"domain_scores_gemma":[0.9987513,0.000036409798,0.00050612475,0.00020706198,0.00038979828,0.000109346794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000228188,0.00010880688,0.00024634358,0.00006961145,0.000033409757,0.000010109148,0.00009984272,0.000009886109,0.000071466035],"category_scores_gemma":[0.00015205103,0.00005546322,0.0000547049,0.00010779374,0.00010298708,0.00007081016,0.00004366188,0.00021309403,0.00000438624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002060331,0.0002029892,0.9863313,0.000021443548,0.0002076532,0.00454989,0.000400147,7.895446e-8,0.00030042027,0.0000010806913,0.00052568904,0.005398967],"study_design_scores_gemma":[0.002235216,0.001377782,0.99132645,0.00014726726,0.00016596667,0.0002090475,0.000018718438,0.0000010403311,0.0009093442,0.0000019723234,0.0035581568,0.000049029415],"about_ca_topic_score_codex":0.000044374538,"about_ca_topic_score_gemma":0.000007687195,"teacher_disagreement_score":0.005349938,"about_ca_system_score_codex":0.00001938306,"about_ca_system_score_gemma":0.00009715899,"threshold_uncertainty_score":0.22617245},"labels":[],"label_agreement":null},{"id":"W2026118034","doi":"10.1016/s0959-8049(02)00235-6","title":"The prognostic significance of the tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Seminoma; Medicine; Hazard ratio; Univariate analysis; Internal medicine; Stage (stratigraphy); Multivariate analysis; Lymphatic system; Pathology; Testicular Germ Cell Tumor; Gastroenterology; Confidence interval; Oncology; Chemotherapy; Biology","score_opus":0.013377882816740225,"score_gpt":0.2404096985549108,"score_spread":0.22703181573817055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026118034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953308,0.044015903,0.000045152752,0.00078161707,0.00016513614,0.00031190278,0.000032615204,0.000007421559,0.0013322573],"genre_scores_gemma":[0.9979507,0.00097615767,0.0000895269,0.00013959405,0.0000905541,0.000004619374,7.928275e-7,0.000024814131,0.0007232401],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985075,0.00030221554,0.00047246166,0.000113415656,0.00041159787,0.00019279981],"domain_scores_gemma":[0.9987487,0.00021089679,0.00055654784,0.00021439523,0.00017545317,0.00009397113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047957743,0.00012839097,0.00022037375,0.00002836844,0.000085148924,0.000028159511,0.00020408278,0.000011043033,0.00005002045],"category_scores_gemma":[0.0006049282,0.000068250956,0.00011347965,0.00020941395,0.00010711373,0.000047372847,0.0000287252,0.00017256536,0.000004634794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013079192,0.00024605863,0.9634855,0.000099019555,0.00019058315,0.0009710542,0.00024204806,0.0007651467,0.007270724,0.000013084426,0.0022282728,0.02435771],"study_design_scores_gemma":[0.002253265,0.00022893335,0.9875262,0.0005501509,0.00011975424,0.00008394327,0.000108887216,0.00057003857,0.0011524846,0.000004134882,0.0073140603,0.000088179724],"about_ca_topic_score_codex":0.0000332229,"about_ca_topic_score_gemma":0.0000190702,"teacher_disagreement_score":0.044642705,"about_ca_system_score_codex":0.00014091075,"about_ca_system_score_gemma":0.0001017868,"threshold_uncertainty_score":0.27831933},"labels":[],"label_agreement":null},{"id":"W2026853385","doi":"10.1016/j.ejca.2010.10.002","title":"Lifestyle factors associated concurrently and prospectively with co-morbid cardiovascular disease in a population-based cohort of colorectal cancer survivors","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"Cancer Council Queensland","keywords":"Medicine; Overweight; Body mass index; Colorectal cancer; Internal medicine; Odds ratio; Diabetes mellitus; Disease; Population; Cancer; Cohort; Prospective cohort study; Obesity; Cohort study; Physical therapy; Endocrinology; Environmental health","score_opus":0.012880109504043188,"score_gpt":0.26699209842188465,"score_spread":0.2541119889178415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026853385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820924,0.00093094865,0.00003604729,0.000099865094,0.00019281976,0.00032597603,0.00004709006,0.000009469766,0.00014856237],"genre_scores_gemma":[0.9995884,0.0001371788,0.000025848121,0.000042002583,0.00013921506,0.0000056962776,0.0000137736015,0.000031416734,0.00001652552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987501,0.00017223241,0.00032444613,0.00015153001,0.00046874015,0.00013294765],"domain_scores_gemma":[0.9990141,0.000046494868,0.0003314596,0.00010212856,0.0003269333,0.00017889912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006391056,0.00013471594,0.00043754972,0.00011955518,0.00003668675,0.000013606406,0.00005518938,0.00003230308,0.000041187905],"category_scores_gemma":[0.00014955021,0.00010398915,0.00016967475,0.00018385607,0.000112186935,0.00008897601,0.000005852215,0.00035512645,1.9233993e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039603093,0.0000764639,0.97565883,0.000039233684,0.00061269203,0.00005321059,0.00030990742,0.00064187846,0.020857243,0.0000032870582,0.000012521472,0.0013386752],"study_design_scores_gemma":[0.0031206103,0.00018617917,0.97224164,0.0003246526,0.00035352857,0.000005480712,0.000031420044,0.000087711654,0.023279263,0.0000019745514,0.00025678455,0.00011073374],"about_ca_topic_score_codex":0.000981948,"about_ca_topic_score_gemma":0.0007053193,"teacher_disagreement_score":0.0034171944,"about_ca_system_score_codex":0.00014667501,"about_ca_system_score_gemma":0.00034123784,"threshold_uncertainty_score":0.42405543},"labels":[],"label_agreement":null},{"id":"W2027589610","doi":"10.1016/j.ejca.2014.11.017","title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Carboplatin; Medicine; Internal medicine; Neutropenia; Paclitaxel; Gastroenterology; Nausea; Ovarian cancer; Clinical endpoint; Progression-free survival; Phases of clinical research; Chemotherapy; Oncology; Urology; Randomized controlled trial; Cisplatin; Cancer","score_opus":0.018460881832693014,"score_gpt":0.28701299381109685,"score_spread":0.26855211197840384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027589610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514115,0.0014569168,0.000010084309,0.00078088,0.0006770493,0.00039694775,0.00071948115,0.000005890653,0.00081161107],"genre_scores_gemma":[0.99878484,0.00036743656,0.000092544615,0.00012038883,0.0005049404,0.0000068040936,0.000049559716,0.00003206299,0.000041395906],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99719167,0.00058939087,0.0011436148,0.00034699676,0.00048703252,0.00024130163],"domain_scores_gemma":[0.9976634,0.0004953894,0.0010748004,0.00028065604,0.00030851155,0.00017724307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068431767,0.0002650393,0.00091408397,0.00030023258,0.00006851995,0.00003357017,0.00009890856,0.00006320126,0.000042861382],"category_scores_gemma":[0.0003274692,0.0001800506,0.00021496708,0.00061264634,0.00014341432,0.00009867216,0.00006184718,0.00035437697,3.8449286e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4515864,0.00256271,0.34490657,0.000081842416,0.015049167,0.0007796627,0.01585293,0.0037973986,0.0057639214,0.00006581074,0.0020704,0.15748319],"study_design_scores_gemma":[0.23197167,0.001940824,0.75756735,0.0005259092,0.0041700834,0.0000033364058,0.00016736158,0.0017087944,0.0012355876,0.0000048438,0.00052862655,0.00017562963],"about_ca_topic_score_codex":0.007225976,"about_ca_topic_score_gemma":0.0037736949,"teacher_disagreement_score":0.41266075,"about_ca_system_score_codex":0.00023777968,"about_ca_system_score_gemma":0.00019200185,"threshold_uncertainty_score":0.999385},"labels":[],"label_agreement":null},{"id":"W2027661693","doi":"10.1016/j.ejca.2010.09.018","title":"Reliability and construct validity of the oral mucositis daily questionnaire in children with cancer","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Mucositis; Medicine; Visual analogue scale; Construct validity; Swallowing; Cancer; Concurrent validity; Population; Physical therapy; Psychometrics; Chemotherapy; Internal medicine; Surgery; Clinical psychology","score_opus":0.017828009070985164,"score_gpt":0.315112345127356,"score_spread":0.29728433605637083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027661693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943522,0.0017931743,0.000007607623,0.0028605128,0.0005091954,0.00023992755,0.000023765548,0.000005004104,0.00020858696],"genre_scores_gemma":[0.99805754,0.0005369944,0.00076223764,0.00030263086,0.00027807022,0.0000033940776,3.014853e-7,0.000018782275,0.00004005101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876064,0.00024514785,0.00040803754,0.00013501864,0.00029258657,0.0001585835],"domain_scores_gemma":[0.9989572,0.000017920816,0.00038799806,0.00021961147,0.00026935607,0.0001478897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072122563,0.00011331801,0.00028533535,0.000047941772,0.000045048248,0.000007671158,0.00010579415,0.000024009307,0.00008766094],"category_scores_gemma":[0.00007262793,0.000063095125,0.00005097385,0.00014560563,0.00031229522,0.000082335406,0.000031082083,0.00050633546,5.7594104e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002646781,0.000054121698,0.9558659,0.000052304844,0.00004513433,0.000022346328,0.00020578314,0.000031451036,0.00040738197,0.000009640983,0.00019894485,0.042842314],"study_design_scores_gemma":[0.0026694764,0.0004564711,0.99291414,0.0008345781,0.00012321527,0.000359598,0.000015797279,0.000007734119,0.0013419173,0.000021685848,0.0011939633,0.000061415776],"about_ca_topic_score_codex":0.00092392234,"about_ca_topic_score_gemma":0.0011979935,"teacher_disagreement_score":0.0427809,"about_ca_system_score_codex":0.00018241206,"about_ca_system_score_gemma":0.0006170882,"threshold_uncertainty_score":0.25729445},"labels":[],"label_agreement":null},{"id":"W2028496722","doi":"10.1016/j.ejca.2010.10.027","title":"Validation of the QUAL-EC for assessing quality of life in patients with advanced cancer","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; York University; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Quality of life (healthcare); Palliative care; Confirmatory factor analysis; Construct validity; Psychometrics; Scale (ratio); Health care; Construct (python library); Test (biology); Medicine; Psychology; Cancer; Clinical psychology; Nursing; Structural equation modeling; Statistics","score_opus":0.027558192126436544,"score_gpt":0.34192417500121247,"score_spread":0.3143659828747759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028496722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720454,0.00045636878,0.00022779856,0.00046112295,0.0008894534,0.00019069856,0.000027073747,0.0000023188616,0.00054063834],"genre_scores_gemma":[0.9992229,0.000037134825,0.000265128,0.00016979316,0.00021497061,0.0000035569853,0.0000016831568,0.000022118998,0.00006274554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863434,0.00017384978,0.000593022,0.00008810268,0.00040414822,0.000106520456],"domain_scores_gemma":[0.99790734,0.000065354005,0.0009790204,0.00017614232,0.0008054227,0.00006671776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008322666,0.00008543823,0.00031607333,0.00006398001,0.00002359153,0.0000080989485,0.0001280643,0.000019274636,0.000063678264],"category_scores_gemma":[0.00024694917,0.00005202913,0.00010686804,0.00017568887,0.00006655769,0.00013835955,0.000017458848,0.0002476167,1.2650212e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015077386,0.00010184688,0.9441655,0.00019427123,0.00006276763,7.2291215e-7,0.0012082965,0.00031285762,0.011657709,0.000022487537,0.000110752764,0.040655024],"study_design_scores_gemma":[0.0040589436,0.00022935506,0.9822029,0.00058919814,0.00006702015,4.8929877e-7,0.0002801602,0.000004684841,0.0100191785,0.0000070211845,0.0024733332,0.000067736546],"about_ca_topic_score_codex":0.00025078203,"about_ca_topic_score_gemma":0.0012089487,"teacher_disagreement_score":0.040587287,"about_ca_system_score_codex":0.000056331002,"about_ca_system_score_gemma":0.00038348298,"threshold_uncertainty_score":0.21216862},"labels":[],"label_agreement":null},{"id":"W2028889234","doi":"10.1016/j.ejca.2014.05.024","title":"Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice","year":2014,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Clinical trial; Clinical endpoint; Context (archaeology); Progression-free survival; Medicine; Clinical Practice; Surrogate endpoint; Intensive care medicine; End point; Endpoint Determination; Clinical study design; Overall survival; Oncology; Medical physics; Internal medicine; Family medicine; Computer science","score_opus":0.17382677235232438,"score_gpt":0.59671152223017,"score_spread":0.42288474987784563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028889234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000482608,0.9881172,0.00004364187,0.0019350101,0.002178052,0.00078218075,0.000080627084,0.0000149860925,0.006365653],"genre_scores_gemma":[0.0006771612,0.9881034,0.0030914582,0.0003228169,0.0074440446,0.000012219039,0.000025556723,0.00010561396,0.00021771724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98243636,0.012088711,0.003963811,0.00054152205,0.00071207207,0.00025750158],"domain_scores_gemma":[0.98924977,0.00482982,0.0041941362,0.00053798116,0.00058312673,0.00060519425],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020094154,0.0003985784,0.004136391,0.00020855902,0.00006138258,0.00009381099,0.00034214577,0.00015413729,0.0003427107],"category_scores_gemma":[0.01900863,0.00024209048,0.0010106856,0.0001497281,0.00022712354,0.00026564134,0.0001150166,0.0015613383,0.00002663406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069141696,0.00075421383,0.0009838839,0.00033501693,0.0021699942,0.0014878534,0.0005356143,3.5143495e-7,1.3319617e-7,0.00004695923,0.00224783,0.99074674],"study_design_scores_gemma":[0.0068166624,0.0027932157,0.0064228303,0.018088507,0.01246243,0.00037098062,0.000898233,0.0000018476583,2.1051918e-7,0.000055724544,0.9518374,0.00025191923],"about_ca_topic_score_codex":0.00006981252,"about_ca_topic_score_gemma":0.00005234855,"teacher_disagreement_score":0.9904948,"about_ca_system_score_codex":0.00026240727,"about_ca_system_score_gemma":0.0021228073,"threshold_uncertainty_score":0.98925465},"labels":[],"label_agreement":null},{"id":"W2030344177","doi":"10.1016/j.ejca.2004.04.005","title":"Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Rhabdomyosarcoma; Medicine; Soft tissue sarcoma; Sarcoma; Confidence interval; Adverse effect; Pediatrics; Event (particle physics); Overall survival; Internal medicine; Surgery; Oncology; Pathology","score_opus":0.014196425769703029,"score_gpt":0.30112492143369146,"score_spread":0.2869284956639884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030344177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98054963,0.011241776,0.00007599271,0.0068305354,0.00044067085,0.000680337,0.00008390681,0.000008858147,0.000088284956],"genre_scores_gemma":[0.9952399,0.00063578476,0.00082700566,0.0023918014,0.0007526808,0.000029679974,0.000006914496,0.00005220338,0.00006402569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983064,0.00021856613,0.0006524343,0.00019892184,0.00039208806,0.00023162251],"domain_scores_gemma":[0.99833745,0.00020711104,0.00076325284,0.0004196392,0.00016917013,0.00010339217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047684825,0.0001996774,0.00046200005,0.00004978036,0.00009296852,0.000017225595,0.00037439857,0.00003779265,0.000115971045],"category_scores_gemma":[0.00008227675,0.000097192526,0.00033243425,0.00013646681,0.00011806511,0.000076345226,0.0000869878,0.0003161766,0.000004056502],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001761514,0.0012859085,0.7977779,0.000010270072,0.0012972474,0.0022317916,0.0032522578,0.00009271947,0.00016525765,0.0000075158655,0.0018801623,0.19023749],"study_design_scores_gemma":[0.009031231,0.000865613,0.95762634,0.000533978,0.00034277875,0.0006903374,0.00012268029,6.939567e-7,0.0008931595,0.000078532576,0.029713143,0.00010148525],"about_ca_topic_score_codex":0.00024304961,"about_ca_topic_score_gemma":0.00010952523,"teacher_disagreement_score":0.190136,"about_ca_system_score_codex":0.00015257318,"about_ca_system_score_gemma":0.00024880774,"threshold_uncertainty_score":0.39633963},"labels":[],"label_agreement":null},{"id":"W2030447282","doi":"10.1016/j.ejca.2008.02.031","title":"Hope in advanced cancer patients","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Optimism, Hope, and Well-being","field":"Psychology","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Cancer; Oncology; Internal medicine","score_opus":0.016498464815631476,"score_gpt":0.3019786826179671,"score_spread":0.2854802178023356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030447282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8895463,0.0043402654,0.00003925251,0.00030794358,0.0023309493,0.000077527555,0.0000053491094,0.000010395144,0.10334204],"genre_scores_gemma":[0.9914407,0.0022061788,0.00017749323,0.0008081562,0.00062186096,0.0000035849464,7.3862395e-7,0.000050324066,0.0046909335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846786,0.00028785242,0.0005271506,0.00016936078,0.00024981337,0.00029797],"domain_scores_gemma":[0.99911696,0.000029930387,0.000368595,0.00015635157,0.00020060787,0.00012755151],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003191955,0.00014377192,0.00024984195,0.00015346683,0.00006261412,0.000011725495,0.00027607684,0.000024683379,0.0016443968],"category_scores_gemma":[0.00002836005,0.00012344908,0.00009658589,0.00020040102,0.00005777287,0.00018108738,0.000030769304,0.00035897756,0.00012814815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091865705,0.00044528695,0.53265226,0.000017198061,0.00018245642,0.001933396,0.0151812,0.0030744935,0.00041016733,0.00008510816,0.045166668,0.3999331],"study_design_scores_gemma":[0.003960658,0.00033522275,0.81143856,0.00018140074,0.000022940807,0.000036260848,0.00015755135,0.0000063455172,0.00016655866,0.000014087184,0.18347044,0.00020997754],"about_ca_topic_score_codex":0.00007518045,"about_ca_topic_score_gemma":0.00003606501,"teacher_disagreement_score":0.3997231,"about_ca_system_score_codex":0.00010331487,"about_ca_system_score_gemma":0.00007536517,"threshold_uncertainty_score":0.99926823},"labels":[],"label_agreement":null},{"id":"W2030451289","doi":"10.1016/s0959-8049(03)00604-x","title":"The current position of complementary/alternative medicine in cancer","year":2003,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Park","funders":"","keywords":"Alternative medicine; Medicine; Position (finance); Current (fluid); Position paper; Cancer Medicine; Intensive care medicine; Cancer; Risk analysis (engineering); Business; Pathology; Engineering; Internal medicine; Finance","score_opus":0.1637877651201059,"score_gpt":0.4748039851118064,"score_spread":0.3110162199917005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030451289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014801981,0.9929713,0.00008729101,0.0010132698,0.002679012,0.0005058218,0.00006804627,0.0000025262336,0.002524717],"genre_scores_gemma":[0.00043778104,0.99675554,0.00003910009,0.000104650055,0.0023754665,0.000014567508,0.000015881942,0.000039839666,0.00021715462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962181,0.0008608723,0.0017941054,0.0001928245,0.0006847656,0.0002493585],"domain_scores_gemma":[0.996957,0.0003048316,0.001993801,0.00019323008,0.0004399088,0.00011122839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001414189,0.00034059052,0.0017453335,0.0003166601,0.00008276851,0.0000060947564,0.00032846368,0.0000065824024,0.0005348236],"category_scores_gemma":[0.00007335975,0.00017461508,0.000346354,0.0003255819,0.00029800623,0.00005128416,0.0000824763,0.000824898,0.0000029304363],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000865816,0.00007584911,0.000442501,0.0029702866,0.00086677267,0.00016602504,0.00044739447,0.0000062258987,7.9459886e-7,0.00006307755,0.0065786066,0.9882959],"study_design_scores_gemma":[0.0020364628,0.0009608837,0.0004596241,0.058478888,0.0016132599,0.00007137098,0.0002038047,0.000001881536,0.0000025740112,0.000027886637,0.9360196,0.00012375109],"about_ca_topic_score_codex":0.00013103055,"about_ca_topic_score_gemma":0.00009926607,"teacher_disagreement_score":0.9881721,"about_ca_system_score_codex":0.00041052114,"about_ca_system_score_gemma":0.00029950886,"threshold_uncertainty_score":0.7120597},"labels":[],"label_agreement":null},{"id":"W2031188948","doi":"10.1016/j.ejca.2011.09.028","title":"Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991","year":2011,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Bundesamt für Zivilluftfahrt","keywords":"Medicine; Internal medicine; Gastroenterology; Stage (stratigraphy); Hazard ratio; Population; Melanoma; Adjuvant; Cancer; Oncology; Confidence interval; Cancer research","score_opus":0.08544655606687808,"score_gpt":0.3678701103826715,"score_spread":0.2824235543157934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031188948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014201792,0.9808143,0.000060378687,0.000080532336,0.0006789103,0.0012117377,0.00015546019,0.0000059817553,0.0027909058],"genre_scores_gemma":[0.10680748,0.89157355,0.000020254081,0.000025213469,0.00030390488,0.00000448566,0.0000052168543,0.000036361664,0.0012235594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99620664,0.0011227687,0.0020531788,0.0002147377,0.00027920277,0.00012345522],"domain_scores_gemma":[0.99562156,0.00016612331,0.0036546069,0.0002544766,0.00019860806,0.00010462522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025449358,0.00024742633,0.0019133892,0.00031913246,0.00002868115,0.000014745675,0.00014216063,0.000057235357,0.00006922221],"category_scores_gemma":[0.0005324548,0.00014455918,0.00030309966,0.00016495577,0.00011897634,0.000057074663,0.00009748239,0.000451125,7.543942e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055705844,0.00026812378,0.000024278348,0.0031531395,0.0006515564,0.00022049272,0.0010654976,0.00000629984,0.00006153339,0.00001416307,0.0007899197,0.98817444],"study_design_scores_gemma":[0.016113393,0.0031212752,0.0015947691,0.030145766,0.0028443728,0.00036649287,0.00030252113,0.000011806246,0.00012215364,0.0000021426958,0.9451991,0.00017621469],"about_ca_topic_score_codex":0.000031072886,"about_ca_topic_score_gemma":0.00005736152,"teacher_disagreement_score":0.9879982,"about_ca_system_score_codex":0.000109139066,"about_ca_system_score_gemma":0.00016564761,"threshold_uncertainty_score":0.5894952},"labels":[],"label_agreement":null},{"id":"W2031521622","doi":"10.1016/s0959-8049(00)00363-4","title":"A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Medical Research Council","keywords":"Osteolysis; Bone marrow; Bone resorption; Pathology; Medullary cavity; Matrix metalloproteinase; In vivo; Cancer research; Medicine; Bone metastasis; Bone cell; Cancer; Chemistry; Breast cancer; Internal medicine; Biology; Surgery","score_opus":0.018851469748815578,"score_gpt":0.3105346783380403,"score_spread":0.29168320858922475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031521622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97586286,0.019109078,0.000056755332,0.0026960238,0.00028926818,0.0005269899,0.0001353525,0.000011737653,0.0013119216],"genre_scores_gemma":[0.99372095,0.001122919,0.0016885368,0.00047779968,0.00020337624,0.000026458838,0.00000986621,0.000066736764,0.0026833476],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99685067,0.00040130524,0.0013514636,0.00023852984,0.0007111944,0.0004468245],"domain_scores_gemma":[0.9981214,0.00005011725,0.0008752777,0.00025143454,0.0003478809,0.00035388468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013166065,0.00029551296,0.0006856882,0.00021440513,0.00012871997,0.000023454832,0.00019409035,0.000033002263,0.00080587657],"category_scores_gemma":[0.000032079002,0.00019134396,0.0001740958,0.00039318157,0.00010822527,0.00015629192,0.000058061443,0.00044842047,0.000022549753],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012444314,0.004514488,0.07307579,0.0018308382,0.004322597,0.009734768,0.011928617,0.00046357428,0.41922656,0.0000376346,0.06824399,0.39417684],"study_design_scores_gemma":[0.044290572,0.0030987067,0.29274115,0.00720002,0.0033244626,0.0029960496,0.001777133,0.000076332224,0.2190769,0.000039853363,0.42403114,0.0013476986],"about_ca_topic_score_codex":0.0006708484,"about_ca_topic_score_gemma":0.00069276907,"teacher_disagreement_score":0.39282915,"about_ca_system_score_codex":0.0003950482,"about_ca_system_score_gemma":0.00078876026,"threshold_uncertainty_score":0.8823783},"labels":[],"label_agreement":null},{"id":"W2032597812","doi":"10.1016/j.ejca.2009.05.008","title":"A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; Hospital for Sick Children; McMaster University Medical Centre; University of British Columbia; Alberta Children's Hospital; SickKids Foundation","funders":"","keywords":"PDGFRA; Imatinib; Medicine; Pharmacokinetics; Refractory (planetary science); Gastroenterology; Immunohistochemistry; Cerebrospinal fluid; Internal medicine; Central nervous system; Vomiting; Imatinib mesylate; Pathology; Oncology; GiST; Stromal cell; Biology","score_opus":0.011340351742568686,"score_gpt":0.27081313020759135,"score_spread":0.25947277846502265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032597812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777211,0.019458184,0.000004724735,0.0015984253,0.00034011435,0.00052871933,0.0000371634,0.000010913275,0.00030066242],"genre_scores_gemma":[0.99889123,0.00041215375,0.00009234267,0.00021300615,0.00033426916,0.0000048931,0.0000049629107,0.00003236464,0.000014775071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739516,0.00050627405,0.0009808145,0.0002343181,0.00045583252,0.00042762028],"domain_scores_gemma":[0.9981287,0.000054020067,0.00069911353,0.00018113456,0.00026738728,0.00066965644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007063976,0.00024301495,0.0006166295,0.000764307,0.0000741275,0.000027945578,0.00013598027,0.000030641044,0.000030482288],"category_scores_gemma":[0.00016066221,0.00019537895,0.00013678313,0.00051731133,0.000025595658,0.00010420463,0.000023158165,0.00035519386,0.000002003191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003537495,0.018162383,0.5201279,0.00047401973,0.0009592579,0.07097332,0.016642239,0.00073561055,0.016571943,0.00005673486,0.015600222,0.33615887],"study_design_scores_gemma":[0.019672245,0.013996751,0.9611957,0.00047306108,0.00063136476,0.00039496078,0.0018803459,0.00011928115,0.00045135064,0.0000023678394,0.00094860635,0.00023394957],"about_ca_topic_score_codex":0.0029955443,"about_ca_topic_score_gemma":0.0028345815,"teacher_disagreement_score":0.4410678,"about_ca_system_score_codex":0.0005680294,"about_ca_system_score_gemma":0.0005596812,"threshold_uncertainty_score":0.79673225},"labels":[],"label_agreement":null},{"id":"W2033048967","doi":"10.1016/j.ejca.2010.07.028","title":"State of the epidemiological evidence on physical activity and cancer prevention","year":2010,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Physical Activity and Health","field":"Medicine","cited_by":503,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Population; Oncology; Prostate cancer; Prostate; Internal medicine; Cancer; Breast cancer; Vitamin D and neurology; Physiology; Environmental health","score_opus":0.25025264415817355,"score_gpt":0.48722203403066894,"score_spread":0.23696938987249538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033048967","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07717315,0.92067915,0.000025861036,0.0011282228,0.00035423168,0.00034013615,0.000022002188,0.000004289477,0.00027293756],"genre_scores_gemma":[0.038063623,0.9603032,0.000021217576,0.00010938662,0.00116894,0.000004896628,2.2713236e-7,0.000023987335,0.00030451518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974733,0.001367652,0.00044716487,0.00018831233,0.00035278636,0.00017077426],"domain_scores_gemma":[0.997358,0.00060717,0.0015113918,0.00022376148,0.00013583689,0.00016383226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010957147,0.00021660839,0.00167749,0.00004815319,0.00005205105,0.000007638644,0.00019786418,0.000048128204,0.000024049705],"category_scores_gemma":[0.00052040425,0.00010221135,0.000592159,0.00013542453,0.00018913457,0.0000993087,0.00007507058,0.0018569437,0.0000038742164],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001556196,0.00030400767,0.000036205784,0.0031303023,0.00010445288,0.000013115689,0.000045738394,0.0000025451554,0.00014706438,0.00001582361,0.00022819407,0.99581695],"study_design_scores_gemma":[0.00047152943,0.0017975911,0.022982236,0.084340915,0.0014662205,0.00006968265,0.0000014988971,0.000010602289,0.00017207381,0.00015984268,0.88834935,0.00017847071],"about_ca_topic_score_codex":0.00001818836,"about_ca_topic_score_gemma":0.000008941914,"teacher_disagreement_score":0.99563843,"about_ca_system_score_codex":0.000115568975,"about_ca_system_score_gemma":0.0005947272,"threshold_uncertainty_score":0.80675995},"labels":[],"label_agreement":null},{"id":"W2034409191","doi":"10.1016/j.ejca.2014.12.001","title":"Internet-based technologies to improve cancer care coordination: Current use and attitudes among cancer patients","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"CHIST-ERA","keywords":"Socioeconomic status; Medicine; Feeling; Family medicine; Descriptive statistics; Demographics; Cancer; The Internet; Health care; Demography; Environmental health; Psychology; Internal medicine; Population; World Wide Web; Social psychology","score_opus":0.039034943466670975,"score_gpt":0.3115488037635708,"score_spread":0.27251386029689983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034409191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9639548,0.03058131,0.00015366527,0.001903623,0.0027918713,0.00026752776,0.000067468296,0.00004907967,0.00023065557],"genre_scores_gemma":[0.9979155,0.0007405169,0.000080562095,0.0003755195,0.00046076087,0.000029563711,0.0000041294506,0.000043151493,0.00035027348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985925,0.00008945253,0.00038566708,0.00023143944,0.0004788729,0.00022206048],"domain_scores_gemma":[0.99746877,0.000022945147,0.00031058118,0.00017707165,0.0017373291,0.00028330082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021471878,0.00019914132,0.00032625065,0.00020468835,0.000036207282,0.000082970604,0.00018147376,0.000034748162,0.00005112276],"category_scores_gemma":[0.00016660526,0.00015447088,0.000091488895,0.00022342107,0.00010764193,0.00023270278,0.000097207696,0.0003443202,0.000003714214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036266624,0.00004956693,0.7124418,0.00012840712,0.00007754103,0.000033669396,0.002079289,0.00008981664,0.00012774608,0.0000035396351,0.009200621,0.27540535],"study_design_scores_gemma":[0.0045543835,0.001261251,0.7478459,0.0025219142,0.0003012796,0.0000043902796,0.0012766148,0.000049828093,0.005205083,0.000003124825,0.23662597,0.00035025246],"about_ca_topic_score_codex":0.0010109878,"about_ca_topic_score_gemma":0.0032525414,"teacher_disagreement_score":0.2750551,"about_ca_system_score_codex":0.0005683993,"about_ca_system_score_gemma":0.00035036026,"threshold_uncertainty_score":0.6299139},"labels":[],"label_agreement":null},{"id":"W2034645531","doi":"10.1016/j.ejca.2009.05.019","title":"Interplay between Numb and Notch in epithelial cancers: Role for dual oxidase maturation factor","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"NUMB; Notch signaling pathway; Cell biology; Biology; Cell fate determination; Cancer research; Signal transduction; Transcription factor; Genetics; Gene","score_opus":0.008499437171411585,"score_gpt":0.2884827553134906,"score_spread":0.279983318142079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034645531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99740195,0.001140207,0.00063031126,0.0004318328,0.00014343309,0.00006785918,0.00002813084,0.0000013809682,0.00015489271],"genre_scores_gemma":[0.9984072,0.00018080235,0.0005104566,0.00015532043,0.0005599685,6.6926674e-7,0.000020904092,0.0000064940814,0.00015819531],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994969,0.000064429216,0.0002084759,0.00009595698,0.000041984473,0.0000922742],"domain_scores_gemma":[0.999724,0.000006354067,0.00012992197,0.000040994975,0.000058693357,0.000040081544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001936242,0.00007053656,0.0000940922,0.00003490562,0.000026093601,0.000012149264,0.000053700693,0.000033504613,0.000006971672],"category_scores_gemma":[0.00002313782,0.000058920225,0.000034014654,0.000026267759,0.00002116552,0.0000088064135,0.000012833243,0.00005936615,8.7769183e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004900781,0.000009914142,0.009954633,0.0000043280406,0.00003380754,0.0000036355448,0.00023282463,0.000043054206,0.77934957,0.0000038880103,0.0004363864,0.20943788],"study_design_scores_gemma":[0.0013036062,0.0006187916,0.66230047,0.000051480885,0.000014324689,0.000020430603,0.000057380545,0.000014345731,0.29968593,0.00006571621,0.03573641,0.00013113176],"about_ca_topic_score_codex":0.0000029226824,"about_ca_topic_score_gemma":0.000021859232,"teacher_disagreement_score":0.65234584,"about_ca_system_score_codex":0.000027358108,"about_ca_system_score_gemma":0.0000544585,"threshold_uncertainty_score":0.2402697},"labels":[],"label_agreement":null},{"id":"W2035703663","doi":"10.1016/j.ejca.2012.01.012","title":"Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Bevacizumab; Medicine; Colorectal cancer; Oncology; Internal medicine; Cost effectiveness; Population; Incremental cost-effectiveness ratio; Quality-adjusted life year; Chemotherapy; Surgery; Cancer","score_opus":0.017638798536171837,"score_gpt":0.2868710473545319,"score_spread":0.26923224881836005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035703663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718708,0.026550021,7.0996964e-7,0.00011535177,0.00039866052,0.0005144759,0.000112319125,0.000001455534,0.0004362194],"genre_scores_gemma":[0.9973327,0.0023050476,0.00001911589,0.000117474214,0.000081712154,0.000020824427,9.086144e-7,0.000019127856,0.000103069855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860954,0.00037451877,0.00039449087,0.000089310204,0.00034895033,0.00018319082],"domain_scores_gemma":[0.99909854,0.00010063803,0.00034977053,0.000071429036,0.00029177338,0.00008787565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005407405,0.00009652514,0.00044152729,0.00003078442,0.00005092668,0.000012989717,0.000088028486,0.000010157339,0.00012424652],"category_scores_gemma":[0.000057298887,0.00008314709,0.00008194544,0.0001502153,0.0001210235,0.00008606065,0.000047565183,0.00015469403,5.8452216e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013176658,0.00018866868,0.9115438,0.000119031145,0.0006158595,0.00005361314,0.0008763716,0.000014496598,0.010793289,9.2369766e-7,0.00030368468,0.074172586],"study_design_scores_gemma":[0.0044511515,0.00083327986,0.98665404,0.0006619712,0.00016760328,0.00011660857,0.00039184117,0.0000015201776,0.0054643834,0.0000014917938,0.0011834758,0.00007265583],"about_ca_topic_score_codex":0.60392016,"about_ca_topic_score_gemma":0.8382379,"teacher_disagreement_score":0.23431772,"about_ca_system_score_codex":0.00044766368,"about_ca_system_score_gemma":0.0006403138,"threshold_uncertainty_score":0.39871734},"labels":[],"label_agreement":null},{"id":"W2035910651","doi":"10.1016/s0959-8049(01)00133-2","title":"Comment on: The EUSOMA Position Paper on the requirements of a specialist breast unit, Eur J Cancer 2000, 36, 2288–2293","year":2001,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Psychosocial; Specialty; Multidisciplinary approach; Social work; Psycho-oncology; Service (business); Medicine; Quality (philosophy); Set (abstract data type); Psychology; Biopsychosocial model; Unit (ring theory); Nursing; Family medicine; Psychiatry; Computer science; Political science; Business","score_opus":0.15129353930882677,"score_gpt":0.3911628514633506,"score_spread":0.23986931215452384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035910651","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0087954365,0.0057057696,0.0000131286415,0.93076855,0.0012171734,0.0003377827,0.00032972428,0.000008031794,0.052824385],"genre_scores_gemma":[0.019558717,0.012482532,0.000037142065,0.9435549,0.018227791,0.000010713449,0.00004410897,0.0001325907,0.0059515247],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962977,0.0009846758,0.0009182773,0.00021835219,0.001257127,0.0003238634],"domain_scores_gemma":[0.99690014,0.000299624,0.0014347956,0.00048681762,0.00078038906,0.00009822954],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084196735,0.00037825262,0.0006828196,0.0001630092,0.00011097736,0.000032374162,0.00052984257,0.00009190025,0.003520205],"category_scores_gemma":[0.00009560341,0.00019912574,0.0003763605,0.00024179208,0.00022968848,0.00007534653,0.00005889182,0.0015687845,0.00003896683],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086425134,0.00010665613,0.0014096105,0.00009940227,0.0008036838,0.001046591,0.00089554174,0.00001756928,0.00040013925,0.000074209514,0.98876756,0.0055148094],"study_design_scores_gemma":[0.001331959,0.000686068,0.00870214,0.00980697,0.0004920096,0.000086294436,0.00021184704,0.0000013655506,0.00079606683,0.000024369487,0.9776783,0.00018261238],"about_ca_topic_score_codex":0.00020108349,"about_ca_topic_score_gemma":0.000028768192,"teacher_disagreement_score":0.04687286,"about_ca_system_score_codex":0.00043231793,"about_ca_system_score_gemma":0.00031620762,"threshold_uncertainty_score":0.9973907},"labels":[],"label_agreement":null},{"id":"W2038349091","doi":"10.1016/j.ejca.2011.09.002","title":"Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute","keywords":"Sunitinib; Medicine; Internal medicine; Cancer research; Oncology; Cancer; Urology","score_opus":0.02376342824592086,"score_gpt":0.2733685222410839,"score_spread":0.249605093995163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038349091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278283,0.0014378958,0.00001538284,0.00009905177,0.00029961302,0.00047977577,0.000036791524,0.000006425735,0.004842225],"genre_scores_gemma":[0.99737585,0.00021780016,0.0014376242,0.00012483113,0.00037414752,0.0000149817815,0.0000058206747,0.00006392613,0.00038504187],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99795914,0.00022543895,0.0008025636,0.0001949645,0.0005555794,0.00026233634],"domain_scores_gemma":[0.99819267,0.000024982664,0.00075853936,0.00024772523,0.00054596894,0.00023014516],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033510025,0.0002321933,0.0005362901,0.00022256956,0.000018223885,0.000007702946,0.00014979311,0.00003145287,0.0009303806],"category_scores_gemma":[0.0000263651,0.00015532042,0.00016287625,0.00020676632,0.00008436363,0.0001602621,0.000028671335,0.00036805216,0.000008527017],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7411074,0.007764436,0.12885062,0.00024441103,0.00060165767,0.0039570555,0.005057563,0.000114722156,0.0049107736,0.0000037142338,0.0011866207,0.10620101],"study_design_scores_gemma":[0.44949484,0.037083015,0.45841384,0.0017148029,0.0007327851,0.000027484637,0.00017616608,0.0000026847179,0.04063709,0.0000044289445,0.011355965,0.00035688523],"about_ca_topic_score_codex":0.000043276894,"about_ca_topic_score_gemma":0.000062786916,"teacher_disagreement_score":0.3295632,"about_ca_system_score_codex":0.00016104594,"about_ca_system_score_gemma":0.00028961187,"threshold_uncertainty_score":0.9999829},"labels":[],"label_agreement":null},{"id":"W2038644375","doi":"10.1016/j.ejca.2011.09.024","title":"Targeted agents: How to select the winners in preclinical and early clinical studies?","year":2011,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Drug development; Clinical trial; Medicine; Task force; Mechanism (biology); Targeted therapy; Drug discovery; Drug; Cancer; Pharmacology; Bioinformatics; Internal medicine; Biology; Political science","score_opus":0.14378565522380493,"score_gpt":0.4285920730104418,"score_spread":0.28480641778663685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038644375","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047283657,0.9933581,0.000023657536,0.00032218266,0.0010496503,0.0002696633,0.000022726019,0.0000015255875,0.00022415027],"genre_scores_gemma":[0.0014012974,0.99550307,0.00017837525,0.0005429843,0.0019692644,0.000008375306,0.000003020935,0.000059641712,0.00033396846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975016,0.0008473646,0.0009871813,0.00031472297,0.00012247793,0.00022663453],"domain_scores_gemma":[0.9983751,0.00016147029,0.00076760165,0.00029401097,0.000222186,0.00017962235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020855442,0.0002576017,0.00092954136,0.000075320844,0.000037592454,0.000045640867,0.00047611704,0.00009965143,0.000009313712],"category_scores_gemma":[0.0013117614,0.00016206769,0.00038327702,0.00013574644,0.00013105571,0.0000037225204,0.00026764025,0.00053156953,0.000005541271],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103232655,0.000041158448,0.00070549425,0.0002906289,0.0007304813,0.00006941457,0.0001413804,0.0000050598287,0.0000061102733,0.000005634912,0.044116005,0.9537854],"study_design_scores_gemma":[0.00043988018,0.0007224425,0.0022098494,0.0016234992,0.00035767912,0.000029378389,0.00002404222,1.5312321e-7,0.0000041001017,0.0000035556498,0.9943929,0.00019255427],"about_ca_topic_score_codex":0.000005908888,"about_ca_topic_score_gemma":0.000048222406,"teacher_disagreement_score":0.95359284,"about_ca_system_score_codex":0.000043801145,"about_ca_system_score_gemma":0.00036076465,"threshold_uncertainty_score":0.6608929},"labels":[],"label_agreement":null},{"id":"W2038780142","doi":"10.1016/j.ejca.2015.02.005","title":"Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Minimal clinically important difference; Quality of life (healthcare); Lapatinib; Placebo; Breast cancer; Discontinuation; SF-36; Randomized controlled trial; Internal medicine; Physical therapy; Adverse effect; Cancer; Health related quality of life; Disease; Alternative medicine","score_opus":0.09232333326504484,"score_gpt":0.4008121555903717,"score_spread":0.3084888223253269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038780142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936742,0.002172035,0.000010051433,0.001166592,0.0003245349,0.0015589356,0.00018181559,0.000010904081,0.0009009281],"genre_scores_gemma":[0.9986515,0.00044012483,0.00009931056,0.000091634414,0.00033582526,0.00003744605,0.0000027479373,0.00008276202,0.00025863657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9877687,0.005707784,0.0041269073,0.00027157026,0.0014628047,0.0006622377],"domain_scores_gemma":[0.9938034,0.0005223629,0.003686737,0.00030881437,0.0009247441,0.00075398467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01585239,0.00026073493,0.0029233657,0.000520531,0.00002568544,0.000014757889,0.00033295396,0.00007749933,0.0006465787],"category_scores_gemma":[0.003489321,0.00020442414,0.00029934067,0.00043472016,0.00023784717,0.00019850656,0.00007254731,0.0009934782,0.0000011859387],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80764824,0.00085054245,0.14349452,0.0008131264,0.00050185906,0.0000667301,0.021513646,0.00028315917,0.016391605,0.000013329624,0.0009370564,0.0074861986],"study_design_scores_gemma":[0.67160183,0.002602907,0.3206353,0.0024761152,0.000033930763,0.0000060302737,0.0010906919,0.00003956471,0.0010632331,0.000009932566,0.00026535644,0.00017514329],"about_ca_topic_score_codex":0.00998591,"about_ca_topic_score_gemma":0.00047116823,"teacher_disagreement_score":0.17714079,"about_ca_system_score_codex":0.001644889,"about_ca_system_score_gemma":0.0041221203,"threshold_uncertainty_score":0.9966067},"labels":[],"label_agreement":null},{"id":"W2039410030","doi":"10.1016/j.ejca.2007.04.018","title":"Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: Vitamin D as a possible explanation","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Manitoba; BC Cancer Agency; CancerCare Manitoba","funders":"National Cancer Institute; Tays","keywords":"Melanoma; Sun exposure; Medicine; Dermatology; Sun protection; Vitamin; Sunlight; Cancer research; Oncology; Internal medicine; Physics; Astronomy","score_opus":0.009482973992361036,"score_gpt":0.2795277690134836,"score_spread":0.27004479502112255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039410030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681572,0.01206491,0.0010226315,0.0040468597,0.0018366063,0.00077693234,0.000103093924,0.000037398637,0.011954411],"genre_scores_gemma":[0.9911013,0.002014974,0.00040702577,0.0017495482,0.0025741074,0.000029777606,0.000014794323,0.00010531897,0.002003105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99675304,0.00027696518,0.0009947026,0.00038431192,0.001024124,0.00056685024],"domain_scores_gemma":[0.9975126,0.00016559019,0.0011556236,0.00041334608,0.00044422343,0.0003086281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001594864,0.0003772535,0.0006210204,0.00023753587,0.00027478018,0.00008627566,0.000499597,0.000076801574,0.0006430671],"category_scores_gemma":[0.00019092284,0.0002099342,0.00021357977,0.00044336866,0.00023008994,0.0002627222,0.00009313641,0.0008171795,0.000080745434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01012752,0.00039496107,0.19100603,0.00023775345,0.005799296,0.005783126,0.029133305,0.0002581687,0.06686513,0.000019937463,0.18278405,0.5075907],"study_design_scores_gemma":[0.009599743,0.0035407944,0.5185702,0.0018873609,0.0007676696,0.00046336025,0.0050369743,0.000030366546,0.24848089,0.00011607809,0.21074297,0.0007636171],"about_ca_topic_score_codex":0.0036826879,"about_ca_topic_score_gemma":0.0011600106,"teacher_disagreement_score":0.5068271,"about_ca_system_score_codex":0.0014445438,"about_ca_system_score_gemma":0.0010581835,"threshold_uncertainty_score":0.85608685},"labels":[],"label_agreement":null},{"id":"W2039704180","doi":"10.1016/j.ejca.2013.01.035","title":"Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group","year":2013,"lang":"de","type":"article","venue":"European Journal of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Serous fluid; Retrospective cohort study; Stage (stratigraphy); Prospective cohort study; Ovarian cancer; Cohort; Internal medicine; Oncology; Cancer; Multivariate analysis; Cohort study; Gynecology","score_opus":0.024531381608693975,"score_gpt":0.2950203833766818,"score_spread":0.27048900176798785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039704180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512736,0.03338687,0.000009233805,0.0062671513,0.004319838,0.0033693262,0.000029057039,0.000009982558,0.0013349184],"genre_scores_gemma":[0.99412376,0.0032865833,0.000062716346,0.0005018284,0.0013770696,0.00005728474,9.5275766e-7,0.00008584664,0.00050398643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99317527,0.0024587621,0.001993768,0.00043682416,0.0014600724,0.00047529835],"domain_scores_gemma":[0.99420536,0.00025448963,0.002998658,0.0013088473,0.0010231821,0.00020948322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026601013,0.0004879223,0.0012964505,0.00015237587,0.00018764821,0.000045140914,0.0012600303,0.00005795477,0.000905608],"category_scores_gemma":[0.00044827882,0.00023771591,0.00055451674,0.00067246624,0.0003828508,0.00014442741,0.0004974189,0.0010034648,0.00003594186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003734796,0.008710083,0.96086377,0.000063100146,0.0046101273,0.00023709494,0.0031222834,0.0003558099,0.00014948145,0.000017852579,0.009539196,0.011957731],"study_design_scores_gemma":[0.00928001,0.008697624,0.9635856,0.0007685225,0.0063047367,0.000016053198,0.004586127,0.000016278307,0.00033883934,0.000013092326,0.006194017,0.00019906674],"about_ca_topic_score_codex":0.001227247,"about_ca_topic_score_gemma":0.0002910013,"teacher_disagreement_score":0.042850107,"about_ca_system_score_codex":0.00025330193,"about_ca_system_score_gemma":0.0005218071,"threshold_uncertainty_score":0.9915772},"labels":[],"label_agreement":null},{"id":"W2040188695","doi":"10.1016/j.ejca.2007.01.020","title":"ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Renal cell carcinoma; Medicine; Performance status; Oncology; Internal medicine; Carcinoma; Overall survival; Urology","score_opus":0.03682240408196857,"score_gpt":0.2735863110909505,"score_spread":0.23676390700898192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040188695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988802,0.0022178795,0.00024151827,0.00083603256,0.0005985111,0.0003669771,0.000019271058,0.000011898072,0.006905902],"genre_scores_gemma":[0.99658644,0.0008280601,0.00042859153,0.00020004918,0.0010214669,0.0000034439242,0.000002154923,0.00004028839,0.0008894802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978852,0.00021378491,0.00066949386,0.00026645523,0.00059772085,0.0003673235],"domain_scores_gemma":[0.9982519,0.00015533465,0.00037658843,0.00038719046,0.0004045885,0.00042439857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020523337,0.00020271973,0.00029513845,0.00011471528,0.000116339084,0.000053850177,0.00017109614,0.000027894846,0.00013661647],"category_scores_gemma":[0.000056386496,0.000112631795,0.00010225632,0.00017864635,0.00011719627,0.000113638016,0.000055274035,0.00039081843,0.000022140075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0119714895,0.00027769592,0.42432928,0.00021194802,0.00012938373,0.00067553326,0.0033608114,0.000101007725,0.27606544,0.00001701846,0.00311486,0.27974555],"study_design_scores_gemma":[0.0021022763,0.0019546128,0.93913555,0.000079266436,0.00012692154,0.0001128304,0.00031961553,0.000034591503,0.025561206,8.6541155e-7,0.030456807,0.00011546986],"about_ca_topic_score_codex":0.0000137247325,"about_ca_topic_score_gemma":0.000011608141,"teacher_disagreement_score":0.5148063,"about_ca_system_score_codex":0.00042324295,"about_ca_system_score_gemma":0.0002325211,"threshold_uncertainty_score":0.45929912},"labels":[],"label_agreement":null},{"id":"W2040407404","doi":"10.1016/j.ejca.2011.05.024","title":"Gene expression analysis of blastemal component reveals genes associated with relapse mechanism in Wilms tumour","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stollery Children's Hospital","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Wilms' tumor; Chemotherapy; Gene; Biology; Wilms tumour; Stromal cell; Blastema; Cancer research; Oncology; Medicine; Internal medicine; Pathology; Regeneration (biology); Genetics","score_opus":0.013997591125990097,"score_gpt":0.22439702190175226,"score_spread":0.21039943077576218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040407404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951648,0.0033048026,0.0005059104,0.000021949272,0.00012113707,0.000050434996,0.000011828638,0.0000020210234,0.00081707735],"genre_scores_gemma":[0.9977054,0.001412923,0.0004515689,0.0000480702,0.00008653488,0.0000011738935,0.000007792664,0.000020774458,0.00026577665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872893,0.00029564253,0.00046874577,0.00014703172,0.00021445924,0.00014518082],"domain_scores_gemma":[0.9989173,0.0000062021286,0.0006662922,0.00013007465,0.00019764526,0.000082526945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005112121,0.00012109037,0.00030663688,0.00016434763,0.00002331106,0.0000051880384,0.00019158615,0.000046362515,0.000041850722],"category_scores_gemma":[0.00001685887,0.00008099609,0.00016104923,0.00025968274,0.00004673433,0.000006392756,0.00004173957,0.00013850957,7.4870246e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048190655,0.00007256655,0.008102371,0.000008722759,0.0010436991,0.00012528036,0.00031377183,0.0029898232,0.98607624,0.000004684027,0.0001615559,0.00061939075],"study_design_scores_gemma":[0.0012432965,0.0006962423,0.06534763,0.0003901237,0.0005652757,0.00001788551,0.00012323707,0.000041552106,0.9312174,0.000010193299,0.0001893695,0.00015785167],"about_ca_topic_score_codex":0.000023208422,"about_ca_topic_score_gemma":0.000037492802,"teacher_disagreement_score":0.05724526,"about_ca_system_score_codex":0.0000294183,"about_ca_system_score_gemma":0.00005854192,"threshold_uncertainty_score":0.33029246},"labels":[],"label_agreement":null},{"id":"W2041130945","doi":"10.1016/j.ejca.2004.10.017","title":"Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":293,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; Telus (Canada)","funders":"","keywords":"Interpretation (philosophy); Clinical trial; Quality of life (healthcare); Baseline (sea); Meaning (existential); Medicine; Medical physics; Psychology; Computer science; Psychotherapist; Pathology; Nursing","score_opus":0.8171980228626496,"score_gpt":0.5882876650280776,"score_spread":0.22891035783457203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041130945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.938427,0.020244049,0.018761339,0.013893171,0.0029670023,0.0005868111,0.004600202,0.0000033055194,0.00051716133],"genre_scores_gemma":[0.9940955,0.0018539098,0.0017993947,0.0016432571,0.0005136277,0.000003389899,0.00004862575,0.00001778294,0.000024495881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9441301,0.018983295,0.035670068,0.0004872086,0.0005190229,0.00021028997],"domain_scores_gemma":[0.95282054,0.0060220347,0.039998595,0.00049622165,0.00046982674,0.00019275755],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.27774876,0.0001536854,0.004265682,0.00030093794,0.00006403114,0.000015326255,0.00072950975,0.000082940256,0.00016045947],"category_scores_gemma":[0.07226151,0.00013071476,0.00060488295,0.00045138036,0.00028929004,0.0003584302,0.00011766547,0.00037347394,0.0000013515336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018523457,0.00088404206,0.8772725,0.0011688863,0.015052452,0.000001032853,0.0036786264,0.049282566,0.000025909605,0.010271397,0.01671296,0.023797285],"study_design_scores_gemma":[0.007315487,0.00019377389,0.9757355,0.0006478966,0.0004811592,0.0000010243557,0.0005740004,0.008279354,0.000007911705,0.0013795022,0.0051673274,0.00021709349],"about_ca_topic_score_codex":0.13613594,"about_ca_topic_score_gemma":0.061215386,"teacher_disagreement_score":0.20548725,"about_ca_system_score_codex":0.00035247876,"about_ca_system_score_gemma":0.0040132664,"threshold_uncertainty_score":0.955915},"labels":[],"label_agreement":null},{"id":"W2041181326","doi":"10.1016/s0959-8049(01)00161-7","title":"The adolescent with cancer","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Scopus; Medicine; Mandate; Task force; Clinical trial; Family medicine; MEDLINE; Cancer; Alternative medicine; Oncology; Internal medicine; Pathology","score_opus":0.03116666699167262,"score_gpt":0.3202539363038924,"score_spread":0.28908726931221973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041181326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79269934,0.06320965,0.0009793398,0.1123583,0.0022698327,0.00036134585,0.000009757654,0.000052442643,0.028059974],"genre_scores_gemma":[0.97121143,0.013579535,0.00021647265,0.006918592,0.0036156576,0.000003340583,4.4093707e-7,0.00006832177,0.004386213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980901,0.00026434968,0.00051797525,0.00013389687,0.0007219713,0.0002717459],"domain_scores_gemma":[0.99849164,0.000059957165,0.00048515046,0.0002710387,0.0004381842,0.00025400493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011039309,0.00015336677,0.000287589,0.000055374654,0.00013663864,0.00004677555,0.00024783236,0.000013955445,0.00030557998],"category_scores_gemma":[0.00007074085,0.00008330191,0.00013341074,0.00020216747,0.00013357394,0.00009038479,0.00003129049,0.00045621663,0.000023180593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070872842,0.00040706454,0.2831047,0.00017485752,0.0012993959,0.0024940912,0.003928482,0.0004983044,0.0010594687,0.000118155454,0.20226803,0.49756017],"study_design_scores_gemma":[0.0021981755,0.0004257676,0.2793969,0.0010734148,0.00015531284,0.00043377953,0.0003413606,0.000005799746,0.00029849613,0.0000058884402,0.71555287,0.000112272195],"about_ca_topic_score_codex":0.000087265136,"about_ca_topic_score_gemma":0.0003668678,"teacher_disagreement_score":0.5132848,"about_ca_system_score_codex":0.00015512726,"about_ca_system_score_gemma":0.00038981455,"threshold_uncertainty_score":0.33969533},"labels":[],"label_agreement":null},{"id":"W2041595299","doi":"10.1016/j.ejca.2008.05.012","title":"Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Chemotherapy; Radiation therapy; Germ cell; Germ cell tumors; Surgery; Retrospective cohort study; Internal medicine; Oncology; Biology","score_opus":0.011850486022384173,"score_gpt":0.23788537317931113,"score_spread":0.22603488715692696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041595299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932881,0.0027202074,0.00000913633,0.00043619695,0.00026123147,0.00016219288,0.000009466534,0.00000848274,0.003104966],"genre_scores_gemma":[0.9960761,0.0017198826,0.00082824315,0.00087759394,0.0002657677,0.0000027623914,0.0000066383504,0.000051036688,0.00017198337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986074,0.000119124525,0.00051692425,0.0001516602,0.00037359825,0.00023127717],"domain_scores_gemma":[0.9990736,0.000058175603,0.00041074827,0.0001402871,0.00014345281,0.00017369607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021943945,0.00018056257,0.00040815357,0.00019252104,0.000051192994,0.00001474819,0.000106494466,0.000016588805,0.00016150439],"category_scores_gemma":[0.000023283756,0.00013371532,0.00015840595,0.00015040168,0.000038167105,0.00011950192,0.000026214673,0.00018997329,0.000028565048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057952513,0.0017748607,0.95108396,0.00008223321,0.00020622119,0.007034749,0.0007434621,0.00012309632,0.0039956616,0.0000029636208,0.012726898,0.021646352],"study_design_scores_gemma":[0.013831746,0.00075939205,0.9676834,0.0003155378,0.000094955,0.0002050222,0.00003112897,0.0000036955626,0.014780568,0.000003114071,0.0021693863,0.00012207533],"about_ca_topic_score_codex":0.000034855475,"about_ca_topic_score_gemma":0.000009838084,"teacher_disagreement_score":0.021524277,"about_ca_system_score_codex":0.00026873418,"about_ca_system_score_gemma":0.000204858,"threshold_uncertainty_score":0.5452753},"labels":[],"label_agreement":null},{"id":"W2041606368","doi":"10.1016/j.ejca.2010.02.031","title":"Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG)","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"PTEN; Microsatellite instability; Medicine; Internal medicine; Hazard ratio; Endometrial cancer; Oncology; Univariate analysis; Cancer; Proportional hazards model; Multivariate analysis; Breast cancer; Confidence interval; Biology; Microsatellite; Gene","score_opus":0.09425914865038842,"score_gpt":0.4007130252521585,"score_spread":0.3064538766017701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041606368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98173094,0.015563494,0.0000066692387,0.0005239267,0.001236841,0.00058745325,0.00018121168,0.000004821516,0.00016466143],"genre_scores_gemma":[0.99107134,0.007241641,0.0005375529,0.00011774145,0.00095683127,0.000013250548,0.000001618627,0.00002502031,0.000035027646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994513,0.0019645302,0.002358181,0.00029928185,0.0006250556,0.00023995813],"domain_scores_gemma":[0.9939689,0.0030352108,0.0020268408,0.00032862442,0.00043059373,0.00020985551],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008101575,0.0002123598,0.0014764535,0.00018862006,0.000043178334,0.0000130106455,0.00023703725,0.00006124135,0.0000748727],"category_scores_gemma":[0.00980375,0.00010380352,0.00022051233,0.00059339404,0.00044891192,0.00010271192,0.000119171724,0.00065884256,4.917895e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09741269,0.0008569253,0.5516083,0.00023235696,0.0012864108,0.00009892905,0.0034464435,0.000026787824,0.080685355,0.000005891265,0.00012389371,0.26421598],"study_design_scores_gemma":[0.04008267,0.0025005406,0.93420124,0.0019742341,0.00058097515,0.000010914725,0.00041711592,0.0000028960706,0.017357014,0.00010838862,0.0026380757,0.00012595646],"about_ca_topic_score_codex":0.00023943147,"about_ca_topic_score_gemma":0.00018545771,"teacher_disagreement_score":0.38259286,"about_ca_system_score_codex":0.0001430747,"about_ca_system_score_gemma":0.00032047884,"threshold_uncertainty_score":0.9985371},"labels":[],"label_agreement":null},{"id":"W2042103604","doi":"10.1016/j.ejca.2012.02.003","title":"Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Prostate cancer; Androgen deprivation therapy; External beam radiotherapy; Cohort; Clinical endpoint; Internal medicine; Oncology; Prostate; Cancer; Surgery; Clinical trial","score_opus":0.008923851486553235,"score_gpt":0.2531272085680636,"score_spread":0.24420335708151036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042103604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.942945,0.05518978,0.000001915811,0.00067741313,0.00038298554,0.00041632782,0.00034460498,0.000006107748,0.000035838097],"genre_scores_gemma":[0.93836164,0.06093865,0.00008163953,0.00020139603,0.00026100923,0.000049870483,0.000011158215,0.000050411363,0.000044224736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833566,0.00019387,0.0006846727,0.00017897578,0.00028030257,0.000326501],"domain_scores_gemma":[0.99860716,0.00007492938,0.0006970429,0.00012229245,0.0002206459,0.00027790564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031068426,0.00022505432,0.00049700664,0.00016920279,0.00002889103,0.00001573412,0.000083634484,0.000028026192,0.00016835914],"category_scores_gemma":[0.000063723346,0.00016128377,0.00009264865,0.0002012314,0.00012257355,0.0001951498,0.00002529139,0.00022795983,0.0000016416727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056888384,0.000637422,0.88058925,0.00007678191,0.00029253907,0.000066065375,0.0027347442,0.0000019493677,0.0003464716,7.7207966e-7,0.0030466437,0.1116385],"study_design_scores_gemma":[0.0070935944,0.0016707432,0.9743662,0.0007008135,0.0003302251,0.000018810148,0.00004413419,0.00000636732,0.012054887,0.0000023531204,0.0035681354,0.00014374488],"about_ca_topic_score_codex":0.00057085446,"about_ca_topic_score_gemma":0.000015315733,"teacher_disagreement_score":0.11149476,"about_ca_system_score_codex":0.00029815265,"about_ca_system_score_gemma":0.00008233949,"threshold_uncertainty_score":0.6576961},"labels":[],"label_agreement":null},{"id":"W2042896255","doi":"10.1016/j.ejca.2011.10.009","title":"Treatment-related mortality in children with acute myeloid leukaemia in Central America: Incidence, timing and predictors","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Hospital for Sick Children","keywords":"Myeloid leukaemia; Incidence (geometry); Medicine; Pediatrics; Myeloid; Chronic myeloid leukaemia; Oncology; Demography; Internal medicine","score_opus":0.024512929396593688,"score_gpt":0.28862630455080257,"score_spread":0.2641133751542089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042896255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954439,0.00091180677,0.000023670296,0.00015353988,0.00005133865,0.000247424,0.000008085275,0.0000112342395,0.0031490338],"genre_scores_gemma":[0.9962521,0.0026407025,0.0006044399,0.00008452529,0.000113024646,0.0000030768474,0.000003664309,0.00003840048,0.00026003155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834025,0.00023820178,0.0005076091,0.00020360884,0.00033327757,0.00037705989],"domain_scores_gemma":[0.9991914,0.000019288049,0.00026591105,0.00016597462,0.00008802719,0.0002694008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029603875,0.00018074378,0.00040375325,0.00029352854,0.000028179065,0.000014160364,0.00014440685,0.000032617874,0.00014156493],"category_scores_gemma":[0.000037611746,0.00012190484,0.00005574211,0.00038810406,0.0001932589,0.00021717473,0.000045770787,0.0005436316,0.000005314173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070486224,0.000087263594,0.9752696,0.000006464999,0.00052568864,0.0030499743,0.0027174414,0.000039545204,0.00053125265,0.0000025945526,0.00008064335,0.016984643],"study_design_scores_gemma":[0.005714563,0.0011280156,0.9905985,0.00023427319,0.00021656753,0.0010315321,0.00015001764,0.00009032745,0.00052300724,0.0000035753678,0.00019844944,0.00011114756],"about_ca_topic_score_codex":0.00091509655,"about_ca_topic_score_gemma":0.00012980896,"teacher_disagreement_score":0.016873496,"about_ca_system_score_codex":0.0007108831,"about_ca_system_score_gemma":0.0005574219,"threshold_uncertainty_score":0.49711353},"labels":[],"label_agreement":null},{"id":"W2043627878","doi":"10.1016/s0959-8049(01)00204-0","title":"Canada's Population Health Model (POHEM)","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Statistics Canada","funders":"","keywords":"Breast cancer; Medicine; Tamoxifen; Psychological intervention; Lung cancer; Health care; Population; Intensive care medicine; Economic evaluation; Cancer; Cost–benefit analysis; Oncology; Environmental health; Internal medicine; Nursing; Economic growth","score_opus":0.08322134139338684,"score_gpt":0.35753648447330155,"score_spread":0.2743151430799147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043627878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92646515,0.012267031,0.004065932,0.034879416,0.00056161487,0.00013219332,0.000009751812,0.000017382565,0.021601496],"genre_scores_gemma":[0.9867748,0.0007062341,0.0009863321,0.0097729275,0.0005822631,2.5833637e-7,0.0000019516367,0.000015915337,0.0011593163],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988447,0.000064322216,0.00037643558,0.00007615291,0.00046102604,0.00017739592],"domain_scores_gemma":[0.9991608,0.000006066734,0.0003013644,0.00009523661,0.0002059589,0.00023055082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004592874,0.00007529654,0.00020004036,0.000047641093,0.000053782765,0.000011171339,0.00008565898,0.00000793113,0.000100088626],"category_scores_gemma":[0.00003543244,0.0000606168,0.00005902633,0.000111538786,0.000010009536,0.00008902554,0.000010734203,0.0001818262,0.0000024766282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009306775,0.000043316013,0.22028065,0.000053772153,0.00013056962,0.0016760342,0.00038197095,0.041500628,0.0004538233,0.0001454573,0.36075935,0.37364376],"study_design_scores_gemma":[0.0018865746,0.00048745755,0.6609871,0.0007682899,0.00007516943,0.0008897238,0.00014673723,0.0036556483,0.00007702267,0.00004900495,0.330811,0.00016628034],"about_ca_topic_score_codex":0.1567652,"about_ca_topic_score_gemma":0.14329183,"teacher_disagreement_score":0.44070646,"about_ca_system_score_codex":0.00048134968,"about_ca_system_score_gemma":0.0012862575,"threshold_uncertainty_score":0.87234086},"labels":[],"label_agreement":null},{"id":"W2044681105","doi":"10.1016/j.ejca.2012.04.010","title":"Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Tissue microarray; Immunohistochemistry; Basal (medicine); Proportional hazards model; Stage (stratigraphy); Pathology; Medicine; Basal cell; Oncology; Pathological; Survival analysis; Internal medicine; Biology","score_opus":0.02692908770305133,"score_gpt":0.301574401429819,"score_spread":0.2746453137267677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044681105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833927,0.00898521,0.003084837,0.001141013,0.00019891947,0.00022109807,0.00006551446,0.000008961426,0.0029017024],"genre_scores_gemma":[0.9971308,0.00007802838,0.0016601883,0.00023661648,0.00045572518,0.000008359373,0.000009319183,0.000030793977,0.00039017532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987211,0.00008598973,0.00044785455,0.00013204434,0.00032663555,0.00028637785],"domain_scores_gemma":[0.99906117,0.00005479134,0.00024609204,0.000119595505,0.00031208326,0.00020627145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054960256,0.00013693195,0.00039636492,0.00016839203,0.000046718964,0.000030339917,0.00009228308,0.000021588434,0.00009385913],"category_scores_gemma":[0.00015179961,0.00010287068,0.00019955341,0.00025362562,0.000041421128,0.0003205483,0.00002719584,0.00016782056,0.000007829578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022153899,0.00082077424,0.7526961,0.00018538859,0.00031308425,0.00008315294,0.0066482434,0.0000442988,0.09001057,0.0000011147896,0.11018396,0.036797922],"study_design_scores_gemma":[0.008501001,0.0015676793,0.8215231,0.00021645658,0.0016031842,0.000021912321,0.0006957005,0.00034681556,0.11366628,0.0000026574319,0.05148999,0.0003652315],"about_ca_topic_score_codex":0.000010451764,"about_ca_topic_score_gemma":0.0000028205804,"teacher_disagreement_score":0.068826996,"about_ca_system_score_codex":0.0001137655,"about_ca_system_score_gemma":0.000078893914,"threshold_uncertainty_score":0.41949448},"labels":[],"label_agreement":null},{"id":"W2044736010","doi":"10.1016/j.ejca.2010.10.026","title":"Factors contributing to the efficacy of concurrent–adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Hong Kong Cancer Fund","keywords":"Nasopharyngeal carcinoma; Medicine; Regimen; Oncology; Cisplatin; Radiation therapy; Internal medicine; Adjuvant; Fluorouracil; Chemoradiotherapy; Chemotherapy","score_opus":0.10007909754137531,"score_gpt":0.404205237086043,"score_spread":0.3041261395446677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044736010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98600364,0.008695257,0.000366227,0.0032257594,0.00081584277,0.0006227495,0.00009765888,0.0000063042526,0.00016659104],"genre_scores_gemma":[0.99807537,0.0006113639,0.00022897212,0.0003524386,0.0006148799,0.0000055006044,0.000003960942,0.000032187305,0.00007532051],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99784964,0.0002211587,0.0011236542,0.00016751056,0.00036066413,0.0002773662],"domain_scores_gemma":[0.9966706,0.0009635086,0.0011343554,0.00018405246,0.00086345023,0.00018405609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021155602,0.00020903045,0.0013392938,0.00011845526,0.00010341916,0.000011638258,0.00019737027,0.000027224378,0.00005634868],"category_scores_gemma":[0.0014877978,0.000116179806,0.00035923146,0.00016989482,0.00017360935,0.000058198606,0.000048191578,0.00027831926,3.8224826e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013928054,0.0005191697,0.14966862,0.00044181553,0.0024968178,0.000045013876,0.007278853,0.00010404056,0.54568446,0.00017112923,0.009122844,0.27053916],"study_design_scores_gemma":[0.024682242,0.003228304,0.8549617,0.0006296806,0.00072562526,0.000016541844,0.00045478417,0.0000320382,0.09098241,0.000009587519,0.024092084,0.0001850383],"about_ca_topic_score_codex":0.000018694629,"about_ca_topic_score_gemma":0.000022567683,"teacher_disagreement_score":0.70529306,"about_ca_system_score_codex":0.000034874407,"about_ca_system_score_gemma":0.00022425824,"threshold_uncertainty_score":0.4737675},"labels":[],"label_agreement":null},{"id":"W2045623031","doi":"10.1016/j.ejca.2006.07.020","title":"Mapping the emergence and development of translational cancer research","year":2006,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; McGill University","funders":"","keywords":"Allegiance; Citation; Cancer; Translational research; Principal (computer security); Data science; Computer science; Biology; Political science; Library science; Biotechnology; Genetics","score_opus":0.35249280971067737,"score_gpt":0.4897122626779003,"score_spread":0.13721945296722293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045623031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9099873,0.027089732,0.0015681149,0.052399777,0.00020585135,0.00021015372,0.000004760971,0.0000033510266,0.008531017],"genre_scores_gemma":[0.9947883,0.0022057043,0.0011552504,0.0005436328,0.0006610059,0.0000022372042,5.046597e-7,0.000010229587,0.00063312816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979594,0.00024408141,0.00042298718,0.00006256753,0.0009987389,0.00031225322],"domain_scores_gemma":[0.9985591,0.000121061836,0.00010645052,0.000059172122,0.0005476582,0.0006065382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004870484,0.000047784895,0.00012913416,0.00012203936,0.00010145035,0.000006661727,0.00009174542,0.000011415084,0.00042286998],"category_scores_gemma":[0.0009593686,0.000027005524,0.000025788206,0.00020766782,0.00015060973,0.000041584586,0.00001724046,0.00039941975,0.0000034228788],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038940346,0.00007616531,0.019508684,0.0003073955,0.00007845576,0.00011749849,0.0041379645,0.0000451009,0.02294436,0.000070270966,0.059197556,0.89312714],"study_design_scores_gemma":[0.0009344995,0.00011980486,0.39400813,0.00061346305,0.00000694095,0.000025967722,0.0002873458,0.00002095975,0.0024207344,0.000026458107,0.6015018,0.00003390327],"about_ca_topic_score_codex":0.000067566245,"about_ca_topic_score_gemma":0.000043651096,"teacher_disagreement_score":0.8930932,"about_ca_system_score_codex":0.000053101296,"about_ca_system_score_gemma":0.0038163594,"threshold_uncertainty_score":0.6770058},"labels":[],"label_agreement":null},{"id":"W2045634297","doi":"10.1016/j.ejca.2009.03.002","title":"Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Medical Research Council; Fondation pour la Recherche Médicale; Australian Research Council; University of New South Wales; Cure Cancer Australia Foundation; Cancer Institute NSW","keywords":"Clusterin; Cancer research; Histone deacetylase; Apoptosis; Biology; Cancer cell; Histone deacetylase inhibitor; Cell growth; Trichostatin A; Cell cycle checkpoint; Programmed cell death; Cell cycle; Cancer; Histone; Gene; Biochemistry; Genetics","score_opus":0.013868872444160962,"score_gpt":0.3486491773841183,"score_spread":0.33478030493995736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045634297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883278,0.006727955,0.00012393449,0.0030833387,0.0005213853,0.00027052045,0.00006516579,0.000007989752,0.00087190827],"genre_scores_gemma":[0.9967672,0.00045700886,0.00020869442,0.0010021603,0.0005385918,0.0000026837165,5.9694435e-7,0.00003190117,0.0009911521],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801534,0.00041729858,0.0007097229,0.00017273054,0.00048930047,0.00019557813],"domain_scores_gemma":[0.9983655,0.000083040315,0.0007405814,0.0003655684,0.00025267518,0.00019258956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005875656,0.0001801608,0.00055522297,0.00014643886,0.000036985755,0.0000068830973,0.0002580158,0.000031005253,0.00038193993],"category_scores_gemma":[0.00021953821,0.000111740286,0.00023500244,0.00020065648,0.00009733023,0.00006629946,0.00007795578,0.0002573491,0.000005881417],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005084223,0.00012043096,0.0066151917,0.00028987226,0.00007229832,0.00021670361,0.0015551927,0.0001855792,0.92114335,0.0000013028226,0.04569097,0.019024896],"study_design_scores_gemma":[0.00381197,0.001855219,0.26699352,0.0026088904,0.00021621423,0.000041361345,0.000035294346,0.000010133152,0.687547,0.0000020456769,0.036728878,0.00014943944],"about_ca_topic_score_codex":0.000008286214,"about_ca_topic_score_gemma":0.000008019554,"teacher_disagreement_score":0.26037833,"about_ca_system_score_codex":0.00014240446,"about_ca_system_score_gemma":0.00010606461,"threshold_uncertainty_score":0.45566365},"labels":[],"label_agreement":null},{"id":"W2045773374","doi":"10.1016/s0959-8049(09)70046-2","title":"Cardiovascular toxicity of molecularly targeted agents","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Credit Valley Hospital","funders":"","keywords":"Medicine; Toxicity; Adverse effect; Cardiac toxicity; Clinical trial; Oncology; Cancer; Breast cancer; Pharmacology; Internal medicine; Bioinformatics; Intensive care medicine","score_opus":0.007077916973406823,"score_gpt":0.23967190849858122,"score_spread":0.2325939915251744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045773374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532985,0.041123215,0.0019637125,0.00010029454,0.00021400709,0.000058167927,0.000004010854,0.000003119065,0.0032349916],"genre_scores_gemma":[0.99721396,0.0016907956,0.00042894413,0.00020670779,0.00028893628,2.2288961e-7,0.000003014636,0.000016871632,0.00015057178],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896765,0.000249476,0.0002925047,0.00011462476,0.00023692539,0.00013881855],"domain_scores_gemma":[0.9992894,0.0000023807,0.00021551656,0.00020349963,0.00019221315,0.000097020056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004623128,0.00010758748,0.00020382597,0.000046104222,0.000025622327,0.000009006066,0.00020617059,0.000042153875,0.000015937956],"category_scores_gemma":[0.00004654562,0.00008712665,0.0004041462,0.00008240228,0.0000351171,0.000004761046,0.000025053556,0.00014254184,0.0000034735172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014142308,0.00005700595,0.00029410332,0.0000073948836,0.00062450004,0.00016312255,0.00005047494,0.0014282182,0.963865,0.0000068563822,0.0024952441,0.030866649],"study_design_scores_gemma":[0.0012383818,0.0012706994,0.013362515,0.000062569394,0.00017368997,0.0000828939,0.000013488811,0.00001449891,0.93698955,0.000010779094,0.04663229,0.00014863501],"about_ca_topic_score_codex":0.0000016199971,"about_ca_topic_score_gemma":1.5172178e-7,"teacher_disagreement_score":0.044137046,"about_ca_system_score_codex":0.0000111799845,"about_ca_system_score_gemma":0.00005655199,"threshold_uncertainty_score":0.35529217},"labels":[],"label_agreement":null},{"id":"W2049025598","doi":"10.1016/j.ejca.2011.09.027","title":"A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Trabectedin; Rhabdomyosarcoma; Medicine; Soft tissue sarcoma; Sarcoma; Internal medicine; Oncology; Surgery; Pathology","score_opus":0.02899925368144633,"score_gpt":0.30697574675091366,"score_spread":0.2779764930694673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049025598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799602,0.016742432,0.00013927993,0.00093504513,0.00031250194,0.0011719187,0.000047492176,0.000016148582,0.0006749496],"genre_scores_gemma":[0.9950074,0.001228419,0.0025173153,0.00023927524,0.0008574167,0.000035465353,0.000024394685,0.00007488261,0.000015452932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965009,0.0006151375,0.0014369724,0.00043056294,0.00060475944,0.0004116317],"domain_scores_gemma":[0.9974398,0.00026300226,0.0012990681,0.00049570954,0.00020856694,0.0002938668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001288055,0.00039427637,0.0010662978,0.0002567163,0.000091073285,0.000028020868,0.00034500874,0.00007100212,0.00015558317],"category_scores_gemma":[0.00016203056,0.00023817437,0.0002275177,0.00031624592,0.0002928185,0.0001712375,0.000101445185,0.00067533273,0.0000035142402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025269665,0.0049091754,0.53548837,0.000010650894,0.0010664627,0.003399707,0.0022883383,7.4584153e-7,0.00071594527,0.000008357373,0.0006834862,0.4261591],"study_design_scores_gemma":[0.12503469,0.011682255,0.85330355,0.00074252015,0.0008960635,0.0040163463,0.00017446291,0.0000063142243,0.0014546122,0.00002925101,0.0024303573,0.0002295551],"about_ca_topic_score_codex":0.0009904004,"about_ca_topic_score_gemma":0.0003130478,"teacher_disagreement_score":0.42592958,"about_ca_system_score_codex":0.00020107937,"about_ca_system_score_gemma":0.00031509312,"threshold_uncertainty_score":0.97124684},"labels":[],"label_agreement":null},{"id":"W2049063681","doi":"10.1016/j.ejca.2010.02.032","title":"Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia","year":2010,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Bosutinib; Chronic myelogenous leukemia; Imatinib; Cancer research; Medicine; Pharmacology; ABL; breakpoint cluster region; Leukemia; Dasatinib; Myeloid leukemia; Immunology; Tyrosine kinase; Internal medicine; Receptor","score_opus":0.17751043491524784,"score_gpt":0.47829605297896555,"score_spread":0.30078561806371773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049063681","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009999608,0.9953416,0.0000010575312,0.00016829056,0.0010616208,0.0008826559,0.000025182298,0.000010483806,0.0024090991],"genre_scores_gemma":[0.000028790206,0.99640125,0.00031842093,0.00022958186,0.0019862815,0.000019159457,0.0000103464345,0.00013636443,0.00086979696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940924,0.0010096487,0.003493107,0.0003581286,0.0006608272,0.00038590757],"domain_scores_gemma":[0.9946942,0.0004062013,0.0034557467,0.000663604,0.0005521515,0.00022814405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030615942,0.0005343824,0.0050962768,0.00030580608,0.000025841544,0.000006333956,0.00050430576,0.00015383746,0.00040120832],"category_scores_gemma":[0.0014414126,0.00034852896,0.0013259568,0.0004215421,0.0002864304,0.00006039266,0.0001587286,0.0022707651,0.00006979283],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004063782,0.00008708639,0.000029907747,0.1604876,0.0011403316,0.0016811078,0.00008518843,5.7241493e-7,0.0000027167773,0.000001916256,0.0043228087,0.8321201],"study_design_scores_gemma":[0.0014716117,0.0005842804,0.00005535068,0.39190602,0.0031581286,0.0011186535,0.000005004882,1.473737e-7,0.0000026928515,0.0000010432547,0.60155696,0.00014011875],"about_ca_topic_score_codex":0.000008394511,"about_ca_topic_score_gemma":0.000024281462,"teacher_disagreement_score":0.83198,"about_ca_system_score_codex":0.003682341,"about_ca_system_score_gemma":0.008232834,"threshold_uncertainty_score":0.99989665},"labels":[],"label_agreement":null},{"id":"W2049481787","doi":"10.1016/s0959-8049(01)00205-2","title":"Economic decision analysis model of screening for lung cancer","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Moffitt Cancer Center","keywords":"Medicine; Lung cancer; Cohort; Epidemiology; Incidence (geometry); Cancer registry; Cost–benefit analysis; Cohort study; Lung cancer screening; Cancer; Demography; Oncology; Internal medicine","score_opus":0.03356050440796819,"score_gpt":0.3519425637998756,"score_spread":0.3183820593919074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049481787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8957911,0.016620968,0.08365794,0.001567355,0.00029741798,0.00020872439,0.00006565943,0.0000069209405,0.0017838883],"genre_scores_gemma":[0.9825209,0.008000234,0.008232524,0.00023273271,0.00048618513,0.0000090439025,0.0000025221718,0.00003069524,0.0004851709],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989496,0.000032206317,0.0005301782,0.00013883633,0.0001974442,0.00015173582],"domain_scores_gemma":[0.9989157,0.000062798455,0.00047562586,0.00016123669,0.00024902038,0.00013564261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003926271,0.00011418861,0.0004520728,0.00022765047,0.00003704109,0.000013011037,0.00010461355,0.000015746318,0.00027899252],"category_scores_gemma":[0.00001911163,0.00008445569,0.00043890142,0.00014778624,0.000023345774,0.00009045091,0.000018127183,0.000082779145,9.859724e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013474972,0.00009863985,0.36603114,0.000044433466,0.0034040106,0.000050728573,0.00020565817,0.4167974,0.00030157223,0.00002850817,0.007825037,0.20386538],"study_design_scores_gemma":[0.020214325,0.0014875891,0.42627445,0.0029607296,0.02526529,0.00006573477,0.00013336976,0.47369343,0.004936869,0.00007096524,0.04438546,0.000511785],"about_ca_topic_score_codex":0.00006084621,"about_ca_topic_score_gemma":0.00012457224,"teacher_disagreement_score":0.20335358,"about_ca_system_score_codex":0.0003399971,"about_ca_system_score_gemma":0.00018967284,"threshold_uncertainty_score":0.34440032},"labels":[],"label_agreement":null},{"id":"W2049492536","doi":"10.1016/j.ejca.2012.07.004","title":"Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: Suggestion of a potential protective role of oestrogen","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Workplace Safety & Insurance Board","funders":"","keywords":"Incidence (geometry); Demography; Nasopharyngeal carcinoma; Medicine; Sex ratio; Internal medicine; Population","score_opus":0.01759209663431291,"score_gpt":0.2766811077521395,"score_spread":0.25908901111782656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049492536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98840827,0.010384312,0.00003267189,0.00027689312,0.00010141557,0.0002141274,0.0000071707536,0.000001561919,0.00057360705],"genre_scores_gemma":[0.9993072,0.00029952193,0.00008481244,0.000032723172,0.00024129587,0.0000042725082,3.3829676e-7,0.000012294498,0.000017510914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983531,0.00038079027,0.0005912454,0.00008383228,0.00040279172,0.00018824426],"domain_scores_gemma":[0.9990476,0.000049233673,0.0005056049,0.000120914556,0.00021748326,0.00005917128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010238246,0.00010582517,0.00044967415,0.00015182715,0.00001834819,0.000002416383,0.00016002948,0.000020755642,0.000016903607],"category_scores_gemma":[0.00012681965,0.00006991332,0.00009018212,0.00023548464,0.00011892844,0.00010676328,0.000043649034,0.0003104105,4.796496e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007676888,0.00020268356,0.86284053,0.00012945941,0.000057793317,0.00008440493,0.011970927,0.00008393343,0.10449808,0.000016163118,0.000037175185,0.019311173],"study_design_scores_gemma":[0.0013400946,0.0006695277,0.9577807,0.0007824689,0.00005957135,0.00006065739,0.0011886498,0.0000415163,0.03797641,0.000015052225,0.000032419113,0.000052917712],"about_ca_topic_score_codex":0.00041739913,"about_ca_topic_score_gemma":0.00009776477,"teacher_disagreement_score":0.0949402,"about_ca_system_score_codex":0.000078466,"about_ca_system_score_gemma":0.00016718985,"threshold_uncertainty_score":0.28509825},"labels":[],"label_agreement":null},{"id":"W2050221637","doi":"10.1016/j.ejca.2012.04.008","title":"Symptom clusters in a population-based ambulatory cancer cohort validated using bootstrap methods","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Institute for Clinical Evaluative Sciences; Public Health Ontario; Queen's University; McMaster University; University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Cohort; Medicine; Population; Anxiety; Clinical psychology; Psychiatry; Internal medicine; Environmental health","score_opus":0.06301375567493227,"score_gpt":0.40011667914446886,"score_spread":0.3371029234695366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050221637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98336977,0.009993171,0.002742945,0.00038629354,0.0021993134,0.00016909551,0.000009541066,0.000018168601,0.0011116926],"genre_scores_gemma":[0.99549127,0.00015578425,0.0018598848,0.0011793175,0.001107708,0.0000036145934,0.0000045063443,0.00006263455,0.0001353053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780923,0.00066997827,0.00062449573,0.00014257361,0.0004166718,0.00033707282],"domain_scores_gemma":[0.9988069,0.00006116777,0.0004187796,0.0001904421,0.00023011146,0.00029258576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018236011,0.00017924292,0.0004203208,0.00028144254,0.00004437939,0.000022327204,0.00011887394,0.0000410848,0.0005009198],"category_scores_gemma":[0.00005349419,0.0001540612,0.00018134525,0.00034175083,0.000037771522,0.00020014783,0.00002048439,0.00038451733,0.0000030455872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029724228,0.00005422647,0.9726877,0.000064832224,0.00014729069,0.00006073338,0.000649756,0.003177313,0.0034845073,0.000003917849,0.00026844034,0.01910399],"study_design_scores_gemma":[0.0017944397,0.000076424694,0.97682047,0.0007662657,0.00036789672,0.00004822264,0.00014636932,0.00074025034,0.0016427846,0.0000016487817,0.017394742,0.00020047475],"about_ca_topic_score_codex":0.0014384302,"about_ca_topic_score_gemma":0.00032778835,"teacher_disagreement_score":0.018903516,"about_ca_system_score_codex":0.00063670345,"about_ca_system_score_gemma":0.00033284337,"threshold_uncertainty_score":0.6282433},"labels":[],"label_agreement":null},{"id":"W2050644751","doi":"10.1016/j.ejca.2011.05.019","title":"Early stopping rules in oncology: Considerations for clinicians","year":2011,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Clinical trial; Harm; Medicine; Clinical Practice; Intensive care medicine; Clinical Oncology; Medical physics; Cancer; Oncology; Family medicine; Internal medicine; Psychology","score_opus":0.866584728659454,"score_gpt":0.6631963191333864,"score_spread":0.20338840952606763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050644751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004975416,0.9711198,0.018902909,0.00015496444,0.0024454568,0.00074243173,0.00020608919,0.000013934808,0.0064094183],"genre_scores_gemma":[0.0000012226207,0.60570794,0.39274508,0.000102744125,0.0012037638,0.000017610995,2.6902893e-7,0.00007298754,0.00014835694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.990269,0.0051777996,0.0038337004,0.00024520542,0.00019910405,0.00027518606],"domain_scores_gemma":[0.9282258,0.067747384,0.003246569,0.00026633838,0.00036981134,0.00014410191],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.012370713,0.00029149937,0.0029683502,0.00023688514,0.000055550787,0.000042399122,0.00039402785,0.0001687019,0.00041323103],"category_scores_gemma":[0.09884424,0.00021598901,0.0008354751,0.00011169988,0.00014065475,0.000061061415,0.00006857308,0.0010812135,0.000034508736],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000337298,0.00009236216,0.0000021463889,0.001979925,0.00027011096,0.00015635834,0.00019602219,2.6104775e-7,7.975569e-8,0.016353408,0.005733855,0.97518176],"study_design_scores_gemma":[0.0007294742,0.0003687172,0.000012682041,0.012637898,0.001114045,0.000034781253,0.000012386791,5.087331e-7,1.952015e-7,0.20585088,0.7790585,0.00017993661],"about_ca_topic_score_codex":0.0000030605343,"about_ca_topic_score_gemma":0.000014523585,"teacher_disagreement_score":0.9750018,"about_ca_system_score_codex":0.00020392193,"about_ca_system_score_gemma":0.0008805554,"threshold_uncertainty_score":0.9087466},"labels":[],"label_agreement":null},{"id":"W2051700063","doi":"10.1016/s0959-8049(00)00296-3","title":"Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions","year":2000,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Histiocytic Disorders and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Children's Hospital","funders":"Histiocytosis Association","keywords":"CD154; CD40; Langerhans cell histiocytosis; Antigen-presenting cell; Cell adhesion molecule; Biology; T cell; Pathology; Immunology; Medicine; Immune system; Cytotoxic T cell; In vitro","score_opus":0.01182003127344445,"score_gpt":0.2533380794896822,"score_spread":0.24151804821623774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051700063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97391474,0.009286235,0.00002171922,0.00023654825,0.00009630491,0.00009617624,0.0000123179025,0.000004245048,0.01633169],"genre_scores_gemma":[0.99190164,0.004483923,0.0003663106,0.00008686488,0.00012443578,0.0000012779394,0.0000016889929,0.000020436966,0.0030134164],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999112,0.0000827464,0.00036921754,0.00010308961,0.00020813291,0.00012480079],"domain_scores_gemma":[0.9995002,0.000027596749,0.00017883012,0.000100259924,0.00006565494,0.0001274608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019961552,0.00010030518,0.00026340698,0.00014057691,0.000033956097,0.0000073163214,0.00005893795,0.000019251442,0.0004965113],"category_scores_gemma":[0.0000197485,0.00007265136,0.00006913126,0.00013277824,0.00004569298,0.000055287575,0.000013080398,0.00013882325,0.000015145152],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025823216,0.0022946065,0.22064656,0.00052215165,0.00019439228,0.0045558535,0.0067513506,0.00053734955,0.058433734,0.000012891808,0.02547747,0.67799133],"study_design_scores_gemma":[0.027875477,0.0026774711,0.66660887,0.0022946862,0.0009909177,0.00037875044,0.00070329907,0.0000998812,0.035140473,0.000050077175,0.26268926,0.00049083366],"about_ca_topic_score_codex":0.000043610333,"about_ca_topic_score_gemma":0.0000165773,"teacher_disagreement_score":0.6775005,"about_ca_system_score_codex":0.00006564193,"about_ca_system_score_gemma":0.00009076284,"threshold_uncertainty_score":0.543645},"labels":[],"label_agreement":null},{"id":"W2051701101","doi":"10.1016/j.ejca.2006.03.023","title":"Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours","year":2006,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; University of Calgary; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Dalhousie University; SickKids Foundation; Hospital for Sick Children","funders":"Centre Hospitalier Universitaire Vaudois; Hospital for Sick Children","keywords":"Temozolomide; Medicine; Pharmacokinetics; Toxicity; Medulloblastoma; Refractory (planetary science); Glioma; Phases of clinical research; Limiting; Internal medicine; Gastroenterology; Oncology; Anesthesia; Surgery; Chemotherapy; Pathology","score_opus":0.0169284012454364,"score_gpt":0.2951601362418788,"score_spread":0.27823173499644244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051701101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98199606,0.015981615,0.000110208246,0.0012523853,0.00017151902,0.00011070055,0.000008010917,0.0000027823376,0.00036672753],"genre_scores_gemma":[0.9971093,0.0009594564,0.0014591971,0.000064750966,0.00036879725,5.113368e-7,0.0000017947565,0.000019148276,0.000017058917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888533,0.00014566141,0.000579125,0.00009717006,0.00016640054,0.00012628427],"domain_scores_gemma":[0.9992651,0.00006148961,0.00041110237,0.000067249144,0.000115226365,0.000079832156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005186331,0.00010106401,0.0002796079,0.0002682812,0.000019780104,0.000009161995,0.000045463043,0.000012082329,0.000045388297],"category_scores_gemma":[0.00004530317,0.000080524784,0.0000774388,0.00020834497,0.00003636987,0.000058156165,0.000020248888,0.00013146966,0.0000012909494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084108044,0.00059786835,0.89778745,0.00006745216,0.0001464606,0.00035633135,0.00016594483,0.009854666,0.020905597,0.000051085266,0.001829028,0.06739702],"study_design_scores_gemma":[0.0069873785,0.00030698368,0.9825333,0.00025131312,0.00028360973,0.000083027226,0.000034403874,0.00095544965,0.005214343,0.000013293006,0.003255971,0.000080981394],"about_ca_topic_score_codex":0.000038048544,"about_ca_topic_score_gemma":0.00001626645,"teacher_disagreement_score":0.08474578,"about_ca_system_score_codex":0.0001794721,"about_ca_system_score_gemma":0.00009453534,"threshold_uncertainty_score":0.3283705},"labels":[],"label_agreement":null},{"id":"W2051778548","doi":"10.1016/j.ejca.2011.03.016","title":"Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature","year":2011,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Toxicity; Medicine; Limiting; Clinical trial; Maximum tolerated dose; Oncology; Internal medicine","score_opus":0.8118245039593,"score_gpt":0.6537769044671239,"score_spread":0.15804759949217606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051778548","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006303104,0.99476707,0.0009738254,0.00009826422,0.00087051076,0.0014087898,0.0008299723,0.000002636047,0.00041861454],"genre_scores_gemma":[0.00031207982,0.970837,0.027912827,0.00038131166,0.00046179726,0.000027573411,0.0000026998891,0.000061019793,0.0000037200498],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9122388,0.071577996,0.014609426,0.0003575133,0.0009253833,0.000290895],"domain_scores_gemma":[0.9516775,0.0294406,0.017269764,0.0007585563,0.0007569148,0.00009667815],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08438427,0.00040413789,0.0063548763,0.0001878173,0.000022305732,0.00001828744,0.0013575777,0.00021346849,0.00025040586],"category_scores_gemma":[0.2063113,0.00020165043,0.0026822626,0.0009420593,0.00027829732,0.00007339847,0.00016182591,0.0018337568,7.857742e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034774552,0.0009899031,0.00006107693,0.08454215,0.0007640629,0.00010851492,0.0003612577,6.1486975e-7,0.000024009816,0.0016977276,0.00092316413,0.9101798],"study_design_scores_gemma":[0.00522769,0.0008131956,0.00034027253,0.90058553,0.005944732,0.00004798927,0.000027251765,0.0000020503007,0.00018449781,0.022775223,0.06363264,0.00041891198],"about_ca_topic_score_codex":0.0000097681195,"about_ca_topic_score_gemma":0.000011511693,"teacher_disagreement_score":0.9097609,"about_ca_system_score_codex":0.00009487111,"about_ca_system_score_gemma":0.00056607026,"threshold_uncertainty_score":0.94281906},"labels":[],"label_agreement":null},{"id":"W2052438254","doi":"10.1016/j.ejca.2005.02.027","title":"Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy","year":2005,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphovascular invasion; Breast cancer; Mastectomy; Radiation therapy; Internal medicine; Stage (stratigraphy); Multivariate analysis; Cancer; Oncology; Gynecology; Metastasis","score_opus":0.013744267115086597,"score_gpt":0.2754487803952661,"score_spread":0.2617045132801795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052438254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98820263,0.00992348,0.00010778283,0.0010819774,0.0001275289,0.00013530963,0.00007683932,0.000005595799,0.00033885415],"genre_scores_gemma":[0.9950583,0.0032720005,0.00040788788,0.00027577562,0.0007859389,0.0000146692355,0.000008445569,0.000047388457,0.00012958703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987074,0.00016314808,0.00035052552,0.00025406302,0.00026516436,0.00025968032],"domain_scores_gemma":[0.999026,0.0000063152956,0.0003734968,0.00015348746,0.00033513745,0.00010557624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015000933,0.0002362042,0.00028190567,0.00008469285,0.000049971874,0.00001997598,0.00020960452,0.000030241297,0.00008552419],"category_scores_gemma":[0.0000067744827,0.0001659173,0.000081300146,0.00013865958,0.000110584464,0.00001880004,0.000029278552,0.00016930648,0.0000031792515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017763644,0.00018485839,0.78668624,0.0000075736057,0.00026276681,0.000028371509,0.00023343148,0.0007659582,0.0011753248,7.1176765e-7,0.0011320816,0.20774634],"study_design_scores_gemma":[0.006295127,0.0006856685,0.96760285,0.00030687114,0.00006187301,0.00009069029,0.000027857293,0.000011686223,0.001734674,5.878706e-7,0.02295155,0.0002305359],"about_ca_topic_score_codex":0.0001555358,"about_ca_topic_score_gemma":0.0005279577,"teacher_disagreement_score":0.2075158,"about_ca_system_score_codex":0.0001642284,"about_ca_system_score_gemma":0.0001504014,"threshold_uncertainty_score":0.6765911},"labels":[],"label_agreement":null},{"id":"W2053227377","doi":"10.1016/j.ejca.2009.05.033","title":"Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?","year":2009,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Cancer Care Ontario","keywords":"Medicine; Clinical trial; Clinical endpoint; Gemcitabine; Oncology; Internal medicine; Pancreatic cancer; End point; Cancer","score_opus":0.30014600536129565,"score_gpt":0.5025954050966652,"score_spread":0.20244939973536957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053227377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022189294,0.97787464,0.0000042640854,0.0019089475,0.0010689589,0.0011272283,0.000060500177,0.0000139628955,0.017719584],"genre_scores_gemma":[0.000095657444,0.98964953,0.0009240364,0.0014619009,0.0025984463,0.000013032731,0.000015977479,0.0000955668,0.0051458413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9857701,0.006382138,0.005751945,0.0004994831,0.00088666583,0.0007096597],"domain_scores_gemma":[0.9918563,0.0026129656,0.0038332636,0.0004522941,0.000537339,0.00070784474],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005101284,0.00054174336,0.008358786,0.00066906813,0.000057879297,0.00003334082,0.00056884735,0.00036290404,0.011175137],"category_scores_gemma":[0.004578854,0.00032134683,0.0017154433,0.0004958524,0.00021557228,0.000088381814,0.00012911668,0.0026685235,0.00030552468],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022733216,0.00073887804,0.00035842223,0.0010949387,0.0010550988,0.008726818,0.00085385825,2.1775801e-7,6.822581e-7,0.000004669516,0.058090776,0.92680234],"study_design_scores_gemma":[0.00772157,0.0049682595,0.00038170358,0.022898575,0.004215918,0.0011911594,0.00021656732,0.0000051846573,7.5457865e-7,0.000011003205,0.9581298,0.00025949522],"about_ca_topic_score_codex":0.000026466565,"about_ca_topic_score_gemma":0.00003364788,"teacher_disagreement_score":0.9265428,"about_ca_system_score_codex":0.0010505555,"about_ca_system_score_gemma":0.0058492967,"threshold_uncertainty_score":0.9999239},"labels":[],"label_agreement":null},{"id":"W2053352189","doi":"10.1016/j.ejca.2011.03.001","title":"Neurocognitive functioning and health-related behaviours in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Neurocognitive; Childhood cancer; Cancer survivor; Medicine; Cancer; Survivorship curve; Cancer survivorship; Psychology; Clinical psychology; Gerontology; Psychiatry; Cognition; Internal medicine","score_opus":0.04635848188355406,"score_gpt":0.3177147073866564,"score_spread":0.27135622550310234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053352189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97497445,0.015678847,0.000021411706,0.0054771607,0.0017547357,0.0010882731,0.00015261665,0.00003701515,0.00081547635],"genre_scores_gemma":[0.9939826,0.0030062944,0.000095198666,0.0018553721,0.000774051,0.00003403007,0.000011079895,0.0001294372,0.00011192131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99360937,0.0016185009,0.0025791733,0.0005991134,0.0010813819,0.0005124476],"domain_scores_gemma":[0.9951089,0.00022354067,0.002821574,0.0005299626,0.00090818014,0.00040784798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036652237,0.00045263086,0.0012720253,0.0002858143,0.00018850745,0.000036709265,0.00039183066,0.000066077424,0.00042662307],"category_scores_gemma":[0.00042756554,0.00034510842,0.00027112095,0.00069101003,0.00023295182,0.0002730576,0.00014669943,0.0013036077,0.000002981951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058708165,0.001194647,0.9019532,0.000037511065,0.00086180476,0.0007145834,0.066145636,0.000036207097,0.00003021279,0.000004000348,0.0006836543,0.027751425],"study_design_scores_gemma":[0.0065022423,0.0013456102,0.9788273,0.0022543208,0.0006198292,0.00029545306,0.009409469,0.0000042689962,0.00016242688,0.000019733709,0.0002621623,0.00029717627],"about_ca_topic_score_codex":0.13814063,"about_ca_topic_score_gemma":0.0748768,"teacher_disagreement_score":0.07687407,"about_ca_system_score_codex":0.00022749297,"about_ca_system_score_gemma":0.0011650976,"threshold_uncertainty_score":0.9999001},"labels":[],"label_agreement":null},{"id":"W2053907102","doi":"10.1016/j.ejca.2013.06.015","title":"The development of a clinical screening instrument for tumour predisposition syndromes in childhood cancer patients","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Human Genome Research Institute; National Institutes of Health","keywords":"Medicine; Geneticist; Referral; Cancer; Delphi method; Cohort; Pediatrics; Genetic predisposition; Family medicine; Internal medicine; Disease","score_opus":0.05564849369361007,"score_gpt":0.359055282305494,"score_spread":0.3034067886118839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053907102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928317,0.0016202021,0.0005284645,0.0033088664,0.0007685417,0.0006409094,0.000013295052,0.00000728715,0.00028072746],"genre_scores_gemma":[0.992931,0.00033884344,0.0055204374,0.00046914036,0.00058257213,0.000033720262,0.000004316389,0.000037674523,0.00008228604],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965763,0.00034094046,0.0020305915,0.0001727627,0.00062269927,0.0002566728],"domain_scores_gemma":[0.9976801,0.0002006696,0.0012174938,0.00014922248,0.0005658004,0.0001866584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002449338,0.0001570049,0.00051300693,0.00010693611,0.000096246025,0.000028690794,0.00023534904,0.000029759794,0.00006625495],"category_scores_gemma":[0.00036800987,0.00010660856,0.00021351504,0.00013599473,0.000073381016,0.00016969435,0.00006155417,0.00033474888,0.0000040836517],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081497664,0.0006353901,0.4717755,0.00016583112,0.00053958286,0.0000072928083,0.0056033763,0.00007386476,0.00019659383,0.000009930179,0.003525653,0.516652],"study_design_scores_gemma":[0.005403325,0.00066992745,0.9845545,0.0019315139,0.00007873113,0.0000075879716,0.0004494041,0.00003488916,0.0006746041,0.000016350026,0.0060663004,0.000112863636],"about_ca_topic_score_codex":0.00007429042,"about_ca_topic_score_gemma":0.0001816571,"teacher_disagreement_score":0.51653916,"about_ca_system_score_codex":0.00012716507,"about_ca_system_score_gemma":0.0005392534,"threshold_uncertainty_score":0.43473712},"labels":[],"label_agreement":null},{"id":"W2054192575","doi":"10.1016/j.ejca.2004.04.022","title":"Change in histological grade in locally recurrent soft tissue sarcomas","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Myxofibrosarcoma; Soft tissue; Medicine; Histology; Sarcoma; Soft tissue sarcoma; Pathology; Lesion","score_opus":0.06276246979244411,"score_gpt":0.33812350644602385,"score_spread":0.27536103665357975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054192575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8926753,0.09100855,0.000048667414,0.014319349,0.00041815112,0.00022011876,0.0000022928743,0.000008790319,0.0012988109],"genre_scores_gemma":[0.99539363,0.0027217383,0.00047849046,0.0009935725,0.00035326005,0.000007930974,0.0000010171095,0.000018290086,0.00003207607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99888235,0.00012787528,0.0004272075,0.00012527742,0.00024148579,0.00019579568],"domain_scores_gemma":[0.9995253,0.000026002064,0.00016164914,0.000099052,0.000055643668,0.00013234428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033519696,0.00011681767,0.00030759268,0.00017425968,0.000013370149,0.000007850666,0.000094568764,0.000021393169,0.0001373045],"category_scores_gemma":[0.000052442305,0.00008264978,0.000076507946,0.00016055703,0.000040290844,0.000058254518,0.000023587045,0.00029482105,0.000028761066],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033819,0.0014181705,0.2882464,0.000025488593,0.00004280634,0.018986927,0.001346822,0.000089811234,0.0002843523,0.00012625863,0.00054852135,0.68854624],"study_design_scores_gemma":[0.0059960997,0.0009974061,0.928859,0.0008871,0.000045272485,0.0003802914,0.000042346644,0.0000040235523,0.0005020295,0.000069919144,0.062121924,0.000094620016],"about_ca_topic_score_codex":0.000108021486,"about_ca_topic_score_gemma":0.00029259868,"teacher_disagreement_score":0.68845165,"about_ca_system_score_codex":0.0004838387,"about_ca_system_score_gemma":0.000087802735,"threshold_uncertainty_score":0.337036},"labels":[],"label_agreement":null},{"id":"W2054521520","doi":"10.1016/j.ejca.2008.02.028","title":"Management of malignant bowel obstruction","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Intestinal and Peritoneal Adhesions","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Bowel obstruction; Vomiting; Octreotide; Gastric outlet obstruction; Abdominal pain; Palliative care; Radiological weapon; Ascites; Surgery; General surgery; Intensive care medicine; Somatostatin; Internal medicine","score_opus":0.03170376239179645,"score_gpt":0.2819649146939523,"score_spread":0.25026115230215584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054521520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683148,0.001407487,0.0001571158,0.0008478963,0.00042430617,0.000045069126,0.0000023213356,0.0000053753756,0.028795602],"genre_scores_gemma":[0.98955554,0.0015622239,0.0029920307,0.0001159243,0.00038427004,3.2698676e-7,3.81367e-7,0.000011832254,0.0053774775],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993127,0.00003998518,0.00029990386,0.000049758106,0.00021869566,0.000078977064],"domain_scores_gemma":[0.9994441,0.0000064989554,0.00019829215,0.00007119637,0.00020483726,0.00007502384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015187896,0.000055749242,0.00013249213,0.00005310559,0.000035672598,0.0000017155762,0.00005862897,0.00000625611,0.00027942963],"category_scores_gemma":[0.00000944314,0.00003835168,0.00009037042,0.00007248358,0.000048969734,0.000035835183,0.00001563142,0.00010959955,0.000017849794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004774711,0.0009717813,0.14206477,0.0013654896,0.0015989152,0.05655604,0.004469255,0.0007274274,0.17575066,0.0016695885,0.068480685,0.54157066],"study_design_scores_gemma":[0.0012297072,0.00082138274,0.8874026,0.0012169614,0.00017157689,0.004174178,0.0001996867,0.000013874374,0.012904178,0.000025434972,0.09175876,0.00008165722],"about_ca_topic_score_codex":0.00000774902,"about_ca_topic_score_gemma":2.9947952e-7,"teacher_disagreement_score":0.74533784,"about_ca_system_score_codex":0.000026656811,"about_ca_system_score_gemma":0.000031940202,"threshold_uncertainty_score":0.30595586},"labels":[],"label_agreement":null},{"id":"W2054735694","doi":"10.1016/j.ejca.2011.06.006","title":"Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: A perspective from Central America","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":218,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; McMaster University; University of Toronto","funders":"Centers for Disease Control and Prevention","keywords":"Anthropometry; Medicine; Malnutrition; Psychological intervention; Pediatrics; Percentile; Cancer; Internal medicine","score_opus":0.030065691348686866,"score_gpt":0.3356621548833044,"score_spread":0.30559646353461756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054735694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98695594,0.0052919416,0.000013411343,0.0064881826,0.0003217262,0.00030985693,0.00027815893,0.000014475398,0.000326294],"genre_scores_gemma":[0.98608154,0.0063972906,0.0008622339,0.006103464,0.00042438626,0.000007263015,0.00000451416,0.00005101183,0.00006828286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974867,0.00041031823,0.000836345,0.00035518143,0.00054510776,0.00036634947],"domain_scores_gemma":[0.9983602,0.00006846453,0.00048303988,0.00018985782,0.00027203458,0.0006263935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029804558,0.00021950134,0.0006660054,0.00014986888,0.000047724647,0.000016243332,0.0001509353,0.000036920752,0.000871781],"category_scores_gemma":[0.0001530988,0.00017158399,0.0001676917,0.00021326024,0.00017203378,0.000119196586,0.00008048335,0.00054076506,0.000015705302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024301196,0.00048365424,0.9773894,0.000011533251,0.00061992626,0.00016014076,0.010632405,0.0000040774735,0.0000063157204,0.000002445892,0.0034096162,0.004850388],"study_design_scores_gemma":[0.007395798,0.00094438344,0.9872614,0.001607761,0.00023403254,0.00004074021,0.0006573293,0.000001209782,0.000058518403,0.000021697095,0.0015764402,0.00020064776],"about_ca_topic_score_codex":0.0056514265,"about_ca_topic_score_gemma":0.00086463266,"teacher_disagreement_score":0.009975076,"about_ca_system_score_codex":0.00047908988,"about_ca_system_score_gemma":0.00026949265,"threshold_uncertainty_score":0.95453906},"labels":[],"label_agreement":null},{"id":"W2056804360","doi":"10.1016/j.ejca.2004.07.006","title":"The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications","year":2004,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":224,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Canadian Institutes of Health Research","keywords":"Ubiquitin; Degradation (telecommunications); Cancer; Protein degradation; Cancer research; Chemistry; Medicine; Cell biology; Biology; Internal medicine; Biochemistry; Computer science; Gene","score_opus":0.04496515888565151,"score_gpt":0.32535474385448687,"score_spread":0.28038958496883537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056804360","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028945078,0.99738884,0.000115912444,0.00040070087,0.00024949192,0.0006067498,0.00009752228,0.000005581478,0.0008457677],"genre_scores_gemma":[0.001619359,0.9965252,0.000058165773,0.00009811238,0.00075044425,0.0001381863,0.000052169053,0.000079180645,0.0006791292],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771446,0.0007467703,0.00083396514,0.00023409059,0.0001930311,0.00027768366],"domain_scores_gemma":[0.9982574,0.00003672982,0.0010670578,0.00032505338,0.0002174275,0.00009634132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010069429,0.00028081093,0.00046892388,0.000091116766,0.00012198783,0.000064422806,0.00060828216,0.00009941485,0.00002894749],"category_scores_gemma":[0.00010039197,0.00017971572,0.00031415347,0.0002240159,0.000083183724,0.0000064343803,0.00007233227,0.00048058975,0.000014738471],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000210052,0.000028546468,0.000008049057,0.0005681511,0.00012680079,0.000011586002,0.000027360824,0.000009793743,0.0021194138,0.00008730981,0.00015564023,0.99683636],"study_design_scores_gemma":[0.0003534038,0.00017220757,0.00005505949,0.004754673,0.00007824738,0.000039090653,0.000010711575,2.4785268e-7,0.0018336697,0.000037250804,0.99245876,0.00020670498],"about_ca_topic_score_codex":0.000016056638,"about_ca_topic_score_gemma":0.00007922338,"teacher_disagreement_score":0.99662966,"about_ca_system_score_codex":0.000157508,"about_ca_system_score_gemma":0.001432563,"threshold_uncertainty_score":0.73285943},"labels":[],"label_agreement":null},{"id":"W2057390542","doi":"10.1016/j.ejca.2010.04.017","title":"An international multicentre validation study of a pain classification system for cancer patients","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Calgary; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cancer pain; Neuropathic pain; Opioid; Palliative care; Analgesic; Brief Pain Inventory; Distress; Chronic pain; Cancer; Physical therapy; Anesthesia; Internal medicine; Clinical psychology","score_opus":0.02654386947233422,"score_gpt":0.32319928854065394,"score_spread":0.2966554190683197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057390542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967044,0.000027222313,0.00086251023,0.00023728091,0.0011980974,0.0004273948,0.0000093842245,0.000009217694,0.0005244865],"genre_scores_gemma":[0.9985855,0.000027915747,0.00047124838,0.00006392998,0.0006776223,0.000009070843,0.0000108268905,0.000018185863,0.00013565742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989181,0.00019776096,0.00040488975,0.00009508306,0.00030889414,0.0000752801],"domain_scores_gemma":[0.99848676,0.00003546622,0.0005539033,0.00012626156,0.0007297567,0.00006788002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011582428,0.00006912018,0.00014025647,0.00011999837,0.000029555695,0.000018950985,0.00015500622,0.000012344919,0.0000513545],"category_scores_gemma":[0.00015426832,0.000054658176,0.000052367137,0.00006245154,0.000012255428,0.00015223572,0.000010467962,0.0001138224,0.0000014115124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061911216,0.00085855974,0.9155657,0.00010965336,0.00021455575,0.0000058122982,0.0018553396,0.00012420575,0.013831245,0.000037359176,0.0009620389,0.0658164],"study_design_scores_gemma":[0.0050367443,0.0007949364,0.9767144,0.000190344,0.00021619505,3.676803e-7,0.0020432773,0.0033705893,0.0008996527,8.7215295e-7,0.010668596,0.000064057895],"about_ca_topic_score_codex":0.000015746953,"about_ca_topic_score_gemma":0.000034441557,"teacher_disagreement_score":0.06575234,"about_ca_system_score_codex":0.00006921885,"about_ca_system_score_gemma":0.000037705653,"threshold_uncertainty_score":0.22288957},"labels":[],"label_agreement":null},{"id":"W2057812738","doi":"10.1016/j.ejca.2013.06.038","title":"Low-dose metronomic chemotherapy: A systematic literature analysis","year":2013,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Chemotherapy; Medicine; Oncology; Internal medicine","score_opus":0.01477124523476248,"score_gpt":0.3211079836013886,"score_spread":0.3063367383666261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057812738","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007099752,0.9670357,0.031185469,0.000015560589,0.00022909105,0.0005786506,0.000052147843,0.000023522172,0.000872731],"genre_scores_gemma":[0.00005082617,0.9912168,0.0053168265,0.00004283045,0.0015519047,0.00004539259,0.000015296515,0.00016701063,0.0015931043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682575,0.0008616395,0.0014947638,0.00027250164,0.0002722654,0.00027309408],"domain_scores_gemma":[0.9957717,0.00009493611,0.003193889,0.000528424,0.0002551632,0.00015586118],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069806847,0.00055190374,0.0031610474,0.00071053556,0.00005118356,0.00020963441,0.0007882614,0.00005226936,0.0011935869],"category_scores_gemma":[0.0000075892103,0.00036019713,0.0022186714,0.0009163025,0.00004214465,0.00024889264,0.000038773025,0.0007491481,0.000025277406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000006178043,0.000058706173,0.000016649903,0.03113283,0.012239865,0.000025856632,0.00019123605,0.000039127488,0.0000040642262,0.00006168962,0.0014952379,0.95472854],"study_design_scores_gemma":[0.00033036154,0.00007083407,0.0000046104183,0.10282658,0.0073302626,0.000013784824,0.000014669787,0.000015099257,0.000011008142,0.000018593033,0.88891643,0.00044777608],"about_ca_topic_score_codex":0.0000037972245,"about_ca_topic_score_gemma":2.0422839e-7,"teacher_disagreement_score":0.9542808,"about_ca_system_score_codex":0.0002278627,"about_ca_system_score_gemma":0.00016539369,"threshold_uncertainty_score":0.999885},"labels":[],"label_agreement":null},{"id":"W2058795397","doi":"10.1016/j.ejca.2012.01.001","title":"ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Prostate Cancer Canada; Alberta Cancer Foundation; University of Calgary; University of Alberta","funders":"","keywords":"Erg; Prostate cancer; Medicine; Hazard ratio; Internal medicine; Proportional hazards model; Oncology; Cancer; Cohort; Prostate; Confidence interval; Ophthalmology","score_opus":0.06908365167858256,"score_gpt":0.350750875269375,"score_spread":0.28166722359079244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058795397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93746364,0.059952993,0.0000033553251,0.0015300356,0.00007443995,0.00048825174,0.00004381651,0.000011925961,0.00043155096],"genre_scores_gemma":[0.98551995,0.010336239,0.00015827116,0.000100054705,0.000343375,0.000025819667,0.0000043189907,0.00004457319,0.00346743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826634,0.000399735,0.00028291065,0.00019482046,0.0004926833,0.00036351194],"domain_scores_gemma":[0.99884856,0.00003975225,0.0002933667,0.00014059366,0.00025415389,0.00042357176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079903327,0.00021025586,0.0003392254,0.000107692715,0.00011901139,0.00004362373,0.000050902923,0.00003054986,0.000120894394],"category_scores_gemma":[0.00003811221,0.00011948499,0.00005404476,0.00015135805,0.00015425899,0.0002269468,0.00003294177,0.00023835612,0.0000020877246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034825187,0.0005135031,0.5531936,0.000096456206,0.00093206705,0.0014586332,0.006181765,0.0000036613135,0.34350437,0.000003271657,0.0038204377,0.05546703],"study_design_scores_gemma":[0.007427616,0.0031778794,0.8670084,0.0018479052,0.00020892362,0.00011464036,0.00015904706,0.000003369783,0.10139633,0.0000047422113,0.01848459,0.00016659164],"about_ca_topic_score_codex":0.000028306606,"about_ca_topic_score_gemma":0.000011334741,"teacher_disagreement_score":0.31381476,"about_ca_system_score_codex":0.0004447434,"about_ca_system_score_gemma":0.0002894586,"threshold_uncertainty_score":0.48724565},"labels":[],"label_agreement":null},{"id":"W2059228450","doi":"10.1016/j.ejca.2014.04.008","title":"A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Erlotinib; Rash; Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; KRAS; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Phases of clinical research; Progressive disease; Gastroenterology; Adverse effect; Cancer; Toxicity; Chemotherapy","score_opus":0.038753429939148994,"score_gpt":0.39656593272489205,"score_spread":0.35781250278574306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059228450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98881185,0.0032012048,0.000065258966,0.0006012273,0.00021421668,0.00038875852,0.000004392371,0.0000073892998,0.006705692],"genre_scores_gemma":[0.9960107,0.0011792853,0.00039777838,0.00018432301,0.00043101542,0.000014266739,7.5869644e-7,0.00003611174,0.0017457289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997498,0.00064016826,0.00089908123,0.0001694954,0.0005192895,0.00027397944],"domain_scores_gemma":[0.998363,0.00016680245,0.00057567627,0.00025910544,0.00042948444,0.0002059086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017606317,0.0001532068,0.00086763455,0.00028005466,0.0000510255,0.0000051289,0.00019632338,0.000027175227,0.0005743145],"category_scores_gemma":[0.0005133525,0.0001127586,0.000090653775,0.00027426204,0.0000997577,0.00010071566,0.000058170903,0.0004822941,0.0000064372657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0098164575,0.010472419,0.5450543,0.00026898354,0.00079778925,0.0008818222,0.009558098,0.00021662649,0.03101494,0.000022414626,0.0022499713,0.38964617],"study_design_scores_gemma":[0.08602472,0.06266422,0.806223,0.002094672,0.001039792,0.00010042512,0.0024402863,0.0005124639,0.00079700706,0.000025719899,0.03778415,0.00029354772],"about_ca_topic_score_codex":0.00012705091,"about_ca_topic_score_gemma":0.000143787,"teacher_disagreement_score":0.38935262,"about_ca_system_score_codex":0.00016127128,"about_ca_system_score_gemma":0.00034438245,"threshold_uncertainty_score":0.62883407},"labels":[],"label_agreement":null},{"id":"W2059931397","doi":"10.1016/s0959-8049(01)00083-1","title":"A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":378,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Ifosfamide; Surgery; Chemotherapy; Amputation; Radiation therapy; Soft tissue; Nausea; Soft tissue sarcoma; Sarcoma; Doxorubicin; Cisplatin","score_opus":0.022868975107689756,"score_gpt":0.3322139599562557,"score_spread":0.30934498484856593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059931397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890306,0.003969865,0.0005698941,0.0041353293,0.00040505105,0.00120661,0.000019683253,0.000020773005,0.00064216735],"genre_scores_gemma":[0.99396163,0.0017894724,0.00047704513,0.0016887824,0.0012501965,0.00004432891,0.0000030522606,0.00007741291,0.00070805225],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982464,0.00023637047,0.00062978885,0.00021722708,0.00040779304,0.00026245674],"domain_scores_gemma":[0.9984491,0.00015675674,0.0005206491,0.00026137347,0.0003747496,0.00023737022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064074266,0.00024007085,0.00062507,0.00013664857,0.00015352936,0.00002801494,0.00014629705,0.00001982563,0.00032681337],"category_scores_gemma":[0.00015826136,0.00015885361,0.00025030706,0.00012725443,0.00003231607,0.00006029122,0.000016583423,0.0002195553,0.00002009312],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041667163,0.008383639,0.022355681,0.000013197292,0.001056097,0.0024150643,0.0019184524,0.000029599718,0.0011933428,0.0000105234785,0.010112745,0.9108445],"study_design_scores_gemma":[0.6243932,0.053051945,0.15831685,0.0005873698,0.0016532448,0.00030410045,0.0007312663,0.000050878614,0.009916221,0.000045151883,0.15058497,0.0003647982],"about_ca_topic_score_codex":0.00003812718,"about_ca_topic_score_gemma":0.000015228388,"teacher_disagreement_score":0.9104797,"about_ca_system_score_codex":0.000120180426,"about_ca_system_score_gemma":0.00008005277,"threshold_uncertainty_score":0.64778626},"labels":[],"label_agreement":null},{"id":"W2061802061","doi":"10.1016/j.ejca.2008.09.007","title":"Proteomics: New technologies and clinical applications","year":2008,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advanced Proteomics Techniques and Applications","field":"Chemistry","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Institute of Mining, Metallurgy and Petroleum; Université de Montréal","funders":"","keywords":"Proteomics; Biomarker discovery; Biomarker; Breast cancer; Genomics; Computational biology; Identification (biology); Computer science; Bioinformatics; Medicine; Cancer; Biology; Internal medicine; Genome","score_opus":0.06127139246840362,"score_gpt":0.39727088313031683,"score_spread":0.3359994906619132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061802061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000023931693,0.97493553,0.021210061,0.0001435985,0.000033183653,0.00034517006,0.000033214514,0.000114309245,0.0031825672],"genre_scores_gemma":[0.0000014672498,0.92745584,0.0704009,0.000015126013,0.00084386417,0.00007831532,0.0000045377246,0.000077380515,0.00112259],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818736,0.000051640687,0.0011973463,0.00026622292,0.00013747536,0.00015998002],"domain_scores_gemma":[0.997568,0.00008075246,0.0016858127,0.00042797325,0.00011783958,0.00011963952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002126845,0.00026989693,0.0009194182,0.000094495226,0.00009039429,0.000032370684,0.00066627323,0.00014918999,0.000050602903],"category_scores_gemma":[0.000065560555,0.0002095661,0.00040558598,0.00014691433,0.00019151863,0.000063878804,0.00017192244,0.0011337794,0.00001652911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000031981876,0.000020154683,0.0000071391178,0.00059311127,0.000095838914,0.000015684314,0.0000049117566,3.4011072e-7,0.0000085568645,0.00012362216,0.003028225,0.99609923],"study_design_scores_gemma":[0.00015687356,0.000026246309,6.478224e-7,0.0031180887,0.00023057457,0.00033156358,0.000009963697,4.390783e-7,0.0000659814,0.00035377988,0.9955005,0.00020530714],"about_ca_topic_score_codex":0.0000017864845,"about_ca_topic_score_gemma":6.8989186e-7,"teacher_disagreement_score":0.9958939,"about_ca_system_score_codex":0.0000859862,"about_ca_system_score_gemma":0.0003843368,"threshold_uncertainty_score":0.85458577},"labels":[],"label_agreement":null},{"id":"W2062296115","doi":"10.1016/j.ejca.2003.09.003","title":"Central nervous system tumours in adolescents","year":2003,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Central nervous system; Nervous system; Medicine; Internal medicine; Psychiatry","score_opus":0.037541578261858485,"score_gpt":0.3235583428242752,"score_spread":0.2860167645624167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062296115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039951672,0.99552524,0.0000028354032,0.000044529548,0.0011994226,0.00034309528,0.000009937666,0.0000079206975,0.002467497],"genre_scores_gemma":[0.015956527,0.98303103,0.000039138835,0.00006622833,0.00069389696,0.00000544635,0.0000022660379,0.00008905886,0.000116383606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975019,0.00056316593,0.0010324037,0.00018475663,0.0003832599,0.00033448747],"domain_scores_gemma":[0.9984611,0.000013359321,0.0009043594,0.00020344256,0.00011820877,0.00029952137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042888592,0.00032204366,0.0016192304,0.00030868346,0.000021361335,0.000027297234,0.00016781587,0.00004791352,0.000044247132],"category_scores_gemma":[0.000024394474,0.00021029911,0.0006488615,0.00024516674,0.000022390403,0.000037714686,0.000021297215,0.00052672083,0.00004953086],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027144097,0.00022945902,0.0040872926,0.010123699,0.00024761492,0.016171107,0.000034345278,0.00000773159,2.3051976e-7,0.000006981977,0.0018311221,0.9672333],"study_design_scores_gemma":[0.0015296936,0.00017396238,0.008869829,0.19136143,0.0016621398,0.0021230439,0.000022859911,4.2870573e-7,0.000001414291,1.1217709e-7,0.7941106,0.00014445951],"about_ca_topic_score_codex":0.000010388803,"about_ca_topic_score_gemma":0.0000051743054,"teacher_disagreement_score":0.9670888,"about_ca_system_score_codex":0.00086261734,"about_ca_system_score_gemma":0.00042220182,"threshold_uncertainty_score":0.8575749},"labels":[],"label_agreement":null},{"id":"W2062393124","doi":"10.1016/j.ejca.2005.08.013","title":"ETS transcription factors and their emerging roles in human cancer","year":2005,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":475,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Transcription factor; Biology; Cell growth; Cancer; Cancer research; Cancer cell; Apoptosis; Programmed cell death; Cell biology; Metastasis; Gene; Immunology; Genetics","score_opus":0.04574721581244759,"score_gpt":0.33002076361046534,"score_spread":0.2842735477980177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062393124","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018539239,0.98035026,0.000025204648,0.00003493067,0.00020717952,0.00012703208,0.000050445648,0.0000028232512,0.0006628845],"genre_scores_gemma":[0.023580233,0.9749009,0.000019409266,0.000046088182,0.0011631864,0.0000058139594,0.00001687647,0.00005897813,0.0002085235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985924,0.00038087755,0.00054167205,0.00019968538,0.00010106367,0.00018429993],"domain_scores_gemma":[0.9992632,0.000006736915,0.0004680394,0.00011974125,0.00005355621,0.00008867828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044277788,0.00028158605,0.0005808733,0.00012503467,0.00004839745,0.000029927523,0.0002193428,0.00008252125,0.00007731252],"category_scores_gemma":[0.000011695988,0.00019130483,0.0002694508,0.00006694947,0.000040787854,0.0000069843763,0.000037449223,0.00035056076,8.400529e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009791818,0.00001419039,0.00010034226,0.00050414196,0.00010907644,0.000010993961,0.00027361486,0.000009013878,0.0056423442,0.0000023673304,0.00020907863,0.99311507],"study_design_scores_gemma":[0.00027929153,0.00010480075,0.00015535677,0.003908926,0.0000973851,0.000024330613,0.000042930722,3.6608648e-7,0.002005391,0.0000018502184,0.99316955,0.00020981037],"about_ca_topic_score_codex":0.00001212467,"about_ca_topic_score_gemma":0.00012311638,"teacher_disagreement_score":0.99296045,"about_ca_system_score_codex":0.00004257957,"about_ca_system_score_gemma":0.00012376242,"threshold_uncertainty_score":0.78011847},"labels":[],"label_agreement":null},{"id":"W2064680741","doi":"10.1016/j.ejca.2011.11.021","title":"Safety of bevacizumab in metastatic breast cancer patients undergoing surgery","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Bevacizumab; Surgery; Metastatic breast cancer; Incidence (geometry); Breast cancer; Adverse effect; Complication; Placebo; Breast surgery; Cancer; Chemotherapy; Internal medicine","score_opus":0.04557765805459347,"score_gpt":0.30990334728207297,"score_spread":0.2643256892274795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064680741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901105,0.0037235788,0.000016637558,0.000456901,0.0007661172,0.00011894564,0.000044237113,0.000004804804,0.0047582565],"genre_scores_gemma":[0.99507195,0.0040537566,0.00013079202,0.00025631522,0.00018798605,0.0000022762654,0.000002305332,0.000027976554,0.0002666317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861234,0.00021872202,0.0006581123,0.00010155364,0.00022766493,0.00018162421],"domain_scores_gemma":[0.99890274,0.00011903551,0.0005243054,0.000084144216,0.00025244773,0.00011731419],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041425644,0.000121538884,0.00043877604,0.00022235683,0.000019133613,0.0000029750545,0.000079858415,0.000011963061,0.0020911894],"category_scores_gemma":[0.0000348179,0.000093589646,0.00015718036,0.00019202309,0.00005303108,0.000109627144,0.00002167412,0.00017070342,0.00000601368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005214917,0.0007612496,0.9144865,0.00018092839,0.0006709282,0.0005011395,0.0017184992,0.00004196882,0.00051820703,0.0000095351725,0.0038680662,0.072028],"study_design_scores_gemma":[0.006341646,0.00044477524,0.9881008,0.0007951605,0.00043536487,0.00007809834,0.000072132134,0.0000035994085,0.0012281183,0.0000120930035,0.0023931833,0.00009502857],"about_ca_topic_score_codex":0.00018180789,"about_ca_topic_score_gemma":0.0003028116,"teacher_disagreement_score":0.07361425,"about_ca_system_score_codex":0.00024119692,"about_ca_system_score_gemma":0.00052370544,"threshold_uncertainty_score":0.998821},"labels":[],"label_agreement":null},{"id":"W2065521889","doi":"10.1016/j.ejca.2011.11.024","title":"Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"Cystectomy; Medicine; Survivorship curve; Urology; Urinary diversion; Bladder cancer; Proportional hazards model; Overall survival; Oncology; Internal medicine; Survival rate; Cancer","score_opus":0.019820169217201592,"score_gpt":0.23461291856718805,"score_spread":0.21479274934998646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065521889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902698,0.0003201707,0.0000606259,0.00008470391,0.00013272798,0.00024019243,0.00012198718,0.0000047598814,0.00876507],"genre_scores_gemma":[0.99916357,0.000016638434,0.00019152752,0.00009266428,0.00018397854,0.0000026425832,0.0000048767497,0.00004066469,0.0003034163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848336,0.0002068062,0.00041196225,0.00012144574,0.00062593067,0.0001505197],"domain_scores_gemma":[0.9986549,0.000021131524,0.00049622415,0.00019746466,0.0005048353,0.00012543195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001462043,0.00016174268,0.0003673943,0.000077801764,0.000038675007,0.0000032801934,0.00016576218,0.000021251293,0.000710453],"category_scores_gemma":[0.000012141943,0.00007974394,0.00013008219,0.00016056457,0.0003216877,0.000072656745,0.000024054136,0.00019524904,0.000002423488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0087986635,0.00073749415,0.98720545,0.000046277688,0.00077915774,0.00023647607,0.0005774558,0.000007812931,0.00032415122,0.000026063219,0.0002996506,0.0009613788],"study_design_scores_gemma":[0.012034853,0.0049370686,0.9741662,0.00025869388,0.00058255275,0.00012017711,0.000055280172,0.0000010348122,0.006714415,0.0000060380708,0.001037336,0.00008636458],"about_ca_topic_score_codex":0.00006143616,"about_ca_topic_score_gemma":0.0000068119407,"teacher_disagreement_score":0.013039232,"about_ca_system_score_codex":0.00005387504,"about_ca_system_score_gemma":0.00036345178,"threshold_uncertainty_score":0.7778962},"labels":[],"label_agreement":null},{"id":"W2068357511","doi":"10.1016/j.ejca.2013.06.026","title":"Body composition and survival in the early clinical trials setting","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"NIH Clinical Center","keywords":"Medicine; Internal medicine; Lactate dehydrogenase; Multivariate analysis; Performance status; Cancer; Clinical trial; Prospective cohort study; Survival analysis; Oncology; Gastroenterology; Surgery; Biology","score_opus":0.1647987161708412,"score_gpt":0.4723839788269288,"score_spread":0.3075852626560876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068357511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96637523,0.0014577615,0.0001000567,0.027836163,0.00038388075,0.00017210074,0.0000010453817,0.00000390869,0.0036698629],"genre_scores_gemma":[0.99348736,0.0007686785,0.00047786385,0.0037336517,0.0014716479,0.0000011202201,5.469154e-7,0.000008346695,0.00005080542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966861,0.0021508907,0.0008243624,0.000056113407,0.00018703316,0.0000954775],"domain_scores_gemma":[0.99899375,0.00037192824,0.00035451647,0.000056990582,0.00012637899,0.00009644245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010616762,0.00004693445,0.0002693637,0.000057288642,0.000039467,0.000036217836,0.000053264364,0.000012691736,0.00013152855],"category_scores_gemma":[0.000269975,0.000027541388,0.00006737058,0.00005433053,0.00003474647,0.00007471853,0.000009008848,0.00038898352,0.000013949114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008137799,0.00027546822,0.6618878,0.00016633811,0.00010196136,0.00048286698,0.0026399735,0.000003570754,0.00744018,0.00023295374,0.040834222,0.28512084],"study_design_scores_gemma":[0.0031041924,0.00026806386,0.9791197,0.00037675077,0.00003802574,0.00009127734,0.00023291583,0.000032318476,0.000034896515,0.000046306177,0.016621836,0.0000336895],"about_ca_topic_score_codex":0.00001620892,"about_ca_topic_score_gemma":0.0000015037061,"teacher_disagreement_score":0.3172319,"about_ca_system_score_codex":0.00001747745,"about_ca_system_score_gemma":0.000038477003,"threshold_uncertainty_score":0.3679579},"labels":[],"label_agreement":null},{"id":"W2068579148","doi":"10.1016/s0959-8049(01)00310-0","title":"Tanning habits and sunburn in a Swedish population age 13–50 years","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Skin Protection and Aging","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sunburn; Medicine; Erythema; Sunbathing; Quarter (Canadian coin); Demography; Population; Environmental health; Dermatology; Geography","score_opus":0.02238806750262489,"score_gpt":0.29818666102680175,"score_spread":0.27579859352417685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068579148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924209,0.001676111,0.00017380482,0.0009438013,0.00022976758,0.000048303955,2.028121e-7,0.000007772307,0.004499328],"genre_scores_gemma":[0.9976509,0.00029698628,0.0002680342,0.00040027616,0.0004578379,3.3715042e-7,3.389726e-7,0.000014517195,0.000910752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994134,0.00007126085,0.0002211108,0.00006179116,0.00014315956,0.000089279805],"domain_scores_gemma":[0.9997112,0.0000092694245,0.00012516887,0.000042146217,0.000039520644,0.00007269477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042530263,0.000048750186,0.000117923635,0.00013633684,0.000020384932,0.000018438408,0.000028995966,0.000008320375,0.000109179055],"category_scores_gemma":[0.00006982564,0.00004235831,0.000030779534,0.00011815542,0.00001364783,0.00008749153,0.0000108316635,0.00021106045,0.0000033112767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023086133,0.000028877232,0.7560949,0.000018861272,0.000029499271,0.0045007607,0.0011464764,0.00020225339,0.004196019,0.000008089208,0.0013660189,0.23217739],"study_design_scores_gemma":[0.0012675981,0.000078432386,0.9660091,0.0004859652,0.000016751013,0.0005618849,0.00009335944,0.000052175867,0.000042753767,0.000017076038,0.03132998,0.000044943834],"about_ca_topic_score_codex":0.000049459424,"about_ca_topic_score_gemma":0.00003082175,"teacher_disagreement_score":0.23213243,"about_ca_system_score_codex":0.00004642682,"about_ca_system_score_gemma":0.000015475262,"threshold_uncertainty_score":0.17273219},"labels":[],"label_agreement":null},{"id":"W2069655417","doi":"10.1016/j.ejca.2007.01.025","title":"Multidisciplinary cancer conferences: A systematic review and development of practice standards","year":2007,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre","funders":"","keywords":"Multidisciplinary approach; Medicine; Systematic review; Health care; Medical education; Best practice; MEDLINE; Family medicine; Nursing; Political science","score_opus":0.21134695626148953,"score_gpt":0.4910460176024804,"score_spread":0.2796990613409909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069655417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000020586779,0.98897237,0.00036801604,0.00011115553,0.00016905923,0.0008889549,0.000034811106,0.000007484376,0.009446073],"genre_scores_gemma":[0.000020666788,0.9952597,0.0034765233,0.00027225874,0.00019433249,0.000016917642,0.0000022352397,0.000068383255,0.00068898546],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958284,0.0005252313,0.0021877144,0.0002087622,0.0010291295,0.00022076548],"domain_scores_gemma":[0.9944094,0.00016241912,0.0035351284,0.00022849586,0.0014172781,0.0002472678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047706114,0.0003352972,0.0032260423,0.00020307115,0.00004997929,0.000019736568,0.00024911357,0.000056060017,0.00032350313],"category_scores_gemma":[0.0007738536,0.00020922735,0.00027506906,0.00025914772,0.00008961206,0.000120919394,0.00009394867,0.000505284,0.000007951234],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042187166,0.00002082733,0.0000092709815,0.60671115,0.00087818387,0.00035512232,0.00029045658,2.2578128e-7,2.6479054e-7,0.00000611989,0.0010718381,0.3906144],"study_design_scores_gemma":[0.0002255293,0.00011104993,0.000013069204,0.49040025,0.0062504113,0.0005287256,0.0001214148,9.32287e-8,8.5588437e-7,1.4157385e-7,0.5022418,0.00010666232],"about_ca_topic_score_codex":0.000016224021,"about_ca_topic_score_gemma":0.000019428413,"teacher_disagreement_score":0.5011699,"about_ca_system_score_codex":0.0004333426,"about_ca_system_score_gemma":0.004283485,"threshold_uncertainty_score":0.85320437},"labels":[],"label_agreement":null},{"id":"W2070125267","doi":"10.1016/s0959-8049(02)00071-0","title":"Embryonal tumours of the central nervous system","year":2002,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medulloblastoma; Pathology; Neuroepithelial cell; Biology; Teratoma; Histopathology; Radiation therapy; Ependymoma; Central nervous system; Medicine; Stem cell; Internal medicine; Neural stem cell; Neuroscience","score_opus":0.0252934877412139,"score_gpt":0.2830282732918381,"score_spread":0.25773478555062423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070125267","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068647,0.99488384,0.00007500948,0.00002171818,0.0012889846,0.00010000355,0.000047853955,0.0000028523773,0.0028932954],"genre_scores_gemma":[0.0068555935,0.9896674,0.000059178794,0.000031386753,0.0019620536,0.0000015002263,0.000004163915,0.000062665116,0.001356056],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99810725,0.00045476216,0.0007830029,0.00015987836,0.00029327552,0.0002018563],"domain_scores_gemma":[0.99810386,0.0000084338535,0.0013111822,0.00031068412,0.00017798433,0.00008783618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003519874,0.00022972398,0.00064705947,0.00003805082,0.000043405726,0.00001727816,0.0006215156,0.000067766334,0.00003861283],"category_scores_gemma":[0.000030747477,0.0001365823,0.0008474526,0.00009379467,0.00006741214,0.0000019750457,0.00009525206,0.00028720882,0.0000046039136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015728063,0.000023678713,0.000020135429,0.0038993044,0.00027066458,0.000032604115,0.00003551467,0.0003538927,0.00020519749,0.000007436827,0.014160861,0.980975],"study_design_scores_gemma":[0.00021794689,0.000085516556,0.00009090588,0.010525201,0.0005009959,0.000382291,0.000017436008,0.000008877037,0.00011439158,2.9151258e-7,0.98790216,0.00015395986],"about_ca_topic_score_codex":0.000004737641,"about_ca_topic_score_gemma":0.0000022059387,"teacher_disagreement_score":0.980821,"about_ca_system_score_codex":0.000080249396,"about_ca_system_score_gemma":0.00036782277,"threshold_uncertainty_score":0.5569664},"labels":[],"label_agreement":null},{"id":"W2070604092","doi":"10.1016/s0959-8049(00)00198-2","title":"Cigarette smoking and the risk of thyroid cancer","year":2000,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Menstrual Health and Disorders","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Cancer Care Ontario; University of Toronto","funders":"Health Canada","keywords":"Medicine; Thyroid cancer; Confidence interval; Etiology; Thyroid; Context (archaeology); Cigarette smoking; Internal medicine; Case-control study; Relative risk; Epidemiology; Population; Cancer; Disease; Demography; Physiology; Environmental health","score_opus":0.013296767539837806,"score_gpt":0.29139270020438524,"score_spread":0.2780959326645474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070604092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92501915,0.048176065,0.000013138528,0.0037926247,0.0001877315,0.000085875334,0.0000071847476,0.0000033819433,0.022714825],"genre_scores_gemma":[0.9682753,0.028421199,0.000045506757,0.0019774397,0.0004101507,8.849362e-7,1.7935884e-7,0.000014800096,0.0008545029],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989428,0.00022881776,0.00037174724,0.00006607469,0.00025606743,0.00013449254],"domain_scores_gemma":[0.99928343,0.000056971883,0.00030976598,0.00010177029,0.00011369977,0.00013434979],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093805644,0.00007358187,0.00023430353,0.00003786147,0.00005921892,0.000006824749,0.00007296987,0.000012085921,0.0010716491],"category_scores_gemma":[0.00006009235,0.0000401556,0.000076799246,0.000079241945,0.00014489879,0.000039634102,0.000009130908,0.00028942135,0.0000019045739],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003784511,0.000031115273,0.07573074,0.00011505118,0.00035240638,0.00007351229,0.0026302503,0.00023934907,0.00010648948,0.000049845872,0.011317901,0.90556884],"study_design_scores_gemma":[0.02400543,0.00097176724,0.682205,0.0013491566,0.0013493905,0.00023398754,0.0006578692,0.00017692805,0.00058301387,0.00016440512,0.2881069,0.00019610804],"about_ca_topic_score_codex":0.0001497352,"about_ca_topic_score_gemma":0.000019478997,"teacher_disagreement_score":0.90537274,"about_ca_system_score_codex":0.000021725456,"about_ca_system_score_gemma":0.00012398239,"threshold_uncertainty_score":0.9998415},"labels":[],"label_agreement":null},{"id":"W2073875556","doi":"10.1016/s0959-8049(12)71631-3","title":"1015 Efficacy of a Novel Peptide-drug Candidate Against Gamma-Synuclein Using a Mouse Model of Human Endometriosis","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Endometriosis Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Endometriosis; Drug; Peptide; Medicine; Cancer research; Pharmacology; Oncology; Internal medicine; Chemistry; Biochemistry","score_opus":0.08176186236141256,"score_gpt":0.35460356628690426,"score_spread":0.2728417039254917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073875556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99162716,0.00500908,0.0005290307,0.00011435956,0.00007713369,0.00023620993,0.00006373219,0.000007774727,0.0023355086],"genre_scores_gemma":[0.99335057,0.001823254,0.0038176796,0.000071113056,0.00029443682,0.0000017776061,0.0000028988477,0.000064101165,0.00057419785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99747694,0.00019518852,0.00089396373,0.00013363604,0.0008800891,0.00042019846],"domain_scores_gemma":[0.99752116,0.0003042941,0.0008160534,0.00028688222,0.00057715765,0.00049447716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013730461,0.00019755246,0.0006791252,0.0008825206,0.000058666552,0.000013809041,0.00021165765,0.000021426253,0.000098754776],"category_scores_gemma":[0.0012816623,0.00014660852,0.00036143654,0.0005785139,0.000116913485,0.00020058938,0.000085994005,0.00031479867,0.000004248445],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001197347,0.002263176,0.019596418,0.00021570342,0.0013174631,0.00008718428,0.0016331418,0.003940887,0.9512921,0.000027346407,0.0009131066,0.01751615],"study_design_scores_gemma":[0.0544039,0.0026900053,0.025987323,0.0026228102,0.0016195824,0.00017014355,0.0004993951,0.0032112794,0.90166163,0.000003563966,0.0065547153,0.0005756229],"about_ca_topic_score_codex":0.00011325262,"about_ca_topic_score_gemma":0.0000120388395,"teacher_disagreement_score":0.053206556,"about_ca_system_score_codex":0.0002731193,"about_ca_system_score_gemma":0.00025779213,"threshold_uncertainty_score":0.59785223},"labels":[],"label_agreement":null},{"id":"W2074839878","doi":"10.1016/j.ejca.2007.07.034","title":"Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Task force; Cancer therapy; Medicine; Task (project management); Cancer; Oncology; Medical physics; Internal medicine; Engineering; Systems engineering; Political science","score_opus":0.2556496433220071,"score_gpt":0.49059934637691094,"score_spread":0.2349497030549038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074839878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9352738,0.047924057,0.002471689,0.012799348,0.0005840086,0.0005938122,0.00013888591,0.0000037762857,0.00021060443],"genre_scores_gemma":[0.98606485,0.005307385,0.005211547,0.002998143,0.0002624121,0.00002931919,0.0000027560022,0.000020158232,0.00010343144],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862266,0.00033516687,0.0006767632,0.00010541071,0.00012922683,0.00013076767],"domain_scores_gemma":[0.996243,0.0025722468,0.0005808724,0.00009243268,0.00048325644,0.000028181945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017428522,0.000120103716,0.00037353084,0.0001070376,0.0001005548,0.0000044555622,0.00007381158,0.000017921464,0.0002870463],"category_scores_gemma":[0.00018330611,0.00006172983,0.000054355918,0.0001911983,0.00024879657,0.000037742757,0.000017223692,0.00016823805,1.8925766e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009519504,0.0007521318,0.03987398,0.000045808592,0.0081169,0.00001931304,0.12701711,0.00009860412,0.22940524,0.00058283703,0.012240866,0.5723277],"study_design_scores_gemma":[0.03419523,0.003088468,0.2988421,0.0009284587,0.0006805973,0.000018694156,0.017337354,0.000025347648,0.4298196,0.0010549393,0.21372576,0.00028343432],"about_ca_topic_score_codex":0.00006151075,"about_ca_topic_score_gemma":0.0008119729,"teacher_disagreement_score":0.57204425,"about_ca_system_score_codex":0.00009211141,"about_ca_system_score_gemma":0.0002886706,"threshold_uncertainty_score":0.3142956},"labels":[],"label_agreement":null},{"id":"W2076145021","doi":"10.1016/j.ejca.2005.04.023","title":"Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer","year":2005,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McGill University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Breast cancer; Medicine; Cancer research; Cancer; Oncology; Internal medicine","score_opus":0.025525145344541873,"score_gpt":0.3317752176529931,"score_spread":0.30625007230845125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076145021","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043663974,0.9924537,0.000006212659,0.00046509507,0.00048375348,0.00024759411,0.00011373021,0.000008023543,0.0018554947],"genre_scores_gemma":[0.007212393,0.98963976,0.00007682152,0.00014838402,0.0024277258,0.000004541941,0.000006755,0.000112611124,0.00037100082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968154,0.00035344143,0.0016961349,0.00027485483,0.0005276949,0.0003325078],"domain_scores_gemma":[0.99760824,0.000054070337,0.0014871436,0.0002423835,0.00031558998,0.00029257167],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006950599,0.00043959648,0.0021910963,0.00058887055,0.000030546053,0.000025390042,0.00028139033,0.000119383774,0.00038300615],"category_scores_gemma":[0.00004092092,0.00031311042,0.0005230105,0.00037649437,0.0001462617,0.00017219243,0.000087075845,0.0009883972,0.00001136229],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001632693,0.00010007626,0.0013263503,0.0034490016,0.00042230194,0.0003717373,0.0002379317,0.000003116859,0.000037494792,0.0000069070265,0.0035500242,0.99033177],"study_design_scores_gemma":[0.0016420868,0.00019276125,0.010368978,0.026715677,0.0016907367,0.0008194435,0.00004106584,0.0000018461569,0.000021154954,0.0000016709479,0.9582184,0.0002861621],"about_ca_topic_score_codex":0.000056155313,"about_ca_topic_score_gemma":0.000037056903,"teacher_disagreement_score":0.9900456,"about_ca_system_score_codex":0.0001976154,"about_ca_system_score_gemma":0.00078400987,"threshold_uncertainty_score":0.9999321},"labels":[],"label_agreement":null},{"id":"W2076679216","doi":"10.1016/j.ejca.2010.02.027","title":"Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth","year":2010,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cellular Mechanics and Interactions","field":"Biochemistry, Genetics and Molecular Biology","cited_by":382,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Dormancy; Extracellular matrix; Fibronectin; Stromal cell; Crosstalk; Integrin; Cell biology; Biology; Cancer research; Cell; Botany; Biochemistry","score_opus":0.024538109528031458,"score_gpt":0.3227761259830812,"score_spread":0.2982380164550497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076679216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000937036,0.9947162,0.0029614347,0.0002089356,0.0006722413,0.00021366515,0.00006758693,0.0000014866217,0.00022137465],"genre_scores_gemma":[0.0015273355,0.99630064,0.00048712798,0.0001404421,0.0010526612,0.00001096688,0.00006665699,0.000055207365,0.00035897034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830204,0.0005298284,0.00063206174,0.00018814938,0.00019380717,0.00015414019],"domain_scores_gemma":[0.99912906,0.000021194086,0.00039761513,0.00025217718,0.00012186955,0.000078090714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007495654,0.000214706,0.00044426505,0.00012937713,0.000037564252,0.000056817178,0.00044949353,0.00005826513,0.00015543963],"category_scores_gemma":[0.00004309774,0.00013920505,0.00042708815,0.00013969223,0.000013820065,0.0000071102677,0.000032554744,0.0005867133,0.000039674545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000583827,0.00013616247,6.0139564e-7,0.0005186307,0.0003392085,0.00039983806,0.00049522513,0.000021164105,0.02581664,0.00010323833,0.0041960212,0.9679149],"study_design_scores_gemma":[0.0002085416,0.00016205179,0.0000028254,0.0013137747,0.00038757388,0.00013542641,0.000040091025,0.000002714032,0.00031340367,0.000016323836,0.99725735,0.00015989594],"about_ca_topic_score_codex":0.000018177858,"about_ca_topic_score_gemma":0.000039620576,"teacher_disagreement_score":0.99306136,"about_ca_system_score_codex":0.000022119184,"about_ca_system_score_gemma":0.00012612803,"threshold_uncertainty_score":0.5676617},"labels":[],"label_agreement":null},{"id":"W2078208862","doi":"10.1016/j.ejca.2013.04.011","title":"Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Sunnybrook Health Science Centre; University of Toronto","funders":"Sanofi; Genentech; PharmaMar; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; Allergan; Bristol-Myers Squibb; Exelixis; GlaxoSmithKline","keywords":"Medicine; Everolimus; Exemestane; Breast cancer; Internal medicine; Subgroup analysis; Aromatase inhibitor; Oncology; Cancer; Metastatic breast cancer; Progression-free survival; Chemotherapy; Aromatase; Confidence interval","score_opus":0.004743695731383681,"score_gpt":0.24916678098884382,"score_spread":0.24442308525746015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078208862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544364,0.0036033392,0.000024015142,0.00030473742,0.00007799473,0.00034519806,0.00013814754,0.0000017703798,0.00006118226],"genre_scores_gemma":[0.9990216,0.0005412018,0.00002430954,0.00017231688,0.00017326773,0.000020423435,0.0000033016588,0.000027747727,0.000015845855],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99772614,0.0010702929,0.00046606868,0.00021611665,0.00031935048,0.00020204145],"domain_scores_gemma":[0.9986131,0.00022901302,0.0005707493,0.00032859232,0.00018620637,0.00007233179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010713299,0.00019949433,0.0004360464,0.000068602516,0.000048482063,0.000021484448,0.00037050195,0.000020552126,0.00014889649],"category_scores_gemma":[0.000053876753,0.00009888679,0.00007730002,0.00025523588,0.00014850608,0.000012460068,0.000076433345,0.00019682868,6.4150225e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029039767,0.0005668702,0.3385803,0.000043796885,0.008751846,0.000047244404,0.00241889,0.03081334,0.49548122,0.0000039872093,0.00062696304,0.09362576],"study_design_scores_gemma":[0.0053286054,0.008471558,0.9542393,0.00017561225,0.0007626097,0.000008241157,0.00042717767,0.00002207078,0.02994386,0.0000020363127,0.0004452776,0.00017364306],"about_ca_topic_score_codex":0.0004117878,"about_ca_topic_score_gemma":0.00017068919,"teacher_disagreement_score":0.615659,"about_ca_system_score_codex":0.0000567323,"about_ca_system_score_gemma":0.00007878754,"threshold_uncertainty_score":0.40324864},"labels":[],"label_agreement":null},{"id":"W2078797757","doi":"10.1016/j.ejca.2008.10.022","title":"A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of Ottawa; Queen's University; Ottawa Hospital","funders":"AstraZeneca","keywords":"Gemcitabine; Medicine; Pharmacokinetics; Cisplatin; Internal medicine; Nausea; Tolerability; Pharmacology; Phases of clinical research; Oncology; Chemotherapy; Gastroenterology; Adverse effect","score_opus":0.032184655486617995,"score_gpt":0.35429100915301104,"score_spread":0.32210635366639306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078797757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969829,0.0008884158,0.000010896332,0.000039094448,0.00021340053,0.0016110546,0.0002319794,0.0000014111328,0.000020890628],"genre_scores_gemma":[0.99938923,0.0003321622,0.00010613725,0.000030279489,0.000075632626,0.000026326808,0.0000060893944,0.000024113278,0.000010056998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971962,0.000497318,0.0012597222,0.00020057798,0.00071758445,0.00012857927],"domain_scores_gemma":[0.99753666,0.00009094368,0.0013572824,0.00010582269,0.0008059446,0.000103319515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066836266,0.00017923735,0.00082645105,0.000184302,0.00003966088,0.000003990526,0.00010139978,0.000017856428,0.000013529741],"category_scores_gemma":[0.00010609177,0.00010942083,0.000044872995,0.00033573297,0.00011561647,0.00017508194,0.000027211929,0.00019791425,4.2641757e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006079781,0.008198417,0.97422564,0.0001687156,0.00046830624,0.00004242838,0.0042088125,0.0012472102,0.0020593887,9.617116e-7,0.000028344411,0.003271968],"study_design_scores_gemma":[0.11881725,0.009853045,0.8683151,0.0005870589,0.00068591605,0.0000028208121,0.00047912865,0.00011888313,0.0010224569,3.5686182e-7,0.000026487634,0.00009148823],"about_ca_topic_score_codex":0.030908106,"about_ca_topic_score_gemma":0.08593115,"teacher_disagreement_score":0.11273747,"about_ca_system_score_codex":0.00020458217,"about_ca_system_score_gemma":0.0012153996,"threshold_uncertainty_score":0.97554517},"labels":[],"label_agreement":null},{"id":"W2078832324","doi":"10.1016/s0959-8049(03)00199-0","title":"Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials","year":2003,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Anastrozole; Fulvestrant; Medicine; Internal medicine; Aromatase inhibitor; Oncology; Breast cancer; Cancer; Metastatic breast cancer; Tamoxifen; Gynecology","score_opus":0.012576969091464623,"score_gpt":0.28481560503664477,"score_spread":0.27223863594518016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078832324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99063206,0.0072249123,0.00007230071,0.00015072414,0.00022415824,0.00041367672,0.0012231313,0.0000014390512,0.00005760755],"genre_scores_gemma":[0.9970576,0.0020861926,0.000515001,0.000023826276,0.00016791407,0.000011976607,0.000024579647,0.000029194383,0.00008367832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983423,0.00040723162,0.00067742274,0.00019929738,0.00013893307,0.00023482609],"domain_scores_gemma":[0.99869645,0.00015019455,0.00070846465,0.00017215282,0.00016182268,0.00011093988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006539085,0.00020560499,0.00051128084,0.0000489934,0.000038054666,0.000012854942,0.0001175787,0.000032992357,0.000032303797],"category_scores_gemma":[0.000048561367,0.00011890161,0.000103403996,0.00007728079,0.00009975197,0.000012726111,0.000015009857,0.00009959112,1.3600894e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14317411,0.00050042506,0.0018211246,0.00004492992,0.002878309,0.000075673364,0.0014492137,0.015381128,0.7991997,0.000007923538,0.0001083276,0.035359155],"study_design_scores_gemma":[0.20076834,0.03450798,0.05471077,0.00043350042,0.0012779952,0.00007196415,0.0020702586,0.00038286482,0.6999394,0.000009671475,0.0052646296,0.00056262076],"about_ca_topic_score_codex":0.00008489005,"about_ca_topic_score_gemma":0.00023005465,"teacher_disagreement_score":0.09926026,"about_ca_system_score_codex":0.000057593777,"about_ca_system_score_gemma":0.00018066906,"threshold_uncertainty_score":0.4848667},"labels":[],"label_agreement":null},{"id":"W2080660025","doi":"10.1016/j.ejca.2013.05.024","title":"The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; University of Toronto; Canada Research Chairs; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Interquartile range; Internal medicine; Biopsy; CD163; Proportional hazards model; Tissue microarray; Oncology; CD30; CD68; Univariate analysis; Cohort; Confidence interval; Reed–Sternberg cell; Lymphoma; Pathology; Hodgkin lymphoma; Immunohistochemistry; Multivariate analysis; Macrophage; Biology","score_opus":0.008944217694203236,"score_gpt":0.2581965383795944,"score_spread":0.24925232068539116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080660025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830015,0.015387981,8.85448e-7,0.00055962784,0.00014268835,0.00022024916,0.000008958205,0.000004462264,0.00067367556],"genre_scores_gemma":[0.99478585,0.0047027525,0.000039821167,0.00006101945,0.00016170133,0.000005351749,6.889685e-7,0.000024236884,0.00021860673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986683,0.00025870622,0.00049748376,0.00010003919,0.00026132233,0.00021414118],"domain_scores_gemma":[0.9988152,0.00021582589,0.00048591805,0.000110270135,0.00022653099,0.00014628329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004915463,0.00013801527,0.00030977718,0.000106121064,0.00004023093,0.00004240103,0.00010330532,0.00001921841,0.00007274886],"category_scores_gemma":[0.00014539633,0.00007294745,0.00015484172,0.00018660058,0.000064859785,0.00008209961,0.000038089067,0.00008783382,0.00001540573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015955738,0.00036789355,0.8936975,0.000023453109,0.00033365336,0.00063161727,0.0003673769,0.00003928616,0.0047875266,0.0000023795044,0.0040445486,0.09554522],"study_design_scores_gemma":[0.0042749066,0.0010709073,0.9916526,0.00026402745,0.00016402095,0.00008165016,0.000059635684,0.000031166026,0.0020453476,0.00001060654,0.00027814048,0.00006697613],"about_ca_topic_score_codex":0.00027330747,"about_ca_topic_score_gemma":0.000025559117,"teacher_disagreement_score":0.09795512,"about_ca_system_score_codex":0.00024959768,"about_ca_system_score_gemma":0.00017095666,"threshold_uncertainty_score":0.29747108},"labels":[],"label_agreement":null},{"id":"W2080767500","doi":"10.1016/s0959-8049(03)00195-3","title":"Cigarette smoking and the risk of invasive epithelial ovarian cancer in a prospective cohort study","year":2003,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Serous fluid; Ovarian cancer; Relative risk; Cohort; Internal medicine; Prospective cohort study; Cohort study; Oncology; Epithelial ovarian cancer; Proportional hazards model; Cancer; Confidence interval; Gynecology","score_opus":0.011286685008375258,"score_gpt":0.2678493100703497,"score_spread":0.2565626250619744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080767500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847424,0.0088217445,0.000015101432,0.001071989,0.00034444605,0.0008239882,0.000021379274,0.0000030684305,0.004155862],"genre_scores_gemma":[0.9939846,0.005366874,0.000050374067,0.000191531,0.0002445847,0.000036069934,1.419708e-7,0.000026588583,0.000099265046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980596,0.0007145324,0.0005199661,0.00017953261,0.00037282126,0.00015358497],"domain_scores_gemma":[0.9987427,0.00014708817,0.0005905409,0.00017591304,0.0002578803,0.00008586374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019209468,0.00014547324,0.0005005854,0.000103969745,0.000056181376,0.000019514557,0.00008390244,0.000016298938,0.00019338673],"category_scores_gemma":[0.00026313082,0.00008343212,0.00010892228,0.00020047558,0.00013167327,0.00006486049,0.000023850538,0.00035689553,6.0784913e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008144889,0.00025370027,0.98384345,0.000015012386,0.0017978742,0.00034565004,0.004322787,0.00013035831,0.000031325508,0.00013764134,0.00011347522,0.00819426],"study_design_scores_gemma":[0.016617674,0.00061492843,0.978312,0.00044364142,0.0014859309,0.000044000204,0.000658883,0.0000036096058,0.0009078564,0.000076628865,0.00075691566,0.000077922756],"about_ca_topic_score_codex":0.0005163774,"about_ca_topic_score_gemma":0.00050953927,"teacher_disagreement_score":0.015803184,"about_ca_system_score_codex":0.00022210393,"about_ca_system_score_gemma":0.00030944252,"threshold_uncertainty_score":0.3402263},"labels":[],"label_agreement":null},{"id":"W2080929033","doi":"10.1016/j.ejca.2011.01.009","title":"Gene expression profiling of human angiotropic primary melanoma: Selection of 15 differentially expressed genes potentially involved in extravascular migratory metastasis","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Melanoma; Biology; Gene expression profiling; Gene; Metastasis; Microarray; Cancer research; Gene expression; Microarray analysis techniques; Phenotype; Pathology; Genetics; Cancer; Medicine","score_opus":0.02750684810143635,"score_gpt":0.2461541850878057,"score_spread":0.21864733698636935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080929033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991578,0.0039779413,0.00320467,0.000016515056,0.00026267054,0.0002356615,0.0000038271683,0.000013288497,0.0007074152],"genre_scores_gemma":[0.9915923,0.0005659092,0.0074231485,0.000031852516,0.00018863889,0.0000034142845,0.0000037064183,0.00003779579,0.00015326527],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805653,0.00034221652,0.0008393891,0.00017381767,0.00042689973,0.0001611402],"domain_scores_gemma":[0.99865913,0.00000908075,0.0007264739,0.00019050439,0.0003166764,0.00009811806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047943494,0.00015965979,0.00047647455,0.00040974742,0.000035474783,0.000007527501,0.00015031893,0.000033921373,0.00030484993],"category_scores_gemma":[0.000019117078,0.00013148277,0.00025371774,0.00017636323,0.00005255665,0.00008982218,0.00005310212,0.00018916538,0.0000012626648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006362722,0.0002946042,0.025130145,0.00023336658,0.00031536998,0.00022467674,0.0004670379,0.00004110771,0.9594002,0.000005105723,0.00010851649,0.013143603],"study_design_scores_gemma":[0.0020219453,0.00073499227,0.14306949,0.00035451306,0.00034979414,0.000043838376,0.00015359807,0.000009725812,0.85276985,0.000006913564,0.0003845506,0.00010074974],"about_ca_topic_score_codex":0.000052564083,"about_ca_topic_score_gemma":0.000052404892,"teacher_disagreement_score":0.11793935,"about_ca_system_score_codex":0.00008077495,"about_ca_system_score_gemma":0.000094603216,"threshold_uncertainty_score":0.5361712},"labels":[],"label_agreement":null},{"id":"W2082615009","doi":"10.1016/j.ejca.2014.04.016","title":"Accounting for respiratory motion in partial breast intensity modulated radiotherapy during treatment planning: A new patient selection metric","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Seroma; Medicine; Radiation therapy; Nuclear medicine; Radiation treatment planning; Radiology; Surgery; Complication","score_opus":0.015155863557386644,"score_gpt":0.2849235039515066,"score_spread":0.26976764039412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082615009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6675315,0.00037150102,0.3317253,0.000048267197,0.00012721644,0.00012477703,0.0000024897402,0.000016569737,0.000052428248],"genre_scores_gemma":[0.99234074,0.000015890268,0.006221259,0.00004904271,0.0012934506,0.0000050539325,9.6226e-7,0.000037099748,0.00003651033],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99911124,0.00011748837,0.0003606916,0.00013161478,0.00011149287,0.00016745328],"domain_scores_gemma":[0.9992811,0.000019382482,0.00043262122,0.00007372769,0.00013111832,0.000062055355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002621435,0.00012799761,0.00021594464,0.00020763783,0.000062856445,0.00002909178,0.00007165261,0.000013420013,0.000043855496],"category_scores_gemma":[0.0000076029346,0.00010850073,0.00009824171,0.00019448207,0.0000112112075,0.00018620207,0.000006301561,0.00012025422,2.1906962e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066561176,0.00010311195,0.16912729,0.00000595434,0.00015539666,0.0000043481573,0.000844543,0.042691022,0.052320227,0.000016050344,0.00014008685,0.73392636],"study_design_scores_gemma":[0.01633764,0.0038654844,0.5884384,0.0006604704,0.00015193406,0.000068688845,0.00016926212,0.028370662,0.23456044,0.00025704261,0.12616786,0.00095212297],"about_ca_topic_score_codex":0.00005400554,"about_ca_topic_score_gemma":0.0000013334248,"teacher_disagreement_score":0.73297423,"about_ca_system_score_codex":0.00030306113,"about_ca_system_score_gemma":0.00004226738,"threshold_uncertainty_score":0.44245315},"labels":[],"label_agreement":null},{"id":"W2082656071","doi":"10.1016/j.ejca.2005.08.011","title":"TFII-I and USF (RBF-2) regulate Ras/MAPK-responsive HIV-1 transcription in T cells","year":2005,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Signaling Pathways in Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; U.S. Forest Service","keywords":"Enhancer; Transcription factor; Psychological repression; Chromatin; Transcription (linguistics); MAPK/ERK pathway; Cell biology; Biology; Molecular biology; Gene; Genetics; Signal transduction; Gene expression","score_opus":0.0289377814907656,"score_gpt":0.3169885214940776,"score_spread":0.288050740003312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082656071","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038124304,0.99487954,0.00008081565,0.00006015938,0.0005239094,0.00018409315,0.00011470355,0.0000038550934,0.00034050166],"genre_scores_gemma":[0.0020637233,0.99479765,0.00022963584,0.00013355532,0.0013701562,0.0000043033046,0.000026336293,0.00009319116,0.0012814351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760437,0.0008656848,0.0007870159,0.0003084669,0.00020637475,0.00022806285],"domain_scores_gemma":[0.9987311,0.000026271091,0.00066535606,0.00026572004,0.00013869783,0.00017288426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000792375,0.000322554,0.0006790468,0.00015359267,0.00003086903,0.00003669104,0.000335911,0.00011464592,0.00006865373],"category_scores_gemma":[0.000079654164,0.00027404106,0.00037468938,0.00011350536,0.00008628339,0.0000075697685,0.00005597004,0.00036998905,0.000017866725],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002506919,0.000053502506,0.00000806804,0.0010867424,0.00022728914,0.000367456,0.0001012166,0.00017971794,0.02591058,0.0000029074884,0.008228505,0.96358335],"study_design_scores_gemma":[0.0007109011,0.00014360025,0.00004416852,0.0048322054,0.00037614768,0.00010731096,0.000009225072,0.0000010997036,0.0031333906,0.0000021781643,0.9903607,0.00027909898],"about_ca_topic_score_codex":0.0000014412017,"about_ca_topic_score_gemma":0.0000046026785,"teacher_disagreement_score":0.9821322,"about_ca_system_score_codex":0.00006972229,"about_ca_system_score_gemma":0.00034105981,"threshold_uncertainty_score":0.99997115},"labels":[],"label_agreement":null},{"id":"W2083608506","doi":"10.1016/j.ejca.2009.09.003","title":"The FAMCARE-Patient scale: Measuring satisfaction with care of outpatients with advanced cancer","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Scale (ratio); Cancer; Medicine; Patient satisfaction; Nursing; Internal medicine; Geography; Cartography","score_opus":0.03948821834718153,"score_gpt":0.37250705413482205,"score_spread":0.3330188357876405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083608506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890451,0.005174418,0.00021006129,0.00093870243,0.0014940958,0.00060706015,0.000039495902,0.000025046602,0.002466027],"genre_scores_gemma":[0.99759,0.0010389806,0.00057692936,0.00036914187,0.00026226146,0.000026257057,0.0000014700818,0.00004567197,0.000089258014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964732,0.000942531,0.001017815,0.0001952796,0.0009584982,0.00041267235],"domain_scores_gemma":[0.9950605,0.00013421931,0.0020649831,0.00029797872,0.002238408,0.00020391976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040551985,0.00021091547,0.00034209888,0.00012131845,0.00072667515,0.000010905241,0.00020192382,0.00003937873,0.00007126827],"category_scores_gemma":[0.00006768293,0.00012122512,0.000068812435,0.00028257235,0.00008405537,0.00028153617,0.00002658701,0.00079869275,0.0000064801056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011819805,0.000008330443,0.65515256,0.00008959564,0.000048913203,0.000008881548,0.008260366,0.0025891836,0.00018785389,0.0000087168055,0.0002863887,0.3321772],"study_design_scores_gemma":[0.0020072828,0.0020171537,0.97650534,0.0028567198,0.00006630158,0.000006345405,0.008395099,0.0000063955754,0.00050082366,0.000005593541,0.0074691284,0.00016382219],"about_ca_topic_score_codex":0.00044089428,"about_ca_topic_score_gemma":0.0029964903,"teacher_disagreement_score":0.33201337,"about_ca_system_score_codex":0.0007130506,"about_ca_system_score_gemma":0.00062248966,"threshold_uncertainty_score":0.5589071},"labels":[],"label_agreement":null},{"id":"W2084846190","doi":"10.1016/j.ejca.2005.01.003","title":"Active and passive smoking and risk of renal cell carcinoma in Canada","year":2005,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Renal cell carcinoma; Passive smoking; Medicine; Oncology; Carcinoma; Internal medicine; Environmental health","score_opus":0.008782710567018053,"score_gpt":0.22202083486845106,"score_spread":0.21323812430143302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084846190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002486,0.004840231,0.0000074508807,0.0004301979,0.00008179545,0.000048369442,0.000020247278,7.254675e-7,0.0045461073],"genre_scores_gemma":[0.99693793,0.0022777712,0.00013594225,0.0003301251,0.00021657595,2.911053e-7,4.525634e-7,0.000011807194,0.000089104666],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99923694,0.00010161891,0.0002951032,0.00008442707,0.0001721946,0.0001097139],"domain_scores_gemma":[0.99936545,0.000043452004,0.00032313447,0.000059918064,0.00008848812,0.00011954915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001442056,0.000077308425,0.00022814792,0.00007357691,0.000020003028,0.0000041435264,0.00004283535,0.000009555871,0.00011764119],"category_scores_gemma":[0.000023968874,0.000062032836,0.000027957825,0.00005114923,0.000038297745,0.00008651079,0.000019765102,0.00028295137,1.1700157e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007542452,0.000016624204,0.47152337,0.0000559836,0.00011101828,0.00047291143,0.0016950128,0.00039444986,0.0037557713,9.090602e-7,0.0019031696,0.5193165],"study_design_scores_gemma":[0.0035722961,0.00021728987,0.9549172,0.00013570985,0.00012723177,0.00007562607,0.00055938435,0.000118558906,0.019083833,0.0000011519479,0.021116385,0.00007531181],"about_ca_topic_score_codex":0.08045265,"about_ca_topic_score_gemma":0.19547786,"teacher_disagreement_score":0.5192412,"about_ca_system_score_codex":0.00033290483,"about_ca_system_score_gemma":0.00089089776,"threshold_uncertainty_score":0.9256707},"labels":[],"label_agreement":null},{"id":"W2085518532","doi":"10.1016/j.ejca.2011.05.017","title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Pazopanib; Placebo; Medicine; Renal cell carcinoma; Quality of life (healthcare); Oncology; Internal medicine; Clinical trial; Phases of clinical research; Alternative medicine; Sunitinib; Pathology; Nursing","score_opus":0.05298764010998183,"score_gpt":0.3047085310886384,"score_spread":0.2517208909786566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085518532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472433,0.0015325008,0.0000244296,0.00010732837,0.00021332222,0.001322276,0.000008682044,0.000006606176,0.0020605442],"genre_scores_gemma":[0.99890655,0.00008819034,0.00059060875,0.00009364472,0.000090784626,0.0000109894245,0.0000055246014,0.00004791695,0.00016581555],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99533725,0.0013655504,0.0021948249,0.00023217346,0.0005548688,0.00031535668],"domain_scores_gemma":[0.9970943,0.0001452372,0.0019153974,0.0002429263,0.00026779002,0.00033434798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023120765,0.00023402806,0.0012264048,0.000307439,0.000026636893,0.0000060171205,0.00014779465,0.00003282905,0.00027709646],"category_scores_gemma":[0.0002824099,0.00015108167,0.00016000519,0.00033546003,0.00006444233,0.00013326644,0.000026195054,0.00044379014,0.000002414287],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8735913,0.0016109541,0.10889674,0.00012006987,0.00009735096,0.00047771068,0.0036484518,0.00006807856,0.00051748543,6.07439e-7,0.00009462857,0.010876592],"study_design_scores_gemma":[0.57200986,0.008641653,0.4173722,0.0005381989,0.00006186453,0.000007910699,0.00013099633,0.000005550896,0.0010966319,9.22474e-7,0.000028778319,0.0001054653],"about_ca_topic_score_codex":0.00038759154,"about_ca_topic_score_gemma":0.00021127699,"teacher_disagreement_score":0.30847546,"about_ca_system_score_codex":0.00039501116,"about_ca_system_score_gemma":0.0008315782,"threshold_uncertainty_score":0.61609316},"labels":[],"label_agreement":null},{"id":"W2086264223","doi":"10.1016/j.ejca.2015.02.008","title":"Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome","year":2015,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Mount Sinai Hospital; Hospital for Sick Children; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Lynch syndrome; PMS2; MSH6; MLH1; MSH2; DNA mismatch repair; Colorectal cancer; Medicine; Family history; Genetics; Cancer; Biology; Internal medicine","score_opus":0.07202537463525692,"score_gpt":0.346753273222186,"score_spread":0.2747278985869291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086264223","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022159735,0.9746249,0.000036980124,0.000058416885,0.0011547456,0.0004402228,0.000021574944,0.000020371495,0.0014830921],"genre_scores_gemma":[0.008615411,0.98915774,0.000929885,0.000060954473,0.0005898751,0.000005970813,0.0000080942455,0.00011089948,0.00052115513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99684674,0.00047933322,0.0014652483,0.00028828098,0.00067120267,0.00024920015],"domain_scores_gemma":[0.99682516,0.00006510233,0.0018464745,0.00036408086,0.0006280582,0.0002711239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001403595,0.0003711542,0.0019180138,0.00035230114,0.000034436307,0.000018465627,0.000262229,0.00011248682,0.00027281788],"category_scores_gemma":[0.00019544669,0.00027367598,0.00048236692,0.00031913785,0.00013756476,0.0000709419,0.000092572074,0.0005892318,0.000027394457],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011567402,0.000065283806,0.00020842938,0.010314644,0.00035066073,0.00028696063,0.00047700922,0.0000032672274,0.00005289304,0.000004233317,0.0015787188,0.9865422],"study_design_scores_gemma":[0.0008445386,0.0012860427,0.006289137,0.013996672,0.0022075959,0.0022401682,0.000030304507,0.000002257669,0.000007950987,0.000011502035,0.9728125,0.00027135696],"about_ca_topic_score_codex":0.0000091055645,"about_ca_topic_score_gemma":0.0000025561874,"teacher_disagreement_score":0.98627084,"about_ca_system_score_codex":0.00033261286,"about_ca_system_score_gemma":0.0011777441,"threshold_uncertainty_score":0.99997157},"labels":[],"label_agreement":null},{"id":"W2086410271","doi":"10.1016/s0959-8049(09)70077-2","title":"IMRT and molecular biological approaches in radiotherapy for prostate cancer","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Prostate cancer; Prostatectomy; Radiation therapy; Brachytherapy; Oncology; Prostate; Cancer; Androgen deprivation therapy; Internal medicine; Prostate-specific antigen; Gynecology; Urology","score_opus":0.07443463574387811,"score_gpt":0.35634603123100633,"score_spread":0.28191139548712824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086410271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88932073,0.09644392,0.0002071221,0.012748682,0.000081780774,0.00041307916,0.0000093918,0.0000067107962,0.0007685619],"genre_scores_gemma":[0.9741626,0.022888359,0.0014260822,0.00072565203,0.0002889552,0.000012232782,0.000002030201,0.000018452329,0.00047564993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916804,0.000093391456,0.00024835445,0.00013313597,0.00014785602,0.00020921612],"domain_scores_gemma":[0.9995875,0.000019399351,0.000106138476,0.0000679408,0.00009484396,0.00012419822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045353317,0.00010494552,0.0002532373,0.00010827667,0.000025749205,0.000018444456,0.00006694277,0.000020225389,0.000031761272],"category_scores_gemma":[0.000021855349,0.00006435975,0.000074471405,0.00010784475,0.00006749117,0.000053681382,0.000007873619,0.00017416368,3.8639604e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005736996,0.0002493228,0.05637774,0.00007454012,0.0002788981,0.0010464402,0.0014996333,0.00013280216,0.10017606,0.00009567868,0.002080007,0.8322519],"study_design_scores_gemma":[0.03547296,0.010593739,0.7471668,0.0012261128,0.00019376878,0.00033757184,0.0004155021,0.00044553477,0.040222354,0.000513782,0.16290343,0.0005084108],"about_ca_topic_score_codex":0.0000058902046,"about_ca_topic_score_gemma":0.0000018430275,"teacher_disagreement_score":0.8317435,"about_ca_system_score_codex":0.0001181232,"about_ca_system_score_gemma":0.00012556215,"threshold_uncertainty_score":0.26245144},"labels":[],"label_agreement":null},{"id":"W2087218253","doi":"10.1016/j.ejca.2009.08.009","title":"The importance of early symptom recognition in the context of early detection and cancer survival","year":2009,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Cancer; Psychological intervention; Context (archaeology); Categorization; Comparability; Intensive care medicine; Internal medicine; Psychiatry","score_opus":0.14630608968694123,"score_gpt":0.3844772522372561,"score_spread":0.23817116255031487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087218253","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05031964,0.94770277,0.00001130005,0.00018049146,0.00035128204,0.00031117533,0.000025531865,0.0000027921583,0.0010950378],"genre_scores_gemma":[0.101560205,0.8976721,0.000015922435,0.00013661472,0.0005297329,0.0000061330734,0.0000011703061,0.000024419074,0.000053690168],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971764,0.00068024866,0.0012074455,0.00015626897,0.000585689,0.00019394408],"domain_scores_gemma":[0.9971511,0.00020482294,0.0018932297,0.0002086884,0.00047067317,0.00007153253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022748641,0.00021538636,0.0010004691,0.00012449925,0.000058859634,0.000031525302,0.0002797041,0.0000597078,0.000021431448],"category_scores_gemma":[0.00014986187,0.00011517453,0.00031012014,0.00034451776,0.00013635222,0.00012651278,0.000022427084,0.0006830145,0.0000015224069],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029210307,0.000012943093,0.002641789,0.00057850714,0.00014274944,0.00007306238,0.0004435383,6.560171e-7,0.000011685676,0.000005567738,0.00013385975,0.9956635],"study_design_scores_gemma":[0.0020184934,0.0026536356,0.104435496,0.057925105,0.002317851,0.00045504398,0.0008529078,0.000001957439,0.000050885752,0.000049721508,0.8289036,0.00033529074],"about_ca_topic_score_codex":0.00036591355,"about_ca_topic_score_gemma":0.00066517986,"teacher_disagreement_score":0.99532825,"about_ca_system_score_codex":0.00013985783,"about_ca_system_score_gemma":0.00036995258,"threshold_uncertainty_score":0.4696681},"labels":[],"label_agreement":null},{"id":"W2089817687","doi":"10.1016/j.ejca.2009.12.007","title":"The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Concordance; Population; Staging system; AJCC staging system; Stage (stratigraphy); Proportional hazards model; Cancer staging; Oncology; Internal medicine; Cohort; Survival analysis; Relative survival; European union; Cancer; Cancer registry","score_opus":0.015582726011172759,"score_gpt":0.27838892508527313,"score_spread":0.26280619907410036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089817687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889339,0.00031152132,0.0020215022,0.005178231,0.0017076826,0.0009451755,0.000037213875,0.000024838579,0.0008399246],"genre_scores_gemma":[0.9955538,0.000034604833,0.00015996158,0.00040723404,0.0035713606,0.000027623926,0.0000034840118,0.000057431684,0.00018449806],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9972654,0.00065697404,0.0008535813,0.00019894484,0.0007192884,0.00030580716],"domain_scores_gemma":[0.99749964,0.00033105002,0.00087394123,0.00031844093,0.0008126817,0.00016426925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034594045,0.00019414093,0.00032115818,0.00007703809,0.00045368992,0.00012223658,0.000702497,0.0000072114985,0.000008944361],"category_scores_gemma":[0.00019204775,0.0000914307,0.00015161691,0.00039228483,0.0001283846,0.00007779585,0.00011649002,0.0005083721,0.000005411921],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038043032,0.0003677203,0.43495354,0.00040948688,0.0024421935,0.001986861,0.020251205,0.052601803,0.0013130849,0.00035863568,0.015436911,0.46607426],"study_design_scores_gemma":[0.0034415466,0.0018066673,0.9175395,0.0023069845,0.00091159245,0.00070800853,0.023118446,0.004411791,0.00046741345,7.652759e-7,0.044955686,0.00033160427],"about_ca_topic_score_codex":0.00017157765,"about_ca_topic_score_gemma":0.00054823037,"teacher_disagreement_score":0.48258597,"about_ca_system_score_codex":0.00013409763,"about_ca_system_score_gemma":0.00023018473,"threshold_uncertainty_score":0.37284356},"labels":[],"label_agreement":null},{"id":"W2090112346","doi":"10.1016/j.ejca.2011.01.017","title":"Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"MAPK/ERK pathway; Kinase; Chemistry; Cell growth; Signal transduction; Cancer research; Molecular biology; Cell biology; Biology; Biochemistry","score_opus":0.026115145101879265,"score_gpt":0.23034161258224584,"score_spread":0.20422646748036657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090112346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833135,0.014804624,0.0007858726,0.000035795045,0.00018643147,0.0003226553,0.000009993559,0.000004587674,0.0005365131],"genre_scores_gemma":[0.9982892,0.0005365963,0.0005070758,0.000083488085,0.00031550738,0.000016275006,0.0000016876844,0.00004664558,0.0002034819],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983214,0.000553336,0.00037878187,0.00022923542,0.0002345265,0.000282684],"domain_scores_gemma":[0.9991213,0.00000721353,0.00039530167,0.00022435338,0.00013760074,0.00011422774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012605273,0.00020034591,0.00021088218,0.00005886222,0.00009599113,0.000037562604,0.00040677525,0.000057364574,0.000053810138],"category_scores_gemma":[0.000039345952,0.00014437444,0.00014995651,0.000113999726,0.00008372804,0.00002699379,0.00011417814,0.00034248456,0.0000057654893],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015368487,0.00017419501,0.0004684453,0.000024601095,0.000057576373,0.00015154434,0.00031124344,0.0000060173925,0.9954741,0.000010551277,0.00019714305,0.002970884],"study_design_scores_gemma":[0.0010056667,0.00050542,0.00037889212,0.00010340011,0.000028780347,0.000017306555,0.00008277987,0.00003890073,0.995195,0.00008572731,0.0023740337,0.00018413708],"about_ca_topic_score_codex":0.000125854,"about_ca_topic_score_gemma":0.000018509778,"teacher_disagreement_score":0.014975715,"about_ca_system_score_codex":0.00004072515,"about_ca_system_score_gemma":0.00015437382,"threshold_uncertainty_score":0.5887419},"labels":[],"label_agreement":null},{"id":"W2091458894","doi":"10.1016/j.ejca.2013.02.026","title":"Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research; Université de Montréal","keywords":"Prostate cancer; Prostatectomy; Medicine; Biochemical recurrence; Oncology; Concordance; Proportional hazards model; Tissue microarray; Cohort; Internal medicine; Lymph node; Hazard ratio; Kappa; Biomarker; Cancer; Biology","score_opus":0.012612525781625437,"score_gpt":0.24605178775608252,"score_spread":0.23343926197445708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091458894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971415,0.0013388868,0.00005564366,0.00037931962,0.00034514535,0.0002141712,0.000032249853,0.000002713178,0.0004903809],"genre_scores_gemma":[0.9990191,0.00026761636,0.000086573404,0.0001445021,0.0001547833,0.0000055836385,0.0000025240552,0.000036135687,0.0002832075],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998735,0.00027206814,0.000404987,0.00014599692,0.00025578917,0.00018617461],"domain_scores_gemma":[0.99903506,0.00000769878,0.00043858998,0.00018693497,0.00027083576,0.00006087965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004018646,0.000115580515,0.00013836095,0.000050930295,0.000036150126,0.000027637021,0.00028858148,0.000030523017,0.00022697546],"category_scores_gemma":[0.00006501122,0.00007971968,0.00009366208,0.00010679886,0.000052211337,0.000013354099,0.00010443883,0.00016302329,0.000008948384],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000731643,0.00006797235,0.09311288,0.000025688236,0.00006380734,0.000007943715,0.00072846154,0.00050763367,0.89886594,0.0000022970244,0.0017363757,0.0048078336],"study_design_scores_gemma":[0.0015227963,0.00022814384,0.5993564,0.00031072408,0.000040458854,0.000020212632,0.00025464626,0.00005982525,0.36841735,0.000019185012,0.029567016,0.00020325225],"about_ca_topic_score_codex":0.000037988102,"about_ca_topic_score_gemma":0.00004440987,"teacher_disagreement_score":0.5304486,"about_ca_system_score_codex":0.00003616679,"about_ca_system_score_gemma":0.00011781146,"threshold_uncertainty_score":0.32508743},"labels":[],"label_agreement":null},{"id":"W2091912934","doi":"10.1016/j.ejca.2014.05.016","title":"Disease-free survival as an end-point in the treatment of solid tumours – Perspectives from clinical trials and clinical practice","year":2014,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Kingston General Hospital","funders":"","keywords":"Clinical trial; Medicine; Clinical endpoint; Clinical Practice; Disease; Adjuvant; Surrogate endpoint; Intensive care medicine; Endpoint Determination; End point; Oncology; Internal medicine; Family medicine","score_opus":0.2265342819112915,"score_gpt":0.5420532033629818,"score_spread":0.3155189214516903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091912934","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042418055,0.98970634,0.0000043269224,0.0018181383,0.0010335831,0.00076297927,0.00021865434,0.000005275645,0.0022088785],"genre_scores_gemma":[0.0049021803,0.98984295,0.00017611384,0.0001632728,0.0047252127,0.0000151198365,0.0000103009515,0.000053751064,0.000111079666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9834748,0.01214044,0.0031401408,0.0004223237,0.00061759114,0.00020469195],"domain_scores_gemma":[0.9886638,0.0069567193,0.0031235435,0.0005486873,0.0003652674,0.00034196643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011065808,0.0004089346,0.0045739342,0.00011969729,0.000056399196,0.000035675257,0.00031741688,0.00006963504,0.0001341924],"category_scores_gemma":[0.0077206884,0.0001957428,0.0015273831,0.000118522126,0.00031731313,0.00010189827,0.000062938736,0.0005877823,0.000005242402],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033993395,0.002033475,0.0020992244,0.0002608456,0.0033928447,0.0014605983,0.0017028495,2.6967192e-7,4.3927997e-8,0.000027421085,0.00087520265,0.9847479],"study_design_scores_gemma":[0.006223664,0.010759643,0.04401129,0.0045171864,0.01620628,0.000102973136,0.0021206874,8.610325e-7,1.0407746e-7,0.000037824444,0.91583985,0.00017965132],"about_ca_topic_score_codex":0.0001395178,"about_ca_topic_score_gemma":0.00015302298,"teacher_disagreement_score":0.98456824,"about_ca_system_score_codex":0.00024931112,"about_ca_system_score_gemma":0.00087618246,"threshold_uncertainty_score":0.9242943},"labels":[],"label_agreement":null},{"id":"W2092281468","doi":"10.1016/j.ejca.2014.03.009","title":"Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostatectomy; Cohort; Hazard ratio; Urology; Stage (stratigraphy); Proportional hazards model; Carcinoma; Prostate cancer; Pathological; Oncology; Internal medicine; Confidence interval; Cancer","score_opus":0.01222377423198053,"score_gpt":0.2717845387000694,"score_spread":0.2595607644680889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092281468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850573,0.012621082,0.000044716602,0.00050825835,0.00010143088,0.000499962,0.00006264361,0.000006038838,0.0010985594],"genre_scores_gemma":[0.99913156,0.00027083224,0.00012312898,0.00014291458,0.0002362438,0.00001929598,0.000006098177,0.000040513787,0.000029406465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857056,0.00017063004,0.0005557153,0.00018447777,0.0002588006,0.0002598345],"domain_scores_gemma":[0.9990333,0.00005013774,0.00033252905,0.00015843521,0.00019779083,0.00022780888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053981325,0.00020353355,0.00052238134,0.00019695249,0.000019677369,0.000018735793,0.00007247417,0.000023766675,0.000059252816],"category_scores_gemma":[0.00007436533,0.00013377551,0.00016542825,0.00013885438,0.000089866524,0.00010518164,0.00003941198,0.00029455047,0.0000014334181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014805536,0.00018676744,0.9804369,0.0001652231,0.00018503987,0.0010859376,0.0011990065,0.000009476309,0.00043222174,0.000004644028,0.00041307532,0.014401114],"study_design_scores_gemma":[0.0055047534,0.0031036297,0.9871262,0.0006624794,0.00014270261,0.00035591013,0.000045012333,0.000032357024,0.0009684924,0.000019430598,0.0019187558,0.00012031493],"about_ca_topic_score_codex":0.000114370705,"about_ca_topic_score_gemma":0.000025500827,"teacher_disagreement_score":0.014280799,"about_ca_system_score_codex":0.00017064722,"about_ca_system_score_gemma":0.00033006983,"threshold_uncertainty_score":0.54552066},"labels":[],"label_agreement":null},{"id":"W2092793828","doi":"10.1016/j.ejca.2006.11.002","title":"Osteonecrosis in children and adolescents with cancer – An adverse effect of systemic therapy","year":2006,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Bone and Joint Diseases","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Pathogenesis; Complication; Adverse effect; Lymphoma; Medullary cavity; Cancer; Bone marrow; Pediatrics; Internal medicine; Surgery; Oncology","score_opus":0.014518979332149705,"score_gpt":0.3090919844142248,"score_spread":0.2945730050820751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092793828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1801647,0.8191045,7.416144e-7,0.000007792003,0.00008138642,0.0005172578,0.000051199168,0.000004911139,0.00006752722],"genre_scores_gemma":[0.11504615,0.8844809,0.000007661527,0.00003777855,0.00028107595,0.000007247958,0.000008175383,0.00007477795,0.000056256875],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99789506,0.000650226,0.0007616809,0.00019742647,0.00032076685,0.00017481764],"domain_scores_gemma":[0.99847436,0.00001931647,0.0010126526,0.00019889929,0.00012230648,0.00017245972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004757774,0.0003181265,0.001755367,0.0002595999,0.000018044891,0.000010703656,0.00012434366,0.000047706373,0.000028238805],"category_scores_gemma":[0.000011739383,0.00018011696,0.0002787813,0.00019679476,0.00007707866,0.00008861755,0.000018127266,0.00038412053,0.0000016963721],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007292593,0.00008695024,0.11293413,0.008986554,0.00035820258,0.00024316972,0.000048217466,0.000006592291,0.000011798582,7.7974605e-8,0.00032335627,0.87627167],"study_design_scores_gemma":[0.012523538,0.0038750765,0.37244996,0.51740015,0.0053337337,0.0016403515,0.000018636174,5.4282094e-7,0.000031164014,1.3946861e-7,0.086231664,0.0004950264],"about_ca_topic_score_codex":0.00023497335,"about_ca_topic_score_gemma":0.000034860954,"teacher_disagreement_score":0.87577665,"about_ca_system_score_codex":0.00011062955,"about_ca_system_score_gemma":0.00035189147,"threshold_uncertainty_score":0.73449564},"labels":[],"label_agreement":null},{"id":"W2094145239","doi":"10.1016/j.ejca.2013.10.011","title":"The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"EORTC Charitable Trust","keywords":"Response Evaluation Criteria in Solid Tumors; Medicine; Medical physics; Solid tumor; Disease; Progressive disease; Cancer; Internal medicine","score_opus":0.1520663244536011,"score_gpt":0.46608803803893295,"score_spread":0.3140217135853318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094145239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850407,0.0010142216,0.0000125410215,0.0117929075,0.00003828581,0.00059532496,0.000008261411,0.000001652116,0.0014960814],"genre_scores_gemma":[0.9989166,0.0005400439,0.000276455,0.00014529064,0.000046073874,0.000044825694,0.000004001619,0.000007269809,0.000019410609],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98959714,0.008938431,0.00082700077,0.000065985856,0.0004601174,0.0001113287],"domain_scores_gemma":[0.9975689,0.0010112628,0.00044762334,0.00027613074,0.0006584443,0.000037632097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026207116,0.00006680124,0.00024046081,0.00011310257,0.00003239501,0.000008523343,0.00021875792,0.000018241233,0.000081168924],"category_scores_gemma":[0.002249921,0.000036116107,0.000040135383,0.0002754597,0.0001313974,0.00004549797,0.00002435286,0.0003216013,0.0000014021984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011787464,0.0025600377,0.10044068,0.00003605205,0.00010684422,0.000038349473,0.028226102,0.0004221146,0.15602444,0.000042031967,0.01279764,0.68751824],"study_design_scores_gemma":[0.003899191,0.0008975386,0.9818709,0.00031688187,0.00005136784,0.000015684307,0.0011560977,0.0035309535,0.0037705908,0.00027910073,0.0041761985,0.000035517292],"about_ca_topic_score_codex":0.0025752557,"about_ca_topic_score_gemma":0.0015973458,"teacher_disagreement_score":0.8814302,"about_ca_system_score_codex":0.00031318076,"about_ca_system_score_gemma":0.00057367166,"threshold_uncertainty_score":0.9082915},"labels":[],"label_agreement":null},{"id":"W2094994198","doi":"10.1016/j.ejca.2010.05.027","title":"The unclear zone in phase II clinical trials","year":2010,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Clinical trial; Medicine; Phase (matter); Internal medicine; Chemistry","score_opus":0.8800723677077351,"score_gpt":0.7352433186910667,"score_spread":0.14482904901666838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094994198","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008313733,0.98365486,0.0044304496,0.0003965565,0.008293505,0.000779323,0.000077665514,0.000014216257,0.0023451396],"genre_scores_gemma":[8.6080325e-7,0.90221566,0.088690795,0.0000952694,0.007803793,0.000009697277,3.5595187e-7,0.00014575254,0.0010378137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9192934,0.06318206,0.015576182,0.0004433286,0.0009899524,0.00051506876],"domain_scores_gemma":[0.7888547,0.20029852,0.009395563,0.00074447965,0.00036292657,0.00034381475],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.19625689,0.00045394595,0.006742186,0.00015637252,0.00014783768,0.000109412606,0.0015054562,0.0002967932,0.00063247955],"category_scores_gemma":[0.48362598,0.00022720003,0.0024217942,0.00032760215,0.00041897423,0.00005496531,0.00028902906,0.0048496183,0.00007068437],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020570167,0.00031544923,4.38577e-7,0.0006936038,0.0003542257,0.0002722256,0.000022888244,8.083086e-8,2.8083977e-7,0.0022367786,0.013769021,0.98212934],"study_design_scores_gemma":[0.0035264157,0.0008441221,0.0000015102514,0.010481415,0.0018953194,0.000043464854,0.0000064980263,0.0000013626977,4.3478505e-7,0.023260135,0.9597045,0.00023481036],"about_ca_topic_score_codex":0.0000010712474,"about_ca_topic_score_gemma":0.000007539261,"teacher_disagreement_score":0.9818945,"about_ca_system_score_codex":0.00009700536,"about_ca_system_score_gemma":0.0007453556,"threshold_uncertainty_score":0.99744624},"labels":[],"label_agreement":null},{"id":"W2096025484","doi":"10.1016/j.ejca.2014.05.021","title":"Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Neutropenia; Paclitaxel; Carboplatin; Internal medicine; Oncology; Chemotherapy; Cisplatin; Febrile neutropenia; Chemoradiotherapy; Induction chemotherapy; Regimen; Head and neck cancer; Fluorouracil; Cancer; Gastroenterology","score_opus":0.015931153559424736,"score_gpt":0.30548498121499645,"score_spread":0.2895538276555717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096025484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880888,0.009419246,0.000028633554,0.0010342731,0.0003156192,0.0003863367,0.00000763294,0.0000036677004,0.0007158168],"genre_scores_gemma":[0.99837667,0.00076311314,0.000055323813,0.00031323906,0.00018404819,0.0000050693898,6.454037e-7,0.00003382411,0.00026808088],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982503,0.00028827574,0.0006919839,0.00017291389,0.00043621447,0.00016030479],"domain_scores_gemma":[0.9986675,0.00005902438,0.0007181738,0.00018540488,0.00027320147,0.00009672665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059087505,0.00017986042,0.00064739183,0.00008987921,0.000044439945,0.000006157514,0.00014433767,0.000023610954,0.000049056118],"category_scores_gemma":[0.00006846404,0.000119425364,0.00010484054,0.00020802314,0.00011657871,0.0000845461,0.000024287698,0.00027807837,4.5306152e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006464329,0.0047935774,0.12005507,0.00033621446,0.00022965303,0.000079151585,0.018418578,0.00007202749,0.42194745,0.000010330617,0.008785217,0.4188084],"study_design_scores_gemma":[0.19063187,0.047849417,0.52789223,0.001264441,0.0004300889,0.0001833535,0.0052010813,0.00015504498,0.18130484,0.00002043735,0.04445865,0.0006085559],"about_ca_topic_score_codex":0.000057698257,"about_ca_topic_score_gemma":0.000020041753,"teacher_disagreement_score":0.41819984,"about_ca_system_score_codex":0.00009762771,"about_ca_system_score_gemma":0.00013765827,"threshold_uncertainty_score":0.4870025},"labels":[],"label_agreement":null},{"id":"W2096137335","doi":"10.1016/j.ejca.2006.11.011","title":"Physical activity and stomach cancer risk: The influence of intensity and timing during the lifetime","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nutritional Studies and Diet","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Cancer Care Ontario","funders":"","keywords":"Intensity (physics); Stomach cancer; Physical activity; Stomach; Cancer; Medicine; Oncology; Demography; Internal medicine; Physics; Physical medicine and rehabilitation; Optics; Sociology","score_opus":0.014409985874752047,"score_gpt":0.29574143783373685,"score_spread":0.2813314519589848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096137335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371475,0.0038059962,0.000012369769,0.0020713801,0.000049438797,0.000056963963,0.0000058028922,0.0000022976835,0.00028101896],"genre_scores_gemma":[0.9964582,0.0027454256,0.000027294538,0.00019025335,0.00051852496,3.9366643e-7,2.75938e-8,0.00000732525,0.00005259369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994527,0.000059935363,0.00013307825,0.000064029286,0.00019200487,0.00009826469],"domain_scores_gemma":[0.99933535,0.00010998808,0.00021885466,0.0000635208,0.00021303767,0.00005924692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005504289,0.000064815475,0.0001662688,0.000018974035,0.00014266753,0.000007990955,0.000052210475,0.0000064942024,0.0000062689573],"category_scores_gemma":[0.000086469096,0.000032047377,0.000045251778,0.000061136394,0.0001953147,0.000048799924,0.00006583906,0.00026720174,3.3898425e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044660643,0.00023261394,0.81543607,0.00021662486,0.00071852637,0.00024728812,0.0040508723,0.00049837196,0.0836107,0.000031387477,0.0016334422,0.088858016],"study_design_scores_gemma":[0.00067690026,0.00011251143,0.9943296,0.00019640883,0.000108698194,0.00007393374,0.00017731654,0.00002073287,0.0024623987,0.0000093173985,0.0017969111,0.000035271853],"about_ca_topic_score_codex":0.00014369817,"about_ca_topic_score_gemma":0.000033461587,"teacher_disagreement_score":0.1788935,"about_ca_system_score_codex":0.000028712559,"about_ca_system_score_gemma":0.000019599145,"threshold_uncertainty_score":0.1306854},"labels":[],"label_agreement":null},{"id":"W2097409338","doi":"10.1016/j.ejca.2007.08.016","title":"Molecular targeted therapy of head and neck cancer: Review and clinical development challenges","year":2007,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cetuximab; Medicine; Epidermal growth factor receptor; Oncology; Head and neck squamous-cell carcinoma; Head and neck cancer; Radiation therapy; Targeted therapy; EGFR inhibitors; Internal medicine; Cancer; Cancer research; Colorectal cancer","score_opus":0.15088480167437454,"score_gpt":0.44914574296447524,"score_spread":0.2982609412901007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097409338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053962454,0.9975242,0.000013470669,0.0008405221,0.000055121815,0.00022269099,0.00000892871,0.000005124093,0.000790301],"genre_scores_gemma":[0.00007476788,0.9978532,0.00042813885,0.0011622687,0.0002982682,0.0000027633205,0.000005051261,0.00004588647,0.00012961784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972047,0.00046572564,0.0016329604,0.00021576823,0.0003271337,0.00015372],"domain_scores_gemma":[0.9978552,0.000053205313,0.0013219704,0.00016035393,0.00033761,0.00027165818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016892691,0.0002664616,0.0022207925,0.00019526579,0.000025203264,0.000008015883,0.000102471815,0.00006242523,0.00020048443],"category_scores_gemma":[0.000073376905,0.00017429994,0.00047737086,0.000171116,0.00010203969,0.00003278127,0.000036236026,0.0005087748,0.0000029881237],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026312451,0.000059414455,0.000041324627,0.012745927,0.0011004255,0.00027402505,0.000037626454,7.030616e-8,0.0000034040286,0.0000023954365,0.000702569,0.9850065],"study_design_scores_gemma":[0.0008137381,0.0002139534,0.00066501036,0.15530613,0.0013391925,0.00014593429,0.0000058956407,1.358509e-7,0.000010967012,4.0226672e-7,0.84136564,0.00013301456],"about_ca_topic_score_codex":0.000002894827,"about_ca_topic_score_gemma":0.0000047857316,"teacher_disagreement_score":0.9848735,"about_ca_system_score_codex":0.000058015168,"about_ca_system_score_gemma":0.0004763663,"threshold_uncertainty_score":0.71077454},"labels":[],"label_agreement":null},{"id":"W2098081297","doi":"10.1016/j.ejca.2008.12.024","title":"Geographical analysis of thyroid cancer in young people from northern England: Evidence for a sustained excess in females in Cumbria","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Thyroid cancer; Chernobyl Nuclear Accident; Demography; Incidence (geometry); Medicine; Thyroid; Confidence interval; Relative risk; Cancer registry; Cancer; Environmental health; Internal medicine","score_opus":0.026406678123146482,"score_gpt":0.3389685070626355,"score_spread":0.31256182893948903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098081297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98700756,0.010148334,0.0002658668,0.0022086224,0.00008355586,0.00013040385,0.000012148302,0.0000030344806,0.00014049507],"genre_scores_gemma":[0.9959748,0.0034493993,0.000106367756,0.00015938946,0.00026084835,0.000003531776,0.0000034347588,0.000012444983,0.000029822397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985218,0.00018965715,0.00069354963,0.00014980107,0.00025984392,0.00018533361],"domain_scores_gemma":[0.9990687,0.00014500428,0.00035768203,0.00012228345,0.00023094733,0.00007538074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089764514,0.000102923885,0.0005038843,0.0008583447,0.000013369949,0.000017687666,0.00014579266,0.00001994578,0.000069211965],"category_scores_gemma":[0.00035710697,0.00008588271,0.00014925157,0.0013574298,0.000022698428,0.00021097019,0.00001054702,0.00022797764,2.977735e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008885515,0.00006795881,0.96760803,0.00002136704,0.0001394322,0.00009883627,0.0036036829,0.005359854,0.0017968103,0.0000018674522,0.00002205459,0.020391569],"study_design_scores_gemma":[0.003469281,0.00015542173,0.9919978,0.0006576497,0.00031376822,0.0000039109073,0.00041211542,0.0026133787,0.00020051208,0.000014344675,0.000079396006,0.00008246846],"about_ca_topic_score_codex":0.0024901764,"about_ca_topic_score_gemma":0.059902947,"teacher_disagreement_score":0.05741277,"about_ca_system_score_codex":0.00014803217,"about_ca_system_score_gemma":0.0002026378,"threshold_uncertainty_score":0.95725137},"labels":[],"label_agreement":null},{"id":"W2099408455","doi":"10.1016/j.ejca.2006.10.018","title":"Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostatectomy; Medicine; Prostate cancer; Logistic regression; Biochemical recurrence; Stage (stratigraphy); Cancer; Urology; Cohort; Internal medicine; Oncology; Surgery; Biology","score_opus":0.01418370198901252,"score_gpt":0.2604767671490646,"score_spread":0.24629306516005206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099408455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97027624,0.026504757,0.00006872696,0.0024126687,0.00025169447,0.00028556818,0.00009545722,0.000008779043,0.00009611749],"genre_scores_gemma":[0.9936937,0.0051396023,0.0002525717,0.00025816652,0.00040646145,0.000008712921,0.0000027166438,0.000028827088,0.0002092066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984317,0.00014258655,0.00055460614,0.00022577631,0.00036879635,0.00027654463],"domain_scores_gemma":[0.9988209,0.000057228983,0.0004806123,0.00014691552,0.0002083535,0.00028598876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008288901,0.00019724043,0.00039126005,0.00008678864,0.00005388235,0.000028279523,0.000112039204,0.000033870412,0.000060691586],"category_scores_gemma":[0.00011021766,0.00011669049,0.00008704074,0.00013384271,0.0004383402,0.00008666009,0.00007325055,0.00039721426,0.0000032356224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001042304,0.0002932122,0.97311527,0.0001814694,0.00015407181,0.0036401963,0.00065476523,0.0000035791802,0.006664719,0.000008195868,0.0024173493,0.0118248975],"study_design_scores_gemma":[0.002725357,0.0015495489,0.9709546,0.0009671367,0.00027308558,0.00046308892,0.00036935322,0.0000083510295,0.012462431,0.000015656859,0.010078787,0.00013259746],"about_ca_topic_score_codex":0.000016587272,"about_ca_topic_score_gemma":0.0000041477356,"teacher_disagreement_score":0.023417505,"about_ca_system_score_codex":0.00009615738,"about_ca_system_score_gemma":0.00009089393,"threshold_uncertainty_score":0.47585002},"labels":[],"label_agreement":null},{"id":"W2099938925","doi":"10.1016/s0959-8049(01)00413-0","title":"Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer","year":2002,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Raltitrexed; Medicine; Tolerability; Internal medicine; Thymidylate synthase; Colorectal cancer; Oncology; Oxaliplatin; Cancer; Fluorouracil; Adverse effect","score_opus":0.025820187014444,"score_gpt":0.3234681150257588,"score_spread":0.2976479280113148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099938925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08676768,0.91084707,0.0000014389093,0.00005339031,0.000189983,0.0009948919,0.000037609592,0.0000059413564,0.0011020047],"genre_scores_gemma":[0.01585682,0.9835318,0.00020622135,0.000026877988,0.00009427078,0.000037413593,0.0000039449715,0.000062012725,0.00018066129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979989,0.00018742113,0.0009139726,0.0002825103,0.0003986236,0.00021859903],"domain_scores_gemma":[0.9985152,0.00004548396,0.0009356065,0.00016616439,0.00022247033,0.00011510427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021857295,0.0003679366,0.0019266792,0.00018045506,0.000033536722,0.0000109678695,0.00012852524,0.00003725675,0.00014639477],"category_scores_gemma":[0.000008606392,0.00022381083,0.00024773547,0.00028712285,0.00011522914,0.00006226322,0.000052351126,0.00030714352,0.000001265036],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022948289,0.00043933612,0.014100916,0.003997399,0.0015337892,0.00014163136,0.00024911467,0.000013367255,1.9758934e-7,0.0000010858532,0.00012023188,0.9771081],"study_design_scores_gemma":[0.0148748765,0.0032647368,0.3459535,0.037053615,0.0021567575,0.000013808002,0.000028757126,0.0000012435602,0.0000030531792,6.3974585e-7,0.59633654,0.00031249912],"about_ca_topic_score_codex":0.00001968249,"about_ca_topic_score_gemma":0.000038325375,"teacher_disagreement_score":0.9767956,"about_ca_system_score_codex":0.00043983944,"about_ca_system_score_gemma":0.000115367315,"threshold_uncertainty_score":0.91267407},"labels":[],"label_agreement":null},{"id":"W2101021708","doi":"10.1016/j.ejca.2011.10.028","title":"Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Surrogate endpoint; Medicine; Clinical trial; Clinical endpoint; Progression-free survival; Internal medicine; Oncology; Quality of life (healthcare); Randomized controlled trial; Cancer; Overall survival","score_opus":0.6241680414480324,"score_gpt":0.5047101953925927,"score_spread":0.11945784605543974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101021708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95602584,0.011334452,0.0059920345,0.018687464,0.0022039386,0.0005232915,0.0001666422,0.000013885404,0.005052458],"genre_scores_gemma":[0.9942181,0.0008669684,0.0013465609,0.0019640985,0.0014369282,0.0000049005616,0.0000026194043,0.000034007753,0.00012578674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888205,0.004513834,0.0060361195,0.000259647,0.00014795562,0.0002219591],"domain_scores_gemma":[0.99132925,0.0017562151,0.006331746,0.0002999862,0.0001066023,0.00017617029],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08182546,0.00014395466,0.0011272586,0.0001830427,0.00009798969,0.00006210782,0.00035703855,0.000060503917,0.00014680272],"category_scores_gemma":[0.005690339,0.000119033684,0.00017463908,0.00008218462,0.000097575954,0.00038438535,0.00008428577,0.0004630145,0.000065824395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001681479,0.0000648859,0.97744596,0.000040413885,0.00012173633,0.000014019224,0.0025130478,0.000086055305,0.00000124697,0.0010323259,0.005405983,0.013106171],"study_design_scores_gemma":[0.0025522793,0.00013686113,0.98161393,0.0002920878,0.000024343162,0.0000072929683,0.00030331186,0.0014715659,0.0000021615508,0.0047944,0.008652658,0.00014908296],"about_ca_topic_score_codex":0.00009455954,"about_ca_topic_score_gemma":0.00008029565,"teacher_disagreement_score":0.076135114,"about_ca_system_score_codex":0.00014203391,"about_ca_system_score_gemma":0.00009141159,"threshold_uncertainty_score":0.94545394},"labels":[],"label_agreement":null},{"id":"W2102303915","doi":"10.1016/s0959-8049(01)00470-1","title":"Symptomatology of cancer patients in palliative care","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; McGill University; Kræftens Bekæmpelse","keywords":"Palliative care; Medicine; Quality of life (healthcare); Scale (ratio); Family medicine; Cancer; Medical record; Nursing; Internal medicine","score_opus":0.0873731865179399,"score_gpt":0.39913566896932473,"score_spread":0.3117624824513848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102303915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513469,0.039819546,0.000010613552,0.00033559036,0.0003384843,0.000075924145,0.000024227362,0.0000033514589,0.008045375],"genre_scores_gemma":[0.9863583,0.012839557,0.00023006089,0.00019461646,0.00016595669,0.0000013637191,0.0000014764399,0.000019867135,0.0001888234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998773,0.00014730306,0.0005658007,0.00009274147,0.00027575437,0.00014543062],"domain_scores_gemma":[0.9985308,0.000052644762,0.00054927386,0.000094036506,0.0006908911,0.000082368584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107993714,0.00010727519,0.00044449457,0.00015642989,0.000010925853,0.0000021403653,0.00011573762,0.000024546063,0.00042685375],"category_scores_gemma":[0.00013096983,0.00008283392,0.00011076227,0.0001736095,0.00007796622,0.00005400126,0.000022387969,0.00018972364,0.0000067134533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012624361,0.00009285326,0.9658987,0.00013690055,0.0001368811,0.00008653789,0.0102359895,0.000055679284,0.00026753388,0.000009425143,0.0022124744,0.020740792],"study_design_scores_gemma":[0.004378147,0.00076771504,0.9351926,0.0037109773,0.0001430821,0.000002971101,0.0011982479,0.000024014396,0.0076327063,0.0000045379334,0.04683142,0.00011359116],"about_ca_topic_score_codex":0.00010514656,"about_ca_topic_score_gemma":0.00010357565,"teacher_disagreement_score":0.044618946,"about_ca_system_score_codex":0.00012263955,"about_ca_system_score_gemma":0.00005937992,"threshold_uncertainty_score":0.46737492},"labels":[],"label_agreement":null},{"id":"W2103370559","doi":"10.1016/s0959-8049(01)00288-x","title":"Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial","year":2001,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Prostate; Prostate cancer; Quality of life (healthcare); Randomized controlled trial; Oncology; Cost effectiveness; Clinical trial; Quality-adjusted life year; Gynecology; Cancer; Internal medicine; Intensive care medicine; Risk analysis (engineering); Nursing","score_opus":0.5404861928672066,"score_gpt":0.5256886785531005,"score_spread":0.01479751431410603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103370559","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.113130845,0.8733773,0.000037521386,0.0014750286,0.0004400887,0.011127053,0.00029672263,0.0000039306283,0.00011150332],"genre_scores_gemma":[0.036911238,0.9618143,0.000049534414,0.00034875423,0.0003155768,0.00043512913,0.0000057976076,0.000066575696,0.00005308987],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.96925884,0.020047994,0.009695797,0.00047163246,0.00019822062,0.00032751827],"domain_scores_gemma":[0.97894794,0.00598729,0.01438157,0.00029270613,0.00026496354,0.00012552232],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.12543628,0.00035458338,0.005082302,0.0003361802,0.00021385719,0.00006517844,0.00032939928,0.000051384606,0.000005194929],"category_scores_gemma":[0.004526707,0.00023844423,0.00025920096,0.0003024908,0.00039028056,0.00019505508,0.00010543242,0.0004909023,5.610378e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10607017,0.0010088786,0.034624025,0.10409738,0.008990098,0.00003459376,0.09390144,0.0008645023,2.0378172e-7,0.00072088937,0.004709884,0.6449779],"study_design_scores_gemma":[0.60913754,0.003974409,0.06647212,0.03176018,0.0011234913,0.00006980119,0.010616217,0.00020261292,9.058539e-8,0.00031964292,0.27526352,0.0010603773],"about_ca_topic_score_codex":0.0011174005,"about_ca_topic_score_gemma":0.00036633085,"teacher_disagreement_score":0.64391756,"about_ca_system_score_codex":0.00023733165,"about_ca_system_score_gemma":0.0003909906,"threshold_uncertainty_score":0.9723474},"labels":[],"label_agreement":null},{"id":"W2103833855","doi":"10.1016/j.ejca.2006.11.012","title":"Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: A potential role for dysregulation of the transforming growth factor-β pathway","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tumor-infiltrating lymphocytes; DNA mismatch repair; Pathological; Immunohistochemistry; Colorectal cancer; Infiltration (HVAC); Transforming growth factor beta; Tissue microarray; Medicine; Pathology; Oncology; Transforming growth factor; Cancer research; Internal medicine; Biology; Cancer; Immunotherapy","score_opus":0.01685859915787254,"score_gpt":0.261255865728977,"score_spread":0.24439726657110447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103833855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397963,0.001208301,0.002123765,0.00007722418,0.0013936063,0.0008137667,0.000045616438,0.000011775218,0.00034631346],"genre_scores_gemma":[0.99867785,0.000045227815,0.00086181064,0.000019095882,0.00032060858,0.0000099457075,0.0000022892164,0.00004273986,0.000020437697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973378,0.00014045312,0.0011927602,0.00022155915,0.00075774523,0.0003496828],"domain_scores_gemma":[0.9979744,0.00014010067,0.0010291365,0.00015541709,0.0005889734,0.000111979105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008361932,0.00021447154,0.0004833862,0.00020348349,0.000065797714,0.000010732217,0.00023744625,0.000053611937,0.00005205861],"category_scores_gemma":[0.00020190385,0.00015681736,0.00037837427,0.00039010704,0.00017210552,0.00008008455,0.000029984396,0.00024802727,2.064718e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008530704,0.00016825601,0.026705293,0.00033922787,0.00014103834,0.000027898956,0.0042157597,0.00491149,0.94156986,0.000031711243,0.000027950728,0.013330785],"study_design_scores_gemma":[0.0053108586,0.0015853334,0.28259552,0.0006690224,0.00012623175,0.000029991566,0.0011767767,0.0012415848,0.7069792,0.000011610911,0.00012481467,0.00014904675],"about_ca_topic_score_codex":0.00015856155,"about_ca_topic_score_gemma":0.00021858585,"teacher_disagreement_score":0.25589022,"about_ca_system_score_codex":0.00081947545,"about_ca_system_score_gemma":0.00092951953,"threshold_uncertainty_score":0.6394826},"labels":[],"label_agreement":null},{"id":"W2106286748","doi":"10.1016/j.ejca.2013.03.009","title":"A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"","keywords":"Medicine; Confidence interval; Breast cancer; Context (archaeology); Internal medicine; Oncology; Population; Prospective cohort study; Cancer; Gynecology","score_opus":0.01904972794500173,"score_gpt":0.3313818041395131,"score_spread":0.3123320761945114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106286748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970907,0.0013843093,0.0000026642902,0.00037159026,0.00025463346,0.00046768106,0.0002502305,8.914916e-7,0.00017731715],"genre_scores_gemma":[0.9989965,0.00065450434,0.000025326231,0.00006413147,0.00020790265,0.00001756969,5.176918e-7,0.000015900028,0.000017664932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981195,0.0008379916,0.00053429574,0.00022403504,0.00013503368,0.00014919638],"domain_scores_gemma":[0.99851745,0.000047429618,0.0007556339,0.00021220522,0.00040662728,0.000060640978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005350626,0.00016537537,0.00031701365,0.00002385061,0.00005360858,0.000010316514,0.00029378824,0.000024242536,0.000056408073],"category_scores_gemma":[0.000081334125,0.000088938556,0.00019189702,0.00011227177,0.0003078228,0.00001598776,0.00020609875,0.00022574213,6.642081e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007017889,0.00033836847,0.9744352,0.000005212461,0.0007527629,0.0000010100233,0.0010116803,0.00011047488,0.014143368,2.8125976e-7,0.00050704577,0.007992785],"study_design_scores_gemma":[0.0023277097,0.00036230005,0.97290576,0.00011616657,0.000093202114,0.000013888486,0.0003050913,0.000008519264,0.023766886,0.000007299842,0.000012904614,0.000080292724],"about_ca_topic_score_codex":0.0014078175,"about_ca_topic_score_gemma":0.00026576675,"teacher_disagreement_score":0.009623519,"about_ca_system_score_codex":0.00011658033,"about_ca_system_score_gemma":0.00028269115,"threshold_uncertainty_score":0.3626809},"labels":[],"label_agreement":null},{"id":"W2106866228","doi":"10.1016/j.ejca.2014.10.030","title":"The Collaborative Wilms Tumour Africa Project; Baseline evaluation of Wilms tumour treatment and outcome in eight institutes in sub-Saharan Africa","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"Society for Industrial and Organizational Psychology; Vrije Universiteit Amsterdam","keywords":"Medicine; Wilms' tumor; Guideline; Pediatrics; Pediatric oncology; Wilms tumour; Internal medicine; Cancer; Pathology","score_opus":0.023479993888161865,"score_gpt":0.28754356368469985,"score_spread":0.264063569796538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106866228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9538823,0.041893464,0.000045908237,0.0006457878,0.00020931878,0.00025569688,0.000016111924,0.0000014248811,0.0030500093],"genre_scores_gemma":[0.9870395,0.012474735,0.00006543693,0.000026453885,0.00017375662,0.000010339258,0.0000039017455,0.000013961049,0.00019192859],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825317,0.0007315002,0.00048689096,0.00014725576,0.00022643319,0.00015473925],"domain_scores_gemma":[0.99915624,0.000030551953,0.00035381442,0.00010080474,0.00030912785,0.00004947494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017865845,0.0001327957,0.00020779995,0.00008874887,0.00004605558,0.000019140956,0.00012915178,0.000032606924,0.000003723738],"category_scores_gemma":[0.00016088426,0.000076954326,0.000057614623,0.00021079987,0.00008349196,0.000010973186,0.00002556438,0.0001246154,8.6999984e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021067555,0.0003365387,0.017834296,0.000056011184,0.00042642272,0.00007061404,0.0029284486,0.01596272,0.8014084,0.00003587366,0.008130781,0.1507031],"study_design_scores_gemma":[0.01742232,0.0047314875,0.08554324,0.00090398605,0.00046549438,0.00007485637,0.00090562983,0.0029690394,0.29566467,0.00010770134,0.5905005,0.00071111764],"about_ca_topic_score_codex":0.000027567401,"about_ca_topic_score_gemma":0.00021100309,"teacher_disagreement_score":0.5823697,"about_ca_system_score_codex":0.000100694066,"about_ca_system_score_gemma":0.0003112429,"threshold_uncertainty_score":0.31381062},"labels":[],"label_agreement":null},{"id":"W2107997901","doi":"10.1016/j.ejca.2005.08.037","title":"A National Cancer Institute of Canada Clinical Trials Group Study – IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer","year":2005,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Occupational Cancer Research Centre; Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Oxaliplatin; Irinotecan; Raltitrexed; Discontinuation; Nausea; Colorectal cancer; Internal medicine; Vomiting; Toxicity; Phases of clinical research; Gastroenterology; Oncology; Cancer; Surgery","score_opus":0.05377478333151524,"score_gpt":0.3981702665883614,"score_spread":0.34439548325684616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107997901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480534,0.0023427166,0.000002467684,0.00034287764,0.0006037326,0.0014606495,0.00015658644,0.0000055575633,0.0002800922],"genre_scores_gemma":[0.99866337,0.0005114183,0.000105171785,0.00012544931,0.0004217581,0.000057976853,0.000004269857,0.00003580297,0.00007477223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957037,0.0006237776,0.0019799534,0.00032894677,0.0010917468,0.00027189293],"domain_scores_gemma":[0.99681073,0.00017615192,0.0016997982,0.00013509557,0.00096921896,0.0002090244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015782159,0.00030108346,0.0014786149,0.00022648691,0.00010762423,0.000010695641,0.00015405638,0.00003117733,0.00013215214],"category_scores_gemma":[0.00040668485,0.00020612826,0.00011092413,0.00037927576,0.00014858537,0.00021535235,0.00009639981,0.0003840429,1.245984e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021034284,0.007942663,0.8406285,0.000043569864,0.0017605788,0.00009659782,0.0030149284,0.0011314531,0.00014283306,0.000001828539,0.00057101186,0.123631746],"study_design_scores_gemma":[0.067502074,0.025814805,0.9017403,0.00044387442,0.0005662303,0.0000037382827,0.0012069338,0.000031548196,0.00016275178,0.0000010089474,0.002332364,0.00019435576],"about_ca_topic_score_codex":0.029398251,"about_ca_topic_score_gemma":0.56076986,"teacher_disagreement_score":0.5313716,"about_ca_system_score_codex":0.00068987283,"about_ca_system_score_gemma":0.0018166478,"threshold_uncertainty_score":0.9770651},"labels":[],"label_agreement":null},{"id":"W2108853240","doi":"10.1016/j.ejca.2012.07.026","title":"Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study analysis","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Pfizer","keywords":"Exemestane; Medicine; Tamoxifen; Internal medicine; Breast cancer; Oncology; Hazard ratio; Adjuvant therapy; Estrogen receptor; Anastrozole; Cancer; Gynecology; Confidence interval","score_opus":0.012927352202042554,"score_gpt":0.3051181696142688,"score_spread":0.29219081741222624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108853240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98404187,0.015460919,0.000008312207,0.00014018263,0.000076963166,0.0001458123,0.00007027059,0.0000022635932,0.000053423206],"genre_scores_gemma":[0.99536675,0.004170111,0.000116248906,0.00006029884,0.00023140507,0.000009400167,0.0000034823174,0.000022691705,0.000019600473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986801,0.00031983122,0.00037282013,0.00019421417,0.00022580057,0.0002071941],"domain_scores_gemma":[0.99912894,0.000025100398,0.00038746532,0.00016775289,0.00019372479,0.00009703371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030607468,0.00018392155,0.00035190381,0.00013638585,0.000039546874,0.000008150257,0.00014193638,0.00001703924,0.000030001376],"category_scores_gemma":[0.000034614666,0.00013185081,0.00010597435,0.00022039708,0.000082825885,0.000018979827,0.00007384029,0.00011766106,0.0000010745191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016684355,0.00075342867,0.81988317,0.000006928225,0.001333425,0.000018542116,0.0016783882,0.0037779333,0.16608338,0.0000013396481,0.00016320574,0.0046318294],"study_design_scores_gemma":[0.00268715,0.0006591354,0.9483775,0.00010871737,0.00020923141,0.000016812439,0.00045745642,0.0000014276002,0.046627916,3.5376667e-7,0.0007279815,0.00012634647],"about_ca_topic_score_codex":0.00010919935,"about_ca_topic_score_gemma":0.00003472752,"teacher_disagreement_score":0.1284943,"about_ca_system_score_codex":0.00004758275,"about_ca_system_score_gemma":0.000049664326,"threshold_uncertainty_score":0.537672},"labels":[],"label_agreement":null},{"id":"W2110297165","doi":"10.1016/j.ejca.2014.08.021","title":"Non-target progression – The fine line between objectivity and subjectivity","year":2014,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Subjectivity; Objectivity (philosophy); Epistemology; Philosophy","score_opus":0.012381203987345386,"score_gpt":0.2699273615332426,"score_spread":0.2575461575458972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110297165","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4760361,0.0320238,0.006289791,0.4777335,0.0029344608,0.00068738847,0.00036453304,0.000013864843,0.0039165565],"genre_scores_gemma":[0.8484448,0.0031292273,0.00047500635,0.09999499,0.046772014,0.000007328844,0.00009793486,0.0001552983,0.0009233593],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856275,0.00030492598,0.00036933256,0.000268312,0.00025187613,0.00024281787],"domain_scores_gemma":[0.99859434,0.00008408265,0.0006689061,0.00033116448,0.00024128352,0.0000802066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094655954,0.00025778427,0.00035712463,0.000051309224,0.000105298415,0.00007048003,0.0003498064,0.0001548668,0.000015290898],"category_scores_gemma":[0.0001275479,0.00017148453,0.00017196561,0.000054292643,0.0001378029,0.000004147339,0.0001928159,0.0009728561,0.0000030862484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097476,0.00001871837,0.008654888,0.00007164558,0.00023397544,0.00013366547,0.000050037543,0.00007181853,0.0043275678,4.735604e-7,0.9471285,0.03921124],"study_design_scores_gemma":[0.000592036,0.0006875694,0.012498907,0.00014473054,0.00013286209,0.00005835032,0.0000023942614,0.000008043286,0.008490598,0.000030881223,0.97712976,0.00022389626],"about_ca_topic_score_codex":0.000013480386,"about_ca_topic_score_gemma":0.00002221518,"teacher_disagreement_score":0.3777385,"about_ca_system_score_codex":0.000032671574,"about_ca_system_score_gemma":0.00019421295,"threshold_uncertainty_score":0.6992936},"labels":[],"label_agreement":null},{"id":"W2110509198","doi":"10.1016/j.ejca.2008.02.041","title":"The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Pfizer (Canada)","funders":"Health Canada; Pfizer Canada; Hamilton Health Sciences; Pfizer","keywords":"Sunitinib; Reimbursement; Medicine; GiST; Cost effectiveness; Clinical trial; Oncology; Economic evaluation; Intensive care medicine; Internal medicine; Cancer; Health care; Stromal cell; Risk analysis (engineering); Pathology","score_opus":0.48949335566860636,"score_gpt":0.49976822103564,"score_spread":0.010274865367033648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110509198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948074,0.0018603003,0.0003168258,0.001729608,0.00010859123,0.00042472815,0.000023186936,0.0000021148926,0.0007272343],"genre_scores_gemma":[0.996256,0.00020701875,0.0030215038,0.000025503312,0.00039341475,0.000006705936,0.000001179269,0.0000199666,0.00006872354],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99744934,0.0009190158,0.0010228731,0.000099947465,0.0002578832,0.00025094056],"domain_scores_gemma":[0.99645305,0.0015784996,0.0011227577,0.0001214684,0.00062595715,0.0000982423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053780065,0.0001050192,0.00045675,0.00009681186,0.00013925345,0.000008465701,0.00017022504,0.0000060404836,0.000107151296],"category_scores_gemma":[0.0021288062,0.000058184138,0.00020938348,0.00008275772,0.00027856044,0.00006650137,0.00003316264,0.00030329966,9.882707e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041176364,0.0031529227,0.13774359,0.0004828489,0.0020241484,0.004969629,0.0076156585,0.013306691,0.67219305,0.0010786946,0.004223671,0.11203271],"study_design_scores_gemma":[0.1521512,0.063758485,0.5339143,0.008233543,0.0032807877,0.06464421,0.0125832455,0.011615065,0.12047864,0.0007632013,0.02777802,0.0007992823],"about_ca_topic_score_codex":0.00014872916,"about_ca_topic_score_gemma":0.00004108303,"teacher_disagreement_score":0.5517144,"about_ca_system_score_codex":0.00018332653,"about_ca_system_score_gemma":0.00090761384,"threshold_uncertainty_score":0.25485337},"labels":[],"label_agreement":null},{"id":"W2111365327","doi":"10.1016/j.ejca.2008.03.019","title":"Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Poly ADP ribose polymerase; Temozolomide; Melanoma; In vivo; Cancer research; Angiogenesis; PARP inhibitor; CD31; Biology; In vitro; Glioma; Polymerase; DNA; Biochemistry","score_opus":0.021716845727099417,"score_gpt":0.27290877613245507,"score_spread":0.25119193040535565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111365327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98277146,0.011935775,0.00005975697,0.0013205244,0.00014488869,0.00008167472,0.000026972759,0.000009490987,0.0036494723],"genre_scores_gemma":[0.99447376,0.003834816,0.00042661658,0.00045431996,0.00060426514,0.0000011403426,0.0000012209589,0.000029615741,0.00017427141],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985884,0.00026680887,0.0004999473,0.00013608983,0.0003390633,0.00016972923],"domain_scores_gemma":[0.9990391,0.000069054695,0.00043118687,0.00010799828,0.00020465013,0.00014797544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004767147,0.00013042944,0.00038018258,0.00020280085,0.00004606487,0.000007222291,0.00006330794,0.000023910683,0.00018834093],"category_scores_gemma":[0.00009651781,0.0001131735,0.00007700874,0.00020543399,0.00017367282,0.00018179078,0.000020436833,0.00020808162,0.00000143732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021460506,0.00027127287,0.13017602,0.000083650855,0.00013631879,0.0011957844,0.0010429752,0.000008633343,0.8515693,0.000021656117,0.004362474,0.008985878],"study_design_scores_gemma":[0.003785321,0.00047788885,0.2611804,0.000601882,0.000036247075,0.00125404,0.000114902214,0.0000067452524,0.72990394,0.00001316183,0.0025059865,0.00011945115],"about_ca_topic_score_codex":0.00035746855,"about_ca_topic_score_gemma":0.000015287596,"teacher_disagreement_score":0.1310044,"about_ca_system_score_codex":0.0000889566,"about_ca_system_score_gemma":0.00022711125,"threshold_uncertainty_score":0.46150813},"labels":[],"label_agreement":null},{"id":"W2115267598","doi":"10.1016/j.ejca.2011.03.004","title":"Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: Results of a Children’s Cancer and Leukaemia Group study","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Division of Computer and Network Systems; Cancer Research UK; Hospital for Sick Children; Children's Cancer and Leukaemia Group","keywords":"ThioTEPA; Medicine; Carboplatin; Radiation therapy; Medulloblastoma; Surgery; Cyclophosphamide; Primitive neuroectodermal tumor; Regimen; Chemotherapy; Cisplatin","score_opus":0.017042383072030206,"score_gpt":0.25593704099907927,"score_spread":0.23889465792704906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115267598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887336,0.010117304,9.3015916e-7,0.00007165251,0.00014936109,0.00071699324,0.0001020523,0.000005876395,0.00010225521],"genre_scores_gemma":[0.9967579,0.0030007763,0.000041333977,0.000014468775,0.00013903288,0.000009236362,0.00000356845,0.00002942363,0.000004218901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821484,0.00026750704,0.0007585834,0.00024568193,0.00027972294,0.00023369095],"domain_scores_gemma":[0.99881417,0.000016572472,0.00067443156,0.0001546413,0.00013672907,0.00020345197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018001217,0.00022521781,0.0006079167,0.00019468882,0.000026695017,0.000008687866,0.000076295626,0.000018966255,0.000004842702],"category_scores_gemma":[0.000017271817,0.00015670985,0.000104101615,0.000116155745,0.00008111324,0.00007422625,0.00003579914,0.00013488228,2.6993376e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026419542,0.0022759407,0.94627196,0.000050827584,0.00044376962,0.0005386477,0.0037634291,0.000013848304,0.00022328547,0.0000036874444,0.00003353055,0.043739114],"study_design_scores_gemma":[0.018376352,0.005892932,0.9707491,0.0014329418,0.0007176592,0.0004530791,0.00039592545,0.00000742943,0.0018651999,2.2534583e-7,0.0000066630605,0.00010251524],"about_ca_topic_score_codex":0.0013003193,"about_ca_topic_score_gemma":0.00018534325,"teacher_disagreement_score":0.0436366,"about_ca_system_score_codex":0.00024608622,"about_ca_system_score_gemma":0.00008404057,"threshold_uncertainty_score":0.6390442},"labels":[],"label_agreement":null},{"id":"W2115421613","doi":"10.1016/j.ejca.2011.05.016","title":"Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ozmosis Research (Canada); Sunnybrook Health Science Centre; BC Cancer Agency","funders":"BC Cancer Agency; Sanofi","keywords":"Capecitabine; Medicine; Oxaliplatin; Bevacizumab; Colorectal cancer; Chemoradiotherapy; Surgery; Total mesorectal excision; Radiation therapy; Rectum; Internal medicine; Clinical endpoint; Cancer; Chemotherapy; Randomized controlled trial","score_opus":0.01696698204803368,"score_gpt":0.2958487950981974,"score_spread":0.2788818130501637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115421613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944332,0.0013714749,0.000084988846,0.00009421788,0.0005664145,0.0009991465,0.000047548147,0.000020798347,0.0023821658],"genre_scores_gemma":[0.9970632,0.0006683667,0.00065974396,0.00012567018,0.00047892303,0.000044491004,0.0000080383725,0.000059700058,0.00089186046],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980809,0.0002319214,0.0006199525,0.00028219644,0.00051870494,0.00026634432],"domain_scores_gemma":[0.99831545,0.00004939525,0.000617405,0.00015147979,0.0005181633,0.0003480962],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002462247,0.0002732025,0.0005349555,0.00012743019,0.00012686351,0.000024407747,0.000106740576,0.000035958892,0.0009767624],"category_scores_gemma":[0.00012237046,0.00016977845,0.00009832989,0.00024996273,0.00013825955,0.0003957703,0.000045593475,0.00031614918,0.000002659522],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44013533,0.0014336256,0.061981905,0.000041241925,0.0006336681,0.0006183304,0.004680398,0.000059108726,0.00017563935,0.000002165495,0.0003321052,0.4899065],"study_design_scores_gemma":[0.33558485,0.05681983,0.59959096,0.0011722918,0.0005950738,0.000056274046,0.0001290756,0.0001137769,0.001977843,0.000003297188,0.0035790964,0.00037760678],"about_ca_topic_score_codex":0.00008754674,"about_ca_topic_score_gemma":0.00019588239,"teacher_disagreement_score":0.5376091,"about_ca_system_score_codex":0.00035090436,"about_ca_system_score_gemma":0.0003852337,"threshold_uncertainty_score":0.99993646},"labels":[],"label_agreement":null},{"id":"W2115951414","doi":"10.1016/j.ejca.2007.05.017","title":"Cost issues in new disease-modifying treatments for advanced cancer: In-depth interviews with physicians","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Guideline; Medicine; Obligation; Disease; Family medicine; Health care; Nursing; Political science","score_opus":0.06417609811830058,"score_gpt":0.327494961731993,"score_spread":0.2633188636136924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115951414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81600106,0.13300307,0.020094851,0.004532501,0.0019031375,0.0010719084,0.00027830183,0.00002188347,0.023093266],"genre_scores_gemma":[0.9839985,0.010565661,0.0012043678,0.00072854204,0.0008449334,0.000015338845,0.000002244666,0.00007438012,0.0025660738],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981956,0.000022747094,0.0010259598,0.00027228356,0.000049975108,0.00043342685],"domain_scores_gemma":[0.9985488,0.0000390109,0.0009791014,0.0001739358,0.000065024964,0.00019410631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007910425,0.00021463302,0.0006192427,0.00032996177,0.00003924493,0.000050508716,0.00028497624,0.00002517824,0.000098871606],"category_scores_gemma":[0.000053472086,0.00020688081,0.00015285687,0.00022252416,0.000044763376,0.0005692149,0.000023953879,0.000201251,0.000019245446],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017882474,0.0001648686,0.26874402,0.000051182826,0.00015155412,0.00012901172,0.0025598328,0.0054171127,0.00003990374,0.0015422559,0.0022831557,0.7171289],"study_design_scores_gemma":[0.007556284,0.0004523552,0.66002846,0.0009881569,0.000038099883,0.0000033839026,0.0002837877,0.0001512284,0.00018732225,0.0012825461,0.3285917,0.00043666756],"about_ca_topic_score_codex":0.00046334023,"about_ca_topic_score_gemma":0.0044882945,"teacher_disagreement_score":0.7166922,"about_ca_system_score_codex":0.0006141585,"about_ca_system_score_gemma":0.00015857077,"threshold_uncertainty_score":0.8436355},"labels":[],"label_agreement":null},{"id":"W2116943896","doi":"10.1016/j.ejca.2008.02.038","title":"Cancer pain assessment – Can we predict the need for specialist input?","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Grey Nuns Community Hospital; University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cancer pain; Cancer; Pain assessment; Pain management; Intensive care medicine; Physical therapy","score_opus":0.03314160721103212,"score_gpt":0.309260427845555,"score_spread":0.2761188206345229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116943896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5488905,0.030909995,0.026134903,0.29245532,0.007792048,0.0028958619,0.0001453204,0.00013481849,0.090641245],"genre_scores_gemma":[0.953302,0.0113773635,0.0014249544,0.009027804,0.008799698,0.000023174032,0.000005531731,0.000074864736,0.015964609],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984944,0.0003168362,0.00041691016,0.00011718848,0.0004265019,0.00022815044],"domain_scores_gemma":[0.9989754,0.00010644374,0.00034396243,0.0001911765,0.00024225468,0.00014076977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017269871,0.00013823774,0.00025883428,0.00009431031,0.00016447081,0.000027114387,0.00024057773,0.000014776047,0.00032587026],"category_scores_gemma":[0.00012360733,0.00008445978,0.00018301002,0.00014909568,0.000095770105,0.000058990492,0.00003522192,0.0002917096,0.0000029832586],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000522814,0.00011349186,0.13044693,0.00012747494,0.00060447573,0.0005436008,0.0018891046,0.0002923093,0.0007151738,0.00017368747,0.72504526,0.1395257],"study_design_scores_gemma":[0.002139688,0.0003257694,0.27867195,0.00025436786,0.00018703598,0.000009446073,0.00023953001,0.00023116103,0.00007760024,0.00002196464,0.7177525,0.000088981134],"about_ca_topic_score_codex":0.000050037354,"about_ca_topic_score_gemma":0.000074327596,"teacher_disagreement_score":0.40441152,"about_ca_system_score_codex":0.00018809928,"about_ca_system_score_gemma":0.00037550466,"threshold_uncertainty_score":0.3568051},"labels":[],"label_agreement":null},{"id":"W2117971266","doi":"10.1016/j.ejca.2010.03.026","title":"Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute of Nursing Research; National Cancer Institute; American Lebanese Syrian Associated Charities","keywords":"Dexamethasone; Medicine; Internal medicine; Pharmacokinetics; Actigraphy; Glucocorticoid; Corticosteroid; Endocrinology; Adverse effect; Pharmacogenetics; Circadian rhythm; Genotype; Biology; Gene","score_opus":0.04374791166370855,"score_gpt":0.33216269684592,"score_spread":0.2884147851822114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117971266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995924,0.00059630256,0.0007193545,0.0011892352,0.000837606,0.0003681309,0.000017032295,0.0000071007457,0.0003412605],"genre_scores_gemma":[0.99416965,0.00022094348,0.0048278137,0.00029840192,0.00039399695,0.0000059485415,0.00000361559,0.00004235845,0.000037290865],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983261,0.00021990821,0.00073696376,0.00017679922,0.00034047334,0.00019973007],"domain_scores_gemma":[0.99850047,0.00020980692,0.00065550714,0.00018016464,0.00025885322,0.00019517884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011768483,0.00016590235,0.0004923169,0.0001910418,0.000026109494,0.000013222248,0.000114536066,0.000037011665,0.000031595297],"category_scores_gemma":[0.0004915486,0.00013032074,0.00014344761,0.0001372814,0.00003090413,0.00009646482,0.000029453646,0.00026768656,7.3786435e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027963696,0.0014930698,0.3025452,0.000485118,0.00084455765,0.00011152354,0.016418165,0.000044478133,0.07368063,0.0001952806,0.0006959011,0.6006897],"study_design_scores_gemma":[0.016565124,0.0039865407,0.95790946,0.0004635679,0.0004166566,0.000026198953,0.0003509852,0.000067739944,0.016390242,0.00023853846,0.0033233545,0.0002616031],"about_ca_topic_score_codex":0.00009383193,"about_ca_topic_score_gemma":0.00044696656,"teacher_disagreement_score":0.6553643,"about_ca_system_score_codex":0.00010370347,"about_ca_system_score_gemma":0.00011064855,"threshold_uncertainty_score":0.53143257},"labels":[],"label_agreement":null},{"id":"W2118088444","doi":"10.1016/j.ejca.2014.12.016","title":"Influence of censoring on conclusions of trials for women with metastatic breast cancer","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"Swiss Cancer Research Foundation","keywords":"Censoring (clinical trials); Medicine; Metastatic breast cancer; Hazard ratio; Discontinuation; Oncology; Internal medicine; Breast cancer; Clinical trial; Cancer; Confidence interval; Pathology","score_opus":0.04598617739027913,"score_gpt":0.32561086766335123,"score_spread":0.27962469027307213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118088444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651766,0.001911884,0.0003738555,0.00031944696,0.00014421447,0.0001262703,0.00035439458,8.6350923e-7,0.00025138742],"genre_scores_gemma":[0.99774915,0.0010365463,0.0005345317,0.00023649924,0.00032812546,0.0000076064885,0.0000016523087,0.00002317752,0.000082683175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99897116,0.00012907256,0.0005006376,0.000098733355,0.00016708697,0.0001333035],"domain_scores_gemma":[0.9981352,0.00007277968,0.0007977326,0.00013537229,0.00072987797,0.00012905624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001066823,0.00009698305,0.0003464337,0.000047593538,0.000019638466,0.000007112244,0.00016395193,0.000013128543,0.00001074924],"category_scores_gemma":[0.00036167505,0.00006967985,0.00007507266,0.000058842044,0.00006629772,0.000004765328,0.000041362564,0.000055898883,2.576512e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01174808,0.00024252418,0.0077551054,0.00018315676,0.0012065088,0.000029713201,0.0015503443,0.32025945,0.6137538,0.00012941918,0.008331235,0.03481064],"study_design_scores_gemma":[0.027041769,0.015650049,0.08162729,0.0017732286,0.00092861085,0.00016204643,0.0017146474,0.00008236902,0.584937,0.00024269757,0.28494546,0.000894851],"about_ca_topic_score_codex":0.000031514403,"about_ca_topic_score_gemma":0.000021175592,"teacher_disagreement_score":0.32017708,"about_ca_system_score_codex":0.00005113297,"about_ca_system_score_gemma":0.00036042364,"threshold_uncertainty_score":0.2841462},"labels":[],"label_agreement":null},{"id":"W2119349383","doi":"10.1016/j.ejca.2015.07.017","title":"Addressing overtreatment of screen detected DCIS; the LORIS trial","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":375,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Medicine","score_opus":0.306547317567451,"score_gpt":0.41124773149740956,"score_spread":0.10470041392995855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119349383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645584,0.015180969,0.000555902,0.0018380425,0.0008030956,0.00023359538,0.000008422896,0.000011359836,0.016810196],"genre_scores_gemma":[0.9969782,0.00020503643,0.000643419,0.00037599474,0.0014504389,0.0000010550295,6.786198e-7,0.000018394148,0.00032678485],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838525,0.00022898309,0.00048449548,0.0000851773,0.0006617312,0.00015434147],"domain_scores_gemma":[0.99851924,0.000042477663,0.0005009173,0.00018022285,0.00056818814,0.00018897551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010874842,0.00010372872,0.00028086483,0.00006535737,0.000041325147,0.000021366157,0.00017465962,0.000017135859,0.0001068352],"category_scores_gemma":[0.00029553793,0.000058547826,0.00015632322,0.00017743661,0.00007343553,0.0001069357,0.000036918653,0.00022221029,0.000008145033],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16736205,0.00032042127,0.030562215,0.00005922886,0.0014580884,0.0023429696,0.0048291055,0.0012450946,0.0072162966,0.00005734049,0.10873462,0.6758126],"study_design_scores_gemma":[0.28496101,0.026356282,0.26140282,0.0058684293,0.0032906386,0.0016315522,0.005110176,0.00033879947,0.03687188,0.00017481566,0.37325203,0.00074156676],"about_ca_topic_score_codex":0.00012805787,"about_ca_topic_score_gemma":0.0000192012,"teacher_disagreement_score":0.675071,"about_ca_system_score_codex":0.00015380718,"about_ca_system_score_gemma":0.00036462554,"threshold_uncertainty_score":0.23875111},"labels":[],"label_agreement":null},{"id":"W2120171585","doi":"10.1016/j.ejca.2013.02.012","title":"Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital","funders":"","keywords":"Medicine; Erlotinib; Rash; T790M; Pharmacodynamics; Pharmacokinetics; Adverse effect; Pharmacology; Internal medicine; Epidermal growth factor receptor; Cohort; Discontinuation; Oncology; Cancer; Gefitinib","score_opus":0.03850557109698171,"score_gpt":0.38690989731739417,"score_spread":0.34840432622041245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120171585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973969,0.0008707579,0.0000209001,0.00046056026,0.00011346727,0.0010204092,0.000013525587,0.0000068076333,0.00009667974],"genre_scores_gemma":[0.99802935,0.00013452202,0.0012635131,0.00023320873,0.00011458341,0.000016037437,0.0000017287188,0.000066276734,0.0001407623],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99760026,0.00041567584,0.0006662238,0.00026305421,0.0007288755,0.00032588627],"domain_scores_gemma":[0.9982056,0.000045020744,0.00030126737,0.00024023738,0.0006634512,0.0005444475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076916977,0.00021154432,0.00059133285,0.00032863667,0.00004270214,0.000047602683,0.00014602447,0.000013790875,0.0001888175],"category_scores_gemma":[0.00015288936,0.00013903408,0.000026548178,0.0003802154,0.00011260198,0.00035379265,0.00008144047,0.00035747484,0.000004464539],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019291397,0.0080552315,0.4320484,0.00039305538,0.00032125603,0.0019135351,0.009575479,0.000248469,0.0118706245,0.0000018990614,0.0020993259,0.5141813],"study_design_scores_gemma":[0.061608437,0.078581765,0.84971166,0.0017242631,0.00024448332,0.000082090904,0.0031181087,0.00009589472,0.0025225088,0.0000046810487,0.001967581,0.00033850872],"about_ca_topic_score_codex":0.00019247024,"about_ca_topic_score_gemma":0.00029493426,"teacher_disagreement_score":0.5138428,"about_ca_system_score_codex":0.00013119492,"about_ca_system_score_gemma":0.0002445763,"threshold_uncertainty_score":0.5669645},"labels":[],"label_agreement":null},{"id":"W2120640970","doi":"10.1016/j.ejca.2009.10.018","title":"Telomere lengths in the oral epithelia with and without carcinoma","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"Ministry of Education, Culture, Sports, Science and Technology","keywords":"Telomere; Chromosome instability; Carcinogenesis; Fluorescence in situ hybridization; Biology; Genome instability; In situ hybridization; Epithelium; Carcinoma in situ; Carcinoma; Pathology; Cancer research; Molecular biology; Cancer; Genetics; Gene; Chromosome; Medicine; DNA damage; Gene expression; DNA","score_opus":0.019044460455417418,"score_gpt":0.28397482572694427,"score_spread":0.26493036527152686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120640970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98397017,0.0053835814,0.00002978287,0.0055136723,0.00008006508,0.00011170124,0.0000018884288,0.000007352836,0.0049018096],"genre_scores_gemma":[0.99573827,0.00065871223,0.0005033049,0.0023900827,0.0003467737,5.054612e-7,3.4519806e-7,0.000018425017,0.00034356533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988021,0.0002096696,0.00031375536,0.00012661696,0.0003451506,0.0002026745],"domain_scores_gemma":[0.9993681,0.000025170537,0.00018117724,0.00017088027,0.00013042113,0.00012430437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066288613,0.00013923596,0.000283549,0.00011912069,0.00004926448,0.000031454816,0.00015797735,0.000015567466,0.00004544397],"category_scores_gemma":[0.000042485248,0.000073050534,0.000046931487,0.00019980648,0.000093864015,0.000114417904,0.000009425684,0.00038821777,0.0000054950556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012783079,0.00013011876,0.72037464,0.000035271245,0.000052779185,0.0020244871,0.0045718364,0.000012909377,0.002826978,0.00008589044,0.00223602,0.26637077],"study_design_scores_gemma":[0.0025098536,0.001151297,0.9720617,0.00028892222,0.00007957308,0.0012698991,0.00062475685,0.000012454651,0.00044962263,0.000015758074,0.02142893,0.00010725756],"about_ca_topic_score_codex":0.000028578163,"about_ca_topic_score_gemma":0.000038279944,"teacher_disagreement_score":0.2662635,"about_ca_system_score_codex":0.000033098397,"about_ca_system_score_gemma":0.00011249154,"threshold_uncertainty_score":0.29789144},"labels":[],"label_agreement":null},{"id":"W2121723241","doi":"10.1016/j.ejca.2008.10.042","title":"Recommendations for the assessment of progression in randomised cancer treatment trials","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council","keywords":"Medicine; Clinical endpoint; Clinical trial; Protocol (science); Disease; Confidence interval; Progression-free survival; Internal medicine; Oncology; Cancer; Intensive care medicine; Overall survival; Pathology; Alternative medicine","score_opus":0.1627223464314168,"score_gpt":0.4608926106396016,"score_spread":0.29817026420818477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121723241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8348287,0.085357204,0.0011207497,0.06259959,0.0025366857,0.0049194805,0.00018088004,0.000016679789,0.008440047],"genre_scores_gemma":[0.96064955,0.036526237,0.0012773192,0.00013292869,0.00046294488,0.00017985032,0.0000021866551,0.000016730964,0.000752266],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986511,0.00026890385,0.0007024866,0.00008240603,0.00018565606,0.00010948681],"domain_scores_gemma":[0.9986195,0.00039974521,0.00060963683,0.000088372166,0.00023528711,0.000047467096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010459414,0.000104132356,0.0005721032,0.00007552069,0.000093839495,0.0000049754535,0.000058272108,0.000009815129,0.00017973153],"category_scores_gemma":[0.00012326267,0.00004830518,0.00026701752,0.00010057393,0.000052746564,0.000037021025,0.000011280003,0.000076332144,2.2766828e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0132694915,0.00071139645,0.06462484,0.000044143748,0.0018911094,0.000095738236,0.0028810655,0.00027313776,0.0012544804,0.00001643762,0.015425093,0.89951307],"study_design_scores_gemma":[0.1127426,0.004846946,0.5293166,0.0010602329,0.0014248566,0.0000553692,0.00052516727,0.0001696816,0.0031921356,0.000011278616,0.34651703,0.00013812097],"about_ca_topic_score_codex":0.00005529349,"about_ca_topic_score_gemma":0.000081426784,"teacher_disagreement_score":0.89937496,"about_ca_system_score_codex":0.00031408135,"about_ca_system_score_gemma":0.0003600121,"threshold_uncertainty_score":0.19698282},"labels":[],"label_agreement":null},{"id":"W2122540164","doi":"10.1016/j.ejca.2008.05.011","title":"The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Breast cancer; Node (physics); Medicine; Oncology; Internal medicine; Cancer; Physics","score_opus":0.005978426652967974,"score_gpt":0.2335564222775682,"score_spread":0.22757799562460024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122540164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954045,0.0021902916,0.00017028244,0.0009927254,0.00007847848,0.0002183221,0.0006308499,0.00000109641,0.00031346385],"genre_scores_gemma":[0.9975068,0.0020417857,0.0001305542,0.00011413203,0.000099513665,0.000016944012,0.0000027106473,0.000026631868,0.000060941762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839133,0.0004763794,0.00047890114,0.00017672981,0.0002731741,0.0002034583],"domain_scores_gemma":[0.9982535,0.00014035286,0.0007067884,0.00015366296,0.00067553174,0.000070144124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043184805,0.00019177263,0.00045410625,0.000049006838,0.00009111469,0.000009287449,0.0001973289,0.000019341685,0.000009957515],"category_scores_gemma":[0.000039412786,0.00010474852,0.000076190496,0.00017364605,0.0007516016,0.000012504531,0.00008052589,0.00010954795,2.5534015e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046454795,0.00048911007,0.70252556,0.0001222129,0.0057638483,0.00015340219,0.034411635,0.0020175374,0.20044707,0.000048417605,0.0004185624,0.007147877],"study_design_scores_gemma":[0.0036298851,0.00027870468,0.9385369,0.00042796278,0.0001417744,0.00008139958,0.002829737,0.0000028676084,0.05391991,0.0000043186274,0.00002945353,0.000117083386],"about_ca_topic_score_codex":0.00034300782,"about_ca_topic_score_gemma":0.00011380579,"teacher_disagreement_score":0.23601137,"about_ca_system_score_codex":0.00007458776,"about_ca_system_score_gemma":0.00018850951,"threshold_uncertainty_score":0.42715207},"labels":[],"label_agreement":null},{"id":"W2123195794","doi":"10.1016/j.ejca.2010.04.014","title":"Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: The EORTC QLQ-ELD15","year":2010,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Quality of life (healthcare); Medicine; Cancer; Focus group; Family medicine; Disease; Gerontology; Internal medicine; Nursing","score_opus":0.139558224137822,"score_gpt":0.42808982444125243,"score_spread":0.2885316003034304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123195794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02748646,0.96832526,0.00028108686,0.0007439161,0.0007073503,0.0018930436,0.00026255188,0.000005201642,0.0002951466],"genre_scores_gemma":[0.069534324,0.92796385,0.00034903426,0.00004301834,0.0010923288,0.00016533835,0.000012691284,0.00012481972,0.0007145955],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965002,0.00088362827,0.0013659158,0.00026362532,0.00073722296,0.00024943176],"domain_scores_gemma":[0.9954582,0.00024444814,0.0020606702,0.00043236042,0.0016556998,0.00014861568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003126812,0.00029629687,0.001340812,0.0001318938,0.00016883641,0.000019086934,0.00034462273,0.00006301397,0.00006168825],"category_scores_gemma":[0.00014693465,0.0001433301,0.00035376332,0.00028782728,0.00025285114,0.000050301718,0.00006320079,0.00037467718,3.622501e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049165724,0.00014475222,0.0036570416,0.008555958,0.00077879714,0.0000014302292,0.0070296894,0.000008679022,0.000077225726,0.000037738766,0.00044820915,0.9787688],"study_design_scores_gemma":[0.002639545,0.0008104229,0.047470544,0.017675202,0.0014116807,0.000013050104,0.0006960086,0.0000020598147,0.0005497657,0.000006914572,0.9285106,0.00021419949],"about_ca_topic_score_codex":0.00094114715,"about_ca_topic_score_gemma":0.015781613,"teacher_disagreement_score":0.9785546,"about_ca_system_score_codex":0.00041376328,"about_ca_system_score_gemma":0.0034039181,"threshold_uncertainty_score":0.88065106},"labels":[],"label_agreement":null},{"id":"W2125138500","doi":"10.1016/j.ejca.2010.05.001","title":"Hospitalisations 1998–2000 in a British Columbia population-based cohort of young cancer survivors: Report of the Childhood/Adolescent/Young Adult Cancer Survivors (CAYACS) Research Program","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Children's Hospital; Interior Health; University of Toronto; BC Cancer Agency","funders":"National Cancer Institute; BC Cancer Agency; Canadian Institutes of Health Research","keywords":"Medicine; Cancer registry; Population; Cohort; Cancer; Cohort study; Odds ratio; Odds; Pediatrics; Demography; Gerontology; Logistic regression; Internal medicine; Environmental health","score_opus":0.021363895202294855,"score_gpt":0.3341225605874934,"score_spread":0.31275866538519853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125138500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956305,0.00216775,0.000012509758,0.002351472,0.0029241177,0.0017336804,0.00025702783,0.00003579916,0.0009546229],"genre_scores_gemma":[0.9960663,0.00086391513,0.00034466642,0.00031950418,0.0013110704,0.0001053525,0.000031074134,0.00014529418,0.0008128276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99193746,0.0013495759,0.0026895606,0.00057243864,0.0027601488,0.0006907972],"domain_scores_gemma":[0.9934928,0.00020818447,0.0022286747,0.00096287177,0.0027369729,0.0003705414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0058397856,0.00030784358,0.0010843406,0.0003375381,0.0002493991,0.00016220531,0.00079239986,0.00014283703,0.0004882814],"category_scores_gemma":[0.001458774,0.00033432426,0.0005088857,0.0016168009,0.0005693134,0.0002913098,0.00013303378,0.0020000834,0.000002211361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012794859,0.00093295256,0.9846652,0.00036333833,0.00028906643,0.00021240993,0.0021201125,0.00032650607,0.00050694944,0.000004647597,0.0027456842,0.007705142],"study_design_scores_gemma":[0.0024323477,0.0002688731,0.98852503,0.004600716,0.00023659297,0.00025893384,0.000539948,0.00007358147,0.00038001648,0.000018254565,0.002352625,0.00031307072],"about_ca_topic_score_codex":0.71539533,"about_ca_topic_score_gemma":0.9493848,"teacher_disagreement_score":0.23398946,"about_ca_system_score_codex":0.00056782964,"about_ca_system_score_gemma":0.0030618529,"threshold_uncertainty_score":0.9999109},"labels":[],"label_agreement":null},{"id":"W2127672786","doi":"10.1016/j.ejca.2005.09.005","title":"Transcription factors in cancer","year":2005,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Transcription factor; Biology; Cell biology; Cancer cell; Cell growth; Gene; Apoptosis; Cancer research; Cancer; Transcriptional regulation; Genetics","score_opus":0.02277975977043206,"score_gpt":0.31496208230951034,"score_spread":0.2921823225390783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127672786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900925,0.0068157073,0.00012056725,0.0007421391,0.0002511916,0.000041542793,0.000008154248,0.0000019924762,0.0019261636],"genre_scores_gemma":[0.9956821,0.0015058257,0.000102063,0.00013094484,0.0010339092,0.0000014266221,0.0000023313085,0.000023828636,0.0015175255],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990869,0.00017150312,0.0002757319,0.00010719694,0.00019702324,0.00016164525],"domain_scores_gemma":[0.99959075,0.0000035615647,0.00010727128,0.00009414989,0.00012004322,0.00008419013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037411635,0.00008336565,0.0001036832,0.00008866114,0.000023554838,0.000012363765,0.00016321264,0.000024821178,0.00017258027],"category_scores_gemma":[0.00003205488,0.00007073719,0.000084406725,0.00008147639,0.000040002906,0.000008475763,0.000016333954,0.00018323016,0.000009044975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011043507,0.00004499698,0.004161612,0.0000064504084,0.000025718338,0.000022370607,0.00033050816,0.0014849948,0.9481933,0.0000017706615,0.008719242,0.036898594],"study_design_scores_gemma":[0.0007392006,0.0001570283,0.01766962,0.000050817973,0.000007309888,0.000009033634,0.000047092548,0.00001179512,0.5036272,6.0581056e-7,0.47758737,0.000092968796],"about_ca_topic_score_codex":0.00003386431,"about_ca_topic_score_gemma":0.00038108102,"teacher_disagreement_score":0.4688681,"about_ca_system_score_codex":0.000088212786,"about_ca_system_score_gemma":0.00011664417,"threshold_uncertainty_score":0.28845787},"labels":[],"label_agreement":null},{"id":"W2128742846","doi":"10.1016/j.ejca.2010.03.040","title":"Prostate cancer: Trends in incidence, survival and mortality in the Netherlands, 1989–2006","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"KWF Kankerbestrijding; European Commission","keywords":"Medicine; Prostate cancer; Incidence (geometry); Cancer registry; Prostate; Population; Relative survival; Cancer; Stage (stratigraphy); Mortality rate; Gynecology; Demography; Internal medicine; Biology","score_opus":0.02281778519748697,"score_gpt":0.3228617211514242,"score_spread":0.30004393595393725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128742846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825698,0.007358573,9.53726e-7,0.004402112,0.00048086868,0.00013328095,0.000026167774,0.00000396603,0.0050242827],"genre_scores_gemma":[0.99235815,0.006435208,0.000037411923,0.00044083403,0.00045109625,0.00001494208,0.0000026728671,0.000019337875,0.00024036819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986898,0.00021077669,0.00043208155,0.00014901249,0.00030972523,0.0002086326],"domain_scores_gemma":[0.9993589,0.000047750156,0.00023359041,0.00016575212,0.00009054962,0.00010347654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001305343,0.00013528086,0.00029695738,0.0001599677,0.00003067758,0.000034946417,0.00012670248,0.000020297222,0.00014078351],"category_scores_gemma":[0.000027777032,0.00007920939,0.00006243077,0.00029281102,0.00008730251,0.000109451255,0.000023853054,0.0005189059,0.0000014336392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018063207,0.00010674315,0.8844807,0.000016308579,0.000046277426,0.0007750933,0.0014088107,0.000027614295,0.00029772834,0.00002846393,0.0012975838,0.11133405],"study_design_scores_gemma":[0.0027987275,0.00028401843,0.96612537,0.00022194714,0.000071099304,0.000061055136,0.00017223836,0.000012035581,0.00017493322,0.000030874995,0.029966807,0.00008090936],"about_ca_topic_score_codex":0.0008622285,"about_ca_topic_score_gemma":0.008534897,"teacher_disagreement_score":0.111253135,"about_ca_system_score_codex":0.000078746896,"about_ca_system_score_gemma":0.00013949229,"threshold_uncertainty_score":0.47626728},"labels":[],"label_agreement":null},{"id":"W2130240428","doi":"10.1016/j.ejca.2004.02.011","title":"Acute neurotoxicity in children with advanced stage B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukaemia treated with the United Kingdom children cancer study group 9002/9003 protocols","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Neurotoxicity; Medicine; Methotrexate; Chemotherapy; Lymphoma; Lymphoblastic lymphoma; Stage (stratigraphy); Internal medicine; Gastroenterology; Pediatrics; Surgery; Oncology; Toxicity; Immunology","score_opus":0.013739474926767484,"score_gpt":0.289184876856828,"score_spread":0.2754454019300605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130240428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876358,0.00023850532,0.00004900813,0.0005168066,0.00002895449,0.0113866525,0.000056202087,0.000030527957,0.000057533234],"genre_scores_gemma":[0.99732107,0.0002182196,0.00019549784,0.00049114187,0.00015211562,0.0014574914,0.00001048732,0.00011717094,0.000036831778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976244,0.0002900401,0.0005612636,0.00044172312,0.0006353111,0.0004472771],"domain_scores_gemma":[0.9983649,0.000036986654,0.0006700187,0.00039259953,0.0002455679,0.0002898985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031730274,0.0004831483,0.0006925542,0.0003337416,0.00017580461,0.00010530467,0.00027283264,0.00003368673,0.00003218356],"category_scores_gemma":[0.000013893183,0.00025466311,0.00009402166,0.0008553615,0.0001866822,0.00022558698,0.00006936478,0.00032183147,0.0000024526696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005653136,0.0015641847,0.972638,0.000015909598,0.0028333415,0.0033313863,0.00062526844,0.0043718084,0.0017310424,0.0000062212825,0.000060944192,0.00716877],"study_design_scores_gemma":[0.0527943,0.008791333,0.9317779,0.0009742246,0.0012726019,0.0011740616,0.00009005071,0.000016085383,0.0025414305,7.85113e-7,0.0002894641,0.0002777456],"about_ca_topic_score_codex":0.0009913502,"about_ca_topic_score_gemma":0.00050319807,"teacher_disagreement_score":0.047141165,"about_ca_system_score_codex":0.0005058952,"about_ca_system_score_gemma":0.00033377804,"threshold_uncertainty_score":0.9999906},"labels":[],"label_agreement":null},{"id":"W2131952826","doi":"10.1016/j.ejca.2012.07.001","title":"Corrigendum to: “Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy” [Eur J Cancer 2012;48(9): 1318–25]","year":2012,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Prostate Cancer Canada; Fondation Cancer; Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research","keywords":"Medicine; Prostate cancer; Cancer; Christian ministry; Radiation therapy; External beam radiotherapy; Oncology; Internal medicine; Biopsy; Gynecology; General surgery","score_opus":0.011773030154220722,"score_gpt":0.2578630884241443,"score_spread":0.24609005826992358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131952826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75871515,0.21588323,0.000002230418,0.0015172831,0.017099835,0.0015323226,0.0050049666,0.000018003477,0.00022700979],"genre_scores_gemma":[0.65139484,0.33061337,0.000079264595,0.0007939263,0.0028435164,0.00047603453,0.00023666592,0.00033255317,0.013229811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951357,0.00047773964,0.0018612541,0.0007233216,0.0008996439,0.000902323],"domain_scores_gemma":[0.99523824,0.000082366714,0.0025424196,0.00041775894,0.00087125634,0.00084792875],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051616685,0.000916119,0.0018740393,0.00059383066,0.00008489254,0.00006527768,0.00037260697,0.0002080806,0.0010722214],"category_scores_gemma":[0.00012925024,0.0007082565,0.00032884648,0.00052531617,0.00024940757,0.00031358987,0.00012259302,0.0013798254,0.000010242931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075488375,0.00054047856,0.5163532,0.00032507387,0.00080567785,0.00020992462,0.0018459721,0.0000022151696,0.000043352145,3.1726574e-7,0.41348523,0.06563366],"study_design_scores_gemma":[0.00694966,0.0022744325,0.73076165,0.0048441514,0.0015606108,0.000027645548,0.00004248476,0.0000074576574,0.0010521725,0.000002156886,0.25193587,0.0005416952],"about_ca_topic_score_codex":0.0046650036,"about_ca_topic_score_gemma":0.00055730925,"teacher_disagreement_score":0.21440844,"about_ca_system_score_codex":0.0014333257,"about_ca_system_score_gemma":0.0007772404,"threshold_uncertainty_score":0.9998409},"labels":[],"label_agreement":null},{"id":"W2132648151","doi":"10.1016/j.ejca.2010.10.015","title":"An analysis of research activity in major UK cancer centres","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nexus (standard); Research policy; Creativity; Quarter (Canadian coin); Productivity; Political science; Public administration; Public relations; Regional science; Economic growth; Sociology; Geography; Law; Economics; Engineering","score_opus":0.15228614505406635,"score_gpt":0.5285338544561421,"score_spread":0.37624770940207575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132648151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98516726,0.0009269019,0.0000256524,0.010803079,0.00022508406,0.00012217292,0.000017025335,0.0000032915495,0.0027095561],"genre_scores_gemma":[0.9965204,0.0017179279,0.00011806983,0.00058058585,0.0006495483,0.000001813573,8.923263e-7,0.000016407625,0.0003943268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966824,0.00073778303,0.00044355827,0.00013720774,0.001362888,0.0006361546],"domain_scores_gemma":[0.9957897,0.00022233558,0.00019497823,0.0002564389,0.0008474025,0.0026891192],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007740775,0.00008134739,0.00042936532,0.0010075766,0.000039677183,0.0000149062425,0.00023026732,0.000037968242,0.0023999643],"category_scores_gemma":[0.007467225,0.000056537254,0.00011836885,0.0012407831,0.00020847245,0.000111016474,0.00003172582,0.0015534709,0.0000052941587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002341821,0.00039658882,0.5138031,0.00017290875,0.00047334397,0.00095700927,0.0009829518,0.00008281662,0.16649549,0.000019985071,0.0075893668,0.30668458],"study_design_scores_gemma":[0.0018392092,0.0006472606,0.9572223,0.00031049902,0.00018203491,0.000008624693,0.00011500878,0.00032863105,0.008721426,0.0000052818305,0.030565731,0.000054015123],"about_ca_topic_score_codex":0.0017303631,"about_ca_topic_score_gemma":0.00401766,"teacher_disagreement_score":0.44341916,"about_ca_system_score_codex":0.00019533836,"about_ca_system_score_gemma":0.0036352333,"threshold_uncertainty_score":0.99851197},"labels":[],"label_agreement":null},{"id":"W2133093025","doi":"10.1016/j.ejca.2010.04.013","title":"Head to head comparison of three generations of Partin tables to predict final pathological stage in clinically localised prostate cancer","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Stage (stratigraphy); Prostatectomy; Receiver operating characteristic; Medicine; Prostate cancer; Pathological; Lymph node; Nuclear medicine; Cancer; Internal medicine","score_opus":0.10041988006776316,"score_gpt":0.41107755924381234,"score_spread":0.3106576791760492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133093025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141145,0.0018256321,0.0004393338,0.0048429207,0.00040291258,0.0005329234,0.00025186012,0.000007042774,0.00028595096],"genre_scores_gemma":[0.9942448,0.0005364066,0.003992875,0.0006706286,0.0003195979,0.000042566982,0.0000063490384,0.000026911028,0.00015985273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975356,0.00016039977,0.001404445,0.00022123383,0.00041256676,0.00026575613],"domain_scores_gemma":[0.9982362,0.000083847255,0.0005844177,0.00024200976,0.00051535224,0.0003382028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094683864,0.0001695986,0.0006939629,0.0001438089,0.000032588807,0.000015277725,0.00016704704,0.00003723473,0.00034695305],"category_scores_gemma":[0.00023834483,0.00012124857,0.00013592573,0.00026556704,0.00010345849,0.00006748051,0.000059593483,0.00040285042,0.0000051702996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021053054,0.0008414585,0.8933194,0.00006994426,0.0000910277,0.00023434761,0.0010645102,0.009019671,0.023329467,0.000024386558,0.0030638806,0.06683659],"study_design_scores_gemma":[0.00447425,0.0051637013,0.9485131,0.0010165783,0.00013461742,0.000012026858,0.00010542891,0.0002967902,0.014874721,0.000010549968,0.025256148,0.0001421175],"about_ca_topic_score_codex":0.00021234553,"about_ca_topic_score_gemma":0.0037952668,"teacher_disagreement_score":0.06669447,"about_ca_system_score_codex":0.00010005563,"about_ca_system_score_gemma":0.00043906903,"threshold_uncertainty_score":0.4944373},"labels":[],"label_agreement":null},{"id":"W2133131144","doi":"10.1016/j.ejca.2010.06.115","title":"A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec; SickKids Foundation; British Columbia Children's Hospital; CancerCare Manitoba; Children's Hospital of Eastern Ontario; Hospital for Sick Children","funders":"Brain Tumour Research","keywords":"Medicine; Temozolomide; Radiation therapy; Dosing; Internal medicine; Regimen; Concomitant; Toxicity; Chemoradiotherapy; Glioma; Surgery; Oncology","score_opus":0.01923961592284209,"score_gpt":0.2662546967762623,"score_spread":0.2470150808534202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133131144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955388,0.0014682781,0.000035983965,0.001340039,0.00045983715,0.0010254575,0.00002959541,0.000009610039,0.00009242697],"genre_scores_gemma":[0.99611044,0.00009893459,0.0029887923,0.00020554166,0.00043847586,0.000016277585,0.0000028873108,0.000072934825,0.00006569004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857163,0.0001446579,0.0005554224,0.00019141276,0.0002430542,0.00029379985],"domain_scores_gemma":[0.9982271,0.00014506072,0.000531707,0.000259812,0.00036062265,0.0004756661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048062325,0.00021424824,0.0005531695,0.00046435703,0.00007231922,0.000027026847,0.00018340962,0.000018116936,0.000102090926],"category_scores_gemma":[0.0000796259,0.00014574088,0.0001301019,0.0002606356,0.000044867276,0.00007428501,0.000010455576,0.0002178139,0.0000032108223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006856842,0.008645861,0.89206517,0.00008236458,0.003125586,0.003708476,0.0026306622,0.0004460143,0.03357829,0.000015948495,0.0070552784,0.041789487],"study_design_scores_gemma":[0.1000913,0.031223359,0.85273343,0.00017575061,0.0010606642,0.00017531645,0.0010419898,0.00018570737,0.0026156437,8.6991577e-7,0.01041309,0.00028285076],"about_ca_topic_score_codex":0.005247154,"about_ca_topic_score_gemma":0.085999124,"teacher_disagreement_score":0.09323446,"about_ca_system_score_codex":0.00022265098,"about_ca_system_score_gemma":0.00047924687,"threshold_uncertainty_score":0.930679},"labels":[],"label_agreement":null},{"id":"W2133289313","doi":"10.1016/s0959-8049(00)00423-8","title":"IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Debulking; Medicine; Internal medicine; Ovarian cancer; Ovarian carcinoma; Pathological; Oncology; Chemotherapy; Carcinoma; Confidence interval; Stage (stratigraphy); Epithelial ovarian cancer; Disease; Epithelial ovarian carcinoma; Ovary; Cancer; Gastroenterology; Biology","score_opus":0.02026180758931394,"score_gpt":0.2641864075520779,"score_spread":0.24392459996276394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133289313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911161,0.0037605015,0.000007923716,0.0021338162,0.0002393039,0.00009965193,0.0000065285253,0.0000063191933,0.0026298545],"genre_scores_gemma":[0.9971485,0.0016095638,0.00010669768,0.00055104966,0.0003632266,7.6991495e-7,0.0000010624791,0.000018560058,0.00020056596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869037,0.00026642522,0.00039331842,0.00014288593,0.00031938124,0.00018762088],"domain_scores_gemma":[0.99919826,0.00006370888,0.00031715332,0.000062556624,0.00019106871,0.00016725693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006570499,0.00012427222,0.00030923513,0.00011065423,0.00004003522,0.000024339506,0.000047617883,0.000047400485,0.00002933239],"category_scores_gemma":[0.00020141434,0.00008126391,0.000042919462,0.000124698,0.000030734922,0.00011454465,0.000026430649,0.00042950577,0.0000023621326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013065812,0.000074418844,0.97258055,0.0000112689995,0.000046464396,0.0015799131,0.0010402444,0.0000034152151,0.001815979,0.000019729534,0.00051649165,0.021004932],"study_design_scores_gemma":[0.0032770783,0.0016898261,0.9872928,0.00009642582,0.00007333468,0.00043295723,0.00019072823,0.000007784576,0.0004496147,0.000008161425,0.0063855774,0.00009567059],"about_ca_topic_score_codex":0.000016458062,"about_ca_topic_score_gemma":0.000019981902,"teacher_disagreement_score":0.020909261,"about_ca_system_score_codex":0.0000787737,"about_ca_system_score_gemma":0.00006558186,"threshold_uncertainty_score":0.33138463},"labels":[],"label_agreement":null},{"id":"W2136482150","doi":"10.1016/j.ejca.2009.05.014","title":"Wounds and survival in cancer patients","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pressure Ulcer Prevention and Management","field":"Health Professions","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Sinai Health System; Statistics Canada; University of Toronto; Humber College; William Osler Health System","funders":"","keywords":"Medicine; Hazard ratio; Cancer; Proportional hazards model; Internal medicine; Charlson comorbidity index; Observational study; Univariate analysis; Multivariate analysis; Survival analysis; Stage (stratigraphy); Prospective cohort study; Surgery; Comorbidity; Oncology; Confidence interval","score_opus":0.04432622346900605,"score_gpt":0.40903709076658323,"score_spread":0.3647108672975772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136482150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86547136,0.0043450976,0.0003195125,0.007743756,0.0033959337,0.00038499883,0.000009765026,0.000020422149,0.11830913],"genre_scores_gemma":[0.9917933,0.0012287449,0.000060379156,0.0022057288,0.00035261558,0.0000023069215,4.6736403e-7,0.00001042134,0.0043460573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842066,0.0006742653,0.0004430165,0.00008244116,0.0002000881,0.00017954395],"domain_scores_gemma":[0.9993522,0.000028175293,0.00031445967,0.00006956613,0.00014558586,0.000089996625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010539173,0.000071902425,0.00015759228,0.00010555326,0.00008070959,0.000008520423,0.000120113546,0.000015961394,0.00054274674],"category_scores_gemma":[0.00004147342,0.00005762968,0.000033264965,0.00008780003,0.000013651939,0.00012566513,0.000045443,0.000333629,0.000013179456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027644713,0.00022413794,0.5822928,0.00009333786,0.00008233403,0.000065812834,0.0040943264,0.00008903938,0.00015922924,0.000720887,0.07061831,0.34128335],"study_design_scores_gemma":[0.0015277345,0.0000804814,0.733999,0.00019880518,0.000016043441,1.5481028e-7,0.00010748974,0.0000044721282,0.0000028754694,0.00008848426,0.26392412,0.000050292914],"about_ca_topic_score_codex":0.000045091347,"about_ca_topic_score_gemma":0.00018900553,"teacher_disagreement_score":0.34123304,"about_ca_system_score_codex":0.00008287972,"about_ca_system_score_gemma":0.00006173791,"threshold_uncertainty_score":0.5942696},"labels":[],"label_agreement":null},{"id":"W2136754957","doi":"10.1016/s0959-8049(01)00184-8","title":"T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell–cell contacts","year":2001,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Ligue Contre le Cancer; Association pour la Recherche sur le Cancer","keywords":"CD8; Cytotoxic T cell; MHC class I; Biology; Major histocompatibility complex; MHC class II; T cell; Tumor-infiltrating lymphocytes; Immunology; Cell biology; Molecular biology; Cancer research; Antigen; Immune system; In vitro; Biochemistry","score_opus":0.011054685184836358,"score_gpt":0.2395517183515804,"score_spread":0.22849703316674405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136754957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619449,0.03098209,0.00008881154,0.0003577839,0.0007995031,0.0001533118,0.000010894098,0.000015271917,0.005647427],"genre_scores_gemma":[0.99127287,0.0034526156,0.00004219004,0.00028337628,0.00016136022,0.000004948072,0.0000066239672,0.00004494496,0.00473109],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759907,0.00088874,0.0008702818,0.00018699608,0.00010498466,0.00034992985],"domain_scores_gemma":[0.998077,0.0003361169,0.0010325452,0.00026154856,0.00026347075,0.000029328297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075580436,0.00025275064,0.00041272363,0.00022942816,0.000429262,0.000040270643,0.00047011714,0.000076289274,0.0003024139],"category_scores_gemma":[0.000101780875,0.0001881508,0.00017777763,0.00024077728,0.0001556594,0.00036574103,0.00011833744,0.0005316104,0.000030164554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002607289,0.00023046878,0.0009970305,0.000011615281,0.00018727318,0.000031269963,0.0051533743,0.0008571988,0.97897136,0.000016474225,0.0006319479,0.010304697],"study_design_scores_gemma":[0.0035612925,0.00048549665,0.007624631,0.0002569447,0.00005553067,0.0002964192,0.0012324619,0.000029066461,0.81244725,0.000011305703,0.17382035,0.00017928043],"about_ca_topic_score_codex":0.00032150827,"about_ca_topic_score_gemma":0.000065860775,"teacher_disagreement_score":0.17318839,"about_ca_system_score_codex":0.00023766528,"about_ca_system_score_gemma":0.0004159024,"threshold_uncertainty_score":0.76725674},"labels":[],"label_agreement":null},{"id":"W2136915299","doi":"10.1016/j.ejca.2011.04.038","title":"Factors affecting treatment choices in paediatric palliative care: Comparing parents and health professionals","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Institute for Clinical Evaluative Sciences; SickKids Foundation","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Quality of life (healthcare); Palliative care; Preference; Health professionals; Scale (ratio); Family medicine; Health care; Visual analogue scale; Nursing; Physical therapy","score_opus":0.18336324046627783,"score_gpt":0.4077298873970138,"score_spread":0.224366646930736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136915299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749665,0.022544302,0.000014934221,0.0006730112,0.0004821955,0.00024355696,0.0000048525762,0.000011900484,0.0010587248],"genre_scores_gemma":[0.997373,0.0013746608,0.0002459823,0.0004494928,0.00047983567,0.0000017577222,0.0000022660668,0.000028455304,0.000044581568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981133,0.0005052327,0.0006391066,0.00017250261,0.00033700746,0.00023287883],"domain_scores_gemma":[0.99869156,0.00008773446,0.0007430047,0.00010580423,0.0001155358,0.0002563584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084445503,0.00017827959,0.0005499387,0.00018094476,0.00007371607,0.000013248826,0.000088484056,0.000017507124,0.000038280104],"category_scores_gemma":[0.00006632368,0.00012322029,0.00009534167,0.00015920323,0.000031396627,0.00011117792,0.000040797982,0.0002748004,0.0000019388394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011455754,0.0001483678,0.914138,0.00014724383,0.00010252245,0.00003996924,0.07201585,0.0000074324125,0.000007815757,0.0000019027382,0.000120686615,0.013155641],"study_design_scores_gemma":[0.002757439,0.00089700765,0.9821436,0.0012493387,0.00005730691,0.0000048152824,0.011740382,0.0000031023505,0.00029168997,0.000002862061,0.00074902124,0.000103483726],"about_ca_topic_score_codex":0.0007798076,"about_ca_topic_score_gemma":0.0009265902,"teacher_disagreement_score":0.06800555,"about_ca_system_score_codex":0.00040018128,"about_ca_system_score_gemma":0.00028772134,"threshold_uncertainty_score":0.50247777},"labels":[],"label_agreement":null},{"id":"W2140531948","doi":"10.1016/j.ejca.2011.06.054","title":"An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal","funders":"","keywords":"Everolimus; Medicine; Renal cell carcinoma; Internal medicine; Adverse effect; Oncology; Sunitinib; Tyrosine-kinase inhibitor; Response Evaluation Criteria in Solid Tumors; Clinical trial; Cancer; Phases of clinical research","score_opus":0.04339297819874657,"score_gpt":0.29240780831487906,"score_spread":0.24901483011613249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140531948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704933,0.0018504527,0.000048984726,0.000037081518,0.00019401645,0.0005692838,0.00006306134,0.00000879977,0.0001790146],"genre_scores_gemma":[0.9978461,0.00025045723,0.0014141306,0.00006128345,0.00031963288,0.000012303306,0.00001685936,0.000068877685,0.000010341801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976033,0.0004041991,0.0007323742,0.00027484162,0.00070552155,0.00027976517],"domain_scores_gemma":[0.9982745,0.000030161696,0.0006156609,0.00020484507,0.0006032809,0.0002715346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034548555,0.0002819119,0.00051465223,0.00027856106,0.000033946217,0.000057760215,0.00022622169,0.00002754497,0.00020860147],"category_scores_gemma":[0.000028181168,0.00018744078,0.00012572891,0.00015341006,0.00018422799,0.0005323801,0.000051928786,0.0002722,8.819467e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026825143,0.002013276,0.9025099,0.00010581003,0.0002989775,0.0006471411,0.00325526,0.000005020152,0.0023754686,0.000001150562,0.000008190166,0.06195461],"study_design_scores_gemma":[0.021561688,0.00496488,0.92144585,0.0006624583,0.00014996769,0.000020689402,0.000052260842,0.000005648563,0.050759513,0.0000010973823,0.00020176911,0.00017416036],"about_ca_topic_score_codex":0.00004817512,"about_ca_topic_score_gemma":0.0000068268,"teacher_disagreement_score":0.06178045,"about_ca_system_score_codex":0.00015953806,"about_ca_system_score_gemma":0.00016938671,"threshold_uncertainty_score":0.76436126},"labels":[],"label_agreement":null},{"id":"W2141031127","doi":"10.1016/s0959-8049(02)00744-x","title":"Radiotherapy quality assurance: time for everyone to take it seriously","year":2003,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Quality assurance; Audit; Medicine; Radiation therapy; Medical physics; Quality (philosophy); Consistency (knowledge bases); Clinical trial; Population; Quality management; Risk analysis (engineering); Operations management; Computer science; Business; Management system; Surgery; Accounting","score_opus":0.039073021993060376,"score_gpt":0.398090619592629,"score_spread":0.3590175975995686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141031127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000015181,0.78244823,0.21457751,0.000100094105,0.00041372376,0.0006556079,0.00019752863,0.000021500204,0.001584284],"genre_scores_gemma":[9.753976e-7,0.93623924,0.049092732,0.00042497003,0.0025276914,0.000052076077,0.00001029945,0.00024586043,0.011406149],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968558,0.00074964244,0.0013702573,0.0003259249,0.0003241392,0.00037424397],"domain_scores_gemma":[0.9970546,0.00018110337,0.0018177464,0.0004085559,0.0003206253,0.00021737427],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012978566,0.00051250565,0.001959528,0.00017085751,0.000084211286,0.00007533144,0.0006459645,0.00005143903,0.0012051694],"category_scores_gemma":[0.000020147638,0.00040642585,0.0010247391,0.000257554,0.00004273816,0.00016073449,0.000019927033,0.00048088442,0.000019153591],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041977757,0.000043805107,0.000011502993,0.000618165,0.00071887585,0.000009475548,0.000073245275,0.000042865526,0.000039709055,0.000054456,0.07712769,0.9212182],"study_design_scores_gemma":[0.00056017446,0.00023647478,0.000006353019,0.004012644,0.00021206371,0.00001438107,0.0000043254195,8.3191617e-7,0.000016856822,0.000034616016,0.99444443,0.0004568349],"about_ca_topic_score_codex":0.000004855122,"about_ca_topic_score_gemma":6.1816394e-7,"teacher_disagreement_score":0.9207614,"about_ca_system_score_codex":0.00025835785,"about_ca_system_score_gemma":0.00044196585,"threshold_uncertainty_score":0.99983877},"labels":[],"label_agreement":null},{"id":"W2142257304","doi":"10.1016/j.ejca.2004.01.033","title":"Economic evaluation of treatments for cancer in childhood","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Utilities Kingston (Canada); McMaster Children's Hospital; McMaster University; University of Alberta; Institute of Health Economics; Hamilton Health Sciences","funders":"","keywords":"Discounting; Economic evaluation; Actuarial science; Front line; Cost–benefit analysis; Quality-adjusted life year; Health care; Public economics; Health economics; Medicine; Quality of life (healthcare); Childhood cancer; Economics; Cost effectiveness; Cancer; Nursing; Risk analysis (engineering); Economic growth; Finance","score_opus":0.30590308880050393,"score_gpt":0.46376212869158007,"score_spread":0.15785903989107614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142257304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649435,0.017978,0.00077437266,0.010821116,0.0013304962,0.0006659841,0.00038059964,0.0000053512654,0.003100566],"genre_scores_gemma":[0.9961558,0.0010953258,0.0010542973,0.00083013397,0.0006727397,0.00004545704,0.000003936478,0.000038911225,0.00010342569],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9956199,0.00033245186,0.003486009,0.0002215116,0.00012094495,0.00021920139],"domain_scores_gemma":[0.9957056,0.00013141801,0.003688358,0.00019080451,0.00018527631,0.00009851556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01704031,0.0001333029,0.0006973707,0.00035637317,0.00004434392,0.000022176662,0.0002306468,0.000033105738,0.0005141318],"category_scores_gemma":[0.0006098294,0.00015154734,0.00017237729,0.0000944534,0.00003365544,0.00036431622,0.000015615597,0.00010584294,0.000090107475],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034822337,0.0010184982,0.25928584,0.00042622664,0.0018344763,0.000008179231,0.019081373,0.59853673,0.000119814096,0.024803754,0.010227765,0.08430913],"study_design_scores_gemma":[0.018262483,0.0005444727,0.9365933,0.000819686,0.00016942433,0.000010787272,0.0007129021,0.0018897464,0.00027600487,0.016589755,0.023688436,0.0004430171],"about_ca_topic_score_codex":0.0005051502,"about_ca_topic_score_gemma":0.00061658246,"teacher_disagreement_score":0.6773075,"about_ca_system_score_codex":0.0019891404,"about_ca_system_score_gemma":0.000708134,"threshold_uncertainty_score":0.61799216},"labels":[],"label_agreement":null},{"id":"W2142375563","doi":"10.1016/j.ejca.2006.12.008","title":"Guidelines on the standards for the training of specialised health professionals dealing with breast cancer","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines; Canadian Breast Cancer Foundation","funders":"","keywords":"Breast cancer; Unit (ring theory); Health professionals; Medicine; Health care; Training (meteorology); Nursing; Cancer; Family medicine; Psychology; Internal medicine; Political science","score_opus":0.4059151458350778,"score_gpt":0.5750220085425631,"score_spread":0.16910686270748532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142375563","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16948812,0.0052346643,0.04121199,0.77879125,0.0017202179,0.0014952719,0.00040357606,0.000015884765,0.0016390062],"genre_scores_gemma":[0.95464224,0.0012820687,0.005193099,0.032896515,0.0056476234,0.000006225984,0.0000027941744,0.000061827086,0.00026761505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716973,0.00019343775,0.0014864372,0.00010109188,0.00085262855,0.00019665253],"domain_scores_gemma":[0.9941026,0.0014679409,0.0016997268,0.00015411485,0.0024676525,0.000107979045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01431773,0.00010832564,0.00029178028,0.00005770672,0.00015095371,0.000014145419,0.00014883195,0.000011987649,0.000375548],"category_scores_gemma":[0.0019506968,0.00004681396,0.00011810232,0.00013212301,0.000072259136,0.00007553161,0.00001588895,0.00029764007,4.4675338e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00982741,0.000086912936,0.0020594413,0.00008231747,0.00045255208,0.000029511371,0.0023666446,0.0013486495,0.0008046584,0.0005243497,0.078577854,0.9038397],"study_design_scores_gemma":[0.012523712,0.0029339257,0.11133295,0.0067211753,0.00077242986,0.00030644558,0.016254943,0.00039089104,0.001639831,0.00009084709,0.8467771,0.0002557463],"about_ca_topic_score_codex":0.00007316242,"about_ca_topic_score_gemma":0.00023381201,"teacher_disagreement_score":0.90358394,"about_ca_system_score_codex":0.00015731533,"about_ca_system_score_gemma":0.0014475228,"threshold_uncertainty_score":0.49622682},"labels":[],"label_agreement":null},{"id":"W2142536562","doi":"10.1016/j.ejca.2009.02.007","title":"Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: Setting an evidence-based benchmark for the best-quality cancer care","year":2009,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; Cancer Institute NSW","keywords":"Medicine; Head and neck cancer; Larynx; Chemotherapy; Population; Otorhinolaryngology; Cancer; Guideline; Surgery; Oncology; Radiology; Internal medicine; Pathology; Environmental health","score_opus":0.07836806220905869,"score_gpt":0.39925449582696526,"score_spread":0.3208864336179066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142536562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96846944,0.02103022,0.0030744586,0.0065905727,0.00018481661,0.0005466978,0.000037375336,0.0000073412507,0.000059105885],"genre_scores_gemma":[0.9909449,0.0009237557,0.006102142,0.001276887,0.00068489264,0.000016910348,0.000006526674,0.00002197259,0.000022002594],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99875563,0.00018600086,0.0005018446,0.00016584787,0.00021606906,0.00017459695],"domain_scores_gemma":[0.99836344,0.00021620083,0.0004698998,0.00015526923,0.00068682875,0.000108344895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00131043,0.0001403889,0.00035256328,0.000047584133,0.00016947386,0.000027070295,0.00009910016,0.00002287349,0.000016511081],"category_scores_gemma":[0.00020878646,0.00009474095,0.000108949134,0.000084987005,0.00006683315,0.00029147317,0.000005741704,0.000119075965,7.461455e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049205576,0.00008363925,0.010821826,0.00036789695,0.00008305321,0.0000047057038,0.006110623,0.0068731722,0.0061252685,0.000011570929,0.00036540232,0.96423227],"study_design_scores_gemma":[0.008957056,0.008185727,0.92052734,0.002206479,0.0004908244,0.000010953005,0.0024825213,0.030425364,0.023149105,0.00002208079,0.0033152793,0.00022725193],"about_ca_topic_score_codex":0.000067104265,"about_ca_topic_score_gemma":0.000047219364,"teacher_disagreement_score":0.96400505,"about_ca_system_score_codex":0.00012200543,"about_ca_system_score_gemma":0.0003335918,"threshold_uncertainty_score":0.38634238},"labels":[],"label_agreement":null},{"id":"W2145376550","doi":"10.1016/j.ejca.2004.12.013","title":"A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix","year":2005,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Hospital Foundation; Cancer Care Ontario","keywords":"Medicine; Head and neck; Basal cell; Cervix; Lovastatin; Oncology; Internal medicine; Head and neck cancer; Head and neck squamous-cell carcinoma; Surgery; Cancer; Cholesterol","score_opus":0.01725690322762069,"score_gpt":0.2808838907825645,"score_spread":0.2636269875549438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145376550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997601,0.0013032018,0.000018931289,0.00007557931,0.0005355846,0.00031557257,0.000069666756,2.6821002e-7,0.00008022517],"genre_scores_gemma":[0.9990684,0.00011662578,0.0002241454,0.000026302127,0.0004643068,0.000002234594,0.0000019174292,0.000011750732,0.0000843312],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876,0.00027373375,0.0005696895,0.00009040587,0.0002209252,0.00008525718],"domain_scores_gemma":[0.9986219,0.000014917964,0.00094202266,0.00016748041,0.0002197674,0.00003390545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031561655,0.00009134383,0.0002455535,0.000033471326,0.000014258485,0.0000031190275,0.00015772815,0.000014509947,0.000016210184],"category_scores_gemma":[0.0000825234,0.0000448818,0.00008125297,0.000105558145,0.00010825575,0.0000070083493,0.00003370543,0.00008434964,3.357799e-8],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.554235,0.007430223,0.040514223,0.0010058512,0.00032269975,0.0000030105066,0.005688032,0.00078216207,0.21433192,0.000011097605,0.0036696645,0.1720061],"study_design_scores_gemma":[0.20344727,0.032811034,0.30363214,0.00048067505,0.0005138568,0.000020530671,0.0004006392,0.0000307982,0.42879084,0.0000034524564,0.029611452,0.00025730958],"about_ca_topic_score_codex":0.000016023076,"about_ca_topic_score_gemma":0.00036897606,"teacher_disagreement_score":0.35078773,"about_ca_system_score_codex":0.000010384742,"about_ca_system_score_gemma":0.00038354372,"threshold_uncertainty_score":0.18302266},"labels":[],"label_agreement":null},{"id":"W2145747549","doi":"10.1016/s0959-8049(00)00434-2","title":"Can improved communication increase patient participation in randomised clinical trials?","year":2001,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Scopus; Medicine; Clinical trial; Randomized controlled trial; Alternative medicine; MEDLINE; Family medicine; Physical therapy; Oncology; Medical physics; Internal medicine; Pathology","score_opus":0.5374740074328287,"score_gpt":0.6116825756824609,"score_spread":0.07420856824963218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145747549","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060653985,0.004118821,0.000073874144,0.92557293,0.0012074271,0.0012659489,0.000029032493,0.000015838217,0.0070621287],"genre_scores_gemma":[0.2839825,0.045306463,0.0012284213,0.64769465,0.017166486,0.00006439654,0.00012679369,0.0002379571,0.0041923607],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9708008,0.020902483,0.005950879,0.0003453658,0.0015669236,0.00043355513],"domain_scores_gemma":[0.97089094,0.022612404,0.003548441,0.00085299445,0.0017413454,0.00035390112],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.065945506,0.00025527383,0.0017041302,0.00033390016,0.000053843884,0.00006103658,0.00055445515,0.0005373101,0.0005459668],"category_scores_gemma":[0.10892587,0.00018859403,0.0007519568,0.0002442969,0.00029702403,0.0000736526,0.00015153733,0.014098037,0.000020619285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0234289,0.00057616463,0.007097579,0.00034449893,0.0007362879,0.004498402,0.00064445444,0.00002945405,0.00013189348,0.000009664092,0.7419044,0.22059831],"study_design_scores_gemma":[0.069139294,0.0024153641,0.016214218,0.005135725,0.001019814,0.00006707216,0.00007181731,0.00021155858,0.000070226415,0.0006679882,0.90461683,0.00037007808],"about_ca_topic_score_codex":0.00022283805,"about_ca_topic_score_gemma":0.00034018245,"teacher_disagreement_score":0.27787828,"about_ca_system_score_codex":0.00039516337,"about_ca_system_score_gemma":0.0016847032,"threshold_uncertainty_score":0.98817647},"labels":[],"label_agreement":null},{"id":"W2145813195","doi":"10.1016/j.ejca.2014.07.010","title":"Factors influencing Oncotype DX use in the management of early breast cancer: A single centre experience","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; Ottawa Hospital","funders":"","keywords":"Medicine; Logistic regression; Internal medicine; Breast cancer; Stage (stratigraphy); Oncology; Adjuvant chemotherapy; Tamoxifen; Retrospective cohort study; Cohort; Multivariate analysis; Gynecology; Cancer","score_opus":0.022659176531209753,"score_gpt":0.26272397893110755,"score_spread":0.2400648023998978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145813195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997539,0.001279558,0.000045614972,0.0002822134,0.00017736635,0.000057740137,0.000016644353,0.0000019159254,0.0005999457],"genre_scores_gemma":[0.99904674,0.00041936545,0.00010086809,0.00016038989,0.00018493203,0.0000022193447,0.0000010374248,0.000016709568,0.00006771222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990486,0.00017170166,0.0002802688,0.00013385616,0.00020382502,0.00016177713],"domain_scores_gemma":[0.9993563,0.0000142706,0.00028101183,0.00017951938,0.00012780193,0.000041046234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018914731,0.00012772705,0.00015399458,0.000036372145,0.00003895526,0.000022987351,0.00026454724,0.0000150705355,0.000018085631],"category_scores_gemma":[0.000010353997,0.000081668906,0.00007781654,0.00010269332,0.00006983386,0.00001472727,0.000071465154,0.00007995037,8.233649e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004072175,0.00016829604,0.92513186,0.000047893776,0.0004185071,0.000047599613,0.009000211,0.0006015685,0.021343961,0.000030618376,0.00060859567,0.04219368],"study_design_scores_gemma":[0.0007430757,0.0001478724,0.982097,0.00024808987,0.000059899572,0.000008828755,0.0015765788,0.0000010983733,0.005823852,0.0000023485666,0.009191066,0.000100260506],"about_ca_topic_score_codex":0.00019648645,"about_ca_topic_score_gemma":0.00020457337,"teacher_disagreement_score":0.05696518,"about_ca_system_score_codex":0.00005450723,"about_ca_system_score_gemma":0.000027424885,"threshold_uncertainty_score":0.33303612},"labels":[],"label_agreement":null},{"id":"W2146941643","doi":"10.1016/j.ejca.2004.10.023","title":"Use of paediatric versus adult oncology treatment centres by adolescents 15–19 years old: the Canadian Childhood Cancer Surveillance and Control Program","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pediatric Oncology Group; University of Toronto; McMaster University; Health Canada","funders":"Health Canada","keywords":"Medicine; Cancer; Childhood cancer; Pediatrics; Pediatric oncology; Cancer registry; Population; Disease control; Disease; Clinical trial; Young adult; Family medicine; Internal medicine; Environmental health","score_opus":0.02276429764748945,"score_gpt":0.30581258148693424,"score_spread":0.2830482838394448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146941643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95414037,0.026674153,0.0000073288684,0.016661976,0.0011562575,0.00078977324,0.00031072594,0.00002258401,0.00023684138],"genre_scores_gemma":[0.98415035,0.0118944915,0.00015921428,0.0026994187,0.0009444705,0.000011681101,0.0000063657244,0.00005208396,0.00008193191],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749273,0.0006161402,0.00069599395,0.00024221964,0.0005247031,0.00042822657],"domain_scores_gemma":[0.9978478,0.00014746682,0.0007000378,0.00026908453,0.0003884958,0.0006471195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061208464,0.00024667804,0.0006018445,0.00015187848,0.00012421729,0.000048801194,0.00020308206,0.000057701574,0.000055627697],"category_scores_gemma":[0.00029836985,0.0001754693,0.00019056747,0.00024198755,0.00021107237,0.00010436281,0.000024472094,0.00041484326,0.0000049132877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046035605,0.0014936466,0.5273718,0.00017360944,0.0021283377,0.00070061634,0.009957835,0.0008575381,0.0002197023,0.000029698691,0.020098029,0.4323656],"study_design_scores_gemma":[0.02185459,0.0029397388,0.8239723,0.00047164445,0.00043492744,0.0000735863,0.0002991906,0.000004240765,0.00013450549,0.0000032596777,0.1495972,0.00021485175],"about_ca_topic_score_codex":0.11092604,"about_ca_topic_score_gemma":0.29926342,"teacher_disagreement_score":0.43215075,"about_ca_system_score_codex":0.0011382976,"about_ca_system_score_gemma":0.0019330279,"threshold_uncertainty_score":0.8949944},"labels":[],"label_agreement":null},{"id":"W2147598185","doi":"10.1016/j.ejca.2015.07.039","title":"Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Action Against Cancer; Ministero della Salute; Fondazione Cariplo; Queen's University Belfast; Queen's University; European Commission; Compagnia di San Paolo","keywords":"Overdiagnosis; Demography; Medicine; Confidence interval; Relative survival; Survival analysis; Internal medicine; Cancer; Cancer registry","score_opus":0.018443326076636304,"score_gpt":0.25160219116347315,"score_spread":0.23315886508683686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147598185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891843,0.0001872074,0.000008136683,0.0002193783,0.00032051993,0.0002627026,0.000012368582,0.0000042249403,0.009801166],"genre_scores_gemma":[0.9991939,0.000028353588,0.000030227406,0.000068658774,0.0001131353,5.610124e-7,7.6106875e-7,0.000025038133,0.0005393502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980106,0.00058700494,0.0005862648,0.00010411713,0.0006109642,0.00010104537],"domain_scores_gemma":[0.9982535,0.00003283983,0.00061384786,0.00023827457,0.00076512905,0.00009637314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008739111,0.000103183615,0.0002899027,0.00013014296,0.000012914416,0.0000063781144,0.0001794464,0.000007792327,0.000023159237],"category_scores_gemma":[0.00030511478,0.00005840087,0.000053110783,0.00037298416,0.00005245335,0.000040005183,0.00007388621,0.00016348269,0.00000283736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011177847,0.0015849863,0.96156746,0.000041695257,0.00030857258,0.0005591443,0.004372297,0.00044183034,0.00016008389,0.0000051331367,0.0021290514,0.017651873],"study_design_scores_gemma":[0.009679483,0.0036861454,0.9678781,0.0002040321,0.00013734061,0.000029195637,0.0015634877,0.0000037333305,0.00026705762,8.1221e-7,0.0164857,0.00006488145],"about_ca_topic_score_codex":0.00013861187,"about_ca_topic_score_gemma":0.000272822,"teacher_disagreement_score":0.017586991,"about_ca_system_score_codex":0.000050411214,"about_ca_system_score_gemma":0.00012852026,"threshold_uncertainty_score":0.23815183},"labels":[],"label_agreement":null},{"id":"W2148946364","doi":"10.1016/j.ejca.2007.01.005","title":"Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Prostate-specific antigen; Prostate; Medicine; Prostate cancer; Antigen; PCA3; Cancer; Oncology; Body mass index; Internal medicine; Urology; Immunology","score_opus":0.026512679403281912,"score_gpt":0.2885526011817928,"score_spread":0.26203992177851093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148946364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96642345,0.022175746,0.0005714713,0.004489,0.0013010446,0.0021176366,0.0003179461,0.00009127524,0.002512441],"genre_scores_gemma":[0.8957443,0.09917873,0.0015847599,0.00046418366,0.0013032516,0.000054850403,0.000026298765,0.00021928072,0.0014243184],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994235,0.0003175045,0.0019779648,0.00079756393,0.0014014487,0.0012705548],"domain_scores_gemma":[0.9965807,0.00017826853,0.0011716065,0.00066581107,0.000711246,0.0006923202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023647202,0.0006850091,0.0010602446,0.00065433723,0.00024550714,0.00021562826,0.0005229902,0.000094906056,0.000583273],"category_scores_gemma":[0.000087489585,0.0004502884,0.00030235402,0.00070706307,0.00023473772,0.000598726,0.00018385086,0.00096728426,0.000019267263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019215807,0.00057221204,0.81677854,0.00030406626,0.00078787963,0.009450098,0.0057179006,0.00151106,0.027959106,0.000019446956,0.009348841,0.10833505],"study_design_scores_gemma":[0.014444732,0.002229287,0.82815593,0.0040683975,0.00013138483,0.00009578849,0.0023564463,0.000088549554,0.020316105,0.000027167776,0.12749045,0.0005957453],"about_ca_topic_score_codex":0.00023858779,"about_ca_topic_score_gemma":0.0004133081,"teacher_disagreement_score":0.11814161,"about_ca_system_score_codex":0.0014079721,"about_ca_system_score_gemma":0.00084379787,"threshold_uncertainty_score":0.9997949},"labels":[],"label_agreement":null},{"id":"W2149957846","doi":"10.1016/j.ejca.2008.03.005","title":"A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL)","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Medical Research Council; National Health and Medical Research Council; National Cancer Institute; Cancer Research UK; National Institutes of Health; Australian Cancer Research Foundation; Associazione Italiana per la Ricerca sul Cancro; Foundation for the National Institutes of Health","keywords":"CDKN2A; Genetics; Mutation; Biology; Computational biology; Gene","score_opus":0.020957081643080026,"score_gpt":0.2814506169532459,"score_spread":0.2604935353101659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149957846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843559,0.010636788,0.003410894,0.000108454515,0.000637617,0.00006827106,0.000011741713,0.0000016616825,0.0007686729],"genre_scores_gemma":[0.99724287,0.0014119955,0.0003616891,0.00013496539,0.00072270876,0.0000012649585,0.0000031087254,0.000019855614,0.00010152786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906844,0.00011851301,0.00046548835,0.00009537631,0.00015724645,0.00009492766],"domain_scores_gemma":[0.99885976,0.00002078679,0.0006202463,0.00015651737,0.00028834856,0.000054339554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030610696,0.00008875752,0.00014885527,0.00003652448,0.000078270634,0.000010883096,0.00017737233,0.000024917837,0.000015058939],"category_scores_gemma":[0.00008249524,0.000067571644,0.000091850314,0.00006728189,0.000118405456,0.0000029549242,0.000039042545,0.00011221498,0.0000021695994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056208804,0.00012191901,0.040284157,0.000021623175,0.00027559872,0.000050072387,0.0020381776,0.028757028,0.8870917,0.000023765146,0.004407024,0.03636684],"study_design_scores_gemma":[0.0013298088,0.0016128565,0.07976633,0.000033593675,0.00012291611,0.00031729363,0.0004209833,0.0004082855,0.82908905,0.00002227893,0.08667624,0.00020038782],"about_ca_topic_score_codex":0.000012236774,"about_ca_topic_score_gemma":0.000073241084,"teacher_disagreement_score":0.082269214,"about_ca_system_score_codex":0.000022080598,"about_ca_system_score_gemma":0.00014851768,"threshold_uncertainty_score":0.27554917},"labels":[],"label_agreement":null},{"id":"W2150700051","doi":"10.1016/j.ejca.2014.04.031","title":"Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study","year":2014,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":122,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"Cancer Research UK; National Cancer Institute; National Institute for Health and Care Research; Sanofi","keywords":"Toxicity; Limiting; Medicine; Pharmacology; Internal medicine; Engineering","score_opus":0.6365875789007553,"score_gpt":0.6253444966340245,"score_spread":0.011243082266730875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150700051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54164934,0.00069656776,0.45106682,0.0012428272,0.00029046996,0.0047483197,0.0002749119,0.0000047215594,0.000026008862],"genre_scores_gemma":[0.5873181,0.00058274,0.41172266,0.000027153468,0.00017733767,0.000120062265,0.0000020480795,0.00004070705,0.000009189394],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98253554,0.013633045,0.0028329478,0.0002971129,0.00046006162,0.00024131661],"domain_scores_gemma":[0.9413501,0.05253085,0.004273811,0.00029580426,0.0014806158,0.00006880104],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.053503502,0.00024664318,0.001440955,0.00012760871,0.00023753008,0.00005140936,0.00031120266,0.000047779056,0.000012970696],"category_scores_gemma":[0.027215257,0.00013171406,0.00027578668,0.00015597863,0.00035989052,0.0001369874,0.0001185499,0.00015372476,3.2257226e-9],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00436555,0.0008607602,0.0016366605,0.0007216698,0.0020218424,1.8081222e-7,0.015665244,0.000017187693,0.08239502,0.0024141627,0.00004002862,0.8898617],"study_design_scores_gemma":[0.10529903,0.054575875,0.19535567,0.0022023076,0.0072641834,0.000004056037,0.037207395,0.02237829,0.33946437,0.23497313,0.0005010851,0.0007745973],"about_ca_topic_score_codex":0.000054685934,"about_ca_topic_score_gemma":0.000061328,"teacher_disagreement_score":0.8890871,"about_ca_system_score_codex":0.0001370854,"about_ca_system_score_gemma":0.0001622155,"threshold_uncertainty_score":0.9809789},"labels":[],"label_agreement":null},{"id":"W2151011925","doi":"10.1016/j.ejca.2014.09.007","title":"Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)","year":2014,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Royal Marsden NHS Foundation Trust; European Association of Urology; Pfizer","keywords":"Renal cell carcinoma; Medicine; Sunitinib; Pazopanib; Concordance; Psychological intervention; Oncology; Intensive care medicine; Medical physics; Internal medicine","score_opus":0.1054404367989314,"score_gpt":0.37642679389260714,"score_spread":0.27098635709367574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151011925","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30110905,0.6962845,0.000034833225,0.00006593271,0.00024109124,0.001095802,0.000047293714,0.0000072746425,0.001114286],"genre_scores_gemma":[0.6545741,0.34413984,0.00028242898,0.000018238628,0.0005542881,0.000029129049,0.000019846837,0.00015462963,0.00022749204],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99078,0.0039927335,0.0027958055,0.00067741727,0.0010822231,0.0006718345],"domain_scores_gemma":[0.9916326,0.0005904818,0.005060309,0.0016635892,0.000664039,0.00038901056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020869125,0.0011544619,0.00359251,0.0005610997,0.00015342681,0.00012060629,0.0010736745,0.00016462995,0.00020501643],"category_scores_gemma":[0.00010941096,0.0005160377,0.002879316,0.00075916987,0.00029854412,0.0003534706,0.0001228189,0.00079758576,0.000009899803],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012812057,0.0025923203,0.03881781,0.010440713,0.0013827157,0.0023116923,0.0016654205,0.0027917358,0.00398095,0.0000019692106,0.00036605817,0.9343674],"study_design_scores_gemma":[0.033820532,0.052069347,0.5515948,0.14173195,0.047610354,0.0026003348,0.0005539402,0.001601255,0.060877424,0.000015198659,0.104115196,0.0034096555],"about_ca_topic_score_codex":0.0011000254,"about_ca_topic_score_gemma":0.00005244374,"teacher_disagreement_score":0.93095773,"about_ca_system_score_codex":0.0037854288,"about_ca_system_score_gemma":0.005090978,"threshold_uncertainty_score":0.9997291},"labels":[],"label_agreement":null},{"id":"W2151981602","doi":"10.1016/j.ejca.2005.08.017","title":"Cancer therapeutics: Targeting the dark side of Myc","year":2005,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Cancer research; Carcinogenesis; Transcription factor; Regulator; Cancer; Proto-Oncogene Proteins c-myc; Biology; Function (biology); Cell growth; Drug development; Gene; Computational biology; Cell biology; Drug; Genetics; Pharmacology","score_opus":0.0326430702517467,"score_gpt":0.3284132160597395,"score_spread":0.29577014580799277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151981602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008760857,0.99735487,0.000238296,0.000100619756,0.0006235438,0.00012622602,0.000020638176,0.0000016737434,0.001446505],"genre_scores_gemma":[0.0007518484,0.99473554,0.0002123716,0.00012835694,0.002896448,0.0000031538907,0.0000115681405,0.0000629112,0.0011978099],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842083,0.00036739215,0.00069855066,0.00015056056,0.00020994668,0.00015270435],"domain_scores_gemma":[0.998239,0.000017080596,0.0012657079,0.00021788495,0.0002135924,0.0000467733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071991363,0.00021253577,0.0004959462,0.000047777994,0.00005645972,0.000019006617,0.00038447554,0.00007349129,0.00006927997],"category_scores_gemma":[0.000017025988,0.00011867868,0.00047025984,0.00007721487,0.000056351815,0.0000033515532,0.00007121132,0.00024947373,0.0000028147547],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014216328,0.000011565968,0.0000018333569,0.0003357603,0.0003433219,0.000005616867,0.000039842147,0.00015572093,0.0031310434,0.000006074122,0.0017271901,0.9942278],"study_design_scores_gemma":[0.00016321127,0.00009078131,0.000013316345,0.0018913064,0.00056709873,0.000027046812,0.000015356638,0.0000024494145,0.000769027,0.0000039788742,0.9963193,0.00013713942],"about_ca_topic_score_codex":0.000005175278,"about_ca_topic_score_gemma":0.000008451842,"teacher_disagreement_score":0.9945921,"about_ca_system_score_codex":0.00003220493,"about_ca_system_score_gemma":0.00027487078,"threshold_uncertainty_score":0.48395762},"labels":[],"label_agreement":null},{"id":"W2152492190","doi":"10.1016/j.ejca.2010.08.008","title":"Quality of pathology reports for advanced ovarian cancer: Are we missing essential information?","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Quality (philosophy); Ovarian cancer; Cancer; Pathology; Oncology; Internal medicine","score_opus":0.025589521434968045,"score_gpt":0.3503520536766089,"score_spread":0.3247625322416408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152492190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.943192,0.005939655,0.0047784145,0.035342533,0.0057580476,0.0006474533,0.00014134319,0.000025729352,0.0041748295],"genre_scores_gemma":[0.9914924,0.0011416834,0.005859054,0.00047439977,0.000872611,0.000014017419,0.000005686892,0.000023609944,0.00011657325],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998281,0.000091585236,0.0010456152,0.00012386893,0.00028437117,0.00017352782],"domain_scores_gemma":[0.99687934,0.00006109261,0.0019092802,0.00024833233,0.0007454513,0.00015649658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008778401,0.00013266425,0.00046777885,0.00011040062,0.00006168346,0.000021501846,0.00008349192,0.00003567715,0.00029458193],"category_scores_gemma":[0.00020481314,0.00010322357,0.00021569555,0.000097542405,0.00006938444,0.00024311144,0.000020904978,0.00024216862,0.0000013798177],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020950944,0.00042944477,0.09463117,0.0006374541,0.0007232637,0.0012698876,0.0018171079,0.00037039616,0.040202945,0.0004075157,0.010708427,0.8467073],"study_design_scores_gemma":[0.010582585,0.00073315296,0.54175,0.001130189,0.0005526141,0.00088378054,0.0002750311,0.000021433929,0.03033707,0.00024897588,0.41321635,0.00026879093],"about_ca_topic_score_codex":0.000029302179,"about_ca_topic_score_gemma":0.000055672757,"teacher_disagreement_score":0.8464385,"about_ca_system_score_codex":0.00007959838,"about_ca_system_score_gemma":0.00039476078,"threshold_uncertainty_score":0.4209335},"labels":[],"label_agreement":null},{"id":"W2153682299","doi":"10.1016/j.ejca.2005.08.020","title":"RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation","year":2005,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Canadian Breast Cancer Research Alliance","keywords":"Transcription factor; Biology; Cell biology; Ubiquitin ligase; Ubiquitin; Genetics","score_opus":0.04550499550321009,"score_gpt":0.2942102279562675,"score_spread":0.24870523245305742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153682299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014916585,0.9964558,0.0009834269,0.000049477483,0.00029374645,0.00014741776,0.00032464325,0.0000026237033,0.0002512097],"genre_scores_gemma":[0.0055888635,0.99038833,0.0012936372,0.000059394784,0.0020290583,0.0000033865695,0.00005729166,0.000053082837,0.00052696804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99844277,0.00026428944,0.0006953894,0.00020957182,0.00026205435,0.00012592906],"domain_scores_gemma":[0.9986663,0.0000148988065,0.0007978175,0.000098797995,0.0003185108,0.000103698614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036769197,0.00022868953,0.0005094745,0.000100670026,0.000041619194,0.000018256751,0.00016231212,0.000100840516,0.0004903325],"category_scores_gemma":[0.00003827759,0.00018583148,0.00038336622,0.00006424638,0.000061755316,0.0000098027795,0.000028235569,0.00022604896,0.0000054952006],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009592115,0.000036652553,0.000017684524,0.0011332624,0.00037258497,0.0000021040828,0.00010163361,0.00001891208,0.027176203,0.00003742112,0.0011831536,0.9698245],"study_design_scores_gemma":[0.00041653594,0.0002134197,0.0001651025,0.002170746,0.0001785333,0.000045770357,0.0000042703477,0.0000053450685,0.0034870922,0.0000060530842,0.9931154,0.00019169124],"about_ca_topic_score_codex":0.00000150096,"about_ca_topic_score_gemma":7.0165345e-7,"teacher_disagreement_score":0.9919323,"about_ca_system_score_codex":0.0000311493,"about_ca_system_score_gemma":0.00022197812,"threshold_uncertainty_score":0.7577988},"labels":[],"label_agreement":null},{"id":"W2153957737","doi":"10.1016/j.ejca.2008.10.025","title":"Cancer clinical trial outcomes: Any progress in tumour-size assessment?","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Disease; Cancer; Clinical trial; Intensive care medicine; Systemic therapy; Drug development; Cancer therapy; Oncology; Drug; Internal medicine; Pharmacology","score_opus":0.043712842698999325,"score_gpt":0.3854307691740995,"score_spread":0.3417179264751002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153957737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98695946,0.00846769,0.00008414021,0.0009866364,0.002025208,0.00016486182,0.000025837624,0.0000033339722,0.0012828158],"genre_scores_gemma":[0.9836229,0.011681774,0.00077935157,0.00086973765,0.0025738163,0.000009975047,0.000002898413,0.000041374027,0.00041818197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981236,0.00029245828,0.00086485303,0.00022638094,0.00024079374,0.00025191638],"domain_scores_gemma":[0.9988206,0.00006617744,0.00052902364,0.00020576887,0.0002120805,0.00016635534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009505463,0.00016464261,0.00035480992,0.000050719547,0.000052012863,0.000026337042,0.00033018042,0.000052119474,0.00008757145],"category_scores_gemma":[0.00023647503,0.00013693898,0.00025007952,0.00008990561,0.00014503347,0.000007698499,0.000097378565,0.00030736887,0.000003915956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005952988,0.0004194055,0.9409737,0.00001259132,0.00024257334,0.0005834439,0.00009891394,0.00024592495,0.0024153986,0.000014522571,0.021645816,0.027394727],"study_design_scores_gemma":[0.029301157,0.0013070863,0.82422745,0.000066534434,0.000051622832,0.00004204176,0.000029305173,0.000009927186,0.00076978334,0.0000077215755,0.14395328,0.00023409586],"about_ca_topic_score_codex":0.000019469677,"about_ca_topic_score_gemma":0.00009042873,"teacher_disagreement_score":0.122307464,"about_ca_system_score_codex":0.000066872904,"about_ca_system_score_gemma":0.00072088075,"threshold_uncertainty_score":0.55842096},"labels":[],"label_agreement":null},{"id":"W2155777530","doi":"10.1016/j.ejca.2011.04.030","title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Dacarbazine; Temozolomide; Medicine; Nausea; Phases of clinical research; Adverse effect; Clinical endpoint; Internal medicine; Oncology; Chemotherapy; Surgery; Randomized controlled trial","score_opus":0.05815835894789728,"score_gpt":0.32202581668227015,"score_spread":0.26386745773437287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155777530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732952,0.00053676224,0.00007884991,0.00012312784,0.0007402488,0.0007757115,0.00001367066,0.000022917067,0.02441353],"genre_scores_gemma":[0.99598354,0.00017315143,0.00033675463,0.000062122635,0.00021825117,0.0000062223307,0.000003129207,0.00003983797,0.003177002],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971997,0.00046246164,0.0013646688,0.00024531456,0.00047264414,0.00025521542],"domain_scores_gemma":[0.99821967,0.00006946847,0.0008841,0.00032712187,0.00028159702,0.00021805044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001745394,0.00021936494,0.0006720191,0.00042719665,0.00003986126,0.000013339717,0.00020264082,0.000030747407,0.0006343825],"category_scores_gemma":[0.0002707507,0.00017407523,0.00018838194,0.00034561948,0.00007435595,0.00009283124,0.000066026114,0.00043099123,0.000013534018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8775952,0.0054907263,0.0019014701,0.00009469198,0.0016515024,0.020577135,0.005965929,0.00011049043,0.018126508,0.000026007741,0.0022488856,0.066211484],"study_design_scores_gemma":[0.8611383,0.016420772,0.09538477,0.0004441297,0.0010483683,0.00031504154,0.0028935242,0.00032218758,0.006690969,0.00000492796,0.014974831,0.00036216713],"about_ca_topic_score_codex":0.0001023399,"about_ca_topic_score_gemma":0.0001212866,"teacher_disagreement_score":0.0934833,"about_ca_system_score_codex":0.000138538,"about_ca_system_score_gemma":0.00014662022,"threshold_uncertainty_score":0.7098582},"labels":[],"label_agreement":null},{"id":"W2156525558","doi":"10.1016/j.ejca.2003.12.027","title":"Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Toxicity; Radiation therapy; Prostate cancer; Internal medicine; Cancer; Adverse effect; Clinical trial; Oncology; Surgery","score_opus":0.012165294417607322,"score_gpt":0.31255944827683235,"score_spread":0.300394153859225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156525558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7866767,0.0023000236,0.2086206,0.00076262734,0.0007469545,0.00047681425,0.00013077122,0.000012144864,0.0002733537],"genre_scores_gemma":[0.99034303,0.0002597863,0.0077833585,0.00016275812,0.0009205255,0.000022090353,0.0000029123835,0.000041013187,0.00046451003],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987903,0.00012329368,0.00054056384,0.00012502709,0.00025636837,0.00016442327],"domain_scores_gemma":[0.9987462,0.000036851914,0.0008404102,0.0001575617,0.0001665972,0.0000523825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000527636,0.0001322495,0.00038310132,0.00011011031,0.000092547365,0.000022749553,0.00028698647,0.000011880056,0.00020664831],"category_scores_gemma":[0.0000067950264,0.00009100906,0.000882928,0.0003381693,0.00006081415,0.00013819507,0.000014745509,0.00015264451,9.054515e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021600166,0.00096678035,0.15963547,0.000057881567,0.03928348,0.00002450276,0.0043097897,0.3397099,0.13084857,0.0059814733,0.0023630192,0.29521894],"study_design_scores_gemma":[0.2584825,0.004258802,0.08904256,0.0016278331,0.010538416,0.000006082841,0.0003307185,0.0026010966,0.25026783,0.009636894,0.37113518,0.0020720866],"about_ca_topic_score_codex":0.000050931074,"about_ca_topic_score_gemma":0.0000096700105,"teacher_disagreement_score":0.36877218,"about_ca_system_score_codex":0.00012997053,"about_ca_system_score_gemma":0.0001899599,"threshold_uncertainty_score":0.37112418},"labels":[],"label_agreement":null},{"id":"W2156982018","doi":"10.1016/s0959-8049(00)00102-7","title":"Insulin-like growth factor physiology and cancer risk","year":2000,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":299,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Population; Physiology; Risk factor; Cancer; Prostate cancer; Circumstantial evidence; Medicine; Biology; Bioinformatics; Internal medicine; Environmental health","score_opus":0.03579919376791735,"score_gpt":0.31435835103427073,"score_spread":0.2785591572663534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156982018","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00520448,0.99064106,0.0000060030907,0.00010580626,0.0014149091,0.00038080086,0.000244248,0.000030294914,0.0019724064],"genre_scores_gemma":[0.0018198587,0.99353,0.00009555752,0.0004629424,0.0029345313,0.000008756102,0.000016442551,0.00020795318,0.0009239945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959579,0.0008929701,0.0016485628,0.0004850233,0.0005045736,0.00051098794],"domain_scores_gemma":[0.9966045,0.00014981159,0.0019095817,0.00036635512,0.00040205798,0.00056769093],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048999756,0.0007323677,0.00290515,0.0005041305,0.00011886993,0.000044969944,0.0003982987,0.00020946549,0.0011391225],"category_scores_gemma":[0.0001311736,0.00049186766,0.0008819018,0.0004032933,0.00020947627,0.00018370629,0.000096911404,0.0019646664,0.00009988779],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019375967,0.00007199882,0.00039811837,0.00357756,0.0011075978,0.0003647013,0.00022399846,6.0681856e-7,0.000014746685,0.0000028019094,0.006771,0.9872731],"study_design_scores_gemma":[0.00148769,0.0006205211,0.0073406347,0.008384239,0.0031175422,0.00041743356,0.000010069875,8.438809e-7,0.000010406898,0.000009242511,0.97815555,0.0004458212],"about_ca_topic_score_codex":0.0000683101,"about_ca_topic_score_gemma":0.0000034463305,"teacher_disagreement_score":0.9868273,"about_ca_system_score_codex":0.00023762559,"about_ca_system_score_gemma":0.00083741907,"threshold_uncertainty_score":0.999774},"labels":[],"label_agreement":null},{"id":"W2157334646","doi":"10.1016/j.ejca.2012.01.038","title":"Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the International Lung Cancer Consortium","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Massachusetts General Hospital","keywords":"Lung cancer; Medicine; Family history; Odds ratio; Internal medicine; Confounding; Family aggregation; Cancer; Confidence interval; Relative risk; Oncology; Disease","score_opus":0.010665304344032381,"score_gpt":0.2941586248469896,"score_spread":0.2834933205029572,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157334646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.904706,0.09084564,0.000066463814,0.0015153703,0.000646321,0.00025726753,0.00075571594,0.000003888028,0.0012033514],"genre_scores_gemma":[0.99581796,0.0023573893,0.000083530555,0.00067125325,0.00041816634,0.000026029691,0.00000910549,0.00002594929,0.0005906192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998125,0.00035969063,0.00057360437,0.00012887947,0.0006392313,0.00017355644],"domain_scores_gemma":[0.9979107,0.00013068336,0.0011585047,0.00026417064,0.00038085453,0.00015511001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000537305,0.00015008061,0.00039735145,0.00017419047,0.000037216523,0.00000896254,0.0002880458,0.000017479955,0.0007829875],"category_scores_gemma":[0.00009347669,0.00007660949,0.00025130797,0.00037429124,0.00015426941,0.00013922514,0.000047483813,0.0002601464,3.6857287e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004481188,0.00016176568,0.9756214,0.000024301331,0.009875779,0.000014655159,0.0034262633,0.0015667665,0.0004666009,0.000008497358,0.006146896,0.0022389495],"study_design_scores_gemma":[0.0029521657,0.000031916825,0.9695449,0.00067404733,0.017384594,0.0000018916714,0.00021524378,0.00033751572,0.00009032451,0.0000016067403,0.008684649,0.00008116139],"about_ca_topic_score_codex":0.006335754,"about_ca_topic_score_gemma":0.0011062957,"teacher_disagreement_score":0.09111197,"about_ca_system_score_codex":0.0010034019,"about_ca_system_score_gemma":0.0014745832,"threshold_uncertainty_score":0.95778066},"labels":[],"label_agreement":null},{"id":"W2160307003","doi":"10.1016/s0959-8049(99)00341-x","title":"Report on the quality of life analysis from the phase III trial of pion versus photon radiotherapy in locally advanced prostate cancer","year":2000,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute","keywords":"Quality of life (healthcare); Prostate cancer; Sexual function; Radiation therapy; Medicine; Checklist; Hormonal therapy; Sexual dysfunction; Clinical trial; Internal medicine; Oncology; Cancer; Physical therapy; Psychology","score_opus":0.04235002998539265,"score_gpt":0.3728951652264665,"score_spread":0.3305451352410738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160307003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834359,0.010279465,0.000020766083,0.0044789347,0.00035685246,0.00060939224,0.000091165275,0.0000039292304,0.0007235381],"genre_scores_gemma":[0.97461796,0.024127604,0.000056662648,0.00062053784,0.00035086175,0.000027952032,0.0000086821465,0.00002305657,0.00016665764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972172,0.0005391416,0.0012904293,0.00019658233,0.0005947835,0.00016186788],"domain_scores_gemma":[0.99761224,0.00032585577,0.0012971762,0.00041344913,0.00024769566,0.00010356863],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015282509,0.00016581407,0.0007291643,0.00008806109,0.00003887009,0.000011048116,0.00017608632,0.000020374966,0.001142889],"category_scores_gemma":[0.00014247028,0.000084904925,0.00036494684,0.0004583505,0.00011835819,0.00006538459,0.0000100281795,0.00024922917,9.0384435e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61925596,0.0017148952,0.030828862,0.000029580946,0.0054361885,0.0003995772,0.0031904771,0.0075980863,0.0028714729,0.000012277858,0.0016308092,0.3270318],"study_design_scores_gemma":[0.59630656,0.012278566,0.3049638,0.0016524516,0.003124816,0.000007929912,0.00061507145,0.00023505017,0.02223883,0.000026534488,0.058181398,0.0003689821],"about_ca_topic_score_codex":0.0012407351,"about_ca_topic_score_gemma":0.00033749844,"teacher_disagreement_score":0.3266628,"about_ca_system_score_codex":0.00025806826,"about_ca_system_score_gemma":0.00043602605,"threshold_uncertainty_score":0.9997702},"labels":[],"label_agreement":null},{"id":"W2161243824","doi":"10.1016/j.ejca.2015.07.006","title":"Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: A systematic review and meta-analysis of randomised trials","year":2015,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Systematic sampling; Confidence interval; Sampling (signal processing); Meta-analysis; Cervical cancer; Population; Sample size determination; Randomized controlled trial; Physical therapy; Demography; Cancer; Surgery; Internal medicine; Environmental health; Statistics","score_opus":0.4234908454320741,"score_gpt":0.48532015200697054,"score_spread":0.06182930657489644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161243824","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043116648,0.9952128,0.00011962627,0.00073009095,0.000038137867,0.0035176564,0.00009573413,0.000010447005,0.00023237111],"genre_scores_gemma":[0.00065120944,0.9975441,0.00015868769,0.0005663214,0.00023920153,0.00064097735,0.000010360835,0.00008842019,0.00010071117],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98225135,0.010229527,0.0048164628,0.00042625016,0.001661437,0.0006149651],"domain_scores_gemma":[0.9929511,0.0015557437,0.0035814377,0.0006233047,0.00079934474,0.0004890987],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.052103754,0.00054128363,0.016820034,0.0005710148,0.00006947924,0.0001452491,0.00056743657,0.000090242975,0.0006904041],"category_scores_gemma":[0.0027031533,0.00026213023,0.0029682855,0.0015235797,0.0000847716,0.000115451054,0.00014028497,0.0012911187,0.0000012456557],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091550435,0.000103581304,0.0000052944156,0.6542888,0.182015,0.0002067572,0.002156569,0.000035435587,9.617635e-7,0.0000054400207,0.00026197007,0.16000465],"study_design_scores_gemma":[0.0050564716,0.00023036063,0.000018326104,0.06836405,0.8160116,0.000088497785,0.00017786257,0.0000379263,5.6555933e-7,0.000002512274,0.109737925,0.00027390796],"about_ca_topic_score_codex":0.00008722796,"about_ca_topic_score_gemma":0.000020925829,"teacher_disagreement_score":0.6339966,"about_ca_system_score_codex":0.00047274702,"about_ca_system_score_gemma":0.00054073386,"threshold_uncertainty_score":0.9999831},"labels":[],"label_agreement":null},{"id":"W2161647960","doi":"10.1016/j.ejca.2015.05.016","title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Ipsen; Astellas Pharma; Daiichi-Sankyo; GlaxoSmithKline; Amgen","keywords":"Hypocalcaemia; Denosumab; Medicine; Zoledronic acid; Internal medicine; Vitamin D and neurology; vitamin D deficiency; Bone disease; Urology; Gastroenterology; Endocrinology; Osteoporosis; Calcium","score_opus":0.02489292853331973,"score_gpt":0.2835046830091163,"score_spread":0.25861175447579654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161647960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608064,0.001831093,0.000026053052,0.0005056554,0.00004695191,0.00020307608,0.000008031645,0.000007669003,0.0012908395],"genre_scores_gemma":[0.9983249,0.00004076118,0.00065447786,0.00040161418,0.0000401782,0.000002631642,0.0000064079036,0.0000346363,0.000494404],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882346,0.00014202177,0.00031008793,0.00010468299,0.00042469252,0.00019506413],"domain_scores_gemma":[0.9986224,0.000011969232,0.0002430023,0.00012528492,0.00031612697,0.0006812059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020852985,0.00012607464,0.0002882934,0.000120562276,0.00001888825,0.000009764293,0.00004375448,0.0000061954925,0.000031908075],"category_scores_gemma":[0.000042792057,0.000069206864,0.00003151292,0.00018244336,0.000039673254,0.00010183813,0.000007614622,0.00016504126,0.00001822907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011457787,0.00043892753,0.96842,0.000030329764,0.00013927274,0.0038508875,0.00014757132,0.00007131867,0.0000011220704,0.000001427787,0.0007555477,0.01468576],"study_design_scores_gemma":[0.02416769,0.0027972464,0.9696569,0.00044966888,0.0003661539,0.000050812483,0.000029798377,0.0000067973706,0.000014050759,0.0000030387848,0.0023803357,0.00007751212],"about_ca_topic_score_codex":0.000046539408,"about_ca_topic_score_gemma":0.000032212385,"teacher_disagreement_score":0.014608248,"about_ca_system_score_codex":0.00020120101,"about_ca_system_score_gemma":0.00045035454,"threshold_uncertainty_score":0.28221738},"labels":[],"label_agreement":null},{"id":"W2161744278","doi":"10.1016/j.ejca.2007.05.027","title":"Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life","year":2007,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lead (geology); Menopause; Medicine; Quality (philosophy); Intensive care medicine; Quality of life (healthcare); Risk analysis (engineering); Chemotherapy; Oncology; Internal medicine; Biology","score_opus":0.05262873262859638,"score_gpt":0.36085461724829293,"score_spread":0.3082258846196966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161744278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232215,0.0027868536,0.0014915194,0.0012752601,0.00052636524,0.00017480348,0.00009270149,0.000009186562,0.0013211684],"genre_scores_gemma":[0.9966163,0.0005880523,0.0005682251,0.0011841368,0.00073632295,4.799475e-7,0.0000045958923,0.000047030862,0.00025484964],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99767786,0.0002497397,0.0010929687,0.00019721946,0.0005648194,0.00021741695],"domain_scores_gemma":[0.99708956,0.000088933084,0.0011383429,0.0006904942,0.0006871762,0.00030549619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035485078,0.00015876134,0.00062278943,0.00014854514,0.000024337385,0.000007836538,0.00046550407,0.00003509159,0.00019619043],"category_scores_gemma":[0.00049522053,0.00012338143,0.0001225238,0.00030151877,0.00006568495,0.00014119412,0.00009014768,0.00035651893,0.0000024924045],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009700237,0.0002602442,0.12031839,0.00029402054,0.001058984,0.00006374382,0.006475267,0.0000168602,0.6278111,0.000009280194,0.0033909553,0.23060095],"study_design_scores_gemma":[0.0075520673,0.0018355178,0.864824,0.0005370531,0.0003905262,0.000017648628,0.0020306024,0.000017847307,0.08224953,0.0000064955593,0.040256895,0.00028184341],"about_ca_topic_score_codex":0.00056613795,"about_ca_topic_score_gemma":0.0013721226,"teacher_disagreement_score":0.7445056,"about_ca_system_score_codex":0.000081612285,"about_ca_system_score_gemma":0.00031205371,"threshold_uncertainty_score":0.50313485},"labels":[],"label_agreement":null},{"id":"W2163823502","doi":"10.1016/j.ejca.2013.02.001","title":"Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université Laval","funders":"","keywords":"Cystectomy; Urothelial carcinoma; Medicine; Urology; Carcinoma; Oncology; Internal medicine; Bladder cancer; Cancer","score_opus":0.016020914517722105,"score_gpt":0.2691430066409575,"score_spread":0.25312209212323544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163823502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577105,0.00018212218,0.00001828353,0.00026524148,0.00008491987,0.00047519637,0.00005757479,0.0000050689378,0.0031405701],"genre_scores_gemma":[0.9993507,0.000015855649,0.00016035441,0.00013987957,0.00008005147,0.0000049157898,0.0000015552189,0.00003113127,0.00021554863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802697,0.0003177677,0.0006219728,0.00015813501,0.0006702948,0.00020486453],"domain_scores_gemma":[0.99806446,0.00007815359,0.0008096622,0.00026472667,0.00061535364,0.00016762778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001508139,0.00022779389,0.000771327,0.00009458439,0.00003287176,0.000005283026,0.00022789642,0.000046649322,0.00091134565],"category_scores_gemma":[0.00007444896,0.0000876643,0.0002921205,0.00018860355,0.00038058884,0.00006404329,0.000030218824,0.00027830774,0.0000036550382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057523004,0.0011459183,0.98676026,0.000022352793,0.0010180331,0.00008524552,0.00018117105,0.000048736823,0.00077901175,0.0000072662756,0.00052487355,0.0036748473],"study_design_scores_gemma":[0.01244735,0.015907144,0.96943057,0.00021124174,0.0005187236,0.00004343171,0.00001937744,0.0000036874671,0.0011812838,0.000003495504,0.0001450385,0.000088651206],"about_ca_topic_score_codex":0.00025137851,"about_ca_topic_score_gemma":0.0000059956174,"teacher_disagreement_score":0.017329667,"about_ca_system_score_codex":0.00016779754,"about_ca_system_score_gemma":0.00044911465,"threshold_uncertainty_score":0.9978596},"labels":[],"label_agreement":null},{"id":"W2164547129","doi":"10.1016/j.ejca.2008.10.028","title":"Evaluation of lymph nodes with RECIST 1.1","year":2008,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":297,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Lymph; Medicine; Lymph node; Malignancy; Radiology; Pathology","score_opus":0.0825629448717539,"score_gpt":0.36703882522295433,"score_spread":0.2844758803512004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164547129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94258016,0.0018875556,0.009116873,0.0055566495,0.00006721742,0.0001347679,0.0000028144575,0.000017562497,0.04063638],"genre_scores_gemma":[0.9865546,0.0005188198,0.012023406,0.00024246004,0.00022278479,0.0000019672468,6.070122e-7,0.000012479499,0.00042284848],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988956,0.00010302919,0.0002459032,0.00005015387,0.00065016863,0.000055149012],"domain_scores_gemma":[0.9986244,0.000014157371,0.00023845852,0.000114764465,0.0009298291,0.00007838439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012221492,0.000044050328,0.00013241191,0.000046809895,0.00002473288,0.0000021906806,0.00006869961,0.0000064275187,0.00022901101],"category_scores_gemma":[0.000119789096,0.000027975524,0.000039926203,0.00009651606,0.00009785857,0.00003282928,0.000007803515,0.00008975679,0.0000036491717],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004650317,0.00044313917,0.04819816,0.00007905223,0.0003626626,0.0003445301,0.000892386,0.00025362126,0.047124777,0.00018171075,0.081332415,0.8203225],"study_design_scores_gemma":[0.010607536,0.0010560772,0.7065259,0.0027273854,0.0020391264,0.0036161125,0.00014618301,0.0029128452,0.0468651,0.00021997484,0.22299345,0.00029030684],"about_ca_topic_score_codex":0.000008280985,"about_ca_topic_score_gemma":3.6807396e-7,"teacher_disagreement_score":0.8200322,"about_ca_system_score_codex":0.000050261297,"about_ca_system_score_gemma":0.00026844008,"threshold_uncertainty_score":0.250751},"labels":[],"label_agreement":null},{"id":"W2165857410","doi":"10.1016/j.ejca.2010.04.004","title":"Nasopharyngeal carcinoma: The next challenges","year":2010,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nasopharyngeal carcinoma; Carcinoma; Medicine; General surgery; Internal medicine; Radiation therapy","score_opus":0.14865409103683305,"score_gpt":0.37409223123384283,"score_spread":0.22543814019700978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165857410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041892232,0.9626653,7.56532e-7,0.002813919,0.0021583391,0.00023470225,0.000009096165,0.000010886039,0.032065067],"genre_scores_gemma":[0.00032778707,0.9908415,0.00004354968,0.0003377705,0.006914985,0.000007862703,0.0000012538021,0.00009982904,0.0014254838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978402,0.00041241155,0.00082636956,0.0001978494,0.00044733475,0.0002757812],"domain_scores_gemma":[0.99816966,0.00013743414,0.00082355127,0.0003699208,0.00029575973,0.00020369115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010468006,0.00035071844,0.0018595007,0.0001282732,0.000109267356,0.000030697505,0.0004167087,0.00007278306,0.00020447682],"category_scores_gemma":[0.00010454212,0.00017050948,0.0007966643,0.00013312305,0.00014222664,0.000068364236,0.00009444744,0.0017808839,0.00007694093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029081262,0.0000259778,0.000004883014,0.003232143,0.00033380385,0.00073482865,0.0003523495,3.5072574e-8,0.0000016403458,0.000018950439,0.011785029,0.9834813],"study_design_scores_gemma":[0.0005767955,0.00037701358,0.0003821308,0.012252869,0.0018081531,0.0009929206,0.000058512444,1.1522458e-7,0.0000012891951,0.0000016099551,0.98339516,0.00015345213],"about_ca_topic_score_codex":0.000003984013,"about_ca_topic_score_gemma":0.000012543804,"teacher_disagreement_score":0.9833278,"about_ca_system_score_codex":0.000110929635,"about_ca_system_score_gemma":0.00073780323,"threshold_uncertainty_score":0.7737153},"labels":[],"label_agreement":null},{"id":"W2167824292","doi":"10.1016/j.ejca.2011.03.022","title":"The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Dexrazoxane; Medicine; Cumulative incidence; Anthracycline; Internal medicine; Oncology; Cumulative dose; Doxorubicin; Incidence (geometry); Cancer; Chemotherapy; Surgery; Breast cancer; Cohort","score_opus":0.013073136837729307,"score_gpt":0.2588794608418741,"score_spread":0.24580632400414476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167824292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956164,0.0028313992,0.00023898539,0.00032778506,0.00017544377,0.0005085778,0.000075582975,0.000008628438,0.00021721427],"genre_scores_gemma":[0.9955292,0.003039133,0.00020512592,0.00075313676,0.00028871212,0.000013171438,0.000012883028,0.00004044772,0.00011820151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984929,0.00012064153,0.00062926713,0.00022091392,0.0002990232,0.00023723573],"domain_scores_gemma":[0.9984894,0.000057292,0.00073250436,0.0002855102,0.00031269333,0.00012259498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005429881,0.00020153058,0.00042670566,0.000060885624,0.00009932851,0.000022695787,0.00022043982,0.000052054023,0.000018312505],"category_scores_gemma":[0.000056009667,0.00011278076,0.00011710573,0.00014739076,0.00032072567,0.0001715156,0.00003675047,0.0003675007,6.361457e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009765803,0.00019471988,0.7010708,0.000081260434,0.0068611014,0.0027726635,0.004867676,0.00011471845,0.1835413,0.000009797794,0.0017630737,0.08895708],"study_design_scores_gemma":[0.00605037,0.00042187845,0.89618725,0.0012777959,0.0014298668,0.0025005494,0.00009101443,0.00001831076,0.09115343,0.000014804935,0.00069241255,0.00016234667],"about_ca_topic_score_codex":0.00079644925,"about_ca_topic_score_gemma":0.0008081856,"teacher_disagreement_score":0.19511642,"about_ca_system_score_codex":0.00021536386,"about_ca_system_score_gemma":0.00070395763,"threshold_uncertainty_score":0.4599066},"labels":[],"label_agreement":null},{"id":"W2168704602","doi":"10.1016/j.ejca.2009.12.024","title":"Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells","year":2010,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Ministry of Education, Culture, Sports, Science and Technology; Cancer Research Institute","keywords":"Cell cycle progression; Cancer cell; Cell cycle; Cancer research; Cancer; Cell biology; Chemistry; Biology; Genetics","score_opus":0.012645919139890929,"score_gpt":0.30360078709736404,"score_spread":0.2909548679574731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168704602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569094,0.0013465736,0.00006749182,0.00021038538,0.0002874932,0.00025912715,0.00001145077,0.000005616883,0.0021208944],"genre_scores_gemma":[0.9951225,0.00024867887,0.0007366856,0.000047051446,0.0007472863,0.0000147138035,0.0000031055702,0.000051201085,0.0030287781],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840796,0.00021194489,0.00040616698,0.00024291953,0.00036015062,0.00037084852],"domain_scores_gemma":[0.9991216,0.0000053858093,0.00033343773,0.00021579431,0.00017505197,0.00014870039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007812389,0.00016570647,0.00018118678,0.00007548961,0.00011200169,0.00006642737,0.0003785979,0.000058004527,0.00011840382],"category_scores_gemma":[0.00003556754,0.00012864488,0.00009836578,0.00009767963,0.000069159716,0.000021443999,0.00012874186,0.0005628582,0.000009061656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009521241,0.00009946142,0.0018538825,0.000038797152,0.000021564885,0.00013763657,0.00014191885,0.00006766551,0.98669434,0.0000050232,0.00028173864,0.010562762],"study_design_scores_gemma":[0.0010277171,0.00043703735,0.00052455097,0.00021320912,0.0000059140325,0.000011803515,0.000055733486,0.0000065008576,0.98662895,0.000010419968,0.010915498,0.00016265365],"about_ca_topic_score_codex":0.000060136128,"about_ca_topic_score_gemma":0.0001886166,"teacher_disagreement_score":0.01063376,"about_ca_system_score_codex":0.000036990674,"about_ca_system_score_gemma":0.00019770864,"threshold_uncertainty_score":0.5245986},"labels":[],"label_agreement":null},{"id":"W2169211898","doi":"10.1016/j.ejca.2013.01.029","title":"Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers?","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; Cancer Care Ontario","funders":"National Cancer Institute","keywords":"MLH1; Genetics; Lynch syndrome; PMS2; Single-nucleotide polymorphism; MSH6; Colorectal cancer; Allele; Medicine; MSH2; Hazard ratio; Population; Oncology; Internal medicine; Cancer; Biology; DNA mismatch repair; Genotype; Confidence interval; Gene","score_opus":0.016521371285488647,"score_gpt":0.263828327230759,"score_spread":0.24730695594527036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169211898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256927,0.0035789816,0.00028615314,0.0012437527,0.0009028579,0.00088028936,0.00009086847,0.00003780152,0.0004099993],"genre_scores_gemma":[0.9962984,0.00038046468,0.0012429716,0.00075266295,0.00075898046,0.000088004505,0.0000044607345,0.00009694656,0.0003771456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977782,0.00045918915,0.0006021543,0.00023908574,0.000567938,0.0003534344],"domain_scores_gemma":[0.9967135,0.00020712757,0.0014596515,0.00023479093,0.0011596937,0.00022523622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070235203,0.00024512157,0.00045360223,0.000082972874,0.00019340633,0.000053917476,0.00024115606,0.000056002908,0.00038272116],"category_scores_gemma":[0.00043397307,0.00015061992,0.00021830654,0.00024825524,0.00015404164,0.00009144633,0.000033446555,0.0004292958,0.000009290803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029226264,0.00023273996,0.86704355,0.00013351314,0.0035045156,0.00058786926,0.005054374,0.0083703725,0.02305968,0.0000019734362,0.045896735,0.043192044],"study_design_scores_gemma":[0.0034438744,0.0014038639,0.98249495,0.00039853106,0.00086546113,0.00016862938,0.0004696968,0.00092048105,0.007455945,0.000042739553,0.0021269682,0.00020887169],"about_ca_topic_score_codex":0.00021795569,"about_ca_topic_score_gemma":0.0005231042,"teacher_disagreement_score":0.11545138,"about_ca_system_score_codex":0.00043735985,"about_ca_system_score_gemma":0.0003514556,"threshold_uncertainty_score":0.6142102},"labels":[],"label_agreement":null},{"id":"W2170352017","doi":"10.1016/j.ejca.2004.03.008","title":"Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial","year":2004,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Medicine; Nausea; Vomiting; Chemotherapy; Internal medicine; Methotrexate; Phases of clinical research; Primary central nervous system lymphoma; Surgery; Lymphoma; Gastroenterology; Oncology","score_opus":0.01570479781532926,"score_gpt":0.2884874343122222,"score_spread":0.27278263649689294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170352017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98830134,0.0033352291,0.000021137275,0.0027943172,0.00014817456,0.00037831298,0.000020521877,0.000008904432,0.004992074],"genre_scores_gemma":[0.99632007,0.0013337855,0.0010899272,0.0005701297,0.0004113077,0.0000064955852,0.000005366283,0.00004382829,0.00021908322],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99840707,0.0000986217,0.0007662679,0.00016650342,0.00037721577,0.00018434913],"domain_scores_gemma":[0.9988706,0.000046424324,0.0005873805,0.00022017432,0.00013656217,0.0001388382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000513882,0.000170895,0.0005082589,0.00017975282,0.000032473436,0.000007990653,0.00011305764,0.000024007744,0.000043082524],"category_scores_gemma":[0.000047559795,0.00011330142,0.00015787981,0.00020010956,0.000094802526,0.00009264053,0.000024790386,0.00012843961,0.000002828233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65010375,0.010895863,0.0023150651,0.00008243016,0.00063572545,0.0067271623,0.003675196,0.0003640477,0.0059543364,0.000013109542,0.002963782,0.31626955],"study_design_scores_gemma":[0.7492271,0.05894132,0.1574491,0.00217281,0.0003272433,0.00059266505,0.00016154557,0.0000034991704,0.017775113,0.000012896086,0.013153237,0.0001834677],"about_ca_topic_score_codex":0.000056557346,"about_ca_topic_score_gemma":0.000014746247,"teacher_disagreement_score":0.31608608,"about_ca_system_score_codex":0.00047753289,"about_ca_system_score_gemma":0.0006163067,"threshold_uncertainty_score":0.4620298},"labels":[],"label_agreement":null},{"id":"W2170845869","doi":"10.1016/s0959-8049(01)00188-5","title":"A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Topotecan; Medicine; Neutropenia; Internal medicine; Tolerability; Gastroenterology; Toxicity; Regimen; Febrile neutropenia; Surgery; Chemotherapy; Adverse effect","score_opus":0.022079824404099866,"score_gpt":0.2601823772802902,"score_spread":0.23810255287619034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170845869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912361,0.0012207344,0.000020240434,0.0017270668,0.0013020175,0.00069963414,0.00003138874,0.000007003446,0.0037558295],"genre_scores_gemma":[0.997789,0.0008938539,0.00038555168,0.00013804814,0.00054356694,0.000015572547,0.000001894458,0.000043390923,0.00018910498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99815524,0.00023530102,0.000704302,0.00017314941,0.0004987341,0.00023327426],"domain_scores_gemma":[0.99870515,0.000058629605,0.0005849251,0.00019793272,0.00028140153,0.00017195201],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004130054,0.00018155534,0.00062566006,0.00017347939,0.000029943125,0.000014692495,0.00012180962,0.000031410902,0.0011058584],"category_scores_gemma":[0.0000749257,0.00012551951,0.00016361434,0.00022742724,0.00007009471,0.00008457241,0.000015488917,0.00027587317,0.0000060585417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68093675,0.0021934493,0.026223332,0.000044775672,0.001128226,0.00059361564,0.0014408729,0.00029649702,0.00007867732,0.000018716673,0.0014861318,0.28555897],"study_design_scores_gemma":[0.8179703,0.009884748,0.16177286,0.00059452606,0.0006054549,0.000006488124,0.000032747143,0.0000165742,0.00041852213,0.0000030028493,0.00854354,0.00015129549],"about_ca_topic_score_codex":0.00018795472,"about_ca_topic_score_gemma":0.000112605994,"teacher_disagreement_score":0.2854077,"about_ca_system_score_codex":0.00031952313,"about_ca_system_score_gemma":0.00019285208,"threshold_uncertainty_score":0.99980724},"labels":[],"label_agreement":null},{"id":"W2171562562","doi":"10.1016/s0959-8049(99)00340-8","title":"Estimates of the lifetime costs of breast cancer treatment in Canada","year":2000,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Cancer Care Ontario; Statistics Canada","funders":"","keywords":"Medicine; Breast cancer; Activity-based costing; Cohort; Health care; Population; Malignancy; Total cost; Cancer; Health economics; Indirect costs; Radiation therapy; Disease; Surgery; Internal medicine; Environmental health; Public health; Nursing","score_opus":0.12053897575857753,"score_gpt":0.3641642208185836,"score_spread":0.24362524506000605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171562562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675747,0.009679002,0.000013440973,0.016943334,0.0005204247,0.00019209814,0.00058041303,0.00000185863,0.0044947136],"genre_scores_gemma":[0.9964209,0.0015189787,0.00014296336,0.0012583499,0.00021317265,0.0000050458016,6.940246e-7,0.000021972304,0.00041790743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963646,0.0003223163,0.0028766792,0.00013471092,0.000114233524,0.00018744243],"domain_scores_gemma":[0.9968644,0.00021009035,0.0025071532,0.00022590272,0.000096068754,0.00009640109],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030153804,0.00011766641,0.0006811789,0.00010256536,0.000034766876,0.0000095993155,0.00030041102,0.000016385537,0.002338927],"category_scores_gemma":[0.00015656216,0.000099121506,0.00010896423,0.00015518698,0.00005160945,0.00013048759,0.00001535401,0.0001067518,0.000025732963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011261504,0.000120222656,0.9332734,0.00012505916,0.000235151,0.000010337056,0.0016601753,0.021604171,0.000026047288,0.0004997203,0.013602733,0.028730405],"study_design_scores_gemma":[0.0012867643,0.000072932504,0.96869606,0.00053348194,0.000018167739,0.000017046557,0.00022251271,0.00077005965,0.000096550815,0.00010472122,0.028047577,0.00013410453],"about_ca_topic_score_codex":0.62077814,"about_ca_topic_score_gemma":0.39961654,"teacher_disagreement_score":0.22116162,"about_ca_system_score_codex":0.0019933463,"about_ca_system_score_gemma":0.0014606749,"threshold_uncertainty_score":0.99857306},"labels":[],"label_agreement":null},{"id":"W2175194472","doi":"10.1016/j.ejca.2015.09.004","title":"Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Adenoid cystic carcinoma; Nomogram; Medicine; Oncology; Internal medicine; General surgery; Carcinoma","score_opus":0.0316167214680522,"score_gpt":0.3102264928031686,"score_spread":0.2786097713351164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2175194472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823797,0.00047498278,0.000022829596,0.0001221503,0.00037862698,0.000363187,0.000027337837,0.0000033883155,0.0003695579],"genre_scores_gemma":[0.99930865,0.000020377405,0.00035159802,0.000024026125,0.00024825722,0.000008943514,0.000008794875,0.0000145295735,0.000014835893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991316,0.00014298,0.00024147509,0.00011672776,0.00027584785,0.00009132325],"domain_scores_gemma":[0.9989644,0.000043584325,0.00019116151,0.000065127824,0.000585469,0.00015024997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004677023,0.0000864011,0.00018701403,0.00007591261,0.00002136194,0.000025541054,0.00006168135,0.000006133855,0.00000563063],"category_scores_gemma":[0.00011128041,0.000056217294,0.000015779044,0.00009415567,0.000022363412,0.00014484086,0.000015155409,0.00008850339,3.7761922e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018424338,0.0007721793,0.99005616,0.0000058753844,0.00009958092,0.00017974486,0.0026226598,0.000037876674,4.2570454e-7,0.0000033904137,0.00004757429,0.004332123],"study_design_scores_gemma":[0.013386013,0.008157514,0.97628206,0.0001533608,0.00010997476,0.000011732864,0.0015789106,0.000039061943,0.0000074620584,0.0000025544014,0.0002151985,0.000056170276],"about_ca_topic_score_codex":0.000027718406,"about_ca_topic_score_gemma":0.00006822986,"teacher_disagreement_score":0.013774089,"about_ca_system_score_codex":0.00008711628,"about_ca_system_score_gemma":0.00011683738,"threshold_uncertainty_score":0.22924747},"labels":[],"label_agreement":null},{"id":"W2177568204","doi":"10.1016/j.ejca.2015.08.027","title":"The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Pfizer Foundation","keywords":"Medicine; Cancer; Quality of life (healthcare); Population; Cohort; Randomized controlled trial; Cohort study; Internal medicine; Gerontology; Environmental health","score_opus":0.23248191235068238,"score_gpt":0.46233974838433134,"score_spread":0.22985783603364895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2177568204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.918921,0.07686721,0.000047798614,0.0009556509,0.0006196717,0.0023887143,0.00010479312,0.0000033503027,0.0000918038],"genre_scores_gemma":[0.9867108,0.012741338,0.000026806592,0.00007799137,0.00021695979,0.0000860376,0.000008761531,0.00004124583,0.00009005472],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98405546,0.010801719,0.003660512,0.00021134819,0.0010100566,0.00026090475],"domain_scores_gemma":[0.9889434,0.0038117815,0.0048696273,0.00028797952,0.0019119631,0.00017524861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021983506,0.00021883148,0.0036712606,0.0005690063,0.00010576944,0.000021529146,0.00017413747,0.00003966052,0.000031699954],"category_scores_gemma":[0.0058749737,0.00011275176,0.0007252881,0.00083340716,0.00028830647,0.000069798094,0.000035066296,0.00021556267,7.347728e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4522364,0.0014719911,0.3479062,0.0014770804,0.030071793,0.000017376056,0.06360837,0.015334377,0.01213561,0.00024937748,0.00049881137,0.0749926],"study_design_scores_gemma":[0.53466874,0.0042405217,0.4303082,0.005559117,0.014801997,8.506986e-7,0.0044475524,0.001998079,0.003161205,0.00019170574,0.0003043882,0.00031764247],"about_ca_topic_score_codex":0.034716707,"about_ca_topic_score_gemma":0.028365996,"teacher_disagreement_score":0.08243235,"about_ca_system_score_codex":0.0007288898,"about_ca_system_score_gemma":0.0010624666,"threshold_uncertainty_score":0.9893638},"labels":[],"label_agreement":null},{"id":"W2187105577","doi":"10.1016/j.ejca.2015.10.017","title":"Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Medicine; Gemcitabine; Internal medicine; Common Terminology Criteria for Adverse Events; Hazard ratio; Gastroenterology; Peripheral neuropathy; Adverse effect; Pancreatic cancer; Cancer; Surgery; Oncology; Confidence interval","score_opus":0.03435072441050757,"score_gpt":0.3016408263974451,"score_spread":0.26729010198693753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187105577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709594,0.0013075761,0.00011265461,0.000116952906,0.00011276409,0.0010802267,0.00013412267,0.0000038294097,0.000035936984],"genre_scores_gemma":[0.99860764,0.00006465833,0.00090194814,0.000021994041,0.00014365208,0.000032638596,0.00002543548,0.000029775174,0.00017224009],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99821925,0.00034738352,0.0005752071,0.0001652132,0.000516621,0.00017633486],"domain_scores_gemma":[0.99776846,0.00010703081,0.0012170466,0.00011095686,0.00062083686,0.00017565105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046146289,0.00020538173,0.0008712917,0.000120344754,0.0000561701,0.00001251849,0.00007268448,0.0000139746035,0.0000340604],"category_scores_gemma":[0.000050282317,0.00010138977,0.0001454011,0.0002685753,0.00004091554,0.0000905463,0.000013439717,0.00008978017,1.03376834e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76456773,0.001038561,0.21246995,0.000047026057,0.011310639,0.000064052205,0.0075178053,0.0002477708,0.0013409082,3.9034117e-7,0.000022055432,0.0013730888],"study_design_scores_gemma":[0.7249625,0.011197392,0.24846616,0.00013645687,0.011869088,0.000008215167,0.0003549675,0.000103281025,0.0025613648,3.933551e-7,0.00021926223,0.00012090901],"about_ca_topic_score_codex":0.000067863104,"about_ca_topic_score_gemma":0.000198275,"teacher_disagreement_score":0.039605252,"about_ca_system_score_codex":0.0005504513,"about_ca_system_score_gemma":0.0006624731,"threshold_uncertainty_score":0.4134555},"labels":[],"label_agreement":null},{"id":"W2193440419","doi":"10.1016/j.ejca.2015.09.011","title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Amgen","keywords":"Denosumab; Zoledronic acid; Medicine; Baseline (sea); Oncology; Internal medicine; Osteoporosis; Biology","score_opus":0.011380613769500943,"score_gpt":0.2879997701606072,"score_spread":0.27661915639110624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2193440419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956511,0.003573418,0.00000983658,0.00007714261,0.00025312376,0.00027731925,0.000026032563,0.0000042247293,0.00012777551],"genre_scores_gemma":[0.99956024,0.00012185338,0.000092917704,0.000030293624,0.000031461022,0.000002546901,0.000035551253,0.000032993066,0.000092120536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978189,0.00066376943,0.0007570633,0.00011803502,0.00040673654,0.00023549424],"domain_scores_gemma":[0.99874794,0.00006511098,0.0006575222,0.00011816004,0.00019476561,0.0002165035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014826091,0.00015467212,0.00051675667,0.00016710108,0.000013415377,0.000003262982,0.00006641984,0.000021959631,0.00003510927],"category_scores_gemma":[0.0002697036,0.00010718998,0.000062531144,0.00021320679,0.000025950827,0.00011205162,0.00002130008,0.00028676525,0.000008055938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01280185,0.0006522617,0.90729934,0.00016662237,0.0002445474,0.00032103597,0.00016921388,0.000020625548,0.000085967644,2.580744e-7,0.00022829694,0.07801001],"study_design_scores_gemma":[0.08164193,0.010884747,0.9024568,0.0018195959,0.0005331172,0.00002684493,0.000016434376,0.00004007491,0.0012352259,8.7872155e-7,0.0011999833,0.00014433825],"about_ca_topic_score_codex":0.000040819716,"about_ca_topic_score_gemma":0.000019774314,"teacher_disagreement_score":0.07786567,"about_ca_system_score_codex":0.0002403363,"about_ca_system_score_gemma":0.00020112943,"threshold_uncertainty_score":0.43710807},"labels":[],"label_agreement":null},{"id":"W2199372343","doi":"10.1016/j.ejca.2004.05.022","title":"New technologies in radiation oncology: opportunities, caveats and the way forward","year":2004,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Radiation therapy; Modalities; Treatment modality; Intensive care medicine; Radiation oncology; Cancer; Therapeutic modalities; Medical physics; Oncology; Surgery; Internal medicine","score_opus":0.02144521395168365,"score_gpt":0.29169166678001623,"score_spread":0.2702464528283326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199372343","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029468138,0.027851148,0.05388816,0.90453905,0.00064206927,0.00041482196,0.00003662031,0.0000720256,0.012261432],"genre_scores_gemma":[0.07122121,0.13301009,0.10375854,0.5987935,0.05648794,0.0001467705,0.00013021642,0.0011734079,0.03527834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987856,0.00024695514,0.00045626724,0.00013202411,0.00018106906,0.00019806511],"domain_scores_gemma":[0.99885994,0.00008749777,0.0007800976,0.00017631752,0.00006601628,0.000030120853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045494715,0.00020638005,0.000423008,0.00018843038,0.000046269884,0.000043721066,0.00036396587,0.00008440496,0.000109156215],"category_scores_gemma":[0.000010106581,0.00013390026,0.000114858936,0.00008245995,0.00017980934,0.00014079607,0.000045335066,0.0015737631,7.00624e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046383702,0.0000048989295,0.00026821744,0.000008374148,0.00011075777,0.00020894245,0.00031786683,0.00005188119,0.000011488165,0.0004626728,0.3686827,0.62982583],"study_design_scores_gemma":[0.0018504384,0.00010803264,0.00009924524,0.00019741709,0.000048101603,0.000020940559,0.00013597301,0.0000030472286,0.00015522161,0.0039415183,0.99329275,0.00014729885],"about_ca_topic_score_codex":0.000084003674,"about_ca_topic_score_gemma":0.0000038602775,"teacher_disagreement_score":0.6296785,"about_ca_system_score_codex":0.0002557492,"about_ca_system_score_gemma":0.00038075467,"threshold_uncertainty_score":0.6837305},"labels":[],"label_agreement":null},{"id":"W2199865317","doi":"10.1016/j.ejca.2015.11.004","title":"Predicting survival of men with recurrent prostate cancer after radical prostatectomy","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre; Université de Montréal","funders":"","keywords":"Nomogram; Medicine; Prostatectomy; Prostate cancer; Biochemical recurrence; Hazard ratio; Urology; Proportional hazards model; Confidence interval; Oncology; Internal medicine; Receiver operating characteristic; Population; Prostate-specific antigen; Cancer","score_opus":0.02516699419955296,"score_gpt":0.2928660753406207,"score_spread":0.2676990811410677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199865317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96699274,0.025592899,0.00003240628,0.0021391364,0.00050953287,0.0005050815,0.00007491026,0.000017670696,0.004135632],"genre_scores_gemma":[0.99484575,0.003462885,0.00042912445,0.00013135704,0.0005983605,0.000049084505,0.0000035787948,0.000059937764,0.00041993996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794406,0.00019602757,0.0006294608,0.0002011557,0.000744094,0.00028521646],"domain_scores_gemma":[0.9979282,0.000028916522,0.00060575287,0.00017729937,0.0008181377,0.00044168872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007597818,0.00020936632,0.00050107297,0.00010771377,0.000026516545,0.00002231305,0.000107939566,0.00001950743,0.00011775948],"category_scores_gemma":[0.000050611212,0.00012959601,0.000112071946,0.00019724025,0.00014574465,0.00015106179,0.000042448974,0.00030182805,0.0000042440633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010993356,0.0004279224,0.89473265,0.0002451522,0.00086807675,0.0016116378,0.004433296,0.00024687088,0.00033177182,0.000007767714,0.0046825674,0.0814189],"study_design_scores_gemma":[0.027444366,0.011016683,0.8522121,0.007003363,0.0013621785,0.00032323704,0.0010234549,0.00010849376,0.010460805,0.000027931324,0.08856924,0.00044818228],"about_ca_topic_score_codex":0.00006537642,"about_ca_topic_score_gemma":0.000033932818,"teacher_disagreement_score":0.08388667,"about_ca_system_score_codex":0.00034918624,"about_ca_system_score_gemma":0.0008049732,"threshold_uncertainty_score":0.5284772},"labels":[],"label_agreement":null},{"id":"W2224326414","doi":"10.1016/j.ejca.2015.09.025","title":"Small data sets to develop and validate prognostic models are problematic","year":2015,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Ipilimumab; Medicine; Nomogram; Prognostic model; Internal medicine; Oncology; Metastatic melanoma; Melanoma; Overall survival; Cancer; Immunotherapy; Cancer research","score_opus":0.13992624113722474,"score_gpt":0.2838337292900866,"score_spread":0.14390748815286186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224326414","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2635926,0.04586967,0.022874484,0.6401447,0.0051918183,0.0029001907,0.002943838,0.000060214996,0.016422465],"genre_scores_gemma":[0.104082964,0.005237595,0.05207559,0.7867849,0.0328155,0.000058218928,0.0031541663,0.0010164932,0.014774571],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819565,0.00035410083,0.0005036739,0.00036915153,0.0002825593,0.00029485545],"domain_scores_gemma":[0.99794286,0.000013472859,0.0005996342,0.0005719579,0.0006711304,0.00020093526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010092738,0.00026778816,0.00035955835,0.0000823822,0.00003579894,0.00007547734,0.00082176743,0.00011858069,0.000011327627],"category_scores_gemma":[0.0002978478,0.00021293297,0.000041599316,0.000082359395,0.00003458984,0.000009654571,0.0005726507,0.0004886838,0.000014779372],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035689518,0.0000101071455,0.00013370464,0.00023899198,0.00015802225,0.0007407228,0.00009234697,0.000107632026,0.002244311,6.6744525e-7,0.9925068,0.0037309735],"study_design_scores_gemma":[0.00048719285,0.00034518962,0.0002721751,0.0007116503,0.00016831033,0.00034172676,0.00001580807,0.000043409596,0.0004810678,0.000080151,0.99671495,0.0003383481],"about_ca_topic_score_codex":0.0000027948638,"about_ca_topic_score_gemma":0.000014337646,"teacher_disagreement_score":0.15950964,"about_ca_system_score_codex":0.000021284342,"about_ca_system_score_gemma":0.0004983724,"threshold_uncertainty_score":0.8683154},"labels":[],"label_agreement":null},{"id":"W2231687092","doi":"10.1016/j.ejca.2015.10.068","title":"Is there any benefit to adding adjuvant chemotherapy after concurrent chemoradiotherapy for nasopharyngeal carcinoma?","year":2015,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Nasopharyngeal carcinoma; Oncology; Medicine; Chemoradiotherapy; Internal medicine; Radiation therapy; Chemotherapy; Meta-analysis; Pemetrexed; Cisplatin","score_opus":0.04478413536822714,"score_gpt":0.32909288279011883,"score_spread":0.2843087474218917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231687092","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051922668,0.20982212,0.0001410224,0.72830635,0.0041341265,0.0011300283,0.0006186412,0.000039698505,0.0038853548],"genre_scores_gemma":[0.08030391,0.006507376,0.0009714485,0.8639522,0.037620794,0.000080043836,0.00002598246,0.00042980778,0.010108441],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712026,0.00009899947,0.0008751115,0.0004448711,0.00083474064,0.0006260437],"domain_scores_gemma":[0.99744326,0.000062666666,0.00061944925,0.00036908605,0.0011103733,0.00039519518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006369124,0.0005720082,0.0016487667,0.00024306726,0.00007310004,0.000056195822,0.00036393228,0.00015102241,0.0009032052],"category_scores_gemma":[0.000033493743,0.00042535405,0.00061147934,0.00016427552,0.00007848043,0.000088946355,0.000047703597,0.0012370145,0.000030044172],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012300474,0.00003688692,0.0017875024,0.00038512162,0.0006928564,0.0011773936,0.0022588044,0.0000017112117,0.00019692305,5.474234e-7,0.917214,0.075018205],"study_design_scores_gemma":[0.0063719205,0.0021274933,0.011136301,0.0021443039,0.00037326742,0.00014622483,0.000051352017,0.0000064381434,0.000692842,0.0000050351164,0.976511,0.00043383424],"about_ca_topic_score_codex":0.000014429292,"about_ca_topic_score_gemma":0.000006193707,"teacher_disagreement_score":0.20331475,"about_ca_system_score_codex":0.0006445303,"about_ca_system_score_gemma":0.00055627554,"threshold_uncertainty_score":0.9998198},"labels":[],"label_agreement":null},{"id":"W2235189674","doi":"10.1016/j.ejca.2015.12.007","title":"Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Research UK; Hospital for Sick Children; Children's Cancer and Leukaemia Group","keywords":"Cyclophosphamide; Pharmacokinetics; Medicine; Pharmacogenetics; Lymphoma; Population; Internal medicine; Oncology; Genotype; Pharmacology; Gastroenterology; Chemotherapy; Biology; Genetics","score_opus":0.00814923718830878,"score_gpt":0.273799806132699,"score_spread":0.2656505689443902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2235189674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916342,0.0035307505,0.00091402995,0.0010929898,0.00011763974,0.00019813098,0.000010891997,0.000008409393,0.0024929773],"genre_scores_gemma":[0.9877805,0.00859978,0.0014215248,0.0005806406,0.0005784745,0.000002066393,5.207779e-7,0.00007224237,0.0009642325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837077,0.0001298431,0.00043229348,0.00019309334,0.0005363457,0.00033764192],"domain_scores_gemma":[0.9989258,0.00006851197,0.00024917524,0.00015242481,0.000257031,0.00034706903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048173845,0.00018857118,0.00030230958,0.0001924852,0.000027889168,0.000019390543,0.00019787505,0.000023234208,0.00015364675],"category_scores_gemma":[0.000037249574,0.000107710366,0.000053049196,0.00021169265,0.00017109147,0.000092095965,0.00007885739,0.00017569942,0.000020171361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002107906,0.00022425273,0.5105739,0.00004830688,0.00033279942,0.0020248212,0.0002543852,0.000079308535,0.11170133,0.0000014929323,0.006008677,0.36664277],"study_design_scores_gemma":[0.048330843,0.0014236269,0.8164614,0.0007337006,0.00034113546,0.0021643278,0.000029451661,0.00012445726,0.10873433,0.00000431664,0.021371344,0.00028107144],"about_ca_topic_score_codex":0.000012480547,"about_ca_topic_score_gemma":0.000001781927,"teacher_disagreement_score":0.3663617,"about_ca_system_score_codex":0.00031982615,"about_ca_system_score_gemma":0.0005146528,"threshold_uncertainty_score":0.4392301},"labels":[],"label_agreement":null},{"id":"W2258872553","doi":"10.1016/j.ejca.2015.12.002","title":"p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Amis de l'Institut Bordet","keywords":"Vemurafenib; Melanoma; Cancer research; PI3K/AKT/mTOR pathway; Medicine; MAPK/ERK pathway; Protein kinase B; V600E; MEK inhibitor; Pharmacology; Apoptosis; Biology; Signal transduction; Mutation; Metastatic melanoma","score_opus":0.0087270120395586,"score_gpt":0.23768664893815036,"score_spread":0.22895963689859175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258872553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98355734,0.0011801539,0.00507837,0.0018650319,0.0005901097,0.00009129756,0.000053828866,0.0000084599615,0.00757541],"genre_scores_gemma":[0.9926917,0.00043771695,0.0005679264,0.0008385139,0.0012486478,0.0000019286128,0.000009133573,0.00004136449,0.004163048],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885035,0.0001946753,0.00033788773,0.000200619,0.00020813386,0.00020835403],"domain_scores_gemma":[0.99906594,0.000017420316,0.00028101917,0.00021751391,0.00023417873,0.00018393746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039363324,0.0001466774,0.00016948668,0.00005881097,0.00004814598,0.00002439247,0.00020213235,0.000037717076,0.00007454101],"category_scores_gemma":[0.00014147496,0.00010086599,0.00009944805,0.00006355256,0.00003461929,0.000014014229,0.00006501051,0.000079613164,0.000047596342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017732137,0.000021189499,0.00071553874,0.000004539134,0.000054868113,0.00004843691,0.00004652768,0.0000044104613,0.8443281,0.000015968124,0.08895835,0.06562475],"study_design_scores_gemma":[0.0006028228,0.00047872934,0.006216835,0.00006055093,0.000017079105,0.00006626401,0.0000141956,2.9013452e-7,0.5047459,0.000006815024,0.4876682,0.00012232517],"about_ca_topic_score_codex":0.0000059670097,"about_ca_topic_score_gemma":0.0000055152204,"teacher_disagreement_score":0.39870983,"about_ca_system_score_codex":0.00003722267,"about_ca_system_score_gemma":0.0000903679,"threshold_uncertainty_score":0.41131958},"labels":[],"label_agreement":null},{"id":"W2269055219","doi":"10.1016/j.ejca.2015.12.023","title":"Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nausea and vomiting management","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Nausea; Chemotherapy-induced nausea and vomiting; Vomiting; Medicine; Antiemetic; Anesthesia; Chemotherapy; Aprepitant; Internal medicine","score_opus":0.038785538848313546,"score_gpt":0.32200235493191753,"score_spread":0.283216816083604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2269055219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956097,0.0010579281,0.0021362477,0.0006348941,0.00006176627,0.00036149446,0.000012454031,0.0000051757547,0.00012032508],"genre_scores_gemma":[0.99530166,0.0022484807,0.0018979307,0.00007924203,0.00016850106,0.0000014539272,4.5814906e-7,0.000036925616,0.00026531547],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987335,0.00009480465,0.0006953898,0.00013049487,0.00021487515,0.00013091046],"domain_scores_gemma":[0.9985378,0.00017698368,0.00084150204,0.00012293411,0.00024846077,0.00007231832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078711717,0.000121637706,0.00043210984,0.00011310092,0.00002740932,0.0000063325824,0.00007346148,0.000023000468,0.000044487726],"category_scores_gemma":[0.00015284536,0.00007379836,0.00011043637,0.00006934497,0.000060028797,0.00008904344,0.000022899123,0.000062832085,1.2526854e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015355611,0.00018900052,0.014363482,0.00034311553,0.0006782574,0.000007491057,0.0005676785,0.000011064416,0.7190661,0.00004324399,0.0001647208,0.24921024],"study_design_scores_gemma":[0.036453597,0.0025060594,0.56901145,0.0023015016,0.00030218594,0.000019540472,0.000094479125,0.0001611213,0.38723207,0.000054379838,0.0017217114,0.0001419177],"about_ca_topic_score_codex":0.0000055056994,"about_ca_topic_score_gemma":0.000004601758,"teacher_disagreement_score":0.554648,"about_ca_system_score_codex":0.000031415486,"about_ca_system_score_gemma":0.00005639915,"threshold_uncertainty_score":0.30094096},"labels":[],"label_agreement":null},{"id":"W2273565724","doi":"10.1016/j.ejca.2015.12.024","title":"Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Internal medicine; Oncology; Breast cancer; Hazard ratio; Adjuvant therapy; Cancer; Confidence interval","score_opus":0.03275624306295245,"score_gpt":0.33879298892192,"score_spread":0.30603674585896756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273565724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862705,0.006074477,0.00011247454,0.0051745544,0.0006826311,0.00023892456,0.0003275128,0.000011298407,0.0011076466],"genre_scores_gemma":[0.98865813,0.008454086,0.00006047013,0.00028908672,0.0009910247,0.0000105465115,0.0000015361585,0.00006584312,0.0014693019],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973834,0.00023684274,0.0009106181,0.0002185123,0.0009946275,0.00025600332],"domain_scores_gemma":[0.9973442,0.00007681908,0.00082946575,0.00036471547,0.0011423406,0.00024245807],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073278445,0.00015842132,0.0004099532,0.00015277059,0.000041202315,0.000028629804,0.0002668141,0.000033035518,0.0027205017],"category_scores_gemma":[0.000056398203,0.00009806039,0.00015925642,0.00018794579,0.00012965502,0.0001705462,0.00004231344,0.00024418722,0.000040524093],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012488266,0.00009517019,0.21756743,0.000024329225,0.00026656728,0.000089396824,0.00096366415,0.000014938814,0.11377527,0.000011861413,0.006794526,0.65914804],"study_design_scores_gemma":[0.0025375772,0.00061383704,0.90352863,0.0016363615,0.00006917956,0.00003431808,0.000046694164,0.000005356615,0.05289247,0.000034006833,0.03847027,0.00013127833],"about_ca_topic_score_codex":0.00046685323,"about_ca_topic_score_gemma":0.000042438496,"teacher_disagreement_score":0.68596125,"about_ca_system_score_codex":0.00027176933,"about_ca_system_score_gemma":0.0003455623,"threshold_uncertainty_score":0.9981911},"labels":[],"label_agreement":null},{"id":"W2299351315","doi":"10.1016/j.ejca.2016.01.006","title":"Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Denosumab; Medicine; Giant cell; Osteoclast; Giant-cell tumor of bone; RANKL; Surgery; Pathology; Internal medicine; Osteoporosis; Receptor","score_opus":0.016343097404480873,"score_gpt":0.24442242144281587,"score_spread":0.228079324038335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299351315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977616,0.00056440936,0.000046346504,0.00089906657,0.00007713852,0.0002707717,0.000013666229,0.0000011044374,0.00036591012],"genre_scores_gemma":[0.9992242,0.00009554759,0.0002892878,0.00003583039,0.000047825943,0.0000025318186,5.2572307e-7,0.000017342292,0.0002869175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999139,0.00006872095,0.00040594468,0.00006250775,0.00023832638,0.00008549853],"domain_scores_gemma":[0.998911,0.000050537416,0.00058962696,0.00011477679,0.00029386365,0.000040191626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021657108,0.00006690944,0.00021876262,0.00005369873,0.000011402601,0.0000021644905,0.00006621798,0.0000066511197,0.000027721033],"category_scores_gemma":[0.00009275139,0.000028540635,0.00008487312,0.00007243016,0.00003386695,0.00006493209,0.000016972015,0.000051012532,8.6047356e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028615468,0.0017341172,0.9437226,0.00013469308,0.00013753692,0.000038788552,0.00042813632,0.000047078374,0.019853776,0.000022746897,0.0015765032,0.029442491],"study_design_scores_gemma":[0.013507635,0.0011480184,0.95601416,0.0012787484,0.000107557564,0.0000033933507,0.00000940934,0.000001970603,0.02716788,0.000006575074,0.00072194496,0.000032682172],"about_ca_topic_score_codex":0.000012055068,"about_ca_topic_score_gemma":0.000009561933,"teacher_disagreement_score":0.029409809,"about_ca_system_score_codex":0.000056808163,"about_ca_system_score_gemma":0.00007522728,"threshold_uncertainty_score":0.11638533},"labels":[],"label_agreement":null},{"id":"W2302140636","doi":"10.1016/j.ejca.2016.01.014","title":"Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Queen's University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Letrozole; Coronary artery disease; Internal medicine; Proportional hazards model; Diabetes mellitus; Hazard ratio; Oncology; Breast cancer; Tamoxifen; Cancer; Gynecology; Endocrinology; Confidence interval","score_opus":0.004264860259195943,"score_gpt":0.19867501296916554,"score_spread":0.19441015270996959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2302140636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98480767,0.014467277,0.00003809787,0.00027274902,0.0001638101,0.0001284001,0.00004919919,0.0000034436118,0.00006935752],"genre_scores_gemma":[0.99723077,0.0021702435,0.000020769547,0.00019416513,0.00022391147,0.00001305811,0.0000023245225,0.00002529376,0.000119451724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910957,0.00014889614,0.00020921735,0.00019774685,0.00014895914,0.00018560246],"domain_scores_gemma":[0.9992729,0.00005897291,0.00021588021,0.00013348315,0.0001358898,0.00018289458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001330787,0.00015579273,0.00022446849,0.000043635056,0.000043876393,0.000007412156,0.000073865165,0.000017985454,0.000006913444],"category_scores_gemma":[0.0001267796,0.00009591555,0.000045756547,0.00002919176,0.00022008002,0.000011004281,0.0000805784,0.00005752293,6.631113e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002273641,0.00024555039,0.7960128,0.00014990101,0.0009837999,0.0004928614,0.0002749637,0.00001179259,0.08751281,0.0000025320915,0.0031908932,0.10884845],"study_design_scores_gemma":[0.0023724136,0.0013311375,0.9895761,0.00060777797,0.00016199489,0.000023264192,0.000031228403,0.000002810996,0.005020246,0.000016884082,0.0007446542,0.000111465306],"about_ca_topic_score_codex":6.702136e-7,"about_ca_topic_score_gemma":0.0000010802905,"teacher_disagreement_score":0.19356333,"about_ca_system_score_codex":0.000035022676,"about_ca_system_score_gemma":0.000049366394,"threshold_uncertainty_score":0.39113227},"labels":[],"label_agreement":null},{"id":"W2306919242","doi":"10.1016/j.ejca.2016.02.016","title":"Endometrial cancer—targeted therapies myth or reality? Review of current targeted treatments","year":2016,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Targeted therapy; Clinical trial; Malignancy; Endometrial cancer; Disease; Translational research; Cancer; Oncology; Bioinformatics; Internal medicine; Pathology; Biology","score_opus":0.1425898234742258,"score_gpt":0.43616294662946836,"score_spread":0.29357312315524253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306919242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008264972,0.9923627,0.000019885847,0.00060949667,0.0033318738,0.0014116468,0.00094873406,0.000025271871,0.0012821584],"genre_scores_gemma":[0.000023654018,0.9934772,0.000096235424,0.00034611332,0.003942755,0.000078360135,0.00006685965,0.00016725567,0.001801556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929446,0.0016238339,0.0031191844,0.0004807311,0.0013229579,0.0005086695],"domain_scores_gemma":[0.9930527,0.000492166,0.0043921056,0.00058119046,0.00096230075,0.00051950145],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001451938,0.000831625,0.005441438,0.0007780866,0.00006538886,0.000021946467,0.0005629445,0.000106564854,0.0053043524],"category_scores_gemma":[0.00096090545,0.0003926107,0.0022360566,0.0015924255,0.00014589164,0.00014373401,0.00009901423,0.00066118746,0.000058152225],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001326134,0.00033870043,0.0000323857,0.052568723,0.0046606134,0.0003123161,0.0000389062,6.71227e-8,0.000006457615,0.000004670552,0.010825656,0.9298854],"study_design_scores_gemma":[0.0063670976,0.0013164597,0.00006312467,0.28061873,0.007360109,0.00008431575,0.0000033197782,1.748895e-8,0.000027127557,0.000004294119,0.7039018,0.0002535951],"about_ca_topic_score_codex":0.000042135343,"about_ca_topic_score_gemma":0.0000048422794,"teacher_disagreement_score":0.92963177,"about_ca_system_score_codex":0.0010514061,"about_ca_system_score_gemma":0.0021986084,"threshold_uncertainty_score":0.9998526},"labels":[],"label_agreement":null},{"id":"W2315538824","doi":"10.1016/s0959-8049(12)71627-1","title":"1009 Targeting Chronic Myeloid Leukemia Stem/progenitor Cells by Effective Inhibition of a Novel AHI-1-BCR-ABL-JAK2 Interaction Complex","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Myeloid leukemia; Progenitor cell; Cancer research; breakpoint cluster region; Stem cell; Medicine; Chemistry; Cell biology; Internal medicine; Biology; Receptor","score_opus":0.022557032013183032,"score_gpt":0.2887791172738332,"score_spread":0.26622208526065017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315538824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871705,0.0077592707,0.0010871803,0.00013087253,0.0011931364,0.0005027545,0.000036381785,0.000025789128,0.002094095],"genre_scores_gemma":[0.995496,0.00043222256,0.00097065506,0.00014655614,0.002322642,0.000009677676,0.000024750954,0.00008612001,0.00051139016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976214,0.00030857508,0.00089118065,0.00020560912,0.00054865424,0.00042458327],"domain_scores_gemma":[0.99779785,0.00011295934,0.0012136818,0.00020614968,0.00037019246,0.00029914372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008850861,0.00028568783,0.000556543,0.00017345772,0.00007872163,0.000020914818,0.0001224653,0.000054159416,0.00045734996],"category_scores_gemma":[0.000057317375,0.00023803132,0.0002600914,0.00020856997,0.00009060898,0.00043496015,0.00006377657,0.00054380693,0.000052839878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068454706,0.0003372838,0.0026764409,0.00024597946,0.00049554504,0.000054482756,0.00086665334,0.0001949019,0.9298293,0.0000035824896,0.01557903,0.04903223],"study_design_scores_gemma":[0.016558073,0.00209256,0.015842149,0.002124456,0.0008030669,0.0004723397,0.00052546686,0.00077705435,0.857002,0.000001022131,0.10341771,0.00038410144],"about_ca_topic_score_codex":0.000063047206,"about_ca_topic_score_gemma":0.0000038825206,"teacher_disagreement_score":0.08783868,"about_ca_system_score_codex":0.0052640066,"about_ca_system_score_gemma":0.000503968,"threshold_uncertainty_score":0.9985546},"labels":[],"label_agreement":null},{"id":"W2316364119","doi":"10.1016/s0959-8049(12)71286-8","title":"638 LKB1 Gene Mutations and Rheb Gene Expression in Renal Cell Cancer","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"RHEB; Gene; Cancer research; Cancer; Genetics; Biology; Gene expression; Mutation; Signal transduction; PI3K/AKT/mTOR pathway; mTORC1","score_opus":0.010797391396967063,"score_gpt":0.2565627565687022,"score_spread":0.24576536517173514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2316364119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95106083,0.046275984,0.001035267,0.00016230442,0.00045051996,0.00005195826,0.000038941733,0.0000014616322,0.0009227494],"genre_scores_gemma":[0.98283803,0.01302219,0.0020507528,0.00030832642,0.0014434409,0.0000037637217,0.000008289315,0.000028318991,0.00029689178],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992127,0.00008793755,0.00027842476,0.00011589649,0.00010773697,0.0001973403],"domain_scores_gemma":[0.99941725,0.000012871408,0.00020798937,0.000113033915,0.00009744546,0.00015140923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002987865,0.00010526509,0.00012089525,0.000056011148,0.00004190049,0.000020624466,0.00011175223,0.000029498708,0.000054542674],"category_scores_gemma":[0.000026970663,0.000093509225,0.00005162398,0.000053715954,0.000040012685,0.000010027079,0.00007119649,0.00011506647,0.0000026199502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000808913,0.000047050027,0.011402519,0.000008469087,0.00001962066,0.00001785047,0.0002897967,0.001630564,0.9757554,0.0000029494752,0.0032408568,0.0075040264],"study_design_scores_gemma":[0.0012200966,0.00015323772,0.052274406,0.000062481835,0.00003951673,0.000035671306,0.00006275391,0.000007472807,0.8406868,0.000012209336,0.105269514,0.00017582066],"about_ca_topic_score_codex":0.000026891492,"about_ca_topic_score_gemma":0.000047140747,"teacher_disagreement_score":0.13506858,"about_ca_system_score_codex":0.000037319485,"about_ca_system_score_gemma":0.00010963515,"threshold_uncertainty_score":0.38131955},"labels":[],"label_agreement":null},{"id":"W2328241164","doi":"10.1016/s0959-8049(12)71628-3","title":"1010 Use of an α5β1 Small Non-peptidic Antagonist to Inhibit Glioblastoma Migration Fostered by Integrin Expression","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Integrin; Antagonist; Glioblastoma; Cancer research; Cell biology; Chemistry; Pharmacology; Biology; Receptor; Biochemistry","score_opus":0.038974186285283784,"score_gpt":0.3170765376672706,"score_spread":0.27810235138198686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328241164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651164,0.00064747856,0.001159107,0.0006649974,0.00021697457,0.00022086538,0.000015344262,0.000009198158,0.00055437436],"genre_scores_gemma":[0.9941117,0.00016928047,0.0029889261,0.00038853913,0.00050554104,0.0000023000266,0.000006525426,0.000059495025,0.0017676686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979568,0.00035552713,0.00062082463,0.0001543248,0.0006089855,0.0003035342],"domain_scores_gemma":[0.9982076,0.000046526908,0.0003634797,0.0002849063,0.00046873448,0.0006287124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078372256,0.00016109747,0.00030849114,0.00027332452,0.00004587123,0.00004549444,0.0001915174,0.000036108846,0.00032676623],"category_scores_gemma":[0.00020896221,0.00012182755,0.000120592114,0.0002337626,0.00005628749,0.00031883453,0.00010995627,0.00042125027,0.000050404222],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021837314,0.00023987466,0.0057032914,0.000048413363,0.000027557706,0.0001091082,0.0010372918,0.000018424682,0.93441236,5.3881405e-7,0.022701366,0.033518054],"study_design_scores_gemma":[0.0015409368,0.0026718082,0.027739601,0.0007649512,0.00004539373,0.0001291693,0.00019135339,0.000042946012,0.87056834,5.1113875e-7,0.09617811,0.00012690072],"about_ca_topic_score_codex":0.00004374803,"about_ca_topic_score_gemma":0.000054503475,"teacher_disagreement_score":0.07347674,"about_ca_system_score_codex":0.00012310085,"about_ca_system_score_gemma":0.00010997519,"threshold_uncertainty_score":0.49679834},"labels":[],"label_agreement":null},{"id":"W2334091744","doi":"10.1016/j.ejca.2016.03.004","title":"Development of molecularly targeted agents and immunotherapies in small cell lung cancer","year":2016,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"British Lung Foundation; Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Lung cancer; Malignancy; Immunotherapy; Targeted therapy; Clinical trial; Oncology; Biomarker; Disease; Cancer; Cancer research; Bioinformatics; Internal medicine; Biology","score_opus":0.05263321894245841,"score_gpt":0.3856924144383269,"score_spread":0.3330591954958685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334091744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016530461,0.99642533,0.000064105065,0.0001272933,0.00028201743,0.00048741934,0.00002552913,0.000005158306,0.0009300727],"genre_scores_gemma":[0.00027477602,0.99691147,0.0011661972,0.0000647732,0.00025397033,0.000027220924,0.0000017373173,0.00009974732,0.0012001286],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99733305,0.0003879444,0.0012469143,0.00023222627,0.00047136928,0.00032847136],"domain_scores_gemma":[0.99813473,0.00006046892,0.0010805542,0.00020282376,0.00036979115,0.00015160682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009879514,0.0003433521,0.001607375,0.00044325402,0.000040722243,0.000019302723,0.00028854585,0.00005003669,0.0002215166],"category_scores_gemma":[0.00006417914,0.00021069814,0.000262599,0.00023620644,0.00011086804,0.000062183644,0.00015161165,0.0005186105,0.0000044432454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012404396,0.00005093687,0.00060324575,0.015136407,0.0015054325,0.00037992492,0.0016994177,5.6037936e-7,0.00026295488,9.823476e-7,0.0011299935,0.9791061],"study_design_scores_gemma":[0.0018366358,0.00011240452,0.0021894171,0.07058959,0.00047762837,0.00002553131,0.000042802003,4.248438e-7,0.00014540069,6.634542e-7,0.9243778,0.00020171028],"about_ca_topic_score_codex":0.000026374868,"about_ca_topic_score_gemma":0.000030623236,"teacher_disagreement_score":0.97890437,"about_ca_system_score_codex":0.0006622271,"about_ca_system_score_gemma":0.0017832941,"threshold_uncertainty_score":0.8592021},"labels":[],"label_agreement":null},{"id":"W2345621429","doi":"10.1016/j.ejca.2016.03.077","title":"The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"South Health Campus; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; McMaster University; University of Toronto; St. Michael's Hospital; University of Calgary","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Government of Canada; Cancer Research Institute","keywords":"Breast cancer; Stage (stratigraphy); Profiling (computer programming); Oncology; Chemotherapy; Gene expression profiling; Cancer; Internal medicine; Medicine; Gene; Gene expression; Biology; Genetics; Computer science","score_opus":0.13688239459677212,"score_gpt":0.44883633151252106,"score_spread":0.3119539369157489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345621429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042666,0.003278661,0.0013327543,0.003317526,0.0006528261,0.0006930174,0.00012472832,0.000009650472,0.00016416216],"genre_scores_gemma":[0.9918045,0.002648117,0.004103929,0.0008242055,0.00031929993,0.0000715559,4.3202817e-7,0.000049586586,0.00017841553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996452,0.0010593175,0.0013921226,0.0001858851,0.0005596124,0.00035106656],"domain_scores_gemma":[0.99338824,0.0031537055,0.0016690412,0.00049033045,0.0011893632,0.00010934254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016403826,0.00015083898,0.00028063278,0.00015482886,0.00041294363,0.000011023549,0.00074100867,0.000055473312,0.0001222456],"category_scores_gemma":[0.0007143962,0.000080483704,0.00009906937,0.00016649804,0.000090300935,0.00020934021,0.00010395398,0.00047331458,0.000009428336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010759684,0.000100116784,0.55403906,0.00017359873,0.00005944512,0.0000115669645,0.008251394,0.0039481986,0.059594415,0.00029647796,0.0019613095,0.36080474],"study_design_scores_gemma":[0.0050951703,0.0002823148,0.9433354,0.015055601,0.000010454406,0.0000040310088,0.00084078126,0.00007830795,0.0055717314,0.00024101068,0.029297477,0.00018769567],"about_ca_topic_score_codex":0.000040859497,"about_ca_topic_score_gemma":0.000049223352,"teacher_disagreement_score":0.38929638,"about_ca_system_score_codex":0.00036426526,"about_ca_system_score_gemma":0.00056125375,"threshold_uncertainty_score":0.32820302},"labels":[],"label_agreement":null},{"id":"W2346277674","doi":"10.1016/j.ejca.2016.03.066","title":"Bias in reporting of randomised clinical trials in oncology","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Oncology; Internal medicine; Medical physics","score_opus":0.9604652932757356,"score_gpt":0.7019667968084751,"score_spread":0.25849849646726053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346277674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97124666,0.0028811067,0.0038264312,0.0033012803,0.0010329526,0.00033758517,0.0000020927105,5.6293123e-7,0.017371299],"genre_scores_gemma":[0.99526095,0.0005677095,0.0013243946,0.00016647312,0.00035002612,0.0000018529323,3.4345494e-8,0.00000810445,0.0023204258],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.31835693,0.44012383,0.23358274,0.0009307779,0.006547678,0.0004580358],"domain_scores_gemma":[0.76550263,0.061426084,0.16956274,0.0013815949,0.0019216061,0.00020532464],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.85020757,0.00011770867,0.00768111,0.0005197127,0.000011087907,0.00005692204,0.00088957476,0.000032886186,0.0051563205],"category_scores_gemma":[0.7239294,0.00003998429,0.0026398615,0.0006003519,0.00006385698,0.00013539071,0.000055480607,0.00020525101,0.00012250015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000691535,0.000059691767,0.26817125,0.000008454842,0.00014383477,0.00028987226,0.00033500456,0.00006453074,0.0008054541,0.000027141254,0.018525107,0.71087813],"study_design_scores_gemma":[0.031625465,0.00043462715,0.44548056,0.0012096147,0.00033672396,0.00008301028,0.00054631947,0.0001414938,0.0002788774,0.001062859,0.5186147,0.00018573273],"about_ca_topic_score_codex":0.0000046621885,"about_ca_topic_score_gemma":0.00005585892,"teacher_disagreement_score":0.7106924,"about_ca_system_score_codex":0.00005279435,"about_ca_system_score_gemma":0.00030164453,"threshold_uncertainty_score":0.9957531},"labels":[],"label_agreement":null},{"id":"W23465562","doi":"10.1016/s0959-8049(00)00092-7","title":"‘Accidental’ anti-angiogenic drugs","year":2000,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre","funders":"National Cancer Institute; Medical Research Council; National Institutes of Health","keywords":"Angiogenesis; Pharmacology; Vascular endothelial growth factor; Cancer research; Medicine; Endothelial stem cell; Thalidomide; Tyrosine kinase; Immunology; Receptor; Biology; Internal medicine; In vitro; VEGF receptors; Multiple myeloma; Biochemistry","score_opus":0.022414667160598468,"score_gpt":0.32139446876343813,"score_spread":0.29897980160283966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W23465562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026977135,0.9939367,0.000039994047,0.000022932636,0.000811806,0.00011981754,0.000051230094,0.000004505611,0.0047432175],"genre_scores_gemma":[0.00038423002,0.99195075,0.00007443758,0.00018736366,0.0040459675,0.000004723047,0.0000337988,0.00014179644,0.0031769392],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978801,0.0003940989,0.00087251276,0.0002987673,0.00027774714,0.00027675266],"domain_scores_gemma":[0.9984231,0.000010490283,0.0009111067,0.00035986354,0.00013642451,0.00015903596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005077295,0.00037734566,0.00092987966,0.00012998183,0.00006011969,0.000047140307,0.00066937966,0.00011473172,0.0006318829],"category_scores_gemma":[0.000014615339,0.00028624077,0.0015970642,0.00014952643,0.000065068365,0.000005512211,0.00010314206,0.0002301719,0.00011452513],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001806756,0.000022427326,0.000015189779,0.00039706661,0.00062813156,0.00007569807,0.000016378312,0.000008339995,0.00008224024,0.000002061604,0.033794116,0.9649403],"study_design_scores_gemma":[0.00026780277,0.00013746101,0.000026574333,0.0026336682,0.0007951824,0.00023054384,0.000007888359,7.5626765e-8,0.00014212969,0.0000010908459,0.9954382,0.00031935223],"about_ca_topic_score_codex":0.0000035497103,"about_ca_topic_score_gemma":0.0000018204477,"teacher_disagreement_score":0.96462095,"about_ca_system_score_codex":0.00005811904,"about_ca_system_score_gemma":0.0004219025,"threshold_uncertainty_score":0.999959},"labels":[],"label_agreement":null},{"id":"W2373606074","doi":"10.1016/j.ejca.2016.03.081","title":"RECIST 1.1—Update and clarification: From the RECIST committee","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1894,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Cancer Society Research Institute; National Cancer Institute; National Cancer Research Institute","keywords":"Response Evaluation Criteria in Solid Tumors; Medicine; Medical physics; Radiology; Disease; Progressive disease; Internal medicine","score_opus":0.022424082969743978,"score_gpt":0.3170312627307039,"score_spread":0.29460717976095996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2373606074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46964106,0.065458275,0.0067907134,0.3917363,0.0023289786,0.00048429833,0.00024920213,0.000043511576,0.06326764],"genre_scores_gemma":[0.98482955,0.0055079428,0.0011244792,0.002432642,0.0011566348,0.000002280925,0.0000034021002,0.00002285207,0.004920198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993033,0.0001283246,0.0002438411,0.00008520279,0.00016220518,0.000077127166],"domain_scores_gemma":[0.99925476,0.000093611394,0.00020493809,0.00018119448,0.00017686305,0.00008861797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002968982,0.00006933054,0.00012453677,0.000021383237,0.00008296892,0.000026572814,0.00009291719,0.000010706583,0.0003734255],"category_scores_gemma":[0.000057735597,0.000030433763,0.00004933706,0.00005344315,0.00008391327,0.00007962236,0.000016165926,0.00010875717,0.000037613394],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022025037,0.000038926806,0.022916727,0.0000036638503,0.00036034794,0.00011292534,0.00044940325,7.601432e-7,0.002245894,0.00031923284,0.08184233,0.8914895],"study_design_scores_gemma":[0.0017851156,0.00010212297,0.24901196,0.00022074091,0.0002612474,0.00005147165,0.000060751056,6.0674273e-7,0.0002797748,0.00015061279,0.74803454,0.00004103059],"about_ca_topic_score_codex":0.000037781338,"about_ca_topic_score_gemma":0.000020802841,"teacher_disagreement_score":0.8914485,"about_ca_system_score_codex":0.00007267913,"about_ca_system_score_gemma":0.00008565142,"threshold_uncertainty_score":0.4088747},"labels":[],"label_agreement":null},{"id":"W2397768676","doi":"10.1016/j.ejca.2016.03.082","title":"RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group","year":2016,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":380,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Canadian Cancer Society Research Institute","keywords":"Response Evaluation Criteria in Solid Tumors; Medicine; Clinical trial; Medical physics; Clinical endpoint; Biomarker; Imaging biomarker; Radiology; Phases of clinical research; Internal medicine; Magnetic resonance imaging","score_opus":0.05869387304731272,"score_gpt":0.3462172372383782,"score_spread":0.2875233641910655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397768676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024684,0.9887686,0.0040614204,0.0037876451,0.00078287727,0.00020873015,0.000043001102,0.0000120083,0.002311069],"genre_scores_gemma":[0.00039550522,0.9929895,0.00094966154,0.00018070327,0.0047941017,0.000004150248,0.000012607638,0.00007824313,0.0005955435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977061,0.000727528,0.0006782851,0.00024582425,0.00048944354,0.00015280856],"domain_scores_gemma":[0.9978621,0.0005512132,0.0008705794,0.0002462193,0.00017873496,0.00029114028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014206278,0.0002292712,0.00075658853,0.000106055246,0.00016430658,0.0001162303,0.00021529,0.000028659508,0.00020504242],"category_scores_gemma":[0.00093679415,0.00011617788,0.0003312728,0.00013236876,0.00027019775,0.00007848246,0.00004721131,0.00081119203,0.000010374958],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008264116,0.000013692939,0.000057413974,0.00016915434,0.0002473563,0.00018678505,0.0006172766,9.687158e-7,0.0000014405531,0.0001504748,0.009310725,0.9891621],"study_design_scores_gemma":[0.00059494295,0.000051232295,0.0011041502,0.038769905,0.0007598386,0.000077102384,0.0002681348,0.0000054603747,1.9840492e-8,0.00007756668,0.9581641,0.00012753099],"about_ca_topic_score_codex":0.000007465061,"about_ca_topic_score_gemma":0.0000017097008,"teacher_disagreement_score":0.98903453,"about_ca_system_score_codex":0.00027003328,"about_ca_system_score_gemma":0.0002972714,"threshold_uncertainty_score":0.47375962},"labels":[],"label_agreement":null},{"id":"W2403529426","doi":"10.1016/j.ejca.2005.04.024","title":"","year":2005,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Nursing Roles and Practices","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"British Columbia Children's Hospital","funders":"","keywords":"Licensure; Nursing; Medicine; Oncology nursing; Health care; Nurse education; Nursing research; Political science","score_opus":0.07619530273324109,"score_gpt":0.45159490868498536,"score_spread":0.37539960595174426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403529426","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030177962,0.021257905,0.00007704322,0.93448,0.013934503,0.00031693367,0.000048271053,0.00003988954,0.026827617],"genre_scores_gemma":[0.0011333069,0.0050744386,0.00074867555,0.7858587,0.17628251,0.0000062322338,0.0000104571145,0.00025818578,0.030627506],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9818536,0.011928947,0.0030870435,0.0003931844,0.0014839907,0.0012532088],"domain_scores_gemma":[0.98602825,0.0016352768,0.0096741095,0.00060989213,0.0017527582,0.0002997238],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006682831,0.0006115656,0.0012658656,0.0004602096,0.0010098807,0.00008177415,0.001484118,0.000493336,0.0030285544],"category_scores_gemma":[0.0004992802,0.0004620513,0.0004989987,0.00024314453,0.00012658162,0.00079083204,0.00016503166,0.022640878,0.00019732991],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004191542,0.000025669235,0.002118301,0.00036519568,0.00032477296,0.0044978084,0.00437921,0.00006657163,0.00005040222,0.0000019553524,0.9250124,0.06273856],"study_design_scores_gemma":[0.0021717697,0.00042731324,0.007079519,0.0059271166,0.00062726333,0.00013239452,0.00067285827,0.0000019242382,0.0000053523404,0.000024078496,0.9824707,0.00045969494],"about_ca_topic_score_codex":0.0000874279,"about_ca_topic_score_gemma":0.00006790143,"teacher_disagreement_score":0.162348,"about_ca_system_score_codex":0.0006572726,"about_ca_system_score_gemma":0.0013557149,"threshold_uncertainty_score":0.9997831},"labels":[],"label_agreement":null},{"id":"W2417591912","doi":"10.1016/j.ejca.2016.05.014","title":"Rethinking end-points for bone-targeted therapy in advanced cancer","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Clinical trial; Oncology; Quality of life (healthcare); Targeted therapy; Placebo; Internal medicine; Cancer; Surgery; Pathology; Alternative medicine","score_opus":0.03743068080916606,"score_gpt":0.32905573617485534,"score_spread":0.2916250553656893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2417591912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95375067,0.014256258,0.0030071402,0.02391993,0.0010756754,0.0006698166,0.000038088252,0.000027435532,0.003254966],"genre_scores_gemma":[0.9848889,0.00466625,0.0045781294,0.0029340587,0.00046645012,0.00001937531,0.000001335598,0.00006627552,0.0023792125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983449,0.00019715281,0.0006014354,0.00017464503,0.00041951932,0.00026234973],"domain_scores_gemma":[0.99878305,0.000094388306,0.00047647566,0.00019338823,0.00028664555,0.00016606979],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013630129,0.00015022304,0.0003549261,0.00020209834,0.000029727895,0.000013895159,0.00015389406,0.000014408738,0.0011666445],"category_scores_gemma":[0.0003010367,0.000093026116,0.0001632537,0.0001320359,0.000045762852,0.00018033688,0.000024337418,0.00014967342,0.000009350163],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004433556,0.00015938134,0.016000787,0.0001110889,0.00028672,0.0006091128,0.0010910664,0.000038126775,0.028162817,0.00010368209,0.0098042805,0.9391994],"study_design_scores_gemma":[0.054509822,0.002123784,0.4366456,0.005366927,0.00041379442,0.000046229354,0.0002886032,0.00008386403,0.013798554,0.0017709903,0.48437843,0.00057341316],"about_ca_topic_score_codex":0.000006984965,"about_ca_topic_score_gemma":0.000015050852,"teacher_disagreement_score":0.938626,"about_ca_system_score_codex":0.00015491371,"about_ca_system_score_gemma":0.000175066,"threshold_uncertainty_score":0.99974644},"labels":[],"label_agreement":null},{"id":"W2473895779","doi":"10.1016/j.ejca.2016.05.027","title":"Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Febrile neutropenia; Schema (genetic algorithms); Population; Receiver operating characteristic; Risk stratification; Predictive value; Pediatrics; Clinical prediction rule; Young adult; Neutropenia; Intensive care medicine; Internal medicine; Machine learning; Environmental health","score_opus":0.011542792625811583,"score_gpt":0.26828698563911757,"score_spread":0.256744193013306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2473895779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950282,0.00079844537,0.0001338403,0.0012465802,0.0003863687,0.00024709117,0.000023127479,0.0000091430165,0.0021272262],"genre_scores_gemma":[0.9960143,0.002883403,0.00006765926,0.00023125662,0.00032823114,0.000013224823,0.0000012930354,0.000038622467,0.00042201512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851966,0.0002387733,0.0005277067,0.00018486903,0.0003052683,0.00022370802],"domain_scores_gemma":[0.998786,0.00002216275,0.00045250132,0.0001760083,0.00043890518,0.00012443331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028046253,0.00014366135,0.0002724294,0.00020162485,0.000038774564,0.000021747566,0.00012316718,0.000020224801,0.00031536564],"category_scores_gemma":[0.0000453084,0.00008530553,0.00006677399,0.00028666295,0.00006049778,0.00027606424,0.000016003853,0.00032216668,0.000019692123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082927186,0.0001772887,0.9293768,0.000020951933,0.0000412191,0.000054129065,0.00015892326,0.00011979118,0.002242859,0.000018286004,0.00096574944,0.065994754],"study_design_scores_gemma":[0.006590626,0.00039022154,0.98745435,0.0015183395,0.00008055354,0.000015144443,0.000041011306,0.0000032927617,0.0012223297,0.00000754003,0.002556371,0.00012024379],"about_ca_topic_score_codex":0.00041028645,"about_ca_topic_score_gemma":0.0036625518,"teacher_disagreement_score":0.06587451,"about_ca_system_score_codex":0.00039649184,"about_ca_system_score_gemma":0.00022587634,"threshold_uncertainty_score":0.34786585},"labels":[],"label_agreement":null},{"id":"W2485724366","doi":"10.1016/j.ejca.2016.06.014","title":"Corrigendum to “Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group” [Eur J Cancer 49 (2013) 1905–1914]","year":2016,"lang":"de","type":"erratum","venue":"European Journal of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Regret; Cohort; Medicine; Ovary; Gynecology; Cohort study; General surgery; University hospital; Surgery; Internal medicine","score_opus":0.0381080573998257,"score_gpt":0.31478450691716864,"score_spread":0.27667644951734294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485724366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7127463,0.11671725,0.000038406335,0.018588925,0.13364565,0.011118497,0.000995167,0.00004625903,0.0061035138],"genre_scores_gemma":[0.94112414,0.025025172,0.000044561784,0.001284136,0.00869589,0.00026743702,0.000009143802,0.00033831393,0.023211217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9864486,0.0039225067,0.0038872778,0.001283183,0.0032797658,0.0011786519],"domain_scores_gemma":[0.9868903,0.000287567,0.007067521,0.0027918152,0.0023500465,0.00061271316],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004395789,0.0014360438,0.0034519692,0.00052067277,0.0004403319,0.00007357705,0.0032521628,0.0002479576,0.0015431495],"category_scores_gemma":[0.00078817684,0.0006996956,0.0012642158,0.0013411333,0.00063558255,0.00016858173,0.0012423885,0.0027566,0.000077530145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014401954,0.0061688703,0.65757304,0.00016853816,0.007817895,0.00072649185,0.002897102,0.0002840772,0.00009293878,0.000009253359,0.31266928,0.0101523185],"study_design_scores_gemma":[0.009211323,0.009452664,0.7103628,0.0040112697,0.0101498775,0.000029316541,0.0019408911,0.0000047793446,0.00013870434,0.0000058280502,0.2541649,0.0005276561],"about_ca_topic_score_codex":0.0030687281,"about_ca_topic_score_gemma":0.0055921585,"teacher_disagreement_score":0.22837779,"about_ca_system_score_codex":0.0011640473,"about_ca_system_score_gemma":0.0028091143,"threshold_uncertainty_score":0.99983895},"labels":[],"label_agreement":null},{"id":"W2493582367","doi":"10.1016/j.ejca.2016.06.005","title":"Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Sick Kids Foundation; William Guy Forbeck Research Foundation; Super Jake Foundation; Children's Neuroblastoma Cancer Foundation","keywords":"Neuroblastoma; Medicine; Oncology; Stage (stratigraphy); Disease; Internal medicine; Database; Computer science; Biology","score_opus":0.014549053758881237,"score_gpt":0.2666189714566038,"score_spread":0.2520699176977226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2493582367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978931,0.00016053629,0.00019660228,0.0004099314,0.00007923167,0.0006173921,0.0006241289,0.0000041153767,0.000014965408],"genre_scores_gemma":[0.99958247,0.00013309356,0.00007993699,0.000047593538,0.00006842057,0.000008569641,0.000004360298,0.000035102352,0.000040458286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976496,0.0006081875,0.00052488013,0.00022807655,0.00081548793,0.00017377427],"domain_scores_gemma":[0.9981889,0.00040233272,0.000637767,0.00027402764,0.0002860438,0.00021091982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036306118,0.00016286402,0.0003052314,0.00014217163,0.000025896188,0.000015985157,0.00026094433,0.000004120612,0.00007149456],"category_scores_gemma":[0.00039990156,0.00007955815,0.000057473182,0.00014629554,0.00015671983,0.00018290438,0.00012015676,0.00020502537,0.0000029325608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005442832,0.0011504346,0.9738843,0.000038139864,0.00037636133,0.0014041084,0.00032010366,0.00004778509,0.0024791507,4.4816997e-7,0.00005703472,0.014799332],"study_design_scores_gemma":[0.011386245,0.0040618223,0.9829169,0.00069026387,0.00028509588,0.0000047544304,0.00009469892,0.000037811868,0.00033517153,0.0000027105168,0.00011678391,0.00006773886],"about_ca_topic_score_codex":0.00018796448,"about_ca_topic_score_gemma":0.00011315651,"teacher_disagreement_score":0.014731593,"about_ca_system_score_codex":0.0000386407,"about_ca_system_score_gemma":0.00011274683,"threshold_uncertainty_score":0.32442874},"labels":[],"label_agreement":null},{"id":"W2499943641","doi":"10.1016/j.ejca.2016.06.023","title":"Honorary and ghost authorship in reports of randomised clinical trials in oncology","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Women's College Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medical journal; Transparency (behavior); Medicine; Clinical trial; Alternative medicine; Family medicine; Protocol (science); Internal medicine; Political science; Pathology; Law","score_opus":0.892526213170257,"score_gpt":0.6578023290602959,"score_spread":0.23472388410996115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2499943641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97910744,0.0066842004,0.001316553,0.003709818,0.00092813384,0.0003561383,0.0000029435996,5.4438027e-7,0.0078942],"genre_scores_gemma":[0.99626833,0.00089664274,0.0007486664,0.00016036269,0.00025443797,0.0000020402858,5.793859e-8,0.000007779027,0.0016616645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.61247706,0.30879977,0.07350138,0.00089531235,0.003971042,0.00035545303],"domain_scores_gemma":[0.94992024,0.024176115,0.024233602,0.0008115201,0.00066625996,0.00019223834],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.68612796,0.00012509953,0.005395817,0.0004908467,0.000012380115,0.00007084344,0.000527815,0.00004466976,0.0028383164],"category_scores_gemma":[0.2613563,0.000045615623,0.001277049,0.00044669985,0.0000985831,0.00017157567,0.000062485204,0.0002144078,0.00003786587],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011946842,0.00007393743,0.38040122,0.000014852315,0.00016226758,0.00081095024,0.0006035129,0.000015140833,0.0005809842,0.000038692688,0.026260931,0.5898428],"study_design_scores_gemma":[0.017537346,0.00042003745,0.66058034,0.0007621561,0.00028080947,0.00018230293,0.00025021532,0.00004126094,0.000099376135,0.0030153652,0.31666717,0.00016360986],"about_ca_topic_score_codex":0.0000043985397,"about_ca_topic_score_gemma":0.0000439527,"teacher_disagreement_score":0.5896792,"about_ca_system_score_codex":0.000034345758,"about_ca_system_score_gemma":0.00023766285,"threshold_uncertainty_score":0.9980732},"labels":[],"label_agreement":null},{"id":"W2507098989","doi":"10.1016/j.ejca.2016.06.016","title":"First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; University of Calgary","funders":"","keywords":"Pazopanib; Sunitinib; Renal cell carcinoma; Medicine; Oncology; Internal medicine","score_opus":0.06636657144106892,"score_gpt":0.29226668905466274,"score_spread":0.22590011761359383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507098989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783051,0.0045637903,0.00028472694,0.006831165,0.00118769,0.00039012864,0.0011588322,0.000015481015,0.0072630583],"genre_scores_gemma":[0.99396473,0.0005718883,0.001693312,0.00044600587,0.001087608,0.000010850071,0.00011505089,0.00009083819,0.0020196938],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99534553,0.00084969646,0.0016299138,0.00050687336,0.0011589198,0.0005090582],"domain_scores_gemma":[0.99570876,0.0014386377,0.0011806729,0.0007136564,0.0005495153,0.0004087558],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017824266,0.00044415978,0.00067882723,0.0002843663,0.00010092326,0.00006637548,0.0006963339,0.000027464637,0.0009307486],"category_scores_gemma":[0.0005715926,0.0002480697,0.0003337076,0.00027234803,0.0002122328,0.00029298774,0.00019741108,0.0006027286,0.00011836863],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.153783,0.005337773,0.10571396,0.0005501036,0.003918174,0.13681468,0.01155808,0.0025496671,0.35992697,0.00013775607,0.16003557,0.059674278],"study_design_scores_gemma":[0.1649434,0.006962664,0.45404702,0.0021952153,0.004903525,0.0010281861,0.0015427055,0.00046667206,0.25784582,0.00009386443,0.10465123,0.0013196819],"about_ca_topic_score_codex":0.0006575331,"about_ca_topic_score_gemma":0.00053371093,"teacher_disagreement_score":0.34833306,"about_ca_system_score_codex":0.0005789714,"about_ca_system_score_gemma":0.000632924,"threshold_uncertainty_score":0.99999714},"labels":[],"label_agreement":null},{"id":"W2508265726","doi":"10.1016/s0959-8049(16)30480-4","title":"1054 Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Cancer Care Ontario; Mount Sinai Hospital","funders":"National Cancer Institute; National Health and Medical Research Council; California Department of Public Health; Medical Research Council; Centers for Disease Control and Prevention; University of Southern California","keywords":"MUTYH; Medicine; Genetics; Mutation; Biology; Gene; Germline mutation","score_opus":0.014550937670041127,"score_gpt":0.2533710973793629,"score_spread":0.2388201597093218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508265726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.921675,0.07648377,0.0005266979,0.00026640063,0.0003130207,0.00013544873,0.000018057104,0.000004596164,0.00057698344],"genre_scores_gemma":[0.99796987,0.0014963235,0.00011870529,0.00004061168,0.000009248353,0.0000064794995,0.0000035615226,0.000015979851,0.00033921626],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906504,0.00023842206,0.00038157517,0.00009909707,0.000041413925,0.0001744269],"domain_scores_gemma":[0.99918514,0.0000737434,0.00043471254,0.00009092116,0.00020320767,0.000012248035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007018046,0.00009828852,0.00025655088,0.00013372998,0.00006294982,0.0000074830396,0.00015426017,0.000028783401,0.00003744175],"category_scores_gemma":[0.0000965108,0.00007577068,0.000056039044,0.00014391886,0.00014338201,0.00009786355,0.00001900926,0.00021031844,0.000003810756],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011909163,0.0010801418,0.12986183,0.00032143094,0.0027867118,0.00009827822,0.11092005,0.1058665,0.13631816,0.0008033013,0.005100866,0.49493358],"study_design_scores_gemma":[0.036636677,0.00564638,0.7406902,0.00083783234,0.0007256289,0.00027219098,0.018310137,0.00026990296,0.010472482,0.00043635964,0.1848934,0.0008088633],"about_ca_topic_score_codex":0.00043420726,"about_ca_topic_score_gemma":0.00041609304,"teacher_disagreement_score":0.61082834,"about_ca_system_score_codex":0.000056621848,"about_ca_system_score_gemma":0.00031593308,"threshold_uncertainty_score":0.3089839},"labels":[],"label_agreement":null},{"id":"W2508992109","doi":"10.1016/s0959-8049(16)31275-8","title":"2359 Optimal therapeutic sequences in the treatment of metastatic pancreatic cancer - a retrospective analysis from two Canadian and French tertiary cancer centres","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pancreatic cancer; Medicine; Oncology; Cancer; Internal medicine","score_opus":0.05599249045552915,"score_gpt":0.369556063328398,"score_spread":0.31356357287286885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508992109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94077104,0.054813214,0.000029779907,0.0027570443,0.00008651549,0.00025776293,0.000075921795,0.0000026830214,0.0012060176],"genre_scores_gemma":[0.98575133,0.012771076,0.00037900795,0.00034934506,0.00027406894,0.000021949889,0.000004641507,0.000016342072,0.00043224593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977678,0.00073831866,0.0005119903,0.00019096886,0.00048193606,0.0003090016],"domain_scores_gemma":[0.9986428,0.00018106047,0.0003183846,0.00019831455,0.0003216403,0.00033779012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076460955,0.00017793615,0.00080472213,0.00036990616,0.000053062573,0.000026856802,0.00017695807,0.000021733462,0.00050593587],"category_scores_gemma":[0.00005991672,0.00009984065,0.00014557099,0.00051691604,0.00023318044,0.00008524051,0.00001117718,0.00021063989,0.0000019765325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024449412,0.000107821004,0.9740154,0.00001173527,0.003455546,0.0005961498,0.009477567,0.00048406553,0.00010282331,0.0000065283984,0.0003928868,0.011104977],"study_design_scores_gemma":[0.0032881047,0.0009839336,0.9843697,0.00018673419,0.0053023854,0.00002983396,0.001642623,0.0011539955,0.000101501,0.000063171894,0.0027792545,0.00009878459],"about_ca_topic_score_codex":0.33051065,"about_ca_topic_score_gemma":0.26882038,"teacher_disagreement_score":0.061690297,"about_ca_system_score_codex":0.00078305573,"about_ca_system_score_gemma":0.0015706792,"threshold_uncertainty_score":0.74452174},"labels":[],"label_agreement":null},{"id":"W2511816660","doi":"10.1016/s0959-8049(16)31601-x","title":"2863 A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Cisplatin; Medicine; Radiation therapy; Head and neck cancer; Cancer; Head and neck; Oncology; Adjuvant radiotherapy; Internal medicine; Chemotherapy; Surgery","score_opus":0.0645999853644802,"score_gpt":0.36645707695452395,"score_spread":0.30185709159004376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511816660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9310071,0.064316,0.00017425632,0.0024363946,0.001164562,0.00021799357,0.000042207426,0.000011983108,0.0006295439],"genre_scores_gemma":[0.98850733,0.0073815025,0.002056149,0.00013061713,0.0013278931,0.0000075526646,9.980631e-7,0.000054062697,0.0005338694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983688,0.00012719903,0.0006788092,0.00017879151,0.00038326613,0.00026315806],"domain_scores_gemma":[0.9983397,0.00008717361,0.00065693597,0.0001488978,0.00048025165,0.00028702256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052816456,0.00019178109,0.0008347858,0.00011698119,0.000083033054,0.000015277776,0.00011067966,0.000028583303,0.00004584044],"category_scores_gemma":[0.00013457761,0.00014646258,0.000121467674,0.00012601963,0.00009907488,0.00010105032,0.00003102344,0.0002749133,0.0000013395147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04676603,0.00049128575,0.42140776,0.00074775796,0.0028657913,0.00023220232,0.017994197,0.0013228841,0.01853537,0.000046460944,0.070575,0.4190153],"study_design_scores_gemma":[0.066866115,0.013722859,0.7878462,0.0027860347,0.00093538745,0.000065409375,0.0015687463,0.00041894327,0.010522721,0.000018433828,0.11480638,0.0004427709],"about_ca_topic_score_codex":0.00023572455,"about_ca_topic_score_gemma":0.0002154931,"teacher_disagreement_score":0.41857252,"about_ca_system_score_codex":0.00021569732,"about_ca_system_score_gemma":0.00027193254,"threshold_uncertainty_score":0.5972571},"labels":[],"label_agreement":null},{"id":"W2513592679","doi":"10.1016/j.ejca.2016.07.012","title":"Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Cribriform; Medicine; Prostate cancer; Cancer; Biopsy; Oncology; Carcinoma; Internal medicine; Radiology","score_opus":0.02244419264009068,"score_gpt":0.2829175789407968,"score_spread":0.2604733863007061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513592679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838852,0.008602146,0.000019615307,0.0059326217,0.0001430728,0.0002855396,0.000077238525,0.000009190291,0.0010453315],"genre_scores_gemma":[0.9904216,0.0072611594,0.0004409066,0.00018173653,0.00022774801,0.000012406088,8.84837e-7,0.000049070455,0.0014044817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987708,0.00005527025,0.00042693963,0.00018106896,0.0003388039,0.00022717002],"domain_scores_gemma":[0.9987541,0.000030797335,0.00048206738,0.00016195406,0.00033820252,0.00023287993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020910875,0.00020225356,0.00050563837,0.00009509897,0.00003550665,0.00001688286,0.00008517398,0.000015859598,0.00017811974],"category_scores_gemma":[0.000029369803,0.000086254826,0.00007553547,0.00010417255,0.00017574459,0.00018089662,0.000030771746,0.000107552376,0.000002094777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026713326,0.00008471007,0.8812215,0.00010008416,0.00047894722,0.00048101498,0.0006356484,0.0000016817032,0.0041230754,0.000012825876,0.0012055038,0.10898371],"study_design_scores_gemma":[0.008258194,0.0025013213,0.95941687,0.0019676234,0.00045240798,0.000464257,0.00016078334,0.0000021029039,0.020795649,0.0000064423816,0.0058246865,0.00014964455],"about_ca_topic_score_codex":0.00010618275,"about_ca_topic_score_gemma":0.00003916793,"teacher_disagreement_score":0.108834065,"about_ca_system_score_codex":0.00019525069,"about_ca_system_score_gemma":0.00037959171,"threshold_uncertainty_score":0.35173696},"labels":[],"label_agreement":null},{"id":"W2514479109","doi":"10.1016/s0959-8049(16)31240-0","title":"2324 Anal Cancer (AC): Chemotherapy treatment trends over time from 1989 to 2010 at the Ottawa Hospital Cancer Centre, Ottawa, Canada","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anal cancer; Cancer; Cancer treatment; Gerontology; Internal medicine","score_opus":0.012564298295751985,"score_gpt":0.25327848467958014,"score_spread":0.24071418638382816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514479109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93998146,0.013346166,0.0000024156438,0.037076723,0.002005071,0.00016086416,0.00037280668,0.000013920026,0.007040566],"genre_scores_gemma":[0.9010038,0.00069231493,0.00005014346,0.0047533945,0.004322899,0.000010417844,0.000018031053,0.00008602764,0.089062974],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977693,0.00016047679,0.0005437012,0.0002999081,0.00079603604,0.00043060072],"domain_scores_gemma":[0.9981448,0.000044904904,0.00038728197,0.00028078127,0.00036736295,0.0007748649],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025914278,0.00033832964,0.0005342261,0.00010302385,0.00010373945,0.00004024215,0.00026744622,0.000033006705,0.008678068],"category_scores_gemma":[0.000027079588,0.00019976792,0.0002575375,0.00031531355,0.00007497908,0.000089340494,0.00005836185,0.00028090298,0.00004962169],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000988169,0.00011842101,0.109595515,0.0000051753937,0.00065933756,0.00069792784,0.0015051018,0.0002668657,0.0017627022,0.0000011017647,0.76676464,0.117635064],"study_design_scores_gemma":[0.0031888036,0.0007335274,0.36806974,0.00012955841,0.00027542916,0.000023501763,0.000094784664,0.000061285245,0.0017267752,0.0000014679058,0.6254872,0.00020796117],"about_ca_topic_score_codex":0.35180387,"about_ca_topic_score_gemma":0.60421497,"teacher_disagreement_score":0.2584742,"about_ca_system_score_codex":0.0024420272,"about_ca_system_score_gemma":0.0014532576,"threshold_uncertainty_score":0.99222815},"labels":[],"label_agreement":null},{"id":"W2517282813","doi":"10.1016/s0959-8049(16)31256-4","title":"2340 A registry of real-world clinical practice on the use of FOLFIRINOX (FFX) in advanced pancreatic cancer (aPC) patients in Canada","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"FOLFIRINOX; Medicine; Cancer registry; Pancreatic cancer; Clinical Practice; Cancer; Oncology; Internal medicine; General surgery; Oxaliplatin; Family medicine","score_opus":0.15866199911647158,"score_gpt":0.42911767129132805,"score_spread":0.27045567217485644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517282813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857491,0.0007732009,0.000004939686,0.0028709034,0.00030140206,0.00030036518,0.000017589582,0.0000015881882,0.009980892],"genre_scores_gemma":[0.9937027,0.0034799164,0.0007556292,0.0009005806,0.0001623179,0.000007318357,0.0000012485722,0.000024926623,0.0009653293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960742,0.0012722671,0.0013935107,0.00015741972,0.000842053,0.00026052076],"domain_scores_gemma":[0.99574447,0.0015637896,0.0012110759,0.00035243173,0.00089056895,0.00023763737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023820717,0.00013424462,0.0007855017,0.00016068068,0.000016151713,0.000005730706,0.00024491752,0.0000296291,0.000090186615],"category_scores_gemma":[0.005407757,0.00008567877,0.00008236754,0.00037978718,0.00015433229,0.00013333977,0.000051509913,0.00072534004,0.0000020675332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004359324,0.00031799258,0.9675685,0.000052353134,0.00015611177,0.00048615734,0.00037842503,0.00035887095,0.000024738414,0.000030039899,0.012886174,0.013381271],"study_design_scores_gemma":[0.0052467515,0.0010227142,0.9612983,0.0014793916,0.00016926871,0.00001225729,0.00046110482,0.00011700284,0.00006880745,0.000008411788,0.030039985,0.00007603331],"about_ca_topic_score_codex":0.39895976,"about_ca_topic_score_gemma":0.5357916,"teacher_disagreement_score":0.13683185,"about_ca_system_score_codex":0.0009321885,"about_ca_system_score_gemma":0.005497653,"threshold_uncertainty_score":0.97526},"labels":[],"label_agreement":null},{"id":"W2521342286","doi":"10.1016/j.ejca.2016.08.013","title":"Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Cisplatin; Human papillomavirus; Medicine; Head and neck; Head and neck squamous-cell carcinoma; Oncology; Basal cell; Head and neck cancer; Internal medicine; Chemotherapy; Cancer; Surgery","score_opus":0.02518798638717055,"score_gpt":0.3171745430417009,"score_spread":0.2919865566545303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521342286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98799205,0.0067219655,0.000007689997,0.0004816184,0.00014505442,0.00013471703,0.000012736315,0.0000119857405,0.004492188],"genre_scores_gemma":[0.99810934,0.0009628473,0.00006111586,0.00015212253,0.00010292632,6.2571127e-7,5.311048e-7,0.000038351624,0.000572157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985994,0.00012681923,0.00060249685,0.00019298644,0.0002470142,0.00023130172],"domain_scores_gemma":[0.9986948,0.000073887946,0.00043421952,0.0001628205,0.00037313643,0.00026118412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003439921,0.0002105925,0.0006164439,0.00013157135,0.00007855039,0.000008099119,0.000070351714,0.00003892721,0.00010297641],"category_scores_gemma":[0.000099850695,0.00012040735,0.0001359194,0.00011671483,0.00018879795,0.00009734453,0.000052181324,0.00029411612,0.0000054007032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00864353,0.00030541862,0.46601647,0.0001492547,0.00035177896,0.0012284198,0.0022907802,0.000034196615,0.38928908,0.000017623652,0.0027827884,0.12889066],"study_design_scores_gemma":[0.012971875,0.008227839,0.97041357,0.001119139,0.00013915707,0.00014276097,0.000047629244,0.0000075960347,0.006111722,0.000013279032,0.00065766927,0.00014775526],"about_ca_topic_score_codex":0.00005812076,"about_ca_topic_score_gemma":0.000015296324,"teacher_disagreement_score":0.5043971,"about_ca_system_score_codex":0.00012779415,"about_ca_system_score_gemma":0.000110136156,"threshold_uncertainty_score":0.4910069},"labels":[],"label_agreement":null},{"id":"W2522519290","doi":"10.1016/j.ejca.2016.08.004","title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharma; Exelixis; Canadian Centre for Applied Research in Cancer Control; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Everolimus; Medicine; Oncology; Renal cell carcinoma; Internal medicine; Urology","score_opus":0.05198801059173726,"score_gpt":0.31286978979389846,"score_spread":0.2608817792021612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522519290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959416,0.0018198786,0.00045595533,0.0004467193,0.00012357741,0.0006069699,0.000051053157,0.0000037639834,0.00055048056],"genre_scores_gemma":[0.9974429,0.00040215784,0.0012097306,0.000107978194,0.00019329089,0.000008182871,0.000007969057,0.0000512576,0.00057650835],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973423,0.00041600651,0.001027695,0.00026233704,0.000689359,0.00026234146],"domain_scores_gemma":[0.99778354,0.00010376415,0.0010429439,0.0003637361,0.00046970815,0.00023628591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007589544,0.0002602713,0.0009310543,0.00047845428,0.000034679244,0.000020181924,0.0003263737,0.000020645024,0.0004025179],"category_scores_gemma":[0.000041524414,0.000140617,0.00021043612,0.00053713046,0.000080386315,0.00020272486,0.00005554113,0.00017475098,0.0000055996597],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6211934,0.010383301,0.2858931,0.00011314736,0.0038707554,0.0024838056,0.0006654763,0.00033957904,0.0054815016,0.0000020021212,0.0011978375,0.0683761],"study_design_scores_gemma":[0.6920449,0.033656634,0.25885105,0.00038463683,0.003458039,0.000017787177,0.00002285479,0.00003822896,0.009342661,0.0000049793525,0.0019269226,0.0002512972],"about_ca_topic_score_codex":0.000051968913,"about_ca_topic_score_gemma":0.00003857105,"teacher_disagreement_score":0.070851535,"about_ca_system_score_codex":0.00026163933,"about_ca_system_score_gemma":0.0002601056,"threshold_uncertainty_score":0.5734195},"labels":[],"label_agreement":null},{"id":"W2525777679","doi":"10.1016/j.ejca.2016.08.022","title":"The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Women's College Hospital; Institute for Clinical Evaluative Sciences","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Tamoxifen; Hazard ratio; Breast cancer; Internal medicine; Proportional hazards model; Population; Myocardial infarction; Confounding; Gynecology; Lower risk; Oncology; Cancer; Confidence interval","score_opus":0.002258297436419322,"score_gpt":0.20662796002816702,"score_spread":0.2043696625917477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525777679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978443,0.000908371,0.0000877024,0.0005641784,0.00012516307,0.00013110528,0.000121821824,0.0000023265256,0.00021508172],"genre_scores_gemma":[0.9982233,0.001079473,0.00004901532,0.000058498023,0.00028368237,0.0000077233635,0.000001105798,0.000029612513,0.00026757803],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998864,0.0003238823,0.0002581622,0.00013830137,0.00020913171,0.00020652042],"domain_scores_gemma":[0.99910706,0.000023031153,0.0003724374,0.0001473449,0.00022209904,0.0001280543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045466676,0.00012962156,0.00014869346,0.00005787793,0.00005641404,0.000015355843,0.00014003218,0.000032942462,0.000011220126],"category_scores_gemma":[0.000031531577,0.000058864174,0.000028856506,0.00012373478,0.00011302342,0.00001935114,0.000041148705,0.00018181819,0.00000297127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012845464,0.000058889425,0.07732948,0.000008475085,0.00121133,0.00010863898,0.0012608217,0.00095763407,0.8714304,0.000010220368,0.0007426109,0.03403605],"study_design_scores_gemma":[0.0039805877,0.008859602,0.9124027,0.00041502927,0.00012910477,0.00010043595,0.00027424292,8.72017e-7,0.06306141,0.000006553603,0.010500058,0.0002694388],"about_ca_topic_score_codex":0.00009843014,"about_ca_topic_score_gemma":0.000078583544,"teacher_disagreement_score":0.8350732,"about_ca_system_score_codex":0.00007606569,"about_ca_system_score_gemma":0.00018327824,"threshold_uncertainty_score":0.24004114},"labels":[],"label_agreement":null},{"id":"W2529000802","doi":"10.1016/s0959-8049(16)31512-x","title":"2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"BRCA mutation; Medicine; Ovarian cancer; Oncology; Internal medicine; Cancer","score_opus":0.08533086144846243,"score_gpt":0.36591788917226764,"score_spread":0.2805870277238052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529000802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965072,0.0015636386,0.00006315637,0.00045844208,0.00019259298,0.0009364191,0.00003090844,0.0000026423384,0.0002449593],"genre_scores_gemma":[0.9988847,0.00027332327,0.00038104304,0.00025874883,0.000102408114,0.000027236712,0.0000037561715,0.000027774688,0.000041060393],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99826586,0.00038654092,0.0006245591,0.00014225238,0.00045313305,0.00012762976],"domain_scores_gemma":[0.99844515,0.00003575129,0.0007371606,0.00018456276,0.000487005,0.00011036631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044703955,0.00014384776,0.0003816925,0.00012346671,0.000026500898,0.000024363711,0.00013830028,0.0000139832255,0.00003959249],"category_scores_gemma":[0.00002311925,0.00008454819,0.000027070177,0.00017969834,0.00007161336,0.00013899834,0.000016232174,0.0001047393,5.259408e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07592023,0.059004027,0.3371652,0.0001401572,0.0019351225,0.0014354876,0.21790972,0.0009853927,0.008663172,0.000006225303,0.001830213,0.29500505],"study_design_scores_gemma":[0.51920533,0.11971546,0.3254942,0.0018461699,0.0012003061,0.00008369805,0.008419341,0.00017900353,0.004426102,0.000010386875,0.019052431,0.00036756526],"about_ca_topic_score_codex":0.00027777016,"about_ca_topic_score_gemma":0.0002343664,"teacher_disagreement_score":0.4432851,"about_ca_system_score_codex":0.00031408056,"about_ca_system_score_gemma":0.00017459919,"threshold_uncertainty_score":0.34477752},"labels":[],"label_agreement":null},{"id":"W2530161807","doi":"10.1016/j.ejca.2016.09.012","title":"The role of S100a4 (Mts1) in Apc- and Smad4-driven tumour onset and progression","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Erasmus+; Nova Scotia Health Research Foundation; Danish Cancer Society Research Center","keywords":"Medicine; Cancer research","score_opus":0.005061197791213262,"score_gpt":0.24786141754280916,"score_spread":0.2428002197515959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530161807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98476815,0.014069086,0.00003759932,0.00047058216,0.000041672898,0.0000440642,0.0000056313474,7.6620955e-7,0.00056247466],"genre_scores_gemma":[0.9964144,0.003127399,0.00011407923,0.000033553293,0.00014133251,9.661178e-7,2.8408243e-7,0.000009947971,0.00015802402],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994753,0.00011047564,0.00017593271,0.000076021,0.00007305095,0.0000891995],"domain_scores_gemma":[0.99965143,0.000010138877,0.00016060172,0.00007047046,0.000060938746,0.000046392335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031409503,0.000057515117,0.00007807383,0.000021043596,0.000031842777,0.000011671643,0.00009129731,0.0000150921,0.000005630564],"category_scores_gemma":[0.000042920143,0.000028585378,0.000026424113,0.000022645138,0.00008926362,0.000004395205,0.00006098656,0.00005216932,4.020348e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000188269,0.000016451622,0.04602597,0.0000054060283,0.000020751633,0.0000139593385,0.000065070475,0.0000019753422,0.6956154,0.000022459684,0.00031806616,0.2577062],"study_design_scores_gemma":[0.0019190783,0.001078072,0.25732598,0.0005404723,0.000018788664,0.00010512999,0.00021164185,0.000012451418,0.50405693,0.00015459654,0.23441926,0.00015759785],"about_ca_topic_score_codex":0.0000033119777,"about_ca_topic_score_gemma":0.000021895414,"teacher_disagreement_score":0.2575486,"about_ca_system_score_codex":0.0000043998366,"about_ca_system_score_gemma":0.000033945176,"threshold_uncertainty_score":0.11656779},"labels":[],"label_agreement":null},{"id":"W2531995633","doi":"10.1016/j.ejca.2016.09.007","title":"Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence","year":2016,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto","funders":"","keywords":"Medicine; Tamoxifen; Breast cancer; Aromatase; Adverse effect; Oncology; Internal medicine; Aromatase inhibitor; Gynecology; Randomized controlled trial; Exemestane; Meta-analysis; Cancer; Osteoporosis","score_opus":0.011175146847431656,"score_gpt":0.2418031503096809,"score_spread":0.23062800346224924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531995633","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24552296,0.64595675,0.00052404037,0.100700386,0.003633804,0.00050863664,0.00016212325,0.000020644453,0.0029706627],"genre_scores_gemma":[0.4492098,0.16809022,0.0003840495,0.2261202,0.14843754,0.000031440344,0.00007644389,0.00082583574,0.0068244673],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962517,0.001989084,0.00050853,0.00034096173,0.00056144415,0.00034826976],"domain_scores_gemma":[0.9980224,0.000088123255,0.00076581544,0.00076912186,0.0002377958,0.000116766416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002345227,0.00034140926,0.00038356317,0.000076765806,0.00013703966,0.00007587229,0.0007044016,0.00024528796,0.000048657894],"category_scores_gemma":[0.00035726328,0.00018089681,0.00092750473,0.000080606726,0.00015972133,0.000011167776,0.00017930879,0.0015224161,0.00005575109],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013654945,0.000007212118,0.00032645246,0.000039904553,0.0019668478,0.001721646,0.00007512432,0.00011133038,0.011371887,2.5294523e-7,0.94414234,0.04010043],"study_design_scores_gemma":[0.00056701014,0.00026813665,0.0001251964,0.001090335,0.0006971465,0.00031031083,0.000013118715,5.5316997e-7,0.010415466,0.000004889526,0.98622817,0.00027966648],"about_ca_topic_score_codex":0.000028593779,"about_ca_topic_score_gemma":7.934854e-7,"teacher_disagreement_score":0.47786653,"about_ca_system_score_codex":0.00005020138,"about_ca_system_score_gemma":0.00020146368,"threshold_uncertainty_score":0.7376758},"labels":[],"label_agreement":null},{"id":"W2533300945","doi":"10.1016/j.ejca.2016.08.021","title":"The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?","year":2016,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Breast cancer; Medicine; Internal medicine; Oncology; Prospective cohort study; Cancer; Scopus; Gynecology; MEDLINE; Biology","score_opus":0.01591910921600549,"score_gpt":0.2623460576485192,"score_spread":0.24642694843251373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533300945","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042560387,0.08452418,0.00053254695,0.8463398,0.008490567,0.0022315576,0.008596409,0.000049862065,0.0066746627],"genre_scores_gemma":[0.52028614,0.15647477,0.0007308402,0.20192468,0.1006591,0.00091531436,0.00018905655,0.001095813,0.017724259],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965444,0.0009382418,0.0007432602,0.00055551523,0.00059022085,0.0006283301],"domain_scores_gemma":[0.9971658,0.00022987681,0.0012102068,0.00045304923,0.00083243503,0.00010861215],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006786282,0.0005379804,0.00053196907,0.00010082854,0.00018571551,0.00008532468,0.00087677146,0.00018624686,0.00006542133],"category_scores_gemma":[0.00027171156,0.0002924585,0.00024137911,0.00015998981,0.00043704346,0.000020834259,0.00026392788,0.0010823857,0.00001285966],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034755408,0.000065462744,0.05518353,0.00008493241,0.0020863009,0.0011032072,0.00056879624,0.000048356287,0.0010167379,8.4312734e-7,0.8626281,0.07373817],"study_design_scores_gemma":[0.003023162,0.0007020462,0.24471913,0.0028963138,0.00043316363,0.00037247117,0.000052840303,0.0000017228851,0.0030712984,0.00002350895,0.74404,0.0006643347],"about_ca_topic_score_codex":0.00012280777,"about_ca_topic_score_gemma":0.00025226062,"teacher_disagreement_score":0.64441514,"about_ca_system_score_codex":0.000303225,"about_ca_system_score_gemma":0.00078051497,"threshold_uncertainty_score":0.99995273},"labels":[],"label_agreement":null},{"id":"W2549598588","doi":"10.1016/j.ejca.2016.10.017","title":"Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"Prostate Cancer Canada; McMaster University","keywords":"Androgen receptor; Cell biology; Nuclear receptor; Biology; Epidermal growth factor receptor; Paracrine signalling; Receptor; Transcription factor; Nuclear transport; Cancer research; Prostate cancer; Cell nucleus; Nucleus; Cancer; Biochemistry; Genetics; Gene","score_opus":0.009691344566271309,"score_gpt":0.22571672654625274,"score_spread":0.21602538197998145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549598588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983373,0.013649875,0.002231673,0.00029227784,0.00018474372,0.00008205276,0.00010079248,0.0000054513525,0.00008012986],"genre_scores_gemma":[0.99506843,0.0027349568,0.0014840601,0.000058635935,0.00038811602,8.1187494e-7,0.0000069355297,0.000056099812,0.00020195899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871576,0.00022773934,0.0004954019,0.00019051968,0.00019677241,0.00017379507],"domain_scores_gemma":[0.99894875,0.000015383719,0.00045941523,0.0001672385,0.00022979865,0.00017943574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033572855,0.00014919396,0.00019738839,0.00004874472,0.00004302082,0.000011381674,0.00020909318,0.000045452813,0.00026696426],"category_scores_gemma":[0.00005646236,0.00011179554,0.00013636723,0.00004745995,0.00014616584,0.00002084556,0.000021103204,0.000075244105,0.000010337396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033804853,0.000054591812,0.0054407967,0.000032889264,0.00010342174,0.000030838015,0.00019714583,0.0000038457965,0.93882775,0.000022744733,0.0008447876,0.05410312],"study_design_scores_gemma":[0.0013103457,0.00050762,0.014659921,0.000110050714,0.000067929395,0.000025781776,0.00005223492,0.000001798005,0.9311806,0.000026748467,0.051854406,0.00020257404],"about_ca_topic_score_codex":0.000002953022,"about_ca_topic_score_gemma":0.0000020191928,"teacher_disagreement_score":0.053900547,"about_ca_system_score_codex":0.000017599696,"about_ca_system_score_gemma":0.000055086617,"threshold_uncertainty_score":0.455889},"labels":[],"label_agreement":null},{"id":"W2555606007","doi":"10.1016/j.ejca.2016.10.013","title":"Current therapy and the evolving molecular landscape of paediatric ependymoma","year":2016,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"St. Jude Children's Research Hospital","keywords":"Ependymoma; Current (fluid); Medicine; Geography; Pathology; Geology; Oceanography","score_opus":0.03223491806093968,"score_gpt":0.3268824091614946,"score_spread":0.2946474911005549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555606007","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008087885,0.99743414,0.000011472554,0.00026345658,0.00037664693,0.0003047147,0.000013931923,0.0000029793298,0.0007838847],"genre_scores_gemma":[0.004164686,0.9949855,0.000039542716,0.000035518508,0.00069569517,0.000007430648,0.0000013327369,0.00004732838,0.00002293141],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981797,0.0004986152,0.0007363745,0.000112425165,0.00033801876,0.00013487364],"domain_scores_gemma":[0.9981213,0.00018297452,0.0011640253,0.00021094842,0.00021076851,0.00010996077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079211977,0.00022720368,0.0011850385,0.0001898821,0.000026966673,0.000019500789,0.00016033908,0.00002488108,0.00018231568],"category_scores_gemma":[0.00006801355,0.00008907769,0.0006157945,0.00014781769,0.00007290322,0.000030567106,0.000043345015,0.00025129443,0.000009752688],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006275109,0.00006108237,0.00019791586,0.0009717716,0.00061125983,0.000471616,0.00005448901,1.6616117e-7,0.0000013462169,0.000032219854,0.0017071633,0.9958282],"study_design_scores_gemma":[0.0044160085,0.00021953664,0.0005341526,0.017507821,0.0016525715,0.0005197492,0.000005125805,5.85175e-7,0.000008226591,0.000006734883,0.975037,0.000092487804],"about_ca_topic_score_codex":0.0000013425453,"about_ca_topic_score_gemma":1.7277311e-7,"teacher_disagreement_score":0.9957357,"about_ca_system_score_codex":0.000041207928,"about_ca_system_score_gemma":0.00019392348,"threshold_uncertainty_score":0.36324826},"labels":[],"label_agreement":null},{"id":"W2557455638","doi":"10.1016/j.ejca.2016.11.002","title":"Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?","year":2016,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Bevacizumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Vascular endothelial growth factor; Paclitaxel; Breast cancer; Chemotherapy; Angiogenesis; Progression-free survival; Cancer; Surgery; VEGF receptors","score_opus":0.022528321830941903,"score_gpt":0.29928357593077204,"score_spread":0.27675525409983015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557455638","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.050692108,0.015675662,0.00011170982,0.8531519,0.012591272,0.0011938515,0.0018311392,0.00010847363,0.06464389],"genre_scores_gemma":[0.097736664,0.02600041,0.00023517267,0.67353696,0.13288714,0.0000300198,0.00010809141,0.0007324165,0.06873312],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969779,0.0005835756,0.0007434974,0.0003678653,0.00082086783,0.0005062924],"domain_scores_gemma":[0.99777484,0.00021663301,0.0009205265,0.00026498645,0.0005564479,0.00026658142],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032165297,0.00049290527,0.0009063617,0.00037964268,0.000066791144,0.00003374856,0.00035161967,0.000206974,0.005805619],"category_scores_gemma":[0.000096476695,0.00031552973,0.0007954335,0.0001223033,0.00017748447,0.00012508634,0.00006467602,0.0015176734,0.00029674245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002730078,0.000071142946,0.0009620814,0.00014736595,0.0042840126,0.013627808,0.00026041703,3.1841535e-7,0.004415933,0.0000015826313,0.9464643,0.02703498],"study_design_scores_gemma":[0.0099573415,0.0024986875,0.0036581142,0.000864436,0.0019357179,0.0007637817,0.0000070655033,0.0000012860413,0.0032212322,0.00001819198,0.9767809,0.00029325634],"about_ca_topic_score_codex":0.000032286687,"about_ca_topic_score_gemma":0.0000025842928,"teacher_disagreement_score":0.17961493,"about_ca_system_score_codex":0.00055869005,"about_ca_system_score_gemma":0.00078085094,"threshold_uncertainty_score":0.99992967},"labels":[],"label_agreement":null},{"id":"W2558389544","doi":"10.1016/j.ejca.2016.09.004","title":"ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Amgen","keywords":"Medicine; Placebo; Hazard ratio; Adverse effect; Internal medicine; Clinical endpoint; Surgery; Gastroenterology; Urology; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.03384322118829779,"score_gpt":0.31353753613760277,"score_spread":0.27969431494930497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2558389544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633896,0.0017001161,0.0002731065,0.00024353975,0.00032517922,0.0007492901,0.00006530954,0.000006242325,0.00029827195],"genre_scores_gemma":[0.9963667,0.0016641392,0.00008451145,0.0001014292,0.0007630776,0.00006482767,0.0000029671917,0.000071784416,0.00088055903],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971255,0.00052240456,0.0010621655,0.0004106133,0.00043087988,0.00044840432],"domain_scores_gemma":[0.99789095,0.00006561613,0.0009814193,0.00031750067,0.000528261,0.00021624188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010138758,0.00033831934,0.00065361947,0.00013741702,0.00007180015,0.000029066607,0.00032261055,0.00006931776,0.00032182568],"category_scores_gemma":[0.00006684389,0.00018092159,0.00011870596,0.0003015897,0.00011493208,0.000022662996,0.00008205359,0.00018088195,0.000002160917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7481511,0.000556638,0.0007016719,0.000028144996,0.0008570373,0.0005874015,0.0019237451,0.0005638795,0.1970783,0.0000023534194,0.00058288284,0.048966836],"study_design_scores_gemma":[0.732818,0.02439321,0.01053251,0.0016322796,0.00047557201,0.00012569867,0.002869359,0.000026717253,0.20364204,0.0000013311796,0.022576455,0.00090680015],"about_ca_topic_score_codex":0.00014574677,"about_ca_topic_score_gemma":0.0028838748,"teacher_disagreement_score":0.048060037,"about_ca_system_score_codex":0.00024965155,"about_ca_system_score_gemma":0.000835554,"threshold_uncertainty_score":0.7377768},"labels":[],"label_agreement":null},{"id":"W2561375354","doi":"10.1016/j.ejca.2016.11.008","title":"Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6)","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Northeast Cancer Centre; BC Cancer Agency; Saint John Regional Hospital; University of the Fraser Valley; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke; Juravinski Cancer Centre; Thunder Bay Regional Health Sciences Centre; Princess Margaret Cancer Centre; Horizon Health Network; London Health Sciences Centre; Krembil Foundation; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Swallowing; Panitumumab; Head and neck cancer; Radiation therapy; Chemoradiotherapy; Head and neck; Oncology; Quality of life (healthcare); Internal medicine; Cancer; Surgery; Cetuximab; Colorectal cancer","score_opus":0.08593652614769312,"score_gpt":0.37001650773539374,"score_spread":0.28407998158770065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2561375354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594497,0.03368556,0.000044981036,0.005507061,0.00029015171,0.0008309628,0.00010859029,0.0000029113153,0.00008010094],"genre_scores_gemma":[0.98942757,0.009362566,0.00015880939,0.0005489255,0.00043152054,0.000014833426,6.783826e-7,0.00003041812,0.000024704017],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973539,0.0008408686,0.000985748,0.00020125808,0.0004037008,0.00021451284],"domain_scores_gemma":[0.99780256,0.00069070555,0.00083854643,0.00018147322,0.00026023097,0.00022646143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002176585,0.00020822874,0.0013834313,0.00008291665,0.00011451976,0.000023253726,0.00013276545,0.000034734432,0.000060198698],"category_scores_gemma":[0.00039966195,0.00009172949,0.00012221289,0.00016922527,0.00034973348,0.00011288359,0.0000172816,0.00020372427,2.0901075e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7836919,0.00007404889,0.053792488,0.00004705134,0.00093460846,0.000035252353,0.004514351,0.0000061480187,0.027366474,0.000012085441,0.00028545441,0.12924014],"study_design_scores_gemma":[0.761409,0.0027471469,0.2286593,0.0010617418,0.0001618073,0.0000069691387,0.0003555691,0.0000076229453,0.0011205822,0.000006379604,0.004316714,0.00014719271],"about_ca_topic_score_codex":0.01386663,"about_ca_topic_score_gemma":0.0819432,"teacher_disagreement_score":0.17486683,"about_ca_system_score_codex":0.00030520308,"about_ca_system_score_gemma":0.0013396002,"threshold_uncertainty_score":0.9927001},"labels":[],"label_agreement":null},{"id":"W2564004013","doi":"10.1016/j.ejca.2016.09.035","title":"Patient-reported outcomes in ductal carcinoma in situ: A systematic review","year":2016,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ductal carcinoma; Medicine; In situ; Carcinoma in situ; Oncology; Carcinoma; Internal medicine; Cancer; Breast cancer; Geography","score_opus":0.09983844675784263,"score_gpt":0.3877804628407758,"score_spread":0.2879420160829331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564004013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066079834,0.99485946,0.0000026702019,0.0002855966,0.00044571006,0.0011708601,0.0000081145445,0.00000686601,0.0025599073],"genre_scores_gemma":[0.0029027557,0.9958245,0.000036481488,0.0006270142,0.00022445754,0.000026123034,0.0000024791802,0.000062870145,0.0002932895],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9943542,0.0009702247,0.0033425225,0.00025913658,0.0007463243,0.0003276289],"domain_scores_gemma":[0.99618423,0.00010749643,0.0028149264,0.00040971205,0.00028621787,0.00019738852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001905326,0.00039852606,0.0044814544,0.00043413328,0.000013871264,0.00001853164,0.0002951858,0.00005875289,0.00011741586],"category_scores_gemma":[0.0009892087,0.00022040296,0.00081905944,0.00044355853,0.000037292528,0.00014088972,0.000068422196,0.00068912253,0.000051359384],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044308043,0.000054503525,0.0028789088,0.7283702,0.00043477435,0.023031615,0.0001320384,3.387643e-7,0.0000013740785,0.0000029424991,0.0014834602,0.24356553],"study_design_scores_gemma":[0.00073765125,0.00020355302,0.0012072952,0.86731124,0.0019718416,0.0026376687,0.000025323836,7.704225e-8,3.8985206e-7,0.0000010389285,0.12570338,0.00020053826],"about_ca_topic_score_codex":0.000027192777,"about_ca_topic_score_gemma":0.000034360706,"teacher_disagreement_score":0.24336499,"about_ca_system_score_codex":0.0007340962,"about_ca_system_score_gemma":0.00080578576,"threshold_uncertainty_score":0.8987772},"labels":[],"label_agreement":null},{"id":"W2566486729","doi":"10.1016/j.ejca.2016.10.031","title":"Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis","year":2016,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Colorectal cancer; Lymph node; Neoadjuvant therapy; Lymph; Meta-analysis; Radiation therapy; Oncology; Cochrane Library; Radiology; Internal medicine; Cancer; Pathology; Breast cancer","score_opus":0.054745097212930985,"score_gpt":0.34094700019170937,"score_spread":0.2862019029787784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566486729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004009087,0.9958262,0.000017163908,0.00020503174,0.00011259659,0.0029546467,0.00026829226,0.000011542501,0.00020364264],"genre_scores_gemma":[0.0022535888,0.99548936,0.000050412254,0.00019057097,0.00016037909,0.00086894096,0.00002516173,0.00010055825,0.000861013],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99593323,0.0009789676,0.0017600532,0.0004715192,0.00056235236,0.00029386536],"domain_scores_gemma":[0.9964379,0.0002861881,0.0021712326,0.00033749305,0.000540825,0.00022632623],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010844838,0.00054183987,0.0066886493,0.0006132564,0.000039777195,0.000035712266,0.00014204721,0.00008698803,0.00036559236],"category_scores_gemma":[0.0003127109,0.0002667687,0.0018490457,0.0009039228,0.00004371201,0.00015464648,0.00003259023,0.00028650454,0.000005691697],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032923438,0.00024932937,0.003494126,0.53162813,0.23691109,0.0005067375,0.00009480635,0.0000038575813,2.195328e-7,3.9108167e-7,0.0003292213,0.22348976],"study_design_scores_gemma":[0.0023641766,0.0011662719,0.002374126,0.20294061,0.77049196,0.000103096034,0.0000022068066,0.0000013464237,0.0000013704612,3.2608466e-7,0.02023672,0.00031780623],"about_ca_topic_score_codex":0.00006229393,"about_ca_topic_score_gemma":0.00008587084,"teacher_disagreement_score":0.53358084,"about_ca_system_score_codex":0.0012224979,"about_ca_system_score_gemma":0.0003074111,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W2588570873","doi":"10.1016/j.ejca.2017.08.019","title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Universitätsklinikum Hamburg-Eppendorf; Centre Léon Bérard; Assistance publique-Hôpitaux de Paris; Baskent Üniversitesi; Gaziantep Üniversitesi; Ege Üniversitesi; Institut Bergonié; University of Sussex; F. Hoffmann-La Roche; Roche","keywords":"Trastuzumab; Medicine; Breast cancer; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Cancer","score_opus":0.028440997345682596,"score_gpt":0.3521403557355309,"score_spread":0.32369935838984826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588570873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206805,0.00440801,0.000043711047,0.00059168995,0.0001696978,0.0017846309,0.00029804365,0.0000033333608,0.00063284696],"genre_scores_gemma":[0.99462825,0.0047163414,0.000045194985,0.000041871663,0.0002673659,0.000021309,0.0000014378217,0.00005119239,0.00022705228],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996888,0.0005838855,0.0010773455,0.00030010962,0.0008526583,0.00029804852],"domain_scores_gemma":[0.9966318,0.00028542016,0.0014091324,0.0005286256,0.00094227615,0.00020271617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019138473,0.00024710162,0.0012996813,0.00020451033,0.00018572618,0.000040376093,0.000452214,0.00003662748,0.0001743371],"category_scores_gemma":[0.00016906078,0.00015789266,0.00034938185,0.00022888524,0.0005749318,0.00009383882,0.0000837159,0.00038379926,2.3220758e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16262214,0.0015865077,0.3491071,0.00022189466,0.015782554,0.00033476582,0.011850166,0.0006127415,0.009162734,0.000008665618,0.00021423404,0.44849652],"study_design_scores_gemma":[0.04130117,0.0060156058,0.9445041,0.00072600343,0.0033986634,0.00024719824,0.0003467731,0.000061372404,0.0028099453,0.0000045560832,0.00044464692,0.0001399777],"about_ca_topic_score_codex":0.001128948,"about_ca_topic_score_gemma":0.00028813086,"teacher_disagreement_score":0.595397,"about_ca_system_score_codex":0.00016895539,"about_ca_system_score_gemma":0.00062767783,"threshold_uncertainty_score":0.6438676},"labels":[],"label_agreement":null},{"id":"W2590821302","doi":"10.1016/j.ejca.2016.12.029","title":"The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Karen Elise Jensens Fond; Cancer Research UK; Genome British Columbia; National Institute for Health and Care Research; Genome Canada","keywords":"Medicine; Diffuse large B-cell lymphoma; Lymphoma; Nuclear medicine; Radiology; Multicenter study; Oncology; Internal medicine; Randomized controlled trial","score_opus":0.008914807066084364,"score_gpt":0.2770373202865452,"score_spread":0.2681225132204608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590821302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982505,0.00016192647,0.0000075188723,0.00006967564,0.00011784124,0.0006511677,0.0004133975,0.00000387676,0.0003240904],"genre_scores_gemma":[0.99926025,0.00019509028,0.00012892709,0.00003659114,0.00004317261,0.000011024601,0.000032962136,0.00005789207,0.00023412252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982917,0.000102393875,0.0006227344,0.00018089495,0.00062659744,0.00017569956],"domain_scores_gemma":[0.9967218,0.00007258794,0.0015626501,0.00041664075,0.0011231154,0.00010317662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021916261,0.00020757511,0.00043400264,0.000056559365,0.00010635993,0.000036714835,0.00033388968,0.000007923724,0.00007515254],"category_scores_gemma":[0.000040214083,0.0001122207,0.00012994271,0.000048218502,0.0001315371,0.00022016074,0.000031584714,0.00006319775,6.988291e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008981802,0.035096794,0.95017695,0.00003403773,0.0011872578,0.00004912717,0.0012219293,9.234584e-7,0.00034562172,8.180771e-7,0.00038192753,0.002522811],"study_design_scores_gemma":[0.10875205,0.0057455534,0.8794564,0.0003234305,0.00042148645,0.0000083658115,0.00032144733,0.000026301132,0.0036123812,2.4372372e-7,0.0012373419,0.00009498262],"about_ca_topic_score_codex":0.00011085688,"about_ca_topic_score_gemma":0.000039293038,"teacher_disagreement_score":0.09977025,"about_ca_system_score_codex":0.00011895888,"about_ca_system_score_gemma":0.000094808915,"threshold_uncertainty_score":0.45762274},"labels":[],"label_agreement":null},{"id":"W2592908133","doi":"10.1016/j.ejca.2017.01.034","title":"Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Male Breast Health Studies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Erasmus MC Kanker Instituut; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Translational Breast Cancer Research Consortium; Breast Cancer Research Foundation; Susan G. Komen for the Cure","keywords":"Breast cancer; Pathological; Medicine; Male breast cancer; Oncology; Cancer; Internal medicine","score_opus":0.040416431834269934,"score_gpt":0.34894057814413304,"score_spread":0.30852414630986313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592908133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.945101,0.0014764079,0.000011385741,0.040684763,0.0024132153,0.00046086157,0.00086535275,0.000015029245,0.008971977],"genre_scores_gemma":[0.990625,0.0035234718,0.00018985695,0.00037886857,0.0027763348,0.000023676293,0.000004425471,0.00003659913,0.00244172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971611,0.00025527124,0.0011829084,0.00025599403,0.0008338499,0.0003108904],"domain_scores_gemma":[0.99479234,0.000036521287,0.0029825857,0.00050882855,0.0014989157,0.00018079122],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001122758,0.00022866359,0.00058974006,0.00010860043,0.00020211989,0.000037370093,0.00067972485,0.000053937987,0.0009917015],"category_scores_gemma":[0.00019725726,0.0001443896,0.00025752938,0.0001073367,0.00039085536,0.00019294677,0.00024586194,0.00046793,0.000006082308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003628135,0.00034650508,0.5935962,0.000258117,0.0002473361,0.00019589422,0.0007267687,0.000033160788,0.005032544,0.000017195749,0.0049453997,0.39097273],"study_design_scores_gemma":[0.0032748785,0.00024115898,0.9736154,0.0016252192,0.00018408199,0.0017298735,0.000117855016,0.00003465287,0.00041309808,0.000003971939,0.018636825,0.00012297663],"about_ca_topic_score_codex":0.00057914323,"about_ca_topic_score_gemma":0.00017212433,"teacher_disagreement_score":0.39084977,"about_ca_system_score_codex":0.00023616597,"about_ca_system_score_gemma":0.00051253574,"threshold_uncertainty_score":0.9999215},"labels":[],"label_agreement":null},{"id":"W2597432644","doi":"10.1016/j.ejca.2017.01.024","title":"Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Cancer; Cmax; Oncology; Pharmacology; Pharmacokinetics; Urology; Androgen deprivation therapy","score_opus":0.07111369384903171,"score_gpt":0.3939819211044353,"score_spread":0.3228682272554036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597432644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645036,0.0010142124,0.000003583196,0.0004652621,0.00029809255,0.0010393533,0.000076749326,0.0000075236076,0.00064483617],"genre_scores_gemma":[0.9973897,0.00059696706,0.00007039572,0.00003032488,0.00022367385,0.000021669144,0.000007425252,0.00006321484,0.0015966368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739575,0.00022100404,0.00081733137,0.00027792846,0.0008789719,0.00040901438],"domain_scores_gemma":[0.9973883,0.000029601522,0.0011593071,0.00043287536,0.00073723885,0.000252659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006459384,0.0002650382,0.0006511945,0.0002739178,0.00021027403,0.0001271125,0.00033887243,0.000025183546,0.00019460126],"category_scores_gemma":[0.00006906309,0.00015530467,0.000071714756,0.00018971025,0.00016628212,0.0004983102,0.000076558135,0.00041992203,0.0000035353987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10813438,0.004655223,0.77775663,0.00035714885,0.0013556773,0.00556025,0.013376542,0.00077966996,0.0076155667,0.0000022281374,0.0007218075,0.079684876],"study_design_scores_gemma":[0.091146626,0.011872828,0.8907031,0.0014068838,0.00029895356,0.00001337206,0.0009783518,0.000028101695,0.0025094147,0.0000014348999,0.0008376614,0.00020326675],"about_ca_topic_score_codex":0.0005415476,"about_ca_topic_score_gemma":0.0015377962,"teacher_disagreement_score":0.11294647,"about_ca_system_score_codex":0.00044110318,"about_ca_system_score_gemma":0.00082228106,"threshold_uncertainty_score":0.63331413},"labels":[],"label_agreement":null},{"id":"W2601178524","doi":"10.1016/j.ejca.2017.02.027","title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":449,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Takeda Oncology; Galderma; Eisai; Therakos; Teva Pharmaceutical Industries","keywords":"Mycosis fungoides; Dermatology; Medicine; Cancer; Oncology; Internal medicine; Lymphoma","score_opus":0.4181450144113252,"score_gpt":0.5248697132950937,"score_spread":0.10672469888376851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601178524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015727278,0.9898324,0.000038721333,0.003082653,0.00031280133,0.003364474,0.0012984675,0.000005465395,0.00049229915],"genre_scores_gemma":[0.0018905343,0.9930707,0.00037510067,0.000019207722,0.00052832824,0.0001818834,0.00008314966,0.00014594293,0.0037051023],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965296,0.0010069227,0.001241617,0.00034464413,0.0004958434,0.00038141693],"domain_scores_gemma":[0.9946649,0.0012778752,0.0016944058,0.0006361901,0.0015249334,0.00020167578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017995258,0.00037676736,0.0017166547,0.0004291041,0.00041110316,0.00006887877,0.00035286037,0.000057939014,0.00019641675],"category_scores_gemma":[0.0002778761,0.00021945365,0.0006115354,0.00013929479,0.0004381528,0.000048876023,0.00005006223,0.00019388959,0.00000806889],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000750455,0.0005106779,0.00017983963,0.002324125,0.00302913,0.00016121885,0.00082817336,0.000003081384,0.000042992175,0.000014230178,0.0070461044,0.98511],"study_design_scores_gemma":[0.0036182597,0.0074184705,0.0003681168,0.0050396807,0.0025974174,0.00081529433,0.00020436247,0.000013027085,0.00008165433,0.000011550303,0.97967374,0.00015843956],"about_ca_topic_score_codex":0.00015787077,"about_ca_topic_score_gemma":0.00014659663,"teacher_disagreement_score":0.98495156,"about_ca_system_score_codex":0.0009403599,"about_ca_system_score_gemma":0.0015990287,"threshold_uncertainty_score":0.89490604},"labels":[],"label_agreement":null},{"id":"W2602445411","doi":"10.1016/j.ejca.2017.02.024","title":"Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Hazard ratio; Oncology; Breast cancer; Odds ratio; Meta-analysis; Triple-negative breast cancer; Chemotherapy; Fluorouracil; Confidence interval; Cancer; Colorectal cancer","score_opus":0.15295055918965886,"score_gpt":0.4102967357081017,"score_spread":0.2573461765184428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602445411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000138628,0.9968205,0.00002041428,0.00021597213,0.00033982916,0.00075289735,0.0010963944,0.00000203484,0.0006133178],"genre_scores_gemma":[0.0037470723,0.9944796,0.000045478668,0.000038099508,0.0008609471,0.00015884338,0.000028547262,0.000072069655,0.0005693225],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99250287,0.0032334453,0.0031838825,0.00038913955,0.00041242913,0.00027825354],"domain_scores_gemma":[0.99044573,0.00030557692,0.007923077,0.00061177707,0.0005930607,0.000120772725],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0050098356,0.0005932629,0.015013431,0.0005733608,0.000058822785,0.000048461214,0.0007175773,0.00010865724,0.00035603403],"category_scores_gemma":[0.00067754637,0.00033734238,0.011097904,0.00029222024,0.00013490701,0.000009634216,0.000118810465,0.00027953758,0.0000022892011],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055527287,0.00010548112,0.000106654035,0.00048786806,0.65173596,0.000085824984,0.000075948716,0.00008472662,0.000026468702,0.000001306956,0.00072968344,0.34100735],"study_design_scores_gemma":[0.029661665,0.00009233716,0.00078736263,0.00081138813,0.60786,0.000025324905,0.0000071354793,4.9045093e-7,0.000011126939,6.5000364e-7,0.3604738,0.00026870743],"about_ca_topic_score_codex":0.00023110132,"about_ca_topic_score_gemma":0.0003231653,"teacher_disagreement_score":0.3597441,"about_ca_system_score_codex":0.000105911706,"about_ca_system_score_gemma":0.00061893667,"threshold_uncertainty_score":0.99990785},"labels":[],"label_agreement":null},{"id":"W2605987398","doi":"10.1016/j.ejca.2017.03.009","title":"Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Chemotherapy; Resection; Hepatectomy; Internal medicine; Overall survival; Colorectal cancer; Cohort; Stage (stratigraphy); Surgery; Gastroenterology; Prospective cohort study; Surgical resection; Cancer","score_opus":0.06698258094259602,"score_gpt":0.30129726608388924,"score_spread":0.23431468514129322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605987398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560356,0.0024079464,0.000029409335,0.00021588613,0.00013820214,0.00014683303,0.00017501049,0.0000026718494,0.0012804548],"genre_scores_gemma":[0.99774426,0.00104307,0.00026751624,0.00015685023,0.00012140028,0.0000025991153,0.000014044612,0.000024493638,0.000625737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998432,0.00027020802,0.00059475086,0.00015184536,0.00041257072,0.00013864947],"domain_scores_gemma":[0.9976273,0.00004593112,0.0011320813,0.0002904152,0.00078272715,0.00012153991],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007766646,0.00014873387,0.00061996386,0.00033969735,0.00005766322,0.000021661184,0.00016199361,0.000028657269,0.003933058],"category_scores_gemma":[0.000096714946,0.00011147731,0.00052395044,0.00023548884,0.00011133199,0.00016314584,0.00003859169,0.00014402825,0.000005896617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030988327,0.00030924773,0.96958894,0.000059846003,0.0047701765,0.00018297718,0.0010967043,0.000003955038,0.0010303693,3.103765e-7,0.0012199782,0.018638652],"study_design_scores_gemma":[0.0026646552,0.0018522503,0.9627015,0.00019550358,0.0035162664,0.0000056816275,0.000031321077,0.00017234428,0.025539992,6.8443e-7,0.0032291957,0.00009058336],"about_ca_topic_score_codex":0.000117450145,"about_ca_topic_score_gemma":0.00024005675,"teacher_disagreement_score":0.024509624,"about_ca_system_score_codex":0.000057068402,"about_ca_system_score_gemma":0.000080137215,"threshold_uncertainty_score":0.9969775},"labels":[],"label_agreement":null},{"id":"W2612095536","doi":"10.1016/j.ejca.2017.04.007","title":"Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Vemurafenib; Medicine; Adverse effect; Internal medicine; Melanoma; Population; Metastatic melanoma; Clinical trial; Oncology; Dermatology; Surgery; Gastroenterology; Cancer; Cancer research","score_opus":0.03186342165667164,"score_gpt":0.3152514821229644,"score_spread":0.2833880604662927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612095536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99838495,0.00045618555,0.00021191304,0.000044266057,0.000113161135,0.00031118593,0.00017230856,9.62709e-7,0.00030504094],"genre_scores_gemma":[0.99910945,0.00011517111,0.00035823983,0.000028654491,0.000050002745,0.0000014996253,0.000101045516,0.000021681171,0.0002142693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844015,0.0004197918,0.00045125905,0.00029847433,0.00024142361,0.00014892894],"domain_scores_gemma":[0.99816024,0.000026592486,0.0007957916,0.00063656515,0.00028245646,0.00009834249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061542314,0.00014972397,0.00034934233,0.00011433764,0.0001168594,0.00009296769,0.00085677055,0.000019098687,0.000023227149],"category_scores_gemma":[0.00013027871,0.00011529119,0.000034196004,0.000097947915,0.00006840123,0.000054604014,0.00046882403,0.00011207045,0.0000010272836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049735247,0.0007747278,0.9769205,0.000025344867,0.0022360454,0.0003649953,0.0015623516,0.000065085784,0.0035692102,0.0000025816921,0.00008872915,0.009416889],"study_design_scores_gemma":[0.01773556,0.001905572,0.97769856,0.00008292719,0.00089188607,0.000006674157,0.00049055764,0.000023904526,0.00089501723,6.986343e-7,0.000118795564,0.00014983193],"about_ca_topic_score_codex":0.000057873203,"about_ca_topic_score_gemma":0.001769566,"teacher_disagreement_score":0.012762035,"about_ca_system_score_codex":0.00001839758,"about_ca_system_score_gemma":0.00009886176,"threshold_uncertainty_score":0.47014382},"labels":[],"label_agreement":null},{"id":"W2613907595","doi":"10.1016/j.ejca.2017.03.033","title":"HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Tamoxifen; Medicine; Exemestane; Hazard ratio; Oncology; Internal medicine; Clinical trial; Breast cancer; Adjuvant therapy; Confidence interval; Cancer","score_opus":0.19449919099568974,"score_gpt":0.41727949380375684,"score_spread":0.2227803028080671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613907595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083524844,0.99154985,0.00029747077,0.00021008356,0.0003583373,0.0016597203,0.004158212,0.000012624032,0.000918444],"genre_scores_gemma":[0.0028099753,0.9932623,0.0011176809,0.00016678119,0.00074678886,0.000061170285,0.00021151609,0.00024099983,0.0013827924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941085,0.00065353827,0.0021500147,0.00066726276,0.0016638672,0.00075682014],"domain_scores_gemma":[0.9936749,0.00027942032,0.002846196,0.0010240037,0.001308847,0.0008666476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014998349,0.0007324612,0.006576857,0.00076029374,0.000120837845,0.00013266885,0.0007882968,0.00014283716,0.0005373178],"category_scores_gemma":[0.00026785917,0.0004512705,0.0027435948,0.0003487981,0.00025478107,0.00018672802,0.00009593327,0.0009799191,0.0000031066536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097618456,0.0002057928,0.002471983,0.004947051,0.14206685,0.00022207406,0.00044217875,0.000026592657,0.0000021415244,6.583516e-7,0.0025196255,0.84611887],"study_design_scores_gemma":[0.0028349326,0.0017896978,0.0053734095,0.004927042,0.2700114,0.00001640208,0.0000132639,0.000017582108,0.000006243286,0.0000018557446,0.7147114,0.00029673154],"about_ca_topic_score_codex":0.00039561072,"about_ca_topic_score_gemma":0.0011457576,"teacher_disagreement_score":0.84582216,"about_ca_system_score_codex":0.00043185562,"about_ca_system_score_gemma":0.0017618742,"threshold_uncertainty_score":0.9997939},"labels":[],"label_agreement":null},{"id":"W2615357223","doi":"10.1016/j.ejca.2017.07.054","title":"Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research","keywords":"Head and neck cancer; Medicine; Head and neck; Medical physics; PET-CT; Cost-effectiveness analysis; Radiology; Nuclear medicine; Cost effectiveness; Computed tomography; Radiation therapy; Surgery; Risk analysis (engineering)","score_opus":0.06751163539046229,"score_gpt":0.4024318930183756,"score_spread":0.33492025762791333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2615357223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98005974,0.009590403,0.0011025823,0.0014270613,0.0005095896,0.0005784561,0.000044693792,0.000007592902,0.0066798837],"genre_scores_gemma":[0.98901844,0.008612007,0.0010466509,0.00026853496,0.00020377206,0.00003291876,0.0000013570544,0.000030076735,0.00078625913],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987539,0.00009067846,0.00047245526,0.00019368833,0.0002785291,0.00021072097],"domain_scores_gemma":[0.9983571,0.000058340047,0.0006341802,0.00028919944,0.0005113255,0.00014984456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007132691,0.00015862213,0.0007937195,0.00019538176,0.00017101332,0.000027181375,0.00017721995,0.0000057583225,0.000052810406],"category_scores_gemma":[0.00008974917,0.000120744764,0.0002499783,0.0001364038,0.00012754681,0.000121937745,0.00007563655,0.00012135382,7.3629667e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037392906,0.00019907224,0.22844723,0.0011853307,0.012149566,0.0012480471,0.00054450217,0.0020987533,0.003181781,0.00012877278,0.0037901404,0.7432875],"study_design_scores_gemma":[0.00805872,0.00066636817,0.9179235,0.0017951586,0.0033928892,0.00003916628,0.00011245419,0.00020619127,0.001832118,0.000009657887,0.06581454,0.00014922202],"about_ca_topic_score_codex":0.0000685281,"about_ca_topic_score_gemma":0.00013664454,"teacher_disagreement_score":0.7431383,"about_ca_system_score_codex":0.00012833226,"about_ca_system_score_gemma":0.000098016,"threshold_uncertainty_score":0.49238285},"labels":[],"label_agreement":null},{"id":"W2618851550","doi":"10.1016/j.ejca.2017.04.020","title":"Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto; McMaster University; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Term (time); Physical medicine and rehabilitation; Brain function; Physical therapy; Physical fitness; Psychology; Neuroscience; Physics","score_opus":0.023339813413109388,"score_gpt":0.29545725244622895,"score_spread":0.2721174390331196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2618851550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946747,0.0011733036,0.00012513135,0.0030046592,0.00037698713,0.00021020917,0.000006207889,0.000018285611,0.000410535],"genre_scores_gemma":[0.9971385,0.00031988585,0.000059692335,0.00022342833,0.0020299817,0.0000032686266,0.000003908188,0.00005378813,0.00016754612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983403,0.0002590141,0.00047131532,0.0002360012,0.0004524716,0.00024088757],"domain_scores_gemma":[0.9985148,0.00008358558,0.00077541906,0.00023229697,0.00017175834,0.00022218481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010647116,0.00020679476,0.0005206327,0.00020280221,0.00014581576,0.000111766,0.00016279382,0.00003079933,0.000022525592],"category_scores_gemma":[0.00018443674,0.00016223398,0.00009850042,0.00013140778,0.00012158572,0.00043377568,0.000032863056,0.0003896888,0.0000029418106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038409184,0.0002738477,0.6659166,0.00028312553,0.0001867216,0.00064785674,0.00794902,0.000075578915,0.0070998515,0.000010966289,0.000335243,0.31338024],"study_design_scores_gemma":[0.006301199,0.0009649818,0.99061245,0.0009483199,0.00025095735,0.00007180772,0.00024971177,0.000068251655,0.00021078289,0.000015569698,0.00012475929,0.00018119179],"about_ca_topic_score_codex":0.00024370274,"about_ca_topic_score_gemma":0.0006653415,"teacher_disagreement_score":0.32469583,"about_ca_system_score_codex":0.00008909012,"about_ca_system_score_gemma":0.00018918425,"threshold_uncertainty_score":0.66157097},"labels":[],"label_agreement":null},{"id":"W2620843145","doi":"10.1016/j.ejca.2017.04.028","title":"Getting under the skin","year":2017,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pertuzumab; Lapatinib; Medicine; Trastuzumab; Trastuzumab emtansine; Breast cancer; Oncology; Internal medicine; Metastatic breast cancer; Capecitabine; Cancer; Colorectal cancer","score_opus":0.08659865713768121,"score_gpt":0.4007143997159772,"score_spread":0.314115742578296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620843145","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090301636,0.012051203,0.000083035025,0.9110861,0.002132294,0.0002048152,0.000014194252,0.000012378103,0.07351301],"genre_scores_gemma":[0.010889311,0.002754422,0.00026187414,0.82145864,0.08889827,0.0000062276617,0.0000069966964,0.0003159955,0.07540825],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963426,0.0007302375,0.00065909134,0.00023613665,0.001527162,0.0005047462],"domain_scores_gemma":[0.99703515,0.00016975058,0.0010954628,0.00087123725,0.0006750111,0.0001533977],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025608405,0.0002736949,0.0005528475,0.00017892066,0.00023072098,0.00019759218,0.001164558,0.00012790738,0.0014288801],"category_scores_gemma":[0.00027417598,0.0001591895,0.00040186016,0.000083085884,0.00029649874,0.00008264619,0.00016471978,0.005799234,0.00020745963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051720457,0.000007932044,0.00014291702,0.00015054329,0.0003128559,0.007916368,0.00016479101,0.000012096439,0.00010814964,0.000002187347,0.94103616,0.050094277],"study_design_scores_gemma":[0.00082309643,0.0002122244,0.0050322865,0.0018186774,0.0002373191,0.0009958098,0.00004480158,0.0000040305663,0.00013715278,0.00002279206,0.99050504,0.00016676617],"about_ca_topic_score_codex":0.000046262605,"about_ca_topic_score_gemma":0.000006919757,"teacher_disagreement_score":0.08962741,"about_ca_system_score_codex":0.00038436893,"about_ca_system_score_gemma":0.0010726716,"threshold_uncertainty_score":0.99948394},"labels":[],"label_agreement":null},{"id":"W2621872277","doi":"10.1016/j.ejca.2017.05.003","title":"Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]","year":2017,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; Prostate cancer; Medicine; PI3K/AKT/mTOR pathway; PTEN; Internal medicine; Androgen receptor; Cancer research; Oncology; Cancer; Chemistry; Androgen deprivation therapy; Apoptosis; Biochemistry","score_opus":0.08206746764147864,"score_gpt":0.38135374974787317,"score_spread":0.2992862821063945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621872277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634544,0.013633673,0.000013627762,0.00075571536,0.015676739,0.0027410076,0.0009404891,0.000017025428,0.0027672702],"genre_scores_gemma":[0.9249758,0.010472474,0.00013404584,0.00013143162,0.0035636306,0.000037886588,0.00008806085,0.00040588807,0.060190767],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.991086,0.001242694,0.0030623956,0.000732567,0.002784808,0.001091551],"domain_scores_gemma":[0.98836386,0.0000509548,0.006265573,0.00092652184,0.003423077,0.0009700122],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002423671,0.0009928655,0.0025272672,0.0014214299,0.0003334742,0.00030796058,0.0013286258,0.00012379591,0.0004919045],"category_scores_gemma":[0.00021612129,0.00062877056,0.00033781104,0.000656259,0.0003074197,0.0006620789,0.00025786832,0.0026203664,0.00001017285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21909867,0.0060739736,0.08879803,0.0025387611,0.008566614,0.04350285,0.033125754,0.0025176632,0.0034665542,0.0000010733241,0.46769536,0.12461469],"study_design_scores_gemma":[0.11494308,0.042586554,0.67147434,0.023796033,0.0032002917,0.0001962561,0.0031369573,0.000034097728,0.0008782268,0.0000016989993,0.13837188,0.0013806033],"about_ca_topic_score_codex":0.001426506,"about_ca_topic_score_gemma":0.0060421275,"teacher_disagreement_score":0.5826763,"about_ca_system_score_codex":0.0021371117,"about_ca_system_score_gemma":0.0063463976,"threshold_uncertainty_score":0.99968064},"labels":[],"label_agreement":null},{"id":"W2636042323","doi":"10.1016/j.ejca.2017.05.031","title":"Health-related quality of life results from the phase III CheckMate 067 study","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Genentech; Astellas Pharma; Merck Sharp and Dohme; Eisai; National Cancer Institute; Dendreon Pharmaceuticals; Incyte; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; LEO Pharma; Prometheus; Helsinn; Roche; EMD Serono; Novartis; GlaxoSmithKline; Merck; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Phase (matter); Medicine; Chemistry","score_opus":0.09786343728687633,"score_gpt":0.4043122046986372,"score_spread":0.30644876741176086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2636042323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970482,0.008948975,0.000013670296,0.016821012,0.00080154504,0.00025369422,0.00008983203,0.000007636873,0.0025816448],"genre_scores_gemma":[0.9965693,0.0012454187,0.000033720975,0.0009705707,0.0005340966,7.4592083e-7,0.000003099932,0.000022336711,0.0006207478],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970673,0.00067528104,0.0015160121,0.00013818243,0.0004468671,0.00015638428],"domain_scores_gemma":[0.9959161,0.00010030161,0.0029538546,0.000630511,0.00024793018,0.00015126521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004533736,0.00012318093,0.0005540178,0.000036287012,0.00022616937,0.000041230258,0.00041669543,0.000017232669,0.00019830317],"category_scores_gemma":[0.00047785015,0.000071973496,0.00020044898,0.00006317498,0.00016618105,0.000099201054,0.000049377442,0.00031710486,0.0000055305086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20477755,0.0026366792,0.055296678,0.00008869505,0.0058089932,0.00042783204,0.033703607,0.000029048548,0.026469294,0.000011936633,0.07759091,0.5931588],"study_design_scores_gemma":[0.059641246,0.0017578613,0.9087711,0.0005051081,0.00013154106,0.000012444871,0.0012007399,0.0000067843484,0.00054550456,0.0000062124723,0.0273211,0.00010033303],"about_ca_topic_score_codex":0.0036544139,"about_ca_topic_score_gemma":0.00025938347,"teacher_disagreement_score":0.85347444,"about_ca_system_score_codex":0.00007548539,"about_ca_system_score_gemma":0.00038044082,"threshold_uncertainty_score":0.5524405},"labels":[],"label_agreement":null},{"id":"W2687302866","doi":"10.1016/j.ejca.2017.04.025","title":"Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Armand Frappier Museum; Centre d'expertise et de recherche en infrastructures urbaines; Université du Québec à Montréal","funders":"","keywords":"FOLFOX; Medicine; Colorectal cancer; Internal medicine; Oncology; Stage (stratigraphy); Lymphocyte; Adjuvant; Adjuvant chemotherapy; Infiltration (HVAC); Cancer; Oxaliplatin; Breast cancer; Biology","score_opus":0.013390824186961902,"score_gpt":0.2790507339218318,"score_spread":0.26565990973486986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2687302866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966263,0.00047495143,0.000012708466,0.00011709524,0.00013541676,0.0006890203,0.00004366431,0.000009701137,0.0018911238],"genre_scores_gemma":[0.999256,0.00019296705,0.0001360855,0.000035834706,0.00013408181,0.000030867974,0.0000069982007,0.00003609667,0.00017103062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985089,0.00012863305,0.0005772464,0.00016301603,0.00045200333,0.00017023046],"domain_scores_gemma":[0.9972532,0.0000412152,0.0014193534,0.00021931437,0.0009530179,0.00011391988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041670247,0.00015806353,0.00034582123,0.00016455518,0.00009010532,0.00004193921,0.0001636988,0.000027249782,0.00008063746],"category_scores_gemma":[0.00041973317,0.00011770108,0.000068876514,0.00012509647,0.00013904531,0.00032327534,0.000030958156,0.00014129627,0.000002210269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035079787,0.00034485472,0.98308283,0.00011983543,0.00017409153,0.00022697561,0.000538321,0.00006401621,0.0036677425,0.0000023700904,0.00010471683,0.008166255],"study_design_scores_gemma":[0.009947052,0.0013533364,0.94418824,0.0017504124,0.00029943438,0.000008221188,0.000047746817,0.00006050379,0.04199997,0.0000018142725,0.00022627605,0.000117021606],"about_ca_topic_score_codex":0.000095150084,"about_ca_topic_score_gemma":0.00008444117,"teacher_disagreement_score":0.03889463,"about_ca_system_score_codex":0.00045344722,"about_ca_system_score_gemma":0.00048239724,"threshold_uncertainty_score":0.47997108},"labels":[],"label_agreement":null},{"id":"W2735105059","doi":"10.1016/j.ejca.2017.05.029","title":"Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto","funders":"","keywords":"Medicine; Confidence interval; Hazard ratio; Cancer; Cancer drugs; Scale (ratio); Intensive care medicine; Medical physics; Oncology; Internal medicine","score_opus":0.10611058934353897,"score_gpt":0.38094412088911817,"score_spread":0.2748335315455792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735105059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96139354,0.026481934,0.0049957293,0.0006604587,0.0026326922,0.00044124332,0.00078104815,0.0000064713954,0.0026068597],"genre_scores_gemma":[0.99404514,0.0024894604,0.001290493,0.00011951692,0.0013298553,0.000017745571,0.0000019770218,0.0000660142,0.0006397964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971095,0.00003147393,0.0022117582,0.0002695125,0.00007108092,0.0003066994],"domain_scores_gemma":[0.99260116,0.00016877174,0.0062002707,0.0004318383,0.00047475696,0.00012318006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022183093,0.0001921615,0.0013692203,0.00014536497,0.0001397869,0.0000794413,0.0008349079,0.00006537583,0.00006674519],"category_scores_gemma":[0.00042915565,0.00019913004,0.0005857573,0.000039677456,0.00022411977,0.0003751091,0.000070065915,0.00021201263,0.0000053966137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001967288,0.00031112533,0.7846652,0.00043712324,0.0015849281,0.0000063919947,0.0049101566,0.004135206,0.0005767858,0.032351796,0.012691529,0.15636247],"study_design_scores_gemma":[0.021338303,0.0037859275,0.77510536,0.002216448,0.00051780057,0.000014776284,0.001233129,0.0036159873,0.003477096,0.018324852,0.16909236,0.0012779678],"about_ca_topic_score_codex":0.00021468995,"about_ca_topic_score_gemma":0.00021803778,"teacher_disagreement_score":0.15640083,"about_ca_system_score_codex":0.00011221886,"about_ca_system_score_gemma":0.00014694032,"threshold_uncertainty_score":0.81202877},"labels":[],"label_agreement":null},{"id":"W2735569299","doi":"10.1016/j.ejca.2017.06.021","title":"Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Society for Medical Oncology; University of Toronto","keywords":"Ipilimumab; Medicine; Meta-analysis; Internal medicine; Adverse effect; Incidence (geometry); Odds ratio; Placebo; Confidence interval; Cancer; Randomized controlled trial; Cochrane Library; Oncology; Immunotherapy; Pathology","score_opus":0.11535894112813506,"score_gpt":0.392580623555264,"score_spread":0.27722168242712897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735569299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010366284,0.9965369,6.080043e-7,0.000037010035,0.00004322772,0.0017259995,0.00034549888,0.000005005891,0.00026908642],"genre_scores_gemma":[0.002006668,0.99671096,0.00000993887,0.000051918436,0.000021644759,0.00007299509,0.00002067391,0.00006273496,0.0010424515],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99504685,0.0015918203,0.0024529477,0.00030688767,0.00040527075,0.00019623352],"domain_scores_gemma":[0.99179715,0.0000823685,0.0069054943,0.00065860717,0.00041920663,0.00013717003],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014875203,0.0005283522,0.010120654,0.0004561007,0.00004964442,0.000026094516,0.00024965862,0.00006910337,0.00040848224],"category_scores_gemma":[0.00008923545,0.00025007912,0.002801731,0.0006213956,0.00014033208,0.00009240612,0.00002208256,0.00034119585,0.0000017133816],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023706016,0.00020505574,0.0041575953,0.32217622,0.6316873,0.00014497728,0.00010470259,0.0000024312924,1.6393071e-7,1.3706597e-7,0.000052432562,0.04123193],"study_design_scores_gemma":[0.002118121,0.00084704376,0.00426036,0.11649464,0.85605145,0.00003271159,0.0000041256417,5.858684e-7,4.378195e-7,1.1164301e-7,0.019994339,0.00019605806],"about_ca_topic_score_codex":0.000966307,"about_ca_topic_score_gemma":0.00041690865,"teacher_disagreement_score":0.22436419,"about_ca_system_score_codex":0.0005267872,"about_ca_system_score_gemma":0.0005055697,"threshold_uncertainty_score":0.9999952},"labels":[],"label_agreement":null},{"id":"W2736317985","doi":"10.1016/j.ejca.2017.07.001","title":"Medication use and kidney cancer risk: A population-based study","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Health Sciences Centre","funders":"","keywords":"Medicine; Kidney cancer; Cancer; Population; Internal medicine; Logistic regression; Comorbidity; Oncology; Environmental health","score_opus":0.01810572566441415,"score_gpt":0.2983849469832216,"score_spread":0.28027922131880745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2736317985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896029,0.0039507514,0.00038511306,0.00064413034,0.005110743,0.00011100566,0.000044314183,0.0000030444915,0.0001479799],"genre_scores_gemma":[0.98525006,0.003033517,0.00018536429,0.00041038505,0.010652352,0.00000458725,0.000005714047,0.000024234467,0.0004337999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990891,0.00019257898,0.00026224775,0.00015631333,0.00018605837,0.00011365197],"domain_scores_gemma":[0.9986524,0.000007921,0.0006480744,0.00030787467,0.00020617372,0.00017756448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005388413,0.00010312011,0.00014844608,0.000041050913,0.0001997827,0.000099903606,0.0002195845,0.000022618793,0.00004750717],"category_scores_gemma":[0.00045995414,0.00008501998,0.000062189574,0.000018328761,0.00004539922,0.000019277066,0.000046625064,0.0001171245,8.8920325e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020202844,0.000059410893,0.92594683,0.000009764995,0.00013974746,0.0000012110424,0.00015794854,0.00015856544,0.009711138,0.0000024341423,0.026682474,0.036928464],"study_design_scores_gemma":[0.0012572518,0.000111832494,0.67192805,0.00003534238,0.00009284767,0.0000020705284,0.000019964291,0.000015938927,0.00040504255,0.0000015977186,0.3260534,0.00007663525],"about_ca_topic_score_codex":0.00080021936,"about_ca_topic_score_gemma":0.00055454375,"teacher_disagreement_score":0.29937094,"about_ca_system_score_codex":0.000019373429,"about_ca_system_score_gemma":0.00020113794,"threshold_uncertainty_score":0.3467014},"labels":[],"label_agreement":null},{"id":"W2737912388","doi":"10.1016/j.ejca.2017.06.017","title":"Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Agence Nationale de la Recherche","keywords":"Medicine; Prospective cohort study; Univariate analysis; Sarcoma; Fibromatosis; Surgery; Proportional hazards model; Stage (stratigraphy); Log-rank test; Internal medicine; Oncology; Multivariate analysis; Pathology","score_opus":0.019999291473354736,"score_gpt":0.2820810608167539,"score_spread":0.26208176934339916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737912388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629671,0.002998455,0.000011825913,0.00063813425,0.000752938,0.0003691908,0.000014151736,0.000013519375,0.032234717],"genre_scores_gemma":[0.99750197,0.000469374,0.0006300415,0.000077903365,0.0010660046,0.000010144895,0.000012096377,0.000039607476,0.00019283792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980085,0.0002625472,0.0005455017,0.00024975973,0.000695642,0.000238047],"domain_scores_gemma":[0.99821305,0.0002977628,0.0005390175,0.00039147417,0.00042701536,0.00013166787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076508604,0.00020004898,0.00050801306,0.00007217086,0.00024444514,0.00006879874,0.00036793726,0.00003113704,0.000094820636],"category_scores_gemma":[0.00043482357,0.00012809203,0.0001560199,0.00014302589,0.00025838864,0.00019838108,0.00017454414,0.0005275324,0.000021263637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020617796,0.0002490746,0.9865096,0.000017588678,0.00040311326,0.0018248485,0.0007428629,0.0000062147074,0.000021059099,0.000012122534,0.0032234048,0.0049282894],"study_design_scores_gemma":[0.011120845,0.00063678616,0.9772635,0.000290837,0.00021023824,0.00012234904,0.00009107335,0.000016295171,0.00003292149,0.000010912275,0.010069753,0.00013447259],"about_ca_topic_score_codex":0.00020900645,"about_ca_topic_score_gemma":0.00003712956,"teacher_disagreement_score":0.03453492,"about_ca_system_score_codex":0.0002912017,"about_ca_system_score_gemma":0.00012268155,"threshold_uncertainty_score":0.5223441},"labels":[],"label_agreement":null},{"id":"W2739201943","doi":"10.1016/j.ejca.2017.06.027","title":"Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Frailty in Older Adults","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Cancéropôle Ile de France; Institut National Du Cancer; Ligue Contre le Cancer","keywords":"Value (mathematics); Cancer; Medicine; Oncology; Internal medicine; Gerontology; Mathematics; Statistics","score_opus":0.04090273044992476,"score_gpt":0.313270540236843,"score_spread":0.2723678097869182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739201943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899128,0.0021724699,0.0008976109,0.0054924916,0.00029797867,0.0009942603,0.000041895808,0.000003714018,0.00018677038],"genre_scores_gemma":[0.9958801,0.0001550737,0.003054759,0.00045501016,0.00017409549,0.000012167728,0.000001811692,0.000035866127,0.0002311144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986485,0.000116313546,0.0004644631,0.00014525856,0.0004111223,0.00021429085],"domain_scores_gemma":[0.9982256,0.0000927219,0.0009001607,0.00022763178,0.00042929756,0.00012454523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057645567,0.00012762756,0.0003155528,0.000058791513,0.00013548558,0.000027746524,0.00016395394,0.000016915501,0.000012519922],"category_scores_gemma":[0.0003965582,0.00007388532,0.00006090609,0.000048,0.00013295017,0.00021069613,0.00006105724,0.00025318816,2.2192248e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052731915,0.0001624261,0.8911917,0.00033864184,0.00012990397,0.000011717322,0.0013255969,0.0040873974,0.00015953305,0.000024157489,0.0013099409,0.10073163],"study_design_scores_gemma":[0.008106857,0.00064152863,0.9825391,0.006143344,0.00006773511,0.000014486849,0.000033797063,0.0005224754,0.00012959554,0.00000504043,0.0017141246,0.00008187125],"about_ca_topic_score_codex":0.00018137295,"about_ca_topic_score_gemma":0.00019270378,"teacher_disagreement_score":0.10064977,"about_ca_system_score_codex":0.00007580163,"about_ca_system_score_gemma":0.00029135688,"threshold_uncertainty_score":0.30129558},"labels":[],"label_agreement":null},{"id":"W2741471119","doi":"10.1016/j.ejca.2017.07.009","title":"Corrigendum to “Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles” [Eur J Cancer 70 (2017) 62–74]","year":2017,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"","keywords":"Epidermal growth factor receptor; Cell biology; Receptor; Extracellular; Chromosomal translocation; Nuclear receptor; Androgen receptor; Cancer research; Biology; Chemistry; Cancer; Biochemistry; Prostate cancer; Transcription factor; Genetics; Gene","score_opus":0.04744978896996189,"score_gpt":0.3105750915173028,"score_spread":0.2631253025473409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741471119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7203354,0.19146858,0.0010604296,0.01913426,0.03916354,0.002771219,0.0054452247,0.00015089197,0.020470414],"genre_scores_gemma":[0.6893451,0.0860656,0.00249095,0.0017056392,0.022859475,0.000056325953,0.00045496997,0.0007512984,0.19627061],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974499,0.00013773776,0.0010404892,0.0004132922,0.0005848669,0.0003737665],"domain_scores_gemma":[0.99680215,0.000025674823,0.0013838374,0.0004125315,0.0006290072,0.0007468141],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004163449,0.000407533,0.0008966277,0.0001056743,0.00019435723,0.0000459572,0.00045343678,0.00018488648,0.001859855],"category_scores_gemma":[0.000091829206,0.00036061677,0.00029375497,0.000114822345,0.00020661658,0.00015110338,0.000026367732,0.001146619,0.000039845265],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083232054,0.00016127671,0.00070088025,0.00083896675,0.000552622,0.0002937134,0.00096923974,0.0000065562785,0.33898127,0.000010164495,0.626841,0.02981197],"study_design_scores_gemma":[0.0013598287,0.00034281268,0.0068685645,0.0011916293,0.00069219794,0.000106777865,0.000049610935,0.00001405962,0.042237125,0.000005214056,0.9467671,0.0003650851],"about_ca_topic_score_codex":0.00004539073,"about_ca_topic_score_gemma":0.0000076562255,"teacher_disagreement_score":0.31992605,"about_ca_system_score_codex":0.00016710129,"about_ca_system_score_gemma":0.0004155621,"threshold_uncertainty_score":0.9998846},"labels":[],"label_agreement":null},{"id":"W2742715943","doi":"10.1016/j.ejca.2017.07.008","title":"Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut pour la Recherche en Santé Publique; Institut National Du Cancer","keywords":"Medicine; Docetaxel; Prostate cancer; Androgen deprivation therapy; Oncology; Internal medicine; Urology; Prostate; Chemotherapy; Cancer; Toxicity; Radiation therapy","score_opus":0.04500592833654836,"score_gpt":0.3658912636773313,"score_spread":0.32088533534078295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742715943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952529,0.0019607756,0.00003884061,0.0004964397,0.000048900365,0.0017711133,0.00016659756,0.000004609398,0.00025980294],"genre_scores_gemma":[0.9965713,0.0024123557,0.0000727218,0.00009092299,0.0000810187,0.00006734544,0.00005479624,0.00003741171,0.0006121088],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99762446,0.00046489507,0.00064769766,0.0002227116,0.0007690381,0.00027121356],"domain_scores_gemma":[0.99742204,0.000070246766,0.0013338198,0.0003562951,0.0006809627,0.00013661383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000946792,0.00024199988,0.0008547085,0.00027540632,0.0001612787,0.00009929215,0.00028292654,0.000017580578,0.00015618776],"category_scores_gemma":[0.000048502137,0.00010199114,0.00015426887,0.00047277487,0.00025252314,0.00026069165,0.000014963864,0.00025961242,5.782995e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7110724,0.00097098807,0.26013714,0.000032145144,0.006066574,0.00042757578,0.0028720128,0.00010803063,0.00096091774,3.2145707e-7,0.00030117508,0.017050741],"study_design_scores_gemma":[0.826316,0.009533164,0.15417977,0.00038410514,0.004300825,0.000012779882,0.00033935744,0.0001729225,0.0036004505,0.0000013018318,0.00095981755,0.00019951092],"about_ca_topic_score_codex":0.00037650316,"about_ca_topic_score_gemma":0.00036544097,"teacher_disagreement_score":0.11524363,"about_ca_system_score_codex":0.00013395378,"about_ca_system_score_gemma":0.00047888752,"threshold_uncertainty_score":0.41590783},"labels":[],"label_agreement":null},{"id":"W2742842577","doi":"10.1016/j.ejca.2017.07.004","title":"Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Uterine cancer; Breast cancer; Population; Cancer; Cohort; Gynecology; Relative risk; Epidemiology; Internal medicine; Cohort study; Incidence (geometry); Confidence interval; Oncology; Obstetrics","score_opus":0.015099615554415394,"score_gpt":0.3208820001586705,"score_spread":0.3057823846042551,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742842577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861573,0.0077459957,0.0037985921,0.0006049524,0.0007587687,0.00010501542,0.00019518743,0.0000016626154,0.00063254917],"genre_scores_gemma":[0.9925298,0.0039216205,0.001993478,0.00009112903,0.0007983524,0.0000067682204,0.0000030382764,0.000027757811,0.0006280281],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931264,0.00007061605,0.00027283528,0.00013166375,0.000106595646,0.00010562894],"domain_scores_gemma":[0.9985301,0.000009792246,0.0007892853,0.00023121471,0.00037564195,0.000064003456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042678555,0.00008962066,0.00013772804,0.00003564677,0.00012968438,0.000034492976,0.00022701082,0.00002489951,0.00003257159],"category_scores_gemma":[0.00018692874,0.000079960715,0.0000832109,0.000017894325,0.00013441266,0.000011811303,0.00005528895,0.00007101245,3.1053526e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090652006,0.000037666145,0.04624167,0.0001663281,0.001163155,0.000025550155,0.0010819572,0.0041627516,0.36896026,0.00003357243,0.015649892,0.5615707],"study_design_scores_gemma":[0.0037124648,0.0007600144,0.21955502,0.00012718124,0.00025180652,0.000054322005,0.00018162854,0.00013160054,0.28296992,0.00010123063,0.4918908,0.0002640202],"about_ca_topic_score_codex":0.000047198344,"about_ca_topic_score_gemma":0.00009449193,"teacher_disagreement_score":0.56130666,"about_ca_system_score_codex":0.000037178426,"about_ca_system_score_gemma":0.00017628867,"threshold_uncertainty_score":0.3260703},"labels":[],"label_agreement":null},{"id":"W2744364225","doi":"10.1016/j.ejca.2017.06.032","title":"A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC)","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Soft tissue sarcoma; Proportional hazards model; Multivariate statistics; Sarcoma; Soft tissue; Hazard ratio; Multivariate analysis; Discriminative model; Cohort; Internal medicine; Surgery; Radiology; Oncology; Computer science; Pathology; Artificial intelligence; Machine learning; Confidence interval","score_opus":0.07583548319883686,"score_gpt":0.3398017020309784,"score_spread":0.26396621883214155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744364225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97444826,0.016650433,0.0021090712,0.004575571,0.00046737603,0.0007293302,0.00025513288,0.000020798967,0.0007440194],"genre_scores_gemma":[0.9919586,0.0025647301,0.0041765813,0.00015850969,0.0005916525,0.000046555906,0.00001622632,0.00005606687,0.00043108137],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998411,0.00010830357,0.0005374703,0.00026698745,0.00038496987,0.00029125222],"domain_scores_gemma":[0.9983956,0.0001232439,0.00045491653,0.0004544839,0.00030815665,0.0002636013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002980182,0.00024250665,0.0005072994,0.00017468432,0.00027496452,0.000077083256,0.00023231283,0.000041507643,0.00003373497],"category_scores_gemma":[0.00019516498,0.00017454596,0.00030344265,0.000049788006,0.00007801089,0.0001845702,0.000038978338,0.00013701289,0.0000072484117],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013103263,0.0012360184,0.34553778,0.000038215923,0.00039526002,0.0013180957,0.0050217826,0.0013580434,0.0015471588,0.000053542662,0.0022620976,0.63992167],"study_design_scores_gemma":[0.02823314,0.0020484526,0.9193491,0.0012850882,0.0009927166,0.0002217738,0.00093963585,0.0077994037,0.0019121538,0.00012718272,0.036806315,0.00028508218],"about_ca_topic_score_codex":0.00014619972,"about_ca_topic_score_gemma":0.00029917006,"teacher_disagreement_score":0.6396366,"about_ca_system_score_codex":0.00077816716,"about_ca_system_score_gemma":0.0002647862,"threshold_uncertainty_score":0.7117778},"labels":[],"label_agreement":null},{"id":"W2745865617","doi":"10.1016/j.ejca.2017.07.034","title":"Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"FP7 Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Medical Research Council; National Institutes of Health; Kuopion Yliopistollinen Sairaala; NordForsk; Jane ja Aatos Erkon Säätiö; Cancer Research UK; Netherlands eScience Center; Academy of Finland; European Commission; Opetus- ja Kulttuuriministeriö; University of Southern California; Wellcome Trust; Cancer Research Wales; California Department of Public Health; National Institute for Social Care and Health Research; Tenovus","keywords":"Medicine; Colorectal cancer; Internal medicine; Polyunsaturated fatty acid; Arachidonic acid; Palmitoleic acid; Gastroenterology; Linoleic acid; Fatty acid; Oncology; Cancer; Biology; Biochemistry","score_opus":0.02739053353744542,"score_gpt":0.32411924639602707,"score_spread":0.29672871285858166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745865617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014073153,0.9925804,0.00020903375,0.000026650147,0.004272066,0.00044727817,0.00027185932,0.0000057065004,0.0007797038],"genre_scores_gemma":[0.00042406862,0.97973573,0.0001789694,0.000023791592,0.018635014,0.0000580718,0.000050918443,0.00007510173,0.000818311],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738216,0.0007677036,0.00088969676,0.00040070727,0.0002891549,0.00027054863],"domain_scores_gemma":[0.99647063,0.000015462316,0.0025996407,0.0003654947,0.00033633332,0.00021245118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013650217,0.00040239608,0.0014684293,0.00024786737,0.00018228768,0.000108722,0.0004353041,0.00014076667,0.00010442593],"category_scores_gemma":[0.00016667653,0.00030175314,0.00092449214,0.00013690442,0.00014337894,0.000016231697,0.000120262426,0.00042375622,0.0000050421586],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032226494,0.000018161882,0.00044030912,0.0008690939,0.0037219417,0.0000031983566,0.00010798733,0.000016807477,0.0009338863,0.0000011460229,0.009101059,0.98446417],"study_design_scores_gemma":[0.001767564,0.00010440087,0.0011449419,0.0011066257,0.007042405,0.000031891886,0.000012709797,0.0000042646443,0.000307988,8.9372026e-7,0.9881404,0.00033590474],"about_ca_topic_score_codex":0.000040967592,"about_ca_topic_score_gemma":0.0002293871,"teacher_disagreement_score":0.98412824,"about_ca_system_score_codex":0.000078899364,"about_ca_system_score_gemma":0.0008359839,"threshold_uncertainty_score":0.99994344},"labels":[],"label_agreement":null},{"id":"W2747443131","doi":"10.1016/j.ejca.2017.06.035","title":"Second malignant neoplasms after childhood non-central nervous system embryonal tumours in North America: A population-based study","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Dalhousie University; Pediatric Oncology Group; Sinai Health System; University of Alberta; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Incidence (geometry); Epidemiology; Population; Cumulative incidence; Embryonal rhabdomyosarcoma; Confidence interval; Cancer; Oncology; Rhabdomyosarcoma; Internal medicine; Pediatrics; Pathology; Sarcoma; Transplantation","score_opus":0.010461112354691913,"score_gpt":0.2702274095563842,"score_spread":0.25976629720169225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747443131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808556,0.00017645664,0.000013643637,0.00026366996,0.00033679284,0.00039838752,0.000033156164,0.000008961381,0.0006833765],"genre_scores_gemma":[0.9990647,0.000009021315,0.00008334704,0.00014241062,0.00038419117,0.000010318011,0.000004034416,0.000045459572,0.00025655556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981056,0.00023016754,0.00049330975,0.00021057056,0.0005705345,0.00038981336],"domain_scores_gemma":[0.9986303,0.000023857365,0.00048552797,0.00033860124,0.0001450717,0.0003766317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002235536,0.000189089,0.00040622003,0.00019448562,0.0001273637,0.000096859585,0.00024523542,0.000012001583,0.00018005405],"category_scores_gemma":[0.00005214659,0.00013724006,0.00014714233,0.00009954243,0.000037517933,0.0001587317,0.000048846912,0.0003576674,0.000035776367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012274497,0.0006687984,0.9721308,0.000050287545,0.00015120071,0.018683491,0.00039924233,0.00029313515,0.00006371301,1.9108394e-7,0.00012494341,0.0062067993],"study_design_scores_gemma":[0.006833357,0.0016895619,0.9901936,0.00042596832,0.00010242639,0.00016348345,0.00016452998,0.00009308673,0.00007401705,1.9834137e-7,0.00015130946,0.00010847646],"about_ca_topic_score_codex":0.00013046387,"about_ca_topic_score_gemma":0.0010588486,"teacher_disagreement_score":0.018520009,"about_ca_system_score_codex":0.00023811834,"about_ca_system_score_gemma":0.00030723054,"threshold_uncertainty_score":0.5596487},"labels":[],"label_agreement":null},{"id":"W2754512231","doi":"10.1016/j.ejca.2017.08.018","title":"Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Palbociclib; Hormone receptor; Oncology; Breast cancer; Medicine; Cancer; Internal medicine; Gynecology; Metastatic breast cancer","score_opus":0.017561565929232806,"score_gpt":0.32859981764821466,"score_spread":0.31103825171898186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754512231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96639556,0.015992502,0.001013598,0.0116970595,0.00062900624,0.00041459338,0.0003438225,0.000028428458,0.0034854081],"genre_scores_gemma":[0.99365216,0.003415322,0.0009362759,0.00056061783,0.0007546583,0.000013807314,0.000005127997,0.000059694725,0.00060233683],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977138,0.00025825572,0.0007528625,0.00033068017,0.00052920147,0.00041520633],"domain_scores_gemma":[0.9969998,0.00004816796,0.0012726971,0.0006206857,0.0007297901,0.00032887663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008257446,0.0002770283,0.0008525792,0.00031427795,0.00019004778,0.000067939895,0.00046983585,0.00003950723,0.00074513734],"category_scores_gemma":[0.00012329483,0.000228567,0.000379959,0.0003889242,0.00027385823,0.0005471529,0.00009171447,0.0006016766,0.00001568761],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007941932,0.00018813257,0.22472988,0.000027702254,0.0018169679,0.0005128873,0.0010149797,0.0006587655,0.012390415,0.000010206617,0.00045330526,0.7502548],"study_design_scores_gemma":[0.0063904235,0.00022963002,0.9734665,0.00046963312,0.00072542665,0.000103102444,0.00022170212,0.000081946746,0.0012074197,0.000019809628,0.01685659,0.00022781256],"about_ca_topic_score_codex":0.00020074502,"about_ca_topic_score_gemma":0.00028376927,"teacher_disagreement_score":0.750027,"about_ca_system_score_codex":0.00052480417,"about_ca_system_score_gemma":0.00029450585,"threshold_uncertainty_score":0.93206924},"labels":[],"label_agreement":null},{"id":"W2763004155","doi":"10.1016/j.ejca.2017.08.032","title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Sciences Centre; Jewish General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Alcohol and Drug Abuse Institute, University of Washington; Merck","keywords":"Ipilimumab; Pembrolizumab; Medicine; Oncology; Internal medicine; Melanoma; Immunotherapy; Cancer; Cancer research","score_opus":0.01614722972116736,"score_gpt":0.29094432069674336,"score_spread":0.27479709097557603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763004155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967468,0.00045618418,0.0000018104803,0.00015653831,0.00053929246,0.00072045275,0.000004368405,0.000004680184,0.0013698817],"genre_scores_gemma":[0.9996476,0.00009347859,0.000054965873,0.000054777498,0.000039594215,0.0000072401454,0.0000011820143,0.000034878412,0.00006626112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997847,0.00021156731,0.0010100962,0.00017770559,0.0005473085,0.00020631142],"domain_scores_gemma":[0.9976316,0.000056505163,0.001507052,0.0004359064,0.0002853646,0.000083553234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004794751,0.00018819301,0.0006890515,0.0002439647,0.00005484463,0.000022135897,0.00021651454,0.000022042394,0.00006466044],"category_scores_gemma":[0.00019701126,0.0001267424,0.00012971763,0.000119276316,0.00008245669,0.00019813827,0.000038479444,0.00025573198,8.4689594e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30845466,0.001032134,0.6333559,0.000016885595,0.00047922193,0.0003816497,0.0014489416,0.00004834285,0.0002606353,1.4139157e-7,0.000035365025,0.054486122],"study_design_scores_gemma":[0.31077358,0.0060979873,0.6817532,0.00031530843,0.00010286675,0.0000045779657,0.0003692727,0.0000021955977,0.00018978133,3.628938e-7,0.00029645322,0.00009440268],"about_ca_topic_score_codex":0.00014415922,"about_ca_topic_score_gemma":0.00033008622,"teacher_disagreement_score":0.05439172,"about_ca_system_score_codex":0.00019696061,"about_ca_system_score_gemma":0.00017549624,"threshold_uncertainty_score":0.51684046},"labels":[],"label_agreement":null},{"id":"W2763638659","doi":"10.1016/j.ejca.2017.07.055","title":"Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Breast Cancer Foundation; Cancer Research UK","keywords":"Medicine; Mammography; Breast cancer; Confidence interval; Meta-analysis; Interquartile range; Family history; Population; Breast cancer screening; Gynecology; Incidence (geometry); Magnetic resonance imaging; Oncology; Internal medicine; Obstetrics; Cancer; Radiology","score_opus":0.15627248715909242,"score_gpt":0.39809858340696763,"score_spread":0.2418260962478752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763638659","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023532335,0.9831079,0.0006228524,0.000041364507,0.00036400362,0.00027936941,0.013084539,0.000002625858,0.00014407543],"genre_scores_gemma":[0.010332286,0.98563385,0.002169032,0.00004070627,0.00092196517,0.00003613693,0.00046426864,0.00009929229,0.0003024658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99532574,0.0011732256,0.0018668816,0.00058369816,0.000750354,0.00030008482],"domain_scores_gemma":[0.988563,0.00006939502,0.008570975,0.0016984228,0.0009299076,0.00016831596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018894424,0.00047270898,0.002622687,0.0003335142,0.00014142609,0.000051926243,0.00199696,0.00012769828,0.00049372634],"category_scores_gemma":[0.0002805389,0.0003533774,0.0016863956,0.00032653383,0.0002416051,0.00003138819,0.0010051421,0.00038331794,0.0000026014472],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013104263,0.00004565355,0.00018883195,0.0005579499,0.17765892,0.000023318687,0.00030330342,0.0016750474,0.00007423007,1.7426325e-7,0.0018206273,0.8175209],"study_design_scores_gemma":[0.000531174,0.00018968237,0.0006827409,0.00043952197,0.21620679,0.00010556935,0.00005072697,0.000010930448,0.00028766165,7.853055e-7,0.7811458,0.00034859654],"about_ca_topic_score_codex":0.0001124752,"about_ca_topic_score_gemma":0.00015518483,"teacher_disagreement_score":0.8171723,"about_ca_system_score_codex":0.00018485587,"about_ca_system_score_gemma":0.0015011358,"threshold_uncertainty_score":0.9998918},"labels":[],"label_agreement":null},{"id":"W2765682155","doi":"10.1016/j.ejca.2017.09.028","title":"Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Cabazitaxel; Medicine; Prostate cancer; Prednisone; Genitourinary system; Oncology; Internal medicine; Prostate; Urology; Cancer; Gynecology; Androgen deprivation therapy","score_opus":0.07250577496601725,"score_gpt":0.4126444029825152,"score_spread":0.34013862801649797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765682155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97294515,0.014860819,0.00016327552,0.0070136166,0.0010618905,0.0026800958,0.00045043384,0.000014094639,0.0008106485],"genre_scores_gemma":[0.98662704,0.0048756637,0.0008504079,0.00019554255,0.0017780096,0.00023230832,0.000015339421,0.0000755353,0.0053501474],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99774575,0.0003230997,0.00065246044,0.00034793597,0.00047301923,0.000457754],"domain_scores_gemma":[0.99764836,0.00014189424,0.00094442983,0.00031149646,0.00056036323,0.00039344098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011130901,0.00028744354,0.0007608743,0.00015556031,0.00074035674,0.00014724601,0.00025486673,0.000043185028,0.00009511837],"category_scores_gemma":[0.00015268728,0.00021058627,0.00022034338,0.00007374923,0.00031757707,0.00035860142,0.000113730865,0.0004024685,0.0000025608913],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3781279,0.0017546073,0.00082378136,0.0007161209,0.002807074,0.005011283,0.006709527,0.00003087174,0.06652182,0.00003214578,0.0152309295,0.52223396],"study_design_scores_gemma":[0.67862767,0.12991709,0.025053095,0.0019745617,0.003839914,0.00079767447,0.002247933,0.00036067519,0.02135562,0.00022572913,0.13479239,0.0008076635],"about_ca_topic_score_codex":0.00023621075,"about_ca_topic_score_gemma":0.00023735935,"teacher_disagreement_score":0.52142626,"about_ca_system_score_codex":0.0006684959,"about_ca_system_score_gemma":0.0011306521,"threshold_uncertainty_score":0.8587459},"labels":[],"label_agreement":null},{"id":"W2773080639","doi":"10.1016/j.ejca.2017.11.012","title":"Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Cancer Research UK","keywords":"Hazard ratio; Medicine; Internal medicine; Confidence interval; Proportional hazards model; Univariate analysis; Neutrophil to lymphocyte ratio; Logistic regression; Lymphocyte; Multivariate analysis; Oncology; Gastroenterology","score_opus":0.025010536197043288,"score_gpt":0.33994306862457024,"score_spread":0.31493253242752695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773080639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99549854,0.0007329994,0.000020921143,0.00045806236,0.0007560031,0.00044064736,0.000038127564,0.000008014505,0.0020466745],"genre_scores_gemma":[0.9984,0.00023383714,0.00044132918,0.00019353502,0.00059429626,0.0000046887903,0.0000037444738,0.00006125362,0.000067318964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971419,0.00044044058,0.0013121216,0.00018997504,0.0006723931,0.00024316534],"domain_scores_gemma":[0.99607134,0.000067951216,0.0025791468,0.0004495946,0.0005931117,0.00023883655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013017778,0.00022961119,0.0007722061,0.00026441042,0.00008010295,0.00004231698,0.00030768674,0.00003117439,0.00011771756],"category_scores_gemma":[0.00088455685,0.00016449363,0.000214878,0.00009249116,0.00019462932,0.00021028663,0.000050985305,0.00024079221,0.0000069334524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14933133,0.004153961,0.47295505,0.0004491031,0.0012661278,0.002884545,0.0011453725,0.0017539925,0.04512066,0.000027866177,0.0061593316,0.31475267],"study_design_scores_gemma":[0.048908148,0.0052005425,0.86931145,0.0027871078,0.0004574112,0.000011094961,0.000050276194,0.000023302104,0.06941146,0.0000051168386,0.0035913715,0.00024274035],"about_ca_topic_score_codex":0.0000022987379,"about_ca_topic_score_gemma":0.0000025594693,"teacher_disagreement_score":0.3963564,"about_ca_system_score_codex":0.00023155987,"about_ca_system_score_gemma":0.00028336854,"threshold_uncertainty_score":0.67078555},"labels":[],"label_agreement":null},{"id":"W2773416496","doi":"10.1016/j.ejca.2017.10.037","title":"A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Human Epidermal Growth Factor Receptor 2; Medicine; Breast cancer; Cancer; Intensive care medicine; Metastatic breast cancer; Epidermal growth factor receptor; Targeted therapy; Value (mathematics); Oncology; Internal medicine; Computer science","score_opus":0.14677084885074435,"score_gpt":0.4564360463690129,"score_spread":0.3096651975182686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773416496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018581287,0.99316585,9.779963e-7,0.002509631,0.00084115734,0.0010193152,0.00043441734,0.0000061497813,0.0018366779],"genre_scores_gemma":[0.0006373939,0.99663746,0.000051990493,0.00042927035,0.0013254564,0.000029908206,0.0000057254474,0.00017042203,0.00071234297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926835,0.0026617586,0.0026001183,0.0003350167,0.0012602742,0.00045939177],"domain_scores_gemma":[0.99289626,0.00015761252,0.0045004017,0.00095885573,0.0012470996,0.00023978834],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031209965,0.000510292,0.0036379276,0.00035675993,0.00008971282,0.000025219217,0.0016083131,0.00011583661,0.0036042333],"category_scores_gemma":[0.00057189463,0.00028927712,0.0014026188,0.00049671583,0.00045032232,0.0001312433,0.00022836572,0.0018056103,0.000012792717],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007418376,0.00010518056,0.0017113008,0.13689794,0.0008645223,0.00007909229,0.00028112883,4.1541878e-7,0.000090717534,0.000012895809,0.020964656,0.838918],"study_design_scores_gemma":[0.00060994225,0.00014910845,0.007893062,0.3550937,0.00056637754,0.00011073144,0.00000945691,1.3782847e-7,0.00004203376,0.000002612073,0.6353566,0.00016622953],"about_ca_topic_score_codex":0.0004448141,"about_ca_topic_score_gemma":0.00004035694,"teacher_disagreement_score":0.83875173,"about_ca_system_score_codex":0.00066699897,"about_ca_system_score_gemma":0.0030987503,"threshold_uncertainty_score":0.99995595},"labels":[],"label_agreement":null},{"id":"W2774227900","doi":"10.1016/j.ejca.2017.10.021","title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"F. Hoffmann-La Roche; Roche","keywords":"Pertuzumab; Anthracycline; Trastuzumab; Medicine; Oncology; Internal medicine; Chemotherapy; Cancer; Breast cancer","score_opus":0.02363119783183756,"score_gpt":0.37978011214785656,"score_spread":0.356148914316019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774227900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307084,0.0028023352,0.000054072523,0.0017847524,0.00020281874,0.0015772951,0.0003471153,0.000007642526,0.00015312001],"genre_scores_gemma":[0.9975265,0.001786866,0.000104186365,0.00009144741,0.0003052286,0.0000148905565,0.0000041982444,0.000085252475,0.00008139956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954165,0.00097225077,0.0011648015,0.0004866115,0.0015047368,0.00045510472],"domain_scores_gemma":[0.9959635,0.00025719788,0.0015387157,0.00086922926,0.0010650035,0.00030634482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029329043,0.00037790128,0.0016515935,0.00034225747,0.00058032986,0.00012617013,0.00054580334,0.000047721256,0.00010850918],"category_scores_gemma":[0.0004384793,0.0002377097,0.00029014377,0.00039421782,0.0006151546,0.00030651668,0.00026150752,0.00076986826,1.6281716e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0806468,0.0006203529,0.6994997,0.000048768932,0.0031113506,0.0001579506,0.008824017,0.00025340333,0.00040178516,2.8743764e-7,0.000030872718,0.2064047],"study_design_scores_gemma":[0.15086105,0.00690232,0.83696014,0.0017245476,0.0023260738,0.000018535216,0.0004957706,0.0002483084,0.00022659227,4.888959e-7,0.000025134219,0.00021103259],"about_ca_topic_score_codex":0.0006312401,"about_ca_topic_score_gemma":0.00045343454,"teacher_disagreement_score":0.20619367,"about_ca_system_score_codex":0.0006893111,"about_ca_system_score_gemma":0.0008224472,"threshold_uncertainty_score":0.969352},"labels":[],"label_agreement":null},{"id":"W2775300375","doi":"10.1016/j.ejca.2017.11.004","title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center","keywords":"Veliparib; Medicine; Internal medicine; Gastroenterology; Clinical endpoint; Hazard ratio; PARP inhibitor; Oncology; BRCA mutation; Phases of clinical research; Pancreatic cancer; Confidence interval; Surgery; Cancer; Clinical trial; Breast cancer; Poly ADP ribose polymerase; Biology","score_opus":0.03449127913236837,"score_gpt":0.3551758726349117,"score_spread":0.3206845935025433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775300375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933184,0.00075093197,0.000009200243,0.0003845564,0.00015222206,0.0005172803,0.000012903774,0.000005128658,0.0048494027],"genre_scores_gemma":[0.9983003,0.00024334014,0.00018871424,0.00003908529,0.00034039863,0.000004217108,0.0000062394774,0.000031128526,0.00084653805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998062,0.00030986525,0.0006809709,0.00015463961,0.00051351317,0.00027901362],"domain_scores_gemma":[0.9979335,0.000043332984,0.00087492424,0.00035135157,0.00056797673,0.00022891317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000912595,0.00015120578,0.0007483539,0.00017385246,0.00012077827,0.000018940069,0.00027262,0.000037004014,0.00022344556],"category_scores_gemma":[0.0004384936,0.00010031186,0.000099215125,0.00009795616,0.00024942655,0.00014865615,0.00006242929,0.00036240867,0.0000063255575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13180998,0.002193578,0.8498898,0.0000394517,0.00040515172,0.0009993821,0.00059615844,0.000002024642,0.0003015299,0.0000031699785,0.00068492856,0.013074861],"study_design_scores_gemma":[0.22529732,0.022581957,0.7503016,0.00048288537,0.0003974032,0.000045301662,0.000027503862,0.000018388324,0.00022965438,0.0000026276446,0.00053536316,0.000079994716],"about_ca_topic_score_codex":0.00013389831,"about_ca_topic_score_gemma":0.000024588868,"teacher_disagreement_score":0.099588186,"about_ca_system_score_codex":0.0001239172,"about_ca_system_score_gemma":0.0005080738,"threshold_uncertainty_score":0.40905988},"labels":[],"label_agreement":null},{"id":"W2775554882","doi":"10.1016/j.ejca.2017.10.027","title":"C-statistic: A brief explanation of its construction, interpretation and limitations","year":2017,"lang":"en","type":"editorial","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Statistic; Interpretation (philosophy); Event (particle physics); Disease; Medicine; Psychology; Actuarial science; Computer science; Statistics; Mathematics; Pathology; Economics","score_opus":0.34385099275191666,"score_gpt":0.5225399485208768,"score_spread":0.17868895576896016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775554882","genre_codex":"editorial","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010915892,0.001591935,0.26884577,0.00027342263,0.7194824,0.00027986596,0.00095265,0.00001575521,0.008449012],"genre_scores_gemma":[0.002094003,0.0064204894,0.6135161,0.000023090122,0.3771854,0.000006021001,0.000010434023,0.00009839632,0.0006460822],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954913,0.0015758252,0.0017878717,0.00020515228,0.0008075658,0.0001322832],"domain_scores_gemma":[0.95376647,0.03882505,0.004673421,0.00024731716,0.0023675396,0.000120222234],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043465523,0.00020731633,0.0008263261,0.00017268411,0.0000843442,0.00009482204,0.00035086487,0.00014416344,0.00009756738],"category_scores_gemma":[0.32507885,0.00018016328,0.00013964082,0.000059472455,0.00029011292,0.00017308899,0.00006224015,0.00070676336,0.0000036316787],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029878743,0.000034695404,0.000008299451,0.0004488083,0.0003011555,0.000037483052,0.00042671224,0.0000050996346,0.000043817457,0.005319001,0.7397542,0.25332198],"study_design_scores_gemma":[0.0037296123,0.0009237411,0.00052498013,0.005158449,0.0017984954,0.000034609864,0.0001599147,0.00015442586,0.00024000296,0.22727479,0.75952214,0.00047885193],"about_ca_topic_score_codex":0.0000029362973,"about_ca_topic_score_gemma":0.000012920415,"teacher_disagreement_score":0.3446703,"about_ca_system_score_codex":0.000068109235,"about_ca_system_score_gemma":0.00036745254,"threshold_uncertainty_score":0.7346845},"labels":[],"label_agreement":null},{"id":"W2775983457","doi":"10.1016/j.ejca.2017.11.014","title":"Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Nova Scotia Cancer Centre; Queen's University; Southlake Regional Health Center","funders":"National Cancer Institute; Canadian Cancer Society Research Institute","keywords":"Anastrozole; Exemestane; Medicine; Breast cancer; Internal medicine; Hazard ratio; Oncology; Aromatase inhibitor; Cancer; Proportional hazards model; Tamoxifen; Confidence interval","score_opus":0.013748039301218713,"score_gpt":0.2628087022108036,"score_spread":0.2490606629095849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2775983457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972994,0.0007837515,0.000010091142,0.0009998117,0.000117351665,0.00023629567,0.00019712278,0.0000057632383,0.0003504114],"genre_scores_gemma":[0.99502736,0.0021906418,0.00017763925,0.00023328574,0.00024043306,0.0000373174,0.0000050599556,0.00007854026,0.0020097336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981572,0.00017631766,0.00044620503,0.00038948996,0.00032261724,0.0005081511],"domain_scores_gemma":[0.99832314,0.000028294387,0.00072134536,0.00044157455,0.0003013952,0.00018424189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023019726,0.00038546335,0.0005639089,0.00014113626,0.00012604702,0.00009233562,0.00048230457,0.00004546468,0.00016613975],"category_scores_gemma":[0.000075581476,0.00022486983,0.00006036955,0.00014601527,0.00026749427,0.00005947432,0.00014489998,0.00023985773,0.000003978541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018839454,0.00019902583,0.9655697,0.000050486124,0.00084282237,0.005630702,0.001089275,0.00039070452,0.0043409704,0.0000010167491,0.00027355037,0.0027723073],"study_design_scores_gemma":[0.008277791,0.0016570009,0.98172,0.0006267307,0.00008270231,0.00031081255,0.001012561,5.6399614e-7,0.0050516967,8.5020713e-7,0.0009313376,0.00032797773],"about_ca_topic_score_codex":0.0012578195,"about_ca_topic_score_gemma":0.02625917,"teacher_disagreement_score":0.02500135,"about_ca_system_score_codex":0.00034192225,"about_ca_system_score_gemma":0.0009168664,"threshold_uncertainty_score":0.9915091},"labels":[],"label_agreement":null},{"id":"W2778766384","doi":"10.1016/j.ejca.2017.11.010","title":"Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Universitair Medisch Centrum Utrecht; ZonMw; Sanofi; Genentech; AstraZeneca; Roche; Amgen","keywords":"Medicine; Breast cancer; Internal medicine; Tamoxifen; Hazard ratio; Oncology; Exemestane; Proportional hazards model; Gynecology; Population; Cohort; Cancer; Confidence interval","score_opus":0.010531406704986482,"score_gpt":0.28227025625185104,"score_spread":0.27173884954686456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778766384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936506,0.0045212475,0.000006655725,0.00034960834,0.00039190685,0.00032795788,0.0005751994,0.0000039943798,0.00017280031],"genre_scores_gemma":[0.99689984,0.0021101576,0.000059719245,0.000057628025,0.00040903073,0.00007585146,0.000051912146,0.000046714933,0.000289113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855524,0.00015563292,0.00046780027,0.0002769346,0.00032005506,0.00022435788],"domain_scores_gemma":[0.99829173,0.000012902023,0.00089642697,0.0004018438,0.00027994678,0.00011716865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011937008,0.0002565592,0.00041897214,0.000041489704,0.00021780343,0.0000316107,0.00028409247,0.000020524545,0.000117678435],"category_scores_gemma":[0.00002567765,0.00019414978,0.00018458585,0.000029859857,0.00008490042,0.0000128734155,0.00009745336,0.000051954754,0.0000022363633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071358663,0.0011961836,0.97629553,0.0000103026005,0.0009247724,0.00007324008,0.00012299618,0.0004360656,0.0007380941,1.1022351e-7,0.0025086848,0.016980417],"study_design_scores_gemma":[0.0055214595,0.0013898528,0.98066545,0.000087920205,0.0003926978,0.000007782643,0.000027858028,0.0000027815859,0.005789026,1.9726285e-7,0.005942489,0.000172497],"about_ca_topic_score_codex":0.0015716229,"about_ca_topic_score_gemma":0.000818498,"teacher_disagreement_score":0.016807921,"about_ca_system_score_codex":0.0002744263,"about_ca_system_score_gemma":0.00007538893,"threshold_uncertainty_score":0.7917198},"labels":[],"label_agreement":null},{"id":"W2784121544","doi":"10.1016/j.ejca.2017.12.010","title":"Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Health Sciences Centre; CancerCare Manitoba; University of Toronto; Sunnybrook Health Science Centre; University of Manitoba; Western University","funders":"","keywords":"Phosphoinositide 3-kinase; Medicine; Oncology; Breast cancer; Meta-analysis; Cancer; Internal medicine; PI3K/AKT/mTOR pathway; Biology; Signal transduction; Genetics","score_opus":0.04518991375417572,"score_gpt":0.364431768677626,"score_spread":0.31924185492345025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784121544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000005583087,0.99671566,0.000033392014,0.0008746823,0.00020192127,0.0017191566,0.0002802154,0.000020268659,0.00014911244],"genre_scores_gemma":[0.000074019335,0.996654,0.00037850995,0.0012683141,0.00043673126,0.00019085918,0.000008132563,0.00017770725,0.0008117765],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99379253,0.0013142328,0.0031303293,0.0005767001,0.0007370378,0.00044917053],"domain_scores_gemma":[0.9938584,0.00015231027,0.004117709,0.000727008,0.00074830215,0.00039624717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001987333,0.0008534836,0.013082633,0.00083064364,0.000057905814,0.000045098077,0.00044177443,0.00008154421,0.0008357495],"category_scores_gemma":[0.00014580195,0.0005289186,0.0034351589,0.0017210444,0.00018754389,0.00025994604,0.00011058966,0.00089419814,0.000020733707],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000890615,0.00006319668,0.000014294381,0.7050606,0.15028846,0.0008071809,0.000108224485,0.000009574626,9.0882025e-7,0.000002226123,0.00038019483,0.1431761],"study_design_scores_gemma":[0.0005273898,0.000100181045,0.000025402045,0.23266804,0.59640265,0.0010987818,0.000017667677,3.4020388e-7,0.0000018420694,0.0000014591593,0.168833,0.0003232379],"about_ca_topic_score_codex":0.000041483345,"about_ca_topic_score_gemma":0.000054766486,"teacher_disagreement_score":0.47239256,"about_ca_system_score_codex":0.0007089711,"about_ca_system_score_gemma":0.0006176705,"threshold_uncertainty_score":0.9997162},"labels":[],"label_agreement":null},{"id":"W2786053204","doi":"10.1016/j.ejca.2018.01.074","title":"Mapping the cancer patient information landscape: A comparative analysis of patient groups across Europe and North America","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University; Queen's University Belfast; European Commission; Public Health Agency; National Institute for Health and Care Research","keywords":"Medicine; Family medicine; Clinical trial; Medical information; Internal medicine","score_opus":0.05532690479406483,"score_gpt":0.40863850270057994,"score_spread":0.3533115979065151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786053204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190766,0.0007040391,0.0012981155,0.000655556,0.0005008473,0.00025143975,0.00016589492,0.000008024846,0.004508424],"genre_scores_gemma":[0.9932846,0.0005667267,0.00020073597,0.0057077683,0.00019491593,0.000009619246,0.00001233826,0.0000053099416,0.000018008755],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99635935,0.001026246,0.0019349494,0.00008371173,0.00034322185,0.00025252477],"domain_scores_gemma":[0.9947055,0.00015442196,0.0029886216,0.00019753414,0.0018207846,0.0001331314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012300665,0.000113501665,0.0003516568,0.00015108976,0.0005373711,0.000032696076,0.00020516313,0.00001874072,0.0004640815],"category_scores_gemma":[0.00015000532,0.000065976565,0.00007547477,0.0010816179,0.00015126257,0.00095666276,0.00012762102,0.00041282168,0.000028051185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030115212,0.00002911403,0.32358146,0.00012556303,0.00035391477,0.0000010622015,0.45845464,0.0008889019,0.000007509573,0.00001302119,0.008632724,0.20761092],"study_design_scores_gemma":[0.00036263632,0.00018635126,0.57432467,0.00014761121,0.00006343222,5.669739e-7,0.016270727,0.0022460923,0.000008034871,0.0000011385546,0.40632403,0.00006467837],"about_ca_topic_score_codex":0.000112838825,"about_ca_topic_score_gemma":0.00022425174,"teacher_disagreement_score":0.4421839,"about_ca_system_score_codex":0.0000718301,"about_ca_system_score_gemma":0.00019425525,"threshold_uncertainty_score":0.5081367},"labels":[],"label_agreement":null},{"id":"W2789828078","doi":"10.1016/j.ejca.2018.01.115","title":"RE: Rydzewska et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Oct; 84:88–101","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Prostate cancer; Abiraterone acetate; Androgen deprivation therapy; Medicine; Oncology; Abiraterone; Hormone therapy; Internal medicine; Cancer; Testosterone (patch); Gynecology; Androgen receptor; Breast cancer","score_opus":0.1329532489911135,"score_gpt":0.41736354855507046,"score_spread":0.28441029956395697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789828078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013308367,0.9880377,0.00003124209,0.005688155,0.000051339764,0.0053572874,0.0003704461,0.000016215887,0.00031452856],"genre_scores_gemma":[0.0002791562,0.9930595,0.00034083737,0.003298044,0.000107408305,0.00076978165,0.000055942044,0.00016315696,0.001926135],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9929382,0.002556415,0.0021406664,0.0007304623,0.0010689526,0.0005652878],"domain_scores_gemma":[0.9949639,0.00017741337,0.00264977,0.0006194326,0.0011345673,0.00045491927],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043287287,0.00082268787,0.0080832895,0.0008957381,0.00011288698,0.00014034104,0.00036155226,0.00005063935,0.00015618165],"category_scores_gemma":[0.0001366675,0.00043443838,0.0010029805,0.0016692281,0.00013619846,0.00029788786,0.00010482772,0.0007559836,0.000016041024],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021854115,0.00029184917,0.00012492744,0.3771465,0.5120145,0.004589186,0.003666266,0.000078526704,0.000037814774,0.000003719956,0.04697644,0.052884873],"study_design_scores_gemma":[0.0034097466,0.0018724566,0.00014254084,0.1542736,0.613596,0.00029719016,0.00017371385,0.00000879171,0.00003147664,0.0000013845121,0.22547205,0.0007210044],"about_ca_topic_score_codex":0.0002323436,"about_ca_topic_score_gemma":0.00036462274,"teacher_disagreement_score":0.2228729,"about_ca_system_score_codex":0.00078295043,"about_ca_system_score_gemma":0.0011554606,"threshold_uncertainty_score":0.99981076},"labels":[],"label_agreement":null},{"id":"W2790268936","doi":"10.1016/j.ejca.2018.02.023","title":"Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"AbbVie; Cancer Research UK; Roche; Merck","keywords":"Temozolomide; Glioma; Oncology; Radiation therapy; Hazard ratio; Gene expression profiling; Internal medicine; Progression-free survival; Biology; Chemotherapy; Medicine; Cancer research; Gene expression; Gene; Genetics","score_opus":0.045674254053372415,"score_gpt":0.34580039851200606,"score_spread":0.3001261444586336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790268936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937486,0.00202038,0.0000075595826,0.0019496785,0.0014013702,0.00047750646,0.000008689459,0.00000794933,0.00037824054],"genre_scores_gemma":[0.9977948,0.00007670644,0.00015536166,0.00026001083,0.0016493385,0.000008316457,8.1491197e-7,0.000032185824,0.000022454016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973836,0.0006243417,0.0010842442,0.00018661507,0.0005078584,0.00021336744],"domain_scores_gemma":[0.99784803,0.0002772568,0.0009953363,0.00033231385,0.00037501767,0.00017202635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010268978,0.00016582201,0.00051246834,0.00021739374,0.000049744856,0.000017851356,0.00024817308,0.00004350235,0.00016948972],"category_scores_gemma":[0.00093658594,0.00009223972,0.00034441653,0.00044206827,0.00025229168,0.000052540818,0.0000553744,0.0003100592,0.00001567968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023310611,0.0028610043,0.93672395,0.000090106594,0.00023935818,0.0030731782,0.00026258262,0.00005179497,0.0046804026,0.000012963503,0.004498374,0.024195664],"study_design_scores_gemma":[0.05763954,0.0029352894,0.8869668,0.0029290975,0.00026894055,0.000078043944,0.0000577391,0.000023301009,0.044620097,0.000016040483,0.0043520546,0.00011301508],"about_ca_topic_score_codex":0.000012777097,"about_ca_topic_score_gemma":0.000041771746,"teacher_disagreement_score":0.049757116,"about_ca_system_score_codex":0.00007320373,"about_ca_system_score_gemma":0.00031235648,"threshold_uncertainty_score":0.37614265},"labels":[],"label_agreement":null},{"id":"W2791246024","doi":"10.1016/j.ejca.2018.02.018","title":"Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Kingston Health Sciences Centre; Queen's University","funders":"European Regional Development Fund; Centro de Investigación Biomédica en Red de Cáncer","keywords":"Breast cancer; Hormone receptor; Oncology; Internal medicine; Medicine; Gynecology; Cancer","score_opus":0.019449076779266935,"score_gpt":0.28840335478993673,"score_spread":0.2689542780106698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791246024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028236,0.0051923264,0.000038092163,0.0008137728,0.0009902308,0.00014194298,0.00013639216,0.000006328615,0.002398558],"genre_scores_gemma":[0.9973293,0.0008838074,0.00011904009,0.00010419649,0.001311783,0.0000069693233,0.0000046385653,0.000044744276,0.00019552448],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99865437,0.00015565609,0.0004301625,0.00023698734,0.00028292154,0.00023992476],"domain_scores_gemma":[0.9984179,0.000017649701,0.0005157032,0.00023771013,0.00070634513,0.00010468117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002532467,0.00022056751,0.00035396533,0.000060137136,0.00009593696,0.000018455577,0.0002672266,0.000029465304,0.000075104945],"category_scores_gemma":[0.000022041071,0.000173339,0.00016380682,0.00013155382,0.00021744602,0.000013179496,0.0001371818,0.00010320438,0.000011557025],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029215178,0.0025496555,0.2703564,0.000024530471,0.0072738496,0.00010081798,0.0033696406,0.000072296796,0.6046114,0.000012766544,0.031048365,0.05136514],"study_design_scores_gemma":[0.01253207,0.0047806567,0.83273673,0.00008788069,0.00043773354,0.000036390284,0.00067159825,4.736316e-7,0.13779095,0.000001615328,0.01061688,0.0003070267],"about_ca_topic_score_codex":0.0001825052,"about_ca_topic_score_gemma":0.00026557944,"teacher_disagreement_score":0.5623803,"about_ca_system_score_codex":0.00010834177,"about_ca_system_score_gemma":0.00012032219,"threshold_uncertainty_score":0.7068559},"labels":[],"label_agreement":null},{"id":"W2793932391","doi":"10.1016/j.ejca.2018.01.084","title":"Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis?","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministero della Salute; Fondazione Cariplo; European Commission; Ministry of Health, British Columbia; Compagnia di San Paolo","keywords":"Stage (stratigraphy); Relative survival; Cancer; Medicine; Demography; Population; Disease; Cancer registry; Internal medicine; Environmental health; Biology","score_opus":0.10159868876976337,"score_gpt":0.3830506512152793,"score_spread":0.28145196244551596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793932391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984034,0.0020888883,0.0004618485,0.0053832247,0.0011856323,0.0003241337,0.000074590134,0.000013367483,0.0064343275],"genre_scores_gemma":[0.97687376,0.00087334967,0.0005156946,0.0064883824,0.0024979892,0.00001894897,0.0000011271691,0.00007537885,0.012655388],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99796563,0.00014920718,0.00064299325,0.000268207,0.0005469746,0.00042695983],"domain_scores_gemma":[0.9981043,0.000048684295,0.00035676386,0.00022954764,0.0008936114,0.00036711214],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010724327,0.00020136942,0.00043836978,0.00015797521,0.00007486255,0.0000419088,0.00029983962,0.000027221882,0.0012249135],"category_scores_gemma":[0.00020277263,0.00016421206,0.00014592975,0.00032423588,0.00006784817,0.00016427225,0.00012603847,0.00023784289,0.00011746199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060757967,0.00016526839,0.84127486,0.00023343627,0.00032480646,0.0023678816,0.0051269056,0.0026247036,0.006374625,0.000030771498,0.031035218,0.10436575],"study_design_scores_gemma":[0.0028603035,0.0014076525,0.40913242,0.0017658876,0.0000915464,0.000026537,0.000083841885,0.00018143508,0.0053153136,0.000002743436,0.5789053,0.00022704146],"about_ca_topic_score_codex":0.0001806831,"about_ca_topic_score_gemma":0.0018383632,"teacher_disagreement_score":0.54787004,"about_ca_system_score_codex":0.00033472388,"about_ca_system_score_gemma":0.0002869595,"threshold_uncertainty_score":0.9996881},"labels":[],"label_agreement":null},{"id":"W2794015106","doi":"10.1016/j.ejca.2018.01.073","title":"Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; BC Cancer Agency","funders":"Institute of Infection and Immunity; National Cancer Institute; Cognitive Neuroscience Society; H. Lundbeck A/S; Jackson College; University of Mumbai; University of Florida; A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal; Celgene; Gilead Sciences; Roche; Novartis","keywords":"Diffuse large B-cell lymphoma; Medicine; Lymphoma; Internal medicine; Oncology","score_opus":0.010957315069320607,"score_gpt":0.24673308295176002,"score_spread":0.23577576788243942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794015106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587566,0.0021301745,0.000005608399,0.00021663719,0.00013375594,0.00031510138,0.00007403301,0.000008342284,0.001240684],"genre_scores_gemma":[0.9987832,0.00052108406,0.000075617485,0.00021414437,0.00008107887,0.000007960439,0.000022762539,0.00003815333,0.00025604243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988068,0.00008873936,0.0003844899,0.00018400674,0.0002864053,0.0002495892],"domain_scores_gemma":[0.9991994,0.000044292352,0.00025843247,0.00014239829,0.00014285064,0.0002126206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009813816,0.00023438812,0.00037623316,0.00011037454,0.00005775931,0.000045780038,0.00006224836,0.000018629815,0.000108040986],"category_scores_gemma":[0.00001077679,0.00013220888,0.00007164675,0.000085922096,0.00008405437,0.00013671328,0.000026779122,0.00006232871,0.00000612286],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002693637,0.00628736,0.96614015,0.000023715978,0.00025261013,0.00023542,0.0014209221,3.406353e-7,0.00005826595,0.0000048560187,0.00067291415,0.024634058],"study_design_scores_gemma":[0.039848372,0.004876444,0.93615574,0.00017425788,0.00022243428,0.000009701037,0.0005798484,0.0000019374415,0.0009062461,0.0000019166532,0.017098013,0.00012511441],"about_ca_topic_score_codex":0.000101173675,"about_ca_topic_score_gemma":0.00023343823,"teacher_disagreement_score":0.039579008,"about_ca_system_score_codex":0.0003908468,"about_ca_system_score_gemma":0.00024812054,"threshold_uncertainty_score":0.5391322},"labels":[],"label_agreement":null},{"id":"W2795615530","doi":"10.1016/j.ejca.2018.02.027","title":"Rational design and identification of immuno-oncology drug combinations","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Canada Research Chairs; University of Toronto; University Health Network; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"World Meteorological Organization","keywords":"Medicine; Clinical trial; Oncology; Drug; Cancer; Internal medicine; Prostate cancer; Gene expression profiling; Computational biology; Bioinformatics; Gene; Gene expression; Pharmacology; Biology; Genetics","score_opus":0.06265323624891216,"score_gpt":0.38105393028601253,"score_spread":0.31840069403710036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795615530","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058739373,0.9967325,0.0011805338,0.00032353427,0.00073149503,0.0003021589,0.000016123457,0.0000039765596,0.0006509515],"genre_scores_gemma":[0.00028962194,0.9972877,0.00060853397,0.000063632186,0.00043401786,0.0000055125697,0.000011526017,0.000033128345,0.0012663599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997686,0.00068243203,0.0011803127,0.00011747009,0.00024577352,0.00008799823],"domain_scores_gemma":[0.99726534,0.00014624203,0.0018533473,0.00015222035,0.00052614394,0.000056693887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020490286,0.00014784574,0.00076451787,0.00023928724,0.000051958043,0.000018657776,0.0001505096,0.000043695658,0.00017659931],"category_scores_gemma":[0.000073447685,0.00010857071,0.00027804298,0.00017927923,0.00020053782,0.00007447839,0.000021321324,0.00020853133,0.0000071955037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002783489,0.00009402318,0.0000037409325,0.0013828108,0.00072231615,0.000023109093,0.00024613543,8.707035e-7,0.00027828699,0.00002496525,0.015606672,0.98133874],"study_design_scores_gemma":[0.0013942491,0.00041326386,0.0002373144,0.005761423,0.0010649239,0.00034259164,0.00002339443,0.0000032600176,0.00008492416,0.000011752331,0.99057305,0.000089879395],"about_ca_topic_score_codex":0.0000030261504,"about_ca_topic_score_gemma":0.0000010622155,"teacher_disagreement_score":0.98124886,"about_ca_system_score_codex":0.00019779742,"about_ca_system_score_gemma":0.0009139033,"threshold_uncertainty_score":0.4427385},"labels":[],"label_agreement":null},{"id":"W2801173321","doi":"10.1016/j.ejca.2018.03.003","title":"Persisting inequalities in survival patterns of childhood neuroblastoma in Southern and Eastern Europe and the effect of socio-economic development compared with those of the US","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Inequality; Neuroblastoma; Demography; Geography; Sociology; Biology; Mathematics; Genetics","score_opus":0.018652579465982783,"score_gpt":0.2676012407192989,"score_spread":0.24894866125331613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801173321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99891686,0.0003030076,0.000003939297,0.00015906755,0.0000442966,0.00018648937,0.00001117817,0.0000012588675,0.0003738929],"genre_scores_gemma":[0.9997798,0.00005184609,0.00001845264,0.000022366694,0.00004748856,0.0000011198217,2.2504288e-7,0.000019326983,0.000059370264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983057,0.00080851384,0.00043435948,0.00009794171,0.0002225538,0.0001309242],"domain_scores_gemma":[0.9991798,0.00016494126,0.00040544028,0.000109848166,0.00008786408,0.00005211173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008334559,0.00011133521,0.00038124292,0.000091213486,0.000029726258,0.000008319405,0.00011896453,0.000007744522,0.000011276912],"category_scores_gemma":[0.00006839847,0.000054058353,0.0000419718,0.00007247542,0.00030410013,0.000036584457,0.00009107089,0.00016986868,7.3908586e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00287493,0.000049560094,0.9786222,0.00012874346,0.0001460658,0.00005224558,0.012596128,0.000040752864,0.0006613079,0.0000026151752,0.0000021509945,0.0048233317],"study_design_scores_gemma":[0.0101337945,0.0015149103,0.98262537,0.0011947686,0.000051597042,0.00005493172,0.00094370905,0.00004379371,0.0033609194,9.129424e-7,0.000028548517,0.000046741472],"about_ca_topic_score_codex":0.00015928029,"about_ca_topic_score_gemma":0.00037065637,"teacher_disagreement_score":0.011652418,"about_ca_system_score_codex":0.000026835862,"about_ca_system_score_gemma":0.00011446822,"threshold_uncertainty_score":0.22044356},"labels":[],"label_agreement":null},{"id":"W2805424085","doi":"10.1016/j.ejca.2018.03.004","title":"Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Research UK; St. Baldrick's Foundation","keywords":"Carboplatin; Cisplatin; Germ cell; Medicine; Germ cell tumors; Oncology; Cancer research; Chemotherapy; Internal medicine; Biology; Genetics","score_opus":0.031423103477794374,"score_gpt":0.3318885768092945,"score_spread":0.30046547333150014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805424085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99109036,0.0042691994,0.000020135773,0.00022699189,0.00077798555,0.00027087564,0.00005628127,0.0000025786744,0.0032856045],"genre_scores_gemma":[0.99881476,0.00029739054,0.00023535964,0.000020821906,0.00043258595,0.0000030152733,0.00000465211,0.000021367772,0.00017006356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976687,0.00028081523,0.0011051067,0.00014523182,0.0006429288,0.00015724947],"domain_scores_gemma":[0.9970634,0.00014584891,0.0020535162,0.00029572647,0.00036021785,0.000081292135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004590977,0.00016542169,0.00045042305,0.00011161078,0.000031914416,0.0000088641855,0.00022457432,0.00002300363,0.00014032154],"category_scores_gemma":[0.000091028625,0.00008596739,0.0003144847,0.00018154041,0.00015871495,0.00003615971,0.000028423965,0.000111263595,0.0000023236285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025902246,0.0031901663,0.9644107,0.000087777575,0.00030798258,0.0024903626,0.0038158349,0.00018492846,0.011927894,0.000014584374,0.000490305,0.010489214],"study_design_scores_gemma":[0.009570076,0.0034596317,0.94608283,0.00032913964,0.0012426539,0.00024409563,0.00067560386,0.00018362996,0.03624808,0.000005195597,0.0018533284,0.0001057256],"about_ca_topic_score_codex":0.00012237448,"about_ca_topic_score_gemma":0.000033425444,"teacher_disagreement_score":0.024320187,"about_ca_system_score_codex":0.00012238852,"about_ca_system_score_gemma":0.00032739245,"threshold_uncertainty_score":0.35056484},"labels":[],"label_agreement":null},{"id":"W2809024048","doi":"10.1016/j.ejca.2018.05.002","title":"Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Celgene","keywords":"Medicine; Neutropenia; Leukopenia; Rhabdomyosarcoma; Refractory (planetary science); Sarcoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Adverse effect; Chemotherapy; Progressive disease; Cancer; Gastroenterology; Surgery; Oncology; Pathology","score_opus":0.019683406023507894,"score_gpt":0.35218080226293264,"score_spread":0.33249739623942476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809024048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971445,0.0006003957,0.000028573555,0.00021384543,0.00006537435,0.0014363934,0.00040610656,0.0000055324213,0.00009923976],"genre_scores_gemma":[0.9991655,0.00012077945,0.00026577382,0.00003521028,0.00024028409,0.00003384108,0.00001951289,0.000049047852,0.00007007783],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978763,0.00026172816,0.0006614541,0.00023465928,0.0007156008,0.00025025956],"domain_scores_gemma":[0.9949976,0.00005331438,0.0012345004,0.00019062066,0.003388606,0.00013532114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040822028,0.00021537114,0.0004957926,0.00046560777,0.00007003414,0.000014533299,0.0001297628,0.000015583315,0.000017025923],"category_scores_gemma":[0.00011087474,0.00012367306,0.00003350211,0.0012032995,0.00018384158,0.00026266885,0.000024153851,0.00023796549,4.0891794e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41202956,0.054137755,0.36555228,0.00014826795,0.0039173365,0.00028126498,0.030466832,0.000059777416,0.004578334,0.0000023450455,0.0031322162,0.12569404],"study_design_scores_gemma":[0.21259663,0.3727628,0.40672228,0.0010419184,0.00039072905,0.000012070502,0.0019018265,0.0000095828145,0.0040513077,0.0000012618124,0.00033604066,0.00017356132],"about_ca_topic_score_codex":0.00005928862,"about_ca_topic_score_gemma":0.00046037434,"teacher_disagreement_score":0.31862503,"about_ca_system_score_codex":0.00014079732,"about_ca_system_score_gemma":0.0007854932,"threshold_uncertainty_score":0.5043241},"labels":[],"label_agreement":null},{"id":"W2883132315","doi":"10.1016/j.ejca.2018.06.006","title":"Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Health Sciences Centre; McMaster University; Cancer Care Ontario; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Cancer Care Ontario","keywords":"Medicine; Retrospective cohort study; Cancer; Breast cancer; Cohort; Cohort study; Oncology; Internal medicine","score_opus":0.011353518716547321,"score_gpt":0.2745977707375885,"score_spread":0.2632442520210412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883132315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908986,0.0043818685,0.000004552696,0.00061076926,0.0010610989,0.00041960122,0.00007035918,0.00001787101,0.0025352538],"genre_scores_gemma":[0.9954769,0.0017232948,0.000008167647,0.0004310089,0.00165807,0.00010160336,8.8983575e-7,0.000050822022,0.0005492409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998425,0.00017319983,0.0004633684,0.00026412506,0.00045934014,0.00021496307],"domain_scores_gemma":[0.99834895,0.000017064132,0.0003798022,0.00023123066,0.00077258394,0.0002503639],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002771816,0.00020771628,0.00045108105,0.00012228123,0.00007161744,0.000039857405,0.000059314556,0.000021638967,0.0015112342],"category_scores_gemma":[0.000021876906,0.00014591792,0.00012948154,0.00021026316,0.00012868967,0.00011780019,0.000036108086,0.00016905225,0.000008149975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011437897,0.00025963486,0.8866679,0.000007132405,0.0009793206,0.00086852064,0.0052745254,3.7199038e-7,0.000033384433,5.213954e-7,0.000888283,0.10387659],"study_design_scores_gemma":[0.0026169475,0.0035540499,0.9717071,0.00029304938,0.0009724454,0.0003002004,0.0005148349,0.0000016698913,0.00017251601,0.0000017280942,0.019720534,0.00014490585],"about_ca_topic_score_codex":0.001035696,"about_ca_topic_score_gemma":0.002348488,"teacher_disagreement_score":0.103731684,"about_ca_system_score_codex":0.00048319265,"about_ca_system_score_gemma":0.00014834825,"threshold_uncertainty_score":0.9994015},"labels":[],"label_agreement":null},{"id":"W2883737490","doi":"10.1016/j.ejca.2018.05.017","title":"Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Pfizer","keywords":"Palbociclib; Medicine; Oncology; Gynecology; Internal medicine; Breast cancer; Pooled analysis; Endocrine system; Cancer; Obstetrics; Meta-analysis; Metastatic breast cancer; Hormone","score_opus":0.027011779279007546,"score_gpt":0.3734886352205431,"score_spread":0.34647685594153554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883737490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97716475,0.019496417,0.00026904128,0.0018558616,0.00038716977,0.00046916478,0.000040754643,0.00002377454,0.0002930451],"genre_scores_gemma":[0.98259205,0.013845214,0.0008700392,0.0011275003,0.0010668127,0.00004366139,0.000001730293,0.000089281035,0.00036368766],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99614716,0.00062076777,0.0016473158,0.00038943038,0.0006727776,0.0005225818],"domain_scores_gemma":[0.99598795,0.00024617242,0.0015205102,0.00042788824,0.0015253929,0.00029210866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014320994,0.00037342764,0.0020720372,0.00056567247,0.000060575665,0.000015224908,0.000309823,0.000034432695,0.0008754083],"category_scores_gemma":[0.00011592094,0.00024338561,0.0003789539,0.0013699332,0.00064031297,0.00023166297,0.000052713618,0.00047380946,0.0000032638895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1717423,0.00046015493,0.15488887,0.00009198276,0.0231355,0.0006567061,0.009110575,0.0017624015,0.004779463,0.0000046642585,0.00018868456,0.6331787],"study_design_scores_gemma":[0.13136226,0.0032955764,0.8513944,0.0012383622,0.0022054787,0.0001645025,0.0026298787,0.00008277286,0.0012035127,0.000015589523,0.0060590343,0.00034859046],"about_ca_topic_score_codex":0.000044606582,"about_ca_topic_score_gemma":0.00022518155,"teacher_disagreement_score":0.69650555,"about_ca_system_score_codex":0.0005180611,"about_ca_system_score_gemma":0.00050149794,"threshold_uncertainty_score":0.99249774},"labels":[],"label_agreement":null},{"id":"W2888094806","doi":"10.1016/j.ejca.2018.07.007","title":"A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Halozyme; Novocure; Celgene; Pfizer; Oncolytics Biotech; Eli Lilly and Company","keywords":"Gemcitabine; Capecitabine; Medicine; Tolerability; Cisplatin; Internal medicine; Oncology; Paclitaxel; Clinical endpoint; Chemotherapy; Phases of clinical research; Adenocarcinoma; Deoxycytidine; Surgery; Gastroenterology; Clinical trial; Cancer; Adverse effect","score_opus":0.03735224206187664,"score_gpt":0.3747354699927424,"score_spread":0.3373832279308657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888094806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990089,0.003184676,0.0011645472,0.0007625654,0.00011983815,0.0013440558,0.00001154188,0.000009604477,0.0033141605],"genre_scores_gemma":[0.98521686,0.0013395264,0.007391184,0.00016345229,0.00076345325,0.000028844775,0.00000282845,0.000059335216,0.005034501],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99688923,0.00057381287,0.0012104649,0.000268225,0.0006341312,0.00042413702],"domain_scores_gemma":[0.9973905,0.00045666794,0.00067625404,0.00029435233,0.0008479718,0.00033423517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022430455,0.00025320245,0.0015412227,0.00034090743,0.00006923224,0.000018173778,0.00018456053,0.000053264634,0.00091237924],"category_scores_gemma":[0.0014947191,0.00014072517,0.00008193592,0.0004924127,0.00051972823,0.00016274824,0.000052771542,0.00045611183,0.000004511695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94887286,0.0005254829,0.027540948,0.00023368889,0.0003972403,0.0015154443,0.0013871348,0.0000129863665,0.0037140658,0.00000507833,0.00047581064,0.015319248],"study_design_scores_gemma":[0.9121537,0.05382727,0.024019022,0.002264684,0.00076302345,0.0007770393,0.0007975553,0.002290871,0.000674048,0.000009227857,0.0021988866,0.00022464994],"about_ca_topic_score_codex":0.00009188937,"about_ca_topic_score_gemma":0.0004854855,"teacher_disagreement_score":0.05330179,"about_ca_system_score_codex":0.00016923911,"about_ca_system_score_gemma":0.0017160518,"threshold_uncertainty_score":0.99899125},"labels":[],"label_agreement":null},{"id":"W2888183528","doi":"10.1016/j.ejca.2018.07.123","title":"Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"S100 Proteins and Annexins","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stoneygate Trust; Queen Mary University of London; Rosetrees Trust; Université Laval","keywords":"Microvesicles; Head and neck; Medicine; Head and neck cancer; Cancer research; Annexin; Annexin A2; Oncology; EGFR inhibitors; Internal medicine; Epidermal growth factor receptor; Pathology; Biology; Cancer; microRNA; Surgery","score_opus":0.014743975935648008,"score_gpt":0.27174469984507704,"score_spread":0.257000723909429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888183528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924466,0.0058106706,0.00006987407,0.00053178164,0.00015747966,0.00006657102,0.0000053699446,0.0000034168527,0.0009082212],"genre_scores_gemma":[0.997115,0.0013633952,0.0003317955,0.00032494927,0.0006828486,0.0000015003613,8.8705775e-7,0.000026024933,0.00015359621],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991247,0.0001462816,0.00021987429,0.00020267966,0.00009694152,0.00020953892],"domain_scores_gemma":[0.99946547,0.000008143619,0.00020448027,0.00010533709,0.0000990845,0.000117479416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003479211,0.00014007007,0.00018875465,0.00006680155,0.00007114671,0.000042556298,0.000113067304,0.000031194755,0.000020911846],"category_scores_gemma":[0.00004396648,0.00012048131,0.0000451403,0.00006124247,0.00017654586,0.000020138887,0.000077809134,0.0001333305,8.311681e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070142775,0.00001743777,0.0151315285,0.000015720967,0.00006202871,0.000062918174,0.00047916852,0.000046394183,0.9398705,0.0000069429534,0.00041854478,0.043187425],"study_design_scores_gemma":[0.0030359789,0.0022985705,0.44710994,0.00039369854,0.000028461138,0.0001147056,0.00043126292,0.00009105428,0.52262586,0.000031660275,0.0234997,0.0003391363],"about_ca_topic_score_codex":0.0001542356,"about_ca_topic_score_gemma":0.00050173595,"teacher_disagreement_score":0.4319784,"about_ca_system_score_codex":0.00004011101,"about_ca_system_score_gemma":0.00009926125,"threshold_uncertainty_score":0.4913085},"labels":[],"label_agreement":null},{"id":"W2888856642","doi":"10.1016/j.ejca.2018.07.147","title":"Using target capture based high throughput DNA sequencing methodology to identify T-cell receptor sequences in mycosis fungoides","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Mycosis fungoides; T-cell receptor; Biology; Polymerase chain reaction; Locus (genetics); DNA sequencing; DNA; Molecular biology; T cell; Computational biology; Genetics; Gene; Immunology; Lymphoma","score_opus":0.15310410891296697,"score_gpt":0.42843620453545256,"score_spread":0.2753320956224856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888856642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781013,0.002422646,0.013502796,0.0028880402,0.00080031785,0.0002892114,0.000017426455,0.000015371614,0.0019628871],"genre_scores_gemma":[0.921295,0.0001408103,0.074646465,0.0023663314,0.00095770607,0.000002970627,0.0000024262058,0.00006494058,0.0005233846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962689,0.0016273765,0.00069064595,0.0003172355,0.00063209253,0.00046373435],"domain_scores_gemma":[0.99794865,0.00021869192,0.0003408781,0.00023627175,0.0009795842,0.00027590606],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026489457,0.00022259391,0.0005716157,0.00048247323,0.00010667656,0.000055780685,0.00030546138,0.000056324607,0.0016782696],"category_scores_gemma":[0.0009175831,0.00018028308,0.00014198566,0.00061682553,0.00020961148,0.00016022849,0.00007355073,0.00046243644,0.000065922526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009660146,0.000059214515,0.019649139,0.00008479275,0.0000944383,0.0009871426,0.0032411038,0.0014897373,0.9679846,0.000007039095,0.003158551,0.0022782264],"study_design_scores_gemma":[0.005101277,0.0026493696,0.013075652,0.0017573747,0.000209326,0.001343541,0.0042107557,0.0012260656,0.94806993,0.00018366368,0.02154502,0.0006279975],"about_ca_topic_score_codex":0.00059183215,"about_ca_topic_score_gemma":0.00023529597,"teacher_disagreement_score":0.061143667,"about_ca_system_score_codex":0.0008708478,"about_ca_system_score_gemma":0.0011009196,"threshold_uncertainty_score":0.9992343},"labels":[],"label_agreement":null},{"id":"W2889303398","doi":"10.1016/j.ejca.2018.07.146","title":"Identifying intratumor heterogeneity in mycosis fungoides using high throughput DNA sequencing","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Mycosis fungoides; Biology; Population; Cell of origin; Pathology; Somatic evolution in cancer; Cell; Genetics; Cancer; Lymphoma; Immunology; Medicine","score_opus":0.09427133997167024,"score_gpt":0.38885588534508925,"score_spread":0.294584545373419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889303398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407756,0.0026098303,0.0012864111,0.0004141049,0.0003846462,0.00014865721,0.0000042199135,0.000011676567,0.0010628718],"genre_scores_gemma":[0.99614996,0.00030352068,0.001736744,0.00047593284,0.0011450724,0.0000010470261,7.59187e-7,0.000054445478,0.00013249315],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99784005,0.00040720176,0.00061086693,0.00021332626,0.0005627579,0.00036577525],"domain_scores_gemma":[0.9986464,0.00004266312,0.00029242126,0.00019840777,0.00064653356,0.00017360045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010921092,0.00016473372,0.0003879285,0.00029138182,0.00011070607,0.000076123,0.00019502288,0.000025045942,0.00034422855],"category_scores_gemma":[0.00027653982,0.00013840015,0.00012451966,0.0003839989,0.00018231524,0.00022292777,0.00008487957,0.00036785187,0.00002933183],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013503074,0.00014934695,0.114329696,0.00017322002,0.0004143572,0.004808483,0.0046152733,0.00066893396,0.8413844,0.000030805477,0.00094738224,0.031127764],"study_design_scores_gemma":[0.011738695,0.0032168606,0.29047343,0.0063401256,0.0005100275,0.01710284,0.003912933,0.0042482316,0.6571619,0.00034048126,0.0038725159,0.0010819819],"about_ca_topic_score_codex":0.00019098085,"about_ca_topic_score_gemma":0.00028385743,"teacher_disagreement_score":0.18422255,"about_ca_system_score_codex":0.000797297,"about_ca_system_score_gemma":0.00051743904,"threshold_uncertainty_score":0.56437945},"labels":[],"label_agreement":null},{"id":"W2889898143","doi":"10.1016/j.ejca.2018.08.002","title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital","funders":"Institut Gustave-Roussy; AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Fulvestrant; Medicine; Internal medicine; Placebo; Oncology; Population; Cancer; Breast cancer; Adverse effect; Estrogen receptor; Pathology","score_opus":0.02433777903888868,"score_gpt":0.2946554894638917,"score_spread":0.270317710425003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889898143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771806,0.004885834,0.0011578775,0.0013999088,0.004324869,0.0006814722,0.009005761,0.000037631275,0.0013260468],"genre_scores_gemma":[0.98510456,0.0027397291,0.0030505492,0.00033671546,0.007567279,0.000032430155,0.0003159306,0.00021105865,0.00064177206],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955767,0.0006293422,0.0013461696,0.0009163259,0.0006883225,0.00084313523],"domain_scores_gemma":[0.99583304,0.00024606023,0.0014109964,0.0005245177,0.0014830268,0.00050234346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078197144,0.0006820375,0.0007999734,0.00012684258,0.00053548935,0.00010356589,0.00090260955,0.00018265634,0.0003784112],"category_scores_gemma":[0.00028861704,0.00062915595,0.00036397125,0.00017519339,0.00047019112,0.000083679915,0.00021541797,0.0005378614,0.000020227946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06772991,0.0001083775,0.000118193646,0.000029955845,0.0011422737,0.000046209494,0.0009979827,0.00077010907,0.90395975,0.00002224325,0.018947026,0.0061279847],"study_design_scores_gemma":[0.083340056,0.014770429,0.029702371,0.0008877101,0.0006031809,0.00007043786,0.0004478608,0.00010478707,0.7710211,0.000057263336,0.09664326,0.002351503],"about_ca_topic_score_codex":0.00050277176,"about_ca_topic_score_gemma":0.00028531824,"teacher_disagreement_score":0.1329386,"about_ca_system_score_codex":0.0005654686,"about_ca_system_score_gemma":0.0008759637,"threshold_uncertainty_score":0.99961597},"labels":[],"label_agreement":null},{"id":"W2890444045","doi":"10.1016/j.ejca.2018.08.010","title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Docetaxel; Abiraterone acetate; Prostate cancer; Oncology; Internal medicine; Prednisone; Hazard ratio; Randomized controlled trial; Cabazitaxel; Quality of life (healthcare); Androgen deprivation therapy; Enzalutamide; Cancer; Confidence interval; Androgen receptor","score_opus":0.2668346676253707,"score_gpt":0.4654540828694023,"score_spread":0.1986194152440316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890444045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01045491,0.9866314,0.000020781286,0.00035898792,0.0003078129,0.0013361935,0.000764916,0.000008886436,0.000116138275],"genre_scores_gemma":[0.012678731,0.98543614,0.0004855081,0.000026780039,0.00025185852,0.00007481305,0.00006775028,0.00010539343,0.0008730504],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99282444,0.0021195184,0.0026900098,0.00053135166,0.001282135,0.0005525393],"domain_scores_gemma":[0.9937719,0.00046254226,0.0037073502,0.00048778096,0.0009572941,0.000613144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003328396,0.000668386,0.007910979,0.0006992726,0.00007141737,0.00004215879,0.00029158118,0.000061716695,0.000085639294],"category_scores_gemma":[0.00026036933,0.00038320612,0.002190713,0.0012211431,0.00044712686,0.00017757082,0.00019671947,0.00060436176,0.0000028038498],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03800663,0.0007400258,0.00789148,0.026288038,0.6444452,0.001667893,0.002034068,0.0011617726,0.000014386201,0.00003357166,0.00047688937,0.27724007],"study_design_scores_gemma":[0.027402667,0.0032657434,0.041011713,0.012014995,0.85372126,0.000016691485,0.00027917532,0.0000721644,0.000025567866,0.00001959884,0.061070856,0.0010995374],"about_ca_topic_score_codex":0.00017289413,"about_ca_topic_score_gemma":0.0002095865,"teacher_disagreement_score":0.27614054,"about_ca_system_score_codex":0.00034747165,"about_ca_system_score_gemma":0.0015959883,"threshold_uncertainty_score":0.99986196},"labels":[],"label_agreement":null},{"id":"W2890765516","doi":"10.1016/j.ejca.2018.07.130","title":"Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Gary Bennett Family Fund; Japan Society for the Promotion of Science; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Bayer HealthCare; National Natural Science Foundation of China; Bayer Fund; National Institutes of Health; Huazhong University of Science and Technology; Pfizer; Dana-Farber Cancer Institute; National Research Foundation of Korea; National Cancer Institute; Entertainment Industry Foundation; China Scholarship Council; Uehara Memorial Foundation","keywords":"Colorectal cancer; Medicine; Internal medicine; Hazard ratio; Proportional hazards model; Gastroenterology; Confidence interval; Microsatellite instability; Confounding; Cancer; Immune system; KRAS; Oncology; Immunology; Allele; Biology","score_opus":0.020160587022981888,"score_gpt":0.32465954127932806,"score_spread":0.30449895425634615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890765516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98379546,0.0052481177,0.000026032067,0.009220843,0.000851097,0.00031408886,0.000052212185,0.000011761176,0.00048037225],"genre_scores_gemma":[0.99598956,0.0013664779,0.000455255,0.0008254215,0.00087828614,0.00007419141,2.2797498e-7,0.00005543593,0.00035511618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997643,0.0005214875,0.00047752893,0.00022758833,0.00063605036,0.00049434917],"domain_scores_gemma":[0.9980419,0.00020106575,0.00016622996,0.00014475494,0.00083466363,0.0006113755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011636791,0.00019108497,0.00042171392,0.0003040856,0.00011936369,0.000052767995,0.000123563,0.00001722622,0.00032610734],"category_scores_gemma":[0.0013459503,0.0001419951,0.00009119717,0.0003309763,0.00013670229,0.000108211956,0.00030923903,0.00028427906,0.000047583748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027386647,0.00019306659,0.46447787,0.00007876691,0.00061512174,0.0024746733,0.01572715,0.000024756888,0.24419515,0.0000011057166,0.024185179,0.22064051],"study_design_scores_gemma":[0.0014862737,0.004287986,0.9169221,0.00084055215,0.00007508243,0.000038215912,0.001571032,0.0000021060923,0.017886095,7.6171546e-7,0.056733247,0.00015653277],"about_ca_topic_score_codex":0.000098629105,"about_ca_topic_score_gemma":0.00011184653,"teacher_disagreement_score":0.45244426,"about_ca_system_score_codex":0.00036061124,"about_ca_system_score_gemma":0.00022157365,"threshold_uncertainty_score":0.5790392},"labels":[],"label_agreement":null},{"id":"W2896936188","doi":"10.1016/j.ejca.2018.09.020","title":"Letter comments on a published article in the New England Journal of Medicine","year":2018,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Seattle Genetics; Takeda Pharmaceuticals U.S.A.","keywords":"Brentuximab vedotin; ABVD; Dacarbazine; Vinblastine; Medicine; Bleomycin; Oncology; Internal medicine; Antibody-drug conjugate; Hodgkin lymphoma; Lymphoma; Vincristine; Chemotherapy; Immunology; Antibody; Monoclonal antibody; Cyclophosphamide","score_opus":0.028634672669147057,"score_gpt":0.29400175790170036,"score_spread":0.2653670852325533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896936188","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033942036,0.0025952528,0.000009254844,0.95722795,0.0014238049,0.00013922065,0.000004163988,0.0000021296146,0.004656182],"genre_scores_gemma":[0.11517247,0.0005740605,0.000069328475,0.8347786,0.04858875,0.0000011804037,0.0000044327453,0.00004344152,0.00076775305],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99687296,0.0006966688,0.0009947951,0.00012819933,0.0010579336,0.00024944879],"domain_scores_gemma":[0.9977595,0.00023141749,0.0011981449,0.0002955823,0.00037698046,0.00013833182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017859743,0.00023447092,0.00064811314,0.00030691706,0.000030645562,0.0000655071,0.00040291966,0.00007326825,0.0008883339],"category_scores_gemma":[0.00026447172,0.00010977962,0.00021268206,0.00016733442,0.000114172486,0.00011696865,0.000026109075,0.0013383781,0.00002621714],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043938367,0.00015092769,0.004148782,0.000026831378,0.00038289293,0.012610029,0.001730561,0.0000019506647,0.000032776392,0.0000012741422,0.9585797,0.02189486],"study_design_scores_gemma":[0.018854294,0.002866045,0.044133574,0.002018908,0.00046869577,0.0012671145,0.000036105703,6.5244797e-7,0.00010417403,0.000028949304,0.9301367,0.000084805884],"about_ca_topic_score_codex":0.000033116467,"about_ca_topic_score_gemma":0.000008630772,"teacher_disagreement_score":0.12244937,"about_ca_system_score_codex":0.00026142652,"about_ca_system_score_gemma":0.0002459876,"threshold_uncertainty_score":0.9726633},"labels":[],"label_agreement":null},{"id":"W2897693137","doi":"10.1016/j.ejca.2018.08.011","title":"Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pfizer","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Estrogen receptor; Gynecology; Pathology","score_opus":0.013393079931901707,"score_gpt":0.2695117375637357,"score_spread":0.256118657631834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897693137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928499,0.0035622946,0.00008919733,0.0012753739,0.00027617626,0.0005673544,0.0011565565,0.000022604621,0.00020053708],"genre_scores_gemma":[0.9965789,0.0006693455,0.0013621936,0.00021946293,0.00087642507,0.000048567814,0.000009026575,0.0001261895,0.000109893284],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99627435,0.000497719,0.0013310135,0.00044484745,0.00078519655,0.0006668615],"domain_scores_gemma":[0.9971424,0.00014813467,0.0012374172,0.00027759912,0.0008282378,0.00036622578],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050219096,0.00046265608,0.001180836,0.00040497057,0.000069782596,0.00002432188,0.00033041782,0.000037982605,0.0012455652],"category_scores_gemma":[0.00007290272,0.00034392072,0.0001226499,0.0005847092,0.0005646978,0.0004525274,0.000057979956,0.00068340957,0.0000058935716],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12705773,0.0010724548,0.2061455,0.00035313176,0.0041470053,0.0018218745,0.05346061,0.0005657761,0.5123243,0.000042466214,0.00030787807,0.09270132],"study_design_scores_gemma":[0.0156688,0.003170993,0.95546424,0.0022526672,0.00017018846,0.00008497546,0.0015473212,0.000010190182,0.020798963,0.000065191074,0.00040923367,0.00035720607],"about_ca_topic_score_codex":0.0010355288,"about_ca_topic_score_gemma":0.0009871095,"teacher_disagreement_score":0.7493188,"about_ca_system_score_codex":0.0012841658,"about_ca_system_score_gemma":0.0005210609,"threshold_uncertainty_score":0.9999013},"labels":[],"label_agreement":null},{"id":"W2898767814","doi":"10.1016/j.ejca.2018.09.031","title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—a meta-analysis","year":2018,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"European Society for Medical Oncology; Pancreatic Cancer Research Fund; Pancreatic Cancer UK; Collins Foundation","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Internal medicine; Tolerability; Liver function; Oncology; Gastroenterology; Cohort; Meta-analysis; Adverse effect","score_opus":0.12129182443133386,"score_gpt":0.3141651089555151,"score_spread":0.19287328452418123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898767814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021453911,0.97548306,0.000022265032,0.0002203123,0.0001655387,0.00136002,0.000069116926,0.000017396156,0.0012083881],"genre_scores_gemma":[0.11760032,0.88050604,0.00027242315,0.0001845689,0.0004898062,0.000049283844,0.00014414852,0.00019769973,0.00055571133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951851,0.00090069557,0.0018064295,0.00061067386,0.0010099378,0.0004871938],"domain_scores_gemma":[0.9960071,0.000083794286,0.0020102437,0.000756188,0.00075602805,0.00038667192],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010073358,0.0009001983,0.005599768,0.0010716548,0.0001065339,0.000057215973,0.00046499015,0.0001294534,0.0016738429],"category_scores_gemma":[0.000048160815,0.0005102375,0.004330543,0.0015029806,0.000115412666,0.0001699921,0.00006190348,0.00083051855,0.00009867226],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014049761,0.0010734788,0.2591166,0.002162985,0.2410349,0.004213176,0.00034646783,0.000011156424,1.0964261e-7,0.0000026330072,0.00039600648,0.4902375],"study_design_scores_gemma":[0.004023288,0.0031547463,0.0044934144,0.0017041566,0.2672743,0.00005414162,0.0000043269615,0.0000068481054,0.0000089608775,0.000001244126,0.71883386,0.00044069285],"about_ca_topic_score_codex":0.00003446313,"about_ca_topic_score_gemma":0.00002191883,"teacher_disagreement_score":0.71843785,"about_ca_system_score_codex":0.00029148386,"about_ca_system_score_gemma":0.00043604654,"threshold_uncertainty_score":0.99973494},"labels":[],"label_agreement":null},{"id":"W2899504353","doi":"10.1016/j.ejca.2018.09.028","title":"Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Perioperative; Soft tissue sarcoma; Interquartile range; Radiation therapy; Chemotherapy; Internal medicine; Propensity score matching; Sarcoma; Myxofibrosarcoma; Soft tissue; Retrospective cohort study; Surgery; Oncology; Pathology","score_opus":0.011671245965287565,"score_gpt":0.30006175525827017,"score_spread":0.2883905092929826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899504353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892045,0.010059742,0.000042035223,0.00020817346,0.000020331163,0.00016196107,0.00003325227,0.00000382661,0.0002661722],"genre_scores_gemma":[0.9977572,0.0011619225,0.00081576314,0.000108004744,0.000077823715,0.0000015394622,0.0000033488932,0.00001731969,0.000057053054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892485,0.00015200015,0.0003106891,0.00020675102,0.00023401983,0.0001717156],"domain_scores_gemma":[0.9990645,0.000038514878,0.00031092906,0.00012664284,0.00034048807,0.000118923825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021732469,0.0001660934,0.000587843,0.00011211245,0.00005323664,0.000021435973,0.00006278856,0.00002642871,0.00025567473],"category_scores_gemma":[0.00002666151,0.00009479206,0.00007690519,0.00022839307,0.00029565638,0.00009040393,0.00001919205,0.00014892343,4.2685608e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027537798,0.0004385306,0.9552996,0.00000929275,0.0012144675,0.000089328765,0.0018208266,0.0000018795964,0.0005486772,0.0000030059916,0.000055779194,0.037764795],"study_design_scores_gemma":[0.0075076604,0.003123427,0.988164,0.00009873409,0.00030829533,0.000021701702,0.000057814214,0.0000054679454,0.00035721395,0.0000017162869,0.00026025166,0.00009371246],"about_ca_topic_score_codex":0.00014022453,"about_ca_topic_score_gemma":0.00014052313,"teacher_disagreement_score":0.03767108,"about_ca_system_score_codex":0.00032678366,"about_ca_system_score_gemma":0.00006241295,"threshold_uncertainty_score":0.3865508},"labels":[],"label_agreement":null},{"id":"W2901532563","doi":"10.1016/j.ejca.2018.09.009","title":"Cancers related to lifestyle and environmental factors in France in 2015","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Centre for Addiction and Mental Health","funders":"Institut National Du Cancer; World Health Organization","keywords":"Environmental health; Medicine","score_opus":0.02539962212874498,"score_gpt":0.3160974693351271,"score_spread":0.29069784720638214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901532563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925062,0.0039160047,0.000012080685,0.0009620376,0.0002593518,0.00007981014,0.000004722197,0.0000034962018,0.002256311],"genre_scores_gemma":[0.9977898,0.0004904787,0.00016667285,0.0008555615,0.0001976283,6.668227e-7,7.1734024e-7,0.000016171456,0.00048232754],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898934,0.00008143099,0.00036634988,0.00012784569,0.00024782796,0.00018721358],"domain_scores_gemma":[0.999554,0.0000144662645,0.00012865521,0.000084823216,0.00003314732,0.00018492102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045365974,0.000096897886,0.00021443177,0.00014833978,0.00002148896,0.000009841921,0.00008808924,0.000019983347,0.00019272997],"category_scores_gemma":[0.000055089607,0.00008011936,0.000032812262,0.00018497655,0.0000777222,0.00012414352,0.000030252737,0.00025358354,0.000012894601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019442383,0.000014836335,0.9803352,0.000005856419,0.000019083629,0.00038772865,0.0025524918,0.00020179508,0.0039034057,0.0000021388762,0.0022297294,0.010153322],"study_design_scores_gemma":[0.0014380432,0.0006155344,0.9595228,0.00053582276,0.000014914173,0.00006214508,0.0006936244,0.00003493858,0.0009401407,0.00000521787,0.03604521,0.00009165315],"about_ca_topic_score_codex":0.0002565088,"about_ca_topic_score_gemma":0.00023155576,"teacher_disagreement_score":0.033815477,"about_ca_system_score_codex":0.00029691035,"about_ca_system_score_gemma":0.00009622022,"threshold_uncertainty_score":0.32671726},"labels":[],"label_agreement":null},{"id":"W2902934037","doi":"10.1016/j.ejca.2018.10.016","title":"Long-term health and social function in adult survivors of paediatric astrocytoma: A report from the Childhood Cancer Survivor Study","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities; Conquer Cancer Foundation","keywords":"Medicine; Childhood cancer; Cancer survivor; Term (time); Pediatrics; Social function; Cancer; Astrocytoma; Internal medicine; Glioma","score_opus":0.025770015046539526,"score_gpt":0.32253999007790873,"score_spread":0.2967699750313692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902934037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98353076,0.0075367326,0.00010956913,0.0066214944,0.001478232,0.0005046761,0.000044374785,0.000017957522,0.00015621285],"genre_scores_gemma":[0.99162364,0.00080237584,0.000057321824,0.001990587,0.0053843395,0.000006860405,0.00000772587,0.00006167562,0.000065495864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995426,0.0013251321,0.0015884389,0.00035251578,0.0009685321,0.00033938818],"domain_scores_gemma":[0.99675757,0.00016697029,0.0018175739,0.00032799423,0.000701209,0.00022869543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003106874,0.0002605486,0.0008178479,0.00019486957,0.00015849617,0.000033950797,0.00024957742,0.000040291638,0.0001331161],"category_scores_gemma":[0.0002705158,0.00018918802,0.00017750188,0.00046023144,0.0001995016,0.00016030764,0.00010268028,0.00059109536,0.0000040146965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016273089,0.00051048247,0.9376174,0.000077353805,0.00042116793,0.00019730651,0.02585648,0.0000028345294,0.00003358328,0.0000020217626,0.0021320113,0.031522043],"study_design_scores_gemma":[0.0054158703,0.0024608911,0.9861956,0.00047452963,0.0002511179,0.00009542386,0.004061263,0.0000020404646,0.000035441535,0.0000056106455,0.00084908097,0.00015309497],"about_ca_topic_score_codex":0.0069424044,"about_ca_topic_score_gemma":0.04044399,"teacher_disagreement_score":0.048578233,"about_ca_system_score_codex":0.0002022695,"about_ca_system_score_gemma":0.00093604566,"threshold_uncertainty_score":0.99967045},"labels":[],"label_agreement":null},{"id":"W2903766708","doi":"10.1016/j.ejca.2018.11.023","title":"Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Organisation for Research and Treatment of Cancer; Austrian Science Fund; Diabetes Institutes Foundation","keywords":"Computerized adaptive testing; Norm (philosophy); Core (optical fiber); Test (biology); Quality of life (healthcare); Psychology; Computer science; Mathematics; Medicine; Political science; Clinical psychology; Biology; Psychotherapist; Law; Telecommunications; Psychometrics","score_opus":0.06964537978872669,"score_gpt":0.32652994652239903,"score_spread":0.2568845667336723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903766708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94583637,0.0088583445,0.0053203427,0.018983858,0.004836545,0.0009609505,0.0002079152,0.000023517045,0.0149721475],"genre_scores_gemma":[0.99474424,0.00024519363,0.00017356152,0.0022794704,0.0021785225,0.0000016285072,0.0000014534668,0.00004759645,0.0003283597],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99695116,0.000991433,0.0011205447,0.00014706804,0.0005535266,0.00023626088],"domain_scores_gemma":[0.99556315,0.00094278716,0.0018155753,0.00049375417,0.0010378875,0.00014682091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00531112,0.00016092823,0.00045965216,0.000047575002,0.00026024782,0.000028883,0.0006529801,0.000019553936,0.000050717063],"category_scores_gemma":[0.00064005336,0.00007406985,0.0003364945,0.00032985568,0.00051166443,0.00008564009,0.00013628833,0.00038877563,0.0000025314162],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0078058154,0.00087079423,0.15941982,0.0010642065,0.0030578512,0.000078648576,0.13616377,0.0009790596,0.006328033,0.0027282129,0.15002729,0.5314765],"study_design_scores_gemma":[0.0050050193,0.0033500874,0.8856776,0.0016738634,0.00041167068,0.00009106302,0.0057700374,0.0004015377,0.000651178,0.00008350444,0.0966476,0.00023684234],"about_ca_topic_score_codex":0.0011220057,"about_ca_topic_score_gemma":0.0026467496,"teacher_disagreement_score":0.72625774,"about_ca_system_score_codex":0.00011799492,"about_ca_system_score_gemma":0.00053156825,"threshold_uncertainty_score":0.3020481},"labels":[],"label_agreement":null},{"id":"W2904424259","doi":"10.1016/j.ejca.2018.10.017","title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Discontinuation; Internal medicine; Incidence (geometry); Clinical trial; Confidence interval; Odds ratio; Surgery","score_opus":0.04551773507185558,"score_gpt":0.3870358535211918,"score_spread":0.3415181184493362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904424259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992565,0.0032554774,0.00068431196,0.0007694158,0.00095405336,0.00064631755,0.000016695958,0.000010987725,0.0010977647],"genre_scores_gemma":[0.9965134,0.0010162446,0.0011284318,0.00047995642,0.0005102398,0.000011704442,0.0000037918905,0.000052897485,0.00028333635],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99648213,0.0007505749,0.0019429356,0.00018255024,0.00032614914,0.00031565252],"domain_scores_gemma":[0.99814755,0.00016060377,0.0011476817,0.0001921901,0.00026614143,0.000085811356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069305887,0.00019625424,0.0007173959,0.00033420525,0.00006124985,0.000010857782,0.00019844297,0.00005058795,0.00038644372],"category_scores_gemma":[0.00017990703,0.00015473763,0.0004256197,0.00034705753,0.000079959944,0.00018820928,0.000018584686,0.0003568369,0.0000044453036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06322264,0.0009664797,0.025812235,0.000046747195,0.0012641869,0.0002488858,0.003348331,0.000054271084,0.57221997,0.000014001727,0.00041345536,0.33238882],"study_design_scores_gemma":[0.15446234,0.0098864455,0.784561,0.0024852692,0.00023522852,0.00011397545,0.0005727244,0.00036782338,0.027093286,0.0000745334,0.019694733,0.00045263767],"about_ca_topic_score_codex":0.000104817074,"about_ca_topic_score_gemma":0.000054531585,"teacher_disagreement_score":0.75874877,"about_ca_system_score_codex":0.0004677132,"about_ca_system_score_gemma":0.00036064003,"threshold_uncertainty_score":0.6310017},"labels":[],"label_agreement":null},{"id":"W2905027834","doi":"10.1016/j.ejca.2018.11.011","title":"A novel risk calculator to predict outcome after surgery for symptomatic spinal metastases; use of a large prospective patient database to personalise surgical management","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"Icotec; DePuy Synthes Spine; Orthofix; Globus Medical; National Institute for Health and Care Research; Ulrich Medical; University College London; Brainlab; OMeGA Medical Grants Association; Zimmer; Aesculap Implant Systems; Medtronic; Relievant Medsystems; Department of Health and Social Care; AO North America","keywords":"Medicine; Confidence interval; Prospective cohort study; Ambulatory; Surgery; Neurosurgery; Cohort; Internal medicine","score_opus":0.04004180242513525,"score_gpt":0.3319087378228681,"score_spread":0.2918669353977329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905027834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95958114,0.00032689737,0.03516097,0.0007918335,0.00045057188,0.0017651365,0.0017557679,0.00001800431,0.000149675],"genre_scores_gemma":[0.9714707,0.000023308054,0.026003363,0.0015978796,0.00037004412,0.00008615368,0.000012535958,0.00006830691,0.0003677005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968122,0.00025764815,0.0011652595,0.00034112492,0.0010167138,0.0004070163],"domain_scores_gemma":[0.99744,0.00011741918,0.00064612273,0.00044059922,0.0006847417,0.0006711459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019927118,0.0002683984,0.0007011043,0.00047543223,0.00005855269,0.000041348678,0.00016043268,0.000012845447,0.00045945065],"category_scores_gemma":[0.0006381774,0.00020536683,0.0004367471,0.00032749775,0.000065730404,0.00020587276,0.0001953065,0.00014466142,0.000028702667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11305164,0.009868167,0.6359676,0.0072893994,0.011350524,0.012970201,0.005995141,0.00031961352,0.00081812416,0.00075585354,0.12701437,0.07459938],"study_design_scores_gemma":[0.013065314,0.0061444514,0.79437786,0.0036279736,0.006593762,0.0001647907,0.0008100435,0.0005655324,0.0006887421,0.000007137406,0.1733225,0.0006319096],"about_ca_topic_score_codex":0.000015085505,"about_ca_topic_score_gemma":0.000009815611,"teacher_disagreement_score":0.15841024,"about_ca_system_score_codex":0.00016350485,"about_ca_system_score_gemma":0.00009919451,"threshold_uncertainty_score":0.83746165},"labels":[],"label_agreement":null},{"id":"W2905201605","doi":"10.1016/j.ejca.2018.11.015","title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":267,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University Health Centre","funders":"AstraZeneca; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Head and neck; Basal cell; Oncology; Head and neck squamous-cell carcinoma; Internal medicine; Head and neck cancer; Surgery; Cancer; Immunotherapy","score_opus":0.0346955478729249,"score_gpt":0.3084686780840385,"score_spread":0.2737731302111136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905201605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965283,0.00095715746,0.000059388232,0.00026023635,0.00022352724,0.001525544,0.00017981346,0.0000112952575,0.00025473765],"genre_scores_gemma":[0.99759907,0.000017149963,0.0013544938,0.00037615706,0.00031856704,0.000018192834,0.000022874465,0.00008171709,0.00021179862],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976248,0.00031812524,0.00083370635,0.00038035694,0.0005442464,0.00029874215],"domain_scores_gemma":[0.998182,0.00013389635,0.0008713726,0.0002623287,0.0003759645,0.00017443352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006078098,0.00031204382,0.00054592174,0.00019576788,0.00013174968,0.00004665508,0.00015110701,0.000025816937,0.00009174229],"category_scores_gemma":[0.00006169832,0.00019542838,0.00010001404,0.0001700813,0.00010225019,0.00010381224,0.000021554946,0.0002573861,8.6129705e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81569594,0.023825394,0.030452594,0.000185379,0.00016134985,0.00037113143,0.012334548,0.000026117757,0.017449288,3.6419326e-8,0.005153936,0.09434427],"study_design_scores_gemma":[0.39341408,0.27820504,0.23889978,0.0022154672,0.0003281097,0.0000065519575,0.00091857626,0.00035418742,0.079419985,0.000001254399,0.0057944795,0.00044248748],"about_ca_topic_score_codex":0.00005287823,"about_ca_topic_score_gemma":0.0001387528,"teacher_disagreement_score":0.42228186,"about_ca_system_score_codex":0.0002127247,"about_ca_system_score_gemma":0.00024924843,"threshold_uncertainty_score":0.7969338},"labels":[],"label_agreement":null},{"id":"W2905379902","doi":"10.1016/j.ejca.2018.10.022","title":"Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universidade de Macau; University of Toronto; National Institutes of Health; University of Nebraska Medical Center; College of Public Health, University of Nebraska Medical Center; American Cancer Society","keywords":"Penetrance; Genetics; Mutation; Cancer; Biology; Gene; Phenotype","score_opus":0.021024972203334134,"score_gpt":0.3048511427004847,"score_spread":0.28382617049715053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905379902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95950496,0.015260237,0.020096246,0.0019940874,0.002124375,0.00020093737,0.00030022633,0.000009457747,0.00050946267],"genre_scores_gemma":[0.9866805,0.0013865602,0.0064932895,0.001511453,0.0036563342,0.000013232364,0.000010485298,0.000058997022,0.00018914595],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979742,0.00038577724,0.00059197453,0.00034859878,0.00039752809,0.00030189173],"domain_scores_gemma":[0.9978418,0.000039189537,0.000477367,0.0005385255,0.00086151605,0.00024162057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000553703,0.00021072604,0.00026289237,0.00008988601,0.0001445132,0.000069591275,0.0008316245,0.000052413554,0.00028972735],"category_scores_gemma":[0.00032498673,0.00020474946,0.00011351197,0.00022265397,0.00015774486,0.000021669133,0.00016815259,0.00017819194,0.000030133117],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012517833,0.000038543607,0.021805858,0.000026517231,0.00064735767,0.00017677895,0.0019584727,0.009037822,0.7294914,0.0000055292066,0.06817443,0.1673855],"study_design_scores_gemma":[0.0042809164,0.0020546135,0.49965152,0.00088185264,0.0003441786,0.00011682822,0.00025517843,0.0002291042,0.28892475,0.0001783082,0.20231326,0.0007694686],"about_ca_topic_score_codex":0.0003145338,"about_ca_topic_score_gemma":0.001188341,"teacher_disagreement_score":0.47784567,"about_ca_system_score_codex":0.0002236949,"about_ca_system_score_gemma":0.00052078784,"threshold_uncertainty_score":0.83494407},"labels":[],"label_agreement":null},{"id":"W2905822848","doi":"10.1016/j.ejca.2018.11.018","title":"An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Merck Sharp and Dohme; EUSA Pharma; Eisai; Genentech; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; F. Hoffmann-La Roche","keywords":"Vemurafenib; Medicine; Internal medicine; Tolerability; Melanoma; Metastatic melanoma; Dacarbazine; Oncology; Clinical trial; Population; Surgery; Adverse effect; Chemotherapy; Cancer research; Cancer","score_opus":0.022977513247716175,"score_gpt":0.2802544449555863,"score_spread":0.25727693170787014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905822848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99885106,0.00019641804,0.0003624159,0.0000063852144,0.000081058315,0.0003530101,0.000026281157,0.0000025212507,0.000120845565],"genre_scores_gemma":[0.99914,0.000014429264,0.000702117,0.000012750086,0.000078423385,0.000002709538,0.000012270876,0.000022069853,0.000015210104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983495,0.0005083318,0.0005206722,0.00023384989,0.00022055389,0.00016707936],"domain_scores_gemma":[0.9987763,0.000012257199,0.00049968384,0.00022656095,0.00037190685,0.00011326762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056890096,0.00014666207,0.0003541755,0.00013977902,0.0000560208,0.0000422916,0.00029862087,0.0000151845725,0.000009827004],"category_scores_gemma":[0.000036545523,0.000105735846,0.000024092098,0.0002829396,0.00004971294,0.00002166043,0.00010344169,0.000086317974,7.1487375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003844666,0.0015286873,0.93505967,0.00007274269,0.0015395039,0.00019245595,0.0013535923,0.00026917376,0.05059719,0.0000043772648,0.000010685201,0.0055272332],"study_design_scores_gemma":[0.0143433735,0.0138411755,0.95963484,0.0002479593,0.0012125291,0.000018295079,0.0009834666,0.00025189127,0.009084357,3.1874094e-7,0.00016212884,0.00021964737],"about_ca_topic_score_codex":0.00005492609,"about_ca_topic_score_gemma":0.00037695072,"teacher_disagreement_score":0.041512832,"about_ca_system_score_codex":0.00002512767,"about_ca_system_score_gemma":0.00007670813,"threshold_uncertainty_score":0.43117827},"labels":[],"label_agreement":null},{"id":"W2906639914","doi":"10.1016/j.ejca.2018.11.024","title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","year":2018,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":468,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Organisation for Research and Treatment of Cancer; Austrian Science Fund","keywords":"Normative; Quality of life (healthcare); Gerontology; Population; Psychology; Environmental health; Medicine; Demography; Political science; Sociology; Psychotherapist; Law","score_opus":0.042608584122500674,"score_gpt":0.33772718398970886,"score_spread":0.2951185998672082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906639914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570427,0.009918183,0.0011821192,0.02835271,0.0009925812,0.0004703491,0.0015702259,0.000014145614,0.00045698317],"genre_scores_gemma":[0.9927931,0.00041240396,0.00003644407,0.0057141883,0.0006784702,0.0000018499752,0.00009264123,0.000030761967,0.00024017956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971368,0.0013168948,0.00074061175,0.00014867695,0.00045687117,0.00020014693],"domain_scores_gemma":[0.99751383,0.00035943155,0.00092753634,0.0004018641,0.00064329104,0.00015404746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004265709,0.00014206395,0.0003473293,0.000035053392,0.00034558133,0.000043829565,0.00028578116,0.000013534147,0.00004666001],"category_scores_gemma":[0.00052940875,0.000078315636,0.00006412202,0.00015160574,0.00032579812,0.000112073394,0.000055098226,0.00025580174,7.232377e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034831405,0.0002493221,0.43582156,0.0016530486,0.002472905,0.000092577764,0.09319579,0.0078811655,0.00008574785,0.0012550623,0.30153888,0.120922506],"study_design_scores_gemma":[0.007048852,0.0007686153,0.88753325,0.00086716627,0.00019467724,0.000020328389,0.004358866,0.006674201,0.00003150398,0.000019248308,0.0922882,0.00019507862],"about_ca_topic_score_codex":0.3665684,"about_ca_topic_score_gemma":0.66548645,"teacher_disagreement_score":0.45171168,"about_ca_system_score_codex":0.00016829757,"about_ca_system_score_gemma":0.0008422595,"threshold_uncertainty_score":0.6376497},"labels":[],"label_agreement":null},{"id":"W2910644531","doi":"10.1016/j.ejca.2018.12.006","title":"The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Ozmosis Research (Canada); Queen Elizabeth II Health Sciences Centre; Regional Municipality of Durham; Centre Hospitalier de l’Université de Montréal; London Health Sciences Centre; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Sunitinib; Medicine; Toxicity; Renal cell carcinoma; Dosing; Clinical endpoint; Internal medicine; Clinical trial; Phases of clinical research; Oncology; Adverse effect; Urology; Confidence interval; Surgery","score_opus":0.09894425372658124,"score_gpt":0.39578725060013864,"score_spread":0.2968429968735574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910644531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293905,0.0030885378,0.000042568456,0.0010548016,0.0004053761,0.0013225905,0.00005252041,0.00000501459,0.0010895472],"genre_scores_gemma":[0.99678355,0.001037203,0.0005423787,0.00027609736,0.000813317,0.000007671115,0.000012988164,0.0000501314,0.000476638],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99725574,0.0007907554,0.0010704746,0.00021439367,0.00045159057,0.00021706568],"domain_scores_gemma":[0.9971353,0.0010361203,0.000898751,0.000331458,0.00033342149,0.00026495542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027205863,0.00019963265,0.00060518313,0.00009635857,0.00009648729,0.000030290488,0.00020202085,0.000027009504,0.00013297435],"category_scores_gemma":[0.00024792735,0.00011297093,0.00029368783,0.0000930674,0.00013057112,0.000074050826,0.00002675277,0.0003350827,0.000008084761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8208541,0.005119008,0.0046039885,0.00014633643,0.0012281758,0.0004909902,0.0019206794,0.00017055165,0.005378675,0.00007201323,0.0016654718,0.15835],"study_design_scores_gemma":[0.68737125,0.14926334,0.06769154,0.0003761408,0.0011280846,0.00012412282,0.00033284412,0.00010029878,0.021621563,0.00003408709,0.07169078,0.0002659649],"about_ca_topic_score_codex":0.0000064240994,"about_ca_topic_score_gemma":0.000003270857,"teacher_disagreement_score":0.15808403,"about_ca_system_score_codex":0.000053844968,"about_ca_system_score_gemma":0.00031293908,"threshold_uncertainty_score":0.46068206},"labels":[],"label_agreement":null},{"id":"W2911762019","doi":"10.1016/j.ejca.2018.12.029","title":"Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"MedImmune","keywords":"Durvalumab; Medicine; Head and neck; Cohort; Head and neck squamous-cell carcinoma; Basal cell; Oncology; Carcinoma; Internal medicine; Head and neck cancer; Surgery; Cancer; Immunotherapy","score_opus":0.011733029195131145,"score_gpt":0.2638317348907226,"score_spread":0.25209870569559145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911762019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99298495,0.0037376906,0.000002414829,0.000253511,0.00013090066,0.00024975534,0.000059675564,0.0000032508494,0.002577848],"genre_scores_gemma":[0.9990143,0.00043796413,0.00012135517,0.00009810468,0.00008801103,3.96742e-7,0.0000060237326,0.000022061298,0.00021173726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987519,0.00010544963,0.0005237786,0.00018167672,0.00029571133,0.00014148372],"domain_scores_gemma":[0.9991676,0.00006714671,0.0003123196,0.00014526643,0.00018256885,0.00012510465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031975954,0.0001285942,0.0004903038,0.00008306801,0.000036925707,0.00000532558,0.000048393085,0.000017353226,0.00002776812],"category_scores_gemma":[0.00004660667,0.000087709835,0.00003441903,0.00009159109,0.000058737915,0.00007428049,0.000047570324,0.00020071976,0.0000013009966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032530323,0.0006580883,0.9249687,0.00007201323,0.000058631464,0.00012898947,0.003935062,0.00002474954,0.0010521292,4.5187352e-7,0.0005502579,0.036020607],"study_design_scores_gemma":[0.073595084,0.0068382933,0.9149866,0.0005792387,0.0000972198,0.000007100081,0.00009626897,0.000013744364,0.00048054682,3.188183e-7,0.003217755,0.00008784078],"about_ca_topic_score_codex":0.0001930745,"about_ca_topic_score_gemma":0.000040827737,"teacher_disagreement_score":0.041064758,"about_ca_system_score_codex":0.000059296082,"about_ca_system_score_gemma":0.00010007479,"threshold_uncertainty_score":0.35767034},"labels":[],"label_agreement":null},{"id":"W2912244263","doi":"10.1016/j.ejca.2018.11.008","title":"Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Mathematical Biology Tumor Growth","field":"Mathematics","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fractal Systems (Canada)","funders":"National Institute of Biomedical Imaging and Bioengineering","keywords":"Medicine; Response Evaluation Criteria in Solid Tumors; Metric (unit); Hazard ratio; Consistency (knowledge bases); Oncology; Population; Internal medicine; Clinical trial; Statistics; Nuclear medicine; Mathematics; Confidence interval; Computer science; Artificial intelligence; Phases of clinical research","score_opus":0.04612288449131625,"score_gpt":0.38822360362178143,"score_spread":0.3421007191304652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912244263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539787,0.00031289714,0.00003589547,0.0011550814,0.000100961675,0.00034813487,0.000008224576,0.000011812811,0.0026291253],"genre_scores_gemma":[0.9938643,0.000006958985,0.0047637117,0.00008353343,0.00012559304,0.000003174398,6.7517345e-7,0.000030390345,0.0011216863],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9957607,0.0027763727,0.0006894169,0.00019786914,0.00039555828,0.00018012445],"domain_scores_gemma":[0.997779,0.0012831548,0.00037233037,0.00014990669,0.0002542323,0.00016135199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009922028,0.000148748,0.00039524073,0.00026601873,0.00004124533,0.00003745536,0.00012791867,0.000032039537,0.00056081556],"category_scores_gemma":[0.003954462,0.00011426429,0.00004290545,0.00015451736,0.00006943285,0.00012010358,0.00009573463,0.00021768188,0.0000690165],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.069333464,0.00062915334,0.15448944,0.0006293851,0.0005237751,0.00087016734,0.012786707,0.000033450524,0.55816495,0.00042320832,0.013074848,0.18904144],"study_design_scores_gemma":[0.0033098517,0.001703015,0.9798976,0.0018341296,0.00014783902,0.00034467442,0.00012259869,0.00039328265,0.004508624,0.0051300735,0.0022543296,0.0003539638],"about_ca_topic_score_codex":9.191226e-7,"about_ca_topic_score_gemma":0.0000024222759,"teacher_disagreement_score":0.82540816,"about_ca_system_score_codex":0.00013376054,"about_ca_system_score_gemma":0.00015155484,"threshold_uncertainty_score":0.6140537},"labels":[],"label_agreement":null},{"id":"W2913258427","doi":"10.1016/j.ejca.2018.11.030","title":"Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Comprehensive Cancer Center, City of Hope; National Institutes of Health; University of South Alabama; Memorial Sloan-Kettering Cancer Center","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Progressive disease; Trastuzumab; Adenocarcinoma; Lung; Cancer; Gastroenterology; Disease; Breast cancer; Epidermal growth factor receptor; Gefitinib","score_opus":0.01237785248314384,"score_gpt":0.3307583307436871,"score_spread":0.3183804782605433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913258427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491674,0.0003972717,0.000024257544,0.00034537542,0.0008485729,0.0008652026,0.00003334042,0.000007080312,0.002562184],"genre_scores_gemma":[0.9984147,0.000079760655,0.00043478925,0.00013140206,0.00014411828,0.000009754293,0.000006396981,0.000032390722,0.0007466997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985311,0.00013533115,0.00043171344,0.00018238429,0.0005581124,0.00016133746],"domain_scores_gemma":[0.9988128,0.000026298256,0.0004100848,0.00013446486,0.00050891883,0.00010743882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022655749,0.0001459853,0.00031523322,0.00015698095,0.000024591513,0.00002735177,0.000111820955,0.0000072166877,0.0009025175],"category_scores_gemma":[0.000052693413,0.00008655911,0.000057627876,0.00020550388,0.00001996575,0.00017312923,0.000023061633,0.00022696788,0.000013736446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039981804,0.0010003533,0.9764345,0.000026875503,0.0011880624,0.00039420807,0.0053124973,0.0003197675,0.000013315695,0.0000032528585,0.0003271688,0.010981762],"study_design_scores_gemma":[0.021999981,0.0034749294,0.9689205,0.00076386466,0.0005249402,0.000012695068,0.0020133762,0.00010211905,0.000019155714,0.0000010859412,0.0020587342,0.000108562024],"about_ca_topic_score_codex":0.00008033322,"about_ca_topic_score_gemma":0.00031759337,"teacher_disagreement_score":0.0180018,"about_ca_system_score_codex":0.001294987,"about_ca_system_score_gemma":0.00040008617,"threshold_uncertainty_score":0.9881934},"labels":[],"label_agreement":null},{"id":"W2913276036","doi":"10.1016/j.ejca.2018.11.027","title":"Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":726,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University","funders":"National Cancer Institute; Bundesministerium für Bildung und Forschung; Takeda Pharmaceuticals North America; Novartis; Deutsche Krebshilfe; Amgen; Pfizer; Deutsche Forschungsgemeinschaft; European Science Foundation; Eli Lilly and Company; Medical Research Council; AstraZeneca Schweiz; PharmaMar; Bayer","keywords":"Osteosarcoma; Medicine; Cohort; Overall survival; Oncology; Internal medicine; Pathology","score_opus":0.01179583201452263,"score_gpt":0.2697008094293999,"score_spread":0.2579049774148773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913276036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938777,0.0012422015,2.4671436e-7,0.0017251701,0.00008495453,0.00094863836,0.0000072779567,0.000006889781,0.0021069369],"genre_scores_gemma":[0.99905145,0.00033438188,0.00006572334,0.00035313214,0.00005995833,0.000012500198,0.0000023692664,0.000048807487,0.00007166825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758965,0.0008387591,0.000503483,0.00026131672,0.00054821203,0.00025856393],"domain_scores_gemma":[0.99904716,0.00014101694,0.00033122004,0.00023251183,0.00011723733,0.00013085007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009822579,0.00023933307,0.0005740442,0.00018607691,0.00003914369,0.000060286067,0.00016768667,0.0000095199375,0.000015849737],"category_scores_gemma":[0.00003812825,0.00012785783,0.000061492945,0.0002747104,0.00012857158,0.00011422069,0.000068870955,0.00031584714,0.0000060422335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003639379,0.0011899305,0.95542186,0.000015316531,0.00019094812,0.0013798281,0.0029662445,0.000003633412,0.0000049977434,0.0000025140794,0.00003525029,0.038425524],"study_design_scores_gemma":[0.008282507,0.0032401679,0.9833585,0.00022332836,0.00018661616,0.000081761216,0.0038270943,0.0000026909318,0.000009435026,5.412754e-7,0.00065075624,0.00013657058],"about_ca_topic_score_codex":0.00038757696,"about_ca_topic_score_gemma":0.00056649436,"teacher_disagreement_score":0.03828895,"about_ca_system_score_codex":0.00008301143,"about_ca_system_score_gemma":0.00005257656,"threshold_uncertainty_score":0.5213891},"labels":[],"label_agreement":null},{"id":"W2914274639","doi":"10.1016/j.ejca.2019.01.002","title":"Symptom documentation and intervention provision for symptom control in children receiving cancer treatments","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Cancer Society","keywords":"Documentation; Intervention (counseling); Medicine; Cancer; Family medicine; Physical therapy; Nursing; Internal medicine; Computer science","score_opus":0.010729551293406445,"score_gpt":0.3285787216826667,"score_spread":0.31784917038926025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914274639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99102426,0.005203513,0.00050593383,0.001620215,0.0005178865,0.00090999436,0.00002391082,0.000012123483,0.00018215764],"genre_scores_gemma":[0.9966258,0.0011986877,0.00030219846,0.0007024402,0.0004954662,0.000017814316,0.000008497399,0.00004277596,0.0006063655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982845,0.00028559912,0.00069477473,0.00021616711,0.00033063604,0.00018831345],"domain_scores_gemma":[0.9988877,0.00008064213,0.0006077241,0.00013001221,0.0001765704,0.0001173536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011179924,0.00015766681,0.0003995836,0.00018147545,0.00003420955,0.000047509486,0.00009020325,0.00002686264,0.00017037295],"category_scores_gemma":[0.000057583464,0.00013122513,0.00014988269,0.00010157029,0.000024925464,0.0003333938,0.000017141572,0.0001769876,0.0000069691464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012217304,0.00015415958,0.8794065,0.00016755305,0.00047409345,0.0000075649427,0.0022647,0.00013043187,0.0024558466,0.000008627795,0.00049142964,0.113217324],"study_design_scores_gemma":[0.019406212,0.0012296849,0.9734211,0.00270727,0.0002976004,0.000045344426,0.0002037364,0.00014483003,0.0005752095,0.000019315008,0.0018082277,0.00014147063],"about_ca_topic_score_codex":0.00026785236,"about_ca_topic_score_gemma":0.0000879329,"teacher_disagreement_score":0.11307585,"about_ca_system_score_codex":0.00029152897,"about_ca_system_score_gemma":0.00008834277,"threshold_uncertainty_score":0.5351205},"labels":[],"label_agreement":null},{"id":"W2916287599","doi":"10.1016/j.ejca.2018.12.032","title":"A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma","year":2019,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"North of England Children’s Cancer Research Fund; Cancer Research UK; Action Medical Research","keywords":"Medicine; Induction chemotherapy; Refractory (planetary science); Chemotherapy; Oncology; Internal medicine; Induction therapy; Clinical trial; Pediatrics","score_opus":0.029294468841033032,"score_gpt":0.3386203844500913,"score_spread":0.30932591560905826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916287599","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002501388,0.9948759,0.00005184804,0.00018079036,0.00023015833,0.00419065,0.000081611426,0.000012572142,0.00012632777],"genre_scores_gemma":[0.000074824515,0.997646,0.00031383598,0.00017343434,0.00040077258,0.000052670122,0.000019066329,0.00019147732,0.0011279499],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99614567,0.000989091,0.0015586308,0.00029672333,0.00073920074,0.00027068003],"domain_scores_gemma":[0.99466634,0.00013680685,0.0038029708,0.0005668905,0.0006131138,0.00021387228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010710381,0.0004238581,0.0035302215,0.00030825436,0.00004013001,0.000018384064,0.000308063,0.000049483253,0.000071124545],"category_scores_gemma":[0.00033499888,0.00023365079,0.0009513727,0.00035361483,0.00005629044,0.00008984112,0.000026466178,0.000646262,0.000032032513],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036400353,0.00013444635,0.000007894048,0.82384235,0.0036682484,0.00012520717,0.000017332884,8.102849e-7,0.0000029619955,0.0000014685902,0.003187541,0.16864774],"study_design_scores_gemma":[0.0036872372,0.0054412414,0.00016114298,0.910188,0.014067054,0.0014132947,0.000002696343,3.3940054e-7,0.000022926573,7.603319e-7,0.06483727,0.00017804257],"about_ca_topic_score_codex":0.000005268287,"about_ca_topic_score_gemma":0.0000011397566,"teacher_disagreement_score":0.1684697,"about_ca_system_score_codex":0.00017376096,"about_ca_system_score_gemma":0.00063391373,"threshold_uncertainty_score":0.9528003},"labels":[],"label_agreement":null},{"id":"W2916875443","doi":"10.1016/j.ejca.2019.01.003","title":"Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials","year":2019,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; University of Toronto; CancerCare Manitoba","funders":"","keywords":"Medicine; Meta-analysis; Hazard ratio; Randomized controlled trial; Confidence interval; Lung cancer; Internal medicine; Relative risk; Systematic review; Radiation therapy; Oncology; Surgery; MEDLINE","score_opus":0.13143423963807155,"score_gpt":0.46120397986925177,"score_spread":0.3297697402311802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916875443","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003902527,0.98918796,0.000034523964,0.00014599408,0.000066375665,0.009942964,0.00026722107,0.000003133456,0.00031280698],"genre_scores_gemma":[0.00055441476,0.9979437,0.000042532192,0.0001026882,0.00007957372,0.000340684,0.000015295713,0.000052223968,0.0008688688],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98142827,0.011516377,0.0057403054,0.00029090667,0.0008040887,0.00022004126],"domain_scores_gemma":[0.98144644,0.0032664211,0.01307751,0.0004276927,0.0016524785,0.00012945292],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01989334,0.0004388674,0.031462055,0.0012219993,0.000019173869,0.000022197546,0.00024460017,0.00006186527,0.00034596206],"category_scores_gemma":[0.006477892,0.00023564225,0.004788103,0.0009070372,0.00008092468,0.0000885542,0.000056981953,0.0004628066,0.000001347655],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015296334,0.00004184313,0.000010785483,0.72256875,0.26604158,0.000028049266,0.00029292656,0.00006142994,0.000020581121,0.000001404495,0.00013417848,0.009268817],"study_design_scores_gemma":[0.012292794,0.00013768749,0.000011058556,0.12248885,0.86065704,0.0000069269795,0.00006764997,0.000045383098,0.000019147761,3.1221663e-7,0.004127554,0.00014557823],"about_ca_topic_score_codex":0.000055040728,"about_ca_topic_score_gemma":0.000021859754,"teacher_disagreement_score":0.60007995,"about_ca_system_score_codex":0.00036819535,"about_ca_system_score_gemma":0.0011449574,"threshold_uncertainty_score":0.9829169},"labels":[],"label_agreement":null},{"id":"W2917106067","doi":"10.1016/s0959-8049(01)00350-1","title":"Estimates of cancer incidence and mortality in Europe in 1995","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":688,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Commission","keywords":"Demography; Incidence (geometry); Cancer; Cancer incidence; Population; Mortality rate; Medicine; Quarter (Canadian coin); Cancer registry; Estimation; Geography; Environmental health","score_opus":0.08907701786376794,"score_gpt":0.3682597860075627,"score_spread":0.2791827681437948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917106067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619782,0.032792285,0.00002787634,0.0006863676,0.0001378638,0.0000738393,0.000004684742,0.00000426832,0.004294609],"genre_scores_gemma":[0.99134773,0.007491122,0.0004448379,0.00043254884,0.00016104266,0.0000013255317,2.1490774e-7,0.000016886657,0.000104273466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985286,0.000121497425,0.0006415432,0.00014169994,0.00037007764,0.00019657698],"domain_scores_gemma":[0.99909395,0.000040036473,0.00034677947,0.00012696245,0.0002700981,0.00012218526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076855085,0.000120403136,0.0003881788,0.00016055536,0.000016000016,0.000012884463,0.00014077405,0.000018695699,0.00031224242],"category_scores_gemma":[0.0002688497,0.0000979848,0.00004559888,0.00044896375,0.000103239065,0.00019938243,0.00004698031,0.0003170583,0.000003875352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013130925,0.000038379487,0.9591687,0.00006364454,0.00003154907,0.0010568461,0.0006709742,0.0005700505,0.002374339,0.0000133894655,0.0006430333,0.035237838],"study_design_scores_gemma":[0.001310407,0.00023281059,0.99232423,0.0017641359,0.00006067341,0.00009455305,0.00009057137,0.00059559813,0.0010355125,0.000019559153,0.0023783538,0.00009356727],"about_ca_topic_score_codex":0.001113284,"about_ca_topic_score_gemma":0.00083966117,"teacher_disagreement_score":0.035144273,"about_ca_system_score_codex":0.00010049939,"about_ca_system_score_gemma":0.00009011204,"threshold_uncertainty_score":0.3995704},"labels":[],"label_agreement":null},{"id":"W2917321490","doi":"10.1016/j.ejca.2019.01.017","title":"Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma","year":2019,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Vemurafenib; Dabrafenib; Trametinib; Medicine; Melanoma; Internal medicine; Oncology; Rash; Dermatology; Cancer research; Metastatic melanoma; MAPK/ERK pathway; Chemistry","score_opus":0.017833210656384584,"score_gpt":0.24688768634669964,"score_spread":0.22905447569031506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917321490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808972,0.0027688395,0.00011980458,0.013325398,0.0010868221,0.00072239264,0.0004943171,0.00000553338,0.0005796836],"genre_scores_gemma":[0.8237546,0.0004738415,0.00024706905,0.1668702,0.0036010107,0.000038339436,0.0010745617,0.00028661604,0.0036537254],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981248,0.00051080034,0.00056048646,0.00027693718,0.00023493597,0.00029206384],"domain_scores_gemma":[0.99874187,0.000028420687,0.0006915774,0.00023419868,0.00025608632,0.000047878635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031910746,0.00029538467,0.00043724978,0.00011760373,0.000027885555,0.00003055511,0.0003773248,0.00013265287,0.000040454885],"category_scores_gemma":[0.00008106976,0.00023651555,0.00022480956,0.00006560113,0.000026271573,0.0000067408964,0.000044310582,0.00053665997,0.0000065994855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003568044,0.00006678362,0.0035356276,0.00007987017,0.0003134276,0.00007049187,0.000057671747,0.000004554051,0.1381047,3.4585102e-7,0.85396934,0.0034403482],"study_design_scores_gemma":[0.003240539,0.002430406,0.007291114,0.00008937566,0.00008851626,0.000005910248,0.0000055711334,0.0000023599493,0.035162974,0.0000032502771,0.95136505,0.00031492423],"about_ca_topic_score_codex":0.000010094503,"about_ca_topic_score_gemma":0.0000048308943,"teacher_disagreement_score":0.15714258,"about_ca_system_score_codex":0.00003425582,"about_ca_system_score_gemma":0.00011334769,"threshold_uncertainty_score":0.9644824},"labels":[],"label_agreement":null},{"id":"W2922245160","doi":"10.1016/j.ejca.2018.11.033","title":"Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health; Astellas Pharma; GlaxoSmithKline","keywords":"Medicine; Hazard ratio; Statin; Incidence (geometry); Prostate cancer; Internal medicine; Confidence interval; Proportional hazards model; Retrospective cohort study; Cohort; Cancer; Medical prescription; Pharmacology","score_opus":0.010151653202058403,"score_gpt":0.28748370502517645,"score_spread":0.27733205182311804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922245160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895914,0.0071198526,0.00048651002,0.000107822816,0.001801244,0.00013153556,0.000035808447,0.0000028444933,0.00072296953],"genre_scores_gemma":[0.98422414,0.010962097,0.00046579127,0.00016106098,0.003547518,0.0000038077728,0.0000028857148,0.000028602353,0.00060412154],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990306,0.000087885084,0.00032901615,0.00019646874,0.00018328302,0.00017276437],"domain_scores_gemma":[0.9991578,0.0000097676875,0.00035494813,0.0001488404,0.00017632572,0.00015232376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005237648,0.00012418114,0.00019045552,0.000044583096,0.00006456668,0.00003909044,0.000117025535,0.000023712724,0.000042400945],"category_scores_gemma":[0.000034715056,0.00010838274,0.0000406623,0.000061902676,0.00011689437,0.0000253558,0.0000888781,0.00013683854,7.6487134e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011640197,0.000022111519,0.45477036,0.000098724,0.00024060564,0.0000024817255,0.0018913782,0.0009938935,0.5138728,0.0000063735138,0.0035854185,0.024399487],"study_design_scores_gemma":[0.0015618568,0.00017592931,0.87409806,0.00029881104,0.00015877608,0.000028254237,0.0004858038,0.00035419516,0.011043109,0.000008817565,0.11150273,0.00028366095],"about_ca_topic_score_codex":0.00029176375,"about_ca_topic_score_gemma":0.00023403224,"teacher_disagreement_score":0.5028297,"about_ca_system_score_codex":0.00002409982,"about_ca_system_score_gemma":0.00020717243,"threshold_uncertainty_score":0.44197196},"labels":[],"label_agreement":null},{"id":"W2935510920","doi":"10.1016/j.ejca.2019.02.003","title":"Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Internal medicine; Confidence interval; Odds ratio; Oncology; Neuroblastoma; Induction chemotherapy; Univariate analysis; Stage (stratigraphy); Logistic regression; Multivariate analysis; Chemotherapy; Biology","score_opus":0.012460676788972742,"score_gpt":0.28648171745998674,"score_spread":0.274021040671014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935510920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966463,0.00023098849,0.000022594682,0.0016936699,0.0007847693,0.0004702866,0.000026683729,0.000008283821,0.00011641502],"genre_scores_gemma":[0.9985539,0.00038744367,0.00006727471,0.00017606543,0.0005726961,0.000004470492,0.0000040417867,0.00003688353,0.00019727259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971859,0.0013214832,0.0005681342,0.00020634664,0.0005103022,0.00020785566],"domain_scores_gemma":[0.99861264,0.00021714445,0.0005240625,0.00030745484,0.00016056752,0.0001781027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076779246,0.00014086247,0.00035941997,0.00020400435,0.00003107053,0.000013078373,0.00019319604,0.000028714061,0.00021827013],"category_scores_gemma":[0.00027734402,0.00008371293,0.0001285176,0.00023788321,0.00006225987,0.00008142341,0.00006102201,0.0005445706,0.00002243771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043334357,0.0006993806,0.7450865,0.0000051211855,0.0007278201,0.0027564343,0.0008012095,0.000104778774,0.13996683,0.0000013628702,0.002194337,0.064321876],"study_design_scores_gemma":[0.006737277,0.0080302395,0.9769018,0.0001293814,0.00008097953,0.00033200387,0.000032325475,0.0000024631647,0.0042777564,0.0000050228737,0.003413565,0.000057152185],"about_ca_topic_score_codex":0.00029047666,"about_ca_topic_score_gemma":0.000058050988,"teacher_disagreement_score":0.23181534,"about_ca_system_score_codex":0.00011546911,"about_ca_system_score_gemma":0.000209555,"threshold_uncertainty_score":0.3413714},"labels":[],"label_agreement":null},{"id":"W2941577587","doi":"10.1016/j.ejca.2019.02.010","title":"Letter in response to ‘Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors’","year":2019,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Myositis; Autoantibody; Medicine; myalgia; Internal medicine; Thymoma; Antibody; Immune checkpoint; Immune system; Cancer; Immunology; Gastroenterology; Immunotherapy","score_opus":0.008134397782211656,"score_gpt":0.24024447246408684,"score_spread":0.2321100746818752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941577587","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54511094,0.0043239235,0.00001595563,0.44792035,0.0015156758,0.0004531817,0.000015013965,0.000014655725,0.0006303225],"genre_scores_gemma":[0.16787289,0.00040126027,0.00011768277,0.822451,0.0071894685,0.000011085468,0.00001281842,0.00025694506,0.0016868265],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99571043,0.0014311398,0.0012450229,0.00038048733,0.00074000447,0.00049291656],"domain_scores_gemma":[0.99820715,0.00020815639,0.0007025742,0.00045003003,0.00023958611,0.0001924893],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001530463,0.00046427638,0.0010654001,0.0005841263,0.000050277707,0.000094499585,0.00024011605,0.00022630453,0.000052873256],"category_scores_gemma":[0.00027123297,0.00039859946,0.0003303985,0.000218844,0.000057649915,0.00015766293,0.00014846626,0.0028720973,0.00009015225],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001133328,0.000019328374,0.0002632367,0.0004452216,0.00011982273,0.035535786,0.00057363126,0.000003648424,0.1846012,1.2582227e-7,0.7720794,0.005225277],"study_design_scores_gemma":[0.003245575,0.0010569278,0.044077218,0.0035460708,0.00015721537,0.0014732924,0.000012237942,0.0000023403834,0.011032812,0.0000011510996,0.9349976,0.00039752823],"about_ca_topic_score_codex":0.00003445444,"about_ca_topic_score_gemma":0.0000013740832,"teacher_disagreement_score":0.37723804,"about_ca_system_score_codex":0.00024273044,"about_ca_system_score_gemma":0.00020805416,"threshold_uncertainty_score":0.9998466},"labels":[],"label_agreement":null},{"id":"W2943776805","doi":"10.1016/j.ejca.2019.04.002","title":"Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Fondazione Sandro Pitigliani; Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Exemestane; Internal medicine; Fulvestrant; Oncology; Breast cancer; Metastatic breast cancer; Aromatase inhibitor; Clinical trial; Cancer; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Aromatase; Gastroenterology; Phases of clinical research; Chemotherapy; Estrogen receptor","score_opus":0.029615690545690812,"score_gpt":0.35564776025566963,"score_spread":0.32603206970997883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943776805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956984,0.0016939625,0.00007459067,0.00014330795,0.0003457795,0.0016747845,0.00027880483,0.0000034790855,0.000086888824],"genre_scores_gemma":[0.99944764,0.00023106953,0.00011634986,0.000017967326,0.00011273254,0.00001576488,0.000008154942,0.000034184686,0.000016150674],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99546736,0.0015837144,0.0012558257,0.00022835482,0.0012683657,0.00019639549],"domain_scores_gemma":[0.9946898,0.00038085782,0.002701393,0.0003370102,0.0017823115,0.000108629174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002767734,0.00021409689,0.0013109527,0.00028818514,0.00002276404,0.0000052092714,0.00019908606,0.000028394443,0.0002986301],"category_scores_gemma":[0.00033558707,0.00013279074,0.00042422873,0.0009705294,0.00019586612,0.00019942285,0.00003854383,0.00033723298,5.0302623e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71176827,0.0016552805,0.09876894,0.000047093952,0.0050914264,0.0000046927635,0.00065772893,0.005135714,0.009914324,0.0000011626596,0.000005186178,0.16695021],"study_design_scores_gemma":[0.39932787,0.00401275,0.5850966,0.0004851015,0.0070801293,0.0000016392439,0.00016082576,0.0007276001,0.0029969353,0.00000186156,0.000015012378,0.00009366906],"about_ca_topic_score_codex":0.00007400851,"about_ca_topic_score_gemma":0.00006009177,"teacher_disagreement_score":0.48632765,"about_ca_system_score_codex":0.00030426655,"about_ca_system_score_gemma":0.00067761523,"threshold_uncertainty_score":0.5415049},"labels":[],"label_agreement":null},{"id":"W2949515538","doi":"10.1016/j.ejca.2019.05.008","title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":217,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Foundation Medicine; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Oncology; Internal medicine; Lung cancer; Chemotherapy; Open label; Cancer; Immunotherapy; Clinical trial","score_opus":0.025837221785027956,"score_gpt":0.32123817474898925,"score_spread":0.2954009529639613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949515538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98513263,0.0037488448,0.000021584561,0.004651016,0.0017973351,0.0032187158,0.0001337003,0.000017187867,0.0012789925],"genre_scores_gemma":[0.9915171,0.0032975841,0.00031805612,0.0008506452,0.0007401135,0.0001060825,0.000064325846,0.00009914552,0.0030069288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967621,0.00026048615,0.0014905626,0.00045075832,0.00066221674,0.00037386638],"domain_scores_gemma":[0.9969842,0.00035756067,0.0016859605,0.0004501919,0.00035143804,0.00017063874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007201812,0.00043412205,0.0010131542,0.00012153198,0.00012858947,0.00010013725,0.00040690266,0.000052230625,0.0008977606],"category_scores_gemma":[0.00006529102,0.00025376625,0.00021627363,0.00029548578,0.0000845087,0.00023314975,0.000047232952,0.0003527733,0.0000100846855],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94241965,0.00091094,0.0004922486,0.000018947294,0.0020070968,0.00067202386,0.0036315739,0.003062141,0.00614513,4.482654e-7,0.00060683367,0.04003297],"study_design_scores_gemma":[0.96652955,0.009960557,0.004053315,0.00076551706,0.0006345913,0.000037295777,0.00060013036,0.0004394968,0.00538084,0.0000017290849,0.011267315,0.0003296897],"about_ca_topic_score_codex":0.0042021135,"about_ca_topic_score_gemma":0.0008734255,"teacher_disagreement_score":0.03970328,"about_ca_system_score_codex":0.0010840083,"about_ca_system_score_gemma":0.0014816495,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W2949516084","doi":"10.1016/j.ejca.2019.04.031","title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","year":2019,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Ipsen; Glenmark Pharmaceuticals; Helsinn; Genomic Health; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Celgene; Eisai; Sanofi; Pfizer; Amgen","keywords":"Geriatric oncology; Medicine; Prostate cancer; Management of prostate cancer; Oncology; Internal medicine; Cancer; Clinical Oncology; Geriatric care; General surgery; Family medicine; Nursing","score_opus":0.04751093748395048,"score_gpt":0.37499147620082046,"score_spread":0.32748053871687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949516084","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014978275,0.9846477,0.0000013643211,0.0032044682,0.0025159754,0.0015362334,0.00037496962,0.0000030451852,0.006218452],"genre_scores_gemma":[0.00070204935,0.99700123,0.0001451459,0.000359158,0.00015795289,0.00004697863,0.0000470125,0.00004000154,0.0015004562],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979391,0.00021751989,0.0011353577,0.00018193419,0.00038230905,0.00014378845],"domain_scores_gemma":[0.9972628,0.00005153147,0.0020486622,0.00022616608,0.00035835034,0.00005249289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004079009,0.00020903003,0.0009530722,0.00019264546,0.000017987968,0.0000074193645,0.0002981888,0.00004259342,0.00022974155],"category_scores_gemma":[0.000011358508,0.00012218828,0.00054254546,0.00031574455,0.00004324107,0.000046458408,0.00011433271,0.00036425286,0.0000068857116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009839481,0.0005891051,0.0027930536,0.0022749868,0.0014426147,0.000014619967,0.0002422256,0.00003976082,5.068703e-7,0.000009729695,0.07069143,0.9218036],"study_design_scores_gemma":[0.0032702384,0.00040545285,0.012460383,0.018054295,0.0013083436,0.0000040657424,0.000030131834,0.0000015920948,0.0000121567455,0.0000016544374,0.9643639,0.00008780654],"about_ca_topic_score_codex":0.00001972157,"about_ca_topic_score_gemma":0.0000064439582,"teacher_disagreement_score":0.9217158,"about_ca_system_score_codex":0.0012201068,"about_ca_system_score_gemma":0.00062770664,"threshold_uncertainty_score":0.49826935},"labels":[],"label_agreement":null},{"id":"W2950568943","doi":"10.1016/j.ejca.2019.05.020","title":"Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"EORTC Charitable Trust; European Organisation for Research and Treatment of Cancer; Merck","keywords":"Pembrolizumab; Medicine; Placebo; Stage (stratigraphy); Oncology; Melanoma; Internal medicine; Predictive value; Cancer; Immunotherapy; Pathology; Cancer research; Alternative medicine","score_opus":0.012460533648180939,"score_gpt":0.2876012665329937,"score_spread":0.2751407328848128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950568943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946205,0.0022622435,0.00007086406,0.00033297407,0.00037815177,0.0010493272,0.000072418654,0.0000042119354,0.0012093026],"genre_scores_gemma":[0.99792093,0.0014128593,0.000053821474,0.00010103601,0.00023236842,0.00000633319,0.0000046271725,0.000030985673,0.00023703217],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99704343,0.00093456195,0.0010497504,0.00018693953,0.00055485487,0.00023047802],"domain_scores_gemma":[0.99816304,0.00031340128,0.0010182483,0.00025024533,0.00018554358,0.000069509144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025279406,0.00017690302,0.00061417563,0.00032848638,0.00002839824,0.000016149588,0.00022470551,0.000039553313,0.00018343284],"category_scores_gemma":[0.00018804295,0.00011764127,0.00012555218,0.00038372312,0.00015314817,0.00013986044,0.00003897331,0.00052694173,7.1489694e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8905464,0.0007032461,0.06453826,0.00020722301,0.0005624463,0.0003322646,0.009133812,0.00038915244,0.015119966,0.0000282196,0.0003848983,0.018054152],"study_design_scores_gemma":[0.54523873,0.016201839,0.42561275,0.0021492525,0.00037858984,0.00006905854,0.0022834972,0.00067526166,0.004862488,0.000015736468,0.0022997842,0.00021299663],"about_ca_topic_score_codex":0.0005335506,"about_ca_topic_score_gemma":0.00006890413,"teacher_disagreement_score":0.36107448,"about_ca_system_score_codex":0.00013427655,"about_ca_system_score_gemma":0.0003634863,"threshold_uncertainty_score":0.47972718},"labels":[],"label_agreement":null},{"id":"W2954759555","doi":"10.1016/j.ejca.2019.05.030","title":"The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Internal medicine; Cohort; Multivariate analysis; Chemotherapy; Chemotherapy regimen; Oncology; Cancer; Framingham Risk Score; Regimen; Disease","score_opus":0.01629554231363399,"score_gpt":0.27775922778053025,"score_spread":0.26146368546689625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954759555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9608911,0.030820232,0.000004459349,0.0044446616,0.0015201395,0.0003730193,0.000004803179,0.000012949224,0.0019286259],"genre_scores_gemma":[0.9795685,0.01756676,0.000038960825,0.0006258291,0.00053380284,0.000012859134,0.0000013765509,0.000049592978,0.0016023119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838895,0.00010181581,0.0005833976,0.00020031183,0.00043424612,0.00029129293],"domain_scores_gemma":[0.9987052,0.00014845139,0.00040875838,0.00021076403,0.0004368371,0.0000900095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045441755,0.00018846155,0.00037291812,0.00011316274,0.00010419742,0.000050048588,0.00022017951,0.000021017442,0.00012303739],"category_scores_gemma":[0.00018342768,0.000117368625,0.00015101115,0.0002631563,0.0000801842,0.00018781386,0.0000561286,0.0003626685,0.0000161664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062144693,0.000082052,0.9048442,0.00009680397,0.00016257177,0.00005230709,0.000974901,0.00014019183,0.00051387714,0.0000016624805,0.003686833,0.088823155],"study_design_scores_gemma":[0.0038446956,0.0005585778,0.9589483,0.0015190594,0.00007537561,0.000010432636,0.00022270695,0.000014369394,0.0005443135,0.000012565487,0.034118935,0.00013067457],"about_ca_topic_score_codex":0.000034115736,"about_ca_topic_score_gemma":0.00056629936,"teacher_disagreement_score":0.08869249,"about_ca_system_score_codex":0.00019770728,"about_ca_system_score_gemma":0.00016097023,"threshold_uncertainty_score":0.47861537},"labels":[],"label_agreement":null},{"id":"W2955938549","doi":"10.1016/j.ejca.2019.05.013","title":"Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"Institut National Du Cancer; Barncancerfonden; Associazione Italiana per la Ricerca sul Cancro; Javna Agencija za Raziskovalno Dejavnost RS; Ligue Contre le Cancer; Swiss Cancer Research Foundation; European Commission; Brain Tumour Charity; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; CHIST-ERA; Agence Nationale de la Recherche; Pfizer; CHILDREN with CANCER UK; Kræftens Bekæmpelse; National Cancer Institute; Seventh Framework Programme; KWF Kankerbestrijding; Pfizer Foundation; Compagnia di San Paolo","keywords":"Medicine; Cohort; Cancer; Population; Pediatrics; Cohort study; Incidence (geometry); Childhood cancer; Confidence interval; Malignancy; Absolute risk reduction; Internal medicine; Environmental health","score_opus":0.009639962416662526,"score_gpt":0.2650829115741077,"score_spread":0.25544294915744514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955938549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935705,0.0019225143,0.000023047358,0.00015117718,0.00061700377,0.0013652749,0.00018190844,0.000013172638,0.0021554215],"genre_scores_gemma":[0.9966575,0.0016161914,0.00026152868,0.00019272874,0.00038295618,0.000016134962,0.000008860809,0.00012111291,0.0007430152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943657,0.0014152416,0.0016107848,0.00045968415,0.0017014261,0.00044718295],"domain_scores_gemma":[0.99600726,0.0003841302,0.0012888316,0.00065287715,0.001256267,0.0004106367],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002780811,0.00033437109,0.0012441362,0.00045080634,0.000036880563,0.000021976333,0.0006096792,0.000058019206,0.0005489395],"category_scores_gemma":[0.0007641905,0.00026155348,0.0001906187,0.0009859797,0.00017006467,0.0001827585,0.00024128742,0.0009324486,0.00005125402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019413023,0.000627923,0.9760528,0.00008170537,0.00094170315,0.0013416398,0.0069082696,0.00493802,0.0026204684,0.0000011988258,0.0027583402,0.0017866377],"study_design_scores_gemma":[0.010359386,0.0016423715,0.9825676,0.0014173244,0.0003786698,0.000014204528,0.0009573336,0.00007239199,0.0019450565,0.0000015497982,0.00041683248,0.00022725578],"about_ca_topic_score_codex":0.014855186,"about_ca_topic_score_gemma":0.0025259864,"teacher_disagreement_score":0.0123292,"about_ca_system_score_codex":0.0010410171,"about_ca_system_score_gemma":0.0021224625,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W2956151376","doi":"10.1016/j.ejca.2019.05.026","title":"Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review","year":2019,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Publication bias; Subgroup analysis; Meta-analysis; Systematic review; MEDLINE; Medicine; Cochrane Library; Relative risk; Confidence interval; Internal medicine; Political science; Law","score_opus":0.7385142302246156,"score_gpt":0.5209842950287482,"score_spread":0.21752993519586739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956151376","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075564594,0.1124091,0.0011292333,0.8720617,0.0013072239,0.0024772177,0.000088218796,0.0000019174631,0.0029689006],"genre_scores_gemma":[0.09882403,0.014569794,0.0012854895,0.83186764,0.0018645131,0.000053655167,0.000006018815,0.00016492956,0.05136393],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8346837,0.14019588,0.01653697,0.00051503454,0.007838082,0.00023033224],"domain_scores_gemma":[0.93580997,0.013334052,0.042589583,0.0037012845,0.0044891564,0.000075941796],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.32895523,0.00036134262,0.005258176,0.0004195521,0.00009313968,0.00080397376,0.0036130229,0.00007738122,0.0008952923],"category_scores_gemma":[0.19933103,0.00010882341,0.0025759814,0.0013324046,0.00013456476,0.0002581804,0.00024595368,0.0011545955,0.00007331306],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009402879,0.0000062556446,0.0012712692,0.012893016,0.0005019869,0.0000068610184,0.00038361052,0.000021611895,0.000013340949,0.000006576061,0.98347574,0.00141033],"study_design_scores_gemma":[0.000111597794,0.00006666158,0.0050373906,0.0735351,0.0036924577,0.000069418835,0.00019887958,0.000060949464,0.000011742149,0.000029547366,0.9170462,0.0001400907],"about_ca_topic_score_codex":0.000008662097,"about_ca_topic_score_gemma":0.0000046748482,"teacher_disagreement_score":0.12962422,"about_ca_system_score_codex":0.000056518646,"about_ca_system_score_gemma":0.0003081222,"threshold_uncertainty_score":0.9802823},"labels":[],"label_agreement":null},{"id":"W2959738210","doi":"10.1016/j.ejca.2019.05.033","title":"Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University; University of Alberta Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Vincristine; Wilms' tumor; Stage (stratigraphy); Doxorubicin; Radiation therapy; Chemotherapy; Surgery; Internal medicine; Cyclophosphamide","score_opus":0.007652578910238929,"score_gpt":0.259228210254897,"score_spread":0.2515756313446581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2959738210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905951,0.0067223925,0.000046276156,0.00019098893,0.0006205121,0.00018705105,0.000028647759,0.0000021485514,0.00160687],"genre_scores_gemma":[0.99647516,0.0016530856,0.000039288254,0.00006895904,0.000619474,0.000002088463,0.000013887224,0.00002221249,0.0011058731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998762,0.00028217418,0.00045081292,0.00018174802,0.00018856504,0.00013468479],"domain_scores_gemma":[0.998914,0.000025091751,0.00063276064,0.00024882538,0.00010931793,0.00006999131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023318887,0.00013566155,0.00025639212,0.00002713109,0.000034275752,0.000011134525,0.0002231067,0.000032389773,0.00009090113],"category_scores_gemma":[0.000023210103,0.0000751114,0.00016544435,0.000062782274,0.00005994123,0.0000042878787,0.00004112632,0.00012332654,0.0000073227875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036570798,0.0014786229,0.59268254,0.000014304962,0.0047827996,0.002439337,0.0017280995,0.006453375,0.30524904,0.000007648957,0.0064538876,0.07505327],"study_design_scores_gemma":[0.009286162,0.026276382,0.6854952,0.0001363408,0.00061138393,0.00065775844,0.0012946132,0.00001647209,0.026723709,0.0000063669886,0.24913427,0.00036134853],"about_ca_topic_score_codex":0.00011614971,"about_ca_topic_score_gemma":0.000074522104,"teacher_disagreement_score":0.27852532,"about_ca_system_score_codex":0.000058605387,"about_ca_system_score_gemma":0.00016503208,"threshold_uncertainty_score":0.3062954},"labels":[],"label_agreement":null},{"id":"W2962859974","doi":"10.1016/j.ejca.2019.06.019","title":"Impact of cisplatin dose and smoking pack-years in human papillomavirus–positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; Regeneron Pharmaceuticals; Princess Margaret Cancer Foundation; Array BioPharma; Johnson and Johnson; AbbVie; Karyopharm Therapeutics; Novartis; MedImmune; Merck; GlaxoSmithKline; Celgene; Bayer Corporation; AstraZeneca; Boehringer Ingelheim; Amgen; Bristol-Myers Squibb Foundation; Pfizer; Roche; Astellas Pharma US","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Chemoradiotherapy; Cisplatin; Gastroenterology; Radiation therapy; T-stage; Oncology; Carcinoma; Human papillomavirus; Cohort; Cancer; Chemotherapy","score_opus":0.013252520509104875,"score_gpt":0.2933935334944531,"score_spread":0.2801410129853482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962859974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98973143,0.0055858297,0.0000012011626,0.000054845244,0.00004182444,0.0001665948,0.000011396942,0.000004762995,0.004402131],"genre_scores_gemma":[0.99906886,0.00037927506,0.000056760375,0.0000854084,0.0001438123,8.604983e-7,0.0000011917281,0.00004363525,0.0002201795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989085,0.00012198239,0.00037780963,0.00014870636,0.00024161956,0.00020133685],"domain_scores_gemma":[0.9992516,0.000036018482,0.00032248918,0.000119968856,0.0001464759,0.00012346015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025912034,0.00016620064,0.0006357963,0.00015494475,0.000026591344,0.000010722871,0.00006740439,0.000021541191,0.00015500015],"category_scores_gemma":[0.000006482717,0.00011253213,0.00009898688,0.00017577791,0.00007609725,0.000088386856,0.000016867556,0.00026055716,0.0000011883965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021219994,0.00010491066,0.9032077,0.00006447112,0.00011740983,0.0009579221,0.002575968,0.000042736232,0.08111565,9.331925e-7,0.00016919644,0.009521105],"study_design_scores_gemma":[0.011108566,0.006018083,0.97500694,0.0003915667,0.00008976967,0.000098365854,0.00011978104,0.00001013742,0.0069380384,5.7154665e-7,0.0001000759,0.0001181117],"about_ca_topic_score_codex":0.00033094146,"about_ca_topic_score_gemma":0.000026407777,"teacher_disagreement_score":0.074177615,"about_ca_system_score_codex":0.00019149974,"about_ca_system_score_gemma":0.00013128106,"threshold_uncertainty_score":0.45889267},"labels":[],"label_agreement":null},{"id":"W2975664877","doi":"10.1016/j.ejca.2019.07.021","title":"The transformation of radiation oncology using real-time magnetic resonance guidance: A review","year":2019,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"Division of Mathematical Sciences; National Institute of Dental and Craniofacial Research; Medical Research Council; Siemens Healthineers; National Cancer Institute; KWF Kankerbestrijding; National Institute for Health and Care Research; National Institutes of Health; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Elekta; Roche; Merck; AstraZeneca; Varian Medical Systems; Cancer Research UK; National Science Foundation","keywords":"Radiation oncology; Transformation (genetics); Medical physics; Magnetic resonance imaging; Medicine; Oncology; Radiation therapy; Internal medicine; Radiology; Chemistry","score_opus":0.030980073222410438,"score_gpt":0.37699613082314143,"score_spread":0.346016057600731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975664877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000013610006,0.98809254,0.004368283,0.00006460715,0.00022587138,0.00052717444,0.000034467765,0.000006778653,0.0066789174],"genre_scores_gemma":[0.0000019582171,0.9965462,0.0024106523,0.000031379408,0.0005640718,0.000008657204,0.000004881559,0.000058824848,0.00037338803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972269,0.00090248213,0.001351883,0.00011770474,0.00023613013,0.00016489535],"domain_scores_gemma":[0.99672127,0.00013534451,0.0026277788,0.00026284068,0.00021108685,0.000041702275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013113571,0.00022409667,0.0011523349,0.0000735877,0.000053089057,0.000015935422,0.00042028644,0.000031091433,0.00021873259],"category_scores_gemma":[0.000012511223,0.0001428329,0.00046190334,0.00020894702,0.00006421036,0.00015515691,0.000015705795,0.00034865164,0.000006019888],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000103914535,0.000010732164,0.0000026517796,0.0025396885,0.00006530334,0.0000019082552,0.000054202115,0.0000094645875,0.000018823292,0.0001186641,0.0017697449,0.9953984],"study_design_scores_gemma":[0.0002040736,0.00016931797,0.000005321361,0.03549172,0.00048323994,0.000014294343,0.0000030155093,0.000017902317,0.000011419573,0.0000151954355,0.96345717,0.0001273337],"about_ca_topic_score_codex":0.0000072262765,"about_ca_topic_score_gemma":1.7045225e-7,"teacher_disagreement_score":0.9952711,"about_ca_system_score_codex":0.00022248433,"about_ca_system_score_gemma":0.00050911924,"threshold_uncertainty_score":0.58245564},"labels":[],"label_agreement":null},{"id":"W2984246397","doi":"10.1016/j.ejca.2019.10.002","title":"Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Medicine; Tolerability; Neutropenia; Internal medicine; Nasopharyngeal carcinoma; Adverse effect; Febrile neutropenia; Phases of clinical research; Population; Performance status; Progressive disease; Oncology; Surgery; Gastroenterology; Toxicity; Cancer; Chemotherapy; Radiation therapy","score_opus":0.025861483595637506,"score_gpt":0.31355744109905515,"score_spread":0.28769595750341764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984246397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959332,0.001791804,0.000006561597,0.00012997503,0.00016927718,0.0009015122,0.000013938012,0.000008589064,0.0010451672],"genre_scores_gemma":[0.9986483,0.00015794502,0.00020429965,0.00018296861,0.000070700284,0.000007906147,0.0000030066128,0.00004800889,0.0006768548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795574,0.0002532438,0.0007803042,0.00020714616,0.00052815786,0.00027541985],"domain_scores_gemma":[0.9985761,0.0000403915,0.00049609464,0.00019992822,0.00052065426,0.0001668419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038833174,0.00022350154,0.0009087943,0.00019879732,0.00003985836,0.000007093894,0.00014007035,0.000011215626,0.000138255],"category_scores_gemma":[0.000050174902,0.00013416563,0.00008091962,0.00034230636,0.000050843155,0.00016866194,0.000046908735,0.00026197234,0.000005233414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052538592,0.031473096,0.71288264,0.00046000857,0.0012314679,0.00290225,0.012205822,0.00015977849,0.0011471016,0.000001988752,0.0009792486,0.18401799],"study_design_scores_gemma":[0.3097722,0.15615156,0.5259276,0.0019815995,0.00073222385,0.0000513321,0.0017305423,0.000046350808,0.0009103482,8.35212e-7,0.0023936885,0.00030174488],"about_ca_topic_score_codex":0.000054955042,"about_ca_topic_score_gemma":0.00018091688,"teacher_disagreement_score":0.2572336,"about_ca_system_score_codex":0.00013712369,"about_ca_system_score_gemma":0.00025194994,"threshold_uncertainty_score":0.5471116},"labels":[],"label_agreement":null},{"id":"W2992092014","doi":"10.1016/j.ejca.2019.07.029","title":"The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Proportional hazards model; Cumulative incidence; Incidence (geometry); Radiation therapy; Chemotherapy; Osteosarcoma; Retrospective cohort study; Survival analysis; Internal medicine; Surgery; Systemic therapy; Oncology; Gastroenterology; Cancer; Pathology; Cohort","score_opus":0.006417361719161677,"score_gpt":0.2630110453473455,"score_spread":0.2565936836281838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992092014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8896823,0.10649347,0.0000063986363,0.0015863996,0.00008446968,0.00012564845,9.2907885e-7,0.0000019938755,0.002018383],"genre_scores_gemma":[0.9876308,0.01156363,0.00024551695,0.00026426563,0.00011350413,0.0000012017158,1.6405893e-7,0.000020078272,0.00016083989],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992351,0.00011266089,0.000300063,0.00006912568,0.00017743072,0.00010563],"domain_scores_gemma":[0.99950355,0.00007471736,0.00018860886,0.00011572945,0.000060652957,0.000056752386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037576392,0.000078828045,0.00023981484,0.000049613787,0.000015245853,0.0000108007125,0.00007158387,0.000010778084,0.00013799767],"category_scores_gemma":[0.000008969694,0.000044199518,0.0000858025,0.00006767715,0.00005469742,0.000034186367,0.000007609219,0.00010657708,0.000002740482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005844434,0.00011066844,0.4251321,0.000009155532,0.0001400848,0.00007158242,0.00034605956,0.0000059505383,0.00883685,0.00006936836,0.00013095577,0.5645628],"study_design_scores_gemma":[0.010013541,0.0008903637,0.74387133,0.00027809464,0.00004447814,0.00016896662,0.0002596498,0.000069076916,0.00883571,0.00004656645,0.2354511,0.00007109835],"about_ca_topic_score_codex":0.0000144449,"about_ca_topic_score_gemma":0.0000063488,"teacher_disagreement_score":0.5644917,"about_ca_system_score_codex":0.000042818665,"about_ca_system_score_gemma":0.000045055825,"threshold_uncertainty_score":0.1802404},"labels":[],"label_agreement":null},{"id":"W2996433778","doi":"10.1016/j.ejca.2019.11.006","title":"Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Osimertinib; Gefitinib; Medicine; Erlotinib; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Post-hoc analysis; Oncology; Discontinuation; Clinical endpoint; Performance status; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.012771670707341618,"score_gpt":0.29648738081276316,"score_spread":0.2837157101054215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996433778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110097,0.0014303828,0.00002063723,0.00043525448,0.0016325332,0.001021266,0.00009309446,0.000026893998,0.0042389953],"genre_scores_gemma":[0.9967675,0.0001985489,0.0008403907,0.0005325807,0.00015469568,0.000027752936,0.000054443943,0.00010921611,0.0013148353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975134,0.00012454779,0.0010010501,0.00036174885,0.0005957892,0.00040346518],"domain_scores_gemma":[0.9975275,0.0001194973,0.0011072197,0.00033086637,0.00064385275,0.00027109374],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014811257,0.00035071728,0.000693494,0.00020671793,0.000059416532,0.000036172998,0.00015887847,0.000042554635,0.0013816894],"category_scores_gemma":[0.00005768518,0.00022026249,0.00015637437,0.00035602765,0.000039282622,0.00025725013,0.0000415237,0.00040003358,0.000029482533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011724161,0.0005248149,0.9504127,0.000060240898,0.0014748349,0.0005630903,0.0020026104,0.0013176509,0.00047741397,4.5574166e-7,0.000755529,0.030686514],"study_design_scores_gemma":[0.058237694,0.0023511162,0.93146974,0.0011134933,0.0012256977,0.000005614242,0.00051918067,0.000056917765,0.00090028497,5.371486e-7,0.0038118616,0.00030787534],"about_ca_topic_score_codex":0.0002853855,"about_ca_topic_score_gemma":0.00019392245,"teacher_disagreement_score":0.046513535,"about_ca_system_score_codex":0.0005033337,"about_ca_system_score_gemma":0.0007340283,"threshold_uncertainty_score":0.9995312},"labels":[],"label_agreement":null},{"id":"W3001622551","doi":"10.1016/j.ejca.2019.12.029","title":"ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Research UK; CHILDREN with CANCER UK; Action Medical Research","keywords":"Medicine; Clinical trial; Agency (philosophy); Intensive care medicine; Oncology; Internal medicine","score_opus":0.04738878254134485,"score_gpt":0.2875636237656424,"score_spread":0.24017484122429753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001622551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788885,0.016607706,0.00028714258,0.0027299842,0.00042451752,0.00097021984,0.000009745787,0.0000065550116,0.000075628275],"genre_scores_gemma":[0.99416244,0.0036033562,0.0009456479,0.000649196,0.0005461313,0.000012166015,0.000012622796,0.000044301905,0.00002413927],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99788547,0.00019486621,0.0011739554,0.00020955602,0.00031587886,0.0002202537],"domain_scores_gemma":[0.99863213,0.000075482814,0.0006876789,0.0000763682,0.0004057337,0.00012262292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015064817,0.00017814616,0.00039349525,0.00031395297,0.000037753594,0.00001696934,0.000114963965,0.000020996657,0.00001833191],"category_scores_gemma":[0.00023832054,0.00013215307,0.00010248952,0.00042467634,0.000051827414,0.0001875544,0.000023063752,0.0001782618,3.4214682e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053557865,0.00024204592,0.13994609,0.00024932637,0.000094647185,0.000023186949,0.003436086,0.000019784497,0.0071688923,0.0000017704024,0.0023584936,0.8411039],"study_design_scores_gemma":[0.029890843,0.004782517,0.9322384,0.00045026335,0.00007486883,0.0000066698526,0.0004372018,0.00010218528,0.006804494,0.000011118382,0.024987724,0.00021374373],"about_ca_topic_score_codex":0.000011326139,"about_ca_topic_score_gemma":0.00002458458,"teacher_disagreement_score":0.84089017,"about_ca_system_score_codex":0.00010069486,"about_ca_system_score_gemma":0.00028169068,"threshold_uncertainty_score":0.5389046},"labels":[],"label_agreement":null},{"id":"W3002908611","doi":"10.1016/j.ejca.2019.10.034","title":"Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; Cancer Care Ontario; McMaster University; Mount Sinai Hospital; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"Cancer Care Ontario","keywords":"Medicine; Hyperthermic intraperitoneal chemotherapy; Ovarian cancer; Pseudomyxoma peritonei; Fallopian tube; Surgery; Oncology; Chemotherapy; Randomized controlled trial; Ovarian carcinoma; Clinical trial; Internal medicine; Cytoreductive surgery; Cancer; Appendix","score_opus":0.039670507845674566,"score_gpt":0.33452734103439685,"score_spread":0.2948568331887223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002908611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001018231,0.99453557,0.000078525496,0.0024151495,0.0002502691,0.0023253046,0.00007471153,0.000021844513,0.00028845595],"genre_scores_gemma":[0.000051246057,0.9957166,0.00040813044,0.0017602777,0.0014808723,0.00015969973,0.000024462335,0.00016211874,0.00023665],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706924,0.00043534854,0.001540104,0.00025985713,0.00043087007,0.00026459072],"domain_scores_gemma":[0.99653333,0.00022783331,0.002276752,0.00025742495,0.0004458786,0.00025874723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081354304,0.00044653672,0.004368428,0.00017461795,0.00006861182,0.000034412045,0.00029619935,0.000055586297,0.000100657184],"category_scores_gemma":[0.00019615081,0.00025069565,0.0010753267,0.0004128579,0.00012540308,0.000080912076,0.000016927805,0.0005138579,0.000026818281],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010118388,0.000059069476,9.3477104e-7,0.71617466,0.0016123203,0.00036580066,0.00016065055,4.9926015e-8,0.0000055465935,0.000020891903,0.004104171,0.2773947],"study_design_scores_gemma":[0.00024263731,0.00032585298,0.000002754396,0.47083357,0.00586492,0.0019454943,0.000026382304,1.853563e-7,0.0000043915506,8.731165e-7,0.5205923,0.00016063663],"about_ca_topic_score_codex":0.0000018036363,"about_ca_topic_score_gemma":5.5711547e-7,"teacher_disagreement_score":0.51648813,"about_ca_system_score_codex":0.00018544379,"about_ca_system_score_gemma":0.0013884909,"threshold_uncertainty_score":0.9999945},"labels":[],"label_agreement":null},{"id":"W3003028831","doi":"10.1016/j.ejca.2019.11.021","title":"Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Genome British Columbia; Jewish General Hospital; University of Victoria","funders":"Deutsche Forschungsgemeinschaft","keywords":"Multiplex; Colorectal cancer; Signature (topology); Medicine; Oncology; Internal medicine; Computational biology; Cancer; Biology; Bioinformatics; Mathematics","score_opus":0.031048421386289694,"score_gpt":0.31723861159962247,"score_spread":0.28619019021333275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003028831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98801005,0.0009542375,0.008956899,0.0008607781,0.00040583845,0.0006008137,0.000037692844,0.000015484666,0.00015821398],"genre_scores_gemma":[0.9975865,0.000037203758,0.0017196855,0.00010192818,0.00040368887,0.000023623645,0.0000012606913,0.000035537316,0.000090576636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867976,0.00012323474,0.000538247,0.0001578183,0.00036676877,0.00013419354],"domain_scores_gemma":[0.9983179,0.000051785966,0.00062715693,0.00006442138,0.00077477563,0.0001639392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042071927,0.000120193596,0.00033125642,0.00015888827,0.00003632764,0.000012604809,0.00009111688,0.000041425796,0.000053940195],"category_scores_gemma":[0.00043414824,0.00010600376,0.00020196728,0.00036741997,0.00003817938,0.000115417206,0.000019891733,0.00024294246,0.0000019385539],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037661787,0.000028517497,0.0016576711,0.00023843566,0.00018141266,0.00001170909,0.0012388829,0.0012495732,0.877156,0.0000012590699,0.0004597029,0.08011501],"study_design_scores_gemma":[0.0040009785,0.013433311,0.17533584,0.00083117466,0.00023183976,0.00001598296,0.0003239062,0.0016360072,0.80081165,0.0000034208024,0.0032354298,0.00014048032],"about_ca_topic_score_codex":0.00015184408,"about_ca_topic_score_gemma":0.00018772382,"teacher_disagreement_score":0.17367817,"about_ca_system_score_codex":0.00010687702,"about_ca_system_score_gemma":0.0001553774,"threshold_uncertainty_score":0.4322708},"labels":[],"label_agreement":null},{"id":"W3003732818","doi":"10.1016/j.ejca.2019.12.019","title":"Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?","year":2020,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Carboplatin; Oxaliplatin; Cisplatin; Medicine; Oncology; Internal medicine; Chemotherapy; Urology; Cancer; Colorectal cancer","score_opus":0.05733706939636016,"score_gpt":0.34325992382897896,"score_spread":0.2859228544326188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003732818","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003532185,0.004242716,0.000044233846,0.9764146,0.0008119542,0.0007346648,0.00068049424,0.000023687291,0.0135154165],"genre_scores_gemma":[0.00811605,0.001034984,0.0007466493,0.96082234,0.00926335,0.000030669005,0.00003132682,0.00023375078,0.01972089],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99610615,0.0004842645,0.0013627488,0.0005391044,0.0010193258,0.0004884174],"domain_scores_gemma":[0.99804455,0.00008257234,0.00070577266,0.00042807576,0.00038024012,0.0003587959],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00050051406,0.0005382537,0.0013798261,0.0003689143,0.000044305434,0.000052822837,0.00041574132,0.00009334793,0.010193258],"category_scores_gemma":[0.00017254581,0.0004270034,0.0004364266,0.000490851,0.00007088969,0.00009241892,0.00009427627,0.0020790522,0.00090533623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011228621,0.00006717285,0.00078173756,0.00026290177,0.00063298526,0.008311397,0.00090640335,0.000033838605,0.0006735288,1.4074871e-7,0.97144085,0.015766207],"study_design_scores_gemma":[0.0044313357,0.0012285667,0.0024282674,0.0017741187,0.0009790829,0.00015859406,0.000017297029,0.000016259379,0.00070461334,0.000019700941,0.98787796,0.00036418508],"about_ca_topic_score_codex":0.0002846257,"about_ca_topic_score_gemma":0.000032442804,"teacher_disagreement_score":0.016437154,"about_ca_system_score_codex":0.00063909724,"about_ca_system_score_gemma":0.0012152259,"threshold_uncertainty_score":0.99987257},"labels":[],"label_agreement":null},{"id":"W3004209283","doi":"10.1016/j.ejca.2019.11.013","title":"The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":478,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; University of Toronto","funders":"Janssen Biotech; Springworks Therapeutics; Novartis; PharmaMar; Desmoid Tumor Research Foundation; Bayer; Eli Lilly and Company; Ignyta; AbbVie","keywords":"Guideline; Medicine; Fibromatosis; Sarcoma; Soft tissue sarcoma; Soft tissue; Intensive care medicine; Surgery; Pathology","score_opus":0.04859617114621662,"score_gpt":0.34104428411748816,"score_spread":0.29244811297127155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004209283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006471991,0.99625766,0.00042703154,0.0006951736,0.00033363793,0.0011438794,0.00013363796,0.000010811308,0.0009334603],"genre_scores_gemma":[0.00031342637,0.98847353,0.010145088,0.00027324908,0.0006203209,0.000022927341,0.000017724475,0.000067310764,0.00006640771],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971169,0.00028763313,0.0016191232,0.00023668077,0.000506542,0.00023312715],"domain_scores_gemma":[0.9964719,0.00011830668,0.001836029,0.00021328508,0.0011755963,0.00018488934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008767661,0.00034126188,0.001512438,0.000081988306,0.00008359763,0.000019343526,0.00019478524,0.000026983531,0.0000055806854],"category_scores_gemma":[0.0004437287,0.00019781345,0.0005543051,0.00028564068,0.00015511835,0.000013466129,0.00011146553,0.00027067814,0.0000022428837],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029674923,0.00007747622,0.0001983439,0.013677744,0.0012969397,0.00040705895,0.00003150804,0.000005589811,6.321912e-8,0.000017692028,0.033245683,0.95074517],"study_design_scores_gemma":[0.0033795326,0.00088517397,0.0006592108,0.009010629,0.007108951,0.00017346191,0.00012617125,0.000023979528,7.0742175e-7,0.000003225476,0.9784459,0.000183065],"about_ca_topic_score_codex":0.0000022554555,"about_ca_topic_score_gemma":6.0037837e-7,"teacher_disagreement_score":0.95056206,"about_ca_system_score_codex":0.00020325146,"about_ca_system_score_gemma":0.00030264066,"threshold_uncertainty_score":0.8066598},"labels":[],"label_agreement":null},{"id":"W3007541271","doi":"10.1016/j.ejca.2020.01.007","title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":240,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Instituto Superior de Agronomia; Merck Sharp and Dohme; Sandoz; Bristol-Myers Squibb Canada; Genentech; Sun Pharma; Genesis Pharma; Eisai; SkylineDx; Pfizer; Biogen; Incyte; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Mylan; Galderma; UCB; AbbVie; Health Research; Novartis; Celgene; LEO Pharma; Bayer; Wyeth; Agence Nationale de la Recherche; Roche; Sanofi; Merck; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Guideline; Epidemiology; Medicine; Basal cell; Dermatology; Oncology; Pathology","score_opus":0.0533766450898083,"score_gpt":0.3284284051082279,"score_spread":0.2750517600184196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007541271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92829037,0.0192052,0.00032170973,0.03131709,0.0008944783,0.0003016769,0.000028641927,0.000008712818,0.019632112],"genre_scores_gemma":[0.99282384,0.0014187975,0.0005092874,0.0032730985,0.0016865326,0.0000012552994,0.0000017212312,0.000043807402,0.00024164047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751526,0.00094854087,0.00095644355,0.00019138926,0.00021748482,0.00017088483],"domain_scores_gemma":[0.99802893,0.00040503134,0.0009345339,0.00021064827,0.00025565425,0.0001651788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010901343,0.00017011944,0.00046162383,0.00004906287,0.00007434258,0.000005204784,0.00022063486,0.000017829656,0.00006860183],"category_scores_gemma":[0.0012315991,0.00010789056,0.00019457936,0.000116688105,0.00020234591,0.000044880588,0.0004021873,0.00038620524,0.000010417131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015462579,0.00023908258,0.49158818,0.000499207,0.00028078855,0.0011505941,0.0067156316,0.00058549223,0.0013691187,0.00003924984,0.4391683,0.05681812],"study_design_scores_gemma":[0.0029637064,0.0037639283,0.9416781,0.00074656506,0.00038818512,0.00014161361,0.00068098155,0.000021002588,0.0043845465,0.000062268075,0.045015443,0.00015364615],"about_ca_topic_score_codex":0.000003486666,"about_ca_topic_score_gemma":0.00000793605,"teacher_disagreement_score":0.45008996,"about_ca_system_score_codex":0.000062337116,"about_ca_system_score_gemma":0.00010887227,"threshold_uncertainty_score":0.43996495},"labels":[],"label_agreement":null},{"id":"W3007800733","doi":"10.1016/j.ejca.2020.01.014","title":"The ‘Good Friday Agreement’ and cancer research on the island of Ireland: Evidence for the impact of a tripartite cancer research partnership","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Economic and Social Research Council; Medical Research Council; EMD Serono; Queen's University Belfast; Cancer Research UK; Roche; UK Research and Innovation; Queen's University; Pfizer","keywords":"Cancer; General partnership; Citation; Citation impact; Medicine; Cancer registry; Gerontology; Demography; Political science; Sociology","score_opus":0.3454335874956846,"score_gpt":0.5758019566808663,"score_spread":0.23036836918518172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007800733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55875534,0.31395903,0.00044502175,0.12195239,0.0005607012,0.0014616146,0.000058237136,0.0000055521264,0.002802128],"genre_scores_gemma":[0.9172333,0.07904943,0.000025716405,0.000538757,0.0017464986,0.000040437466,1.3554042e-7,0.000024940244,0.0013407961],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99668294,0.0014915828,0.0004924492,0.00016780359,0.0007960712,0.00036917557],"domain_scores_gemma":[0.99247843,0.0057764235,0.00040291323,0.00027765255,0.00092027907,0.00014432477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074918116,0.0001231669,0.00032543732,0.00007466564,0.00039822276,0.000026070958,0.000485409,0.000033765922,0.00029222606],"category_scores_gemma":[0.0012467777,0.000047194822,0.00017286905,0.0004103185,0.0010050795,0.00008048635,0.000059382844,0.0009793118,0.0000017679397],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06869789,0.00034036627,0.07830427,0.0004869412,0.004446186,0.00015570156,0.029033208,0.006154354,0.02739683,0.001895709,0.56766015,0.21542838],"study_design_scores_gemma":[0.014015401,0.023381341,0.19142216,0.005950049,0.00061045226,0.000075779666,0.0054452145,0.001606332,0.017287513,0.00077437755,0.7390735,0.00035784752],"about_ca_topic_score_codex":0.00016313474,"about_ca_topic_score_gemma":0.00019679614,"teacher_disagreement_score":0.35847798,"about_ca_system_score_codex":0.00017355398,"about_ca_system_score_gemma":0.00079038565,"threshold_uncertainty_score":0.42546767},"labels":[],"label_agreement":null},{"id":"W3008798432","doi":"10.1016/j.ejca.2020.01.008","title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Canada; Janssen Pharmaceuticals; Merck Sharp and Dohme; NeraCare; Sun Pharma; Universidad de Cantabria; ZonMw; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares; Vertex Pharmaceuticals; Mylan; Regeneron Pharmaceuticals; Eisai Korea; Agence Nationale de la Recherche; F. Hoffmann-La Roche; Millennium Challenge Corporation; Università Degli Studi di Modena e Reggio Emila; Immunocore; Novartis Pharma; AbbVie; Novartis; Celgene; Pfizer; Biogen; Arthrex GmbH; LEO Pharma; LEO Pharma Research Foundation; Wyeth; Janssen Biotech; Les Laboratories Pierre Fabre; Meso Scale Diagnostics; Sanofi; Roche; Merck; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Leo Baeck Institute; Bristol-Myers Squibb; Amgen; Meadows Foundation; EMD Serono; Almirall; Galderma; BioNTech","keywords":"Medicine; Cetuximab; Systemic therapy; Radiation therapy; Guideline; Oncology; Lymph node; Internal medicine; Cancer; Dissection (medical); Surgery; Pathology; Colorectal cancer; Breast cancer","score_opus":0.035986421571088084,"score_gpt":0.2937085446046721,"score_spread":0.257722123033584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008798432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86291397,0.007859004,0.000042604348,0.023729358,0.0010241044,0.00030080526,0.000040101677,0.000011439115,0.10407861],"genre_scores_gemma":[0.9935687,0.00031120412,0.00017066985,0.002504922,0.0024542748,0.0000016288913,0.0000015263365,0.000067982925,0.00091904914],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9978811,0.0004376328,0.0008593399,0.00021000575,0.00041525118,0.00019666058],"domain_scores_gemma":[0.99835783,0.00007569108,0.0007548381,0.0003176259,0.00029588086,0.00019811478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035128806,0.00023081592,0.00045513193,0.000059416267,0.000084221036,0.000010927511,0.00032026705,0.000012920134,0.000183184],"category_scores_gemma":[0.00010086944,0.00013323869,0.00035736218,0.0001716808,0.00012539464,0.000045287066,0.00028791453,0.00027526414,0.000044511315],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060659936,0.0011943904,0.16235779,0.00053779944,0.0010158448,0.008326916,0.03795807,0.001897956,0.01218768,0.000023712142,0.68366677,0.084767066],"study_design_scores_gemma":[0.010910525,0.013978883,0.5384039,0.00090241426,0.0008845864,0.00028494885,0.002241658,0.000025081092,0.087337196,0.000008812999,0.34464517,0.00037679906],"about_ca_topic_score_codex":0.0000073113265,"about_ca_topic_score_gemma":0.000011151931,"teacher_disagreement_score":0.37604612,"about_ca_system_score_codex":0.0002143526,"about_ca_system_score_gemma":0.00021522134,"threshold_uncertainty_score":0.5433316},"labels":[],"label_agreement":null},{"id":"W3010077430","doi":"10.1016/j.ejca.2020.01.017","title":"Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Janssen Biotech; AstraZeneca France; Seattle Genetics; Janssen Canada; Meso Scale Diagnostics; Sanofi; AstraZeneca; Astellas Pharma; Ipsen; Clovis Oncology; Roche; Astellas Pharma US; Novartis; British Microcirculation Society; Pfizer","keywords":"Abiraterone acetate; Natural history; Prostate cancer; Medicine; Abiraterone; Oncology; Internal medicine; Cancer; Prostate; Urology; Androgen deprivation therapy; Androgen receptor","score_opus":0.04109552292384717,"score_gpt":0.30676500082791774,"score_spread":0.2656694779040706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010077430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9447435,0.0408361,0.000005527851,0.009089695,0.0001223447,0.00057222473,0.000013093206,0.000016119388,0.0046013645],"genre_scores_gemma":[0.98439664,0.007663425,0.00043702804,0.0015399761,0.00013287818,0.000013941399,0.0000026554396,0.00004494103,0.0057685194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855876,0.00018215699,0.00036295247,0.0002088949,0.00043338683,0.00025385455],"domain_scores_gemma":[0.99923784,0.000021051863,0.00021663883,0.000101518264,0.0001253891,0.00029757907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033101087,0.00018501599,0.0003664892,0.00015725996,0.000028785877,0.000021535492,0.00010476379,0.00000779924,0.00013739281],"category_scores_gemma":[0.000017784112,0.000112695365,0.000046127992,0.00015017606,0.000100357545,0.00013717593,0.00004938086,0.000379136,0.000012300976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04791662,0.000619435,0.57220685,0.0024250438,0.0028726284,0.06692349,0.013939823,0.0006848685,0.0054151234,0.00005020025,0.040580567,0.24636532],"study_design_scores_gemma":[0.03139428,0.0043483768,0.8742501,0.0016724548,0.0007578587,0.00019797316,0.0005191317,0.00045237213,0.0010580461,0.0000054047878,0.08494778,0.000396222],"about_ca_topic_score_codex":0.00008396214,"about_ca_topic_score_gemma":0.000036478523,"teacher_disagreement_score":0.30204323,"about_ca_system_score_codex":0.0005271496,"about_ca_system_score_gemma":0.0001445776,"threshold_uncertainty_score":0.45955834},"labels":[],"label_agreement":null},{"id":"W3011435761","doi":"10.1016/j.ejca.2020.02.021","title":"Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sandoz; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; InflaRx; Les Laboratories Pierre Fabre; Helsinn; OncoSec Medical; Roche; CureVac; Regeneron Pharmaceuticals; Novartis; Alcedis; Bristol-Myers Squibb; Sanofi; Merck; Boehringer Ingelheim; Amgen; Array BioPharma","keywords":"Medicine; Oncology; Melanoma; Blockade; Clinical trial; Internal medicine; Survival analysis; Progression-free survival; MEK inhibitor; Kinase; Cancer research; Overall survival; MAPK/ERK pathway; Biology; Receptor","score_opus":0.009071601066493962,"score_gpt":0.22957760785355402,"score_spread":0.22050600678706006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011435761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639285,0.0023190002,0.00057493045,0.00018722625,0.00007360502,0.00011938189,0.00014914128,0.0000015423232,0.00018234506],"genre_scores_gemma":[0.99930584,0.00024827867,0.00021591083,0.000045224715,0.00009846846,9.925225e-7,0.000051300714,0.00002025678,0.00001371172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989778,0.00021737875,0.00041419687,0.00011356733,0.00017112805,0.000105949825],"domain_scores_gemma":[0.9988885,0.00000816044,0.0006422117,0.000118778386,0.00026361455,0.000078728146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000311972,0.00012231585,0.00021986863,0.000027234735,0.000026860125,0.00000862775,0.000076605065,0.000014801528,0.000028271415],"category_scores_gemma":[0.00003939615,0.00007223303,0.00011471548,0.000064026426,0.0000784177,0.000014840615,0.000053921212,0.000098170116,0.0000012840464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015855076,0.00009230882,0.0039384533,0.00006729345,0.0002072439,0.000027678134,0.00026392503,0.00041665707,0.98685116,0.000018139044,0.00041667503,0.0061149504],"study_design_scores_gemma":[0.0048927623,0.0054148734,0.14714539,0.00017533083,0.00010719028,0.000013553356,0.00013117245,0.000015741425,0.8402896,0.00002918727,0.0015963563,0.00018884502],"about_ca_topic_score_codex":0.000007660631,"about_ca_topic_score_gemma":0.0000026429868,"teacher_disagreement_score":0.14656158,"about_ca_system_score_codex":0.000010328619,"about_ca_system_score_gemma":0.000082218576,"threshold_uncertainty_score":0.29455775},"labels":[],"label_agreement":null},{"id":"W3016271100","doi":"10.1016/j.ejca.2020.02.039","title":"Reducing pain and distress related to needle procedures in children with cancer: A clinical practice guideline","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; University of Ottawa; Hospital for Sick Children; University of Toronto; University of Alberta","funders":"","keywords":"Medicine; Guideline; Distress; Distraction; Grading (engineering); Quality of evidence; Sedation; Hypnosis; Cancer pain; Quality of life (healthcare); Pain assessment; Physical therapy; Intensive care medicine; Cancer; Alternative medicine; Pain management; Randomized controlled trial; Nursing; Clinical psychology; Surgery; Psychology","score_opus":0.03171411331836964,"score_gpt":0.4038313233151992,"score_spread":0.37211720999682957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016271100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001432219,0.99282646,0.00038225544,0.0042158915,0.000103350656,0.0010817723,0.00001989283,0.0000480302,0.0011791046],"genre_scores_gemma":[0.00020808379,0.9864528,0.009734473,0.0019891758,0.0013132932,0.000022673772,0.000011166223,0.000112929214,0.00015536015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99506783,0.0016836086,0.0021177903,0.00040565655,0.00047813528,0.00024695738],"domain_scores_gemma":[0.99702126,0.00025036396,0.0018419137,0.00024544605,0.00029344636,0.00034754843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058035874,0.00034660957,0.0016299337,0.0003462817,0.000029581955,0.000044519922,0.00031122233,0.00007478177,0.00003060252],"category_scores_gemma":[0.004175605,0.00024091612,0.00019761191,0.00072367716,0.000058183,0.00013397298,0.0001407182,0.0012846758,0.0000036962151],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014530406,0.000066478424,0.004836416,0.001778714,0.00067522697,0.0009728417,0.000101788464,0.000013216874,1.6566067e-7,0.0000010270252,0.06632393,0.9250849],"study_design_scores_gemma":[0.00087751634,0.0009334404,0.002694787,0.031165132,0.0027022942,0.00052951084,0.000036545553,0.000007750277,8.832467e-8,0.0000012520344,0.96080637,0.00024531345],"about_ca_topic_score_codex":0.000062229024,"about_ca_topic_score_gemma":0.000010104768,"teacher_disagreement_score":0.92483956,"about_ca_system_score_codex":0.00023816037,"about_ca_system_score_gemma":0.00086661824,"threshold_uncertainty_score":0.9824275},"labels":[],"label_agreement":null},{"id":"W3016291997","doi":"10.1016/j.ejca.2020.02.050","title":"The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novo Nordisk Fonden; Ferring; Roche; Merck; Bayer","keywords":"Radiation oncology; Medicine; Medical physics; Clinical trial; Cancer; Clinical Oncology; Oncology; State (computer science); Radiation therapy; Internal medicine; Computer science","score_opus":0.25181968435030094,"score_gpt":0.5496809856460632,"score_spread":0.2978613012957622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016291997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786579,0.0075662276,0.00062710576,0.0121157905,0.00027396425,0.0004021837,0.0000051458687,0.0000019739016,0.0003497135],"genre_scores_gemma":[0.9739723,0.02349498,0.0016181374,0.00009020734,0.00073788234,0.0000033517972,5.608275e-7,0.000015190713,0.000067373],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975123,0.0009900846,0.0010165928,0.00012144104,0.00023618809,0.00012340993],"domain_scores_gemma":[0.9970992,0.0015273602,0.00082170434,0.000056537992,0.00038308586,0.000112104965],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.026614744,0.000048751204,0.00035365552,0.00008038699,0.00009445763,0.000019006633,0.00006891044,0.000007899727,0.0000017627788],"category_scores_gemma":[0.008966955,0.000029830691,0.00004649169,0.00009855633,0.0005179468,0.000047201647,0.000022161163,0.0001457763,3.6806885e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009089025,0.000026944097,0.045085095,0.000057355162,0.000049445574,0.000035958994,0.0030367642,0.000059002832,0.010891454,0.00001534239,0.00030778506,0.93952596],"study_design_scores_gemma":[0.022180269,0.014930266,0.63717496,0.00083959225,0.00035606985,0.0001240763,0.0023277716,0.008913145,0.009090898,0.0002671839,0.3036412,0.00015459325],"about_ca_topic_score_codex":0.00003323496,"about_ca_topic_score_gemma":0.0000109487055,"teacher_disagreement_score":0.93937135,"about_ca_system_score_codex":0.00009345033,"about_ca_system_score_gemma":0.00055306806,"threshold_uncertainty_score":0.99938095},"labels":[],"label_agreement":null},{"id":"W3016541505","doi":"10.1016/j.ejca.2020.02.016","title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; European Medicines Agency","keywords":"Dosing; Pembrolizumab; Schedule; Medicine; Cancer; Oncology; Medical physics; Intensive care medicine; Computer science; Internal medicine; Immunotherapy","score_opus":0.0689261964846432,"score_gpt":0.3315198737791199,"score_spread":0.2625936772944767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016541505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97585183,0.0011625142,0.021541443,0.0009001407,0.000097927696,0.0003611823,0.0000073031415,0.0000043130003,0.00007331885],"genre_scores_gemma":[0.996668,0.000035361765,0.0020950078,0.0009258416,0.00023628137,0.0000026382597,0.0000028236936,0.000029613211,0.0000044661965],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990267,0.00009974565,0.0002906588,0.00012338645,0.0003507466,0.00010873025],"domain_scores_gemma":[0.999231,0.000034949873,0.00026636646,0.000052783278,0.00034503834,0.00006987291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004353496,0.00009626882,0.00017527866,0.00009638058,0.000044340184,0.00002282151,0.00003421711,0.000015382451,0.000041197516],"category_scores_gemma":[0.000035199595,0.000073461364,0.000046952722,0.00014116992,0.000021345613,0.000117414624,0.0000042419333,0.0001184728,1.4649312e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02000173,0.00004593662,0.02262444,0.00005486903,0.000054505523,0.0000038172097,0.00036392198,0.9180665,0.0009043049,3.3036673e-7,0.000018620012,0.037860997],"study_design_scores_gemma":[0.018608319,0.0012215364,0.051422097,0.00095486216,0.00016710113,7.997998e-7,0.00003253664,0.92653036,0.00034844017,0.0000013080241,0.0006207013,0.00009195989],"about_ca_topic_score_codex":0.0000173755,"about_ca_topic_score_gemma":0.000004853327,"teacher_disagreement_score":0.03776904,"about_ca_system_score_codex":0.00022835689,"about_ca_system_score_gemma":0.0002359258,"threshold_uncertainty_score":0.29956675},"labels":[],"label_agreement":null},{"id":"W3020690864","doi":"10.1016/j.ejca.2020.03.009","title":"Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Instituto de Salud Carlos III; School of Medicine and Dentistry, University of Rochester; Ministry of Economy; University of Pennsylvania; Universitat de Barcelona; Federación Española de Enfermedades Raras; Society of Gastrointestinal Radiologists; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Breast Cancer Research Foundation","keywords":"Medicine; Breast cancer; Confidence interval; Gynecology; Hazard ratio; Ovarian cancer; Cancer; Obstetrics; Oncology; Genetic testing; Risk assessment; Internal medicine","score_opus":0.013868625000380042,"score_gpt":0.25648146244967057,"score_spread":0.24261283744929052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020690864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936358,0.0028573533,0.0015037673,0.0010693562,0.0004307338,0.00014021894,0.000118496246,0.000006820786,0.00023746314],"genre_scores_gemma":[0.9956547,0.0017982309,0.0011463395,0.00008338102,0.0011974879,0.0000060026546,0.000009426707,0.000052095453,0.000052328334],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980898,0.0005179225,0.0005729215,0.00025870977,0.00036067513,0.00020001043],"domain_scores_gemma":[0.9975019,0.000018526942,0.0016368006,0.00013158548,0.0006094601,0.00010172616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008595109,0.00016440153,0.00023043579,0.00010638688,0.00007006873,0.00003509356,0.00017177624,0.00005273884,0.00006414645],"category_scores_gemma":[0.00023390546,0.00015052907,0.00007487147,0.00034555144,0.000051204624,0.000032073614,0.000033951725,0.00031661108,0.0000014468042],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016476295,0.00007867096,0.19914763,0.000091344016,0.001051406,0.000030019235,0.0056502777,0.270037,0.39921933,0.0000011891069,0.004512209,0.11853329],"study_design_scores_gemma":[0.007951175,0.001812577,0.5517474,0.0008314956,0.0009739576,0.00020224068,0.0025000507,0.0012987953,0.4199354,0.000018408464,0.01195416,0.0007743758],"about_ca_topic_score_codex":0.00036458994,"about_ca_topic_score_gemma":0.00028972482,"teacher_disagreement_score":0.35259974,"about_ca_system_score_codex":0.0004139658,"about_ca_system_score_gemma":0.00051285024,"threshold_uncertainty_score":0.61383975},"labels":[],"label_agreement":null},{"id":"W3024772134","doi":"10.1016/j.ejca.2020.05.002","title":"Arterial thrombosis and coronavirus disease 2019 in a patient with cancer","year":2020,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Thrombosis; Surgery","score_opus":0.09104485470296189,"score_gpt":0.41974627530076525,"score_spread":0.3287014205978034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024772134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023429843,0.004871759,0.000010612514,0.9683986,0.0005390781,0.00039616894,0.002242353,0.000009502291,0.000102133556],"genre_scores_gemma":[0.05057244,0.028888755,0.00007109453,0.910692,0.009175475,0.00002518846,0.000121975485,0.00012372957,0.0003293814],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742365,0.0003749384,0.0006463944,0.0003127587,0.0009204968,0.00032176994],"domain_scores_gemma":[0.9981771,0.0004621018,0.0004877257,0.00019762974,0.00029866231,0.00037676815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002464399,0.00027051553,0.0007698362,0.00014031887,0.00003962355,0.000037833666,0.00017148445,0.000044927383,0.0004847757],"category_scores_gemma":[0.0010832845,0.00017590387,0.00014660729,0.0001489151,0.0002455389,0.00006346575,0.00015528027,0.001947575,0.000018384528],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023414043,0.000067710236,0.0066779563,0.0005205528,0.00043477435,0.020272046,0.00025743866,0.000029024191,0.000057583107,1.1193424e-7,0.9559924,0.013349004],"study_design_scores_gemma":[0.0027014676,0.0013611157,0.08732773,0.0021401541,0.00039253145,0.0000073422793,0.000009077551,0.0000060125376,0.0000035535036,0.000004183137,0.90587056,0.00017624687],"about_ca_topic_score_codex":0.00014791636,"about_ca_topic_score_gemma":0.00003467514,"teacher_disagreement_score":0.08064978,"about_ca_system_score_codex":0.00028212366,"about_ca_system_score_gemma":0.00091498706,"threshold_uncertainty_score":0.84613526},"labels":[],"label_agreement":null},{"id":"W3026082052","doi":"10.1016/j.ejca.2020.04.024","title":"Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"CIHR Skin Research Training Centre; National Center for Advancing Translational Sciences; National Institutes of Health; National Cancer Institute; NIH Office of the Director; Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Hepatocellular carcinoma; Medicine; Term (time); Oncology; Internal medicine; Stereotactic radiation therapy; Radiation therapy; Radiology; Radiosurgery; Physics","score_opus":0.08145537976148619,"score_gpt":0.29072477661150137,"score_spread":0.20926939685001517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026082052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848655,0.01160932,0.0006226485,0.001964242,0.0001795905,0.00059928244,0.000009012562,0.0000127911,0.00013761825],"genre_scores_gemma":[0.9972197,0.0012454202,0.00030191906,0.000598656,0.00045486365,0.0000075408702,0.0000126445675,0.00006154108,0.00009775379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846494,0.00020790767,0.0005974947,0.00017295907,0.00037759417,0.00017910088],"domain_scores_gemma":[0.99871576,0.000046735695,0.0005337569,0.00017841766,0.00029727927,0.00022804223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045591712,0.00019115958,0.00055256416,0.00010414249,0.000045805926,0.000022153816,0.00013730356,0.000030669486,0.0001201774],"category_scores_gemma":[0.000075039716,0.00013730089,0.0004813233,0.00012701744,0.000035500274,0.00013605144,0.000020227919,0.00015985378,0.000006865235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009005491,0.00010148725,0.9494422,0.0001411748,0.0006612074,0.00037994175,0.00070464343,9.867529e-7,0.013882978,0.0000025990328,0.00018204903,0.033600148],"study_design_scores_gemma":[0.0076545095,0.0019525866,0.92461157,0.00012500594,0.00061552227,0.00004536723,0.000022458851,0.00042093123,0.060157806,0.0000021834337,0.004258286,0.0001337617],"about_ca_topic_score_codex":0.000009703236,"about_ca_topic_score_gemma":6.439055e-7,"teacher_disagreement_score":0.046274826,"about_ca_system_score_codex":0.00006268441,"about_ca_system_score_gemma":0.00014462062,"threshold_uncertainty_score":0.55989677},"labels":[],"label_agreement":null},{"id":"W3029182802","doi":"10.1016/j.ejca.2020.04.015","title":"Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Immunocore; Merck Sharp and Dohme; Sandoz; Bristol-Myers Squibb Canada; Genentech; SkylineDx; EORTC Charitable Trust; Sun Pharma; Sysmex Corporation; Pfizer; InflaRx; European Organisation for Research and Treatment of Cancer; Les Laboratories Pierre Fabre; Swedish Orphan Biovitrum; Array BioPharma; Roche; Regeneron Pharmaceuticals; Novartis; Sanofi; GlaxoSmithKline; Merck; Bayer; AstraZeneca; Amgen","keywords":"Medicine; Adjuvant; Pegylated interferon; Internal medicine; Stage (stratigraphy); Oncology; Adjuvant therapy; Cancer; Immunology","score_opus":0.07156594054221829,"score_gpt":0.3098397527023926,"score_spread":0.23827381216017432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029182802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544317,0.00023858894,0.000055454,0.0017555625,0.000107299085,0.0017876534,0.000033864326,0.0000062265563,0.0005721796],"genre_scores_gemma":[0.99841183,0.0006120332,0.0000867162,0.0001365548,0.00017003885,0.000010141956,0.000010740105,0.000036362406,0.0005256045],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981897,0.0005337146,0.0005918116,0.00015795455,0.00040268138,0.00012414606],"domain_scores_gemma":[0.99854916,0.00006119626,0.0006035301,0.00012823066,0.00058188994,0.00007599608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074668275,0.0001220556,0.00035266162,0.000105442086,0.00006232007,0.000014781263,0.000085208514,0.000013208257,0.00003880349],"category_scores_gemma":[0.00006618984,0.00006462109,0.00004694699,0.00025623152,0.000074887525,0.00005843849,0.000023689818,0.00013328972,2.385033e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9067316,0.0005497532,0.013780559,0.0000763181,0.0004091924,0.00003585148,0.006332857,0.00037610685,0.012531122,0.00000202059,0.00039810519,0.05877653],"study_design_scores_gemma":[0.56957716,0.051730346,0.34916964,0.0005515635,0.00017253982,0.0000040171694,0.00040501717,0.00014071687,0.0121702505,0.0000011008954,0.015952064,0.00012554675],"about_ca_topic_score_codex":0.00008073728,"about_ca_topic_score_gemma":0.000121216326,"teacher_disagreement_score":0.3371544,"about_ca_system_score_codex":0.00019672024,"about_ca_system_score_gemma":0.00017297911,"threshold_uncertainty_score":0.26351714},"labels":[],"label_agreement":null},{"id":"W3031653176","doi":"10.1016/j.ejca.2020.05.008","title":"Working in the dark: Interaction with a sub clinical COVID-19 subject and lessons learned","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Subclinical infection; Coronavirus disease 2019 (COVID-19); Subject (documents); Identification (biology); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Psychology; Virology; Computer science; Internal medicine; Disease; Biology","score_opus":0.31710044421252226,"score_gpt":0.5323709537481809,"score_spread":0.21527050953565863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031653176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5618305,0.0016245139,0.0012881941,0.43296123,0.00018233985,0.00022423154,0.0000014039141,0.0000137299785,0.0018738017],"genre_scores_gemma":[0.97252584,0.0055173687,0.00009008416,0.021052526,0.0007483992,0.0000016819872,2.9952005e-7,0.000016996579,0.000046795547],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759084,0.0010539887,0.00054813747,0.00018370178,0.00044891314,0.00017441345],"domain_scores_gemma":[0.9956221,0.0035031564,0.00028937627,0.00011986538,0.00012441403,0.00034110172],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0039360276,0.000096742166,0.0003332714,0.00006898155,0.00006852714,0.000041205403,0.00016390132,0.000016574359,0.00003497859],"category_scores_gemma":[0.022204716,0.00005259194,0.000097507196,0.00027265435,0.00019895125,0.000069518464,0.00008483417,0.0011271104,0.0000057041652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011719322,0.00019525964,0.62721866,0.000195549,0.0003934711,0.0048792954,0.0070819096,0.00049251947,0.00054750516,0.0000413818,0.011212515,0.3360226],"study_design_scores_gemma":[0.006720361,0.0030755352,0.43774712,0.0007122647,0.00018439816,0.000064001404,0.0015636677,0.00021592947,0.000028905879,0.000033610057,0.54952675,0.00012742355],"about_ca_topic_score_codex":0.000021817714,"about_ca_topic_score_gemma":0.00009627093,"teacher_disagreement_score":0.5383143,"about_ca_system_score_codex":0.000093497845,"about_ca_system_score_gemma":0.00050762447,"threshold_uncertainty_score":0.98603165},"labels":[],"label_agreement":null},{"id":"W3032372859","doi":"10.1016/j.ejca.2020.04.007","title":"Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Loxo Oncology; St. Baldrick's Foundation; National Cancer Institute; Bayer Canada; National Institutes of Health; Alex's Lemonade Stand Foundation for Childhood Cancer; Novartis; Roche","keywords":"Homogeneous; Neuroblastoma; Medicine; Internal medicine; Oncology; Overall survival; Loss of heterozygosity; Proportional hazards model; Biology; Gene; Allele; Cell culture; Genetics","score_opus":0.03619330808815777,"score_gpt":0.3371904795180543,"score_spread":0.3009971714298965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032372859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901534,0.00025410965,0.000035628957,0.009225669,0.00007351649,0.0001668082,0.000028895543,0.0000055139517,0.000056460947],"genre_scores_gemma":[0.9977136,0.00075431284,0.00020957636,0.0009914017,0.00027538938,0.0000015576171,0.000011903661,0.000013935185,0.00002830992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830914,0.00058183767,0.0005628774,0.00015918139,0.00026534608,0.0001216043],"domain_scores_gemma":[0.9985429,0.00032091778,0.00074739236,0.00010669116,0.00013599168,0.00014611008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005071689,0.00009407183,0.00038425403,0.000029944824,0.00002325456,0.000012730074,0.00009209236,0.000033169425,0.000015657453],"category_scores_gemma":[0.00079283846,0.000049288054,0.000076560784,0.000084221756,0.00007563879,0.000032752956,0.000038818576,0.00042725814,0.0000021448611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016179895,0.00020765337,0.97623634,0.000003894777,0.00029807846,0.0023310988,0.000102106365,0.0000023268642,0.0012610318,0.0000010803724,0.00051264954,0.017425751],"study_design_scores_gemma":[0.0025489759,0.0028353657,0.9915918,0.000043466367,0.00010000789,0.00042072465,0.000010686171,0.000004407889,0.00012976691,0.0000021355156,0.0022740648,0.00003860824],"about_ca_topic_score_codex":0.000017218037,"about_ca_topic_score_gemma":0.00002471909,"teacher_disagreement_score":0.017387142,"about_ca_system_score_codex":0.00005788024,"about_ca_system_score_gemma":0.000084915846,"threshold_uncertainty_score":0.20099084},"labels":[],"label_agreement":null},{"id":"W3037021593","doi":"10.1016/j.ejca.2020.05.009","title":"Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Genentech; Ipsen; Calithera Biosciences; Exelixis; Seattle Genetics; AbbVie; Merck; Bayer; Bristol-Myers Squibb; AstraZeneca; Xencor; Pfizer; Novartis","keywords":"Cabozantinib; Medicine; Oncology; Internal medicine; Renal cell carcinoma; Immune checkpoint; Clear cell renal cell carcinoma; Confidence interval; Blockade; Cancer; Immunotherapy; Receptor","score_opus":0.02767225652805078,"score_gpt":0.2604464641133596,"score_spread":0.2327742075853088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037021593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98349893,0.0081984345,0.000070654365,0.0015355882,0.00012018201,0.00021117477,0.000012209195,0.0000066075268,0.006346233],"genre_scores_gemma":[0.99782914,0.0002347882,0.0008988405,0.00019013295,0.00028602235,0.0000029169742,0.0000011352498,0.000061802224,0.0004952184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976945,0.00039801747,0.0008926265,0.0002217754,0.0005163446,0.0002767202],"domain_scores_gemma":[0.9984814,0.000045710614,0.0007241784,0.00023444586,0.00020926433,0.0003050008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005635677,0.00023553448,0.00069448433,0.00015507717,0.000017731125,0.000013416798,0.00017504148,0.000022514461,0.00047480746],"category_scores_gemma":[0.000050248054,0.00018149917,0.00035550026,0.000271227,0.00007627001,0.00010362585,0.000076740864,0.00055271457,0.000033388344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075980346,0.0005800629,0.0298281,0.0005096999,0.00015362915,0.008934748,0.0027131366,0.00023081759,0.9433713,5.3276904e-7,0.00027382077,0.005806127],"study_design_scores_gemma":[0.0053533157,0.0019449814,0.374143,0.00018548012,0.0003284579,0.000102576276,0.00012691905,0.00007011019,0.6153395,9.947777e-7,0.0022779924,0.00012666942],"about_ca_topic_score_codex":0.000076749806,"about_ca_topic_score_gemma":0.0000071481345,"teacher_disagreement_score":0.3443149,"about_ca_system_score_codex":0.00012655635,"about_ca_system_score_gemma":0.0002749673,"threshold_uncertainty_score":0.74013215},"labels":[],"label_agreement":null},{"id":"W3042190218","doi":"10.1016/j.ejca.2020.05.010","title":"Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Fondation contre le Cancer; Vlaamse regering; Kom op tegen Kanker; Fonds Wetenschappelijk Onderzoek; National Cancer Institute; Cancer Research UK; Neuroblastoma UK; Oak Foundation; Olivia Fund; Instituto de Salud Carlos III; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Neuroblastoma; Medicine; Clinical trial; Drug development; Drug; ATRX; Oncology; Pharmacology; Internal medicine; Biology; Mutation; Genetics","score_opus":0.04454238105661854,"score_gpt":0.3303695918244042,"score_spread":0.2858272107677856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042190218","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13566443,0.8544197,0.0002099166,0.002299285,0.00096065935,0.004630711,0.0014708044,0.000037700996,0.00030679195],"genre_scores_gemma":[0.013124211,0.97021395,0.010407307,0.001104083,0.0014268587,0.0003495537,0.00014919293,0.00051811576,0.0027067196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957271,0.00047136223,0.0019356498,0.00063312496,0.00072250643,0.0005102576],"domain_scores_gemma":[0.99416786,0.0005941108,0.0031925072,0.0002621336,0.0015179022,0.00026549504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005399386,0.0007160865,0.0019255686,0.0002959557,0.00021428964,0.00006563923,0.0007515871,0.00007441912,0.000055113112],"category_scores_gemma":[0.000113649425,0.00044529844,0.00051061244,0.0007485848,0.00026159798,0.00020528323,0.0004208104,0.00093589455,0.0000012463823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013266134,0.00032146124,0.0009505285,0.003027429,0.0050609917,0.000067896566,0.0014398467,0.000025541394,0.0003536804,0.000005677123,0.0130126905,0.9744076],"study_design_scores_gemma":[0.006334264,0.002024049,0.012438621,0.0059021576,0.00090291945,0.00019324291,0.00016470552,0.000021103187,0.00237362,0.0000037823932,0.9692184,0.00042316603],"about_ca_topic_score_codex":0.000009677792,"about_ca_topic_score_gemma":0.000118460724,"teacher_disagreement_score":0.9739845,"about_ca_system_score_codex":0.0003131804,"about_ca_system_score_gemma":0.005179662,"threshold_uncertainty_score":0.9997999},"labels":[],"label_agreement":null},{"id":"W3042196922","doi":"10.1016/j.ejca.2020.05.023","title":"COVID-19, palliative care and public health","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute for Health and Care Research","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Palliative care; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Public health; Betacoronavirus; Medicine; Virology; Nursing; Internal medicine; Outbreak; Infectious disease (medical specialty)","score_opus":0.3079182638075168,"score_gpt":0.4708955457118974,"score_spread":0.1629772819043806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042196922","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3757845,0.37923512,0.0047499053,0.22475703,0.0004466619,0.00028016284,0.00008255543,0.000038615002,0.01462546],"genre_scores_gemma":[0.9544867,0.020154463,0.0017336282,0.0228635,0.00067659444,4.608027e-7,0.0000030788487,0.00002116567,0.000060366907],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989597,0.00020837616,0.00034432358,0.00009868746,0.0002493107,0.00013957238],"domain_scores_gemma":[0.9982572,0.000055779496,0.00037791912,0.00006253402,0.0003336199,0.000912944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027009947,0.000088269175,0.00031997173,0.000057682628,0.000039104212,0.000011396329,0.00008149589,0.000010747062,0.00016434141],"category_scores_gemma":[0.0009118655,0.00006643059,0.00007697711,0.00013513096,0.00007290296,0.0000637906,0.000028680228,0.00019595919,0.000004502193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006521099,0.000063646134,0.525434,0.001660319,0.00056852616,0.0008862482,0.16551113,0.000056964076,0.0007678745,0.00018710176,0.076735675,0.2274764],"study_design_scores_gemma":[0.00206816,0.0013025665,0.025603428,0.00048302615,0.000045545232,0.0000106275365,0.008863435,0.000008788,0.00021728704,0.0000049619193,0.9613203,0.00007187107],"about_ca_topic_score_codex":0.000029073659,"about_ca_topic_score_gemma":0.000010832452,"teacher_disagreement_score":0.8845846,"about_ca_system_score_codex":0.00013995865,"about_ca_system_score_gemma":0.0008642129,"threshold_uncertainty_score":0.27089608},"labels":[],"label_agreement":null},{"id":"W3049645030","doi":"10.1016/j.ejca.2020.06.038","title":"Letter comments on ʻIndications for hyperthermic intraperitoneal chemotherapy (Hipec) with cytoreductive surgery: a systematic reviewʼ","year":2020,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Hyperthermic intraperitoneal chemotherapy; Cytoreductive surgery; Medicine; Intraperitoneal chemotherapy; Surgery; Chemotherapy; General surgery; Internal medicine; Cancer","score_opus":0.035802352667559934,"score_gpt":0.28105714077736765,"score_spread":0.24525478810980772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3049645030","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004086284,0.004885706,0.000119934535,0.9876545,0.00086301006,0.0015294504,0.00011015543,0.000031966003,0.0007190088],"genre_scores_gemma":[0.018130317,0.0014666953,0.0005121883,0.9626494,0.015978618,0.00010313725,0.000069064125,0.00023859853,0.00085200084],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970092,0.0004615795,0.0010856036,0.00033027527,0.00071994774,0.00039339904],"domain_scores_gemma":[0.99726135,0.000280895,0.0015340883,0.00031798755,0.00043540433,0.00017026112],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048595943,0.00047699845,0.0016620994,0.00021610536,0.00012267915,0.000065302964,0.00031878936,0.000097831035,0.00016419329],"category_scores_gemma":[0.00008733054,0.00029950755,0.00055119273,0.00020094456,0.00017419505,0.00008583603,0.000016484317,0.0013846392,0.00004959285],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007742993,0.000081838036,0.00004591537,0.013030123,0.0012035077,0.0020975077,0.00072123774,0.0000013877508,0.0005106015,0.000004437526,0.9791243,0.0024048272],"study_design_scores_gemma":[0.001454866,0.0014225756,0.00025317428,0.036658786,0.0011939605,0.000872877,0.00007549687,0.0000035588055,0.000639677,0.0000062203785,0.95705336,0.00036542382],"about_ca_topic_score_codex":0.0000050502026,"about_ca_topic_score_gemma":6.9602015e-7,"teacher_disagreement_score":0.025005106,"about_ca_system_score_codex":0.00022053641,"about_ca_system_score_gemma":0.0003411291,"threshold_uncertainty_score":0.9999457},"labels":[],"label_agreement":null},{"id":"W3080398436","doi":"10.1016/j.ejca.2020.07.004","title":"Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Horizon 2020 Framework Programme; Kom op tegen Kanker; Vlaamse regering; European Commission; Stichting Tegen Kanker; Horizon 2020; KWF Kankerbestrijding; Univerzita Karlova v Praze","keywords":"Pregnancy; Medicine; Obstetrics; Cancer; Internal medicine; Biology","score_opus":0.022362036773851363,"score_gpt":0.26433504907149996,"score_spread":0.2419730122976486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080398436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668187,0.030583834,0.0000036778997,0.0018355773,0.0002092843,0.00011278566,0.000018961022,0.000011252168,0.00040591115],"genre_scores_gemma":[0.9748113,0.023341186,0.00012807918,0.00038451506,0.00067949673,0.000025740168,5.450855e-7,0.0000376516,0.0005914958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991179,0.000033652082,0.00031248518,0.00014806465,0.00022237765,0.0001654801],"domain_scores_gemma":[0.9994075,0.0000054299185,0.0001775972,0.000066816116,0.00005038402,0.00029227446],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000037685808,0.000138893,0.000249789,0.00004679095,0.000048006765,0.000022160324,0.00005461595,0.000013630858,0.0012023571],"category_scores_gemma":[0.000005791498,0.00010207332,0.00008383856,0.00005689873,0.000029437584,0.000064693035,0.000049067712,0.000120008386,0.000015544952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000644664,0.000030147632,0.81162286,0.00006458666,0.00023865562,0.0014808937,0.0029803729,0.000015981042,0.00024082174,1.7179124e-7,0.00029399045,0.18238685],"study_design_scores_gemma":[0.0021194106,0.00024388406,0.86211705,0.0012311323,0.00011564252,0.00011448563,0.00002149667,0.0000011686038,0.0045202593,9.560516e-8,0.12941891,0.00009644858],"about_ca_topic_score_codex":0.000049574926,"about_ca_topic_score_gemma":0.00007830314,"teacher_disagreement_score":0.18229039,"about_ca_system_score_codex":0.0003448736,"about_ca_system_score_gemma":0.000081601065,"threshold_uncertainty_score":0.9997107},"labels":[],"label_agreement":null},{"id":"W3082639272","doi":"10.1016/j.ejca.2020.07.028","title":"Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Medac; Les Laboratories Pierre Fabre; Novartis; Bristol-Myers Squibb; Novartis Pharma; Roche; Amgen","keywords":"Pembrolizumab; Medicine; Type 1 diabetes; Internal medicine; Melanoma; Diabetes mellitus; Adjuvant; Oncology; Gastroenterology; Cancer; Immunotherapy; Endocrinology; Cancer research","score_opus":0.0122356714177343,"score_gpt":0.21873178121989825,"score_spread":0.20649610980216396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082639272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990786,0.00807011,0.000014251317,0.0012913261,0.00007921289,0.00024652973,0.000008614062,0.0000052473406,0.0003768648],"genre_scores_gemma":[0.99861014,0.0005085638,0.00037055297,0.00025870657,0.00018090689,0.000001000311,0.00000292508,0.0000399932,0.000027221764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983684,0.0002252471,0.0006596803,0.00013273102,0.00044261402,0.00017134035],"domain_scores_gemma":[0.9982186,0.000042131927,0.0010434351,0.00020206739,0.0003654418,0.00012835572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049375946,0.00016781787,0.00047985584,0.00008086716,0.000023603905,0.000009593375,0.00019121982,0.000023304363,0.00010140741],"category_scores_gemma":[0.000081360595,0.00008994272,0.00012464054,0.00042221055,0.00011378631,0.00008239544,0.00002796813,0.00034153386,0.0000013253568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15941447,0.0009469105,0.3922556,0.00044042146,0.0032586649,0.00007994588,0.0057780463,0.00009803532,0.34216917,0.0000048201973,0.0018915362,0.09366239],"study_design_scores_gemma":[0.024387665,0.011342093,0.8674718,0.0010210213,0.00032175574,0.0000043809455,0.000265979,0.000026675432,0.09042882,0.0000010395797,0.0045672003,0.00016154133],"about_ca_topic_score_codex":0.00014540085,"about_ca_topic_score_gemma":0.00002268344,"teacher_disagreement_score":0.4752162,"about_ca_system_score_codex":0.0000667602,"about_ca_system_score_gemma":0.00042390332,"threshold_uncertainty_score":0.36677575},"labels":[],"label_agreement":null},{"id":"W3082648913","doi":"10.1016/j.ejca.2020.08.017","title":"High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Hôpital Maisonneuve-Rosemont; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire Sainte-Justine; Jewish General Hospital; Hôpital Charles-Le Moyne; McGill University; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"McGill University; Jewish General Hospital; AstraZeneca Canada","keywords":"Medicine; Incidence (geometry); Cancer; Intensive care unit; Population; Observational study; Emergency medicine; Lung cancer; Cohort study; Coronavirus disease 2019 (COVID-19); Mechanical ventilation; Internal medicine; Pediatrics; Intensive care medicine; Disease; Infectious disease (medical specialty)","score_opus":0.06917273912418564,"score_gpt":0.36884440009216835,"score_spread":0.2996716609679827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082648913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98955655,0.00017652936,0.00008310449,0.008774627,0.0003850675,0.000935302,0.000024766656,0.00002348923,0.00004054748],"genre_scores_gemma":[0.9927882,0.00019196757,0.00004588554,0.00633229,0.000561593,0.000009920188,0.000011362115,0.000033221437,0.000025554265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790496,0.0002932138,0.00062033307,0.0002245484,0.0007369979,0.00021997496],"domain_scores_gemma":[0.9980552,0.00004795677,0.0005625778,0.00013877844,0.00053091836,0.00066457014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005486389,0.00016693793,0.00041684267,0.0001002984,0.000071634975,0.000025738129,0.00009207625,0.000023553539,0.00030004614],"category_scores_gemma":[0.00060388754,0.00012842116,0.00006688515,0.0003674728,0.0000505948,0.00025111396,0.000031214462,0.00027979104,0.000003777691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012890027,0.00047532862,0.9898137,0.0001348624,0.00023521051,0.00029702813,0.0029611983,0.001892856,0.0000070070455,0.0000011739543,0.001289438,0.0016032251],"study_design_scores_gemma":[0.009028979,0.0021415285,0.9859181,0.00020513099,0.00022066441,0.0000011148591,0.00011779965,0.000056631103,0.0000071025056,9.784789e-7,0.002170942,0.00013103221],"about_ca_topic_score_codex":0.006745741,"about_ca_topic_score_gemma":0.0029128005,"teacher_disagreement_score":0.007739976,"about_ca_system_score_codex":0.0007969843,"about_ca_system_score_gemma":0.0011263578,"threshold_uncertainty_score":0.99986845},"labels":[],"label_agreement":null},{"id":"W3083087427","doi":"10.1016/j.ejca.2020.07.013","title":"Response to letter commenting on ʻindications for hyperthermic intraperitoneal chemotherapy (Hipec) with cytoreductive surgery: a systematic reviewʼ","year":2020,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Intraperitoneal and Appendiceal Malignancies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; Cancer Care Ontario; McMaster University; Mount Sinai Hospital; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"Ministeriet Sundhed Forebyggelse","keywords":"Medicine; Pseudomyxoma peritonei; Hyperthermic intraperitoneal chemotherapy; Cytoreductive surgery; Peritoneal mesothelioma; General surgery; Mesothelioma; Surgery; Intensive care medicine; Cancer; Internal medicine; Appendix; Pathology; Ovarian cancer","score_opus":0.03298479309252966,"score_gpt":0.2867103920666103,"score_spread":0.25372559897408065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083087427","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024126025,0.0020866212,0.00019222667,0.9709814,0.0006092536,0.0016122193,0.0000778066,0.000031778884,0.00028264854],"genre_scores_gemma":[0.025685852,0.0003103315,0.001087427,0.9610654,0.010447283,0.00011923517,0.00002616632,0.00023365984,0.0010246114],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649674,0.0009109419,0.0011137266,0.0003551456,0.00069413625,0.00042933694],"domain_scores_gemma":[0.9970801,0.0006305509,0.0012678347,0.0003323617,0.00047413813,0.00021503757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012464595,0.00045174675,0.0015426786,0.00031694505,0.0001573292,0.000081929014,0.00031727372,0.00008323424,0.00011356526],"category_scores_gemma":[0.0003048919,0.00029659542,0.00048116132,0.00028695332,0.00011360214,0.00007444973,0.000022958775,0.0012023927,0.000054254422],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050705513,0.00006089394,0.000031787058,0.008140896,0.00083496433,0.0024507502,0.0013254228,0.000003761731,0.0047720377,0.0000027716378,0.9751127,0.002193499],"study_design_scores_gemma":[0.0011491469,0.0018738786,0.0003368934,0.03969776,0.0007565936,0.00074559776,0.00012441177,0.0000028242714,0.0012478094,0.000002294048,0.9537013,0.00036149408],"about_ca_topic_score_codex":0.000004377571,"about_ca_topic_score_gemma":7.602614e-7,"teacher_disagreement_score":0.031556863,"about_ca_system_score_codex":0.00025807202,"about_ca_system_score_gemma":0.00039334773,"threshold_uncertainty_score":0.9999486},"labels":[],"label_agreement":null},{"id":"W3087594404","doi":"10.1016/j.ejca.2020.09.014","title":"Repurposing anticancer drugs for the management of COVID-19","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Repurposing; Drug repositioning; Coronavirus disease 2019 (COVID-19); Medicine; Pandemic; Clinical trial; Intensive care medicine; Drug; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Scope (computer science); Pharmacology; Outbreak; Disease; Infectious disease (medical specialty); Virology; Internal medicine; Computer science; Biology","score_opus":0.18667845250718568,"score_gpt":0.5322897284930083,"score_spread":0.3456112759858226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087594404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.1938304e-7,0.98340976,0.00298055,0.010702477,0.00046310175,0.0012278022,0.000048171594,0.0000101279675,0.0011575856],"genre_scores_gemma":[0.00003406918,0.99418235,0.0008163071,0.002126335,0.0014173537,0.00003057984,0.0000017883644,0.00008074897,0.0013104923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964653,0.00044983713,0.0015600183,0.00028752827,0.00094854785,0.0002887416],"domain_scores_gemma":[0.9928244,0.004347482,0.0015654785,0.00041718065,0.00044096398,0.00040451222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035919012,0.00028147767,0.0019067697,0.00013632415,0.000111445544,0.000026432721,0.0006169395,0.000034884848,0.0001596458],"category_scores_gemma":[0.005996736,0.00015051667,0.0012644317,0.00039413446,0.0002683038,0.00003613893,0.0003202888,0.0007474368,0.000010474793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002718346,0.00003381028,0.0000050960475,0.0611945,0.0033027413,0.00046488695,0.00018774674,0.000018129978,3.644447e-7,0.00006378179,0.01142857,0.9230285],"study_design_scores_gemma":[0.001252307,0.00041662436,0.000022005748,0.026500627,0.005762435,0.000011964167,0.000075343894,0.000009744575,8.117619e-7,0.000013931678,0.96581334,0.00012085886],"about_ca_topic_score_codex":0.000007234704,"about_ca_topic_score_gemma":5.6691067e-7,"teacher_disagreement_score":0.9543848,"about_ca_system_score_codex":0.00052074087,"about_ca_system_score_gemma":0.0017391262,"threshold_uncertainty_score":0.7179086},"labels":[],"label_agreement":null},{"id":"W3089003689","doi":"10.1016/j.ejca.2020.08.015","title":"Randomised controlled trial confirms benefit of enhanced recovery after surgery on length of stay in ovarian cancer: How low can we go?","year":2020,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Enhanced Recovery After Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Ovarian cancer; Peritoneal carcinomatosis; Randomized controlled trial; Cytoreductive surgery; Surgery; Cancer; Internal medicine; Colorectal cancer","score_opus":0.018345450546559755,"score_gpt":0.24835886745525979,"score_spread":0.23001341690870003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089003689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5180539,0.01619982,0.00025825555,0.43928295,0.016901115,0.005395834,0.0008744591,0.000043460932,0.0029902025],"genre_scores_gemma":[0.8077945,0.02768343,0.00016294928,0.13636467,0.019125303,0.00032441644,0.000074032316,0.00055797724,0.007912741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919378,0.0016553117,0.003482126,0.00065691845,0.0015556522,0.00071219966],"domain_scores_gemma":[0.99044126,0.002378937,0.005332142,0.0006608144,0.00087806064,0.0003087877],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020827628,0.0008563684,0.005666007,0.0011761339,0.00003083306,0.000048370213,0.00044729386,0.00035857965,0.0010050194],"category_scores_gemma":[0.0012075991,0.0006712197,0.0022565392,0.0005280672,0.00021143767,0.00020400107,0.00006664545,0.003147583,0.000006810765],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7858788,0.00022651357,0.00026016973,0.0011350524,0.0029279755,0.005759776,0.00047303256,0.00018904178,0.0050581014,3.5643123e-7,0.18008168,0.01800954],"study_design_scores_gemma":[0.80268735,0.0036765311,0.0012077203,0.022122843,0.0020680614,0.000062334264,0.0000590393,0.000012700829,0.038194574,0.000027340673,0.12871598,0.0011655495],"about_ca_topic_score_codex":0.000077390236,"about_ca_topic_score_gemma":0.000106724154,"teacher_disagreement_score":0.3029183,"about_ca_system_score_codex":0.0005532028,"about_ca_system_score_gemma":0.0019578624,"threshold_uncertainty_score":0.9999082},"labels":[],"label_agreement":null},{"id":"W3089141494","doi":"10.1016/j.ejca.2020.08.014","title":"Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University Health Network","funders":"Andrew McDonough B+ Foundation; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Epigenetics; Medicine; Vorinostat; Bioinformatics; Drug development; Epigenetic therapy; Histone deacetylase; DNA methylation; Histone; Pharmacology; Drug; Biology; Genetics; Gene; Gene expression","score_opus":0.04278918794120522,"score_gpt":0.3388631460835769,"score_spread":0.2960739581423717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089141494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013645092,0.97600335,0.022536783,0.000047626156,0.00035998426,0.0007387032,0.00010216741,0.0000017604725,0.00007317783],"genre_scores_gemma":[0.001639377,0.99038994,0.0056765466,0.000017854416,0.0019289333,0.000028350561,0.00012358338,0.00008146156,0.000113947375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980782,0.00015885837,0.001062524,0.0002780513,0.00020217894,0.00022017922],"domain_scores_gemma":[0.99799097,0.000028218525,0.0013225077,0.00016708796,0.00036032283,0.0001308976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007526739,0.00026353484,0.0007485333,0.00010284637,0.00005508404,0.000014109335,0.00034898135,0.000070149224,0.0000065293075],"category_scores_gemma":[0.00016388323,0.00020618286,0.0004670799,0.000103169215,0.00003755466,0.0000028048719,0.00005210127,0.0001365842,9.1818004e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048933864,0.000020465044,0.00001732785,0.001419952,0.00039765515,0.0000012412668,0.00003100783,0.00009633025,0.0005606979,0.0000027111807,0.0011455708,0.9962581],"study_design_scores_gemma":[0.00059138815,0.00079009176,0.00009357364,0.0006699754,0.00061256334,0.000006425316,0.0000109921875,0.0000026449547,0.004227587,0.0000114758295,0.9927643,0.0002189647],"about_ca_topic_score_codex":6.593431e-7,"about_ca_topic_score_gemma":0.0000025411189,"teacher_disagreement_score":0.99603915,"about_ca_system_score_codex":0.00003393873,"about_ca_system_score_gemma":0.0010921378,"threshold_uncertainty_score":0.84078926},"labels":[],"label_agreement":null},{"id":"W3089157576","doi":"10.1016/j.ejca.2020.08.021","title":"Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Response Evaluation Criteria in Solid Tumors; Internal medicine; Concordance; Oncology; Progression-free survival; Placebo; Ovarian cancer; Cancer; Chemotherapy; Progressive disease; Pathology","score_opus":0.018693872539351578,"score_gpt":0.3029631482047462,"score_spread":0.2842692756653946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089157576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793995,0.0006777817,0.00011225376,0.017758084,0.000097400414,0.0016238537,0.00006673334,0.000017653412,0.00024671288],"genre_scores_gemma":[0.9902822,0.0004236092,0.00044867917,0.008039075,0.0005063669,0.00007777097,0.000009067251,0.00008783371,0.00012543338],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.996596,0.001135477,0.0008124817,0.00040744906,0.0006829004,0.00036569007],"domain_scores_gemma":[0.9981564,0.0002020348,0.0006427768,0.00023833293,0.0005011633,0.00025927485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001206362,0.00034257717,0.00069725537,0.00018302556,0.0000628731,0.000052606305,0.00018572978,0.000056441364,0.00012596269],"category_scores_gemma":[0.00012051435,0.00019464846,0.00006589741,0.0008438082,0.00020080227,0.00017275696,0.000018579634,0.00070982677,0.000004615875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7531212,0.00020741914,0.19090281,0.000016521417,0.0002137729,0.0011443672,0.008914668,0.00009963903,0.0017819883,8.4114805e-7,0.00085994083,0.042736817],"study_design_scores_gemma":[0.1908883,0.012902612,0.780287,0.0022993495,0.00005916741,0.00004113203,0.00023313024,0.000018245282,0.0028725152,0.0000032514145,0.010103878,0.0002913758],"about_ca_topic_score_codex":0.00013126055,"about_ca_topic_score_gemma":0.000106952044,"teacher_disagreement_score":0.58938426,"about_ca_system_score_codex":0.00033614394,"about_ca_system_score_gemma":0.00040140992,"threshold_uncertainty_score":0.7937534},"labels":[],"label_agreement":null},{"id":"W3091306549","doi":"10.1016/j.ejca.2020.08.025","title":"Effect of delay in surgical therapy for early-stage cervical cancer: An implication in the coronavirus pandemic","year":2020,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"GlaxoSmithKline Australia; Clovis Oncology; Meso Scale Diagnostics; Merck","keywords":"Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Cervical cancer; Coronavirus; Stage (stratigraphy); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Intensive care medicine; 2019-20 coronavirus outbreak; Cancer; Internal medicine; Virology; Disease","score_opus":0.1011628135426316,"score_gpt":0.4463273385856284,"score_spread":0.3451645250429968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091306549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63843584,0.009524338,0.000022342545,0.35047156,0.00029758838,0.0009992549,0.00009877721,0.0000095805135,0.00014068605],"genre_scores_gemma":[0.7669992,0.0077422806,0.00001350855,0.22041474,0.0046373773,0.000032776912,0.000026657262,0.00007438537,0.000059090817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996535,0.001483271,0.00087981776,0.00023891736,0.00053023594,0.00033273277],"domain_scores_gemma":[0.99798286,0.00075510226,0.0006645273,0.00026428356,0.00018202997,0.00015120038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019797157,0.00024988927,0.0008025901,0.00019378072,0.000030262889,0.00002117525,0.00038175646,0.00014771719,0.00010850696],"category_scores_gemma":[0.00011192916,0.00014986398,0.00024755296,0.00023428102,0.00006387049,0.000078750396,0.000019673089,0.002130568,0.000002197182],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015162316,0.00012774761,0.25263765,0.0019010499,0.00020771513,0.0063943397,0.0038895488,0.00007378916,0.000644633,0.0000042500315,0.076442905,0.64251405],"study_design_scores_gemma":[0.005722725,0.004629737,0.21960962,0.00070953474,0.00009060177,0.00012355491,0.000014905134,0.000021085283,0.00010784773,0.000005909741,0.7688313,0.00013313873],"about_ca_topic_score_codex":0.0012237153,"about_ca_topic_score_gemma":0.00035524173,"teacher_disagreement_score":0.6923884,"about_ca_system_score_codex":0.00037341242,"about_ca_system_score_gemma":0.00074677466,"threshold_uncertainty_score":0.9256376},"labels":[],"label_agreement":null},{"id":"W3091531967","doi":"10.1016/j.ejca.2020.08.019","title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; University of Alberta; McMaster University; London Health Sciences Centre; Western University; Ottawa Hospital; Cancer Care South East; University of Ottawa","funders":"Canadian Institutes of Health Research; Government of Ontario; Cancer Care Ontario","keywords":"Medicine; Prostate cancer; Castration; Oncology; Breast cancer; Internal medicine; Prostate; Cancer; Urology; Hormone","score_opus":0.048361779295356656,"score_gpt":0.3167577680065265,"score_spread":0.2683959887111698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091531967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961976,0.00072917657,0.000007213799,0.0011110716,0.00023857605,0.00088151096,0.00071414356,0.000004731852,0.00011598037],"genre_scores_gemma":[0.9989546,0.00020083097,0.0004208464,0.00012267231,0.00013530982,0.000011791687,0.000068413014,0.000028269242,0.000057299527],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99774516,0.00026850533,0.0010990115,0.00015926646,0.00055765157,0.00017039503],"domain_scores_gemma":[0.9979698,0.00006353939,0.0012255568,0.000110021654,0.0003640005,0.00026707657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025937683,0.00016537264,0.00065945747,0.00009459471,0.000025440442,0.000009864484,0.000054517615,0.00002094751,0.0002564244],"category_scores_gemma":[0.00011445695,0.000108155225,0.000106775035,0.00019607616,0.00005031376,0.00013141097,0.000009876151,0.00016249059,0.000001383176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96572316,0.00072114565,0.021457847,0.00011395996,0.0005185321,0.00053619157,0.00066054723,0.00004868418,0.0009641366,4.073236e-7,0.00043525256,0.00882014],"study_design_scores_gemma":[0.59553343,0.012015343,0.3887608,0.0006264041,0.0007297635,0.000007039668,0.000114539274,0.00001760907,0.0014786717,6.4034197e-7,0.0006093093,0.00010642936],"about_ca_topic_score_codex":0.00036913776,"about_ca_topic_score_gemma":0.00046686523,"teacher_disagreement_score":0.3701897,"about_ca_system_score_codex":0.00009738075,"about_ca_system_score_gemma":0.000980752,"threshold_uncertainty_score":0.4410442},"labels":[],"label_agreement":null},{"id":"W3091969870","doi":"10.1016/s0959-8049(20)30642-0","title":"Psychosocial outcomes following contralateral prophylactic mastectomy in women with unilateral, nonhereditary breast cancer","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Mount Sinai Hospital; University of Toronto; Women's College Hospital","funders":"","keywords":"Psychosocial; Medicine; Mastectomy; Breast cancer; Cancer; Prophylactic Mastectomy; Gynecology; Internal medicine; Psychiatry","score_opus":0.017869513010948274,"score_gpt":0.28764494035013966,"score_spread":0.26977542733919135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091969870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708752,0.0003272945,0.000015567415,0.022956895,0.0015894296,0.00018642045,0.000019646075,0.000027191327,0.0040023727],"genre_scores_gemma":[0.99550545,0.000080422426,0.00009615712,0.0026852402,0.0012748387,0.000009482804,3.0248478e-7,0.000049554874,0.00029853746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974749,0.000562377,0.0005170925,0.00020768517,0.0007107566,0.0005271933],"domain_scores_gemma":[0.99894387,0.000045210516,0.0003880742,0.000089568646,0.00017767456,0.00035562212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008005736,0.00019647054,0.0004272477,0.00008977188,0.0001682061,0.00012087802,0.0004610074,0.0000362774,0.00069455],"category_scores_gemma":[0.000045116736,0.0001474299,0.00011405395,0.0004259277,0.00014976409,0.000689048,0.00003394701,0.00045754664,0.000012831722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011903822,0.00007385489,0.9039604,0.00003881252,0.0002916172,0.0021241582,0.063569635,0.00038042245,0.0002862416,0.00002434864,0.0020353254,0.026024818],"study_design_scores_gemma":[0.0033829827,0.00022989094,0.9621001,0.0002364309,0.000054514672,0.000010162843,0.0056066783,0.0000059367158,0.000010794308,0.0000282455,0.028003836,0.0003304678],"about_ca_topic_score_codex":0.0007311344,"about_ca_topic_score_gemma":0.0005626789,"teacher_disagreement_score":0.058139678,"about_ca_system_score_codex":0.00042187705,"about_ca_system_score_gemma":0.0005920657,"threshold_uncertainty_score":0.76048356},"labels":[],"label_agreement":null},{"id":"W3092199341","doi":"10.1016/s0959-8049(20)30555-4","title":"Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; McMaster University Medical Centre","funders":"","keywords":"Breast cancer; Oncology; Medicine; Hormone receptor; Internal medicine; Adjuvant; Lymph node; Adjuvant chemotherapy; Cancer; Chemotherapy; Gynecology","score_opus":0.035008317269886846,"score_gpt":0.2892350216319747,"score_spread":0.25422670436208783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092199341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9260939,0.00068950746,0.00020006883,0.059598465,0.0003795498,0.0009289604,0.0112374,0.000011116485,0.0008610616],"genre_scores_gemma":[0.97462547,0.0028472731,0.0005407865,0.020763142,0.0008053791,0.000050788374,0.00006880257,0.00011980318,0.00017856709],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963751,0.0015338025,0.00075291906,0.00053681614,0.00044465318,0.00035672553],"domain_scores_gemma":[0.9969488,0.00045491842,0.00081675715,0.00034466895,0.0011559832,0.0002788657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026914023,0.00048701093,0.0005242937,0.00008846532,0.0002608649,0.00006575324,0.0005728862,0.000046168498,0.00013836562],"category_scores_gemma":[0.00038475633,0.00029109896,0.000172258,0.00038026262,0.00018423822,0.00004968981,0.00027275298,0.00026812206,0.000014298275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05427154,0.0013584031,0.32722092,0.000030385248,0.0042162677,0.00008929206,0.071772076,0.014099287,0.05666413,0.0000058885244,0.11937814,0.35089368],"study_design_scores_gemma":[0.0056007374,0.0006467068,0.9635892,0.0014067597,0.00010304824,0.0000048083652,0.0016843571,0.0000197525,0.023652196,0.0000014170245,0.002949312,0.00034171005],"about_ca_topic_score_codex":0.002098595,"about_ca_topic_score_gemma":0.0007560174,"teacher_disagreement_score":0.6363683,"about_ca_system_score_codex":0.0005209561,"about_ca_system_score_gemma":0.00032647862,"threshold_uncertainty_score":0.9999541},"labels":[],"label_agreement":null},{"id":"W3092366929","doi":"10.1016/s0959-8049(20)30860-1","title":"Development of a multiplexed protein panel using a targeted proteomics approach for the study of CDK4/6 inhibitors resistance in hormone receptor positive breast cancer","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Breast cancer; Proteomics; Hormone receptor; Receptor; Cancer; Hormone; Oncology; Medicine; Computational biology; Cancer research; Bioinformatics; Internal medicine; Biology; Genetics; Gene","score_opus":0.05152386587998115,"score_gpt":0.2897392281280002,"score_spread":0.23821536224801904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092366929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293334,0.0052402797,0.007863922,0.00097477005,0.0000774934,0.0027886522,0.000092141825,0.000008913664,0.000020457464],"genre_scores_gemma":[0.8942753,0.00004603902,0.10502948,0.000093695635,0.00035934412,0.000098065306,0.0000019862498,0.00006747106,0.000028634066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99767864,0.00022183733,0.0011083821,0.00024055758,0.00050388003,0.00024668826],"domain_scores_gemma":[0.99764156,0.00004234328,0.0012730163,0.00016089635,0.00075644214,0.00012572003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000683069,0.00022876977,0.000618416,0.000115005685,0.00007329471,0.000009447386,0.00024594172,0.000027473705,0.000014236518],"category_scores_gemma":[0.000098487275,0.00015912527,0.00011382687,0.00046387938,0.000114973016,0.00012986285,0.00005938996,0.0003453949,1.7941065e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020819642,0.00056779216,0.0023754134,0.00030171455,0.0006638172,0.00001975642,0.035510466,0.0033812234,0.9166456,0.0000025548864,0.000040505707,0.019671522],"study_design_scores_gemma":[0.060907327,0.0037691456,0.35633245,0.006555001,0.0009299726,0.00007804191,0.045266014,0.0030958643,0.5174201,0.000010126773,0.004494292,0.0011416163],"about_ca_topic_score_codex":0.0000594125,"about_ca_topic_score_gemma":0.000046763675,"teacher_disagreement_score":0.39922547,"about_ca_system_score_codex":0.00035449574,"about_ca_system_score_gemma":0.0006143688,"threshold_uncertainty_score":0.648894},"labels":[],"label_agreement":null},{"id":"W3092817339","doi":"10.1016/j.ejca.2020.09.016","title":"Cribriform architecture prostatic adenocarcinoma in needle biopsies is a strong independent predictor for lymph node metastases in radical prostatectomy","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Prostate Cancer Canada","keywords":"Prostatectomy; Medicine; Urology; Stage (stratigraphy); Nomogram; Prostate cancer; Dissection (medical); Lymph node; T-stage; Biopsy; Prostate-specific antigen; Adenocarcinoma; Cancer; Internal medicine; Radiology","score_opus":0.029600350541589156,"score_gpt":0.2858860472379933,"score_spread":0.25628569669640416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092817339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96808374,0.016101778,0.000505488,0.013406657,0.00016257787,0.0011622957,0.0003557423,0.000017552109,0.00020416538],"genre_scores_gemma":[0.9950686,0.0006756287,0.001668244,0.0020355945,0.000355613,0.00007991548,0.00001619064,0.000061886036,0.000038316513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795884,0.000136077,0.00078898895,0.00028459556,0.00044124067,0.00039023533],"domain_scores_gemma":[0.99896896,0.00007349899,0.00033713493,0.00013589057,0.00014649425,0.00033801384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038688412,0.0002515838,0.00059120613,0.00023757464,0.000032719094,0.000045108456,0.00015793601,0.000029816645,0.000115642164],"category_scores_gemma":[0.00014102909,0.00018346182,0.00018700951,0.00029667286,0.00008469291,0.00014575059,0.000050565246,0.00035362178,0.0000043369523],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006870482,0.00068547577,0.91640395,0.0011633764,0.0006290073,0.0034500598,0.01311377,0.0016106508,0.001511136,0.000037396196,0.0031189201,0.05140577],"study_design_scores_gemma":[0.032885216,0.0040937597,0.9264252,0.0026374587,0.0005422975,0.0002868937,0.0016431208,0.00067901117,0.013083806,0.000105782376,0.017203206,0.00041420443],"about_ca_topic_score_codex":0.000041548585,"about_ca_topic_score_gemma":0.000017407116,"teacher_disagreement_score":0.050991565,"about_ca_system_score_codex":0.00036955165,"about_ca_system_score_gemma":0.00048842013,"threshold_uncertainty_score":0.74813557},"labels":[],"label_agreement":null},{"id":"W3095171343","doi":"10.1016/s0959-8049(20)31128-x","title":"Theranostic 64Cu-DOTHA2-PSMA for metastatic prostate cancer treatment, a preclinical study","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Radioligand; Biodistribution; Prostate cancer; Glutamate carboxypeptidase II; Medicine; In vivo; Cancer research; Radionuclide therapy; Oncology; Pharmacology; Nuclear medicine; Cancer; Internal medicine; Biology; Receptor","score_opus":0.17313713155374894,"score_gpt":0.4549716049300678,"score_spread":0.28183447337631884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095171343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96753484,0.006575673,0.000641837,0.022405252,0.00016208213,0.0012525001,0.00009932313,0.000027983913,0.0013005164],"genre_scores_gemma":[0.9947474,0.00091405516,0.0005300772,0.0014799353,0.0010990393,0.0000685796,0.0000024889882,0.000040966108,0.0011174284],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987953,0.00012844965,0.0005279136,0.00018299533,0.00019486732,0.00017048148],"domain_scores_gemma":[0.9988996,0.00015919354,0.0002652445,0.000120429446,0.00019497823,0.00036056718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027763596,0.00014612457,0.0003740794,0.000018843748,0.00005716315,0.000021894195,0.00012220348,0.000009719292,0.0002970921],"category_scores_gemma":[0.00017584658,0.00009825778,0.00018581269,0.00012742588,0.000053692685,0.00005087246,0.000012341781,0.00019725092,0.00001291076],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023879023,0.007770263,0.09924099,0.0011126581,0.009312172,0.0021735074,0.018695494,0.0022617641,0.21769275,0.000056446443,0.026677746,0.5911272],"study_design_scores_gemma":[0.049193587,0.014185569,0.044779442,0.0005124034,0.007906992,0.00019780901,0.0014232972,0.001617035,0.05643736,0.000057632307,0.8230906,0.0005982407],"about_ca_topic_score_codex":0.0000036422466,"about_ca_topic_score_gemma":0.00000153939,"teacher_disagreement_score":0.7964129,"about_ca_system_score_codex":0.00006859857,"about_ca_system_score_gemma":0.00021054567,"threshold_uncertainty_score":0.40068358},"labels":[],"label_agreement":null},{"id":"W3095997051","doi":"10.1016/s0959-8049(20)31131-x","title":"NLS designed algorithm to develop peptides with a net-neutral charge as potential next-generation vectors for drug delivery to the nucleus","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Importin; Nuclear localization sequence; NLS; Nuclear transport; Nucleus; Cell biology; Nuclear pore; Biophysics; Chemistry; Cell nucleus; Biology","score_opus":0.01794120370272476,"score_gpt":0.22901074182508271,"score_spread":0.21106953812235796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095997051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95679986,0.0003761945,0.03825407,0.0037423999,0.00046837464,0.00021434992,0.00001747709,0.000005632423,0.00012164425],"genre_scores_gemma":[0.9780917,0.00006935522,0.0118303755,0.005793291,0.003921806,0.000004131083,0.000010547866,0.000041989173,0.00023678134],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992986,0.00009026931,0.00018406672,0.00015453261,0.00011814784,0.00015441915],"domain_scores_gemma":[0.999318,0.0000036104461,0.000111877736,0.00008145046,0.00032704714,0.00015800775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019148017,0.00010984544,0.00010052775,0.000024142353,0.00010462522,0.00006813993,0.00016575922,0.000017397995,0.000027021977],"category_scores_gemma":[0.00004154909,0.00007277366,0.00005841484,0.00011182674,0.000013912218,0.000011325054,0.0000343287,0.00007573643,0.000017320348],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083053805,0.000007930091,0.00003574848,0.0000048134484,0.00010494549,0.000018927289,0.00065380137,0.001890383,0.8534634,0.0000051566262,0.05738855,0.0855958],"study_design_scores_gemma":[0.001227714,0.002961306,0.0025855808,0.00003054348,0.00011656038,0.000074068244,0.00023817878,0.00037972315,0.35527787,0.0000028704828,0.63681906,0.00028656254],"about_ca_topic_score_codex":0.000007985977,"about_ca_topic_score_gemma":0.000023585353,"teacher_disagreement_score":0.57943046,"about_ca_system_score_codex":0.00001704752,"about_ca_system_score_gemma":0.00011625717,"threshold_uncertainty_score":0.29676238},"labels":[],"label_agreement":null},{"id":"W3096231293","doi":"10.1016/s0959-8049(20)31126-6","title":"The integrated stress response exposes a therapeutic vulnerability in KRAS driven lung cancer","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"KRAS; Lung cancer; Integrated stress response; Cancer research; Biology; Reprogramming; Adenocarcinoma; Cancer; Cellular stress response; Adaptation (eye); Mutation; Medicine; Fight-or-flight response; Gene; Oncology; Genetics; Translation (biology); Messenger RNA; Neuroscience","score_opus":0.048106868434828066,"score_gpt":0.37534946813468645,"score_spread":0.32724259969985836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096231293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9351401,0.01212455,0.0001747272,0.052015536,0.00018855094,0.00015961115,0.00001868423,0.000009517657,0.00016874238],"genre_scores_gemma":[0.99227667,0.004304775,0.0000846526,0.0027170882,0.00041515823,0.0000071092627,0.0000010069189,0.000022950639,0.00017061661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959438,0.0027487872,0.00056508416,0.00014872002,0.0002652515,0.00032836216],"domain_scores_gemma":[0.9989286,0.00018043029,0.00021044162,0.0001405619,0.00026384144,0.0002761118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001779125,0.00012047723,0.00033590742,0.000059049184,0.000066093955,0.000027904563,0.00026017881,0.000018900571,0.00026356083],"category_scores_gemma":[0.00168868,0.00006872372,0.00012227349,0.00019458678,0.0001708717,0.00007698739,0.000052041483,0.0007571942,0.0000049518026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032225996,0.00010162528,0.7864028,0.00007604446,0.00034397616,0.0014378907,0.0016949507,0.0012671555,0.04667994,0.0000069258554,0.014145804,0.11561685],"study_design_scores_gemma":[0.0031708325,0.0019026258,0.9168264,0.0006146945,0.000055036362,0.000061827806,0.00054585526,0.0017867496,0.0007379682,0.0000061122087,0.07419687,0.00009500701],"about_ca_topic_score_codex":0.000070790324,"about_ca_topic_score_gemma":0.00019813898,"teacher_disagreement_score":0.13042358,"about_ca_system_score_codex":0.00018574776,"about_ca_system_score_gemma":0.00031769546,"threshold_uncertainty_score":0.3289674},"labels":[],"label_agreement":null},{"id":"W3096567634","doi":"10.1016/s0959-8049(20)31120-5","title":"Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer reveals unique features that may inspire new sequential therapies in nonresponders","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Decipher Biosciences (Canada)","funders":"","keywords":"Pembrolizumab; Cystectomy; Bladder cancer; Urothelial cancer; Medicine; Chemotherapy; Oncology; Immunotherapy; Disease; Cancer; Internal medicine","score_opus":0.03865897088886258,"score_gpt":0.3137503165967124,"score_spread":0.27509134570784977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096567634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9569457,0.024789784,0.00019811596,0.014801257,0.0003409166,0.0004844887,0.000061007708,0.000021420925,0.0023572943],"genre_scores_gemma":[0.99006724,0.0026028338,0.00064548966,0.005621669,0.00063069095,0.0000065722375,0.0000053009853,0.00009032566,0.00032986279],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978533,0.00043513245,0.00059408863,0.0002642877,0.00055304845,0.0003001891],"domain_scores_gemma":[0.9985388,0.000045973942,0.00052222476,0.00019189481,0.00037732878,0.0003238054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027833832,0.00028538523,0.00059573393,0.00019338394,0.000035373534,0.000027924103,0.00025124484,0.000060398863,0.00040966494],"category_scores_gemma":[0.0001112758,0.00022093217,0.0002739226,0.0002993808,0.00009285511,0.00017934515,0.000050508355,0.0005008502,0.000004082454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012726903,0.00025668042,0.055824984,0.0005692869,0.0026905076,0.0054145884,0.019460093,0.0020245132,0.8346408,0.00011449548,0.0057362015,0.06054097],"study_design_scores_gemma":[0.02158024,0.0038288916,0.28939572,0.0030192551,0.001156558,0.00023989035,0.0027712744,0.000012970902,0.66817343,0.00009824135,0.009061838,0.0006616712],"about_ca_topic_score_codex":0.00042244064,"about_ca_topic_score_gemma":0.000119644734,"teacher_disagreement_score":0.23357075,"about_ca_system_score_codex":0.00018730486,"about_ca_system_score_gemma":0.0013942615,"threshold_uncertainty_score":0.90093523},"labels":[],"label_agreement":null},{"id":"W3097135495","doi":"10.1016/s0959-8049(20)31240-5","title":"CD8+ T tumour-infiltrating lymphocytes lacking CD5 cell surface expression exhibited increased levels of activation and exhaustion","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"CD5; CD8; T cell; Cytotoxic T cell; Cancer research; Cell; Biology; Receptor; Molecular biology; Flow cytometry; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.03549726996102447,"score_gpt":0.2753930583163978,"score_spread":0.23989578835537334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097135495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936089,0.002462387,0.0016990218,0.001024528,0.00007533683,0.00009908461,0.000010120426,0.000012562854,0.0010080903],"genre_scores_gemma":[0.9971998,0.0005044934,0.0014230709,0.0004786712,0.00031986937,2.6938537e-7,0.0000022540596,0.000025880037,0.000045719436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988504,0.00017395304,0.0004724434,0.0001165307,0.0002787265,0.000107924156],"domain_scores_gemma":[0.9989022,0.00007459148,0.0006327264,0.00006792068,0.000207787,0.000114777366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046556257,0.00011419741,0.0002414626,0.000056211178,0.000056483357,0.000020855967,0.00006538877,0.00002302737,0.00017745199],"category_scores_gemma":[0.00011375466,0.00009101851,0.000077613106,0.00016893947,0.000044983368,0.00018510366,0.000020422738,0.00014999362,0.0000011700652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00228738,0.000024384726,0.006930029,0.00014674696,0.00004178731,0.000026017316,0.0010551852,0.00023831865,0.9788567,4.741558e-7,0.0005582396,0.009834748],"study_design_scores_gemma":[0.004304385,0.0003876794,0.06632558,0.0013575808,0.00006269033,0.000027990956,0.00042706472,0.00028487874,0.9253182,9.248692e-7,0.001410064,0.00009298837],"about_ca_topic_score_codex":0.000023872053,"about_ca_topic_score_gemma":8.733868e-7,"teacher_disagreement_score":0.059395555,"about_ca_system_score_codex":0.000077714154,"about_ca_system_score_gemma":0.00014662853,"threshold_uncertainty_score":0.3711627},"labels":[],"label_agreement":null},{"id":"W3107572250","doi":"10.1016/j.ejca.2020.10.023","title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Rimouski; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Jewish General Hospital; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Hospitalier de l’Université de Montréal; Hôpital Maisonneuve-Rosemont; Nova Scotia Cancer Centre; Centre hospitalier universitaire de Québec; McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"AstraZeneca Canada","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Interquartile range; Radiation therapy; Urology; Clinical endpoint; Internal medicine; Toxicity; Cancer; Oncology; Randomized controlled trial; Gastroenterology","score_opus":0.02884639329967923,"score_gpt":0.31182372463287966,"score_spread":0.2829773313332004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107572250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9374489,0.056569804,0.00007943592,0.0045384085,0.0002640382,0.0009937006,0.000025041545,0.000010511969,0.00007013866],"genre_scores_gemma":[0.8144399,0.18318066,0.0001233897,0.001353755,0.0008033603,0.000043872937,0.0000032401615,0.000032950524,0.000018853832],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998521,0.0002510236,0.0006555613,0.00018410233,0.0002206912,0.00016763588],"domain_scores_gemma":[0.9989542,0.00006076127,0.000553652,0.00008624013,0.000113072165,0.00023207472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053820445,0.00016328259,0.00049727334,0.000090039335,0.000033731267,0.000033507127,0.00007470055,0.000018583616,0.00014657342],"category_scores_gemma":[0.000074360694,0.00011383857,0.000119276716,0.00015499892,0.0000528998,0.00012083489,0.000010021518,0.0002355337,0.0000010506757],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.347191,0.00025300754,0.03322488,0.000023010474,0.00041928614,0.000368281,0.0049148155,0.000060433358,0.0026460637,0.0000011197604,0.0011053801,0.6097927],"study_design_scores_gemma":[0.92436856,0.0064884233,0.020199733,0.0003478247,0.00017180106,0.000020007537,0.00010658586,0.000218652,0.0068596923,0.000007455438,0.04105758,0.0001537143],"about_ca_topic_score_codex":0.000039863833,"about_ca_topic_score_gemma":0.000011170736,"teacher_disagreement_score":0.609639,"about_ca_system_score_codex":0.00014653438,"about_ca_system_score_gemma":0.00021875356,"threshold_uncertainty_score":0.46422023},"labels":[],"label_agreement":null},{"id":"W3107733830","doi":"10.1016/j.ejca.2020.10.008","title":"Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval; Jewish General Hospital; McGill University Health Centre; Hôpital du Sacré-Cœur de Montréal; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; Hôtel-Dieu de Québec; McGill University; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; University Health Network","funders":"AstraZeneca Canada","keywords":"Durvalumab; Medicine; Hazard ratio; Pneumonitis; Internal medicine; Cohort; Proportional hazards model; Lung cancer; Univariate analysis; Stage (stratigraphy); Retrospective cohort study; Confidence interval; Oncology; Incidence (geometry); Survival analysis; Multivariate analysis; Cancer; Lung; Immunotherapy","score_opus":0.01454905598128353,"score_gpt":0.2502036527384733,"score_spread":0.23565459675718975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107733830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959045,0.0013011816,0.00006470392,0.00059373054,0.00010911486,0.0014814496,0.000009060632,0.00002708248,0.000509173],"genre_scores_gemma":[0.9980963,0.0004146375,0.00023749791,0.0003963189,0.00022925697,0.000025398818,0.000017973167,0.000088488756,0.0004941628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782145,0.0002072391,0.0006415578,0.00033170613,0.0007138889,0.00028418005],"domain_scores_gemma":[0.9984344,0.000025226767,0.00079500885,0.00019268977,0.0003210761,0.00023159113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003588257,0.00030828026,0.0007291552,0.00018934457,0.00008800861,0.00004088525,0.00014867469,0.000023717479,0.00007407631],"category_scores_gemma":[0.0000069402486,0.00020374199,0.00009997184,0.00077688246,0.00003392381,0.00018928562,0.000011618788,0.0003469651,9.339786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054857057,0.0008192598,0.9305287,0.000054869488,0.00095076783,0.00042799528,0.005955822,0.0010986404,0.0007961673,2.2547948e-8,0.00045082503,0.0040598875],"study_design_scores_gemma":[0.0851849,0.0038607675,0.906346,0.00041975928,0.0005562026,0.0000025558038,0.0004958036,0.0007381946,0.00070523325,8.067258e-9,0.0014246256,0.00026591858],"about_ca_topic_score_codex":0.0023585574,"about_ca_topic_score_gemma":0.0015306141,"teacher_disagreement_score":0.030327845,"about_ca_system_score_codex":0.0017316864,"about_ca_system_score_gemma":0.00043630443,"threshold_uncertainty_score":0.83083576},"labels":[],"label_agreement":null},{"id":"W3113349188","doi":"10.1016/j.ejca.2020.10.020","title":"Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"European Commission; Cancer Research UK","keywords":"Medicine; Hazard ratio; Neuroblastoma; Internal medicine; Incidence (geometry); Confidence interval; Oncology; Stage (stratigraphy); Chemotherapy; Proportional hazards model","score_opus":0.02892416511138282,"score_gpt":0.29626241335433623,"score_spread":0.2673382482429534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113349188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939717,0.00048338893,0.00005509465,0.0029136776,0.00065699196,0.0005381199,0.000019366682,0.000024496592,0.0013371862],"genre_scores_gemma":[0.9973998,0.00031700393,0.00006569381,0.0005863862,0.0010391362,0.000008372817,7.963996e-7,0.000051420102,0.0005313593],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9969903,0.0009529038,0.00065116014,0.00024376692,0.0007284299,0.00043340886],"domain_scores_gemma":[0.998553,0.000092553666,0.00043677472,0.0002537721,0.00013053662,0.0005334138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000462238,0.00019265962,0.00039675648,0.0000878159,0.000100760386,0.00006840906,0.00040161452,0.000019308614,0.00015580992],"category_scores_gemma":[0.00032991453,0.00011485755,0.00017164389,0.00033430327,0.00009706735,0.00017701132,0.000115896095,0.0007826362,0.000057046807],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51300275,0.0020094714,0.063004486,0.00074007665,0.0014657493,0.19196434,0.028094053,0.008406785,0.025274675,0.0003299399,0.027587371,0.13812032],"study_design_scores_gemma":[0.2677152,0.027745793,0.6001697,0.0016266635,0.0005572015,0.001259199,0.0048485515,0.0012353476,0.0102710035,0.000005531273,0.083887815,0.00067798625],"about_ca_topic_score_codex":0.00008175456,"about_ca_topic_score_gemma":0.000021836124,"teacher_disagreement_score":0.5371652,"about_ca_system_score_codex":0.00016498195,"about_ca_system_score_gemma":0.00025029166,"threshold_uncertainty_score":0.46837547},"labels":[],"label_agreement":null},{"id":"W3113567260","doi":"10.1016/j.ejca.2020.11.037","title":"Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Multidisciplinary approach; Coronavirus disease 2019 (COVID-19); Pandemic; Medicine; Neuroendocrine tumors; Multidisciplinary team; Intensive care medicine; 2019-20 coronavirus outbreak; General surgery; Pathology; Political science; Disease; Nursing","score_opus":0.09474657299753617,"score_gpt":0.43797489380208654,"score_spread":0.34322832080455035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113567260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046667762,0.94386625,0.00060624786,0.051140226,0.0002066294,0.0033577518,0.0001466624,0.0000095306805,0.00020000311],"genre_scores_gemma":[0.0010562779,0.9944846,0.0028772077,0.001157513,0.00016546181,0.00007649781,0.000016382628,0.00007124357,0.00009481785],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691397,0.0010707059,0.00086767453,0.00024489948,0.0006049418,0.0002978259],"domain_scores_gemma":[0.9974575,0.00085618376,0.00095778593,0.00031105606,0.00017638145,0.00024110705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049860205,0.00027652323,0.000936223,0.00017685548,0.00008163789,0.00004704104,0.00037609498,0.0000030048334,0.00004401161],"category_scores_gemma":[0.00039698128,0.000127969,0.00020767927,0.00034485062,0.00015084898,0.000117007956,0.00012498678,0.0008770604,0.0000018544298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026719654,0.00036654333,0.0022989514,0.023790065,0.0011335838,0.0119871115,0.00014179791,0.00001673007,1.7461464e-7,0.00007221707,0.02249489,0.935026],"study_design_scores_gemma":[0.0020535197,0.0017978436,0.0013480727,0.004203412,0.002017643,0.0027742684,0.00016015994,0.0000048199117,5.159149e-7,0.0000036045283,0.985556,0.00008013653],"about_ca_topic_score_codex":0.00000429211,"about_ca_topic_score_gemma":0.000008672498,"teacher_disagreement_score":0.9630611,"about_ca_system_score_codex":0.00010805357,"about_ca_system_score_gemma":0.000307021,"threshold_uncertainty_score":0.5218425},"labels":[],"label_agreement":null},{"id":"W3114638465","doi":"10.1016/j.ejca.2020.11.010","title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Merck Sharp and Dohme; National Institutes of Health","keywords":"Pembrolizumab; Medicine; Adverse effect; Pneumonitis; Melanoma; Internal medicine; Discontinuation; Progression-free survival; Surgery; Survival analysis; Gastroenterology; Overall survival; Cancer; Immunotherapy","score_opus":0.02761193364044567,"score_gpt":0.3175923673352526,"score_spread":0.2899804336948069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114638465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961662,0.0016748826,0.0005014366,0.0011467246,0.00003675539,0.00015861716,0.000009735089,0.0000046343475,0.0003010146],"genre_scores_gemma":[0.99806595,0.00064724236,0.00054715475,0.00059275166,0.00007241421,7.7101265e-7,0.000004363773,0.000023133078,0.00004621788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848545,0.00021121808,0.0007716909,0.00014639148,0.00027640257,0.00010884379],"domain_scores_gemma":[0.99891406,0.000072787945,0.0005878472,0.00012661585,0.00017168421,0.00012697694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043542258,0.000120362194,0.0005224652,0.00014306208,0.000022234497,0.000009094193,0.00008250475,0.000021926558,0.0000875531],"category_scores_gemma":[0.00004064341,0.00007421643,0.00013145772,0.00047665584,0.00009626615,0.000093188,0.000010262949,0.00025261223,4.8796966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05986135,0.00008664939,0.9027446,0.00003212866,0.0010202436,0.000067740024,0.00035165242,0.00009893207,0.000021105701,0.0000012253507,0.000022569926,0.035691794],"study_design_scores_gemma":[0.023243425,0.0029128382,0.9723687,0.000210808,0.00051550183,0.0000074921504,0.00002917782,0.000013657415,0.000016000262,3.088421e-7,0.0005922552,0.00008979257],"about_ca_topic_score_codex":0.0000057744014,"about_ca_topic_score_gemma":0.000046012556,"teacher_disagreement_score":0.06962413,"about_ca_system_score_codex":0.00004873382,"about_ca_system_score_gemma":0.00009285506,"threshold_uncertainty_score":0.3026458},"labels":[],"label_agreement":null},{"id":"W3114998407","doi":"10.1016/j.ejca.2020.11.027","title":"The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Uveitis; Melanoma; Internal medicine; Oncology; Population; Adverse effect; Nivolumab; Immunology; Immunotherapy; Cancer; Cancer research","score_opus":0.011812348237438586,"score_gpt":0.25196241724153284,"score_spread":0.24015006900409425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114998407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932257,0.002386886,0.0000048027923,0.0037011371,0.000099036566,0.0001702287,0.0000060480725,0.000005106782,0.00040105602],"genre_scores_gemma":[0.9979313,0.0011414622,0.000155898,0.00035444472,0.00022329995,0.0000012840525,0.0000025977633,0.00001957369,0.00017015792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991137,0.00017012656,0.00029873187,0.0000849754,0.00021144659,0.000121066936],"domain_scores_gemma":[0.99929863,0.000076178105,0.00035257425,0.00005677893,0.0001287957,0.000087050146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020581852,0.000088559966,0.00022872075,0.000024598798,0.00005802923,0.000014127313,0.000053342657,0.000020412092,0.000026813937],"category_scores_gemma":[0.00009824168,0.00004566888,0.00004002373,0.00008888,0.000029659599,0.000066471366,0.000014346717,0.00022488763,0.0000049682744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033059213,0.000057739722,0.8155487,0.000005593939,0.00036698597,0.0005264103,0.00057782425,0.000004369298,0.00011582325,6.118626e-7,0.00007560023,0.17941442],"study_design_scores_gemma":[0.009863764,0.0045786523,0.96994436,0.00011359498,0.00009047332,0.000024703442,0.000050876653,0.0000014390016,0.00072949525,0.00000216546,0.014546982,0.000053481497],"about_ca_topic_score_codex":0.0000031146214,"about_ca_topic_score_gemma":0.000010014347,"teacher_disagreement_score":0.17936094,"about_ca_system_score_codex":0.0001289789,"about_ca_system_score_gemma":0.000079442965,"threshold_uncertainty_score":0.18623228},"labels":[],"label_agreement":null},{"id":"W3115666250","doi":"10.1016/j.ejca.2020.11.023","title":"Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne","funders":"","keywords":"Pertuzumab; Medicine; Rash; Internal medicine; Hazard ratio; Metastatic breast cancer; Cohort; Proportional hazards model; Breast cancer; Oncology; Cohort study; Cancer; Confidence interval","score_opus":0.03363012525165893,"score_gpt":0.3112171129630532,"score_spread":0.2775869877113943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115666250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860769,0.0010052688,0.000026381487,0.01150924,0.00012813673,0.0003672803,0.00083922385,0.000007751194,0.00003983053],"genre_scores_gemma":[0.99851763,0.00033427737,0.000024977762,0.0006539113,0.00036278617,0.000009678582,0.000022311307,0.000038436654,0.000035981273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608755,0.0018150185,0.0005545917,0.00023438307,0.0010552106,0.00025326468],"domain_scores_gemma":[0.9980076,0.00053450663,0.0006200195,0.00010903667,0.00046915066,0.00025966755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015656,0.00017802004,0.00078165124,0.00012533739,0.000102223465,0.00007009511,0.00015634594,0.000023838404,0.00008937307],"category_scores_gemma":[0.00033912936,0.00011398228,0.00011786024,0.00060686335,0.00007251567,0.00014358124,0.00007676712,0.00065419014,0.0000013588407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004265817,0.00009042869,0.9804759,0.000010410065,0.0041351463,0.00005416594,0.0028138736,0.00006311946,0.000008957568,2.0570462e-7,0.00044088505,0.0076411124],"study_design_scores_gemma":[0.027520778,0.00087807345,0.9681295,0.00012488905,0.0024672756,4.2282446e-7,0.00052540173,0.00004481758,0.000009109072,0.0000019018734,0.0001800281,0.00011781035],"about_ca_topic_score_codex":0.00067137915,"about_ca_topic_score_gemma":0.0007020017,"teacher_disagreement_score":0.02325496,"about_ca_system_score_codex":0.0006655,"about_ca_system_score_gemma":0.00034478202,"threshold_uncertainty_score":0.46480623},"labels":[],"label_agreement":null},{"id":"W3119297022","doi":"10.1016/j.ejca.2020.10.032","title":"A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS)","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"University Health Network","keywords":"Neutropenia; Medicine; Febrile neutropenia; Internal medicine; Doxorubicin; Tolerability; Adverse effect; Gastroenterology; Vomiting; Phases of clinical research; Surgery; Chemotherapy; Oncology","score_opus":0.00421235592845011,"score_gpt":0.2316386944021195,"score_spread":0.2274263384736694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119297022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989738,0.0002659881,0.00007617879,0.00008729332,0.00012852649,0.00016299121,0.000006170785,0.0000011843546,0.0002978874],"genre_scores_gemma":[0.99925077,0.00007955291,0.00045547407,0.00004768109,0.00009919788,0.0000011511615,0.00001080871,0.000025900497,0.000029457355],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99900365,0.00013419855,0.0004155464,0.00014690185,0.0001913222,0.00010835432],"domain_scores_gemma":[0.9991255,0.000007801455,0.00039073743,0.00010383686,0.00033854897,0.000033606277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019390414,0.00010291935,0.00023486228,0.000102738166,0.000011790571,0.000005381123,0.00006979071,0.000032647,0.00001509673],"category_scores_gemma":[0.000055528522,0.00008208025,0.000033048553,0.00023643313,0.00003712264,0.00001665131,0.000021444635,0.0001503045,2.6950255e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24261722,0.006777032,0.06311053,0.00016412414,0.00026970007,0.00036460048,0.0021564253,0.0027509602,0.57210934,0.000029109162,0.0010836279,0.108567335],"study_design_scores_gemma":[0.4346528,0.04105933,0.21168384,0.0010845573,0.000102943704,0.00003691832,0.00057963905,0.000094259594,0.27774316,0.000021029406,0.03244992,0.0004916052],"about_ca_topic_score_codex":0.000010977711,"about_ca_topic_score_gemma":0.00021429556,"teacher_disagreement_score":0.29436618,"about_ca_system_score_codex":0.00004316782,"about_ca_system_score_gemma":0.00011779823,"threshold_uncertainty_score":0.33471355},"labels":[],"label_agreement":null},{"id":"W3119551045","doi":"10.1016/j.ejca.2020.12.006","title":"Corrigendum to “A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation” [Eur J Canc 131 (2020) 68–75]","year":2021,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Dosing; Regret; Schedule; Medicine; Cancer; Medical physics; Family medicine; Internal medicine; Computer science; Statistics; Mathematics","score_opus":0.05203422038001544,"score_gpt":0.3276092768531242,"score_spread":0.27557505647310876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119551045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87207067,0.0488998,0.028296823,0.0022267376,0.04100616,0.004414661,0.00044770067,0.000040802082,0.0025966375],"genre_scores_gemma":[0.97794574,0.0011802518,0.004598112,0.0026766537,0.0049805013,0.00004441301,0.00021492281,0.0003752232,0.007984195],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99683857,0.00030362094,0.0008808981,0.0004672404,0.0011270626,0.00038263417],"domain_scores_gemma":[0.9968654,0.000054792356,0.0009328828,0.0002760132,0.0016567917,0.00021414743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010298061,0.00041307058,0.0007330863,0.00044939088,0.00014427876,0.00010138777,0.00014473472,0.00011898728,0.00029655138],"category_scores_gemma":[0.00010495457,0.00034178427,0.00018493854,0.0004372744,0.00004850643,0.00015445029,0.000025199697,0.0007232657,7.8319033e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018509235,0.00017431877,0.005425117,0.00037912914,0.00040722045,0.000073813935,0.00051686517,0.91193515,0.00016739308,3.2233342e-7,0.026678171,0.03573325],"study_design_scores_gemma":[0.031534128,0.002909867,0.049524307,0.018421596,0.0015181863,0.000016158807,0.00014903434,0.754409,0.0001529669,0.0000025425074,0.14049888,0.000863301],"about_ca_topic_score_codex":0.00024882748,"about_ca_topic_score_gemma":0.00019488727,"teacher_disagreement_score":0.15752612,"about_ca_system_score_codex":0.0015803125,"about_ca_system_score_gemma":0.0025316544,"threshold_uncertainty_score":0.99990344},"labels":[],"label_agreement":null},{"id":"W3128456160","doi":"10.1016/j.ejca.2020.12.023","title":"Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Public Health Ontario; Women's College Hospital; University of Toronto; Jewish General Hospital","funders":"Cancer Research UK","keywords":"Medicine; Genetic testing; Breast cancer; Clinical Practice; Cancer; Oncology; Family medicine; Intensive care medicine; Internal medicine","score_opus":0.21592314187092146,"score_gpt":0.5008142002287164,"score_spread":0.28489105835779494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128456160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027427737,0.99447817,0.0028011566,0.00044273274,0.0013604228,0.00021963869,0.000043703938,0.000003348731,0.0006234022],"genre_scores_gemma":[0.0000031913107,0.8558829,0.13637467,0.00095866766,0.0062364587,0.0000118516145,0.000014720588,0.0000961642,0.0004213972],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968747,0.00068510615,0.0016630699,0.00038741107,0.00019883523,0.00019090567],"domain_scores_gemma":[0.99405414,0.0002820391,0.001699783,0.0003190729,0.003514697,0.00013026889],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0021787612,0.00026882064,0.00083165755,0.000061827785,0.00006852528,0.00007428919,0.00034066135,0.00011654431,0.000015208933],"category_scores_gemma":[0.010644748,0.00022262886,0.00045255263,0.00013207103,0.00008514822,0.0000066797,0.00016051656,0.00031829387,0.000002751199],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012085223,0.000017419336,0.000010957179,0.000686607,0.0005124491,0.00005746091,0.000009170091,0.00003558093,0.000024352243,0.000001433828,0.058146544,0.94048595],"study_design_scores_gemma":[0.00042044124,0.0003021167,0.000030279778,0.0036873207,0.0012937118,0.00096908724,0.000029327115,0.000004295309,0.000011867369,0.0000022993756,0.99301416,0.00023510962],"about_ca_topic_score_codex":0.0000015456699,"about_ca_topic_score_gemma":0.0000023148991,"teacher_disagreement_score":0.9402508,"about_ca_system_score_codex":0.000061371895,"about_ca_system_score_gemma":0.0017397469,"threshold_uncertainty_score":0.997689},"labels":[],"label_agreement":null},{"id":"W3136113179","doi":"10.1016/j.ejca.2021.02.022","title":"Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"National Cancer Institute; European Regional Development Fund; Manchester Biomedical Research Centre; Parc Geneteg Cymru; National Institutes of Health; Centro de Investigación Biomédica en Red de Cáncer; Syöpäsäätiö; Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; Instrumentariumin Tiedesäätiö; Ministerio de Sanidad, Servicios Sociales e Igualdad; Emil Aaltosen Säätiö; Ministero della Salute; KWF Kankerbestrijding; Ministerio de Economía y Competitividad; LOEWE Zentrum AdRIA; Deutsche Krebshilfe; National Institute for Health and Care Research; Generalitat de Catalunya; Kreftforeningen; Suomen Lääketieteen Säätiö; Academy of Finland; Centres de Recerca de Catalunya; Health and Care Research Wales","keywords":"Hysterectomy; Medicine; Lynch syndrome; Oophorectomy; Gynecology; General surgery; Surgery; Internal medicine; DNA mismatch repair; Cancer","score_opus":0.015165376337600487,"score_gpt":0.2756392994169821,"score_spread":0.2604739230793816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136113179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99012977,0.0074249147,0.000043338725,0.00014586787,0.0006194808,0.0002629407,0.00005819893,0.000011300394,0.0013041807],"genre_scores_gemma":[0.99455166,0.0005687937,0.0043609613,0.000075192,0.00011948031,0.0000052268674,0.00000511132,0.000052084,0.00026147478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973077,0.0002893662,0.0012954082,0.00034305194,0.0005189988,0.00024543668],"domain_scores_gemma":[0.99775815,0.000055946606,0.0008333891,0.00041903756,0.0007420622,0.00019141042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011796945,0.00020648284,0.00076965435,0.00022265998,0.000021514083,0.0000108797685,0.00012913469,0.00004430255,0.00026565106],"category_scores_gemma":[0.00051975343,0.00017586215,0.00020338519,0.0004933117,0.00014168209,0.00010672465,0.00010677109,0.00038935544,8.989249e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017618996,0.00029723693,0.5345316,0.0009546126,0.00096126867,0.03804609,0.0041398685,0.000082959086,0.41269308,0.000008440342,0.0008327811,0.0056901462],"study_design_scores_gemma":[0.004108029,0.0010748851,0.94094205,0.0022923618,0.00031452312,0.015117834,0.00055676996,0.00003831168,0.03330003,0.00001907238,0.002035322,0.00020080316],"about_ca_topic_score_codex":0.000065740656,"about_ca_topic_score_gemma":0.000049696984,"teacher_disagreement_score":0.40641046,"about_ca_system_score_codex":0.00017860964,"about_ca_system_score_gemma":0.00087006117,"threshold_uncertainty_score":0.717145},"labels":[],"label_agreement":null},{"id":"W3136212749","doi":"10.1016/j.ejca.2021.01.053","title":"Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Cancer Society; National Institutes of Health; Novartis Pharmaceuticals Corporation; GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Internal medicine; Hazard ratio; Breast cancer; Chemotherapy; Oncology; Gastroenterology; Confidence interval; Cancer","score_opus":0.11838979315974739,"score_gpt":0.41610397808041366,"score_spread":0.29771418492066626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136212749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8279341,0.012116598,0.000392236,0.098639116,0.008512754,0.000496739,0.0005146719,0.00003824148,0.051355537],"genre_scores_gemma":[0.9470206,0.006625859,0.00084382825,0.005958047,0.018828351,0.00000550781,0.00013239053,0.00008961769,0.020495813],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996784,0.00051904557,0.00091456214,0.0002690687,0.0012413318,0.00027200658],"domain_scores_gemma":[0.99751824,0.00025698956,0.00047498877,0.00043925914,0.0010524913,0.00025804926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018489639,0.00015283855,0.00033384623,0.000052488875,0.00008373012,0.00011314516,0.00059900235,0.00003053335,0.0025869997],"category_scores_gemma":[0.0013737918,0.00010338696,0.0002030393,0.00027563627,0.00010763722,0.000101655074,0.000134977,0.0008230987,0.00013605488],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08705505,0.00039738644,0.00035292262,0.000010716819,0.00075903453,0.005205392,0.0012584798,0.000094029936,0.015321104,0.00002355838,0.72588104,0.16364132],"study_design_scores_gemma":[0.118325606,0.00046818124,0.0024062195,0.00050304737,0.00010232682,0.000109539455,0.0002274011,0.00007041006,0.005318761,0.00002023886,0.8723416,0.00010670931],"about_ca_topic_score_codex":0.00008116994,"about_ca_topic_score_gemma":0.00010119006,"teacher_disagreement_score":0.16353461,"about_ca_system_score_codex":0.00027790954,"about_ca_system_score_gemma":0.0015094709,"threshold_uncertainty_score":0.99832475},"labels":[],"label_agreement":null},{"id":"W3155170388","doi":"10.1016/j.ejca.2021.02.034","title":"Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"Queen's University","keywords":"Medicine; Stage (stratigraphy); Breast cancer; Oncology; Adjuvant therapy; Disease; Adjuvant; Endocrine system; Internal medicine; Cancer; Hormone; Biology","score_opus":0.018514273418529972,"score_gpt":0.309976300297621,"score_spread":0.29146202687909106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155170388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97595245,0.020688083,0.000040536906,0.00016885254,0.00005819918,0.0001522539,0.0028927552,7.3822645e-7,0.00004612075],"genre_scores_gemma":[0.9865917,0.012988041,0.0002936826,0.000030963583,0.000045000805,0.000005964818,0.000008821993,0.000015078767,0.00002072354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980437,0.0004386338,0.00097474136,0.00019184081,0.00021501885,0.00013606927],"domain_scores_gemma":[0.9969407,0.00018238906,0.0019913896,0.00025943018,0.0005723179,0.00005377382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073827856,0.000161115,0.00081113697,0.00010941204,0.000026971898,0.000004468096,0.00020809713,0.000017526869,0.0000330706],"category_scores_gemma":[0.00031030923,0.00011003236,0.0003365996,0.0002512022,0.0001861261,0.0000101053565,0.000097096636,0.00009802642,1.9893365e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003690106,0.00019475639,0.89493275,0.00022058297,0.0024114193,0.000009995848,0.0003987745,0.011522526,0.070602946,0.000009700048,0.000032215576,0.0159742],"study_design_scores_gemma":[0.002295095,0.00026082454,0.8448739,0.0006276737,0.0007948739,0.000003306685,0.00009702124,0.00003325109,0.15077543,0.000010957894,0.00015166281,0.00007598765],"about_ca_topic_score_codex":0.00040196872,"about_ca_topic_score_gemma":0.0001731737,"teacher_disagreement_score":0.080172494,"about_ca_system_score_codex":0.000023824661,"about_ca_system_score_gemma":0.00026843578,"threshold_uncertainty_score":0.44869894},"labels":[],"label_agreement":null},{"id":"W3156859909","doi":"10.1016/j.ejca.2021.03.013","title":"The European Union and personalised cancer medicine","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"European union; Limiting; Cancer; Precision medicine; Personalized medicine; Medicine; Risk analysis (engineering); Political science; Bioinformatics; Business; Pathology; Biology; Economic policy; Internal medicine; Engineering","score_opus":0.011315964440657451,"score_gpt":0.2617101666602155,"score_spread":0.25039420221955805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156859909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6575788,0.27797273,0.0010339882,0.023839716,0.0021977567,0.00008190981,0.00004055272,0.0000052278233,0.03724926],"genre_scores_gemma":[0.91895294,0.0745466,0.00008669373,0.0012037907,0.003134749,8.2241473e-7,0.000005176616,0.000035334288,0.0020339012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988507,0.00050248177,0.00024723573,0.00012912745,0.00013831459,0.00013215559],"domain_scores_gemma":[0.999194,0.000031729847,0.00019938088,0.00015146987,0.00031698213,0.00010641833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010641398,0.000095744705,0.000108912514,0.000016431224,0.00011683874,0.000039667262,0.0001573898,0.00001236638,0.000049565748],"category_scores_gemma":[0.00016937293,0.00006422564,0.000056877743,0.00005689363,0.00012548613,0.000003071367,0.000092464084,0.000114077935,0.0000017207811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013023078,0.000029063438,0.0056635253,0.00002290906,0.0002983691,0.0003415799,0.00056730304,0.00029750474,0.35776103,0.0001550613,0.1244295,0.5103039],"study_design_scores_gemma":[0.0010199626,0.00017169633,0.032369927,0.00008897685,0.000059553877,0.000085741856,0.00023730194,0.0000059195504,0.007791358,0.000019321202,0.95804834,0.0001019101],"about_ca_topic_score_codex":0.000021305943,"about_ca_topic_score_gemma":0.00014068771,"teacher_disagreement_score":0.8336188,"about_ca_system_score_codex":0.000019175193,"about_ca_system_score_gemma":0.00013818257,"threshold_uncertainty_score":0.26190457},"labels":[],"label_agreement":null},{"id":"W3157427665","doi":"10.1016/j.ejca.2021.03.044","title":"Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Toronto; Health Sciences Centre; Queen's University; Sunnybrook Health Science Centre","funders":"Canadian Cancer Society; Canadian Centre for Applied Research in Cancer Control","keywords":"Medicine; Clinical trial; Cancer; Cancer drugs; Surrogate endpoint; Internal medicine; Intensive care medicine; Oncology","score_opus":0.06016700009938333,"score_gpt":0.35882097839758315,"score_spread":0.29865397829819984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157427665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8530906,0.04832863,0.0029214818,0.014022048,0.0026282954,0.00035571767,0.0003195545,0.000012537452,0.07832116],"genre_scores_gemma":[0.975616,0.011051729,0.0009858721,0.005048417,0.004981931,0.00000552299,0.00000790322,0.0001555646,0.0021471004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99547553,0.00062456477,0.0028594944,0.00037629032,0.0002422626,0.00042184713],"domain_scores_gemma":[0.9943882,0.0006665008,0.0036960272,0.0005073189,0.00055118575,0.00019074875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013675162,0.00027322175,0.0010064024,0.00005556134,0.0002871697,0.0001073175,0.0012027767,0.00008040177,0.00073648756],"category_scores_gemma":[0.00072267296,0.00016844572,0.0009317398,0.00025451122,0.00071423006,0.00033091608,0.00027528687,0.0007285985,0.0000135886985],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024224033,0.0005043447,0.051592957,0.00018909803,0.002030641,0.000052138726,0.007824784,0.0018066579,0.0017346103,0.0017173251,0.089508645,0.84279656],"study_design_scores_gemma":[0.005521716,0.00042671897,0.35482377,0.0007029234,0.0005604022,0.000059464513,0.001291434,0.0033707323,0.0005020802,0.001446816,0.6307288,0.0005651489],"about_ca_topic_score_codex":0.00019927268,"about_ca_topic_score_gemma":0.00009714197,"teacher_disagreement_score":0.8422314,"about_ca_system_score_codex":0.00015588464,"about_ca_system_score_gemma":0.00047407852,"threshold_uncertainty_score":0.80640227},"labels":[],"label_agreement":null},{"id":"W3161195108","doi":"10.1016/j.ejca.2021.04.004","title":"Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Genentech; Eisai; U.S. Department of Defense; Exelixis; Congressionally Directed Medical Research Programs; Gateway for Cancer Research; Astellas Pharma; Ariad Pharmaceuticals; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer","keywords":"Medicine; Oncology; Internal medicine; Clinical trial; Clinical Oncology; Intensive care medicine; Cancer","score_opus":0.14483004459395793,"score_gpt":0.45094211694231795,"score_spread":0.30611207234836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161195108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952988,0.0016200066,0.00016555762,0.0012585338,0.00034138883,0.00061644695,0.00016258565,0.0000091042375,0.00052756636],"genre_scores_gemma":[0.996125,0.0007816525,0.0017485984,0.00042978636,0.00032337476,0.000010340621,0.00002434996,0.00006087496,0.00049602427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995365,0.0014092781,0.0020950323,0.00031541457,0.0005365927,0.0002786614],"domain_scores_gemma":[0.99473685,0.0007752191,0.0018091135,0.00037820474,0.0020568096,0.00024378038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031998602,0.00028666604,0.0019970096,0.00010038786,0.00006887169,0.000033113643,0.00016277914,0.00005115953,0.00025777024],"category_scores_gemma":[0.0014856666,0.00015858942,0.0004940813,0.00014901267,0.00018731206,0.00009738534,0.000052394964,0.00018018918,0.0000023947357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029610569,0.0016487497,0.9476057,0.0002471215,0.0027543164,0.0014268671,0.00058579684,0.00006837221,0.0025363094,0.0000040499513,0.005541596,0.00797052],"study_design_scores_gemma":[0.024072113,0.010063345,0.9348272,0.00072696374,0.0017293947,0.0000737355,0.000101157646,0.0000067146448,0.0210089,0.000005045156,0.0072256895,0.00015973952],"about_ca_topic_score_codex":0.000012702765,"about_ca_topic_score_gemma":0.00005092154,"teacher_disagreement_score":0.018472591,"about_ca_system_score_codex":0.00023001434,"about_ca_system_score_gemma":0.00071889674,"threshold_uncertainty_score":0.64670885},"labels":[],"label_agreement":null},{"id":"W3161474882","doi":"10.1016/j.ejca.2021.04.006","title":"Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Canada Research Chairs; Kingston General Hospital; Institute for Clinical Evaluative Sciences; Children's Hospital of Eastern Ontario; London Health Sciences Centre; McMaster Children's Hospital; Hospital for Sick Children; University of New Brunswick; SickKids Foundation; University of Toronto","funders":"C17 Children's Cancer and Blood Disorders","keywords":"Medicine; Cog; Confidence interval; Internal medicine; Chemotherapy; Pediatrics; Population; Environmental health","score_opus":0.0194081694370935,"score_gpt":0.3052791409037299,"score_spread":0.28587097146663637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161474882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917111,0.00024416207,0.00010839932,0.0009792603,0.00006855105,0.006788595,0.000050945455,0.000007099909,0.000041933195],"genre_scores_gemma":[0.9984917,0.000011239568,0.00013438002,0.00039484192,0.00008457876,0.0006356616,0.00007870385,0.000044776,0.00012410499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788034,0.00039603302,0.0005593729,0.00024480035,0.00061469164,0.0003047893],"domain_scores_gemma":[0.99838257,0.00027819382,0.00040313287,0.00016266096,0.0004913008,0.00028213995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024072577,0.0002109506,0.0005726511,0.000113174356,0.00009593277,0.000041095667,0.00007340268,0.00002361503,0.00003482172],"category_scores_gemma":[0.00022106287,0.00014657556,0.00005736885,0.00016928885,0.000016580389,0.0000555521,0.000018550572,0.00020920082,1.26611e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015821799,0.00075472286,0.9748373,0.0000483885,0.000515174,0.001913413,0.0031341647,0.0006454583,0.000020489431,8.7155934e-7,0.00038590567,0.016161911],"study_design_scores_gemma":[0.037539925,0.0049317116,0.9545548,0.0011992222,0.00022293595,0.000046893634,0.0008711459,0.00018341742,0.00008660241,4.2827156e-7,0.00024510737,0.000117829324],"about_ca_topic_score_codex":0.44768423,"about_ca_topic_score_gemma":0.98466843,"teacher_disagreement_score":0.5369842,"about_ca_system_score_codex":0.023382293,"about_ca_system_score_gemma":0.019153738,"threshold_uncertainty_score":0.98640674},"labels":[],"label_agreement":null},{"id":"W3164115667","doi":"10.1016/j.ejca.2021.03.029","title":"Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Samsung; Genentech; Merck Sharp and Dohme; Eisai; MacroGenics; Puma Biotechnology; PharmaMar; Celgene; Jounce Therapeutics; Mylan; Genomic Health; Ipsen; Syndax Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Olaparib; Metastatic breast cancer; Internal medicine; Oncology; Taxane; Nausea; BRCA mutation; Breast cancer; Interim analysis; Adverse effect; Cancer; Clinical trial","score_opus":0.04795153637465649,"score_gpt":0.4481784648935772,"score_spread":0.4002269285189207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164115667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917503,0.0033249112,0.0012719978,0.0017259632,0.0004532901,0.00031769075,0.00020775737,0.000013858442,0.0009342258],"genre_scores_gemma":[0.99195373,0.0057728887,0.00097434863,0.00060008274,0.0003757493,0.000021406577,0.000012403577,0.00007255344,0.00021682598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931108,0.003470603,0.0021403597,0.00041591938,0.0005287408,0.00033358243],"domain_scores_gemma":[0.99651283,0.00065160776,0.0013336559,0.00034240718,0.0009262664,0.00023323216],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004023026,0.00030055217,0.0016057325,0.0009170924,0.000028068225,0.000025853546,0.00021290928,0.000040302195,0.001396962],"category_scores_gemma":[0.00017801505,0.0002597752,0.00058234495,0.0024921063,0.00020638025,0.00019905026,0.000043040734,0.000829339,0.0000037196867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03754733,0.0046195826,0.6848266,0.0006708327,0.010481573,0.0077842954,0.004237555,0.014681321,0.059795484,0.000039725124,0.00058353157,0.17473213],"study_design_scores_gemma":[0.04376302,0.00087940687,0.91732603,0.005002081,0.00138629,0.00018703706,0.0003808671,0.0009904376,0.028487409,0.00008724018,0.0011624108,0.0003477751],"about_ca_topic_score_codex":0.00077003584,"about_ca_topic_score_gemma":0.002100003,"teacher_disagreement_score":0.23249939,"about_ca_system_score_codex":0.0006927628,"about_ca_system_score_gemma":0.0009158318,"threshold_uncertainty_score":0.99998546},"labels":[],"label_agreement":null},{"id":"W3170601740","doi":"10.1016/j.ejca.2021.04.041","title":"Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Institute of Dental and Craniofacial Research; National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute; Cancer Research UK","keywords":"Medical physics; Clinical trial; Quality assurance; Medicine; Imaging biomarker; Magnetic resonance imaging; Computer science; Radiology; Pathology","score_opus":0.2061265245229712,"score_gpt":0.48300888817508164,"score_spread":0.27688236365211044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170601740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49758732,0.21878485,0.24568991,0.032282006,0.0041968925,0.0012099206,0.00005941598,0.000021682547,0.00016797708],"genre_scores_gemma":[0.91486716,0.005931352,0.07472271,0.002924237,0.0013824707,0.000017135368,0.000018930508,0.00007393548,0.00006207828],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99448335,0.0023274736,0.0023369829,0.0002906661,0.0003028451,0.0002587013],"domain_scores_gemma":[0.99024254,0.006748842,0.0018254241,0.0001929344,0.00088112836,0.00010912987],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013423582,0.0001996153,0.0010368988,0.00010980383,0.00009480619,0.00004689817,0.00019917467,0.000024811035,0.000031195366],"category_scores_gemma":[0.021727286,0.00013011592,0.0005214776,0.00021026522,0.0004989287,0.00012500458,0.00003904135,0.00041240657,3.3906332e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005159617,0.00022281402,0.18030246,0.00013948018,0.0033014852,0.00029303227,0.008669386,0.00021570064,0.14634153,0.00035478733,0.026799224,0.6282005],"study_design_scores_gemma":[0.09138334,0.00093461754,0.25623634,0.025007715,0.0039129895,0.0002393481,0.0829813,0.31539142,0.009748674,0.000601146,0.21246572,0.0010973831],"about_ca_topic_score_codex":0.00003607115,"about_ca_topic_score_gemma":0.000026650312,"teacher_disagreement_score":0.6271031,"about_ca_system_score_codex":0.00014346204,"about_ca_system_score_gemma":0.00025026067,"threshold_uncertainty_score":0.98651314},"labels":[],"label_agreement":null},{"id":"W3170973356","doi":"10.1016/j.ejca.2021.05.004","title":"Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council","keywords":"Medicine; Gastroenterology; Internal medicine; Helicobacter pylori; Lymphoma; Stomach; Stage (stratigraphy); Pathology","score_opus":0.022011406955105117,"score_gpt":0.30919923522421594,"score_spread":0.2871878282691108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170973356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302936,0.0049735224,0.0000808182,0.0002704756,0.00015653069,0.0008825671,0.000027185784,0.0000039608944,0.0005755566],"genre_scores_gemma":[0.9971598,0.0022233867,0.00024842127,0.000047482827,0.00021252576,0.000031366868,0.000011879812,0.000025170608,0.00003999254],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99780625,0.00050144905,0.0006126372,0.00018665876,0.0007185092,0.0001744674],"domain_scores_gemma":[0.9977031,0.00005549452,0.0007387739,0.00017343494,0.0012220797,0.000107124484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010560952,0.00017451135,0.0005261169,0.00019417684,0.000047641937,0.000017463653,0.000053492906,0.000026916112,0.000100421734],"category_scores_gemma":[0.00010193239,0.00012321555,0.00009884255,0.0003952082,0.000095972544,0.00018221003,0.00002203919,0.000121150275,5.195096e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09399038,0.0076174233,0.17017798,0.00005171978,0.0012810567,0.00031378272,0.0056633065,0.0001843694,0.0061813225,0.000020034648,0.0000968024,0.7144218],"study_design_scores_gemma":[0.26384625,0.014464219,0.69658,0.0003504716,0.00045147334,0.000074325195,0.00027735782,0.00015898958,0.0234498,0.000011884422,0.0002520349,0.00008318864],"about_ca_topic_score_codex":0.00010417949,"about_ca_topic_score_gemma":0.000032539552,"teacher_disagreement_score":0.71433866,"about_ca_system_score_codex":0.0007662433,"about_ca_system_score_gemma":0.0012411969,"threshold_uncertainty_score":0.5024584},"labels":[],"label_agreement":null},{"id":"W3172271613","doi":"10.1016/j.ejca.2021.05.003","title":"Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Prostate Cancer Fight Foundation; Prostate Cancer Foundation","keywords":"Enzalutamide; Medicine; Tolerability; Prostate cancer; Hazard ratio; Discontinuation; Internal medicine; Retrospective cohort study; Cohort; Propensity score matching; Abiraterone acetate; Oncology; Confidence interval; Urology; Population; Cancer; Androgen deprivation therapy; Adverse effect; Androgen receptor","score_opus":0.051821641529548455,"score_gpt":0.32560697302654446,"score_spread":0.273785331496996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172271613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962376,0.0014681882,0.000018262306,0.0000324445,0.00019394692,0.0016364768,0.00012372882,0.000007068583,0.0002823211],"genre_scores_gemma":[0.9991058,0.00044266004,0.00012846652,0.0000042876623,0.00004977145,0.00003627118,0.000026323029,0.000038293805,0.00016808927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969589,0.00087820424,0.00067321357,0.00030119647,0.00094532483,0.00024315319],"domain_scores_gemma":[0.99618566,0.0001268005,0.0007905166,0.00024116425,0.002492988,0.00016285693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088327547,0.00022404002,0.0009806658,0.00014790393,0.000070708076,0.000025769463,0.0001197647,0.00001651274,0.00006440979],"category_scores_gemma":[0.000076413664,0.00015576449,0.000111777095,0.00052169716,0.00029620543,0.00018210089,0.00005579928,0.0003239841,0.0000011353741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030268399,0.001336339,0.9494327,0.00040071362,0.0030400995,0.0027418009,0.0028869172,0.0003417947,0.008668426,0.0000019355987,0.000029695266,0.0008512098],"study_design_scores_gemma":[0.019609949,0.008184715,0.92288035,0.0016969395,0.0009250205,0.000008472186,0.00039325785,0.000013197916,0.046133313,0.0000032228127,0.000019519652,0.00013202542],"about_ca_topic_score_codex":0.00041653067,"about_ca_topic_score_gemma":0.001050637,"teacher_disagreement_score":0.037464887,"about_ca_system_score_codex":0.0005128931,"about_ca_system_score_gemma":0.0006069377,"threshold_uncertainty_score":0.6351891},"labels":[],"label_agreement":null},{"id":"W3174706170","doi":"10.1016/j.ejca.2021.05.025","title":"Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; BC Cancer Agency; Jewish General Hospital","funders":"Daiichi Sankyo Europe; EMD Serono; Genentech; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; MacroGenics; Silverback Therapeutics; Pfizer; NuCana; Regeneron Pharmaceuticals; Mylan; Unum Therapeutics; Helsinn Therapeutics; Amgen; Radius Health; Syndax Pharmaceuticals; Clovis Oncology; Teva Pharmaceutical Industries; Helsinn; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Eli Lilly and Company; AstraZeneca; Foundation Medicine; National Cancer Research Institute; Genomic Health; Mersana Therapeutics; Karyopharm Therapeutics; Puma Biotechnology","keywords":"Capecitabine; Trastuzumab; Metastatic breast cancer; Oncology; Medicine; Human Epidermal Growth Factor Receptor 2; Internal medicine; Placebo; Breast cancer; Cancer; Pathology; Colorectal cancer","score_opus":0.05052952878100639,"score_gpt":0.3440817760243052,"score_spread":0.29355224724329876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174706170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996543,0.00047365468,0.00001979051,0.0015275639,0.00007993148,0.0007173167,0.000417714,0.0000044005214,0.00021664081],"genre_scores_gemma":[0.9983582,0.000121589386,0.0005315975,0.00028372102,0.00015408768,0.00002342598,0.000036274887,0.00003651832,0.00045460268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976304,0.0007208457,0.00086670363,0.00020753984,0.00039330812,0.00018116191],"domain_scores_gemma":[0.99758905,0.00016994785,0.0008597151,0.0001167445,0.0010482911,0.0002162396],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034737485,0.00019867248,0.0008205675,0.00015405353,0.00003090976,0.000009766959,0.00007758368,0.000020236559,0.0016386003],"category_scores_gemma":[0.0001135049,0.00012568987,0.00006501523,0.0003040228,0.00008082326,0.00018018072,0.000022844873,0.00018315249,4.9334596e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3272972,0.001961232,0.64927894,0.00031246681,0.0017472439,0.00007785146,0.0050580897,0.00005379111,0.0065189893,0.0000054563075,0.0012021839,0.006486518],"study_design_scores_gemma":[0.10077379,0.0063705742,0.8866827,0.00058325846,0.00049336656,0.000009834362,0.0002674148,0.0000018601386,0.004569008,0.0000012967083,0.000117209114,0.00012968162],"about_ca_topic_score_codex":0.00077511143,"about_ca_topic_score_gemma":0.0013014798,"teacher_disagreement_score":0.23740375,"about_ca_system_score_codex":0.00021863029,"about_ca_system_score_gemma":0.0006155957,"threshold_uncertainty_score":0.999274},"labels":[],"label_agreement":null},{"id":"W3181497580","doi":"10.1016/j.ejca.2021.05.013","title":"Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; McMaster Children's Hospital; Pediatric Oncology Group","funders":"Canada Research Chairs; National Institute for Health and Care Research; Pediatric Oncology Group of Ontario","keywords":"Mucositis; Medicine; Cryotherapy; Adverse effect; Guideline; Randomized controlled trial; Pediatric cancer; Cancer; Surgery; Radiation therapy; Intensive care medicine; Internal medicine; Pathology","score_opus":0.07387556107058897,"score_gpt":0.4443201350289781,"score_spread":0.37044457395838915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181497580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009139738,0.9952473,0.00011400268,0.0014699599,0.00093417044,0.0010779399,0.0001709986,0.0000019688675,0.00006970018],"genre_scores_gemma":[0.0005943858,0.9958138,0.0020862843,0.00038157045,0.0008246596,0.000038675105,0.000026256637,0.00006790075,0.0001664961],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955658,0.00086541875,0.0026242167,0.00030866484,0.00038771465,0.00024821717],"domain_scores_gemma":[0.9961436,0.0005387391,0.0022837182,0.00020928729,0.00061017176,0.00021451367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023077305,0.000292454,0.0017544561,0.00012924708,0.0000450317,0.000019306319,0.00013082348,0.000082217215,0.000084985724],"category_scores_gemma":[0.000070726805,0.00018124365,0.0003512337,0.00023117638,0.00006196002,0.00011643158,0.000047796755,0.0005786772,0.000001254036],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033265376,0.00028762207,0.0014174117,0.012288465,0.00028209353,0.00021262815,0.00016430672,0.000003331793,5.23513e-8,0.0000020625441,0.003676713,0.98133266],"study_design_scores_gemma":[0.0043188003,0.0013155581,0.0008494384,0.01521748,0.008162709,0.00017759984,0.000053477495,0.0000073812794,0.0000013935284,0.0000010683136,0.9697456,0.00014950304],"about_ca_topic_score_codex":0.00007237048,"about_ca_topic_score_gemma":0.00007698892,"teacher_disagreement_score":0.9811832,"about_ca_system_score_codex":0.0002476935,"about_ca_system_score_gemma":0.0013001177,"threshold_uncertainty_score":0.7390902},"labels":[],"label_agreement":null},{"id":"W3182206294","doi":"10.1016/j.ejca.2021.05.037","title":"Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Veliparib; Medicine; Carboplatin; Internal medicine; Hazard ratio; Oncology; Metastatic breast cancer; Breast cancer; Placebo; Population; Clinical endpoint; Surgery; Cancer; Confidence interval; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.022183947749891336,"score_gpt":0.3362273108954843,"score_spread":0.31404336314559295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182206294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928461,0.005057759,0.00015336758,0.00088414794,0.00024289463,0.00044181096,0.00022711475,0.0000046915948,0.0001421519],"genre_scores_gemma":[0.992937,0.0059945453,0.0004681101,0.00016921967,0.0003312846,0.0000058566643,0.000016964987,0.00003415325,0.00004282496],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966777,0.0005306564,0.0018160105,0.00028385926,0.0005033161,0.00018845756],"domain_scores_gemma":[0.99694043,0.00037863015,0.0013934646,0.00025341837,0.00081860495,0.00021545216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013220792,0.0002019923,0.0014058086,0.00027395785,0.000032445907,0.000010139267,0.00008700345,0.000047351612,0.00022539862],"category_scores_gemma":[0.00023872622,0.00015399134,0.00023792921,0.0006885811,0.00022699514,0.00010562867,0.000037113183,0.00036330995,1.4429557e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48877147,0.0007398471,0.45364606,0.000115312585,0.0022875115,0.00008359173,0.000451262,0.0016786484,0.00040871213,0.0000027346732,0.000053404343,0.051761463],"study_design_scores_gemma":[0.35785234,0.0013448759,0.6376666,0.0007536245,0.0013822328,0.000012448583,0.00003487204,0.000111631576,0.00019302989,0.0000015330274,0.00054082647,0.000105998035],"about_ca_topic_score_codex":0.000054015123,"about_ca_topic_score_gemma":0.0002434249,"teacher_disagreement_score":0.18402053,"about_ca_system_score_codex":0.000102586826,"about_ca_system_score_gemma":0.0002947613,"threshold_uncertainty_score":0.6279584},"labels":[],"label_agreement":null},{"id":"W3184815468","doi":"10.1016/j.ejca.2021.06.024","title":"Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Olaparib; Medicine; Oncology; Nomogram; Ovarian cancer; Internal medicine; Chemotherapy; Progression-free survival; Complete response; BRCA mutation; Cancer; Poly ADP ribose polymerase; Biology; Gene","score_opus":0.020710705882438084,"score_gpt":0.3215840565726184,"score_spread":0.30087335069018034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184815468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861818,0.0011754491,0.0011929204,0.009311519,0.000694873,0.0010903736,0.00008560317,0.000017452081,0.00025003875],"genre_scores_gemma":[0.9919488,0.0003143224,0.004937422,0.0020944553,0.00035727693,0.00009984364,0.000011541461,0.000086580156,0.00014979845],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978243,0.0004376908,0.0005270367,0.000322808,0.00057206914,0.00031606128],"domain_scores_gemma":[0.9980014,0.0003257197,0.00036342192,0.0002430526,0.00084464153,0.00022179332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009497788,0.00023332187,0.00043682646,0.00019444713,0.00009976423,0.00005162229,0.00011535439,0.000032775508,0.00005064182],"category_scores_gemma":[0.00043429135,0.00017425224,0.00012188988,0.00040224026,0.000065926164,0.00011272322,0.000021669919,0.00031954123,0.0000012654787],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12408679,0.0013641312,0.2850636,0.00008213854,0.00095578743,0.00090967503,0.008200036,0.00071595126,0.006126827,0.00005019723,0.00234666,0.5700982],"study_design_scores_gemma":[0.03823312,0.0052309907,0.9315194,0.0043060733,0.00007942534,0.000028458247,0.00031295928,0.00005210659,0.0036792564,0.00004102009,0.016214708,0.000302473],"about_ca_topic_score_codex":0.000006294884,"about_ca_topic_score_gemma":0.000052467247,"teacher_disagreement_score":0.6464558,"about_ca_system_score_codex":0.00032742327,"about_ca_system_score_gemma":0.00047746542,"threshold_uncertainty_score":0.71058},"labels":[],"label_agreement":null},{"id":"W3186276439","doi":"10.1016/j.ejca.2021.06.009","title":"Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Kom op tegen Kanker; KWF Kankerbestrijding; Fonds Wetenschappelijk Onderzoek; European Commission","keywords":"Medicine; Breastfeeding; Breast cancer; Metastasis; Hazard ratio; Lactation; Obstetrics; Proportional hazards model; Weaning; Internal medicine; Breast feeding; Gynecology; Cancer; Mammary gland; Involution (esoterism); Pregnancy; Oncology; Postpartum period; Pediatrics; Confidence interval; Biology","score_opus":0.03171030240588214,"score_gpt":0.3409036699697863,"score_spread":0.3091933675639042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186276439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94977504,0.0072643883,0.00007781548,0.040982813,0.0004526559,0.000235768,0.00017690234,0.0000070266587,0.0010275905],"genre_scores_gemma":[0.98725504,0.0010865334,0.00013860824,0.009942361,0.0009653365,0.000013885359,0.0000030280858,0.00003737307,0.0005578316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986583,0.0001591648,0.00048305074,0.00015267407,0.00032883175,0.00021798484],"domain_scores_gemma":[0.99873257,0.00008542128,0.00046252256,0.00015221935,0.00045659358,0.00011067783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005857091,0.00013517565,0.00033196728,0.00009809184,0.00006671295,0.000045385743,0.0001765543,0.000020727231,0.0008138476],"category_scores_gemma":[0.00012360331,0.00008465335,0.00022648572,0.0002317557,0.00005299404,0.00009217602,0.000026205418,0.0003846876,0.0000056064187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010422774,0.00019899032,0.79592377,0.00010052797,0.00033268318,0.0018191296,0.027043847,0.00003292234,0.0026824398,0.000026546397,0.01336613,0.15743074],"study_design_scores_gemma":[0.0032476222,0.00021508538,0.9160157,0.00038045226,0.00017341287,0.00060251873,0.0033582659,0.000010527159,0.00022326528,0.0000048041893,0.07565593,0.000112424634],"about_ca_topic_score_codex":0.00017158018,"about_ca_topic_score_gemma":0.0003032006,"teacher_disagreement_score":0.15731831,"about_ca_system_score_codex":0.00019435071,"about_ca_system_score_gemma":0.00047016333,"threshold_uncertainty_score":0.891106},"labels":[],"label_agreement":null},{"id":"W3187855084","doi":"10.1016/j.ejca.2021.07.001","title":"Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"Economic and Social Research Council; National Institute for Health and Care Research; UK Research and Innovation","keywords":"Medicine; Reimbursement; Clinical trial; Food and drug administration; Cancer drugs; Family medicine; Cancer; Internal medicine; Intensive care medicine; Oncology; Pharmacology; Health care","score_opus":0.18552405241209738,"score_gpt":0.4727837509154125,"score_spread":0.2872596985033151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187855084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692716,0.0021588122,0.0021959,0.016546762,0.0009299123,0.00082376203,0.00008390895,0.00004186574,0.007947485],"genre_scores_gemma":[0.9862943,0.0012249582,0.0073147276,0.00072447606,0.0009494693,0.00000852235,0.0000012209529,0.000084537496,0.003397756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945132,0.0031656015,0.0010528711,0.0003162411,0.0007547605,0.00019731368],"domain_scores_gemma":[0.9920759,0.0057298867,0.0011378069,0.00025534673,0.00057163055,0.00022942015],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006967609,0.00024104046,0.000837527,0.000049759667,0.00012632704,0.000080129656,0.00020531348,0.000018549112,0.00013954274],"category_scores_gemma":[0.021476133,0.00013066141,0.00006546507,0.00028543727,0.00023406104,0.00008140274,0.000078714664,0.000470608,5.0157104e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034019226,0.0003187316,0.91716987,0.000048595528,0.0022328827,0.00039566748,0.003916524,0.0000012590322,0.0002310173,0.00053735333,0.0533984,0.021409525],"study_design_scores_gemma":[0.003645629,0.0010728876,0.98379725,0.00047739793,0.0013173809,0.000021522732,0.00073576276,0.000006139316,0.00017892977,0.007861025,0.00069481705,0.0001912742],"about_ca_topic_score_codex":0.00006454841,"about_ca_topic_score_gemma":0.001883851,"teacher_disagreement_score":0.06662738,"about_ca_system_score_codex":0.00009101642,"about_ca_system_score_gemma":0.00024341235,"threshold_uncertainty_score":0.9867664},"labels":[],"label_agreement":null},{"id":"W3189971813","doi":"10.1016/j.ejca.2021.05.040","title":"Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Pharmacyclics; Chugai Pharmaceutical; Genentech; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Cancer Research UK; Seagen; Cilag; Puma Biotechnology; Arog Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Ipsen; Array BioPharma; Mersana Therapeutics; Exelixis; Karyopharm Therapeutics; Symphogen; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Amgen; Deciphera Pharmaceuticals; Takeda Oncology; Halozyme; Sanofi; GlaxoSmithKline; Celgene; Daiichi Sankyo Europe; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Clinical endpoint; Oncology; Internal medicine; Confidence interval; Clinical trial; Surrogate endpoint","score_opus":0.10619197210280618,"score_gpt":0.4763975619444084,"score_spread":0.37020558984160223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189971813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608583,0.002976145,0.0021139223,0.0051001552,0.0025214574,0.00082774594,0.00015170082,0.000015879123,0.00020713553],"genre_scores_gemma":[0.9810453,0.0012377208,0.0056906,0.005740191,0.0052317306,0.000031534943,0.000020012394,0.00006768255,0.00093519344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964481,0.0010228608,0.0017854816,0.00023233848,0.0002728286,0.0002383638],"domain_scores_gemma":[0.9973264,0.00042191258,0.00091871095,0.00014387298,0.0009429084,0.00024624408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038595165,0.00015407614,0.0007510419,0.00011571293,0.00005624579,0.000034997778,0.00008895859,0.00005192171,0.00034099],"category_scores_gemma":[0.0027580685,0.0001155409,0.00054508337,0.00024266954,0.000043466705,0.00007781513,0.000022581047,0.0003420887,0.0000068453232],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032051675,0.0026362017,0.00038108794,0.000029683128,0.0005836455,0.00026143022,0.00024658648,0.0000034869095,0.18020204,0.0000014941439,0.013803045,0.76979965],"study_design_scores_gemma":[0.06840702,0.051883712,0.0021625424,0.00040049542,0.0008105639,0.00029636078,0.00013814624,0.0001617992,0.017162465,0.0000046403065,0.8583926,0.00017963441],"about_ca_topic_score_codex":0.000006005892,"about_ca_topic_score_gemma":0.000026489717,"teacher_disagreement_score":0.8445896,"about_ca_system_score_codex":0.00023990647,"about_ca_system_score_gemma":0.0015171941,"threshold_uncertainty_score":0.4711621},"labels":[],"label_agreement":null},{"id":"W3192310119","doi":"10.1016/j.ejca.2021.06.050","title":"Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; American Lebanese Syrian Associated Charities; National Center for Advancing Translational Sciences; St. Jude Children's Research Hospital; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Relative risk; Nephrectomy; Interquartile range; Cumulative incidence; Kidney disease; Dialysis; Confidence interval; Internal medicine; Incidence (geometry); Cancer; Kidney transplantation; Hazard ratio; Context (archaeology); Surgery; Kidney; Transplantation","score_opus":0.012950081809439172,"score_gpt":0.27631949751203094,"score_spread":0.26336941570259176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192310119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769824,0.0048306347,0.000012881628,0.016353197,0.0008255032,0.00042483138,0.00018307586,0.000018496647,0.0003689485],"genre_scores_gemma":[0.9943483,0.0017479577,0.0001450761,0.001890299,0.0013239267,0.000009628055,0.000021524536,0.00010498156,0.00040832086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637544,0.00080709177,0.0012737514,0.0003759482,0.00085997523,0.000307812],"domain_scores_gemma":[0.9972028,0.00013821416,0.0011448527,0.0005767519,0.0006610758,0.0002763184],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013705762,0.00029217225,0.0007548028,0.0001389855,0.000075686294,0.000042103602,0.00033767766,0.000058861155,0.0012594699],"category_scores_gemma":[0.00064097595,0.00021555979,0.00023706745,0.0007336181,0.00008520036,0.00015871882,0.00008196935,0.00088064384,0.00000561962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022428739,0.0010008737,0.93754596,0.00003341587,0.001028591,0.0021212567,0.016154995,0.00019897943,0.021834949,5.553175e-7,0.007172253,0.012683861],"study_design_scores_gemma":[0.0049550193,0.00020622871,0.9424105,0.001248665,0.00033816998,0.00025223158,0.0020529404,0.000005657927,0.04172475,0.000014018311,0.006584404,0.00020737496],"about_ca_topic_score_codex":0.005393476,"about_ca_topic_score_gemma":0.023580331,"teacher_disagreement_score":0.0198898,"about_ca_system_score_codex":0.0002881461,"about_ca_system_score_gemma":0.0020365415,"threshold_uncertainty_score":0.9996535},"labels":[],"label_agreement":null},{"id":"W3194046747","doi":"10.1016/j.ejca.2021.06.021","title":"Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"University of Leeds; University of Minnesota; Vanderbilt University","keywords":"Guideline; Medicine; Childhood cancer; Harmonization; Cancer; Disease; Pediatrics; Gerontology; Internal medicine; Pathology","score_opus":0.012802223724285355,"score_gpt":0.2845759712367446,"score_spread":0.27177374751245925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194046747","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031236464,0.9914564,0.00015437948,0.002287218,0.00094209396,0.0015983352,0.00040855588,0.000011598281,0.000017770159],"genre_scores_gemma":[0.008098048,0.9884903,0.00006015255,0.0019112513,0.00092731445,0.00008035481,0.00028091605,0.00008018986,0.00007146696],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99642104,0.0010777534,0.0015417073,0.0003271351,0.00047468164,0.0001576861],"domain_scores_gemma":[0.9965505,0.00020936634,0.0019911088,0.00031157208,0.0007371087,0.0002003254],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089141703,0.00036986434,0.0018711025,0.00009568141,0.000081993174,0.000061752864,0.00023148794,0.000059322185,0.00008573366],"category_scores_gemma":[0.00048128943,0.00024796958,0.00040517907,0.00023549574,0.000081317216,0.00015754582,0.00008307359,0.0005242721,7.3552735e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058798294,0.00033414594,0.008752631,0.37231818,0.0070733684,0.00025575288,0.0010016878,0.00001143697,0.00007007805,0.0000082544475,0.007838057,0.60227764],"study_design_scores_gemma":[0.001574272,0.00006462956,0.051292818,0.9118999,0.010030599,0.000212986,0.0000476146,0.0000174897,0.000018850344,0.0000027863098,0.024500826,0.0003371774],"about_ca_topic_score_codex":0.00020219028,"about_ca_topic_score_gemma":0.00036605817,"teacher_disagreement_score":0.60194045,"about_ca_system_score_codex":0.00022346019,"about_ca_system_score_gemma":0.00038008578,"threshold_uncertainty_score":0.99999726},"labels":[],"label_agreement":null},{"id":"W3194121438","doi":"10.1016/j.ejca.2021.07.010","title":"Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; U.S. Food and Drug Administration; Deciphera Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"GiST; Dosing; Adverse effect; Medicine; Internal medicine; Oncology; Stromal cell","score_opus":0.020634625787434795,"score_gpt":0.3470929225564217,"score_spread":0.3264582967689869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194121438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518687,0.0007523027,0.00029615598,0.0028962619,0.000108357955,0.00029668288,0.000011702759,0.00001647447,0.0004351836],"genre_scores_gemma":[0.98011065,0.000047701542,0.01922266,0.00013635308,0.00019460358,0.000016318629,0.000007970279,0.000036766294,0.00022700048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731034,0.00044342256,0.0009028895,0.0002629894,0.00071432715,0.00036603623],"domain_scores_gemma":[0.9980309,0.00010500202,0.00043000455,0.0001853647,0.0006494794,0.0005992303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006310633,0.00020428289,0.0003908576,0.00013742923,0.0000356852,0.000044635566,0.0001068206,0.000008535079,0.0002095224],"category_scores_gemma":[0.0017049592,0.00014398483,0.00021990956,0.00016289503,0.00008142996,0.00016748768,0.0000771737,0.00051267626,0.000014940779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007450994,0.0009146171,0.9212484,0.00007774442,0.000040787734,0.02461568,0.0001139285,0.00011927969,0.0033019849,0.0000038999865,0.00006474447,0.04204795],"study_design_scores_gemma":[0.005070573,0.004064655,0.9853094,0.003615643,0.00008998025,0.0008448793,0.00011306781,0.0001632526,0.00041727297,0.000023006824,0.00018477821,0.00010346239],"about_ca_topic_score_codex":0.000004074913,"about_ca_topic_score_gemma":0.00001682253,"teacher_disagreement_score":0.06406104,"about_ca_system_score_codex":0.00018425588,"about_ca_system_score_gemma":0.0006162547,"threshold_uncertainty_score":0.58715314},"labels":[],"label_agreement":null},{"id":"W3195214939","doi":"10.1016/j.ejca.2021.07.014","title":"Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Pazopanib; Sunitinib; Cabozantinib; Axitinib; Medicine; Internal medicine; Oncology; Progression-free survival; Tyrosine-kinase inhibitor; Cancer; Overall survival","score_opus":0.0666762809095978,"score_gpt":0.38117108280769635,"score_spread":0.31449480189809853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195214939","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050519062,0.99357235,0.00001126862,0.0029067867,0.00002977865,0.0032609922,0.00008150602,0.0000051353913,0.00008166934],"genre_scores_gemma":[0.0001610833,0.995365,0.0014273078,0.0018093016,0.000056582496,0.00065242406,0.000026863801,0.00011169319,0.00038969744],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99232316,0.0038930618,0.0022810118,0.00041598792,0.0008049614,0.00028182773],"domain_scores_gemma":[0.9952336,0.00021819794,0.002777318,0.0006395158,0.0006929634,0.0004383895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022097838,0.0006521755,0.012239626,0.00077655923,0.000022146354,0.000029661647,0.0002894142,0.00006087197,0.0026284188],"category_scores_gemma":[0.00011211152,0.00030416195,0.0022060585,0.0013694118,0.00008464743,0.00006171796,0.00003734323,0.00047343355,0.000010108606],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006114813,0.00042043292,0.000040007042,0.5120222,0.32650554,0.005471214,0.00043193361,0.000013978712,0.000016460392,2.5769225e-7,0.0011275877,0.15333892],"study_design_scores_gemma":[0.0015814153,0.0020988632,0.000019428062,0.21467088,0.60998476,0.00032202416,0.000014768863,8.6987757e-7,0.000024065832,1.4432958e-7,0.17102697,0.0002558332],"about_ca_topic_score_codex":0.000023105298,"about_ca_topic_score_gemma":0.00003685042,"teacher_disagreement_score":0.2973513,"about_ca_system_score_codex":0.0004482907,"about_ca_system_score_gemma":0.0021423122,"threshold_uncertainty_score":0.99994105},"labels":[],"label_agreement":null},{"id":"W3199294338","doi":"10.1016/j.ejca.2021.08.022","title":"Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Medicine; ALK inhibitor; Anaplastic large-cell lymphoma; Clinical trial; Oncology; Lymphoma; Neuroblastoma; Internal medicine; Cancer research; Lung cancer; Biology","score_opus":0.041580548120102416,"score_gpt":0.33837193790057607,"score_spread":0.29679138978047365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199294338","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018301738,0.9958239,0.000039613366,0.000086792235,0.0004919746,0.0007244216,0.00022512466,0.000010607529,0.00076738175],"genre_scores_gemma":[0.0065837307,0.9908528,0.00009660615,0.000085587744,0.0013195579,0.000044559176,0.000068327325,0.00013154176,0.0008173186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99673194,0.0005966262,0.0012137035,0.0003540798,0.00053460547,0.00056903326],"domain_scores_gemma":[0.99774826,0.0003090191,0.0009046101,0.00022852875,0.00041944414,0.00039014276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006053415,0.00043291386,0.0016255031,0.0009717788,0.00006147533,0.000074922085,0.00014073728,0.00008765324,0.0003013481],"category_scores_gemma":[0.0003056327,0.00032341926,0.0008627947,0.0008577421,0.0000480423,0.00015953172,0.000077570054,0.0004712604,0.000035334775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018871427,0.00024639303,0.000045708694,0.0070015443,0.00029312063,0.014706407,0.00001699084,0.000008642241,0.000008139381,0.000009392978,0.0064572967,0.97101766],"study_design_scores_gemma":[0.0055441274,0.0025428317,0.0004222002,0.013184186,0.001377187,0.001614939,0.000048608603,0.000004453697,0.000040411684,0.0000133776775,0.9749175,0.00029023495],"about_ca_topic_score_codex":0.0000035825167,"about_ca_topic_score_gemma":0.000058174104,"teacher_disagreement_score":0.97072744,"about_ca_system_score_codex":0.0005160335,"about_ca_system_score_gemma":0.002046184,"threshold_uncertainty_score":0.9999218},"labels":[],"label_agreement":null},{"id":"W3201187245","doi":"10.1016/j.ejca.2021.08.008","title":"Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Nomogram; Sarcoma; Medicine; Radiology; Oncology; Pathology","score_opus":0.02790402171631311,"score_gpt":0.31170356384297787,"score_spread":0.28379954212666475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201187245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884094,0.009808015,0.00037955682,0.0004769876,0.00012485476,0.00008639096,0.0000018756834,0.000003147527,0.0002782139],"genre_scores_gemma":[0.9925461,0.0006721445,0.006593552,0.000031386804,0.00008756041,0.0000031707345,0.0000055437213,0.000015092927,0.00004548967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888444,0.0001487989,0.00047556625,0.00012057234,0.00026376618,0.000106864136],"domain_scores_gemma":[0.99926436,0.000037446967,0.00024920114,0.00008885832,0.000280166,0.000079984704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004025061,0.000088965025,0.00022557075,0.00009547431,0.00002136141,0.000019169867,0.000044624485,0.00001085502,0.00005574215],"category_scores_gemma":[0.000059329872,0.00007105358,0.000048082755,0.00013959935,0.000034892746,0.000072575574,0.000027282666,0.00011464649,0.0000026782443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010402892,0.00031907123,0.79829305,0.00003749863,0.0000728015,0.000954147,0.00037252714,0.000023130811,0.0036832676,0.000016959219,0.000008871139,0.19611467],"study_design_scores_gemma":[0.0021835987,0.00018897511,0.9660714,0.00078703696,0.00008633946,0.0003799382,0.00007840929,0.000045076096,0.029376863,0.000009194036,0.0007310607,0.00006207233],"about_ca_topic_score_codex":0.000030669908,"about_ca_topic_score_gemma":0.00010347932,"teacher_disagreement_score":0.1960526,"about_ca_system_score_codex":0.00012192313,"about_ca_system_score_gemma":0.00015699616,"threshold_uncertainty_score":0.2897481},"labels":[],"label_agreement":null},{"id":"W3201876104","doi":"10.1016/j.ejca.2021.08.023","title":"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Medac; PharmaMar; Deutsche Krebshilfe; Eisai; European Commission; Chugai Pharmaceutical; Seagen; F. Hoffmann-La Roche; Incyte; Mersana Therapeutics; Karyopharm Therapeutics; Clovis Oncology; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Takeda Oncology; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Bevacizumab; Medicine; Hazard ratio; Oncology; Placebo; Internal medicine; Population; Ovarian cancer; Cancer; Confidence interval; Chemotherapy; Pathology; Biology","score_opus":0.13387170100280063,"score_gpt":0.42754352639227555,"score_spread":0.2936718253894749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201876104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854989,0.007279042,0.00023681673,0.004985444,0.0008440989,0.00078197673,0.00008356154,0.00001022168,0.00027992897],"genre_scores_gemma":[0.9946349,0.003313433,0.0004888454,0.00031521925,0.00019234767,0.00003728379,0.0000067651904,0.00004223726,0.0009689563],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948795,0.0022816616,0.0017448966,0.0002324977,0.0006244868,0.00023699497],"domain_scores_gemma":[0.995407,0.0011184214,0.002361925,0.0003097536,0.00071430515,0.00008863862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023242114,0.00022836184,0.0010739517,0.0001386303,0.00009718234,0.000023963074,0.00017522028,0.000046614015,0.00040371314],"category_scores_gemma":[0.0018485696,0.00010195663,0.00019058636,0.0006231252,0.00013666583,0.00014897049,0.000039634662,0.0002874233,5.7654455e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020563101,0.0007749973,0.17005333,0.0002267725,0.0011836557,0.00021584798,0.010521236,0.008048126,0.049174204,0.00012809082,0.0016602266,0.7374504],"study_design_scores_gemma":[0.073323436,0.0023937388,0.8683776,0.006261362,0.0008359375,0.00015789596,0.0015919612,0.0014835221,0.04202949,0.00021036254,0.0030513469,0.00028334509],"about_ca_topic_score_codex":0.00033054056,"about_ca_topic_score_gemma":0.0017492026,"teacher_disagreement_score":0.73716706,"about_ca_system_score_codex":0.0007710705,"about_ca_system_score_gemma":0.0011609875,"threshold_uncertainty_score":0.4420376},"labels":[],"label_agreement":null},{"id":"W3202679461","doi":"10.1016/j.ejca.2021.08.045","title":"Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Asymptomatic; Medicine; Immunotherapy; Adverse effect; Internal medicine; Immune system; Creatine kinase; Cancer; Biomarker; Gastroenterology; Oncology; Immunology; Biology","score_opus":0.02848893888801255,"score_gpt":0.28379796881887803,"score_spread":0.25530902993086546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202679461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909309,0.005385259,0.0001497234,0.00034365623,0.00018574961,0.0028793756,0.000040955707,0.000019897014,0.00006448187],"genre_scores_gemma":[0.99826986,0.00029643936,0.00082548003,0.00008236651,0.00009713135,0.00009879378,0.000014834267,0.00008244489,0.00023262456],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9948387,0.0005658227,0.0029380084,0.00033094938,0.00095427816,0.00037224052],"domain_scores_gemma":[0.9960587,0.00010493534,0.001484849,0.00044380774,0.0016907194,0.00021696184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032239838,0.00034812474,0.0016081389,0.0001985855,0.0000592009,0.000044092365,0.00021205303,0.000057481204,0.000042633437],"category_scores_gemma":[0.0008168632,0.00022252569,0.000576464,0.00062836317,0.00009790739,0.00009540704,0.000049441674,0.00028291126,0.0000016709162],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05005917,0.003722646,0.1739697,0.016170617,0.0069962814,0.0013560761,0.0024926802,0.0002799573,0.72468334,0.0000143829875,0.00008888601,0.020166248],"study_design_scores_gemma":[0.022386728,0.009318912,0.5532656,0.06538639,0.00093165506,0.00005525736,0.0005846345,0.000080554404,0.34747845,0.0000023514767,0.000103653576,0.00040581851],"about_ca_topic_score_codex":0.00017102051,"about_ca_topic_score_gemma":0.000029073128,"teacher_disagreement_score":0.3792959,"about_ca_system_score_codex":0.000312787,"about_ca_system_score_gemma":0.0005118327,"threshold_uncertainty_score":0.90743345},"labels":[],"label_agreement":null},{"id":"W3202997693","doi":"10.1016/j.ejca.2021.08.013","title":"Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Internal medicine; Post-hoc analysis; Melanoma; Gastroenterology; Surgery; Cancer; Immunotherapy","score_opus":0.010574117557572711,"score_gpt":0.26825047468346064,"score_spread":0.25767635712588793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202997693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935371,0.004550844,0.000028290122,0.00074756955,0.0001514009,0.00020676834,0.000027323695,0.0000070781603,0.00074361323],"genre_scores_gemma":[0.9975908,0.0007531983,0.00013822818,0.00073851744,0.00009632441,0.0000038388343,0.0000128160345,0.00005084031,0.0006154562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838,0.00017803686,0.00049040106,0.00022946768,0.00043998536,0.00028210584],"domain_scores_gemma":[0.9990241,0.00003422714,0.00028343347,0.0002018199,0.00024771006,0.00020874054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021776385,0.00021432756,0.00048159168,0.0001809801,0.000038456452,0.00004211928,0.00009819756,0.000021416916,0.0002251293],"category_scores_gemma":[0.000036461064,0.00014488587,0.000062776024,0.00026025312,0.00010265173,0.00026802026,0.00003443218,0.0003150249,0.000001566458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036219336,0.00038561935,0.9173668,0.00008204118,0.00017440069,0.0032584504,0.00026829474,0.000055995886,0.00011051775,0.000001483444,0.00007758959,0.041999474],"study_design_scores_gemma":[0.03762655,0.001355502,0.95747876,0.0013896758,0.00009669236,0.000050690334,0.00004584237,0.000003948855,0.00022332669,0.0000016962875,0.0015366416,0.00019067911],"about_ca_topic_score_codex":0.000040341423,"about_ca_topic_score_gemma":0.00034163758,"teacher_disagreement_score":0.04180879,"about_ca_system_score_codex":0.00019684063,"about_ca_system_score_gemma":0.00041323958,"threshold_uncertainty_score":0.5908274},"labels":[],"label_agreement":null},{"id":"W3206004382","doi":"10.1016/j.ejca.2021.09.027","title":"SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute for Health and Care Research","keywords":"Haematopoiesis; Stem cell; Medicine; Oncology; Cancer; Transplantation; Internal medicine; Immunology; Virology; Biology; Genetics","score_opus":0.03553037471266609,"score_gpt":0.34056498595165413,"score_spread":0.30503461123898806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206004382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99607897,0.0027572112,0.000058141046,0.0006402852,0.00008490363,0.00012543936,0.00008763765,0.000004782164,0.00016263759],"genre_scores_gemma":[0.9966162,0.00116943,0.00007091088,0.001842071,0.00012444193,0.000002234596,0.000007972498,0.00003436934,0.00013240793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982578,0.0002578909,0.00061287306,0.00018063266,0.00045968476,0.00023109844],"domain_scores_gemma":[0.9987913,0.000025615394,0.0003585188,0.00022062476,0.00041841005,0.00018555085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002939189,0.00015231437,0.0006125735,0.00035119333,0.000021098876,0.000015082267,0.00010801551,0.000027133314,0.0002842761],"category_scores_gemma":[0.000009838575,0.000100606725,0.00014705681,0.0007139217,0.000037937105,0.000122323,0.0000127123085,0.0002736622,0.000001912191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002291556,0.0002909174,0.9780414,0.00020172627,0.00069692865,0.0010625648,0.003978733,0.00026732005,0.0013338713,4.4354667e-7,0.00010972701,0.011724782],"study_design_scores_gemma":[0.003366747,0.0007788483,0.9820443,0.0009023703,0.0017081978,0.000056689427,0.00010851523,0.00003093567,0.010195297,3.1738304e-7,0.00068928435,0.00011852413],"about_ca_topic_score_codex":0.00042907472,"about_ca_topic_score_gemma":0.0039003212,"teacher_disagreement_score":0.011606258,"about_ca_system_score_codex":0.0001707024,"about_ca_system_score_gemma":0.00079862244,"threshold_uncertainty_score":0.41026235},"labels":[],"label_agreement":null},{"id":"W3206372141","doi":"10.1016/j.ejca.2021.09.016","title":"Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb Canada; Astellas Pharma Canada; International Studies Association; Novartis; Celgene; Bayer; AstraZeneca; Amgen; Pfizer; Meso Scale Diagnostics; AbbVie; Merck","keywords":"Maximum tolerated dose; Medicine; Clinical trial; Therapeutic window; Intensive care medicine; Medical physics; Computer science; Pharmacology; Internal medicine","score_opus":0.4579977353478128,"score_gpt":0.597604700362081,"score_spread":0.13960696501426823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206372141","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037503294,0.9947623,0.0009935809,0.0005384839,0.0006593621,0.0010042985,0.00001377482,0.000005388504,0.0019853134],"genre_scores_gemma":[0.00003764611,0.99232334,0.0031229095,0.00035025808,0.0014647904,0.000034148743,0.000010715242,0.00011139845,0.0025447733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99406856,0.0038144207,0.0012463939,0.00019491106,0.00044789922,0.00022781515],"domain_scores_gemma":[0.9968919,0.0011590755,0.0008546776,0.00035673307,0.00066491135,0.00007267442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00718415,0.00028426579,0.0017645743,0.00029221844,0.00005872762,0.000064003376,0.0003600279,0.000060521492,0.00022467643],"category_scores_gemma":[0.0003179109,0.00016213588,0.00085441396,0.0004303982,0.00012453509,0.000081814935,0.000043794123,0.0011766152,0.0000037009413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034210095,0.00012896601,0.000004916047,0.0025469433,0.0016226352,0.00035220716,0.0015782521,5.488916e-7,0.0001081411,0.000005836184,0.0029690785,0.99034035],"study_design_scores_gemma":[0.0035094428,0.0009395927,0.000031091076,0.015373161,0.0008476641,0.0002521904,0.0002803322,0.0000025665636,0.000016542845,0.000007886241,0.9786022,0.00013737599],"about_ca_topic_score_codex":0.0000038634894,"about_ca_topic_score_gemma":8.378171e-7,"teacher_disagreement_score":0.990203,"about_ca_system_score_codex":0.00027856923,"about_ca_system_score_gemma":0.0010085541,"threshold_uncertainty_score":0.6611709},"labels":[],"label_agreement":null},{"id":"W3210305189","doi":"10.1016/j.ejca.2021.10.013","title":"Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation; Children's Hospital Foundation","keywords":"Coronavirus disease 2019 (COVID-19); Interim; Interim analysis; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; 2019-20 coronavirus outbreak; Virology; Oncology; Clinical trial; Internal medicine; Political science; Outbreak","score_opus":0.2063322602505753,"score_gpt":0.5219672568233104,"score_spread":0.3156349965727351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210305189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028358113,0.9698263,0.000053499345,0.0008612908,0.00023286596,0.00052434206,0.00008844191,0.000005298488,0.000049894832],"genre_scores_gemma":[0.025785109,0.9729129,0.00006274673,0.0007306506,0.00032137998,0.000008933248,0.00005291864,0.00006526736,0.000060110702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99111825,0.0053379587,0.0015239142,0.0002908373,0.0014970133,0.00023203],"domain_scores_gemma":[0.9942537,0.00021862757,0.002081482,0.00044503386,0.0024271903,0.0005740004],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00872464,0.00029842719,0.0023870568,0.0014055899,0.000030925567,0.000020603122,0.00022557355,0.000067169516,0.0011061161],"category_scores_gemma":[0.0022137351,0.00020236555,0.00046402105,0.0016326597,0.000028983555,0.00012097784,0.000042931577,0.000610354,0.0000016696532],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034895854,0.00022630394,0.012398663,0.004489321,0.0023007295,0.00024753134,0.0007175138,0.00052505435,8.748327e-7,3.6447986e-7,0.00050563685,0.97509843],"study_design_scores_gemma":[0.006055294,0.003066822,0.16164422,0.029758438,0.028386252,0.000030390884,0.0000776979,0.000024855804,0.0000011387267,6.992754e-7,0.7706982,0.00025598006],"about_ca_topic_score_codex":0.00039113936,"about_ca_topic_score_gemma":0.0010104642,"teacher_disagreement_score":0.9748424,"about_ca_system_score_codex":0.0027671584,"about_ca_system_score_gemma":0.014996644,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W3210607689","doi":"10.1016/j.ejca.2021.09.019","title":"Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Biomarker; Meta-analysis; Medicine; Melanoma; Oncology; Circulating tumor DNA; Internal medicine; Metastatic melanoma; Cancer research; Cancer; Biology; Genetics","score_opus":0.06604791049850364,"score_gpt":0.344113629553365,"score_spread":0.2780657190548613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210607689","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018337681,0.99894714,0.00013957133,0.00008655115,0.0000710566,0.0004503233,0.00010067356,0.0000012984249,0.00018502977],"genre_scores_gemma":[0.00022342458,0.99852365,0.0002848772,0.00043397993,0.00013075609,0.00003319672,0.0000381075,0.0000638895,0.0002680916],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961517,0.0013708032,0.0016952798,0.00034453103,0.00023214734,0.00020553677],"domain_scores_gemma":[0.997203,0.000102613914,0.0019200187,0.00040237853,0.00023888856,0.00013312827],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018564202,0.00038287288,0.0052829375,0.00022060442,0.00003107035,0.0000734052,0.0003347266,0.00004411783,0.00009703108],"category_scores_gemma":[0.00054848637,0.00027183676,0.0023111124,0.00044362596,0.000032074262,0.000004887105,0.000149286,0.00027541743,0.0000029415016],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000045231523,0.00006354864,0.000004999168,0.7140546,0.26898167,0.0015448562,0.000053171345,0.00013440714,0.00003384771,0.000020270598,0.0012386222,0.013865498],"study_design_scores_gemma":[0.00015352342,0.00006856205,0.0000029337289,0.029190252,0.8002526,0.00042010815,0.000015607808,0.0000014960342,0.000005353802,0.0000014071894,0.16957407,0.0003140678],"about_ca_topic_score_codex":0.00000941437,"about_ca_topic_score_gemma":0.000055345954,"teacher_disagreement_score":0.68486434,"about_ca_system_score_codex":0.000060278377,"about_ca_system_score_gemma":0.0003701517,"threshold_uncertainty_score":0.99997336},"labels":[],"label_agreement":null},{"id":"W3212635215","doi":"10.1016/j.ejca.2021.09.047","title":"A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"Cancer Research UK; National Cancer Institute; Medical Research Council; National Institute for Health and Care Research; Cancer Research Wales","keywords":"Colorectal cancer; Hazard ratio; Single-nucleotide polymorphism; Medicine; Genome-wide association study; Internal medicine; Oncology; SNP; Confidence interval; Survival analysis; Cancer; Genotype; Biology; Genetics; Gene","score_opus":0.014511171931558457,"score_gpt":0.27992806314526997,"score_spread":0.26541689121371154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212635215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99698085,0.0009810798,0.000026606565,0.00004996121,0.00066317286,0.0006456151,0.000107404936,0.000004451313,0.0005408745],"genre_scores_gemma":[0.9985422,0.00025466023,0.0006392179,0.00011885175,0.00010920245,0.000029977116,0.000010194358,0.000090994974,0.00020473269],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733293,0.00024125853,0.0007799238,0.00032718218,0.00087080663,0.000447905],"domain_scores_gemma":[0.9976636,0.00013324522,0.00048296386,0.00019511755,0.0013356906,0.00018937538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043247527,0.0002594381,0.0007577241,0.0002484291,0.000031267147,0.000015102853,0.00019882557,0.000044175704,0.00028059754],"category_scores_gemma":[0.00016031569,0.0001930859,0.00011150194,0.00052850024,0.00011075674,0.00013510881,0.000066832305,0.00037959663,9.410444e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012072884,0.00034030818,0.96417093,0.00016431433,0.0001148638,0.00018738759,0.0009882576,0.001014794,0.0016525115,2.3789832e-7,0.0000449237,0.019248612],"study_design_scores_gemma":[0.02283765,0.003601547,0.95832014,0.0011876452,0.00009447386,0.000006240203,0.00014056118,0.000022142493,0.012579417,0.0000013367458,0.0009944744,0.00021436141],"about_ca_topic_score_codex":0.000091656846,"about_ca_topic_score_gemma":0.0026494686,"teacher_disagreement_score":0.019034252,"about_ca_system_score_codex":0.0005436386,"about_ca_system_score_gemma":0.0008897621,"threshold_uncertainty_score":0.7873815},"labels":[],"label_agreement":null},{"id":"W3212987218","doi":"10.1016/j.ejca.2021.10.015","title":"Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Sanofi Genzyme; Cilag; Astellas Pharma; Genentech; UroGen Pharma; Boston Scientific Corporation; Array BioPharma; Invitae; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; Daiichi Sankyo Company; Ipsen; Clovis Oncology; Astellas Pharma US","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Internal medicine; Oncology; Adverse effect; Post-hoc analysis; Subgroup analysis; Multivariate analysis; Cancer; Androgen receptor; Confidence interval; Pathology","score_opus":0.030634154938138557,"score_gpt":0.29665330578475313,"score_spread":0.2660191508466146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212987218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97577965,0.022205433,0.00006053353,0.0011204219,0.000029636401,0.0003211976,0.00004286509,0.000003818303,0.00043646718],"genre_scores_gemma":[0.97970504,0.018753743,0.0002700409,0.000061765146,0.000044169843,0.000012642711,0.000031125503,0.000025850799,0.0010956276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983733,0.0002005596,0.00052345387,0.00021076095,0.0004957007,0.0001962111],"domain_scores_gemma":[0.998836,0.000042576852,0.0003860792,0.00015265607,0.00045175973,0.00013095826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045487357,0.00015127311,0.0005024032,0.00019701042,0.00004447457,0.0000384639,0.00006097204,0.00001807356,0.000051985986],"category_scores_gemma":[0.000018101004,0.000102026876,0.00009295434,0.0005908653,0.00011258736,0.00012475149,0.000019150062,0.00017194977,2.380971e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016754866,0.00034584725,0.83920085,0.00026432428,0.0043734526,0.0065147104,0.004220195,0.0018149304,0.08997327,0.00003367711,0.0003470763,0.03615678],"study_design_scores_gemma":[0.01866367,0.0031454482,0.92216545,0.0008593612,0.0014279692,0.00014315968,0.0012241893,0.00026999635,0.050176278,0.00002482099,0.0016290719,0.0002706074],"about_ca_topic_score_codex":0.00023018579,"about_ca_topic_score_gemma":0.0012424879,"teacher_disagreement_score":0.08296456,"about_ca_system_score_codex":0.00024881514,"about_ca_system_score_gemma":0.00042389194,"threshold_uncertainty_score":0.41605353},"labels":[],"label_agreement":null},{"id":"W3214450343","doi":"10.1016/j.ejca.2021.09.005","title":"Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Nasopharyngeal carcinoma; Internal medicine; Concomitant; Radiation therapy; Retrospective cohort study; Chemoradiotherapy; Incidence (geometry); Oncology; Induction chemotherapy; Confounding; Cohort; Cancer; Surgery","score_opus":0.017822382903148918,"score_gpt":0.32837707308294334,"score_spread":0.3105546901797944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214450343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436135,0.011910329,0.000011048213,0.00052121986,0.00052309775,0.0001805651,0.000087417226,0.0000069398106,0.0023980434],"genre_scores_gemma":[0.99167144,0.006964347,0.00008679087,0.0002055229,0.00046154615,0.000004065632,0.0000024082728,0.00003151974,0.0005723486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843466,0.00014860215,0.00061477744,0.00021487224,0.0003025283,0.0002845463],"domain_scores_gemma":[0.9982805,0.000027951513,0.0004359971,0.00017799216,0.00088210026,0.00019542487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045040878,0.00020496397,0.00090792443,0.000117200754,0.000040457664,0.000008338237,0.00007768849,0.000028854118,0.00040744612],"category_scores_gemma":[0.00013466335,0.00014225443,0.00031170514,0.00028026645,0.00005831886,0.00009042779,0.000046347574,0.00037165772,0.000004044771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015156545,0.00028911603,0.9773449,0.000042015487,0.001230789,0.0019729245,0.005162269,0.00018974172,0.006598462,0.0000017464887,0.0015081756,0.0041442225],"study_design_scores_gemma":[0.0064049764,0.0013123236,0.9853856,0.0012558536,0.00033491512,0.00014261284,0.00066891866,0.00016337716,0.0036407073,0.0000029008581,0.0005696419,0.00011817198],"about_ca_topic_score_codex":0.0005927662,"about_ca_topic_score_gemma":0.001329688,"teacher_disagreement_score":0.008040717,"about_ca_system_score_codex":0.002036623,"about_ca_system_score_gemma":0.0010503709,"threshold_uncertainty_score":0.5800967},"labels":[],"label_agreement":null},{"id":"W3215111763","doi":"10.1016/j.ejca.2021.09.024","title":"KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; University of Toronto; Jewish General Hospital; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Trametinib; Pembrolizumab; Dosing; Medicine; Adverse effect; Internal medicine; Melanoma; Oncology; Immunotherapy; MAPK/ERK pathway; Cancer; Cancer research; Biology; Kinase","score_opus":0.00713408438545517,"score_gpt":0.24500162893397942,"score_spread":0.23786754454852424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215111763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704796,0.00072763534,0.0003569797,0.000068695656,0.0001705547,0.00011005432,0.000018741042,0.0000029165492,0.0014964343],"genre_scores_gemma":[0.998213,0.00011529211,0.0010886192,0.00009923812,0.0001463742,0.0000016221667,0.000022615894,0.000039794308,0.00027347333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871534,0.00023719211,0.0003751221,0.00021819123,0.0002691101,0.00018502137],"domain_scores_gemma":[0.99861264,0.000017270551,0.00045938508,0.00018221671,0.0006388084,0.00008969272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018106551,0.00015866973,0.00026943345,0.0000736254,0.000029089804,0.000015737305,0.00015101366,0.000031783075,0.000058521186],"category_scores_gemma":[0.000109712324,0.00011068992,0.000058332203,0.00020063063,0.00006245159,0.000016918846,0.000033316006,0.0001609172,0.0000016997184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088814884,0.0017633785,0.38942814,0.00023253277,0.0012449251,0.0046261773,0.0034473948,0.015775008,0.38260326,0.000074708434,0.0013396649,0.11064994],"study_design_scores_gemma":[0.013357325,0.009827985,0.70784605,0.00037900647,0.00010598767,0.00022774548,0.00043208798,0.000010447813,0.2631801,0.000010784281,0.0042878417,0.000334649],"about_ca_topic_score_codex":0.000005513683,"about_ca_topic_score_gemma":0.00012882553,"teacher_disagreement_score":0.3184179,"about_ca_system_score_codex":0.000034456654,"about_ca_system_score_gemma":0.00041848436,"threshold_uncertainty_score":0.4513804},"labels":[],"label_agreement":null},{"id":"W3216319709","doi":"10.1016/j.ejca.2021.09.043","title":"Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Docetaxel; Medicine; Prostate cancer; Chemotherapy; Oncology; Internal medicine; Nivolumab; Cancer; Immunotherapy","score_opus":0.033042106537681054,"score_gpt":0.33079038096837576,"score_spread":0.29774827443069474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216319709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830204,0.0069805873,0.00001007071,0.007755016,0.00035790334,0.0007568523,0.00048849214,0.000009230619,0.0006214322],"genre_scores_gemma":[0.99319637,0.0027805956,0.00030673368,0.0004222737,0.0005432512,0.000021537875,0.00009091033,0.00005602688,0.0025823126],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973905,0.00038420892,0.00079561776,0.00028178794,0.0008079247,0.00033997002],"domain_scores_gemma":[0.9981497,0.00008640631,0.0005634629,0.00029487806,0.0007223607,0.00018317532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006773623,0.00022463687,0.00048500823,0.00008500021,0.00015114175,0.00007977865,0.00017601835,0.000018844941,0.00027453242],"category_scores_gemma":[0.000110487745,0.00012482794,0.00012555112,0.0003829656,0.00011742145,0.0001815393,0.000041220545,0.00045176936,0.0000048994452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80272603,0.0026184323,0.007301682,0.00009366893,0.0023101543,0.004444874,0.013165682,0.0005483106,0.0055258744,0.000006891161,0.008488495,0.15276988],"study_design_scores_gemma":[0.83621985,0.009733015,0.10699675,0.0017725184,0.0006916541,0.000025800711,0.00096908427,0.00009033138,0.009173597,0.000025176678,0.033951513,0.00035069484],"about_ca_topic_score_codex":0.00032611183,"about_ca_topic_score_gemma":0.0004063385,"teacher_disagreement_score":0.1524192,"about_ca_system_score_codex":0.00046273487,"about_ca_system_score_gemma":0.001679876,"threshold_uncertainty_score":0.5090336},"labels":[],"label_agreement":null},{"id":"W4200390731","doi":"10.1016/j.ejca.2021.11.026","title":"Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Placebo; Abiraterone acetate; Prednisone; Post-hoc analysis; Prostate cancer; Urology; Internal medicine; Gastroenterology; Androgen deprivation therapy; Enzalutamide; Cancer; Pathology","score_opus":0.023766139638104037,"score_gpt":0.3155620819471137,"score_spread":0.2917959423090097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200390731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972483,0.0018793056,0.0000030745048,0.0000767467,0.000056074743,0.00040272635,0.00031351537,0.0000015277624,0.000018735183],"genre_scores_gemma":[0.9992203,0.00049925904,0.00006165081,0.000017422253,0.000022392813,0.0000048119787,0.000009771349,0.00002216909,0.00014218208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818814,0.00039073173,0.00052462635,0.00015540764,0.0005806639,0.00016045923],"domain_scores_gemma":[0.99796516,0.00003813688,0.00058902404,0.00018003868,0.0011391008,0.00008855432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003649354,0.00013809584,0.0006290443,0.00024859316,0.00002353427,0.000013167693,0.00007157899,0.000012796905,0.000054560693],"category_scores_gemma":[0.000038612598,0.00008077664,0.00017358536,0.0006984671,0.00012805744,0.00016181114,0.00005446216,0.00016664741,1.260199e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010171651,0.00047319417,0.95675796,0.000059364895,0.008137656,0.00030852327,0.01088541,0.0038616539,0.005618076,3.9253402e-7,0.000031701416,0.0036943848],"study_design_scores_gemma":[0.013846425,0.0030852172,0.9772885,0.00035172145,0.0018615728,0.0000036780443,0.0010698234,0.00003780792,0.0023799487,4.3973972e-7,0.0000054720913,0.00006941291],"about_ca_topic_score_codex":0.0003682152,"about_ca_topic_score_gemma":0.0013575763,"teacher_disagreement_score":0.020530488,"about_ca_system_score_codex":0.00019245943,"about_ca_system_score_gemma":0.0008013849,"threshold_uncertainty_score":0.3293976},"labels":[],"label_agreement":null},{"id":"W4206062027","doi":"10.1016/j.ejca.2021.12.012","title":"Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Hamilton Health Sciences; Kingston Health Sciences Centre; Queen's University","funders":"Genentech; Servier; Cilag; Astellas Pharma; Incyte; Ipsen; Clovis Oncology; Strong; Sanofi; Exelixis; Eisai; Pfizer; Les Laboratories Pierre Fabre; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Clinical endpoint; Internal medicine; Adverse effect; Population; Urology; Tolerability; Phases of clinical research; Oncology; Surgery; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Nivolumab","score_opus":0.04576036169986496,"score_gpt":0.3418975716791859,"score_spread":0.2961372099793209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206062027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573076,0.0013730463,0.000002035177,0.000056731784,0.00011872868,0.0015066162,0.00020284315,0.0000064615124,0.0010028055],"genre_scores_gemma":[0.99923146,0.00012226198,0.00013940595,0.00009388568,0.00006603643,0.0000244467,0.000032030446,0.00006973513,0.00022072539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699736,0.0008435242,0.0009963901,0.0002740678,0.0006671658,0.00022147976],"domain_scores_gemma":[0.9981697,0.000030278636,0.0009654948,0.0003744674,0.00029365695,0.00016639874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005820452,0.00022480302,0.00066494336,0.00022574277,0.00006437041,0.00001405846,0.00039794564,0.00001364647,0.00013726701],"category_scores_gemma":[0.000015012217,0.00016894592,0.00005212866,0.00027839403,0.000046863053,0.0002626737,0.00009307571,0.0003264925,4.5389714e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18038142,0.0876236,0.6601731,0.0000775736,0.00063447485,0.0017758217,0.008574901,0.00026487478,0.0013404534,2.5237435e-7,0.00025375857,0.058899734],"study_design_scores_gemma":[0.19518933,0.11908987,0.6834398,0.00019369295,0.0003262263,0.000039733437,0.00077848975,0.000023700466,0.000308378,2.7965126e-7,0.0004888721,0.00012161364],"about_ca_topic_score_codex":0.00052649796,"about_ca_topic_score_gemma":0.00003859306,"teacher_disagreement_score":0.058778122,"about_ca_system_score_codex":0.00032999474,"about_ca_system_score_gemma":0.00034571794,"threshold_uncertainty_score":0.6889415},"labels":[],"label_agreement":null},{"id":"W4206703690","doi":"10.1016/j.ejca.2020.09.013","title":"Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pneumocystis jirovecii pneumonia detection and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; SickKids Foundation","funders":"","keywords":"Medicine; Odds ratio; Dapsone; Trimethoprim; Confidence interval; Pneumonia; Internal medicine; Pentamidine; Surgery; Malignancy; Sulfamethoxazole; Adverse effect; Pediatrics; Antibiotics; Dermatology","score_opus":0.012992564197071552,"score_gpt":0.28727122408514394,"score_spread":0.2742786598880724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206703690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973509,0.0009997186,0.000023463002,0.00034944428,0.00008013976,0.0008059031,0.00021478227,0.000013686938,0.00016196615],"genre_scores_gemma":[0.9992484,0.00027928184,0.000035717352,0.00008376473,0.00025619305,0.000011192065,5.0388047e-7,0.00006031187,0.000024652927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99749875,0.0005470726,0.0008681156,0.00027402616,0.0005711131,0.00024091697],"domain_scores_gemma":[0.99780804,0.000091791466,0.0011910233,0.00025212526,0.0003311418,0.0003258713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003925559,0.00029297918,0.0008733116,0.0002677843,0.00004152963,0.000012840946,0.00015762437,0.000028557628,0.00011949975],"category_scores_gemma":[0.00018757454,0.00018652197,0.0002821131,0.00051567634,0.000070783804,0.000088918896,0.000023459945,0.00059589796,0.000004733798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034855516,0.0008954769,0.93241507,0.000035040535,0.0022264852,0.00363394,0.00097051676,0.005379956,0.00909015,2.5635597e-7,0.000022792268,0.041844793],"study_design_scores_gemma":[0.013270758,0.029974258,0.9528074,0.00031701082,0.00084676576,0.0016220434,0.00009084093,0.00008813302,0.0008055345,3.2659148e-7,0.00003486648,0.00014203569],"about_ca_topic_score_codex":0.0014402467,"about_ca_topic_score_gemma":0.00029026883,"teacher_disagreement_score":0.04170276,"about_ca_system_score_codex":0.00028059562,"about_ca_system_score_gemma":0.0003264575,"threshold_uncertainty_score":0.7606145},"labels":[],"label_agreement":null},{"id":"W4213440518","doi":"10.1016/j.ejca.2022.01.017","title":"Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Moderna; Genentech; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Hazard ratio; Placebo; Internal medicine; Confidence interval; Proportional hazards model; Melanoma; Oncology; Gastroenterology; Surgery; Cancer; Immunotherapy; Pathology","score_opus":0.01622387118143329,"score_gpt":0.29033985869362205,"score_spread":0.27411598751218874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213440518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925806,0.0047770943,0.000015040449,0.00060102186,0.00053284026,0.000867397,0.00009006348,0.0000057482403,0.0005301761],"genre_scores_gemma":[0.99738866,0.0018105125,0.000035130302,0.00004851296,0.00046719002,0.00002373244,0.000006814538,0.000035343197,0.00018411403],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99561214,0.002148685,0.0010061353,0.00019844565,0.00077120244,0.00026337517],"domain_scores_gemma":[0.9978003,0.0006616729,0.001001334,0.00028022323,0.00016511652,0.000091375914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002515488,0.00018717577,0.00068993954,0.00040679338,0.00008089982,0.000013090548,0.00030002574,0.000029599563,0.0001562395],"category_scores_gemma":[0.00066675525,0.00014113421,0.0001491598,0.00047423498,0.00021778849,0.000094256226,0.00007941641,0.00079379784,3.1359525e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.969317,0.00077547366,0.0049723284,0.00008474638,0.0003340532,0.001108453,0.008532136,0.0014113927,0.0010786972,0.000021290549,0.0013930332,0.0109713925],"study_design_scores_gemma":[0.781309,0.035690416,0.15097632,0.0008006252,0.0009044617,0.0002985036,0.009782987,0.0008465972,0.0015939797,0.000012066137,0.017502518,0.00028252054],"about_ca_topic_score_codex":0.0005533759,"about_ca_topic_score_gemma":0.00007846892,"teacher_disagreement_score":0.188008,"about_ca_system_score_codex":0.00022831047,"about_ca_system_score_gemma":0.0006743033,"threshold_uncertainty_score":0.5755286},"labels":[],"label_agreement":null},{"id":"W4214630410","doi":"10.1016/j.ejca.2021.12.037","title":"Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review","year":2022,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Surrogate endpoint; Internal medicine; End point","score_opus":0.41112392989742086,"score_gpt":0.4530464411382088,"score_spread":0.04192251124078794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214630410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002104686,0.98785764,0.0008537997,0.00039879832,0.0034067286,0.0020168326,0.004631864,0.000007961791,0.0008053475],"genre_scores_gemma":[0.00003396238,0.9957325,0.0005760194,0.0010594102,0.0017030056,0.00015115173,0.00003805311,0.00010620509,0.0005997018],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98363346,0.0014615475,0.013957693,0.0004759351,0.00013026119,0.00034112725],"domain_scores_gemma":[0.9754629,0.002187703,0.021221384,0.0005789539,0.00023888775,0.0003101554],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.025365598,0.00046695114,0.015527381,0.0002486953,0.00005587262,0.00006577906,0.0011941125,0.00013880394,0.0021477055],"category_scores_gemma":[0.021284917,0.00037283858,0.003371226,0.00024873766,0.00007503342,0.00014919983,0.00018253842,0.000626233,0.0001807393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016151942,0.00016301981,0.00009356674,0.5825436,0.00235643,0.00013269058,0.00014111795,0.000001949338,5.3641266e-8,0.0023109368,0.09293062,0.31916448],"study_design_scores_gemma":[0.00040126557,0.0003138672,0.00006936241,0.16738372,0.0017398667,0.00002581525,0.000008523189,0.000001160273,7.213185e-8,0.00017507997,0.82956004,0.0003212502],"about_ca_topic_score_codex":0.0000160466,"about_ca_topic_score_gemma":0.0000026036148,"teacher_disagreement_score":0.7366294,"about_ca_system_score_codex":0.00023859715,"about_ca_system_score_gemma":0.00049376074,"threshold_uncertainty_score":0.9998723},"labels":[],"label_agreement":null},{"id":"W4214867180","doi":"10.1016/j.ejca.2022.01.024","title":"Contemporary clinical trials in hematologic cancer: Have we forgotten where we came from?","year":2022,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Randomized controlled trial; Clinical trial; Cancer; Oncology; Internal medicine","score_opus":0.2439319816977893,"score_gpt":0.44694375151801263,"score_spread":0.20301176982022334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214867180","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068773543,0.22346947,0.000028236409,0.7579018,0.0062193023,0.0007982869,0.0006865049,0.00004872891,0.0039703436],"genre_scores_gemma":[0.013217261,0.12062164,0.00048336215,0.8027839,0.053362187,0.00007396637,0.00016774045,0.00052038097,0.008769567],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9718894,0.016653938,0.0077034375,0.0009153953,0.0021203624,0.00071747246],"domain_scores_gemma":[0.98677075,0.00380734,0.007606751,0.00093879376,0.00042270526,0.0004536677],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.019175977,0.000831785,0.0059828083,0.00059641106,0.0001054227,0.000096898366,0.0011949469,0.0004925794,0.008030963],"category_scores_gemma":[0.0026990063,0.0006755534,0.0021302702,0.00032347083,0.00028265888,0.00022213021,0.00033761884,0.009674094,0.00005821298],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002023104,0.00016054859,0.028797956,0.0007555307,0.0015961392,0.018890835,0.0015802702,0.000014094789,0.000013929973,0.000001064507,0.935774,0.010392499],"study_design_scores_gemma":[0.009275925,0.0011088661,0.0048633027,0.0087475795,0.00083417277,0.00028450598,0.0008883129,0.0000059361682,0.00002100569,0.00008245892,0.9732542,0.0006337194],"about_ca_topic_score_codex":0.0017775939,"about_ca_topic_score_gemma":0.00062572677,"teacher_disagreement_score":0.10284784,"about_ca_system_score_codex":0.0008571736,"about_ca_system_score_gemma":0.0031285582,"threshold_uncertainty_score":0.9995696},"labels":[],"label_agreement":null},{"id":"W4220929644","doi":"10.1016/j.ejca.2022.02.009","title":"Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Tolerability; Internal medicine; Adverse effect; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Discontinuation; Gastroenterology; Progression-free survival; Surgery; Oncology; Phases of clinical research; Toxicity; Clinical trial; Chemotherapy; Cancer; Immunotherapy","score_opus":0.019830718021931138,"score_gpt":0.24461704209194424,"score_spread":0.2247863240700131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220929644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964871,0.001844187,0.000007313661,0.000064224114,0.000028786519,0.0013620058,0.000034224297,0.000009336389,0.00016283125],"genre_scores_gemma":[0.999589,0.00006467699,0.000109776716,0.00002402437,0.000023842838,0.000015509479,0.000032173444,0.00006119966,0.00007975107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975376,0.00052257767,0.00080541946,0.00025326852,0.00064330356,0.0002378249],"domain_scores_gemma":[0.9983684,0.000029604314,0.00079241086,0.00026575723,0.00037386586,0.00016996461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041743345,0.000252356,0.0007596464,0.0003055712,0.00010274562,0.0000065964637,0.00014714735,0.000016241818,0.00016417363],"category_scores_gemma":[0.000016762518,0.00017548312,0.00007707868,0.0005247121,0.00007625874,0.00010534089,0.000085113075,0.00031436436,3.0202827e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054230645,0.0054141874,0.91983,0.00006220194,0.00047704432,0.0013163722,0.003415861,0.00014982805,0.00058909925,7.3175744e-7,0.000029616234,0.014484374],"study_design_scores_gemma":[0.13966164,0.083963536,0.7715281,0.00031693233,0.0010458237,0.000065226086,0.0005990415,0.00019672267,0.0016581967,3.0875682e-7,0.00075646,0.0002079591],"about_ca_topic_score_codex":0.000065535765,"about_ca_topic_score_gemma":0.000012494788,"teacher_disagreement_score":0.14830188,"about_ca_system_score_codex":0.00014738,"about_ca_system_score_gemma":0.00019882036,"threshold_uncertainty_score":0.71559936},"labels":[],"label_agreement":null},{"id":"W4221041809","doi":"10.1016/j.ejca.2022.01.042","title":"Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial","year":2022,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Androgen deprivation therapy; Prostate cancer; Medicine; Radiation therapy; Oncology; Cancer; Internal medicine; Randomized controlled trial; Androgen; Urology; Hormone","score_opus":0.037241826905770825,"score_gpt":0.346108554949665,"score_spread":0.3088667280438942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221041809","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28179654,0.029947694,0.000017009173,0.68301,0.0012433154,0.0035986437,0.00016324074,0.000016314441,0.00020724643],"genre_scores_gemma":[0.009142985,0.17013972,0.00013844986,0.80953956,0.007945236,0.0005052533,0.00010918523,0.00021064158,0.0022689519],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961497,0.001134992,0.0010537391,0.000401126,0.00085690204,0.00040353558],"domain_scores_gemma":[0.9981719,0.00021059625,0.00090251345,0.00031242345,0.00018721963,0.00021535021],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018314772,0.0003658723,0.00096554024,0.00059979723,0.00010737093,0.00007221377,0.00025490692,0.000065246466,0.0009864911],"category_scores_gemma":[0.00008814776,0.00025574482,0.00024090592,0.00024297678,0.000084907086,0.00007813396,0.00004440366,0.0020164952,0.000002079555],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3699309,0.000175521,0.00048146304,0.000036700363,0.0005826945,0.0024635892,0.0023073633,0.000021184316,0.000119419536,1.0426882e-7,0.47395357,0.14992748],"study_design_scores_gemma":[0.36887383,0.007378331,0.00017235761,0.00040791984,0.000094045325,0.00002780919,0.00003673093,0.00000781556,0.0003326784,0.00000393444,0.6225121,0.000152464],"about_ca_topic_score_codex":0.00019278449,"about_ca_topic_score_gemma":0.000006976744,"teacher_disagreement_score":0.27265358,"about_ca_system_score_codex":0.0009693303,"about_ca_system_score_gemma":0.0005934188,"threshold_uncertainty_score":0.99998945},"labels":[],"label_agreement":null},{"id":"W4225291722","doi":"10.1016/j.ejca.2022.03.029","title":"Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical endpoint; Avelumab; Neuroendocrine tumors; Internal medicine; Gastroenterology; Progressive disease; Oncology; Surgery; Clinical trial; Chemotherapy; Immunotherapy; Cancer; Pembrolizumab","score_opus":0.05478826897775532,"score_gpt":0.35685768525688955,"score_spread":0.3020694162791342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225291722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728506,0.011193489,0.000010424228,0.0119314855,0.0009818433,0.0009932137,0.00038979336,0.000042259115,0.0016068632],"genre_scores_gemma":[0.9920327,0.0025543463,0.0010386597,0.00090755994,0.00059287413,0.000032756612,0.00004906952,0.00012430713,0.0026677381],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918061,0.0036506976,0.0019099406,0.0005097239,0.0013977151,0.0007258316],"domain_scores_gemma":[0.99632484,0.0011792426,0.0013009205,0.0004174823,0.000257151,0.000520349],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019304197,0.00034952332,0.0012138353,0.0005598028,0.0001791293,0.00010091774,0.0004635531,0.0000034325515,0.0011703228],"category_scores_gemma":[0.003063152,0.00028504131,0.00018439074,0.0006361984,0.0001841467,0.00028243693,0.00042023693,0.0015027637,0.000011389747],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08749457,0.0026421922,0.01751547,0.0003111418,0.0011828884,0.5964728,0.001136121,0.0058454084,0.026498597,0.00008163078,0.12747036,0.13334884],"study_design_scores_gemma":[0.17227498,0.020892367,0.08621826,0.0011024728,0.00078801665,0.02618445,0.0014549006,0.0012194716,0.013007969,0.0006867525,0.67508584,0.0010844987],"about_ca_topic_score_codex":0.000218979,"about_ca_topic_score_gemma":0.00006877448,"teacher_disagreement_score":0.57028836,"about_ca_system_score_codex":0.00018102069,"about_ca_system_score_gemma":0.00035785022,"threshold_uncertainty_score":0.9999602},"labels":[],"label_agreement":null},{"id":"W4241605155","doi":"10.1016/j.ejca.2012.06.013","title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":229,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cancer Research UK","keywords":"Medicine; Ipilimumab; Melanoma; Guideline; Oncology; Vemurafenib; Internal medicine; Stage (stratigraphy); Systemic therapy; Adjuvant therapy; Skin cancer; Cancer; Surgery; Dermatology; Breast cancer; Immunotherapy; Pathology; Cancer research; Metastatic melanoma","score_opus":0.02186877716028896,"score_gpt":0.2939923508756755,"score_spread":0.27212357371538654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241605155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96697736,0.026782144,0.00042907856,0.00072232774,0.0004452781,0.000075124255,0.000048893715,0.000003562952,0.00451622],"genre_scores_gemma":[0.9952442,0.0018420957,0.0013137354,0.00019663497,0.0010628677,0.0000016725509,0.000016079282,0.00003401763,0.00028868252],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988063,0.00032890672,0.00046847278,0.00011380429,0.00010283652,0.00017969185],"domain_scores_gemma":[0.99912083,0.000014015307,0.0003724738,0.0001804918,0.00013960285,0.00017260134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053730706,0.00014429304,0.00020000251,0.00005488621,0.00003939696,0.000008828515,0.00011623657,0.000019573812,0.00010077805],"category_scores_gemma":[0.000022778737,0.00010728588,0.00011723048,0.000033638025,0.000078972866,0.0000064399565,0.00009010505,0.000048434547,0.000009547345],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011285095,0.0007785621,0.09784544,0.000058771016,0.00063943205,0.00030206214,0.0007492624,0.00019535983,0.35840854,0.00003640344,0.11517896,0.4246787],"study_design_scores_gemma":[0.0021500783,0.0019718194,0.045305755,0.00008286115,0.00015270896,0.000115074996,0.000083345505,0.000009666508,0.14421336,0.0000036354736,0.80570626,0.0002054331],"about_ca_topic_score_codex":0.0000025270037,"about_ca_topic_score_gemma":0.000006563845,"teacher_disagreement_score":0.6905273,"about_ca_system_score_codex":0.000015985108,"about_ca_system_score_gemma":0.000045493645,"threshold_uncertainty_score":0.43749914},"labels":[],"label_agreement":null},{"id":"W4256754952","doi":"10.1016/s0959-8049(02)81121-2","title":"Phase II study of the DNA methyltransferase I (DNMT1) inhibitor MG98 in patients (pts) with renal cell carcinoma (RCC). A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)","year":2002,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Renal cell carcinoma; Medicine; Clinical trial; Internal medicine; Oncology; Cancer; DNMT1; Methyltransferase; DNA; Biology; Genetics","score_opus":0.05604389073097916,"score_gpt":0.33422354576702235,"score_spread":0.2781796550360432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256754952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967685,0.0012965568,0.000026826356,0.00011724054,0.0009637582,0.00047590135,0.00009446849,4.1409996e-7,0.0002563548],"genre_scores_gemma":[0.9990441,0.0002041691,0.000033258308,0.000059378293,0.0005419604,0.000005265687,0.0000024014662,0.000017165556,0.000092297225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960457,0.0015159765,0.0014472427,0.00017112124,0.0006887318,0.000131248],"domain_scores_gemma":[0.99783313,0.000058490714,0.0012982754,0.0002009663,0.00053895515,0.00007019743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024329005,0.0001396173,0.0004193109,0.000052697927,0.000062054256,0.0000054653974,0.00032675653,0.00004164513,0.000028977449],"category_scores_gemma":[0.0004061901,0.00007987093,0.00019397291,0.00019017947,0.00011071488,0.000009632878,0.00006287299,0.00021359682,4.044679e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056901805,0.015301936,0.15689857,0.0001223207,0.0011144362,0.000021961248,0.0023043014,0.009509703,0.7017233,0.000009707909,0.004955254,0.05113673],"study_design_scores_gemma":[0.21763389,0.027108487,0.15941378,0.00027402103,0.00055243145,0.0000015726632,0.00016131446,0.00007056474,0.57955074,0.000008899401,0.014866782,0.00035752836],"about_ca_topic_score_codex":0.002496998,"about_ca_topic_score_gemma":0.025615051,"teacher_disagreement_score":0.16073208,"about_ca_system_score_codex":0.000059154383,"about_ca_system_score_gemma":0.0006625151,"threshold_uncertainty_score":0.9921649},"labels":[],"label_agreement":null},{"id":"W4280507434","doi":"10.1016/j.ejca.2022.03.039","title":"Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"","keywords":"Cluster analysis; Cancer; Quality of life (healthcare); Medicine; Statistics; Internal medicine; Mathematics; Nursing","score_opus":0.06629689353926983,"score_gpt":0.38279932505966846,"score_spread":0.31650243152039864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280507434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883497,0.008099703,0.00011461422,0.0010886901,0.0013842117,0.00022960312,0.00010735919,0.000012791024,0.00061335467],"genre_scores_gemma":[0.9983681,0.0003465307,0.000032506905,0.00037486825,0.00029014578,0.0000062594304,0.0000051581687,0.000036785983,0.00053963705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965024,0.0010153505,0.0013328539,0.00016019531,0.0007826244,0.0002065535],"domain_scores_gemma":[0.9976697,0.000049179427,0.0014670808,0.00021756253,0.00042781408,0.00016867972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028064153,0.00013198207,0.0006343905,0.000098107004,0.000114898394,0.000010495111,0.00019616589,0.000015361416,0.0007099352],"category_scores_gemma":[0.0000818629,0.00011787115,0.0001885985,0.00032923592,0.00006260238,0.00009096689,0.00010694084,0.0004069091,0.0000012319183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008988542,0.00122209,0.7140878,0.0012870803,0.0018898589,0.00016261199,0.110871434,0.06302404,0.0053065293,0.000014235533,0.004187586,0.0889582],"study_design_scores_gemma":[0.007622709,0.0028706295,0.95306534,0.00058370497,0.00020759797,0.000051233623,0.026160242,0.00014540402,0.0009092592,0.000008234976,0.008097172,0.00027846597],"about_ca_topic_score_codex":0.0031098262,"about_ca_topic_score_gemma":0.002517495,"teacher_disagreement_score":0.23897755,"about_ca_system_score_codex":0.00030763316,"about_ca_system_score_gemma":0.00049397943,"threshold_uncertainty_score":0.77732927},"labels":[],"label_agreement":null},{"id":"W4280518749","doi":"10.1016/j.ejca.2022.04.016","title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta","funders":"National Cancer Institute; Foundation Medicine; Eisai; Merck Sharp and Dohme; Ipsen; Astellas Pharma; Sanofi; Chugai Pharmaceutical; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Prostate cancer; Tolerability; Olaparib; Medicine; Adverse effect; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.04573720873806924,"score_gpt":0.3604040520670452,"score_spread":0.31466684332897593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280518749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99327356,0.003334574,0.0000027943083,0.0017087541,0.00009838308,0.0012768755,0.00008100728,0.000004304653,0.00021977103],"genre_scores_gemma":[0.9990087,0.00026252508,0.00007634737,0.00014177634,0.000043843043,0.000074342955,0.0000115352495,0.000022437755,0.0003584839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977035,0.00070832146,0.00046437356,0.00019690712,0.000739794,0.00018712811],"domain_scores_gemma":[0.9992037,0.0000470555,0.0003051186,0.00019741204,0.00015527103,0.00009148195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080862583,0.00014116622,0.00030740869,0.00008879394,0.00016190772,0.000031722746,0.00013323556,0.0000037120515,0.00025232122],"category_scores_gemma":[0.000007631436,0.00007674392,0.000051103794,0.0002617494,0.000075583455,0.0000959241,0.00009283875,0.00032040788,7.728624e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007077732,0.0010989655,0.96005213,0.000037966984,0.0012485024,0.00072003977,0.0061206836,0.0015888679,0.000078794365,0.0000013754067,0.00023127951,0.021743674],"study_design_scores_gemma":[0.010076944,0.002335535,0.9780029,0.00011543486,0.0005403947,0.000002984137,0.006919205,0.000021255404,0.000034696317,0.00001000568,0.00185544,0.000085175874],"about_ca_topic_score_codex":0.00077501364,"about_ca_topic_score_gemma":0.0011127465,"teacher_disagreement_score":0.021658497,"about_ca_system_score_codex":0.00040767997,"about_ca_system_score_gemma":0.00016847067,"threshold_uncertainty_score":0.31295264},"labels":[],"label_agreement":null},{"id":"W4280548742","doi":"10.1016/j.ejca.2022.03.040","title":"Health-related quality of life in patients treated with pembrolizumab for microsatellite instability–high/mismatch repair–deficient advanced solid tumours: Results from the KEYNOTE-158 study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Quality of life (healthcare); Microsatellite instability; Internal medicine; Cohort; Population; Colorectal cancer; Oncology; Cancer","score_opus":0.029199044914299515,"score_gpt":0.3058733676291945,"score_spread":0.27667432271489495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280548742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325395,0.0026888992,0.000010180991,0.001182662,0.0004997926,0.001694917,0.0005212796,0.000023799614,0.000124533],"genre_scores_gemma":[0.9988649,0.00007031589,0.00032719725,0.00041879513,0.0000823538,0.000025724827,0.000051743573,0.00006726426,0.000091702175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99397546,0.0018558913,0.0023725897,0.0004316208,0.0009937285,0.00037068827],"domain_scores_gemma":[0.9961142,0.00036715102,0.002036962,0.0005734183,0.0007081078,0.00020016303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031384334,0.00026448572,0.000985959,0.00013544105,0.00015609947,0.000014859911,0.00035901627,0.000024315834,0.00008013944],"category_scores_gemma":[0.00070238975,0.00017785851,0.00021463059,0.0005336483,0.00012994844,0.00006108884,0.00013024619,0.0006406583,0.0000011716583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10526443,0.002622521,0.8503325,0.000097864984,0.0005010784,0.000046047368,0.016642727,0.014342193,0.00095065846,0.0000018724237,0.000969226,0.008228893],"study_design_scores_gemma":[0.032237235,0.011471903,0.9517004,0.00033650995,0.000119968005,0.00000626103,0.0023752707,0.000039794562,0.00041223303,0.000007017202,0.0011168694,0.00017653043],"about_ca_topic_score_codex":0.0017181531,"about_ca_topic_score_gemma":0.0005626099,"teacher_disagreement_score":0.10136792,"about_ca_system_score_codex":0.0007717317,"about_ca_system_score_gemma":0.00076368236,"threshold_uncertainty_score":0.725286},"labels":[],"label_agreement":null},{"id":"W4280610096","doi":"10.1016/j.ejca.2022.03.042","title":"Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Medicine; Metformin; Internal medicine; Prostate cancer; Abiraterone acetate; Concomitant; Cancer; Oncology; Androgen deprivation therapy; Insulin","score_opus":0.005896620798558395,"score_gpt":0.2522685977528329,"score_spread":0.24637197695427449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280610096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844219,0.014296468,0.000042372496,0.00010090498,0.0002756697,0.00022532702,0.00036245873,0.0000013689872,0.000273528],"genre_scores_gemma":[0.99429375,0.0047048074,0.00026084116,0.00013183094,0.00016925954,0.000020062604,0.000013487124,0.000024746081,0.00038121946],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99855095,0.00029124971,0.0005088512,0.00019062846,0.00030345848,0.00015487518],"domain_scores_gemma":[0.99895793,0.000051966144,0.0006282145,0.00012981154,0.00014663288,0.00008545667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058258505,0.00015747704,0.0005264101,0.00022939566,0.000052141564,0.000013666229,0.00011297451,0.000011784132,0.000049132468],"category_scores_gemma":[0.00003498274,0.000121696925,0.000091159396,0.00024058178,0.00010027001,0.00001379894,0.000053139953,0.00016027447,4.66416e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00847418,0.00054052024,0.066075094,0.00085576146,0.008918701,0.00008009586,0.006927335,0.018235177,0.8017669,0.00011436469,0.005393971,0.082617946],"study_design_scores_gemma":[0.019929001,0.0068104276,0.74085975,0.0003165682,0.0054183207,0.00006310401,0.0037976105,0.000323077,0.10285713,0.000027722355,0.11881403,0.0007832349],"about_ca_topic_score_codex":0.00025256234,"about_ca_topic_score_gemma":0.0007944598,"teacher_disagreement_score":0.6989097,"about_ca_system_score_codex":0.000037590948,"about_ca_system_score_gemma":0.0002958242,"threshold_uncertainty_score":0.49626565},"labels":[],"label_agreement":null},{"id":"W4281706448","doi":"10.1016/j.ejca.2022.04.021","title":"Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Sunitinib; Hazard ratio; Internal medicine; Oncology; Papillary renal cell carcinomas; Everolimus; Biomarker; Proportional hazards model; Renal cell carcinoma; Confidence interval; Clear cell renal cell carcinoma; Retrospective cohort study","score_opus":0.05651395345854476,"score_gpt":0.32688808438246064,"score_spread":0.2703741309239159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281706448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898413,0.007955734,0.0000066063367,0.00017571166,0.00012661316,0.00015437308,0.00031065647,0.0000031655288,0.0014258655],"genre_scores_gemma":[0.9985551,0.00036674298,0.00019605641,0.000037548383,0.0000658153,0.00000293818,0.00005563639,0.000032217635,0.0006879204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971627,0.00062153017,0.0009539138,0.00024615577,0.0007702613,0.0002454452],"domain_scores_gemma":[0.99794513,0.0001221329,0.00089254824,0.0006784759,0.00014502788,0.00021669686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006275739,0.00022314944,0.001162422,0.000899893,0.000030193072,0.000004492917,0.00028428933,0.000014175375,0.000603605],"category_scores_gemma":[0.000050594605,0.00014220201,0.0006859933,0.0007213991,0.00002982315,0.00005589199,0.00013457863,0.0002571054,0.0000012347907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028745208,0.0019152368,0.96154356,0.000025705896,0.0051714447,0.0029872917,0.0010133613,0.0070965877,0.008277844,0.0000011695557,0.0014999544,0.007593347],"study_design_scores_gemma":[0.004933891,0.011788103,0.97330487,0.00002618503,0.0061977366,0.000032306263,0.0001075985,0.000112706664,0.0014319179,8.0471835e-7,0.0019604599,0.000103405066],"about_ca_topic_score_codex":0.0014303261,"about_ca_topic_score_gemma":0.000050242692,"teacher_disagreement_score":0.01176135,"about_ca_system_score_codex":0.004267651,"about_ca_system_score_gemma":0.0005641299,"threshold_uncertainty_score":0.9995548},"labels":[],"label_agreement":null},{"id":"W4281754969","doi":"10.1016/j.ejca.2022.05.001","title":"Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"National Institute for Health and Care Research","keywords":"Medicine; Internal medicine; Odds ratio; Metronidazole; Retrospective cohort study; Confidence interval; Cancer; Clostridium difficile; Surgery; Antibiotics","score_opus":0.014218570216613286,"score_gpt":0.2518381329794141,"score_spread":0.2376195627628008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281754969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928538,0.005449047,0.000007452722,0.00039056348,0.00034743088,0.00028181888,0.00007188764,0.000010517756,0.00058746384],"genre_scores_gemma":[0.994442,0.004764673,0.000013059458,0.00008230938,0.00023198315,0.00001704967,0.000007178351,0.000046915327,0.00039485478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783415,0.0002883361,0.00051785476,0.00022087358,0.00083189044,0.0003068908],"domain_scores_gemma":[0.99909747,0.000052352254,0.0002917627,0.00013985537,0.00021482239,0.00020374062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005493027,0.00017771621,0.0003597374,0.00039350905,0.00013084873,0.000026395966,0.000116730844,0.000020293464,0.0003001044],"category_scores_gemma":[0.000010738453,0.0001380043,0.00008869209,0.0005569702,0.000051367762,0.00008641284,0.00007238739,0.00071832555,0.0000035077567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022048298,0.0006276208,0.9484207,0.00014306665,0.00008357571,0.0006120252,0.0011132902,0.0012648524,0.0016522902,0.0000013698353,0.0012046029,0.042671748],"study_design_scores_gemma":[0.011830748,0.0032633396,0.96195805,0.00047911576,0.00032219986,0.00015758818,0.0002671865,0.00008710211,0.009570219,0.0000014406623,0.011749256,0.00031378036],"about_ca_topic_score_codex":0.00014697906,"about_ca_topic_score_gemma":0.00004296219,"teacher_disagreement_score":0.042357966,"about_ca_system_score_codex":0.00043789102,"about_ca_system_score_gemma":0.0002670068,"threshold_uncertainty_score":0.5627652},"labels":[],"label_agreement":null},{"id":"W4281999473","doi":"10.1016/j.ejca.2022.04.026","title":"Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute for Health and Care Research; Institute of Cancer Research; Cancer Research UK; MedImmune; Roche; Clovis Oncology; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Hazard ratio; Mucin; Chemotherapy; Adenocarcinoma; Internal medicine; Oncology; Neoadjuvant therapy; Cohort; Gastroenterology; Post-hoc analysis; Confidence interval; Pathology; Cancer","score_opus":0.01734372737016166,"score_gpt":0.28875828146701227,"score_spread":0.2714145540968506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281999473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766952,0.021452984,0.0000041469884,0.0010135523,0.00015620132,0.00039492815,0.00009858997,0.000003310643,0.0001811063],"genre_scores_gemma":[0.99884,0.00037622274,0.000063023355,0.00033591257,0.00012834142,0.0000070566434,0.0000071856152,0.000030135649,0.00021214141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970394,0.00091042183,0.00067901297,0.00019193308,0.0009390152,0.00024020967],"domain_scores_gemma":[0.9985198,0.00010736614,0.000655516,0.00024994827,0.0003034927,0.000163927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017282662,0.00016320225,0.00080678024,0.0003478018,0.00009317026,0.000018220268,0.00021148099,0.000012468548,0.0004951001],"category_scores_gemma":[0.000084236024,0.00009006041,0.00027047892,0.0006531183,0.000095902025,0.000057547215,0.00009223574,0.00038818817,4.5515486e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0113701485,0.00035372595,0.9481098,0.000027005572,0.0022702126,0.00041735344,0.0011538146,0.00023812769,0.00024288538,0.0000049932905,0.00014707207,0.03566487],"study_design_scores_gemma":[0.012949003,0.0062049185,0.97903615,0.000045730794,0.00096664805,0.000014387589,0.00022917143,0.00001822154,0.00030175305,0.0000028903478,0.00015887723,0.00007222901],"about_ca_topic_score_codex":0.00019421,"about_ca_topic_score_gemma":0.0001127193,"teacher_disagreement_score":0.03559264,"about_ca_system_score_codex":0.00025394533,"about_ca_system_score_gemma":0.00032100346,"threshold_uncertainty_score":0.5420999},"labels":[],"label_agreement":null},{"id":"W4282915730","doi":"10.1016/j.ejca.2022.03.018","title":"Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"National Cancer Institute; Medical Research Council","keywords":"Osteosarcoma; Medicine; Physical therapy; Cancer research","score_opus":0.015455905230921807,"score_gpt":0.27156078751563373,"score_spread":0.2561048822847119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282915730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569094,0.001307456,0.0000625813,0.0014528545,0.00035053107,0.00015499255,0.0000076407605,0.000014648965,0.00095837767],"genre_scores_gemma":[0.99766743,0.000031758245,0.00020124306,0.0010600197,0.0008608076,0.0000034448935,0.00000418959,0.000050294584,0.000120839664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789727,0.0004296375,0.0004489803,0.0001921459,0.0008207316,0.00021125737],"domain_scores_gemma":[0.99905,0.00007200788,0.00041106265,0.00015315256,0.0001603024,0.00015345679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084822625,0.00014920947,0.00036046075,0.00017453452,0.00014081871,0.00003289457,0.0001255137,0.000009168738,0.00020768693],"category_scores_gemma":[0.00005744598,0.00012372775,0.000075658274,0.00022063575,0.00009163288,0.00014152302,0.00011418561,0.0006931361,0.000003631659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014939118,0.00031772495,0.9472849,0.00007917242,0.00012599716,0.0002545433,0.005447178,0.0005178588,0.000060049984,0.00002156868,0.0005815626,0.04381558],"study_design_scores_gemma":[0.0064038257,0.0022580102,0.9800126,0.0006006914,0.00011430567,0.00006762718,0.00082926336,0.000041139192,0.000038124137,0.000015814725,0.0094571635,0.00016142447],"about_ca_topic_score_codex":0.000050018447,"about_ca_topic_score_gemma":0.000036032034,"teacher_disagreement_score":0.043654155,"about_ca_system_score_codex":0.00015453478,"about_ca_system_score_gemma":0.00017409587,"threshold_uncertainty_score":0.5045471},"labels":[],"label_agreement":null},{"id":"W4282978369","doi":"10.1016/j.ejca.2022.05.002","title":"Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Sunnybrook Health Science Centre; Dalhousie University; University of Toronto; CancerCare Manitoba; University Health Network; Princess Margaret Cancer Centre; University of Calgary; University of Alberta; William Osler Health System; Queen's University; Juravinski Cancer Centre; University of Manitoba","funders":"","keywords":"Renal cell carcinoma; Medicine; Oncology; Immune checkpoint; Internal medicine; Nivolumab; Cancer research; Immunotherapy; Cancer","score_opus":0.010588852068646605,"score_gpt":0.221175130064015,"score_spread":0.21058627799536841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282978369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939991,0.0026440984,0.00002702992,0.00028183564,0.00012791573,0.00049562316,0.000038463975,0.000011837371,0.0023740523],"genre_scores_gemma":[0.9971518,0.0002356653,0.00067141716,0.00011441707,0.00011594011,0.00001292651,0.000019294952,0.00011617242,0.001562384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756,0.00019518191,0.0007933115,0.0002524106,0.0009103274,0.00028873788],"domain_scores_gemma":[0.99776167,0.000043091262,0.0011062679,0.00037179206,0.0005090748,0.00020812987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028921122,0.00032555044,0.00071055064,0.00020389247,0.00012075548,0.000011809359,0.00021540685,0.000016606891,0.0004985297],"category_scores_gemma":[0.000008124966,0.00019508299,0.0002409013,0.00029517952,0.00008155375,0.000101126316,0.0000703229,0.00042919515,0.000005372153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027527215,0.0020631184,0.92369336,0.00014268323,0.00047082966,0.0016165464,0.00130283,0.0033402708,0.03442924,2.2849261e-7,0.0003788606,0.0050347955],"study_design_scores_gemma":[0.023105606,0.020967705,0.78746396,0.00012843164,0.00025051224,0.000032842898,0.00016650277,0.0000094557445,0.165265,2.4953076e-7,0.0024214792,0.0001882724],"about_ca_topic_score_codex":0.000055662113,"about_ca_topic_score_gemma":0.000007213565,"teacher_disagreement_score":0.13622944,"about_ca_system_score_codex":0.00033124018,"about_ca_system_score_gemma":0.00024285584,"threshold_uncertainty_score":0.7955254},"labels":[],"label_agreement":null},{"id":"W4283025610","doi":"10.1016/j.ejca.2022.05.010","title":"The MUSES∗: a prognostic study on 1360 patients with sinonasal cancer undergoing endoscopic surgery-based treatment","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Surgical Oncology","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Università degli Studi dell'Insubria","keywords":"Medicine; Nomogram; Confidence interval; Population; Histology; Surgical margin; Adjuvant therapy; Surgery; Internal medicine; Cancer","score_opus":0.03341204246902888,"score_gpt":0.3068335041085461,"score_spread":0.2734214616395172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283025610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939366,0.0010911229,0.0000067470046,0.0027632152,0.0006715764,0.0004630393,0.000010774096,0.000012784568,0.0010441274],"genre_scores_gemma":[0.9980677,0.00012811704,0.000015166878,0.000904373,0.00032682522,0.000051070157,0.0000019891793,0.000040875533,0.0004639175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770135,0.00082659523,0.00043076026,0.000164955,0.00060878455,0.00026758466],"domain_scores_gemma":[0.99823725,0.00090746663,0.00035609628,0.00016145043,0.00017025803,0.00016748796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005683091,0.00015794778,0.00037525664,0.000099674784,0.00029315884,0.00002161146,0.00010938717,0.0000083380055,0.00025364617],"category_scores_gemma":[0.00011197245,0.00008161632,0.00012602044,0.0002016824,0.00005286326,0.000032406682,0.000025823725,0.00030441597,0.0000056961794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032480222,0.0020303808,0.9570602,0.000013567222,0.00036168398,0.001665089,0.0005001267,0.0008341938,0.000021616246,0.0000037059722,0.0011181603,0.03314325],"study_design_scores_gemma":[0.009260041,0.017556963,0.8740909,0.0002245878,0.00026917245,0.000012882317,0.00028350973,0.000012660162,0.000048091322,7.456739e-7,0.098145194,0.00009523568],"about_ca_topic_score_codex":0.00004995876,"about_ca_topic_score_gemma":0.00016949011,"teacher_disagreement_score":0.09702703,"about_ca_system_score_codex":0.00060113997,"about_ca_system_score_gemma":0.0011457414,"threshold_uncertainty_score":0.3328217},"labels":[],"label_agreement":null},{"id":"W4283701700","doi":"10.1016/j.ejca.2022.05.007","title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Merck","keywords":"Pembrolizumab; Salivary gland; Medicine; Carcinoma; Oncology; Internal medicine; Pathology; Cancer; Immunotherapy","score_opus":0.02752118178310694,"score_gpt":0.3232095080446759,"score_spread":0.295688326261569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283701700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953544,0.002833109,7.7081717e-7,0.00017936659,0.00006691168,0.001029875,0.000012524605,0.000002591795,0.0005204507],"genre_scores_gemma":[0.9996339,0.00008791383,0.000013083817,0.00012808054,0.000048606176,0.000041698113,0.000010150982,0.000023970057,0.000012561097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968576,0.0013940713,0.00047454526,0.00013345486,0.0010097867,0.00013057604],"domain_scores_gemma":[0.99909216,0.000049385428,0.0003703855,0.00018721294,0.00025662468,0.000044237633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016728106,0.00012546152,0.00031190604,0.00018378285,0.000037381655,0.000007553302,0.00012478458,0.0000056719846,0.00019391986],"category_scores_gemma":[0.000028721894,0.00007163189,0.000057738176,0.00029677703,0.000017616747,0.00006618128,0.000015676342,0.00019466979,5.436622e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008290678,0.00498927,0.9543095,0.000007645602,0.00015260841,0.00044066957,0.004263853,0.00205006,0.000007703897,6.1547e-7,0.000085263186,0.025402123],"study_design_scores_gemma":[0.08310881,0.011979659,0.90338844,0.00009717873,0.0003908847,0.000025944444,0.0006472784,0.00008664075,0.000044674878,0.0000032744563,0.00016359848,0.00006361379],"about_ca_topic_score_codex":0.00010351391,"about_ca_topic_score_gemma":0.00005979806,"teacher_disagreement_score":0.074818134,"about_ca_system_score_codex":0.00028075709,"about_ca_system_score_gemma":0.00017429651,"threshold_uncertainty_score":0.29210636},"labels":[],"label_agreement":null},{"id":"W4284884980","doi":"10.1016/j.ejca.2022.05.023","title":"Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company; Ono Pharmaceutical; Ignyta; Chugai Pharmaceutical; EMD Serono; Genentech; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Eisai; Puma Biotechnology; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Mirati Therapeutics; National Medical Research Council; Kissei; GlaxoSmithKline; Novartis Institutes for BioMedical Research; Amgen; Dainippon Sumitomo Pharma; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Rash; Internal medicine; Adverse effect; Clinical endpoint; Maculopapular rash; Discontinuation; Brain metastasis; Lung cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Gastroenterology; Phases of clinical research; T790M; non-small cell lung cancer (NSCLC); Cancer; Surgery; Toxicity; Epidermal growth factor receptor; Metastasis; Gefitinib; Clinical trial","score_opus":0.06437095391339918,"score_gpt":0.3997258231664293,"score_spread":0.3353548692530301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284884980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806321,0.0057524303,0.00018713123,0.0015666354,0.0009133438,0.002568533,0.0011337484,0.000013799178,0.0072322697],"genre_scores_gemma":[0.9924605,0.00033879717,0.00082889805,0.00030814673,0.00043043445,0.00020858807,0.000026478074,0.00007750318,0.0053206924],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978147,0.00025324055,0.0009526648,0.00030101114,0.0003857731,0.00029261742],"domain_scores_gemma":[0.9977579,0.000093975825,0.0011404307,0.00029337086,0.0004933174,0.00022100013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006073763,0.00024073223,0.00063221826,0.00017266053,0.00024953013,0.000043543165,0.00032342694,0.0000132746245,0.00025400915],"category_scores_gemma":[0.000041696738,0.00018372796,0.00016492524,0.00027243924,0.0000390408,0.00012447489,0.000113277034,0.00015886979,0.0000016761592],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07966519,0.16688545,0.01783648,0.00057068,0.01416291,0.005959494,0.089434095,0.0040041916,0.15686654,0.00003848816,0.05429747,0.410279],"study_design_scores_gemma":[0.51761097,0.1425594,0.0032948917,0.00086655276,0.0128491465,0.00021887613,0.012763795,0.0009161202,0.03427135,0.000018880293,0.2739223,0.0007077518],"about_ca_topic_score_codex":0.00035914406,"about_ca_topic_score_gemma":0.00009911137,"teacher_disagreement_score":0.43794575,"about_ca_system_score_codex":0.0010764917,"about_ca_system_score_gemma":0.0010684828,"threshold_uncertainty_score":0.74922085},"labels":[],"label_agreement":null},{"id":"W4285792204","doi":"10.1016/j.ejca.2022.06.008","title":"Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas","year":2022,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Energy Market Authority of Singapore; Myrovlytis Trust; Bristol-Myers Squibb; Childhood Cancer Canada; Andrew McDonough B+ Foundation; Exelixis; Roche; Ipsen; Osteosarcoma Institute; Bayer; Servier; Pfizer","keywords":"Medicine; Clinical trial; Sarcoma; Medical physics; Oncology; Internal medicine; Pathology","score_opus":0.08674196651169577,"score_gpt":0.3584144020360257,"score_spread":0.27167243552432996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285792204","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016549535,0.9975267,0.000015617255,0.00018861741,0.00069772743,0.0011991618,0.000045983685,0.000007664164,0.00015304101],"genre_scores_gemma":[0.0027383026,0.9938875,0.002177543,0.00005169693,0.000734712,0.00011897496,0.00004750692,0.00011267067,0.0001311087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961553,0.00040628389,0.002108023,0.00032494147,0.00063839596,0.00036705687],"domain_scores_gemma":[0.99738926,0.00018056262,0.0017629995,0.00024213642,0.00021134384,0.00021371403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014887727,0.00041599886,0.0019747491,0.00073865184,0.0000661161,0.000011031439,0.00022102246,0.000044236574,0.00029616273],"category_scores_gemma":[0.0002306678,0.00028892624,0.0006468435,0.00052953104,0.00004630254,0.0000554623,0.0000843419,0.00058622676,0.0000045140264],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010259172,0.0007841009,0.00090746884,0.0040764688,0.00048342184,0.0012752161,0.00020505616,0.000008011169,0.000004914712,0.000002147942,0.0024803325,0.9896703],"study_design_scores_gemma":[0.003642257,0.00070301467,0.0017052526,0.0072951745,0.0014048353,0.00023639873,0.00014588676,0.0000015579836,0.000066652006,0.0000010130075,0.9845702,0.00022772737],"about_ca_topic_score_codex":0.0000125261395,"about_ca_topic_score_gemma":0.000025418407,"teacher_disagreement_score":0.9894425,"about_ca_system_score_codex":0.0006561866,"about_ca_system_score_gemma":0.0019133523,"threshold_uncertainty_score":0.9999563},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4285792418","doi":"10.1016/j.ejca.2022.06.006","title":"Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference","year":2022,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Germ cell tumors; Teratoma; Germ cell; Pathology; Malignancy; Consensus conference; Ovarian cancer; Grading (engineering); Malignant transformation; Biology; Somatic cell; Yolk sac; Sarcoma; Medicine; Cancer; Internal medicine; Chemotherapy; Embryo","score_opus":0.22525705659946463,"score_gpt":0.4165859327629026,"score_spread":0.191328876163438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285792418","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026670662,0.9957725,0.000010542369,0.00021317431,0.00042827087,0.00035455334,0.00017207499,0.000008203333,0.0003736586],"genre_scores_gemma":[0.048357558,0.9508595,0.00014442061,0.000118056094,0.00034843115,0.000010097328,0.000030340216,0.00005004486,0.00008155601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973202,0.0009664277,0.0010017549,0.00022667057,0.0003436077,0.00014135432],"domain_scores_gemma":[0.9961574,0.0010479761,0.0021520918,0.00035719285,0.00015025174,0.00013508518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005918305,0.00026841537,0.001221891,0.00006876562,0.00008559017,0.000040516265,0.00017704132,0.000044672044,0.00043470282],"category_scores_gemma":[0.0008488039,0.00013876191,0.0004326147,0.00011826429,0.00016516595,0.000014922288,0.00009184104,0.00065975444,0.00000230934],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011079749,0.00011823958,0.0014572443,0.0010309811,0.0009766524,0.034343533,0.00012147459,8.698541e-7,0.000001912849,0.000006487557,0.00029260904,0.9615392],"study_design_scores_gemma":[0.0014136836,0.00042705907,0.042299293,0.019132243,0.011902999,0.010058661,0.000062595616,0.000002207346,8.2388567e-7,0.000041779393,0.91448146,0.00017720024],"about_ca_topic_score_codex":0.000014253198,"about_ca_topic_score_gemma":0.0000013873747,"teacher_disagreement_score":0.961362,"about_ca_system_score_codex":0.000058301215,"about_ca_system_score_gemma":0.0007328425,"threshold_uncertainty_score":0.56585467},"labels":[],"label_agreement":null},{"id":"W4286447573","doi":"10.1016/j.ejca.2022.06.045","title":"Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials","year":2022,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Avid Radiopharmaceuticals; Astellas Pharma; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; Mirati Therapeutics; Genentech; Symphogen; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Biomarker; Medicine; Clinical trial; Pharmacodynamics; Oncology; Internal medicine; Imaging biomarker; Drug development; Biomarker discovery; Drug; Pharmacokinetics; Pharmacology; Radiology; Magnetic resonance imaging","score_opus":0.45040254010270075,"score_gpt":0.6640550157850593,"score_spread":0.21365247568235857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286447573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019237732,0.9929102,0.000016916843,0.00012876456,0.00046969965,0.00048107037,0.00016061538,0.0000057768484,0.0039031997],"genre_scores_gemma":[0.0015945734,0.99705946,0.00007495052,0.000052460164,0.0009936438,0.0000176825,0.00003167301,0.00005645673,0.00011906865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913159,0.0039465497,0.004008683,0.00021765019,0.00029505033,0.00021615924],"domain_scores_gemma":[0.99456424,0.0014333683,0.003334787,0.00025608903,0.00010402856,0.00030751794],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010627376,0.0002710634,0.0034198854,0.000236305,0.000027446711,0.0000069676585,0.00040047074,0.00008458939,0.0047895634],"category_scores_gemma":[0.0011020012,0.00018416368,0.002493421,0.00046934522,0.00016089961,0.00003871331,0.00006267931,0.0015077291,0.000007888475],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010332142,0.0008334604,0.000028045422,0.0015935574,0.0028964109,0.0006815443,0.000019325897,0.0000057517695,0.000621825,7.8822654e-7,0.0034734788,0.9888126],"study_design_scores_gemma":[0.0069468655,0.0009748283,0.000045062967,0.0028720552,0.0041383426,0.00062844617,0.000010144934,0.000016302523,0.00001660163,0.0000011308285,0.9842138,0.00013638037],"about_ca_topic_score_codex":0.0000036742492,"about_ca_topic_score_gemma":1.4136573e-7,"teacher_disagreement_score":0.9886762,"about_ca_system_score_codex":0.00067810074,"about_ca_system_score_gemma":0.0021255307,"threshold_uncertainty_score":0.9961202},"labels":[],"label_agreement":null},{"id":"W4288950951","doi":"10.1016/j.ejca.2022.03.016","title":"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Chugai Pharmaceutical; Genentech; Geistlich Pharma; PharmaMar; Ono Pharmaceutical; Eisai; NuCana; EMD Serono; Mersana Therapeutics; Deciphera Pharmaceuticals; Clovis Oncology; Incyte; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Quality of life (healthcare); Medicine; Cervical cancer; Internal medicine; Population; Chemotherapy; Oncology; Cancer; Physical therapy","score_opus":0.022188848600309397,"score_gpt":0.2960530835257411,"score_spread":0.2738642349254317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288950951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993101,0.0040499084,0.000016409325,0.00035376998,0.00093380903,0.0002783219,0.000020639736,0.000011464223,0.0012346964],"genre_scores_gemma":[0.9986867,0.00046281453,0.00004029728,0.00040553816,0.00023966882,0.000033397777,0.0000029337943,0.000043674863,0.00008501873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972888,0.00040016545,0.0008620808,0.0002437222,0.0009556587,0.0002495444],"domain_scores_gemma":[0.9977017,0.0002441206,0.001196143,0.00021419143,0.00032382164,0.00032004307],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051108695,0.00021056486,0.000717805,0.00017983615,0.000084102496,0.00000989861,0.00011394121,0.000025388743,0.0010824057],"category_scores_gemma":[0.00014049812,0.0001477483,0.00013739323,0.00048733712,0.00010136858,0.000068852365,0.000069651804,0.00042107794,5.9746174e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17731713,0.0022183028,0.51107854,0.0010076072,0.0049923514,0.00031083956,0.0048546228,0.0005748723,0.0034543923,0.000029527417,0.00048038867,0.29368144],"study_design_scores_gemma":[0.03325811,0.020581417,0.93947566,0.000553622,0.0003775095,0.00001485846,0.00048761675,0.000008502902,0.0018814894,0.000008463625,0.0031578718,0.00019486013],"about_ca_topic_score_codex":0.00013779466,"about_ca_topic_score_gemma":0.000012979833,"teacher_disagreement_score":0.42839715,"about_ca_system_score_codex":0.0004313008,"about_ca_system_score_gemma":0.00023143727,"threshold_uncertainty_score":0.9998307},"labels":[],"label_agreement":null},{"id":"W4289766408","doi":"10.1016/j.ejca.2022.06.011","title":"Incorporating progesterone receptor expression into the PREDICT breast prognostic model","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Servicio Gallego de Salud; Institute of Biomedical Sciences, Academia Sinica; National Medical Research Council; Cancer Council Tasmania; Cancer Council Victoria; Medical Research Council; Canadian Institutes of Health Research; Programme Grants for Applied Research; Manchester Biomedical Research Centre; U.S. Army; Imperial Experimental Cancer Medicine Centre; National Institutes of Health; National University Health System; Ministero dello Sviluppo Economico; National Health and Medical Research Council; Oulun Yliopisto; Deutsche Krebshilfe; Norges Forskningsråd; Stockholms Läns Landsting; Karolinska Institutet; Centers for Disease Control and Prevention; Leids Universitair Medisch Centrum; National Research Foundation of Korea; Korea Health Industry Development Institute; Ministry of Education, Science and Technology; Bundesministerium für Bildung und Forschung; Ministry of Education, Culture, Sports, Science and Technology; Ministerio de Economía y Competitividad; Academy of Finland; National Breast Cancer Foundation; Ministry of Health, Labour and Welfare; Wellcome Trust; Memorial Sloan-Kettering Cancer Center; Fondation du cancer du sein du Québec; Mark Foundation For Cancer Research; Cancer Australia; Huntsman Cancer Institute; KWF Kankerbestrijding; National University of Singapore; Cancer Research UK; Deutsches Krebsforschungszentrum; National Institute for Health and Care Research; National Research Foundation; National Research Foundation Singapore; Breast Cancer Research Foundation; University of Cambridge; Huntsman Cancer Foundation; Cancer Council NSW; Susan G. Komen for the Cure; Taiwan Biobank; Kreftforeningen; Academia Sinica; HORIZON EUROPE Framework Programme; Associazione Italiana per la Ricerca sul Cancro; Ministère du Développement Économique, de l’Innovation et de l’Exportation; Lon V. Smith Foundation; Agency for Science, Technology and Research; Kerry Group Kuok Foundation; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Breast Cancer Campaign; University of Utah; Cancer Council South Australia; Fonds Wetenschappelijk Onderzoek; National University Cancer Institute, Singapore; Cancerfonden; National Cancer Institute; Cancer Institute NSW; Intermountain Healthcare; Japan Agency for Medical Research and Development; Medical Research and Materiel Command; Ministry of Health -Singapore; European Commission; U.S. Department of Health and Human Services","keywords":"Progesterone receptor; Oestrogen receptor; Expression (computer science); Oncology; Internal medicine; Medicine; Biology; Breast cancer; Computer science; Estrogen receptor; Cancer","score_opus":0.010208485526578246,"score_gpt":0.24246274836484374,"score_spread":0.2322542628382655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289766408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98547685,0.007866062,0.0012614066,0.0036849016,0.0005899903,0.00021462276,0.000069894406,0.00001105694,0.0008252184],"genre_scores_gemma":[0.99759275,0.00014623838,0.001033049,0.00022754299,0.00067058404,0.00003575017,0.000011818601,0.000034022956,0.00024826403],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99882615,0.00031759008,0.00027347027,0.00015467485,0.00029385302,0.00013428331],"domain_scores_gemma":[0.999236,0.0000110019755,0.00038454286,0.00017047906,0.00014212567,0.000055867495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004720431,0.00012280987,0.00012047778,0.000026077949,0.0002983026,0.000020645093,0.0003000554,0.0000100997095,0.000034120247],"category_scores_gemma":[0.000033192548,0.00008069424,0.00007562759,0.00007441291,0.000071859286,0.000007523508,0.00033091297,0.00018605695,0.0000018594542],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002470289,0.0005124419,0.11084512,0.000064188025,0.00084668683,0.00010501961,0.0065616523,0.059460454,0.6149977,0.000041245454,0.05401111,0.1500841],"study_design_scores_gemma":[0.02423169,0.009718147,0.26335743,0.0017845386,0.0016033959,0.0029866023,0.015171085,0.003694383,0.19568741,0.0006055757,0.47802922,0.0031305396],"about_ca_topic_score_codex":0.000005515183,"about_ca_topic_score_gemma":0.0000060038356,"teacher_disagreement_score":0.4240181,"about_ca_system_score_codex":0.000064308835,"about_ca_system_score_gemma":0.0001440746,"threshold_uncertainty_score":0.32906157},"labels":[],"label_agreement":null},{"id":"W4291012346","doi":"10.1016/j.ejca.2022.06.041","title":"Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sandoz; Merck Sharp and Dohme; EMD Serono; Genentech; Qbiotics; Sun Pharma; Astellas Pharma; Eisai; Daiichi-Sankyo; BeiGene; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Amarin Corporation; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; Les Laboratories Pierre Fabre; Array BioPharma; AbbVie; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Sanofi; Celgene; Novartis; Merck; GlaxoSmithKline; American Society of Clinical Oncology; Bristol-Myers Squibb; Amgen; Hexal AG; Incyte; Pfizer; Gilead UK and Ireland Corporate Contributions; Castle Biosciences; Roche; Astellas Pharma US","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Cancer; Internal medicine; Hazard ratio; Oncology; Stage (stratigraphy); Adjuvant; Immunotherapy; Confidence interval","score_opus":0.02135862200431434,"score_gpt":0.31096001516852717,"score_spread":0.28960139316421285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291012346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545956,0.0007648071,0.000014972036,0.00037252175,0.0011478945,0.00044813787,0.00006316566,0.000009077666,0.001719854],"genre_scores_gemma":[0.99822795,0.00015159191,0.00022845308,0.00013509378,0.00011866547,0.0000071044005,0.000008295817,0.000055940705,0.0010668881],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974603,0.00042261824,0.0008537561,0.00019681935,0.00080862024,0.00025789926],"domain_scores_gemma":[0.9986111,0.000056162902,0.00075512007,0.00027862875,0.00019601447,0.000102961916],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009964657,0.00019788014,0.00060518284,0.00024873167,0.00008171949,0.00002306997,0.00022892596,0.000014746279,0.0024270366],"category_scores_gemma":[0.000023864464,0.00014757439,0.0001935639,0.00021504347,0.00006992125,0.00012633721,0.00008527513,0.00036630113,0.000002437652],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78519297,0.0016420525,0.14931433,0.000097177246,0.0013181239,0.00029536622,0.0027973272,0.0001452245,0.0016242217,0.000008011484,0.0012481472,0.05631703],"study_design_scores_gemma":[0.2973337,0.008689255,0.67685246,0.00025499862,0.0001865517,0.0000065361614,0.0011952826,0.0000070479296,0.00022224085,4.1183316e-7,0.015059865,0.00019167311],"about_ca_topic_score_codex":0.00010752767,"about_ca_topic_score_gemma":0.000017681063,"teacher_disagreement_score":0.5275381,"about_ca_system_score_codex":0.0005627233,"about_ca_system_score_gemma":0.0003470104,"threshold_uncertainty_score":0.9984849},"labels":[],"label_agreement":null},{"id":"W4294760508","doi":"10.1016/j.ejca.2022.08.003","title":"A risk stratification model for toxicities in phase 1 immunotherapy trials","year":2022,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"CRIS Cancer Foundation; Sociedad Española de Oncología Médica","keywords":"Medicine; Clinical trial; Adverse effect; Toxicity; Internal medicine; Oncology; Risk stratification; Immunotherapy; Pharmacology; Intensive care medicine; Cancer","score_opus":0.2056162104715523,"score_gpt":0.4513113053180979,"score_spread":0.2456950948465456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294760508","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006868531,0.99504346,0.0021968023,0.000119241675,0.00060453836,0.0011243089,0.00035477616,0.00000865479,0.00047950694],"genre_scores_gemma":[0.00007156987,0.99694884,0.00055486313,0.0001570775,0.000723331,0.000100294885,0.000039400373,0.00010247519,0.0013021395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956239,0.0013277233,0.0023152374,0.0001971902,0.00034498048,0.00019098102],"domain_scores_gemma":[0.9960939,0.00036553762,0.0031008006,0.00026249458,0.0001125645,0.00006465166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006683629,0.00028941588,0.0021708906,0.0004119953,0.00007370798,0.000041488525,0.0002672164,0.000052890326,0.00082827156],"category_scores_gemma":[0.00025164493,0.00020473964,0.001378985,0.00024437672,0.00004942315,0.0000838448,0.000012951464,0.00059205934,0.0000014168971],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036793563,0.00016596011,7.8720694e-7,0.0014035704,0.00091514864,0.000030214058,0.0005178175,0.000054132164,0.000077113575,0.0000068663344,0.0027421308,0.99040693],"study_design_scores_gemma":[0.008265973,0.00097123376,0.0000039355878,0.0050031506,0.0011882174,0.00006648069,0.00008721487,0.0001863307,0.000010195546,0.000021740234,0.9840032,0.00019232724],"about_ca_topic_score_codex":0.000011819119,"about_ca_topic_score_gemma":0.000007790937,"teacher_disagreement_score":0.9902146,"about_ca_system_score_codex":0.00050437887,"about_ca_system_score_gemma":0.0012439362,"threshold_uncertainty_score":0.9068993},"labels":[],"label_agreement":null},{"id":"W4296929566","doi":"10.1016/j.ejca.2022.09.002","title":"Corrigendum to ‘p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib’[Eur J of Cancer 55 (2016) 98–110]","year":2022,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Vemurafenib; Melanoma; Medicine; Cancer research; Protein kinase B; PI3K/AKT/mTOR pathway; MAPK/ERK pathway; Metastatic melanoma; Phosphorylation; Chemistry; Signal transduction","score_opus":0.015286994784977513,"score_gpt":0.2587760244581139,"score_spread":0.24348902967313635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296929566","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5170059,0.1117972,0.0033245392,0.0060548414,0.19157326,0.0025947536,0.007887383,0.00009335049,0.15966874],"genre_scores_gemma":[0.18313183,0.020470703,0.0015233725,0.006665242,0.022825392,0.00010242989,0.0017345716,0.0007869956,0.76275945],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964208,0.00055124366,0.0010871928,0.0006315181,0.00078995427,0.0005193114],"domain_scores_gemma":[0.9967121,0.000018346193,0.0014604157,0.0006317388,0.0007300834,0.00044730978],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007396342,0.000538935,0.0008204907,0.00029379938,0.00013997118,0.00005541726,0.0007942398,0.00019646401,0.0009588105],"category_scores_gemma":[0.00022024121,0.0005076895,0.00036592188,0.00028928285,0.00006377285,0.00001795524,0.00038121827,0.0008132593,0.000037457456],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038974686,0.00005352741,0.00014151973,0.00006640832,0.00028674075,0.00012932684,0.00017070184,0.00006567586,0.31583282,0.000003816144,0.67177504,0.011084678],"study_design_scores_gemma":[0.00065525546,0.0011950745,0.0025851608,0.00034249967,0.00017864037,0.00007146529,0.0000896151,0.0000021174353,0.09218858,0.000002440914,0.90217596,0.00051320245],"about_ca_topic_score_codex":0.00027952372,"about_ca_topic_score_gemma":0.00014186888,"teacher_disagreement_score":0.6030907,"about_ca_system_score_codex":0.00023199196,"about_ca_system_score_gemma":0.0011335182,"threshold_uncertainty_score":0.99995446},"labels":[],"label_agreement":null},{"id":"W4306711477","doi":"10.1016/j.ejca.2022.10.003","title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Aptitude Health; Oncolytics Biotech; Eisai; Seagen; Bayer HealthCare; G1 Therapeutics; Silverback Therapeutics; Puma Biotechnology; BioTheranostics; Ipsen; OncoSec Medical; Syndax Pharmaceuticals; Mersana Therapeutics; Queen Mary University of London; Clovis Oncology; Mylan; MacroGenics; Celldex Therapeutics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Ipsen Biopharmaceuticals; F. Hoffmann-La Roche; Radius Health; Amgen; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Baxalta; Foundation Medicine; Genomic Health; AbbVie; Revolution Medicines; Exelixis; Sanofi; Incyte; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Breast cancer; Nausea; Population; Vinorelbine; Gemcitabine; Oncology; Eribulin; Metastatic breast cancer; Capecitabine; Cancer; Chemotherapy; Physical therapy; Colorectal cancer; Cisplatin","score_opus":0.05695953814471598,"score_gpt":0.39383531743827,"score_spread":0.336875779293554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306711477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768846,0.008865759,0.00018202867,0.011459462,0.0008557728,0.0010130854,0.00051293295,0.0000074808886,0.00021885199],"genre_scores_gemma":[0.9978086,0.00092167483,0.00018618171,0.0007649444,0.00019231546,0.000031412823,0.0000040668597,0.000046392448,0.000044412787],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9937803,0.0023762868,0.0021647913,0.00020943406,0.0011605974,0.0003085677],"domain_scores_gemma":[0.9964573,0.00027345636,0.0025383746,0.0002876467,0.00029812072,0.00014510764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044186437,0.00022175345,0.0012995601,0.00030108466,0.00006620646,0.000007619773,0.00034120498,0.000015585758,0.000855952],"category_scores_gemma":[0.00018484573,0.00016287006,0.00025053206,0.0008511509,0.00019854328,0.00012465096,0.000040427065,0.00078739505,3.0735927e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7728052,0.0011598567,0.00083911774,0.00013841005,0.00074373104,0.00009506236,0.015902987,0.002586125,0.0008469902,0.00007353487,0.00031504105,0.20449392],"study_design_scores_gemma":[0.9161226,0.012233646,0.04986624,0.0008104125,0.00019929255,0.000110427594,0.0119191585,0.000060848834,0.0006769149,0.00014156308,0.0075399852,0.00031890217],"about_ca_topic_score_codex":0.0016028754,"about_ca_topic_score_gemma":0.00056685857,"teacher_disagreement_score":0.20417503,"about_ca_system_score_codex":0.0013372971,"about_ca_system_score_gemma":0.0018517073,"threshold_uncertainty_score":0.9372074},"labels":[],"label_agreement":null},{"id":"W4307041077","doi":"10.1016/j.ejca.2022.10.011","title":"Head and neck cancer predictive risk estimator to determine control and therapeutic outcomes of radiotherapy (HNC-PREDICTOR): development, international multi-institutional validation, and web implementation of clinic-ready model-based risk stratification for head and neck cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"U.S. National Library of Medicine; National Institute of Biomedical Imaging and Bioengineering; National Institutes of Health; National Cancer Institute; National Institute of Dental and Craniofacial Research; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Head and neck cancer; Radiation therapy; Cohort; Stage (stratigraphy); Propensity score matching; Internal medicine; Oncology","score_opus":0.05362125233116699,"score_gpt":0.3936935447252118,"score_spread":0.3400722923940448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307041077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743131,0.0072740717,0.014565471,0.0012406321,0.00026541838,0.00066058885,0.0016591315,0.000007645169,0.000013960251],"genre_scores_gemma":[0.98749644,0.003596232,0.008192596,0.00038118535,0.00012316456,0.000122057936,0.00001669435,0.000025679235,0.000045950546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835414,0.00015107299,0.0007678466,0.00023807857,0.00034527338,0.00014356474],"domain_scores_gemma":[0.9983818,0.00013713019,0.0007900964,0.0000844034,0.00047049508,0.00013608905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006753561,0.00018347948,0.00049340446,0.00016735413,0.00022917517,0.000018768786,0.000076114105,0.000020481828,0.00005561417],"category_scores_gemma":[0.00006617091,0.00014721684,0.000052077357,0.00008092438,0.00013344528,0.000119418735,0.00002865763,0.0001599539,5.187841e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021515023,0.00010981958,0.8689622,0.0000931421,0.000905641,0.000001988292,0.0022416282,0.004493749,0.0032022716,0.000013800183,0.00017262848,0.1176516],"study_design_scores_gemma":[0.016619407,0.0014519795,0.9404119,0.0002185344,0.00042971567,0.0000089934065,0.0003147357,0.036535576,0.0009372207,0.00001212524,0.002918543,0.0001412556],"about_ca_topic_score_codex":0.00020588658,"about_ca_topic_score_gemma":0.0004675748,"teacher_disagreement_score":0.11751034,"about_ca_system_score_codex":0.00019357508,"about_ca_system_score_gemma":0.00068804517,"threshold_uncertainty_score":0.60033286},"labels":[],"label_agreement":null},{"id":"W4307460411","doi":"10.1016/s0959-8049(22)00845-0","title":"Superior efficacy of a dual EGFR-DNA targeting combi-molecule “ZR2002” in comparison with its analogues 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline in a human osteosarcoma xenograft model","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Quinazolinone synthesis and applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"In vivo; Prodrug; Chemistry; Quinazoline; Pharmacology; Western blot; Epidermal growth factor receptor; Pharmacokinetics; Metabolite; Phosphorylation; Mechanism of action; In vitro; DNA damage; Cancer research; DNA; Receptor; Biochemistry; Biology; Stereochemistry","score_opus":0.02085764652218134,"score_gpt":0.27539861340429855,"score_spread":0.2545409668821172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307460411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940947,0.0035558064,0.000043531563,0.00029164815,0.000020385603,0.00011250518,0.00005853195,0.000011896897,0.0018109563],"genre_scores_gemma":[0.99912184,0.00010476725,0.0004148537,0.00004240414,0.00010042125,0.000017333019,0.000015952539,0.000055323668,0.00012707479],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977426,0.00020761839,0.0010392286,0.0002708676,0.00040905798,0.00033063858],"domain_scores_gemma":[0.9988007,0.00008560166,0.00066745095,0.00020906416,0.00012276294,0.00011444844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074064144,0.000226141,0.000562871,0.00024279146,0.00014636588,0.000034515037,0.00034315424,0.00002602276,0.00020631777],"category_scores_gemma":[0.000040665636,0.00021150999,0.00009509902,0.0003151206,0.00011328772,0.000108561006,0.00017680648,0.00057529367,9.179376e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008920811,0.0018143234,0.07373559,0.00020633939,0.00015455339,0.00048494153,0.0070416047,0.033950195,0.8714674,0.0003777937,0.00040712088,0.0094680805],"study_design_scores_gemma":[0.037723195,0.0032456378,0.29425344,0.002454465,0.00067887525,0.00055388495,0.015915107,0.04527198,0.58299255,0.00013090468,0.013985074,0.0027949053],"about_ca_topic_score_codex":0.000058895937,"about_ca_topic_score_gemma":0.00012858622,"teacher_disagreement_score":0.28847483,"about_ca_system_score_codex":0.00012861371,"about_ca_system_score_gemma":0.0001185056,"threshold_uncertainty_score":0.8625127},"labels":[],"label_agreement":null},{"id":"W4307460419","doi":"10.1016/s0959-8049(22)01123-6","title":"Spatial transcriptomics analysis for spatial biomarker discovery in glioblastoma","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Transcriptome; Computational biology; Spatial analysis; Tumour heterogeneity; Biology; Computer science; Glioblastoma; Gene; Gene expression; Cancer; Cancer research; Genetics","score_opus":0.016149360673012588,"score_gpt":0.25037736121148446,"score_spread":0.23422800053847187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307460419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8971686,0.0014240828,0.09974162,0.00026486706,0.0009148504,0.00012105045,0.00016142507,0.0000032472642,0.00020029192],"genre_scores_gemma":[0.99839574,0.00017203411,0.00022361735,0.0003003095,0.00052243593,0.000008779001,0.000024728937,0.000040877912,0.00031148625],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854493,0.0002735159,0.0005088635,0.00021808415,0.00023196025,0.00022266826],"domain_scores_gemma":[0.9993936,0.00001414714,0.0002595113,0.00016059139,0.00009896707,0.000073187424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006668989,0.0001505395,0.00026880813,0.00023188196,0.00009587449,0.00003998988,0.00032700578,0.000026094547,0.0000827648],"category_scores_gemma":[0.000027374792,0.00014522113,0.0004353717,0.00025779128,0.0000459928,0.000011071136,0.000048875336,0.00017924358,4.3363139e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007928236,0.0003712689,0.057940226,0.000030573836,0.0013852895,0.00011166917,0.0004798143,0.02285073,0.8502062,0.000013527454,0.0017436029,0.05693884],"study_design_scores_gemma":[0.018392662,0.0072510513,0.22670288,0.000075379015,0.0019890522,0.000121915735,0.00064002664,0.0077867564,0.19537999,0.000064402826,0.54011536,0.0014805255],"about_ca_topic_score_codex":0.0001436936,"about_ca_topic_score_gemma":0.0011351987,"teacher_disagreement_score":0.6548262,"about_ca_system_score_codex":0.00006150867,"about_ca_system_score_gemma":0.0001321532,"threshold_uncertainty_score":0.5921946},"labels":[],"label_agreement":null},{"id":"W4307460432","doi":"10.1016/s0959-8049(22)01112-1","title":"Expression of the sortilin 1 receptor (SORT1) in healthy and tumor tissues","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Medicinal Plant Pharmacodynamics Research","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Cancer; Breast cancer; Medicine; Immunohistochemistry; Tissue microarray; Pancreatic cancer; Colorectal cancer; Internal medicine; Cancer research; Oncology; Ovarian cancer; Pathology","score_opus":0.1084201530627934,"score_gpt":0.4659941842901355,"score_spread":0.3575740312273421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307460432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98587596,0.008168909,0.000006341509,0.0030101608,0.0012970055,0.00016838707,0.00005558279,0.000003547455,0.0014141278],"genre_scores_gemma":[0.9959334,0.0018692166,0.000050810388,0.0012940392,0.00022481901,0.000005204408,0.0000011502192,0.000017423516,0.00060393877],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961746,0.0025371115,0.000538101,0.000114765026,0.00041755792,0.00021790044],"domain_scores_gemma":[0.99899656,0.00021268014,0.00045468047,0.00009248687,0.000090392525,0.00015322494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003263992,0.000091547656,0.00021203232,0.0001414662,0.00014693543,0.000005070882,0.00042237304,0.000015602682,0.0029692727],"category_scores_gemma":[0.000106506064,0.000064763524,0.00005177714,0.00021249392,0.00013879195,0.000057834604,0.00023898047,0.0014597591,0.0000037283307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010895725,0.00048858655,0.1323722,0.0002411004,0.000116509116,0.00077163323,0.004720941,0.0077699316,0.719727,0.00008398935,0.057677705,0.065134704],"study_design_scores_gemma":[0.006452998,0.0013245207,0.036743663,0.0002268769,0.000081688384,0.00031439387,0.0011609304,0.0019435238,0.07157588,0.00006396538,0.87989193,0.00021960716],"about_ca_topic_score_codex":0.000013910802,"about_ca_topic_score_gemma":0.0000110957035,"teacher_disagreement_score":0.82221425,"about_ca_system_score_codex":0.000097125674,"about_ca_system_score_gemma":0.00019428106,"threshold_uncertainty_score":0.99794215},"labels":[],"label_agreement":null},{"id":"W4307571104","doi":"10.1016/j.ejca.2022.10.013","title":"Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Skeletal muscle; Obesity paradox; Overweight; Internal medicine; Body mass index; Cancer; Lung cancer; Weight loss; Oncology; Hazard ratio; Obesity; Proportional hazards model; Population; Endocrinology; Confidence interval","score_opus":0.018650681478596793,"score_gpt":0.2964493872988066,"score_spread":0.2777987058202098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307571104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930883,0.005603998,0.000039949107,0.00013942273,0.0002691024,0.0006406068,0.0000676687,0.0000052255405,0.00014574936],"genre_scores_gemma":[0.9985867,0.0010377351,0.000038183876,0.000035476143,0.00016644124,0.000026606456,0.0000016744995,0.00004081617,0.00006637907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986845,0.00030155218,0.00038835005,0.00015588173,0.00030811783,0.00016158863],"domain_scores_gemma":[0.9989524,0.00011143644,0.0005449829,0.00010954393,0.00021752423,0.00006412028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007113895,0.00015304452,0.0006130969,0.00013079564,0.000057288427,0.0000056850695,0.00009544947,0.000016038071,0.00010743243],"category_scores_gemma":[0.000031034142,0.00010663933,0.00010890686,0.00017754939,0.000088877845,0.000051237814,0.000015783806,0.00029193005,6.1928525e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.085127905,0.00036702616,0.58616483,0.00047034954,0.0018374017,0.0002048449,0.0046245297,0.0069724806,0.12705337,0.000016878743,0.00025491766,0.18690549],"study_design_scores_gemma":[0.032252826,0.023793772,0.9029859,0.0011257604,0.0004300827,0.00002968475,0.00033668004,0.00016275924,0.03147514,0.000016438371,0.00711189,0.00027910864],"about_ca_topic_score_codex":0.0026203487,"about_ca_topic_score_gemma":0.0005093022,"teacher_disagreement_score":0.31682104,"about_ca_system_score_codex":0.0004279071,"about_ca_system_score_gemma":0.00031830993,"threshold_uncertainty_score":0.43486258},"labels":[],"label_agreement":null},{"id":"W4307908218","doi":"10.1016/s0959-8049(22)01056-5","title":"Comparative pan-cancer transcriptomics reveals that aberrant expression of long non-coding RNAs define cancers, tumor progression and immune cell exclusion","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Biology; Epigenetics; Cancer; Transcriptome; Long non-coding RNA; Gene; Context (archaeology); Computational biology; Genome; Gene expression; Cancer research; RNA; Genetics; Bioinformatics","score_opus":0.022714271353579896,"score_gpt":0.3011476798402584,"score_spread":0.2784334084866785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307908218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91930395,0.06394891,0.01437445,0.00023469831,0.0007018785,0.00044962304,0.00008553274,0.000006000624,0.00089492864],"genre_scores_gemma":[0.9916341,0.007017717,0.00057505886,0.000112950955,0.0002225672,0.000026394186,0.000014288356,0.000060076036,0.0003368821],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976206,0.0005260907,0.00058255624,0.00032262973,0.0006293281,0.0003187905],"domain_scores_gemma":[0.9985307,0.000016030677,0.0007970654,0.00025236365,0.00025843055,0.00014539977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009537015,0.00023166761,0.00043134415,0.00013904649,0.00024464398,0.000027802264,0.00040004478,0.000039295952,0.0001738298],"category_scores_gemma":[0.000015750395,0.00020273858,0.00017907326,0.00017680654,0.00010575304,0.000018529989,0.00036820341,0.00051119324,6.113488e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013614249,0.00007274283,0.00016107893,0.0000966121,0.00007900738,0.0001040489,0.00074516085,0.0025677907,0.98429537,0.000002002113,0.0015018762,0.009012864],"study_design_scores_gemma":[0.002337857,0.000838905,0.0025153433,0.00052411214,0.00007062344,0.00008697131,0.0004055583,0.00016740257,0.9852397,0.000006253231,0.0075816116,0.00022567797],"about_ca_topic_score_codex":0.000046334284,"about_ca_topic_score_gemma":0.000019843013,"teacher_disagreement_score":0.07233009,"about_ca_system_score_codex":0.00018481904,"about_ca_system_score_gemma":0.000343966,"threshold_uncertainty_score":0.82674396},"labels":[],"label_agreement":null},{"id":"W4307908390","doi":"10.1016/s0959-8049(22)01140-6","title":"MDNA132 is an IL-13 Superkine selective to IL-13Rα2 with broad potential for delivery of immunotherapies to the tumor microenvironment","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Receptor; Tumor microenvironment; Immunotherapy; Cancer research; In vitro; In vivo; Agonist; Immune system; Ligand (biochemistry); Signal transduction; Chemistry; Cell biology; Biology; Immunology; Biochemistry","score_opus":0.008167275047325858,"score_gpt":0.2142363708548399,"score_spread":0.20606909580751404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307908390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98805755,0.005355878,0.0028518976,0.0019074079,0.00082634133,0.0004608647,0.00047107032,0.000008231243,0.000060727132],"genre_scores_gemma":[0.99436116,0.0002040985,0.0008516413,0.002802709,0.00014170435,0.000032954686,0.0000073112333,0.000056861,0.0015415482],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984603,0.00046241464,0.00044045952,0.00021244344,0.00011947623,0.00030492095],"domain_scores_gemma":[0.9991927,0.000028161989,0.00031509178,0.00026728958,0.00015480278,0.000041922984],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064537406,0.00018890496,0.00030857846,0.00012786474,0.0003625388,0.000020112859,0.00058659294,0.000017135233,0.0012395435],"category_scores_gemma":[0.000009771827,0.00012907751,0.00015364829,0.0001404135,0.00008026167,0.00009126813,0.00015465933,0.00033517604,0.000025511801],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003635351,0.00016980451,0.00006153581,0.0000057122274,0.00054858014,0.000019383184,0.0058747516,0.0020214175,0.9547373,0.000017063507,0.008471582,0.024437495],"study_design_scores_gemma":[0.0027473564,0.008388872,0.009104235,0.00005273869,0.00014353853,0.0002710834,0.0032266034,0.000004127519,0.36731035,0.000012060465,0.6084962,0.00024285902],"about_ca_topic_score_codex":0.00009292998,"about_ca_topic_score_gemma":0.000030114279,"teacher_disagreement_score":0.6000246,"about_ca_system_score_codex":0.00012044624,"about_ca_system_score_gemma":0.000105308325,"threshold_uncertainty_score":0.9996735},"labels":[],"label_agreement":null},{"id":"W4307910028","doi":"10.1016/s0959-8049(22)00827-9","title":"BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Exon; Cancer research; Mutant; EGFR inhibitors; Mutation; Lung cancer; Epidermal growth factor receptor; Molecular biology; Gene; Chemistry; Biology; Medicine; Cancer; Genetics; Internal medicine","score_opus":0.00955288568830906,"score_gpt":0.27470809078443814,"score_spread":0.2651552050961291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307910028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94966376,0.020832112,0.00021325247,0.021273108,0.00042942187,0.0005159645,0.00009138055,0.000014114256,0.006966894],"genre_scores_gemma":[0.9964058,0.00064374163,0.00035268476,0.00078722264,0.00025890587,0.000030152683,0.0000085661495,0.000028386581,0.0014845378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893546,0.00015051792,0.0003567003,0.00015870732,0.00023799427,0.00016060467],"domain_scores_gemma":[0.99932337,0.000066145214,0.00025056157,0.00009549622,0.00017082298,0.00009358892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004086385,0.00011735823,0.00018129822,0.00014204749,0.00046133777,0.000035130266,0.00006799458,0.00000980298,0.000058916983],"category_scores_gemma":[0.00006673932,0.00008540368,0.000051394272,0.0003367024,0.00007961179,0.00013075308,0.000051536925,0.00034017256,0.0000012383053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006710211,0.0026968683,0.5751934,0.00069986266,0.0027736023,0.0058254544,0.09699079,0.0119782295,0.03567338,0.0007902634,0.18577173,0.07489621],"study_design_scores_gemma":[0.008687648,0.0008666532,0.7375179,0.00067625724,0.00070265774,0.00027522352,0.003721808,0.00018860509,0.0009295023,0.000099731085,0.24607182,0.0002622022],"about_ca_topic_score_codex":0.000050295075,"about_ca_topic_score_gemma":0.00041413878,"teacher_disagreement_score":0.1623245,"about_ca_system_score_codex":0.00029913292,"about_ca_system_score_gemma":0.0001912621,"threshold_uncertainty_score":0.3548284},"labels":[],"label_agreement":null},{"id":"W4307910079","doi":"10.1016/s0959-8049(22)01038-3","title":"Targeting acidosis to improve immunotherapy in a pancreatic ductal adenocarcinoma model","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Helix Biopharma (Canada)","funders":"","keywords":"Cancer research; Bicarbonate; Medicine; Pancreatic cancer; Tumor microenvironment; Immunotherapy; Blockade; Combination therapy; Cancer; Internal medicine; Receptor","score_opus":0.009070897357579218,"score_gpt":0.24379465239852524,"score_spread":0.23472375504094603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307910079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9495283,0.047150638,0.0011345507,0.00036957208,0.0011872519,0.00011599164,0.000029694533,0.000003158422,0.0004808618],"genre_scores_gemma":[0.9924369,0.0027176393,0.0010471649,0.0010322623,0.0017821868,0.000016657421,0.000004022089,0.00004871371,0.0009144826],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877775,0.00021007593,0.00037445017,0.00019056821,0.00021830873,0.00022885251],"domain_scores_gemma":[0.99943167,0.0000044235585,0.00021399882,0.0001695199,0.00008719233,0.000093172115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063423655,0.00012748854,0.00020126736,0.00009830807,0.00007902772,0.00001958741,0.0003059043,0.00001480601,0.00009283316],"category_scores_gemma":[0.000037227823,0.000123216,0.00012544137,0.00012812502,0.000020007305,0.0000069311113,0.00013711806,0.0002185208,0.0000021983988],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005348955,0.000040481627,0.0022051602,0.0000061747,0.00007695315,0.00002230906,0.000657385,0.021938087,0.9560494,0.0000051792063,0.0053384756,0.013125519],"study_design_scores_gemma":[0.00878745,0.0025406554,0.050915435,0.00009203785,0.00017055206,0.00030123058,0.0015624325,0.001847328,0.07612109,0.000065300286,0.85650665,0.001089869],"about_ca_topic_score_codex":0.000024185156,"about_ca_topic_score_gemma":0.0000064129176,"teacher_disagreement_score":0.8799283,"about_ca_system_score_codex":0.00006323975,"about_ca_system_score_gemma":0.00018405788,"threshold_uncertainty_score":0.5024603},"labels":[],"label_agreement":null},{"id":"W4307910880","doi":"10.1016/s0959-8049(22)01122-4","title":"An open-source, pathologist-in-the-loop workflow for quantitative and spatially-driven analysis of multiplexed immunohistochemistry images of the solid tumor microenvironment","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cell Image Analysis Techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Workflow; Tumor microenvironment; Glioblastoma; Pathology; Digital pathology; Segmentation; Immunohistochemistry; Computer science; Biology; Computational biology; Medicine; Cancer research; Artificial intelligence; Database; Tumor cells","score_opus":0.01219462191157636,"score_gpt":0.30631497063820456,"score_spread":0.2941203487266282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307910880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99425846,0.0026581127,0.0025571645,0.00012035588,0.00001710204,0.00019959571,0.000060859616,0.0000012145438,0.000127102],"genre_scores_gemma":[0.9949887,0.00039184646,0.004234687,0.00016197002,0.000026563304,0.000016096472,0.000018955088,0.000018720371,0.00014250587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985233,0.000522267,0.00048446085,0.00018166921,0.00017810914,0.00011021828],"domain_scores_gemma":[0.9986047,0.000038177866,0.00083753344,0.00038421384,0.00010994802,0.00002539561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010429926,0.00010990493,0.00030343415,0.00008069408,0.00008562243,0.000021181677,0.0008717842,0.000012612991,0.000032402208],"category_scores_gemma":[0.000094666626,0.000077773606,0.00021153051,0.0001992084,0.00020064076,0.0000081698845,0.00031999746,0.00013493511,4.0773557e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027671023,0.0001491405,0.0056430995,0.000011919912,0.0003874784,0.000012427689,0.00035134744,0.007882133,0.98292875,8.913847e-7,0.00055136404,0.001804715],"study_design_scores_gemma":[0.0011337181,0.0011272207,0.041122306,0.00004190374,0.001027832,0.000022530614,0.00103022,0.0005768341,0.94908994,0.000008407856,0.004639677,0.00017943355],"about_ca_topic_score_codex":0.000042726337,"about_ca_topic_score_gemma":0.000037911243,"teacher_disagreement_score":0.035479207,"about_ca_system_score_codex":0.00003079511,"about_ca_system_score_gemma":0.000054079992,"threshold_uncertainty_score":0.31715155},"labels":[],"label_agreement":null},{"id":"W4307910992","doi":"10.1016/s0959-8049(22)01026-7","title":"Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Sunitinib; Medicine; Internal medicine; Oncology; GiST; Renal cell carcinoma; Clinical endpoint; Cancer; Gastroenterology; Stromal cell; Clinical trial","score_opus":0.06421344486638042,"score_gpt":0.3753560655216989,"score_spread":0.3111426206553185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307910992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930544,0.000110136745,0.0000054089146,0.0014641322,0.00006040765,0.004420699,0.00010359021,0.000006160631,0.0007750983],"genre_scores_gemma":[0.9988279,0.0000053938484,0.00018597051,0.000068115514,0.00024471263,0.00037839086,0.000012863353,0.000028411065,0.0002482509],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970542,0.0009501662,0.0007814168,0.00016143154,0.0008396031,0.00021316954],"domain_scores_gemma":[0.99856347,0.00021967618,0.0005647736,0.00023942551,0.00026738166,0.00014528178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014781024,0.00013207977,0.00033780618,0.00014094688,0.00015859262,0.000020647685,0.00024086196,0.0000034285918,0.00038059242],"category_scores_gemma":[0.0003846939,0.00007794207,0.0000780212,0.0003421695,0.00006993564,0.000076530094,0.000099446166,0.0005625132,0.0000029593525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8289117,0.028841212,0.03610952,0.000041754614,0.00084650493,0.0393514,0.022029363,0.0025020046,0.0015737689,0.00000931027,0.004018373,0.03576506],"study_design_scores_gemma":[0.64393497,0.21745855,0.10219408,0.0008278643,0.00030778052,0.00090262026,0.02690546,0.000062486906,0.00082953315,0.000026406275,0.006370758,0.00017947587],"about_ca_topic_score_codex":0.00060936547,"about_ca_topic_score_gemma":0.00029950144,"teacher_disagreement_score":0.18861733,"about_ca_system_score_codex":0.00016417206,"about_ca_system_score_gemma":0.00045122355,"threshold_uncertainty_score":0.41672203},"labels":[],"label_agreement":null},{"id":"W4307911011","doi":"10.1016/s0959-8049(22)00972-8","title":"Characterizing mechanisms of resistance to BRAF and MEK inhibitors in cancers with Class 2 BRAF mutations: uncovering novel therapeutic opportunities","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre; University of Toronto; University Health Network; McGill University; Jewish General Hospital","funders":"","keywords":"Melanoma; Cancer research; Vemurafenib; Medicine; Mutant; Targeted therapy; Cancer; MEK inhibitor; Biology; MAPK/ERK pathway; Gene; Internal medicine; Signal transduction; Genetics; Metastatic melanoma","score_opus":0.02404520859833804,"score_gpt":0.23654860479195203,"score_spread":0.212503396193614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307911011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454993,0.0018859705,0.0017311627,0.0004558716,0.00021650532,0.00008535422,0.000052133648,0.0000021407425,0.0010209032],"genre_scores_gemma":[0.9981677,0.00021816666,0.00052486104,0.00061407447,0.000097086355,0.0000070362626,0.000004491374,0.000023550205,0.000343029],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99920297,0.00010578792,0.00027484415,0.000121417936,0.00017555535,0.000119418655],"domain_scores_gemma":[0.9994945,0.000009220622,0.00026491893,0.00009059589,0.00007674138,0.00006400742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003807009,0.000091029375,0.00014018765,0.000089471374,0.000057271096,0.000013470111,0.00012162689,0.000010380754,0.000016124899],"category_scores_gemma":[0.000012494751,0.000082067876,0.00003080864,0.000089636036,0.000032692587,0.000010429069,0.00006661823,0.00010883534,8.751698e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040670368,0.000019390334,0.00054554915,0.00002851694,0.00005807191,0.00007172529,0.0007997651,0.0018448904,0.99012756,0.00016786864,0.00012114472,0.005808805],"study_design_scores_gemma":[0.004147246,0.0033663567,0.02067581,0.0006386904,0.00009786415,0.00024776085,0.009688226,0.000035885547,0.7272537,0.00013840581,0.23307836,0.0006317114],"about_ca_topic_score_codex":0.000019875937,"about_ca_topic_score_gemma":0.00014133407,"teacher_disagreement_score":0.2628739,"about_ca_system_score_codex":0.00005555861,"about_ca_system_score_gemma":0.00021549201,"threshold_uncertainty_score":0.3346631},"labels":[],"label_agreement":null},{"id":"W4307911017","doi":"10.1016/s0959-8049(22)00883-8","title":"Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG) IND.237","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network; Queen's University","funders":"Stand Up To Cancer; Ontario Institute for Cancer Research; Government of Ontario; American Association for Cancer Research","keywords":"Medicine; Neutropenia; Internal medicine; Cancer; Adverse effect; Dosing; Breast cancer; Clinical endpoint; Cohort; Surrogate endpoint; Cmax; Pharmacokinetics; Oncology; Clinical trial; Toxicity","score_opus":0.030776345458151153,"score_gpt":0.3292102583652843,"score_spread":0.2984339129071331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307911017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927105,0.003672752,0.00009566176,0.00047344388,0.00058635895,0.0014112953,0.0010055901,0.000009640361,0.000034778244],"genre_scores_gemma":[0.9978981,0.00011968245,0.0011426872,0.0002565867,0.00027023806,0.000120092634,0.00001312982,0.00013380828,0.00004564995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947074,0.0008458206,0.0022171447,0.0004250441,0.0012026144,0.0006019565],"domain_scores_gemma":[0.9960546,0.00011008509,0.0024079655,0.0003431263,0.00070094335,0.00038331735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018424361,0.00042849514,0.0017090378,0.0012153053,0.00013731916,0.000016161239,0.00038431346,0.00002852493,0.00049978326],"category_scores_gemma":[0.0001205027,0.000355817,0.00015726051,0.0015877794,0.00014869068,0.00042287342,0.00012681283,0.00087156723,2.3948368e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06642862,0.014583667,0.35468912,0.0003816658,0.0017175341,0.0010702504,0.025424428,0.16945615,0.017064141,0.0000070142055,0.00018099838,0.3489964],"study_design_scores_gemma":[0.19386834,0.021714376,0.7629085,0.0049053626,0.00097175676,0.00016996806,0.010357223,0.0002580187,0.00094464805,0.0000044294293,0.0030698008,0.0008275863],"about_ca_topic_score_codex":0.018415665,"about_ca_topic_score_gemma":0.03865394,"teacher_disagreement_score":0.40821937,"about_ca_system_score_codex":0.0019111312,"about_ca_system_score_gemma":0.0019221376,"threshold_uncertainty_score":0.9998894},"labels":[],"label_agreement":null},{"id":"W4307911408","doi":"10.1016/s0959-8049(22)00994-7","title":"Molecular characterization of next generation AR-NTD inhibitors","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia","funders":"","keywords":"LNCaP; Androgen receptor; Enzalutamide; Prostate cancer; Cancer research; Context (archaeology); Biology; Cancer; Chemistry; Pharmacology; Genetics","score_opus":0.0435423406231177,"score_gpt":0.30436734805353705,"score_spread":0.26082500743041936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307911408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398243,0.0025198816,0.00017152457,0.0017844633,0.00042169626,0.000108083215,0.000011319462,0.000004087501,0.0009965161],"genre_scores_gemma":[0.9976256,0.0007095833,0.000079013575,0.00022982016,0.00051996595,0.0000034094608,0.000023630088,0.000020800402,0.0007881986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893427,0.00019337115,0.00028965613,0.0000704997,0.00041950063,0.000092710696],"domain_scores_gemma":[0.9993659,0.0000045743936,0.00026313265,0.000081614555,0.00021438679,0.0000703527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037906264,0.000059749163,0.00014021371,0.00012712412,0.000056051304,0.000011223257,0.00006679262,0.0000062311474,0.000440751],"category_scores_gemma":[0.000015248531,0.000047357193,0.000079766876,0.00016784942,0.000026311485,0.00008896649,0.00003604513,0.00017547999,0.0000025548734],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027525585,0.000069425616,0.0022475885,0.00002021482,0.000085937005,0.00033060947,0.0003771643,0.00013198917,0.96220106,0.000013452939,0.0008412746,0.033406038],"study_design_scores_gemma":[0.0043656803,0.0021629026,0.03495647,0.00016236102,0.0001899029,0.00017675932,0.00020952473,0.0004094343,0.85150653,0.0000073877823,0.10571511,0.00013794984],"about_ca_topic_score_codex":0.0000031359068,"about_ca_topic_score_gemma":2.552846e-7,"teacher_disagreement_score":0.110694535,"about_ca_system_score_codex":0.00013206572,"about_ca_system_score_gemma":0.00017857253,"threshold_uncertainty_score":0.48259145},"labels":[],"label_agreement":null},{"id":"W4308158641","doi":"10.1016/j.ejca.2022.10.017","title":"Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Cohort; Toxicity; Cancer; Population; Acute toxicity; Colorectal cancer; Internal medicine; Cohort study; Emergency medicine; Environmental health","score_opus":0.1279048075481206,"score_gpt":0.4373227682302942,"score_spread":0.3094179606821736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308158641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894211,0.008398289,0.000036838333,0.0011268808,0.00044070382,0.00032894404,0.000043023163,0.0000038022067,0.00020038665],"genre_scores_gemma":[0.9985436,0.0004519686,0.000024999747,0.0005509449,0.00033118724,0.000040481915,0.000011840179,0.000012748158,0.000032233766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967386,0.0014322321,0.00056614913,0.0000982941,0.001064279,0.00010041239],"domain_scores_gemma":[0.9984608,0.00012519592,0.0007174084,0.000078037985,0.0005938864,0.000024616023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00542532,0.00007939975,0.0002170931,0.00010659025,0.000095345844,0.000010806487,0.0001207368,0.000010739857,0.00045365107],"category_scores_gemma":[0.00006782751,0.000058229944,0.00010960035,0.00023968413,0.00001670371,0.00008427323,0.000012445795,0.00019479264,6.7336896e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022027784,0.0005379449,0.7723697,0.000093344504,0.00039613023,0.000023141862,0.007782721,0.11956494,0.064538114,0.00003353876,0.0006586869,0.03179899],"study_design_scores_gemma":[0.005817289,0.00027904948,0.99154633,0.00010239662,0.00007965652,0.000013886395,0.00033377434,0.0008090009,0.0005235653,0.000015529757,0.00042022712,0.00005929459],"about_ca_topic_score_codex":0.00035760782,"about_ca_topic_score_gemma":0.00003835997,"teacher_disagreement_score":0.21917665,"about_ca_system_score_codex":0.000689923,"about_ca_system_score_gemma":0.0004814683,"threshold_uncertainty_score":0.4967161},"labels":[],"label_agreement":null},{"id":"W4308313407","doi":"10.1016/j.ejca.2022.06.053","title":"Erratum to ‘Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma’ [Eur J Cancer 170 (2022) 209-235]","year":2022,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Izaak Walton Killam Health Centre","funders":"","keywords":"Comparability; Table (database); Quality of life (healthcare); Limiting; Medicine; Cancer; Quality (philosophy); Psychology; Computer science; Database; Internal medicine; Mathematics","score_opus":0.01197354581781933,"score_gpt":0.26909128130042925,"score_spread":0.2571177354826099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308313407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8721043,0.06338257,0.000016849917,0.0030424667,0.026041703,0.0013615515,0.00025456425,0.000057772333,0.033738222],"genre_scores_gemma":[0.8830296,0.008445377,0.00017082847,0.0021385767,0.01143169,0.00017649413,0.00014024017,0.00048081588,0.09398637],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99670136,0.00027377743,0.000716601,0.00056512235,0.0012166731,0.00052644993],"domain_scores_gemma":[0.9980672,0.000053583375,0.0007536154,0.00027462468,0.00053031323,0.00032064665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037155786,0.0005679015,0.0011847029,0.00047823746,0.00028623833,0.00009076136,0.00023309757,0.000060642462,0.00073948037],"category_scores_gemma":[0.00006637207,0.0004162213,0.00020791417,0.00050591247,0.00014527528,0.0001551662,0.00028610782,0.0019163772,0.000006718524],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055704103,0.0006325382,0.37169933,0.00042521665,0.0017930892,0.0016893883,0.0046825153,0.0002844318,0.000021297205,0.0000063823227,0.4900129,0.123182476],"study_design_scores_gemma":[0.005127244,0.004753808,0.6361876,0.0029440897,0.00089097465,0.000034841134,0.00037239314,0.000013610236,0.000005318904,0.000006344002,0.34921637,0.00044737515],"about_ca_topic_score_codex":0.0002946011,"about_ca_topic_score_gemma":0.00084926654,"teacher_disagreement_score":0.26448828,"about_ca_system_score_codex":0.0009202843,"about_ca_system_score_gemma":0.00080224616,"threshold_uncertainty_score":0.99982893},"labels":[],"label_agreement":null},{"id":"W4309047234","doi":"10.1016/j.ejca.2022.11.007","title":"Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Cancéropôle Ile de France; Ligue Contre le Cancer; Fondation ARC pour la Recherche sur le Cancer; Association for International Cancer Research; National Cancer Institute; Institut National Du Cancer; Cancer Research UK; European Commission; Fondation du cancer du sein du Québec; Génome Québec","keywords":"Breast cancer; Medicine; Oncology; Odds ratio; Family history; Hazard ratio; Internal medicine; Population; Single-nucleotide polymorphism; Cancer; Receiver operating characteristic; Demography; Confidence interval; Genetics; Environmental health; Biology; Genotype","score_opus":0.007315677548566145,"score_gpt":0.2478647363540857,"score_spread":0.24054905880551955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309047234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640036,0.0011365614,0.00018815909,0.0007487609,0.00042186133,0.00021032795,0.0008695651,0.0000020222294,0.000022380407],"genre_scores_gemma":[0.9972673,0.0006345554,0.00009777374,0.00019210707,0.00083220704,0.0000919393,0.000005782558,0.000021191847,0.00085715525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898857,0.00020398981,0.0002677806,0.00013531015,0.0002486333,0.00015572907],"domain_scores_gemma":[0.9990639,0.000022892169,0.0004880556,0.00011726896,0.00023103814,0.00007682729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007219602,0.00008018494,0.000098986304,0.000044908455,0.00020403578,0.000021409245,0.00019095934,0.000011675191,0.00007139423],"category_scores_gemma":[0.00009393018,0.000060043763,0.00006103609,0.000102472775,0.0000315057,0.000012135144,0.00011940126,0.00011219905,1.8530176e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005218281,0.000070642425,0.8421181,0.000088645174,0.0005966865,0.0000045926695,0.0032897305,0.046917263,0.032292362,9.214548e-7,0.014393723,0.05500909],"study_design_scores_gemma":[0.00074258,0.00039220948,0.9876318,0.000032391672,0.000115869196,0.000007015563,0.00016325577,0.0006795029,0.0029839159,0.0000019743215,0.00715927,0.00009022092],"about_ca_topic_score_codex":0.000041134863,"about_ca_topic_score_gemma":0.000079318335,"teacher_disagreement_score":0.14551373,"about_ca_system_score_codex":0.00021887297,"about_ca_system_score_gemma":0.00026405003,"threshold_uncertainty_score":0.24485137},"labels":[],"label_agreement":null},{"id":"W4309487577","doi":"10.1016/s0959-8049(22)01550-7","title":"Racial disparity and time to treatment initiation effects on survival differences in breast cancer: a DAGs-based review protocol for a systematic review of cohort studies","year":2022,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Breast cancer; Medicine; Psychological intervention; Ethnic group; Causation; Race (biology); Health equity; Gerontology; Cancer; Public health; Internal medicine; Psychiatry; Pathology","score_opus":0.17477746782358652,"score_gpt":0.46803372466690285,"score_spread":0.29325625684331635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309487577","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007978045,0.87268364,0.0000033499039,0.0005397263,0.000092962066,0.12639949,0.00012277914,0.0000051929223,0.00014484489],"genre_scores_gemma":[0.000008096272,0.8904449,0.00003020308,0.00084337045,0.00025389701,0.108329594,0.000009079282,0.000034964676,0.000045916247],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9951988,0.0017907872,0.0017925497,0.00029070725,0.0007190258,0.00020813977],"domain_scores_gemma":[0.9964642,0.0005963371,0.0021722796,0.00023845298,0.00037737432,0.00015135271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028652754,0.00040794848,0.0048638205,0.00018811772,0.00005666634,0.0000142630815,0.00020074943,0.000028881232,0.00017314791],"category_scores_gemma":[0.0008509812,0.00024172197,0.0005188731,0.00038284098,0.000035885623,0.000059083068,0.00004649221,0.00027144913,0.000003296998],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029183505,0.00006783948,0.00020806941,0.84211516,0.0007316656,0.000093471775,0.000037862188,7.399159e-7,1.3181744e-7,0.0000013472821,0.0008920759,0.15555982],"study_design_scores_gemma":[0.0011778878,0.0020352134,0.00044624356,0.872623,0.0064198477,0.00005818339,0.0000069693187,0.0000013202732,5.5199564e-7,4.543113e-7,0.11706145,0.00016883216],"about_ca_topic_score_codex":0.000024746652,"about_ca_topic_score_gemma":0.000014560693,"teacher_disagreement_score":0.155391,"about_ca_system_score_codex":0.0010135693,"about_ca_system_score_gemma":0.0008568488,"threshold_uncertainty_score":0.98571354},"labels":[],"label_agreement":null},{"id":"W4309487584","doi":"10.1016/s0959-8049(22)01496-4","title":"Post-treatment quality of life among Sri Lankan women with breast cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Breast cancer; Sri lanka; Quality of life (healthcare); Cancer; Disease; Gynecology; Oncology; Internal medicine; Nursing; South asia","score_opus":0.01897384143464649,"score_gpt":0.2852528841884676,"score_spread":0.26627904275382114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309487584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986576,0.003456005,0.0000059688887,0.002705838,0.0004982614,0.0001253065,0.00030938158,0.000012110168,0.006311118],"genre_scores_gemma":[0.99635375,0.00041616746,0.000016408394,0.0012255886,0.00059192016,0.000019653344,0.0000033274102,0.00002618766,0.0013469928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979992,0.00039996646,0.0005044313,0.00015239106,0.0007127088,0.00023128574],"domain_scores_gemma":[0.9983202,0.000035532852,0.0006158614,0.00022528453,0.0004992742,0.00030380764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007332881,0.00015503998,0.00047281117,0.000108898465,0.00007916007,0.000012077796,0.0001594629,0.000011822677,0.0031985498],"category_scores_gemma":[0.000019631903,0.000107640684,0.00013186113,0.0002105643,0.00008255531,0.000078551115,0.000051278465,0.00029554957,0.0000020925643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013348828,0.00045005255,0.8661197,0.00018491878,0.0014452675,0.0005456484,0.025979515,0.0008806776,0.0032477095,0.000032132863,0.0017054972,0.08606007],"study_design_scores_gemma":[0.0035904348,0.0023253292,0.8830835,0.0001430606,0.0001561626,0.00012172982,0.00791302,0.0000018284449,0.00023499649,0.0000014430955,0.10227605,0.00015243121],"about_ca_topic_score_codex":0.0035993895,"about_ca_topic_score_gemma":0.002474534,"teacher_disagreement_score":0.10057055,"about_ca_system_score_codex":0.00071484473,"about_ca_system_score_gemma":0.0007606092,"threshold_uncertainty_score":0.9977127},"labels":[],"label_agreement":null},{"id":"W4309488905","doi":"10.1016/s0959-8049(22)01462-9","title":"Black seed oil supplement had positive effects on blood concentration and mRNA expression levels of estrogen and SHBG in premenopausal women with overweight and obesity: a crossover, double blind, placebo controlled randomized clinical trial","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Adipokines, Inflammation, and Metabolic Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Sex hormone-binding globulin; Phytoestrogens; Overweight; Medicine; Internal medicine; Estrogen; Endocrinology; Obesity; Crossover study; Placebo; Hormone; Physiology; Traditional medicine","score_opus":0.01870598150671551,"score_gpt":0.3049160191192032,"score_spread":0.2862100376124877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309488905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956583,0.0023044026,0.00002708579,0.00020546894,0.00018639794,0.0012591318,0.00003813393,0.000004407404,0.00031669182],"genre_scores_gemma":[0.9981572,0.0008455412,0.000110907094,0.00015176121,0.00044938305,0.00005105353,0.000005833223,0.000018566807,0.000209757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970676,0.0012445254,0.000860527,0.00019302957,0.0004628557,0.00017146452],"domain_scores_gemma":[0.9982985,0.00045273922,0.00080064405,0.00008945833,0.00015233978,0.00020630403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027173473,0.00016325909,0.00096174,0.000078799516,0.000079058154,0.000034102406,0.00005159349,0.000020483776,0.000082379134],"category_scores_gemma":[0.00022850801,0.00011029787,0.00006437117,0.0000700902,0.00017031161,0.00012540452,0.00004490357,0.0002188004,1.3425058e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98163754,0.00042020634,0.007709354,0.000088633205,0.0006364987,0.00012951264,0.0022024456,0.00007378246,0.0050614555,0.00005789658,0.000047868278,0.0019347905],"study_design_scores_gemma":[0.9641601,0.005228914,0.024402121,0.0003935605,0.0009850234,0.000034047833,0.00020224486,0.00006627431,0.003983799,0.0000130907365,0.00042078522,0.000110033194],"about_ca_topic_score_codex":0.000010791765,"about_ca_topic_score_gemma":0.0000043034293,"teacher_disagreement_score":0.017477449,"about_ca_system_score_codex":0.000052053925,"about_ca_system_score_gemma":0.00026433164,"threshold_uncertainty_score":0.44978166},"labels":[],"label_agreement":null},{"id":"W4309488916","doi":"10.1016/s0959-8049(22)01365-x","title":"Breast Cancer Whole Blood Screening: Analytical and Clinical Performance from Early Analysis of the International Identify Breast Cancer (IDBC) Study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Cancer Foundation; Alberta Health Services","funders":"","keywords":"Medicine; Breast cancer; Mammography; Internal medicine; Cancer; Oncology; Blood test; Confidence interval; Asymptomatic; Breast imaging; Breast cancer screening; Gynecology","score_opus":0.018540393745387622,"score_gpt":0.3134527153798365,"score_spread":0.29491232163444886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309488916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388736,0.0029571005,0.00003435681,0.0009575446,0.0005569182,0.00008405354,0.0014515449,0.0000022017166,0.00006892761],"genre_scores_gemma":[0.99687356,0.0014949875,0.000029158016,0.0002897228,0.001005829,0.0000060346647,0.0000161367,0.000021496666,0.0002630556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980861,0.00037996058,0.0006051773,0.0002714123,0.00051117915,0.00014615316],"domain_scores_gemma":[0.9986993,0.000016256126,0.00049189833,0.00025727198,0.00038678368,0.00014848882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005933395,0.00013380799,0.00026823484,0.00010769053,0.00013705708,0.000047125923,0.00053675513,0.000022405067,0.0005056589],"category_scores_gemma":[0.000018877354,0.000106491076,0.00030781602,0.00025256065,0.00013878127,0.000013583215,0.00034823082,0.00023789707,4.175237e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072686316,0.00043061454,0.9802517,0.000004649169,0.0034440546,0.000016298658,0.0001289543,0.0017998633,0.0035561302,6.285416e-7,0.0014458708,0.00819434],"study_design_scores_gemma":[0.0020517197,0.00022070894,0.9917112,0.000031405427,0.0025503596,0.000022551196,0.00026148278,0.0003704504,0.0002765189,0.0000017923015,0.0023776067,0.00012418626],"about_ca_topic_score_codex":0.00028713592,"about_ca_topic_score_gemma":0.00021360042,"teacher_disagreement_score":0.011459486,"about_ca_system_score_codex":0.000027752834,"about_ca_system_score_gemma":0.0001739844,"threshold_uncertainty_score":0.55366105},"labels":[],"label_agreement":null},{"id":"W4311257614","doi":"10.1016/j.ejca.2022.12.003","title":"Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Zoledronic acid; Medicine; Breast cancer; Bisphosphonate; Internal medicine; Anastrozole; Oncology; Tamoxifen; Adjuvant; Metastatic breast cancer; Cancer; Osteoporosis","score_opus":0.023892468603735523,"score_gpt":0.3310243368701438,"score_spread":0.3071318682664083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311257614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940149,0.0012744598,0.0000021776093,0.002043236,0.0006025956,0.0011102753,0.00032591657,0.000008613372,0.00061782775],"genre_scores_gemma":[0.9981774,0.00063043274,0.000042828575,0.0001475524,0.0001788855,0.00008837054,0.0000041664434,0.000046725516,0.00068363507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979473,0.00047943657,0.0006957216,0.00016405812,0.00045907323,0.0002544513],"domain_scores_gemma":[0.998286,0.00015412075,0.00083108194,0.0002622849,0.00027134325,0.00019515037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052375207,0.00018693527,0.0005693887,0.000090124435,0.0002081904,0.0000069942835,0.00016492227,0.000013307928,0.00033286578],"category_scores_gemma":[0.000028125123,0.000089792535,0.00025771407,0.0001729404,0.000056728924,0.000049323346,0.000054591143,0.00023197496,0.0000023229652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014080848,0.005129319,0.7358374,0.000116162686,0.0021096736,0.00040654934,0.009714682,0.00084709586,0.0013727996,0.0000044512763,0.0014791025,0.2289019],"study_design_scores_gemma":[0.017702421,0.0050447118,0.9684137,0.00022574559,0.000956752,0.00009480027,0.0006673292,0.000020897714,0.00041036756,0.0000038171365,0.0063704606,0.00008901642],"about_ca_topic_score_codex":0.00144507,"about_ca_topic_score_gemma":0.00056944543,"teacher_disagreement_score":0.23257625,"about_ca_system_score_codex":0.00031773193,"about_ca_system_score_gemma":0.00041512673,"threshold_uncertainty_score":0.36616334},"labels":[],"label_agreement":null},{"id":"W4319922981","doi":"10.1016/j.ejca.2023.02.002","title":"Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; PharmaMar; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Astellas Pharma; Eisai; Genomic Health; Fondation ARC pour la Recherche sur le Cancer; Seagen; Genentech; Veracyte; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Medpace; Puma Biotechnology; Regeneron Pharmaceuticals; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Kræftens Bekæmpelse; European Commission; Exelixis; Amgen; Pfizer; Celgene","keywords":"Neratinib; Trastuzumab; Medicine; Placebo; Oncology; Breast cancer; Internal medicine; Pertuzumab; Adjuvant; Adjuvant therapy; Double blind; Cancer; Alternative medicine; Pathology","score_opus":0.0521616362129542,"score_gpt":0.38182823190836057,"score_spread":0.32966659569540635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319922981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305863,0.0036681937,0.00014075445,0.006102722,0.0010428295,0.0038354346,0.00015296042,0.000047747137,0.0019507083],"genre_scores_gemma":[0.9910945,0.0023586492,0.00008203492,0.0009691576,0.0032535254,0.0006101033,0.000015219582,0.00018840464,0.001428354],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942933,0.001461751,0.0013188121,0.00048590318,0.0016425395,0.0007977149],"domain_scores_gemma":[0.997339,0.00031722712,0.00060885935,0.00036874635,0.0008274446,0.0005387394],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038363547,0.00048065893,0.0014848753,0.0006333779,0.00009569678,0.00014068924,0.00035067895,0.00007477766,0.0020512512],"category_scores_gemma":[0.00007712314,0.00031616839,0.00046736977,0.0007713653,0.00020164726,0.00021372683,0.00003891519,0.0011547062,0.00004012928],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93735856,0.00069102785,0.0017677513,0.00005251472,0.0007266706,0.004834051,0.0008678191,0.0027567935,0.0013839353,0.0000021334097,0.002468398,0.04709037],"study_design_scores_gemma":[0.97586286,0.0059865355,0.009231945,0.0013793039,0.00023559568,0.0001278071,0.00012661262,0.0006860642,0.0008087153,0.0000022424888,0.0051929955,0.00035931097],"about_ca_topic_score_codex":0.00038868122,"about_ca_topic_score_gemma":0.00053071073,"teacher_disagreement_score":0.04673106,"about_ca_system_score_codex":0.0006496776,"about_ca_system_score_gemma":0.0026138052,"threshold_uncertainty_score":0.999929},"labels":[],"label_agreement":null},{"id":"W4321763927","doi":"10.1016/j.ejca.2023.02.016","title":"Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Merck Sharp and Dohme","keywords":"Microsatellite instability; Pembrolizumab; Colorectal cancer; Medicine; Oncology; DNA mismatch repair; Cancer; Internal medicine; Cancer research; Microsatellite; Biology; Genetics; Immunotherapy","score_opus":0.028705581448300196,"score_gpt":0.316547097866866,"score_spread":0.2878415164185658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321763927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917717,0.0077319588,0.00016428478,0.00048684748,0.000891782,0.0007353467,0.00026699205,0.00008577732,0.00045987274],"genre_scores_gemma":[0.99402165,0.0031701343,0.0013159985,0.00014840717,0.0003111305,0.00004957629,0.000041435494,0.00009441329,0.0008472501],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9964756,0.0002814546,0.001414809,0.0004824218,0.0007616926,0.00058401603],"domain_scores_gemma":[0.99676454,0.00021300955,0.0010185643,0.00042821778,0.0012751434,0.00030053136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012595339,0.00035662358,0.0012370934,0.0007394386,0.000102858365,0.00002592828,0.0003405762,0.00007522744,0.0003767111],"category_scores_gemma":[0.00032698113,0.00029468705,0.0010552102,0.002088142,0.00021890784,0.00009355147,0.00009270825,0.00036236225,0.000009500126],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04040257,0.0009214231,0.28796038,0.0017781579,0.012431419,0.0006641753,0.00818697,0.101004444,0.33433336,0.000044381803,0.007296289,0.20497642],"study_design_scores_gemma":[0.013544286,0.006964958,0.81431323,0.0015565366,0.009770791,0.00010388221,0.00052872906,0.0030158865,0.10717814,0.000035676305,0.042252928,0.0007349494],"about_ca_topic_score_codex":0.00014167774,"about_ca_topic_score_gemma":0.00022541011,"teacher_disagreement_score":0.5263529,"about_ca_system_score_codex":0.00062110083,"about_ca_system_score_gemma":0.0006266861,"threshold_uncertainty_score":0.9999505},"labels":[],"label_agreement":null},{"id":"W4322761313","doi":"10.1016/j.ejca.2023.02.018","title":"Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","year":2023,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; University of British Columbia","funders":"Astellas Pharma; Advanced Accelerator Applications; Medical Research Council; Sanofi; Movember Foundation; AstraZeneca; Chugai Pharmaceutical; Daiichi-Sankyo; Pfizer; Amgen","keywords":"Cancer; Medicine; Prostate cancer; Prostate; Oncology; Castration; Internal medicine; Hormone","score_opus":0.06118626479028528,"score_gpt":0.3776068249279193,"score_spread":0.31642056013763403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322761313","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0416478,0.94655293,0.0000023345524,0.00096524804,0.0009786984,0.0062275254,0.0032775588,0.00003212756,0.00031575197],"genre_scores_gemma":[0.0064316113,0.9762073,0.00042482567,0.000038791717,0.00012999558,0.0007525035,0.00009807421,0.00025443325,0.015662462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928687,0.0006591794,0.002912727,0.00083463377,0.0019032285,0.0008215143],"domain_scores_gemma":[0.9904866,0.00016322407,0.0056938883,0.0007810829,0.0024675885,0.00040762383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010923485,0.00091009954,0.002864069,0.00041633623,0.00021546733,0.00006665038,0.0005390899,0.00007198357,0.00021285709],"category_scores_gemma":[0.00009838688,0.00049340853,0.0004640671,0.0013731244,0.0007383727,0.00020519733,0.00027184468,0.0009662273,0.0000025671386],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00998623,0.00035476196,0.0042195795,0.050473157,0.005740361,0.00571447,0.0013729192,0.00044648635,0.00011577978,0.000013846454,0.00148109,0.9200813],"study_design_scores_gemma":[0.022746189,0.004684345,0.0232647,0.24930936,0.012420674,0.0003851365,0.0015719705,0.000017409404,0.00061202655,0.000025721823,0.6835072,0.0014552537],"about_ca_topic_score_codex":0.00031760105,"about_ca_topic_score_gemma":0.0005256349,"teacher_disagreement_score":0.91862607,"about_ca_system_score_codex":0.00087963307,"about_ca_system_score_gemma":0.0055120615,"threshold_uncertainty_score":0.99975175},"labels":[],"label_agreement":null},{"id":"W4328135909","doi":"10.1016/j.ejca.2023.03.013","title":"Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Observational study; Clinical trial; Psychological intervention; Randomized controlled trial; Medicine; Cancer; Quality (philosophy); Set (abstract data type); Medical physics; Computer science; Internal medicine; Nursing","score_opus":0.20530063998526987,"score_gpt":0.47118711439527894,"score_spread":0.26588647441000907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328135909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838301,0.011587309,0.000007368704,0.0024616718,0.0002031483,0.00027296392,0.00031192115,9.751207e-7,0.0013245504],"genre_scores_gemma":[0.95799625,0.04117052,0.000038767004,0.000038229526,0.000561817,0.000007937736,0.000013866829,0.000026001358,0.00014662523],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976791,0.0011290404,0.0005375616,0.00017434951,0.0002959467,0.00018401163],"domain_scores_gemma":[0.99819165,0.00043607928,0.00041075205,0.0004697762,0.00045254116,0.00003922193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005626919,0.00007436178,0.00016836113,0.000084919775,0.00011041012,0.000018440018,0.00053282885,0.000017364946,0.00000690518],"category_scores_gemma":[0.00031521526,0.000040526662,0.00006557547,0.0003067027,0.0004144282,0.000006293047,0.00031391426,0.0001732805,5.7465104e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016324571,0.00029091694,0.35932168,0.00007276417,0.00047441368,0.000009939794,0.0029598516,0.0019147318,0.14661014,0.0011790073,0.0127523,0.47278178],"study_design_scores_gemma":[0.001804781,0.0015863491,0.79511267,0.00030203545,0.00010426626,0.0000031108245,0.0015297303,0.00022571333,0.082050525,0.0003518302,0.11682339,0.00010562674],"about_ca_topic_score_codex":0.0016375483,"about_ca_topic_score_gemma":0.008729286,"teacher_disagreement_score":0.47267616,"about_ca_system_score_codex":0.00006333554,"about_ca_system_score_gemma":0.00041185765,"threshold_uncertainty_score":0.4871146},"labels":[],"label_agreement":null},{"id":"W4360874226","doi":"10.1016/j.ejca.2023.03.024","title":"Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Novartis Pharma; Genentech; Ipsen; PharmaMar; Eisai; Basilea Pharmaceutica; Daiichi Sankyo Europe; Servier; AstraZeneca; Novocure; Institut National Du Cancer; Eisai Canada; BeiGene; Agios Pharmaceuticals; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boston Pharmaceuticals; Taiho Pharmaceutical; Bayer HealthCare; Sanofi; Exelixis; GlaxoSmithKline; Relay Therapeutics; Amgen; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Neuroendocrine tumors; Medicine; MEN1; Everolimus; Internal medicine; Neuroendocrine carcinoma; PTEN; Oncology; Carcinoma; Endocrine system","score_opus":0.07200199533469943,"score_gpt":0.4166217661205312,"score_spread":0.3446197707858318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360874226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788863,0.0011503954,0.00016229713,0.017461278,0.00040265423,0.000627784,0.00004073999,0.000040314662,0.0012282025],"genre_scores_gemma":[0.9908548,0.004052443,0.0030154933,0.00035328377,0.0006561131,0.000012695866,0.000034486864,0.0000775725,0.00094310206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978008,0.00030694672,0.00063329964,0.00034766397,0.00056483,0.00034643975],"domain_scores_gemma":[0.99839187,0.00037765646,0.00027957896,0.00043325042,0.00028126134,0.00023638041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012281906,0.00015087618,0.00041484163,0.00051269296,0.000044853718,0.000017238346,0.00031070397,0.0000018718549,0.000040002407],"category_scores_gemma":[0.0024161607,0.00011358099,0.000048940994,0.0006725253,0.000156519,0.00027007508,0.00023280297,0.00040965114,0.0000039247543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0138659915,0.00044670014,0.43497497,0.0018521465,0.0003505145,0.07191681,0.00030263313,0.00418241,0.16949916,0.00033769553,0.060112532,0.24215844],"study_design_scores_gemma":[0.016186077,0.0049089347,0.55781305,0.0017123184,0.0002246643,0.0032026134,0.00044379287,0.006672904,0.043945782,0.0011298766,0.3633149,0.00044509527],"about_ca_topic_score_codex":0.000046779795,"about_ca_topic_score_gemma":0.000098476245,"teacher_disagreement_score":0.30320236,"about_ca_system_score_codex":0.000074528085,"about_ca_system_score_gemma":0.00014581704,"threshold_uncertainty_score":0.46316984},"labels":[],"label_agreement":null},{"id":"W4366496702","doi":"10.1016/j.ejca.2023.04.007","title":"Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Afatinib; Refractory (planetary science); Medicine; Oncology; Internal medicine; Pediatrics; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.04850224767936248,"score_gpt":0.3747968129093108,"score_spread":0.32629456522994826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366496702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956053,0.0012526205,0.0000052514156,0.0005976361,0.0007867086,0.0005492089,0.00007194346,0.000021624599,0.0011097391],"genre_scores_gemma":[0.99749964,0.00101038,0.00010365258,0.000048095884,0.0009379696,0.000004040258,0.000027664813,0.00006544529,0.0003031057],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99629647,0.0006556882,0.0011499752,0.00023576619,0.0012966581,0.00036545243],"domain_scores_gemma":[0.9976901,0.00015959538,0.00081309286,0.00028232692,0.00078747334,0.0002674597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023677351,0.0001786809,0.0005059654,0.00077489286,0.000031259955,0.000016390415,0.0002369436,0.000038969018,0.00015078108],"category_scores_gemma":[0.0008664818,0.0001283122,0.0001258108,0.0014241809,0.0000956751,0.0001404452,0.00006108537,0.0007014537,0.000028257438],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42619795,0.0026842777,0.03321975,0.00031843575,0.0002369496,0.0019290075,0.003640005,0.0003662772,0.0033827035,0.0000015687942,0.062751755,0.46527132],"study_design_scores_gemma":[0.50758535,0.028565746,0.4148127,0.004074782,0.0002598562,0.000022117005,0.0003375973,0.00021362992,0.0016839537,0.000007923985,0.042062033,0.00037433373],"about_ca_topic_score_codex":0.000026767131,"about_ca_topic_score_gemma":0.000017988481,"teacher_disagreement_score":0.46489698,"about_ca_system_score_codex":0.00024586267,"about_ca_system_score_gemma":0.00074359495,"threshold_uncertainty_score":0.52324194},"labels":[],"label_agreement":null},{"id":"W4366496785","doi":"10.1016/j.ejca.2023.04.014","title":"Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ontario Ministry of Research, Innovation and Science; Government of Ontario; Public Health Agency; Princess Margaret Cancer Foundation","keywords":"Squamous cell cancer; Head and neck; Medicine; Head and neck cancer; Oncology; Cancer; Kinetics; DNA; Internal medicine; Cancer research; Surgery; Biology; Genetics","score_opus":0.0160783280508068,"score_gpt":0.2699332835673543,"score_spread":0.2538549555165475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366496785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225813,0.0061820457,0.000029805287,0.00016953758,0.00060412847,0.00008971955,0.000052416763,0.0000036880333,0.0006105096],"genre_scores_gemma":[0.99547875,0.0035500803,0.00015053315,0.0002160253,0.000418761,0.0000032574198,0.0000149638645,0.00004146715,0.000126152],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988913,0.000103208076,0.00042385308,0.00018125652,0.00016461882,0.00023576662],"domain_scores_gemma":[0.99929535,0.000027607308,0.00029359115,0.00010586611,0.00016079907,0.0001168043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025775822,0.0001386127,0.00017633593,0.00010066557,0.000035760957,0.000035602625,0.00014472488,0.000020622088,0.000018025235],"category_scores_gemma":[0.00013979746,0.0001334143,0.0000642743,0.00016464503,0.000034714212,0.000005761626,0.00010055511,0.00014078541,0.0000048394268],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061312516,0.00058885285,0.2806353,0.0003490282,0.00012817157,0.00071216916,0.001461939,0.017768532,0.5045723,0.000014097957,0.02644808,0.16670844],"study_design_scores_gemma":[0.008247831,0.0024377378,0.8606284,0.00043797365,0.00013181167,0.00003629557,0.00021145461,0.0005082949,0.032864224,0.000055505065,0.09376214,0.0006782979],"about_ca_topic_score_codex":0.000031565458,"about_ca_topic_score_gemma":0.00016246983,"teacher_disagreement_score":0.5799931,"about_ca_system_score_codex":0.000046744313,"about_ca_system_score_gemma":0.00009374375,"threshold_uncertainty_score":0.5440477},"labels":[],"label_agreement":null},{"id":"W4367397422","doi":"10.1016/j.ejca.2023.04.016","title":"Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; Merck","keywords":"Pembrolizumab; Medicine; Metformin; Placebo; Stage (stratigraphy); Internal medicine; Oncology; Predictive value; Cancer; Phases of clinical research; Clinical trial; Immunotherapy; Pathology; Alternative medicine; Insulin; Biology","score_opus":0.04977394313242677,"score_gpt":0.3597668600185554,"score_spread":0.3099929168861286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367397422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722981,0.026224967,0.000038518992,0.00003101665,0.00020803632,0.0007589314,0.00025160186,0.0000017438203,0.00018709741],"genre_scores_gemma":[0.95026,0.04917131,0.00004292681,0.000005461749,0.00037407514,0.00003179967,0.00002212669,0.000028261793,0.00006407688],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99744725,0.0011977296,0.00061472354,0.00020314974,0.0003163047,0.00022084686],"domain_scores_gemma":[0.9987484,0.00021836314,0.00051590137,0.00017739927,0.00028079396,0.000059102167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026143482,0.00013375812,0.000349858,0.00020874816,0.00004456694,0.00001271069,0.00018074062,0.00003701497,0.000014115419],"category_scores_gemma":[0.00030619145,0.00009449746,0.00006260951,0.0002533227,0.00017314707,0.000014483091,0.00005406099,0.00013227161,1.6530653e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40902537,0.0010828194,0.007371283,0.00026516258,0.0010876649,0.000075402066,0.012637548,0.001539552,0.120678715,0.00010215092,0.0009127872,0.44522154],"study_design_scores_gemma":[0.5514911,0.042070106,0.08590806,0.00043996313,0.0006580553,0.0000064141286,0.004673287,0.00057670445,0.29091576,0.0001174866,0.02274642,0.0003966462],"about_ca_topic_score_codex":0.00026234172,"about_ca_topic_score_gemma":0.00031634886,"teacher_disagreement_score":0.4448249,"about_ca_system_score_codex":0.00005515672,"about_ca_system_score_gemma":0.00024727784,"threshold_uncertainty_score":0.38534945},"labels":[],"label_agreement":null},{"id":"W4379508165","doi":"10.1016/j.ejca.2023.05.002","title":"Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Organisation for Research and Treatment of Cancer; Brain Tumour Foundation of Canada; Brain Tumor Funders' Collaborative; Universität Zürich; James S. McDonnell Foundation","keywords":"Medicine; Oncology; Internal medicine; Isocitrate dehydrogenase; Population; Proportional hazards model; Cancer; Cohort; Progression-free survival; Cancer registry; IDH1; Chemotherapy; Biology; Mutation","score_opus":0.027814665840399298,"score_gpt":0.28705535723403786,"score_spread":0.25924069139363853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379508165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755806,0.0012931657,0.0000158815,0.020397035,0.00057355856,0.0002717366,0.00022618976,0.00003633208,0.0016055354],"genre_scores_gemma":[0.99733573,0.0004214068,0.000045871053,0.00094949105,0.0007876394,0.000005824993,0.000018318911,0.00005346437,0.00038227008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979448,0.00040379583,0.0005292689,0.00024576706,0.0005932993,0.00028311877],"domain_scores_gemma":[0.9977518,0.0006331167,0.0005791478,0.00031992645,0.0004839086,0.00023212422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007943593,0.00022667802,0.0004043189,0.00009883502,0.00017669148,0.00007806297,0.00020564621,0.00002002114,0.00016133935],"category_scores_gemma":[0.00031881587,0.00012607864,0.000124811,0.00055206614,0.00017247967,0.000106862906,0.000059446524,0.000324901,0.00011508668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01450512,0.00055308646,0.80683345,0.00004596567,0.0025878176,0.034003228,0.006010509,0.000559106,0.001218085,0.000026482108,0.12745655,0.0062006065],"study_design_scores_gemma":[0.010062491,0.0017016304,0.9651296,0.0007459508,0.00036485982,0.0001531156,0.00068312004,0.000010278549,0.0014046363,0.0000057771467,0.019579675,0.00015884385],"about_ca_topic_score_codex":0.0000915054,"about_ca_topic_score_gemma":0.0018598605,"teacher_disagreement_score":0.15829617,"about_ca_system_score_codex":0.0001322201,"about_ca_system_score_gemma":0.00029518348,"threshold_uncertainty_score":0.5141338},"labels":[],"label_agreement":null},{"id":"W4383107148","doi":"10.1016/j.ejca.2023.112966","title":"Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis","year":2023,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; BC Cancer Agency","funders":"Eisai; National Institute for Health and Care Research; Genentech; AstraZeneca; Mersana Therapeutics; Clovis Oncology; Cancer Research UK; Amgen","keywords":"Ovarian cancer; Cancer; Oncology; Internal medicine; Poly ADP ribose polymerase; Medicine; Polymerase; Cancer research; Biology; Genetics; DNA","score_opus":0.12187028416771417,"score_gpt":0.3790859937164474,"score_spread":0.25721570954873324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383107148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009650151,0.98111194,0.00011345633,0.002572833,0.0024869512,0.0016571037,0.0021967143,0.000039874285,0.00017100127],"genre_scores_gemma":[0.04880686,0.9475677,0.00006695652,0.0005427508,0.0014392846,0.00053151464,0.00015466093,0.0002684696,0.0006217797],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9912296,0.0019028859,0.0037843643,0.0010814347,0.0011247202,0.0008769999],"domain_scores_gemma":[0.9941676,0.00033831675,0.0035119164,0.0005302438,0.00096559117,0.00048631732],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026117458,0.0011769282,0.0064477855,0.0026996974,0.00015247548,0.00011562719,0.00052255514,0.0003047163,0.0021488087],"category_scores_gemma":[0.00020169266,0.0008730702,0.0020010113,0.0032738238,0.00028065027,0.00036907048,0.0002053485,0.0018669283,0.000008668943],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031511202,0.0015224449,0.031112755,0.011849629,0.15526505,0.0038385838,0.0033242798,0.0065830047,0.000052457326,0.000069082314,0.0027321812,0.7804994],"study_design_scores_gemma":[0.05177716,0.0038166263,0.09132457,0.069315985,0.43870157,0.0001353115,0.00043810578,0.0024349724,0.00026698408,0.00012715337,0.33590046,0.005761113],"about_ca_topic_score_codex":0.0034666073,"about_ca_topic_score_gemma":0.026783757,"teacher_disagreement_score":0.7747383,"about_ca_system_score_codex":0.0028239843,"about_ca_system_score_gemma":0.002127279,"threshold_uncertainty_score":0.999372},"labels":[],"label_agreement":null},{"id":"W4384938676","doi":"10.1016/j.ejca.2023.113245","title":"Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; U.S. Food and Drug Administration; Ipsen; PharmaMar; Eisai; MacroGenics; Pfizer; Symphogen; Incyte; Amgen; Deciphera Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Exelixis; Karyopharm Therapeutics; Iterion Therapeutics; Sanofi; PTC Therapeutics; GlaxoSmithKline; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; AstraZeneca; Springworks Therapeutics; Abbott Laboratories","keywords":"Tolerability; Sunitinib; Medicine; Imatinib; Open label; Oncology; Internal medicine; Adverse effect; Cancer","score_opus":0.07365699301019253,"score_gpt":0.3952851022484515,"score_spread":0.32162810923825896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384938676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754614,0.000110435525,9.66914e-7,0.0003935473,0.00008674979,0.001189654,0.000014667767,0.000011602311,0.0006462502],"genre_scores_gemma":[0.9993601,0.00005286626,0.0003509263,0.000035224428,0.000025315601,0.00005712665,0.0000072523453,0.000031899872,0.00007928116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976943,0.00047235042,0.00078083685,0.00025937197,0.00046079574,0.00033231082],"domain_scores_gemma":[0.99876934,0.00015643633,0.00033458104,0.000217202,0.00026580784,0.00025661278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008185929,0.00021150625,0.00054426305,0.00030865593,0.00003718579,0.000055335247,0.00009193353,0.00000928079,0.000067834655],"category_scores_gemma":[0.00041529263,0.00013350611,0.000037135283,0.0004220091,0.00006039303,0.0001702318,0.000105947656,0.00025880436,0.0000065603144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020363675,0.006492501,0.8819759,0.000018124378,0.0001893777,0.008504458,0.0018327321,0.000005940243,0.000012401626,1.7736977e-7,0.000026946873,0.080577746],"study_design_scores_gemma":[0.10315905,0.034350432,0.8607976,0.00048122698,0.00009144373,0.00004124541,0.0008279934,0.000018016506,0.000029164474,0.0000017340076,0.00011062957,0.00009150331],"about_ca_topic_score_codex":0.00019230951,"about_ca_topic_score_gemma":0.00046241854,"teacher_disagreement_score":0.082795374,"about_ca_system_score_codex":0.0003401094,"about_ca_system_score_gemma":0.00018523846,"threshold_uncertainty_score":0.5444221},"labels":[],"label_agreement":null},{"id":"W4385155205","doi":"10.1016/j.ejca.2023.113249","title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","year":2023,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; PARP inhibitor; Androgen receptor; Cancer research; Poly ADP ribose polymerase; DNA repair; Medicine; Cancer; Internal medicine; Oncology; Biology; Gene; Polymerase; Genetics","score_opus":0.10310390274270996,"score_gpt":0.4134314400773371,"score_spread":0.31032753733462715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385155205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003796653,0.9935954,0.000067527115,0.0022637397,0.0013466418,0.0011411656,0.0010629331,0.000026200043,0.00011667786],"genre_scores_gemma":[0.00022959147,0.99575853,0.00030175512,0.00027257617,0.0018198076,0.00019605964,0.00009752054,0.00017079466,0.0011533501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671733,0.00071962696,0.0015093858,0.00032829447,0.0003320351,0.0003933224],"domain_scores_gemma":[0.9966508,0.0004786179,0.0019482195,0.00023254713,0.0004458255,0.00024396038],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017079173,0.0004079919,0.0013035253,0.000260946,0.0003136912,0.00010867298,0.00015761002,0.00006522855,0.00009452883],"category_scores_gemma":[0.0001481857,0.00025970643,0.00042679755,0.0002526106,0.00024876613,0.00011762809,0.000039706614,0.00056853256,0.000012678663],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007581287,0.000040822393,0.000013860641,0.0035885226,0.0016175673,0.0001381166,0.0004681131,0.000002183835,0.0007895245,0.00010956601,0.010290323,0.9821833],"study_design_scores_gemma":[0.0029763419,0.0007884737,0.000015650518,0.016994754,0.0017012074,0.00023024346,0.00010679453,0.0000027931594,0.00028091198,0.00006913971,0.9765747,0.00025896335],"about_ca_topic_score_codex":0.000036442238,"about_ca_topic_score_gemma":0.00004823453,"teacher_disagreement_score":0.9819243,"about_ca_system_score_codex":0.00032694876,"about_ca_system_score_gemma":0.0012206185,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W4385755852","doi":"10.1016/j.ejca.2023.113290","title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Enzalutamide; Internal medicine; Androgen deprivation therapy; Bone metastasis; Oncology; Urology; Post-hoc analysis; Prostate-specific antigen; Metastasis; Antiandrogen; Cancer; Androgen receptor","score_opus":0.06086182586563502,"score_gpt":0.38923981250666795,"score_spread":0.3283779866410329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385755852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749374,0.0005580725,0.000018872708,0.00031913118,0.00015587539,0.001330579,0.000061964485,0.000005611053,0.00005613261],"genre_scores_gemma":[0.99713403,0.002521605,0.000047185553,0.000057384284,0.00007807525,0.000017060096,0.00001849636,0.000026737393,0.00009943996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571913,0.0015273963,0.0015590357,0.0002164683,0.00077816745,0.00019976865],"domain_scores_gemma":[0.9972737,0.00037759804,0.0011339418,0.00024964637,0.0008511045,0.000114009745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003400088,0.0001518843,0.00094015343,0.00038450395,0.00004372482,0.000012869852,0.000158356,0.000021607373,0.00003408788],"category_scores_gemma":[0.00021898953,0.00008099054,0.00036155412,0.0015866171,0.0002138744,0.00009910078,0.000037135997,0.0003437276,0.0000010598793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02758011,0.00066109,0.94634914,0.000025494193,0.004689445,0.0001634519,0.002245576,0.0012265863,0.00014564194,9.939821e-7,0.00005640926,0.016856043],"study_design_scores_gemma":[0.05531003,0.0024005794,0.9388691,0.00018074611,0.0016214567,0.0000014312828,0.00074317894,0.00040983813,0.00035466836,0.0000025549873,0.00003485577,0.000071522656],"about_ca_topic_score_codex":0.00012559374,"about_ca_topic_score_gemma":0.00057785836,"teacher_disagreement_score":0.02772992,"about_ca_system_score_codex":0.00014088288,"about_ca_system_score_gemma":0.00059017586,"threshold_uncertainty_score":0.33026984},"labels":[],"label_agreement":null},{"id":"W4386003022","doi":"10.1016/j.ejca.2023.113291","title":"Computational intelligence analysis of high-risk neuroblastoma patient health records reveals time to maximum response as one of the most relevant factors for outcome prediction","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Ministero dell’Istruzione, dell’Università e della Ricerca; European Commission; Ministero della Salute; Fondazione Italiana per la Lotta al Neuroblastoma","keywords":"Hazard ratio; Confidence interval; Internal medicine; Log-rank test; Survival analysis; Medicine; Proportional hazards model; Neuroblastoma; Retrospective cohort study; Progression-free survival; Outcome (game theory); Recursive partitioning; Random forest; Oncology; Mathematics; Overall survival; Artificial intelligence; Biology; Computer science","score_opus":0.03431217403188956,"score_gpt":0.33453180566429497,"score_spread":0.3002196316324054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386003022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948209,0.000052974174,0.0010987036,0.0027562792,0.00019070244,0.00045095716,0.0005805144,0.000012643563,0.000036353016],"genre_scores_gemma":[0.99831665,0.00010362436,0.0005808914,0.00026903875,0.000046786157,0.0000041667195,0.000013182433,0.00003009058,0.000635553],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9970425,0.00079754164,0.0009971686,0.00017430552,0.0007705155,0.0002179674],"domain_scores_gemma":[0.99746203,0.0005650285,0.0008853058,0.00022783481,0.0006129748,0.0002467999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012024391,0.0001248294,0.0004976931,0.00062103634,0.00008020354,0.000009120171,0.00016756241,0.000014256925,0.0001650921],"category_scores_gemma":[0.001362145,0.00008287509,0.00027815744,0.0013717645,0.00005807298,0.000051837626,0.000070618225,0.00019901383,0.00002313615],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049966052,0.001546732,0.29011592,0.00043736445,0.008736625,0.0003207463,0.0046986486,0.37787032,0.01716118,0.000027227656,0.02188505,0.22723413],"study_design_scores_gemma":[0.00097244757,0.008760406,0.9832888,0.00033111023,0.000554501,0.000013999835,0.00008746308,0.0013396007,0.0035510398,0.00008407136,0.0009530932,0.000063447944],"about_ca_topic_score_codex":0.00006810526,"about_ca_topic_score_gemma":0.000011119665,"teacher_disagreement_score":0.6931729,"about_ca_system_score_codex":0.00016521284,"about_ca_system_score_gemma":0.00029368297,"threshold_uncertainty_score":0.33795482},"labels":[],"label_agreement":null},{"id":"W4386815910","doi":"10.1016/j.ejca.2023.113342","title":"Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Orion Corporation; Astellas Pharma; Genentech; UroGen Pharma; Daiichi Sankyo Europe; Sanofi; Bayer HealthCare; Incyte; MacroGenics; Invitae; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Prostate cancer; Placebo; Medicine; Oncology; Internal medicine; Overall survival; Crossover; Crossover study; Cancer; Pathology; Alternative medicine","score_opus":0.038797972953451436,"score_gpt":0.4012976965375424,"score_spread":0.36249972358409094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386815910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955766,0.0006726626,0.00002390218,0.0010343088,0.00016140332,0.0017119583,0.0003487239,0.000012539664,0.0004578686],"genre_scores_gemma":[0.9983142,0.0005355025,0.000024467203,0.00012600758,0.00026536852,0.000040524985,0.000018819755,0.00005196144,0.0006231494],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99602664,0.0018796945,0.0005507706,0.0002886782,0.00091779087,0.00033645565],"domain_scores_gemma":[0.9974228,0.0014871064,0.000364861,0.00030056437,0.00022014201,0.00020453549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027365936,0.0002619869,0.0008738135,0.0002075855,0.00007369771,0.000051360905,0.00015980403,0.00001377736,0.00010208188],"category_scores_gemma":[0.0002473827,0.0001315935,0.00015418754,0.0005388458,0.00009873477,0.000097870456,0.000060329625,0.00041158617,0.000015357959],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61682916,0.0010013388,0.22526121,0.00009864793,0.004484987,0.010680334,0.014152292,0.01823312,0.07112419,1.3444274e-7,0.004827552,0.033307012],"study_design_scores_gemma":[0.3365866,0.01206627,0.5984755,0.0017056202,0.0014383467,0.000007622831,0.0012241404,0.0011572852,0.046512228,0.000004156759,0.00055148586,0.00027075535],"about_ca_topic_score_codex":0.003307056,"about_ca_topic_score_gemma":0.00067298056,"teacher_disagreement_score":0.3732143,"about_ca_system_score_codex":0.00024394337,"about_ca_system_score_gemma":0.0003196341,"threshold_uncertainty_score":0.53662264},"labels":[],"label_agreement":null},{"id":"W4386826646","doi":"10.1016/j.ejca.2023.113343","title":"EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023","year":2023,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"Recordati Rare Diseases","keywords":"Mycosis fungoides; Medicine; Brentuximab vedotin; Life expectancy; Disease; Stage (stratigraphy); Quality of life (healthcare); Oncology; Internal medicine; Intensive care medicine; Lymphoma; CD30; Population","score_opus":0.1916347257755578,"score_gpt":0.4523152921208744,"score_spread":0.2606805663453166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386826646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009701058,0.99277323,0.00002948531,0.0035232157,0.00063034135,0.0015665542,0.00082686957,0.000013765612,0.00053953275],"genre_scores_gemma":[0.000037777485,0.9898382,0.00019767198,0.00009509949,0.00047550752,0.000093521674,0.000088633315,0.00015861503,0.0090149725],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701554,0.0006064462,0.0013548309,0.00024021484,0.00046250716,0.0003204574],"domain_scores_gemma":[0.99632186,0.0012005748,0.0011568668,0.0004187679,0.00071943837,0.00018247082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010006455,0.00034819776,0.0017148848,0.00039723565,0.0001333339,0.000033642216,0.00031687523,0.000056020745,0.00067969563],"category_scores_gemma":[0.00027436763,0.0001982084,0.0010552034,0.00048187186,0.00015139674,0.000023901266,0.000045660683,0.00031028717,0.00013038616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019525093,0.00018476036,0.000022626658,0.0032419066,0.0038623433,0.0009861861,0.00014039571,0.000008075583,0.0000024262943,0.000009157705,0.05576231,0.93558455],"study_design_scores_gemma":[0.0012658318,0.0016273442,0.000059291735,0.008269504,0.0033086555,0.0032738626,0.00012656675,0.000010281525,0.00000274436,0.0000065308786,0.9818991,0.0001503307],"about_ca_topic_score_codex":0.00003265354,"about_ca_topic_score_gemma":0.000036279867,"teacher_disagreement_score":0.9354342,"about_ca_system_score_codex":0.00050238275,"about_ca_system_score_gemma":0.0012380698,"threshold_uncertainty_score":0.80827045},"labels":[],"label_agreement":null},{"id":"W4386898883","doi":"10.1016/j.ejca.2023.113348","title":"Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; University Health Network; University of Toronto; Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Concomitant; Abiraterone acetate; Prostate cancer; Internal medicine; Hazard ratio; Aspirin; Proportional hazards model; Oncology; Statistical significance; Androgen deprivation therapy; Cancer; Confidence interval","score_opus":0.011349390985719802,"score_gpt":0.3166517822665936,"score_spread":0.3053023912808738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386898883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550545,0.003222096,0.0000070821493,0.00026124643,0.0006408135,0.00018173963,0.00010745163,0.000001306104,0.00007278526],"genre_scores_gemma":[0.9960208,0.0033849627,0.000012187891,0.000034240296,0.00028949307,0.000011121871,0.0000027147537,0.00001195449,0.00023254145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980341,0.0012276358,0.00035287402,0.000112208734,0.00016751164,0.000105655476],"domain_scores_gemma":[0.99927086,0.00011951527,0.0003070914,0.00017434325,0.000077019315,0.000051180785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018486186,0.000095609,0.00033211705,0.00015755309,0.000026493162,0.0000053094204,0.0001248621,0.000010823331,0.000015268113],"category_scores_gemma":[0.00012432037,0.00005744288,0.00012781123,0.00035993938,0.00007433831,0.0000031822456,0.00003524011,0.000076390366,1.9767167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009141841,0.00037011682,0.57494986,0.00008690642,0.0072130607,0.000018072988,0.0079514645,0.01659038,0.320349,0.000008539074,0.0012815797,0.06203916],"study_design_scores_gemma":[0.0039226543,0.0020656302,0.960164,0.00006260182,0.0014815792,0.0000033500035,0.00039755294,0.000041528667,0.01658203,0.0000013011272,0.015203706,0.000074042124],"about_ca_topic_score_codex":0.00013114695,"about_ca_topic_score_gemma":0.0012049009,"teacher_disagreement_score":0.38521415,"about_ca_system_score_codex":0.00004556611,"about_ca_system_score_gemma":0.00029246332,"threshold_uncertainty_score":0.23424529},"labels":[],"label_agreement":null},{"id":"W4387061861","doi":"10.1016/j.ejca.2023.113350","title":"European trends in ovarian cancer mortality, 1990–2020 and predictions to 2025","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Ovarian cancer; Demography; Mortality rate; Population; Medicine; Cancer; Developed country; Environmental health; Internal medicine","score_opus":0.045705239180212215,"score_gpt":0.35132625847268467,"score_spread":0.30562101929247243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387061861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8853706,0.0062164003,0.00009709296,0.0518202,0.002003256,0.000305625,0.00016464034,0.000073979914,0.053948186],"genre_scores_gemma":[0.98891544,0.0048395977,0.00014611418,0.0011748635,0.001411774,0.000012424997,0.0000073378383,0.00005851025,0.0034339111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998401,0.00022571241,0.00052343577,0.0002463442,0.00033775708,0.00026578637],"domain_scores_gemma":[0.9991144,0.000026722717,0.00017547482,0.00020544312,0.00011685898,0.00036108482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000745633,0.00016983779,0.00033598757,0.0004377384,0.000060919923,0.000042908152,0.00011893699,0.000016648799,0.0006893551],"category_scores_gemma":[0.000034905646,0.00013747014,0.00011367798,0.0009087211,0.00003941991,0.00009506623,0.000082848754,0.00025693642,0.00006264945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025492124,0.00022423088,0.5376982,0.00005546749,0.0007160255,0.005462146,0.0018670952,0.001647102,0.000673997,0.0000656549,0.16473266,0.28660247],"study_design_scores_gemma":[0.0023797313,0.00036362238,0.86391,0.000493413,0.00024344136,0.000052556392,0.000072920506,0.000037645936,0.00007994105,0.0000067391957,0.13225602,0.00010397332],"about_ca_topic_score_codex":0.00028438616,"about_ca_topic_score_gemma":0.00044012413,"teacher_disagreement_score":0.32621178,"about_ca_system_score_codex":0.00019631388,"about_ca_system_score_gemma":0.00011856015,"threshold_uncertainty_score":0.75479543},"labels":[],"label_agreement":null},{"id":"W4387747187","doi":"10.1016/j.ejca.2023.113389","title":"Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities","year":2023,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"World Health Organization; Medical Research Council; National Institute for Health and Care Research; Global Alliance for Chronic Diseases","keywords":"Medicine; Guideline; Quality (philosophy); Health care; Systematic review; Data extraction; MEDLINE; Family medicine; Pathology","score_opus":0.2479638531528237,"score_gpt":0.5663559122406171,"score_spread":0.3183920590877934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387747187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019452695,0.99210083,0.0007294801,0.0004594381,0.0010595721,0.00445204,0.00093948125,0.000037786387,0.000026826381],"genre_scores_gemma":[0.00021179939,0.9961809,0.00032564136,0.0017474472,0.0007385382,0.00017469918,0.000035866433,0.00013743379,0.00044769587],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98943716,0.0037112138,0.005015019,0.0003987285,0.0009887527,0.00044909967],"domain_scores_gemma":[0.98924774,0.0017503692,0.0067062518,0.00076562323,0.0011925378,0.00033746523],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010179818,0.00054465845,0.008421624,0.0004581038,0.00012147972,0.000021097607,0.00081872405,0.00011715675,0.000036704227],"category_scores_gemma":[0.00076659286,0.0003420731,0.001447605,0.0014155894,0.00016327684,0.0000894663,0.000054983906,0.00070371706,0.000014094461],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018292939,0.000057694546,0.00015725399,0.91683054,0.0017770056,0.000045730612,0.0018730343,0.0000016706606,5.3610887e-7,0.000035521858,0.0003853515,0.07865273],"study_design_scores_gemma":[0.00086594623,0.0003717853,0.000047815996,0.62217295,0.00082662975,0.00014195527,0.0007059318,2.0095602e-7,8.421405e-7,0.0000041669605,0.3746457,0.00021604293],"about_ca_topic_score_codex":0.000039311075,"about_ca_topic_score_gemma":0.00003820498,"teacher_disagreement_score":0.37426037,"about_ca_system_score_codex":0.0008357093,"about_ca_system_score_gemma":0.0011628459,"threshold_uncertainty_score":0.99990314},"labels":[],"label_agreement":null},{"id":"W4388379556","doi":"10.1016/j.ejca.2023.113420","title":"Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Positive Living Society of British Columbia","funders":"Pfizer","keywords":"Palbociclib; Medicine; Placebo; Quality of life (healthcare); Breast cancer; Internal medicine; Oncology; Mood; Cancer; Physical therapy; Gynecology; Metastatic breast cancer; Clinical psychology","score_opus":0.01585629647036171,"score_gpt":0.2924184670737479,"score_spread":0.2765621706033862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388379556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952754,0.00055980944,0.000022989296,0.0012412369,0.00031858069,0.0023339132,0.00005177803,0.000092970055,0.00010334666],"genre_scores_gemma":[0.996861,0.0007866798,0.00016967511,0.00044509553,0.0002370082,0.00018650385,0.000005932197,0.00020979054,0.0010983617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950156,0.0013351305,0.0014053729,0.00044973145,0.0012694049,0.00052475784],"domain_scores_gemma":[0.99591464,0.0002537168,0.0020746489,0.0005108404,0.0010068262,0.00023931747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001198372,0.0005641021,0.0016294272,0.00036074885,0.00016538151,0.000073704,0.00032358585,0.000028396415,0.00024381262],"category_scores_gemma":[0.00011685582,0.00023772939,0.00018143818,0.0011553715,0.00032645598,0.0003248983,0.00004856148,0.00075091614,0.000009659617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.223209,0.0005770911,0.7400164,0.000011585385,0.0022862635,0.0011716795,0.0055135167,0.000766439,0.000057131012,8.170539e-7,0.00003727504,0.02635281],"study_design_scores_gemma":[0.23796481,0.0036112713,0.755142,0.0004951782,0.00055524945,0.00017209328,0.0013208926,0.000017167444,0.00018253567,0.000004079837,0.0002600881,0.00027467328],"about_ca_topic_score_codex":0.0024029517,"about_ca_topic_score_gemma":0.0014933491,"teacher_disagreement_score":0.026078137,"about_ca_system_score_codex":0.00025267378,"about_ca_system_score_gemma":0.00043857205,"threshold_uncertainty_score":0.96943235},"labels":[],"label_agreement":null},{"id":"W4388452153","doi":"10.1016/j.ejca.2023.113421","title":"Peptide absent sequences emerging in human cancers","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"RNA and protein synthesis mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Penn State College of Medicine","keywords":"Cancer; Exome sequencing; Biology; Somatic cell; Gene; Proteome; Computational biology; Cancer research; Bioinformatics; Mutation; Genetics","score_opus":0.021879059698199334,"score_gpt":0.29709883584678265,"score_spread":0.27521977614858334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388452153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210167,0.0020328553,0.00014787349,0.00050195307,0.000445596,0.00004649237,0.0000024886788,0.000005645718,0.004715452],"genre_scores_gemma":[0.9956937,0.001414595,0.00015224903,0.00014962202,0.00057498325,0.0000025225088,0.000001941391,0.000022017399,0.0019883655],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913114,0.00016152574,0.00027166487,0.00011458691,0.00015360134,0.00016750398],"domain_scores_gemma":[0.99959695,0.000005089571,0.00017829746,0.000103106315,0.000058079106,0.000058461734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073350145,0.00008275256,0.00010953174,0.000087044726,0.000045395107,0.00001663894,0.00020569612,0.000017443239,0.00008194516],"category_scores_gemma":[0.000033767425,0.00007106724,0.000074938995,0.00012036307,0.000027783244,0.000004801735,0.000040421102,0.000082939136,0.000012666912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031637945,0.000004797024,0.0017737306,0.000008866942,0.0000338599,0.00014532506,0.0001759184,0.0022286281,0.97155535,0.000021717038,0.0048599252,0.019160258],"study_design_scores_gemma":[0.000894726,0.00045146747,0.018885314,0.00030861798,0.00002258344,0.00003461061,0.00062014296,0.00002230851,0.65747154,0.00018072013,0.32080635,0.000301608],"about_ca_topic_score_codex":0.000043692056,"about_ca_topic_score_gemma":0.00008582165,"teacher_disagreement_score":0.31594643,"about_ca_system_score_codex":0.000034054658,"about_ca_system_score_gemma":0.00008318264,"threshold_uncertainty_score":0.28980377},"labels":[],"label_agreement":null},{"id":"W4388598915","doi":"10.1016/j.ejca.2023.113430","title":"Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Ministero dell'Istruzione e del Merito; Servier; Associazione Italiana per la Ricerca sul Cancro; Ministero dell’Istruzione, dell’Università e della Ricerca; Università degli Studi di Verona; Ministero della Salute","keywords":"Medicine; Surgery; Perioperative; Adverse effect; Clinical endpoint; Neutropenia; Randomized controlled trial; Internal medicine; Chemotherapy","score_opus":0.06684031746382872,"score_gpt":0.3925037928245874,"score_spread":0.3256634753607587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388598915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905819,0.0010615118,0.000008870749,0.001963829,0.00025361142,0.0011614435,0.000016237724,0.000010001365,0.004942554],"genre_scores_gemma":[0.9934207,0.00030312443,0.00027869642,0.00030935882,0.0005006014,0.00003244125,0.000009620566,0.00004335497,0.005102055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997294,0.00084351527,0.0006117437,0.00020745998,0.00064158876,0.0004016625],"domain_scores_gemma":[0.9985543,0.00017228343,0.00030471303,0.00025740959,0.00051247526,0.00019881756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018800787,0.00017427844,0.0006108799,0.00020471281,0.00024959026,0.00006836415,0.00044313757,0.000027939313,0.00040740022],"category_scores_gemma":[0.00045701463,0.00009427801,0.000051957388,0.00053342397,0.00020710746,0.00023045581,0.00021238404,0.0006267225,0.00003983971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30357718,0.0032198213,0.67010593,0.000055133907,0.00079879735,0.0023177625,0.0045927404,0.000014591628,0.00071745104,0.000025207572,0.010131378,0.0044439933],"study_design_scores_gemma":[0.40449104,0.031175124,0.5554826,0.00058545975,0.00043662655,0.000052432155,0.0009394171,0.0002805209,0.00007274228,0.000004754113,0.0063178665,0.00016142314],"about_ca_topic_score_codex":0.000085522406,"about_ca_topic_score_gemma":0.0000401786,"teacher_disagreement_score":0.114623345,"about_ca_system_score_codex":0.00019198096,"about_ca_system_score_gemma":0.0006152593,"threshold_uncertainty_score":0.4460747},"labels":[],"label_agreement":null},{"id":"W4388848431","doi":"10.1016/j.ejca.2023.113458","title":"First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Novartis Pharmaceuticals UK Limited; Chugai Pharmaceutical; Italfarmaco; Bristol-Myers Squibb; AstraZeneca; Symphogen; Sun Pharma; Eisai; Sanofi; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Daiichi-Sankyo","keywords":"Medicine; Rash; Nausea; KRAS; Adverse effect; Internal medicine; Gastroenterology; Dysgeusia; Pharmacology; Oncology; Cancer; Colorectal cancer","score_opus":0.013822229583305158,"score_gpt":0.26503973175402923,"score_spread":0.2512175021707241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388848431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992032,0.00006885923,0.00009249082,0.000016380453,0.00010765375,0.00026784526,0.000011658051,0.0000059538716,0.00022598275],"genre_scores_gemma":[0.9993877,0.00002814916,0.00021291603,0.000023992288,0.00014959661,0.000012854176,0.000012399502,0.000045371416,0.00012701818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985841,0.00014338946,0.0005469326,0.00022095325,0.0002763902,0.0002282367],"domain_scores_gemma":[0.9989804,0.000009319995,0.00043241834,0.000192287,0.00030430336,0.000081265025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027070084,0.00016978492,0.00029826834,0.00016391109,0.00006208179,0.00001962141,0.00018715455,0.000019090967,0.00001524576],"category_scores_gemma":[0.00003836903,0.0001183972,0.00003697995,0.00025343834,0.000032983313,0.000019800567,0.000046787092,0.00014986839,0.0000013559198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003942447,0.0009984439,0.782536,0.00014924775,0.0002460527,0.0013860863,0.004928544,0.06887817,0.13373749,0.000014747208,0.00013421642,0.00304857],"study_design_scores_gemma":[0.040601123,0.03042758,0.67184436,0.0036173344,0.00014832827,0.000059543236,0.0055719726,0.00034238218,0.24310865,0.000008565727,0.0030670771,0.0012030998],"about_ca_topic_score_codex":0.000028024844,"about_ca_topic_score_gemma":0.0016307954,"teacher_disagreement_score":0.11069164,"about_ca_system_score_codex":0.000028667848,"about_ca_system_score_gemma":0.00011130178,"threshold_uncertainty_score":0.48280975},"labels":[],"label_agreement":null},{"id":"W4390129317","doi":"10.1016/j.ejca.2023.113505","title":"The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immunotherapy; Medicine; Adverse effect; Side effect (computer science); Internal medicine; Oncology; Immune system; Immunology","score_opus":0.01502355529334317,"score_gpt":0.3225996918108311,"score_spread":0.30757613651748794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390129317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97489816,0.019857526,0.00030497953,0.0013558366,0.0012739169,0.0013263645,0.000013224476,0.000035887922,0.0009340998],"genre_scores_gemma":[0.99518657,0.0028132955,0.000078387304,0.00036353155,0.00032298462,0.00006593911,0.000004674808,0.000065323526,0.001099312],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99684227,0.0010269197,0.0012043031,0.00017052256,0.00043562122,0.000320381],"domain_scores_gemma":[0.99550474,0.0021045164,0.0014412407,0.00052259135,0.00035621264,0.00007072915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00474479,0.00022487395,0.0011790917,0.00037752482,0.00015379314,0.00004244009,0.0003806383,0.00005473674,0.000018986415],"category_scores_gemma":[0.0007164396,0.00013010214,0.0010942097,0.0010944668,0.00011515172,0.00006788369,0.000032325515,0.0002329775,0.0000058987985],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014751469,0.00007443071,0.0010914339,0.004689445,0.021237578,0.00033615314,0.00110371,0.00011154227,0.7849292,0.0000109329985,0.0023410872,0.16932303],"study_design_scores_gemma":[0.05669533,0.029907418,0.43128672,0.04966207,0.032139514,0.0008547275,0.0021064854,0.001403743,0.31234476,0.00004713307,0.08217061,0.0013814694],"about_ca_topic_score_codex":0.000032147454,"about_ca_topic_score_gemma":0.00003409889,"teacher_disagreement_score":0.47258443,"about_ca_system_score_codex":0.0002753487,"about_ca_system_score_gemma":0.00029661047,"threshold_uncertainty_score":0.5305411},"labels":[],"label_agreement":null},{"id":"W4390754195","doi":"10.1016/j.ejca.2024.113530","title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Pembrolizumab; Discontinuation; Medicine; Adverse effect; Internal medicine; Clinical trial; Immune system; Cancer; Oncology; Immunotherapy; Immunology","score_opus":0.024230192302989534,"score_gpt":0.32023523195457865,"score_spread":0.2960050396515891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390754195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779889,0.008652884,0.00037792395,0.000906727,0.0010023458,0.0004775872,0.00010327628,0.0000168034,0.01047355],"genre_scores_gemma":[0.9975299,0.001383686,0.00021784619,0.00032866784,0.00026092635,0.0000022177805,0.00001478995,0.000045344965,0.0002166263],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975654,0.0004930785,0.0007579338,0.0001458912,0.0009118102,0.00012590396],"domain_scores_gemma":[0.9984018,0.000050288734,0.00050737563,0.00022153037,0.0007389088,0.000080076876],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020405839,0.00013722561,0.00030774786,0.0002146574,0.00002901555,0.000011855687,0.00012512726,0.000026238244,0.0011858125],"category_scores_gemma":[0.000054998207,0.00009914389,0.00022003376,0.00024178303,0.000072743824,0.00012189658,0.0000070137107,0.00018310272,0.0000042360057],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03030584,0.00031854675,0.0022098727,0.00014858277,0.0004074753,0.000022214825,0.0007226958,0.0012425688,0.01742485,0.000010859563,0.0014945801,0.9456919],"study_design_scores_gemma":[0.053455,0.014898635,0.64095247,0.008752449,0.0012732788,0.000036867794,0.00017922919,0.024038574,0.074531294,0.00003371473,0.18137342,0.0004750709],"about_ca_topic_score_codex":0.000016829656,"about_ca_topic_score_gemma":0.0000043747273,"teacher_disagreement_score":0.94521683,"about_ca_system_score_codex":0.0002723335,"about_ca_system_score_gemma":0.0005697799,"threshold_uncertainty_score":0.99972725},"labels":[],"label_agreement":null},{"id":"W4391288586","doi":"10.1016/j.ejca.2024.113580","title":"Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Veliparib; Carboplatin; Paclitaxel; Medicine; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; Biology; Cisplatin; Genetics","score_opus":0.032102466033714055,"score_gpt":0.34669834975439096,"score_spread":0.3145958837206769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391288586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700507,0.019420823,0.00036125848,0.0055094855,0.0015214029,0.0007126043,0.00073131354,0.000045211873,0.0016471884],"genre_scores_gemma":[0.9916357,0.004543741,0.0005013446,0.00047341202,0.0020827372,0.00003326116,0.000025717734,0.00008676601,0.00061736646],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99663377,0.00075697,0.0012462517,0.00039964326,0.0006443884,0.0003189853],"domain_scores_gemma":[0.99825054,0.00046900974,0.0005357942,0.000194252,0.00028346662,0.0002669086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015592945,0.00031216143,0.0010729579,0.0002744562,0.000044690543,0.00008752309,0.00012209236,0.00005100186,0.00035597704],"category_scores_gemma":[0.0001579245,0.00021900622,0.00019132247,0.00033827047,0.00020873346,0.00028042484,0.000024384613,0.0007810088,0.000005637642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9426694,0.00015821168,0.00012689142,0.000051444073,0.000676153,0.0018441163,0.0016897592,0.000587523,0.0077143894,0.000019450992,0.0018504136,0.042612266],"study_design_scores_gemma":[0.978718,0.0011293428,0.004045166,0.0040092026,0.0004548844,0.0002791008,0.00012155008,0.00080290955,0.0009399207,0.0000843303,0.009117629,0.00029797162],"about_ca_topic_score_codex":0.0004641055,"about_ca_topic_score_gemma":0.00017054577,"teacher_disagreement_score":0.042314295,"about_ca_system_score_codex":0.0003346668,"about_ca_system_score_gemma":0.00073599076,"threshold_uncertainty_score":0.8930815},"labels":[],"label_agreement":null},{"id":"W4391430347","doi":"10.1016/j.ejca.2024.113585","title":"Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Manchester Biomedical Research Centre; Array BioPharma; Ipsen; Genentech; Deutsche Krebshilfe; Eisai; National Institute for Health and Care Research; Italfarmaco; Seagen; Sanofi Pasteur; Galecto; SkylineDx; Cancer Research UK; NeraCare; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; Pfizer; InflaRx; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen","keywords":"Medicine; Pembrolizumab; Placebo; Internal medicine; Hazard ratio; Adverse effect; Incidence (geometry); Melanoma; Gastroenterology; Clinical trial; Surgery; Oncology; Cancer; Immunotherapy; Confidence interval; Pathology","score_opus":0.012444828162958286,"score_gpt":0.2935422822969203,"score_spread":0.28109745413396203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391430347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912768,0.005636235,0.000056452394,0.00032736614,0.0009814437,0.00084298686,0.000080453785,0.00000876112,0.0007895204],"genre_scores_gemma":[0.99698365,0.0022313017,0.000031682626,0.00003543699,0.00056578225,0.000009655295,0.0000047164017,0.00003818742,0.00009957387],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99714065,0.00074849103,0.001077419,0.00021093254,0.0005856547,0.00023683812],"domain_scores_gemma":[0.99853915,0.00041810342,0.00059510843,0.0002237197,0.00014547659,0.000078468336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024537216,0.00020087631,0.00058673613,0.0003981805,0.00003401354,0.000030241601,0.00022487281,0.00005125393,0.00006961651],"category_scores_gemma":[0.00015315662,0.00013548647,0.0001617515,0.00041563937,0.00023184021,0.00016093971,0.00004284077,0.00061980344,7.06454e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92412496,0.00045258377,0.0056664166,0.00039613148,0.0010475686,0.0012819985,0.015207723,0.00020539942,0.01849623,0.000020749034,0.0007915982,0.03230862],"study_design_scores_gemma":[0.71699834,0.017312339,0.24372631,0.0040650447,0.0008741931,0.000104367726,0.0033309471,0.001569595,0.008372558,0.000010499104,0.0033316303,0.00030417586],"about_ca_topic_score_codex":0.00020307391,"about_ca_topic_score_gemma":0.00006204055,"teacher_disagreement_score":0.23805991,"about_ca_system_score_codex":0.00016311281,"about_ca_system_score_gemma":0.00052223477,"threshold_uncertainty_score":0.5524978},"labels":[],"label_agreement":null},{"id":"W4392640282","doi":"10.1016/j.ejca.2024.114001","title":"Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut Gustave-Roussy; Agence Nationale de Sécurité du Médicament et des Produits de Santé; Institute of Cancer Research; National Science Foundation; Institut National Du Cancer; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Medicine; Chemotherapy; Oncology; Immunotherapy; Internal medicine; Neuroblastoma; BETA (programming language); Cancer; Computer science; Biology","score_opus":0.003721293559937281,"score_gpt":0.238811641408448,"score_spread":0.2350903478485107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392640282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994354,0.002023219,0.00005129637,0.0022162872,0.00023066971,0.00040066044,0.000029347626,0.000034217017,0.00066027424],"genre_scores_gemma":[0.99659073,0.0008185369,0.0007078703,0.0004895346,0.000269966,0.000009298755,0.000005498424,0.00016970406,0.0009388685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777067,0.00023017201,0.0004581154,0.00034289202,0.00078764866,0.0004104873],"domain_scores_gemma":[0.99882704,0.000056425062,0.00030814385,0.00030386655,0.00027200422,0.00023252574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025089472,0.00031619752,0.00047708343,0.0003319313,0.000058624628,0.000104709405,0.00020076752,0.000026121776,0.00051029894],"category_scores_gemma":[0.000009570102,0.00016231154,0.00011483323,0.0004435328,0.00014844254,0.00027781082,0.000030316894,0.0007350313,0.0000663371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036744468,0.0021104706,0.7286238,0.0003237977,0.0026901157,0.017221112,0.0011897301,0.00008827275,0.0026300761,0.000010813133,0.0053570718,0.20301026],"study_design_scores_gemma":[0.025608717,0.007998879,0.95164335,0.0019881513,0.00016222744,0.00021054721,0.000030161595,0.000009785959,0.005578356,0.00001065848,0.0065244585,0.00023472864],"about_ca_topic_score_codex":0.000023654844,"about_ca_topic_score_gemma":0.000014395796,"teacher_disagreement_score":0.22301951,"about_ca_system_score_codex":0.00019837094,"about_ca_system_score_gemma":0.00020346962,"threshold_uncertainty_score":0.6618873},"labels":[],"label_agreement":null},{"id":"W4393065619","doi":"10.1016/j.ejca.2024.113697","title":"A Multicountry Discrete Choice Experiment (DCE) to Understand Patients’ Preferences for HR+/HER2− Early Breast Cancer (EBC) Treatments","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Optimal Experimental Design Methods","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Canadian Breast Cancer Network; Jewish General Hospital","funders":"","keywords":"Breast cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.13649237935061648,"score_gpt":0.4587046145328622,"score_spread":0.32221223518224573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393065619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95528585,0.011303052,0.021968555,0.0014727645,0.0046467357,0.00090227165,0.0005650393,0.0000468655,0.0038088842],"genre_scores_gemma":[0.9830293,0.00020031739,0.011833934,0.0003642682,0.0008266508,0.000034605862,0.0000014835432,0.000080883125,0.0036285555],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99553657,0.000708289,0.0010908619,0.00057358213,0.0016588598,0.0004318425],"domain_scores_gemma":[0.9974565,0.00069092144,0.00043526458,0.00033221097,0.0006517561,0.0004333369],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019594764,0.0003342152,0.0004826263,0.00033280387,0.00016005561,0.0008499092,0.00087839016,0.00003700295,0.0010136196],"category_scores_gemma":[0.000308846,0.00021531327,0.00030442726,0.00053421775,0.000107422886,0.00079529354,0.00013773987,0.00020977361,0.000093791765],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035843686,0.00070022803,0.048709918,0.000083150604,0.0015626181,0.00018763094,0.0338907,0.0031930814,0.036093142,0.00024892643,0.05872641,0.8130198],"study_design_scores_gemma":[0.010454325,0.0075956685,0.70735955,0.0028912406,0.00075427274,0.00006398432,0.009339661,0.001898758,0.030989086,0.0013432356,0.22529902,0.0020112186],"about_ca_topic_score_codex":0.00017993017,"about_ca_topic_score_gemma":0.00003420854,"teacher_disagreement_score":0.81100863,"about_ca_system_score_codex":0.0006051898,"about_ca_system_score_gemma":0.00024310852,"threshold_uncertainty_score":0.99989957},"labels":[],"label_agreement":null},{"id":"W4393065682","doi":"10.1016/j.ejca.2024.113693","title":"Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University of British Columbia; McGill University Health Centre; McGill University; University of Ottawa; Dalhousie University; University of Toronto; University of Alberta Hospital; Université de Montréal; University of Saskatchewan; Université Laval; University of Alberta; University of Calgary","funders":"","keywords":"Perspective (graphical); Psychological intervention; Delphi; Breast cancer; Medicine; Delphi method; Medical physics; Dermatology; Family medicine; Cancer; Internal medicine; Nursing; Computer science; Artificial intelligence","score_opus":0.02808879577937963,"score_gpt":0.35218622342550204,"score_spread":0.3240974276461224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393065682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48778206,0.110936515,0.0013115039,0.3804204,0.0047710235,0.0015733809,0.0009256452,0.000089064444,0.012190398],"genre_scores_gemma":[0.99540985,0.0013421272,0.00020472017,0.0017262505,0.0009528151,0.00002186115,0.0000046829514,0.00004264406,0.0002950304],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99890906,0.00016575365,0.0004094873,0.00013930256,0.00018956044,0.00018681237],"domain_scores_gemma":[0.99905264,0.0001167102,0.00014719869,0.000092280185,0.00035956316,0.00023158995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040721035,0.00011588276,0.000223731,0.00058204564,0.000047646397,0.00004666691,0.00008004281,0.000027165719,0.00017938342],"category_scores_gemma":[0.0001566682,0.00010179087,0.00021968091,0.00021005163,0.00003243793,0.000094618874,0.000005002738,0.00027009632,0.000011348881],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011727765,0.0002615646,0.0061070747,0.0008733604,0.001401086,0.003586144,0.019953493,0.015853224,0.0020328776,0.0045068883,0.49859512,0.4456564],"study_design_scores_gemma":[0.014649098,0.0024548518,0.7037536,0.021075152,0.0006837912,0.0023094015,0.004019277,0.017766625,0.0009271245,0.00033398584,0.2312343,0.0007928209],"about_ca_topic_score_codex":0.008624362,"about_ca_topic_score_gemma":0.015981449,"teacher_disagreement_score":0.6976465,"about_ca_system_score_codex":0.0013885986,"about_ca_system_score_gemma":0.0007902662,"threshold_uncertainty_score":0.9979773},"labels":[],"label_agreement":null},{"id":"W4393078914","doi":"10.1016/j.ejca.2024.113608","title":"Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Stage (stratigraphy); Breast cancer; Oncology; Placebo; Chemotherapy; Internal medicine; Adjuvant; Adjuvant chemotherapy; Cancer; Immunotherapy; Pathology","score_opus":0.04050519310740351,"score_gpt":0.3783540340905074,"score_spread":0.33784884098310386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393078914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9364786,0.026687423,0.00092293596,0.016694235,0.0031503036,0.0052394224,0.009968844,0.00021762235,0.0006406115],"genre_scores_gemma":[0.943818,0.027667344,0.00023856485,0.0012396097,0.005664702,0.00030992183,0.00006565468,0.00054681156,0.02044943],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914417,0.0015651289,0.0021553396,0.0011887716,0.0022969847,0.001352037],"domain_scores_gemma":[0.99428195,0.0016467081,0.0010604239,0.0012719021,0.0009108832,0.0008281061],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031735387,0.0009529825,0.0016328577,0.0003452313,0.00044949452,0.00051996537,0.0014541504,0.00011340799,0.0042334828],"category_scores_gemma":[0.0005203978,0.0005295828,0.00066632836,0.0008527707,0.00031503994,0.00040328558,0.00019456986,0.0021735295,0.000067061505],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4388661,0.0011095968,0.001260128,0.000154176,0.0032143036,0.0053456104,0.008055466,0.00044707744,0.0033309131,0.000004056543,0.21143709,0.32677546],"study_design_scores_gemma":[0.2888669,0.017088516,0.015344292,0.0025789626,0.0012359335,0.0007414629,0.0021599915,0.0018292613,0.003688445,0.000015329406,0.6654174,0.0010335103],"about_ca_topic_score_codex":0.006867269,"about_ca_topic_score_gemma":0.0014777262,"teacher_disagreement_score":0.4539803,"about_ca_system_score_codex":0.0015933515,"about_ca_system_score_gemma":0.0037844449,"threshold_uncertainty_score":0.9997461},"labels":[],"label_agreement":null},{"id":"W4393079203","doi":"10.1016/j.ejca.2024.113664","title":"Quality of life following completion of treatment among Sri Lankan women with breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Breast cancer; Cancer; Quality of life (healthcare); Gynecology; Obstetrics; Internal medicine; Nursing","score_opus":0.030098045793783668,"score_gpt":0.31501649920649716,"score_spread":0.2849184534127135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393079203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862955,0.0068452475,0.00007945594,0.0007776936,0.0006154587,0.00009695232,0.00008889848,0.00001352743,0.0051872334],"genre_scores_gemma":[0.99827814,0.000600061,0.00003131543,0.0001326701,0.0005557486,0.0000049329037,0.0000021054343,0.000021653133,0.00037337185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985281,0.00019293504,0.00054312183,0.000128934,0.00044726706,0.00015960263],"domain_scores_gemma":[0.9990104,0.00004837412,0.00033485834,0.00014912851,0.00027551645,0.00018176495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065127626,0.0001339784,0.0005113538,0.00011595644,0.000021396118,0.000014980458,0.00008191915,0.00001815002,0.00040759737],"category_scores_gemma":[0.000015899413,0.00008717357,0.00019464156,0.0002139155,0.00007002328,0.000098870856,0.000013924885,0.00015966743,0.0000017122633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052126,0.00023257293,0.8005587,0.0012066462,0.0035587468,0.00046644887,0.02730611,0.00055034243,0.01252613,0.000103381295,0.001514103,0.1467642],"study_design_scores_gemma":[0.002742494,0.0014674062,0.95580244,0.0023319032,0.00035904863,0.000043822623,0.0025027918,0.000019959649,0.0007523975,0.0000044507374,0.03382412,0.00014914875],"about_ca_topic_score_codex":0.0019784,"about_ca_topic_score_gemma":0.0012564593,"teacher_disagreement_score":0.15524375,"about_ca_system_score_codex":0.00046155328,"about_ca_system_score_gemma":0.00050863845,"threshold_uncertainty_score":0.44629052},"labels":[],"label_agreement":null},{"id":"W4393082101","doi":"10.1016/j.ejca.2024.113884","title":"Variations in time to breast cancer treatment initiation and survival across ethnoracial groups: a DAGs based approach to systematic review","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Breast cancer; Medicine; Demography; Oncology; Cancer; Internal medicine; Sociology","score_opus":0.07403372060609446,"score_gpt":0.38140102273512994,"score_spread":0.30736730212903546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393082101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49132302,0.37008432,0.029640019,0.07711099,0.0025533384,0.00851492,0.0011149519,0.00022148078,0.019436982],"genre_scores_gemma":[0.9910474,0.0021389895,0.0007922446,0.0046191355,0.0007880545,0.00008313705,0.0000073710357,0.000044160493,0.00047955397],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99826145,0.00030047953,0.00060063804,0.00019064326,0.00045054263,0.0001962304],"domain_scores_gemma":[0.9992143,0.000053435393,0.00014983122,0.00013061578,0.00022629632,0.00022555751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015226933,0.00014940681,0.00052897586,0.00013770202,0.000041956064,0.00009083452,0.00010933916,0.000019359653,0.00013270919],"category_scores_gemma":[0.0001236944,0.00010719544,0.00009622332,0.00052488636,0.000015132641,0.00016101419,0.000027534867,0.00015932674,0.00004999149],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008139613,0.002245769,0.06884504,0.45945635,0.0048480337,0.007930015,0.073956735,0.0183836,0.00681867,0.0006720877,0.0512456,0.2974585],"study_design_scores_gemma":[0.0060405135,0.002474684,0.25463194,0.7103982,0.0039120633,0.0013046105,0.0010306248,0.004815444,0.000110037494,0.000016083688,0.014284506,0.0009813143],"about_ca_topic_score_codex":0.00013555115,"about_ca_topic_score_gemma":0.00008178969,"teacher_disagreement_score":0.49972433,"about_ca_system_score_codex":0.00054294977,"about_ca_system_score_gemma":0.00027474613,"threshold_uncertainty_score":0.4371303},"labels":[],"label_agreement":null},{"id":"W4393098411","doi":"10.1016/j.ejca.2024.113688","title":"Psychometric validation of the Danish BREAST-Q reconstruction module","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eli Lilly Canada; Pfizer; Eli Lilly and Company; Pfizer Canada; Bristol-Myers Squibb","keywords":"Danish; Breast reconstruction; Breast cancer; Medical physics; Medicine; Oncology; Internal medicine; Cancer; Philosophy","score_opus":0.022230372356727347,"score_gpt":0.2886490288463309,"score_spread":0.26641865648960356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393098411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97152114,0.0046786354,0.0007997086,0.0057029095,0.0043439865,0.000108338856,0.00001600257,0.000018205386,0.012811077],"genre_scores_gemma":[0.9963944,0.00037870233,0.00038512397,0.000089993715,0.0008611031,3.8901644e-7,5.0267414e-7,0.000022253507,0.001867514],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99905455,0.00010467676,0.0003594591,0.0000807701,0.0003233679,0.00007716216],"domain_scores_gemma":[0.9993073,0.000023675659,0.00020767254,0.00014662517,0.00026029217,0.000054449363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046372338,0.0000652093,0.00013161043,0.00019468284,0.000021418806,0.000022564542,0.000113253,0.0000131886245,0.00032167058],"category_scores_gemma":[0.00009849137,0.000040548508,0.00013032225,0.0005644315,0.000050781757,0.00013498185,0.000015986354,0.00023907593,0.000016458554],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009890013,0.000039172406,0.016317729,0.00014437534,0.00019364216,0.000030325258,0.00035655484,0.00021664001,0.017157782,0.000030605446,0.016428221,0.94898605],"study_design_scores_gemma":[0.0022486537,0.0005050285,0.86949784,0.0044226656,0.00050684414,0.008143732,0.00014845101,0.00033558914,0.03733884,0.00019026545,0.07649775,0.00016434208],"about_ca_topic_score_codex":0.0000056215313,"about_ca_topic_score_gemma":0.0000011181135,"teacher_disagreement_score":0.9488217,"about_ca_system_score_codex":0.000081379025,"about_ca_system_score_gemma":0.0001024191,"threshold_uncertainty_score":0.35220674},"labels":[],"label_agreement":null},{"id":"W4393098418","doi":"10.1016/j.ejca.2024.113687","title":"Sexual HEalth and therapy adherence of hormone-sensitive breast CANcer survivors on maintenance endocrine therapy – The SHE-CAN project at Mount Sinai Hospital, Canada","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Endocrine system; Breast cancer; Cancer; Hormone therapy; Hormonal therapy; Sex therapy; Oncology; Intensive care medicine; Hormone; Internal medicine; Sexual dysfunction","score_opus":0.03650446727899321,"score_gpt":0.31378351637744306,"score_spread":0.27727904909844986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393098418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8991805,0.058987413,0.00002462863,0.039842844,0.00067715906,0.00044765256,0.00012188966,0.000013733141,0.00070420996],"genre_scores_gemma":[0.93576443,0.056572553,0.000025067704,0.004860277,0.0004410291,0.0000130472645,0.000002849571,0.0000361045,0.0022846456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980896,0.00026418673,0.00049961335,0.00024819857,0.0006155393,0.00028287477],"domain_scores_gemma":[0.99864775,0.0000927412,0.00043191513,0.0002376734,0.0003801345,0.00020977108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050971087,0.00020827516,0.00037337176,0.00006979079,0.0000963208,0.000027196598,0.0001958153,0.000013730167,0.00015356235],"category_scores_gemma":[0.000031011066,0.00011726434,0.00006389271,0.0002683404,0.00018952656,0.000065868255,0.000028898181,0.00039173596,0.000005195807],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033369013,0.00022581278,0.013148544,0.00021531805,0.0008056503,0.00088191667,0.0071308254,0.000048134818,0.0058660666,0.0002740297,0.28987393,0.67819285],"study_design_scores_gemma":[0.0044593047,0.007467566,0.40427724,0.002866684,0.00006554768,0.0010743387,0.004782849,0.00024054336,0.002157214,0.000017077109,0.57213503,0.00045660938],"about_ca_topic_score_codex":0.0963326,"about_ca_topic_score_gemma":0.020791443,"teacher_disagreement_score":0.6777363,"about_ca_system_score_codex":0.00052479526,"about_ca_system_score_gemma":0.0026204323,"threshold_uncertainty_score":0.9970766},"labels":[],"label_agreement":null},{"id":"W4393098420","doi":"10.1016/j.ejca.2024.113689","title":"Patient-reported outcomes of clinical importance during five years after breast cancer diagnosis using real world data","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eli Lilly Canada; Pfizer Canada; Pfizer; Eli Lilly and Company","keywords":"Medicine; Breast cancer; Real world data; Cancer; Intensive care medicine; Oncology; Internal medicine; Data science; Computer science","score_opus":0.1540550876079539,"score_gpt":0.43953349595926955,"score_spread":0.28547840835131566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393098420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888385,0.008201729,0.000011994972,0.0009413428,0.0012123396,0.000106865715,0.00023168662,0.000019306846,0.00043626688],"genre_scores_gemma":[0.9946991,0.0028802024,0.0005526287,0.00034835783,0.0011995853,0.0000044355443,0.000003694583,0.000049889328,0.00026210814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970373,0.00015837277,0.001518967,0.00032703852,0.0006987165,0.00025963],"domain_scores_gemma":[0.998017,0.00008737798,0.00087808765,0.00046577034,0.0003173739,0.0002343742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001038138,0.00017513735,0.0006649848,0.00018622633,0.00002901994,0.000040779505,0.0002681771,0.000024676978,0.0005734425],"category_scores_gemma":[0.00013396624,0.00013573021,0.00027112677,0.00040259724,0.00013354495,0.00039807128,0.00017869353,0.0004875042,0.000004865318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007209823,0.000040971263,0.94277185,0.00007275273,0.0006370744,0.0059076026,0.0003085259,0.00007692236,0.000085200896,0.0000016140905,0.0030847045,0.046291802],"study_design_scores_gemma":[0.00088363816,0.00011973356,0.98935246,0.0024387818,0.0006139654,0.00026193634,0.000121384735,0.000120160075,0.00007779869,0.0000024563667,0.00587194,0.00013573542],"about_ca_topic_score_codex":0.00084778754,"about_ca_topic_score_gemma":0.0007402903,"teacher_disagreement_score":0.04658062,"about_ca_system_score_codex":0.00017360938,"about_ca_system_score_gemma":0.00049307273,"threshold_uncertainty_score":0.6278793},"labels":[],"label_agreement":null},{"id":"W4393098443","doi":"10.1016/j.ejca.2024.113728","title":"Cold heart: active breathing coordinator-assisted deep inspiration breath hold leads to a safer heart sparing approach to early and locally advanced breast cancer treatment","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Vagus Nerve Stimulation Research","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"SAFER; Medicine; Breast cancer; Breathing; Cardiology; Internal medicine; Intensive care medicine; Cancer; Anesthesia; Computer science; Computer security","score_opus":0.04743574637019007,"score_gpt":0.33018275617701004,"score_spread":0.28274700980682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393098443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871205,0.0010357822,0.0035482869,0.0047880467,0.0004032411,0.0006473019,0.0000699162,0.00007086352,0.0023160656],"genre_scores_gemma":[0.9962765,0.00007672316,0.00090075826,0.0012154554,0.00036627264,0.000041194144,5.975036e-7,0.000086878674,0.0010356515],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99725014,0.00048460104,0.000514023,0.0005879013,0.00071250903,0.000450839],"domain_scores_gemma":[0.99867475,0.00014125256,0.00013158444,0.00022716427,0.00030516688,0.0005201029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052654877,0.00028862833,0.00037928752,0.00043649855,0.0002343959,0.0004436863,0.0002449736,0.00003658991,0.000051373074],"category_scores_gemma":[0.00011200713,0.00023851497,0.00013082364,0.00083099055,0.00006891577,0.0006589078,0.00012304194,0.0004020609,0.00004469698],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016562741,0.0002815447,0.013952057,0.000120028904,0.0001237364,0.00046193824,0.004651318,0.088413075,0.7479369,0.0003552549,0.0009290408,0.14111881],"study_design_scores_gemma":[0.0038153317,0.0026613793,0.8636213,0.0017240702,0.00015583422,0.001191567,0.00015673361,0.011995664,0.080693014,0.000011483342,0.03310505,0.00086856785],"about_ca_topic_score_codex":0.00019792159,"about_ca_topic_score_gemma":0.000063078514,"teacher_disagreement_score":0.8496693,"about_ca_system_score_codex":0.00075647305,"about_ca_system_score_gemma":0.00028533398,"threshold_uncertainty_score":0.97263587},"labels":[],"label_agreement":null},{"id":"W4393098859","doi":"10.1016/j.ejca.2024.113958","title":"A randomized, double-blind, phase III study in India to evaluate efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) in comparison with Perjeta® (pertuzumab) in patients with HER2-positive metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Pertuzumab; Biosimilar; Immunogenicity; Pharmacokinetics; Medicine; Double blind; Pharmacology; Internal medicine; Trastuzumab; Placebo; Immunology; Antibody; Cancer; Pathology","score_opus":0.03121014927277414,"score_gpt":0.3622070905831796,"score_spread":0.33099694131040547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393098859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98224634,0.014718698,0.00017810793,0.0007389962,0.00027398404,0.0015608281,0.00014618655,0.000007733112,0.00012915285],"genre_scores_gemma":[0.99850106,0.0008369731,0.00028372483,0.00021747939,0.000032613614,0.000026265187,0.0000071667887,0.000047081216,0.000047615096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99493885,0.002480611,0.0014866842,0.000425384,0.00024741588,0.00042108243],"domain_scores_gemma":[0.9985348,0.00039921518,0.00045636244,0.00018443739,0.00032957937,0.000095616306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029771514,0.0003925918,0.001493377,0.00064788054,0.000050810293,0.00004601456,0.0003088227,0.00006162432,0.00024885367],"category_scores_gemma":[0.000047253943,0.00024119695,0.00013393088,0.00085724756,0.00035941193,0.0001468276,0.00012276748,0.0008981396,0.0000027678557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89600587,0.0039928737,0.03800069,0.00008984221,0.0028101446,0.0003349922,0.007534238,0.0010038487,0.0020965498,0.000008068694,0.000113882634,0.048008975],"study_design_scores_gemma":[0.78422177,0.0044883164,0.20179413,0.0020481849,0.001615096,0.00007555383,0.00075070804,0.00030550515,0.003872214,0.0000030238082,0.0003551544,0.000470341],"about_ca_topic_score_codex":0.00042084174,"about_ca_topic_score_gemma":0.0005088048,"teacher_disagreement_score":0.16379344,"about_ca_system_score_codex":0.00028663978,"about_ca_system_score_gemma":0.00028874064,"threshold_uncertainty_score":0.9835726},"labels":[],"label_agreement":null},{"id":"W4393098982","doi":"10.1016/j.ejca.2024.113663","title":"Prevalence of depression, anxiety and stress and its associated factors among women with breast cancer in Sri Lanka","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Sri lanka; Anxiety; Breast cancer; Depression (economics); Medicine; Clinical psychology; Cancer; Oncology; Psychology; Psychiatry; Internal medicine; Socioeconomics; Sociology","score_opus":0.008473525110552728,"score_gpt":0.2517961527974652,"score_spread":0.24332262768691248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393098982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97158134,0.02727212,0.0000022003765,0.00016589701,0.00019921924,0.00007935936,0.00023414743,0.0000094553225,0.00045623773],"genre_scores_gemma":[0.9916435,0.007873381,0.0000023028472,0.000037785554,0.00013023145,0.0000027560154,7.160553e-7,0.000022295864,0.00028705728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990138,0.0001180922,0.00026724135,0.00015382667,0.00028384823,0.00016320623],"domain_scores_gemma":[0.99937534,0.000032887234,0.00017044638,0.00006989945,0.0001937093,0.00015773649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033698638,0.00012136747,0.0002552266,0.000105208084,0.000019550638,0.000024783432,0.000066865556,0.000024994126,0.00020558006],"category_scores_gemma":[0.000021222671,0.00007890028,0.0000285299,0.00018797754,0.000061193474,0.00016479744,0.00003142754,0.00028237182,1.9039308e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030233097,0.000022730525,0.9717645,0.0006694716,0.00013530604,0.0001314083,0.011628324,0.000038896615,0.00060560054,8.3897004e-7,0.00006265522,0.014637918],"study_design_scores_gemma":[0.00082573865,0.00014181176,0.9909799,0.0053772083,0.00010993711,0.000049781916,0.0013017097,0.000035530906,0.0007091462,9.709368e-7,0.00037819557,0.000090045745],"about_ca_topic_score_codex":0.00019835713,"about_ca_topic_score_gemma":0.0007897439,"teacher_disagreement_score":0.02006211,"about_ca_system_score_codex":0.00012733004,"about_ca_system_score_gemma":0.00014089532,"threshold_uncertainty_score":0.321746},"labels":[],"label_agreement":null},{"id":"W4393339865","doi":"10.1016/j.ejca.2024.114038","title":"Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Delphi; Database; Delphi method; Data sharing; Data collection; Head and neck cancer; Computer science; Medicine; Medical physics; Cancer; Alternative medicine; Statistics; Internal medicine; Pathology; Mathematics","score_opus":0.7091116833437596,"score_gpt":0.6582342566007282,"score_spread":0.05087742674303142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393339865","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15174223,0.13841118,0.019092608,0.43292627,0.008332132,0.007353553,0.23982276,0.00013631009,0.0021829605],"genre_scores_gemma":[0.33752763,0.46150464,0.15878439,0.0021795991,0.030593723,0.0003663583,0.0034793653,0.0004019299,0.0051623615],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99508446,0.0028226299,0.0008608134,0.00040806632,0.0004642858,0.00035971333],"domain_scores_gemma":[0.9906903,0.007968544,0.00023887337,0.0003116153,0.00048021507,0.00031046165],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.046871632,0.000105810235,0.00036938192,0.00020639999,0.00046961242,0.00053418695,0.000518618,0.000046695088,0.00012747617],"category_scores_gemma":[0.011386003,0.000087122135,0.000049531496,0.0002209267,0.00079856697,0.00039089978,0.00043029495,0.00043606514,0.0000010356637],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047989987,0.0000364118,0.0002530301,0.00011163891,0.00017382248,0.000045878045,0.00042789162,4.481754e-7,0.0002943927,0.0008382864,0.8489118,0.1484265],"study_design_scores_gemma":[0.0012775584,0.00024925612,0.0001789438,0.0006587778,0.00015351684,0.000014604755,0.00075118226,0.0005754878,0.000039445236,0.00076141796,0.9952331,0.00010667761],"about_ca_topic_score_codex":0.0007169831,"about_ca_topic_score_gemma":0.002703863,"teacher_disagreement_score":0.43074664,"about_ca_system_score_codex":0.000055783137,"about_ca_system_score_gemma":0.0010654661,"threshold_uncertainty_score":0.9969415},"labels":[],"label_agreement":null},{"id":"W4393346266","doi":"10.1016/j.ejca.2024.114042","title":"Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University; University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"Movember Foundation","keywords":"Germ cell tumors; Germ cell; Teratoma; Oncology; Medicine; Internal medicine; Biology; Pathology; Chemotherapy; Genetics; Gene","score_opus":0.012609782547822562,"score_gpt":0.2814938925314393,"score_spread":0.2688841099836167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393346266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909683,0.005968925,0.000011287645,0.00017275989,0.00024441586,0.0002487406,0.0018941814,0.000007807218,0.00048359684],"genre_scores_gemma":[0.99928594,0.0002826766,0.00010856396,0.000039803956,0.00012345507,0.000002887468,0.000028293787,0.0000374261,0.000090938505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849,0.00017602097,0.00057546754,0.0001536776,0.00045660537,0.00014825986],"domain_scores_gemma":[0.99852914,0.00020019812,0.0005566173,0.00024105803,0.00034344185,0.00012953776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021845747,0.00017499151,0.00038934493,0.00006118591,0.000025205161,0.000025742056,0.0001176612,0.00000944306,0.00012424395],"category_scores_gemma":[0.000069426744,0.00008312425,0.00022929409,0.00012697796,0.00010774716,0.000068812114,0.000021057594,0.00014982479,0.0000052936507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008665217,0.0011727056,0.94692236,0.00037848754,0.0040604426,0.0012566104,0.0023697668,0.0009842914,0.00040791888,0.0000141586,0.0038740563,0.029893983],"study_design_scores_gemma":[0.005066367,0.0020934986,0.98822963,0.001548089,0.001278477,0.00000897139,0.00008523441,0.000053135856,0.0010344886,0.000012876722,0.0004960335,0.00009316943],"about_ca_topic_score_codex":0.00032169113,"about_ca_topic_score_gemma":0.000017452427,"teacher_disagreement_score":0.041307297,"about_ca_system_score_codex":0.00011207122,"about_ca_system_score_gemma":0.0005252736,"threshold_uncertainty_score":0.33897087},"labels":[],"label_agreement":null},{"id":"W4396902028","doi":"10.1016/j.ejca.2024.114119","title":"Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Centre hospitalier universitaire de Québec; Ottawa Hospital; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; McGill University Health Centre; Hôpital Maisonneuve-Rosemont","funders":"Desmoid Tumor Research Foundation","keywords":"Pazopanib; Sorafenib; Medicine; Oncology; Internal medicine; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer; Sunitinib; Renal cell carcinoma","score_opus":0.022802650063123642,"score_gpt":0.31288952556066607,"score_spread":0.2900868754975424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396902028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663144,0.0025225964,0.000013421702,0.00011298688,0.00017030718,0.0002757488,0.000007813388,0.000012704651,0.00025300708],"genre_scores_gemma":[0.99905974,0.00021658411,0.00036203128,0.000044223067,0.00011445634,0.000004831305,4.960501e-7,0.00004067132,0.00015695876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864835,0.00014369717,0.00048369743,0.00017824818,0.0003757327,0.00017030333],"domain_scores_gemma":[0.999329,0.000036004378,0.00017126414,0.00013006973,0.00022770475,0.00010600374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034172935,0.00014906752,0.0003779025,0.00018369827,0.00002477076,0.000017528797,0.00008369291,0.0000072582357,0.000035855806],"category_scores_gemma":[0.00006819833,0.000099969715,0.00004034574,0.00023798045,0.00012563558,0.000118807926,0.000050002596,0.00023627082,0.0000023413447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008908221,0.0005453274,0.9635453,0.000098984376,0.0001508071,0.0033056359,0.021361424,0.0000054302977,0.00018743901,0.0000011193051,0.00015892819,0.0097487895],"study_design_scores_gemma":[0.0069015506,0.0017421262,0.9850566,0.0016739194,0.00009905981,0.000092889706,0.0034007542,0.00000974409,0.00014192073,4.6188327e-7,0.0007800483,0.000100952544],"about_ca_topic_score_codex":0.0001394994,"about_ca_topic_score_gemma":0.00015282369,"teacher_disagreement_score":0.02151128,"about_ca_system_score_codex":0.00009268313,"about_ca_system_score_gemma":0.00010020361,"threshold_uncertainty_score":0.40766466},"labels":[],"label_agreement":null},{"id":"W4399458651","doi":"10.1016/j.ejca.2024.114145","title":"Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer","year":2024,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"National Cancer Institute; Loxo Oncology; Norgine; EUSA Pharma; Y-mAbs Therapeutics; Solving Kids' Cancer; Rally Foundation; Amgen; Eli Lilly and Company; Pediatric Brain Tumor Foundation","keywords":"PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Protein kinase B; Cancer; Product (mathematics); Medicine; Cancer research; Internal medicine; Chemistry; Phosphorylation; Signal transduction; Biochemistry","score_opus":0.01731181423656138,"score_gpt":0.3037225914434496,"score_spread":0.28641077720688823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399458651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010225987,0.98859066,0.000048936166,0.000043167125,0.00046229514,0.0005157889,0.00008124396,0.0000030629942,0.000028868659],"genre_scores_gemma":[0.04527455,0.9525138,0.0003059866,0.00003442538,0.0016219317,0.000029967698,0.000017577415,0.000104074585,0.0000976482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792254,0.00015402514,0.0009017458,0.00043921702,0.0002902544,0.00029219512],"domain_scores_gemma":[0.99868447,0.000009115913,0.0008139026,0.00015979625,0.00019429825,0.00013844472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006917018,0.00038883902,0.0008146854,0.00021926178,0.000038396167,0.00003063976,0.00024823484,0.00008601466,0.0000061752885],"category_scores_gemma":[0.000033767265,0.00026678856,0.00013646623,0.00019277066,0.00011395541,0.000009650906,0.00011361236,0.00037318433,4.8992416e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012939135,0.00003799652,0.0033783643,0.0047712782,0.00047402026,0.000016760521,0.00008015891,0.000017156695,0.00021056607,7.538679e-7,0.0029215028,0.98796207],"study_design_scores_gemma":[0.0019926901,0.0012082064,0.0027052215,0.035477974,0.0015363381,0.00023863652,0.000036380734,0.0000011027333,0.0011245419,0.000003203068,0.95502543,0.0006502514],"about_ca_topic_score_codex":0.000016544742,"about_ca_topic_score_gemma":0.000072830815,"teacher_disagreement_score":0.9873118,"about_ca_system_score_codex":0.000104661405,"about_ca_system_score_gemma":0.0013826131,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W4399722033","doi":"10.1016/j.ejca.2024.114183","title":"Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Janssen Pharmaceuticals; AstraZeneca; Pfizer; Amgen; Astellas Pharma; Abbott Laboratories","keywords":"Abiraterone acetate; Prednisone; Medicine; Prostate cancer; Oncology; Covariate; Internal medicine; Placebo; Cancer; Statistics; Androgen deprivation therapy; Mathematics; Pathology","score_opus":0.04673604915791438,"score_gpt":0.3859914848494938,"score_spread":0.33925543569157945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399722033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082214,0.0044936636,0.000029885627,0.0018307795,0.00016439173,0.0025235638,0.00010905681,0.0000033000017,0.000023193008],"genre_scores_gemma":[0.997285,0.0020607908,0.00009253652,0.00012490837,0.00007533307,0.00016735154,0.000027665707,0.00003145988,0.00013495346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742514,0.00056323485,0.0010005885,0.00021302138,0.0005377614,0.00026024514],"domain_scores_gemma":[0.9988848,0.00021059565,0.00035793192,0.00015196603,0.0003383499,0.000056330082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029240334,0.00017767349,0.0005415297,0.00024820754,0.000022573706,0.00004033691,0.00017617969,0.0000138817895,0.00002070475],"category_scores_gemma":[0.00005705321,0.00007951022,0.000046297366,0.000478884,0.00012886578,0.00014852732,0.000023311388,0.00045989733,5.8526206e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02769841,0.00433084,0.8638662,0.00036861916,0.0003752418,0.0007200918,0.010431426,0.00071390293,0.000047379806,0.000007649033,0.00009268836,0.09134756],"study_design_scores_gemma":[0.054076485,0.009967481,0.9311367,0.0018027583,0.00022815689,0.0000052520736,0.0013093749,0.0009374221,0.000059689082,0.000009451096,0.00037119782,0.000095977],"about_ca_topic_score_codex":0.00017063953,"about_ca_topic_score_gemma":0.0014486169,"teacher_disagreement_score":0.09125158,"about_ca_system_score_codex":0.00026395704,"about_ca_system_score_gemma":0.00043716928,"threshold_uncertainty_score":0.32423323},"labels":[],"label_agreement":null},{"id":"W4400139079","doi":"10.1016/j.ejca.2024.114197","title":"Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Mount Sinai Hospital; University of Ottawa; University of Toronto; University Health Network; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Prostate Cancer Foundation","keywords":"Concomitant; Oncology; Medicine; Prostate cancer; Internal medicine; Exploratory analysis; Spartan; Cancer","score_opus":0.013570473368670862,"score_gpt":0.3064280081891086,"score_spread":0.29285753482043775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400139079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983533,0.013399588,0.000012921269,0.00030265926,0.0022581187,0.00022249325,0.00017799623,0.0000012567415,0.000091943286],"genre_scores_gemma":[0.99245065,0.0064160363,0.000010101045,0.000020971096,0.00085655967,0.000015631753,0.000003004761,0.000016887438,0.0002101374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788237,0.0011323487,0.00050524785,0.00015793378,0.0002072667,0.00011486169],"domain_scores_gemma":[0.9991987,0.00012732005,0.00031827425,0.00019967505,0.000088313405,0.00006774866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017840948,0.00012976931,0.0003985,0.00016849456,0.000025515732,0.000013571429,0.000119977885,0.000017147599,0.000013239606],"category_scores_gemma":[0.00009801271,0.00007600699,0.00020677656,0.00032490588,0.00012435319,0.0000058866963,0.000022916407,0.000096951735,2.2205793e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1390548,0.00019346237,0.005049434,0.00019505178,0.0049299933,0.000027867613,0.0035298574,0.0035221898,0.80097413,0.000027539225,0.0022434732,0.040252216],"study_design_scores_gemma":[0.0752592,0.0259891,0.24809708,0.0021396724,0.012217041,0.000022648954,0.0014315319,0.00040914517,0.33917272,0.000013696566,0.29452747,0.0007207128],"about_ca_topic_score_codex":0.00007779329,"about_ca_topic_score_gemma":0.0007827805,"teacher_disagreement_score":0.4618014,"about_ca_system_score_codex":0.00006396102,"about_ca_system_score_gemma":0.00043913687,"threshold_uncertainty_score":0.30994752},"labels":[],"label_agreement":null},{"id":"W4400270515","doi":"10.1016/j.ejca.2024.114122","title":"Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo; Medical Research Council; Fondazione Beretta; Barts Charity; UK Research and Innovation","keywords":"Medicine; Hazard ratio; Paraganglioma; Internal medicine; Adverse effect; Retrospective cohort study; Spinal cord compression; Pheochromocytoma; Confidence interval; Surgery; Gastroenterology; Urology; Spinal cord","score_opus":0.007814760789540626,"score_gpt":0.25867270423788497,"score_spread":0.25085794344834433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400270515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931676,0.0032119683,0.00007624633,0.00034807555,0.00046815537,0.00015090163,0.00000821436,0.000023673123,0.0025451856],"genre_scores_gemma":[0.99806327,0.000017709352,0.0001563052,0.00012168496,0.00017087518,0.0000011517623,0.000006359966,0.00004991631,0.0014127371],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9984071,0.00017110328,0.00055485446,0.00015951807,0.00048549645,0.00022191582],"domain_scores_gemma":[0.9993174,0.000030222915,0.00020645547,0.00011920492,0.00015242533,0.0001743005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044717992,0.00016420541,0.00031819812,0.0003285809,0.000024969582,0.000008763961,0.000092815906,0.000015103494,0.00047229338],"category_scores_gemma":[0.000034049037,0.00010692958,0.00013383589,0.00053203054,0.00005246606,0.00018927791,0.000022273254,0.00043089315,0.00013037086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068940897,0.0013788758,0.13672888,0.0008234842,0.0019977838,0.7095506,0.0045379843,0.0015927092,0.00015780271,0.00021680685,0.007582798,0.12853816],"study_design_scores_gemma":[0.011602398,0.0023276734,0.961991,0.004119904,0.0004672332,0.011282211,0.00010998808,0.0002003172,0.00020056234,0.000057723195,0.007348893,0.00029205898],"about_ca_topic_score_codex":0.0000045795587,"about_ca_topic_score_gemma":0.000004547881,"teacher_disagreement_score":0.8252621,"about_ca_system_score_codex":0.00012520699,"about_ca_system_score_gemma":0.00019954066,"threshold_uncertainty_score":0.5171281},"labels":[],"label_agreement":null},{"id":"W4400391734","doi":"10.1016/j.ejca.2024.114204","title":"Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Amgen","keywords":"KRAS; Medicine; Pharmacokinetics; Lung cancer; Oncology; Internal medicine; Pharmacology; Cancer; Colorectal cancer","score_opus":0.010072802012246071,"score_gpt":0.3122388276896341,"score_spread":0.30216602567738804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400391734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864761,0.0054837866,0.00009415214,0.00075995526,0.00048884057,0.00055731664,0.000032831722,0.00005529328,0.0060516726],"genre_scores_gemma":[0.9934055,0.0004915317,0.000588751,0.000312,0.00024142064,0.000013376571,0.000022815077,0.000088665045,0.0048358995],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998355,0.00013776701,0.0005461966,0.00025058433,0.00041882138,0.0002916773],"domain_scores_gemma":[0.99896884,0.00004556355,0.00023856903,0.00018205808,0.0003506494,0.00021430946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020679194,0.00023581844,0.00039176462,0.00023196833,0.000053426735,0.000062081665,0.00011999119,0.000023963265,0.00033854877],"category_scores_gemma":[0.000048519018,0.00013849812,0.00009828163,0.0005285431,0.000055814457,0.00031528162,0.000018572335,0.0003180081,0.00003893009],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016553728,0.0013504328,0.37092602,0.0005804857,0.0029435798,0.013068457,0.0081205685,0.0016234198,0.002451081,0.00003002596,0.011307571,0.5710446],"study_design_scores_gemma":[0.030823126,0.0067120185,0.8521573,0.009191791,0.0018485417,0.00019929314,0.00038288947,0.0001257685,0.0010366461,0.000010072566,0.097008295,0.0005042757],"about_ca_topic_score_codex":0.000041109808,"about_ca_topic_score_gemma":0.00007371128,"teacher_disagreement_score":0.57054037,"about_ca_system_score_codex":0.0005337668,"about_ca_system_score_gemma":0.00062460423,"threshold_uncertainty_score":0.5647789},"labels":[],"label_agreement":null},{"id":"W4400407256","doi":"10.1016/j.ejca.2024.114221","title":"Corrigendum to “Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119]","year":2024,"lang":"en","type":"erratum","venue":"European Journal of Cancer","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Ottawa Hospital; Princess Margaret Cancer Centre; Centre hospitalier universitaire de Québec; McGill University Health Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pazopanib; Sorafenib; Medicine; Oncology; Center (category theory); Internal medicine; Cancer; Chemistry","score_opus":0.029476480018442306,"score_gpt":0.3143837742553579,"score_spread":0.2849072942369156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400407256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9300285,0.028743805,0.0000131609195,0.00048255967,0.036054198,0.0018216461,0.00035192448,0.000042987616,0.0024612446],"genre_scores_gemma":[0.84382933,0.0057702675,0.00044606213,0.0005554556,0.003931993,0.00012875916,0.000024928368,0.0004986627,0.14481454],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9955716,0.00033399698,0.001466387,0.0007198572,0.0012838993,0.0006242602],"domain_scores_gemma":[0.9965954,0.00003471504,0.0009767537,0.00047415073,0.0014357017,0.0004832931],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005638213,0.0007267933,0.0017096937,0.0007489399,0.00008016134,0.000056799094,0.0004159889,0.00006959125,0.0003147874],"category_scores_gemma":[0.00026688405,0.0005389531,0.00016680115,0.0007539684,0.000277861,0.00015119648,0.00029618025,0.001665667,0.000013068056],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023348879,0.0010297603,0.47553012,0.0006841324,0.0007807096,0.006298225,0.018285498,0.000012362969,0.000024564468,4.5967388e-7,0.48840907,0.0066102254],"study_design_scores_gemma":[0.011471074,0.004433292,0.7413803,0.013636147,0.0008710337,0.00013142524,0.004482862,0.000010511543,0.00003303884,8.0549137e-7,0.2228558,0.0006937329],"about_ca_topic_score_codex":0.002375198,"about_ca_topic_score_gemma":0.0058760573,"teacher_disagreement_score":0.26585016,"about_ca_system_score_codex":0.0006473771,"about_ca_system_score_gemma":0.000905179,"threshold_uncertainty_score":0.9997062},"labels":[],"label_agreement":null},{"id":"W4400747878","doi":"10.1016/j.ejca.2024.114226","title":"Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute","keywords":"Pancreatic cancer; Germline; Cancer; Medicine; Cohort; Oncology; Gene; Internal medicine; Genetics; Biology","score_opus":0.007398081677925854,"score_gpt":0.2734831380641447,"score_spread":0.2660850563862189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400747878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93363756,0.06419803,0.00019658677,0.00018390815,0.0009528954,0.00020871822,0.0003707879,0.0000039686415,0.00024752042],"genre_scores_gemma":[0.98668563,0.011963302,0.0003664942,0.000068247435,0.0005376074,0.000021983558,0.000028563249,0.00005189427,0.0002762666],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99828166,0.00020799499,0.0007709277,0.00024608776,0.0002973156,0.00019600832],"domain_scores_gemma":[0.9987804,0.000016068745,0.0004593232,0.00019325654,0.000476125,0.000074770105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038064408,0.00017201112,0.000292297,0.00014863294,0.000021853335,0.00001638675,0.00022769578,0.000052913172,0.00019795202],"category_scores_gemma":[0.000039695424,0.00015182976,0.00016099481,0.00025170852,0.00009829301,0.000019503384,0.000058795646,0.00014201226,0.0000017206675],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005095718,0.00022956876,0.35589537,0.00041360423,0.0010100232,0.000058434078,0.00093895773,0.008662267,0.54315406,0.000010024786,0.0020802845,0.08703781],"study_design_scores_gemma":[0.0022008338,0.00047229533,0.85468847,0.0016290981,0.00062733184,0.000013876097,0.00012134717,0.0006257447,0.12755613,0.00001403115,0.011735482,0.00031537583],"about_ca_topic_score_codex":0.00017196617,"about_ca_topic_score_gemma":0.0003683263,"teacher_disagreement_score":0.49879307,"about_ca_system_score_codex":0.00018383314,"about_ca_system_score_gemma":0.0005201088,"threshold_uncertainty_score":0.61914384},"labels":[],"label_agreement":null},{"id":"W4401306183","doi":"10.1016/j.ejca.2024.114255","title":"Evaluation of a medical student-delivered smoking prevention program utilizing a face-aging mobile app for secondary schools in Germany: The Education Against Tobacco cluster-randomized controlled trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Calgary","funders":"National Institutes of Health; Deutsche Krebshilfe","keywords":"Medicine; Randomized controlled trial; Intervention (counseling); Cluster (spacecraft); Cluster randomised controlled trial; Physical therapy; Internal medicine; Psychiatry","score_opus":0.04184753190616727,"score_gpt":0.4273532845656893,"score_spread":0.385505752659522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401306183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816379,0.0073629515,0.0007600204,0.0008834298,0.0017751862,0.0069955955,0.0000021006229,0.000022549524,0.00056027906],"genre_scores_gemma":[0.99756724,0.00042055768,0.00008014346,0.000094347175,0.0008204292,0.0009056361,0.000009466049,0.000028735158,0.0000734255],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951343,0.0016691191,0.0011902248,0.00015716488,0.0017066521,0.00014253148],"domain_scores_gemma":[0.9982169,0.00027465026,0.00063256326,0.00012232614,0.0006819014,0.00007160403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02157908,0.00012764649,0.00060769974,0.00025616834,0.000052940304,0.00010168823,0.00015848166,0.000048856735,0.00012837643],"category_scores_gemma":[0.00085815723,0.000080920014,0.0004121143,0.00019555032,0.000043471617,0.00019748758,0.0000264027,0.0005107132,4.3350036e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.106354885,0.0003718039,0.00049392704,0.00009151961,0.00045260953,0.000007334249,0.00238596,0.0002905992,0.00027824147,0.00001458271,0.0002115783,0.88904697],"study_design_scores_gemma":[0.9698292,0.00069812126,0.0049852454,0.0045945887,0.0033307113,0.00002740557,0.004482045,0.010637498,0.00016190686,0.00006171108,0.0010736852,0.000117907926],"about_ca_topic_score_codex":0.000010872788,"about_ca_topic_score_gemma":0.000007788517,"teacher_disagreement_score":0.88892907,"about_ca_system_score_codex":0.00033023168,"about_ca_system_score_gemma":0.0019511188,"threshold_uncertainty_score":0.74789214},"labels":[],"label_agreement":null},{"id":"W4401344760","doi":"10.1016/j.ejca.2024.114263","title":"Treating cancer-associated venous thromboembolism: A practical approach","year":2024,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Pfizer UK; Bristol-Myers Squibb Canada; Genentech; F. Hoffmann-La Roche; Grifols; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Servier; Astellas Pharma; Eisai; Daiichi-Sankyo; Ipsen; BeiGene; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Amgen; James G. Boswell Foundation; Pfizer; Incyte; Alexion Pharmaceuticals; Merck KGaA; Sanofi; Genomic Health; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Intensive care medicine; Cancer; Venous thromboembolism; Gastrointestinal cancer; Lung cancer; Genitourinary system; Anemia; Review article; Internal medicine; Colorectal cancer; Thrombosis; Pathology","score_opus":0.09458164962141223,"score_gpt":0.4194309385135028,"score_spread":0.3248492888920906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401344760","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005664892,0.9674475,0.000035282214,0.0006214931,0.0017168082,0.0006868085,0.000052796582,0.00006353894,0.02931913],"genre_scores_gemma":[0.00021097896,0.99321777,0.00057871465,0.00033085077,0.0034152193,0.000051960156,0.000024397677,0.0002992304,0.0018708892],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958598,0.0007076405,0.0015903822,0.0004649184,0.0008459147,0.00053133414],"domain_scores_gemma":[0.9970721,0.00010812885,0.001751512,0.0003648714,0.00034636437,0.00035701657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001522095,0.00063230423,0.004355532,0.00043799987,0.000106395426,0.00015777725,0.0003313102,0.00013984718,0.00034050734],"category_scores_gemma":[0.0002656318,0.00042120877,0.0013283868,0.00059966143,0.0000885589,0.00012776577,0.00017659979,0.0016682289,0.00013577964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018157258,0.0010735779,0.0000037871732,0.0143361455,0.0060439063,0.0025080976,0.0005382652,0.000009005228,8.857615e-7,0.000117297284,0.092404924,0.88294595],"study_design_scores_gemma":[0.0005948449,0.00062720355,0.00011056068,0.049694423,0.03058685,0.0005631532,0.00010058521,0.000011185079,6.0298015e-7,0.000007657911,0.9173592,0.0003437483],"about_ca_topic_score_codex":0.000071216105,"about_ca_topic_score_gemma":0.000010614325,"teacher_disagreement_score":0.8826022,"about_ca_system_score_codex":0.00090374914,"about_ca_system_score_gemma":0.0015488417,"threshold_uncertainty_score":0.999824},"labels":[],"label_agreement":null},{"id":"W4402468279","doi":"10.1016/j.ejca.2024.114329","title":"TNM 8 staging system beyond p16: Double HPV/p16 status is superior to p16 alone in predicting outcome in oropharyngeal squamous cell carcinoma","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"European Regional Development Fund; Rigshospitalet; Cancerföreningen i Stockholm; National Institute for Health and Care Research; Generalitat de Catalunya; NIHR BioResource; Cancer Research UK; Candys Foundation; Medical Research Council; Swedish Cancer Foundation; Kræftens Bekæmpelse; Villadsen Family Foundation; Gentofte Hospital; Cancer Research Institute","keywords":"Human papillomavirus; Oncology; Medicine; Internal medicine; Basal cell; Overall survival","score_opus":0.026909437626907142,"score_gpt":0.30687235302145716,"score_spread":0.27996291539455004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402468279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95006543,0.030309929,0.000027016522,0.002135316,0.0017464691,0.00033001424,0.000040264225,0.000046517536,0.015299041],"genre_scores_gemma":[0.9959377,0.00034570455,0.00021604168,0.00075586495,0.0011285899,0.000010411285,0.00000150219,0.00010321001,0.0015009668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969492,0.0001830262,0.0012177937,0.00037241835,0.0006044939,0.0006730426],"domain_scores_gemma":[0.99893546,0.00008255049,0.0001719001,0.00022058043,0.00018407978,0.00040542858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011418858,0.00029497445,0.0008739324,0.000565235,0.00007563748,0.00008273629,0.00018684808,0.00003602696,0.00019726841],"category_scores_gemma":[0.000043221422,0.0002374261,0.0001637326,0.00058813835,0.000041517505,0.00023266047,0.00012120394,0.00078521797,0.00005060778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014218254,0.00010344221,0.9288435,0.0017638583,0.00008845104,0.013746763,0.024019966,0.00026295506,0.004677003,0.000010286583,0.0056959568,0.019365968],"study_design_scores_gemma":[0.019652003,0.0026515636,0.87686986,0.0051794047,0.00040815838,0.00045767418,0.010232041,0.00090351625,0.0068639717,0.0000021162512,0.07602123,0.0007584578],"about_ca_topic_score_codex":0.00073225534,"about_ca_topic_score_gemma":0.00030902025,"teacher_disagreement_score":0.07032528,"about_ca_system_score_codex":0.0011415067,"about_ca_system_score_gemma":0.0004764495,"threshold_uncertainty_score":0.9681955},"labels":[],"label_agreement":null},{"id":"W4402468317","doi":"10.1016/j.ejca.2024.114327","title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Placebo; Adjuvant; Melanoma; Oncology; Stage (stratigraphy); Internal medicine; Adjuvant therapy; Surgery; Immunotherapy; Cancer; Pathology; Cancer research; Biology","score_opus":0.025528941858408725,"score_gpt":0.3106194375100184,"score_spread":0.2850904956516097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402468317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723182,0.0019524277,0.00011835856,0.0009943752,0.0012964373,0.0003205969,0.000010835441,0.000011687246,0.022977116],"genre_scores_gemma":[0.99638385,0.00048702024,0.000032785032,0.00012436054,0.00040367566,0.0000034271463,0.0000022387997,0.000021464662,0.0025411635],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981205,0.0003820268,0.0006926744,0.00015296917,0.00048377423,0.00016805062],"domain_scores_gemma":[0.99930364,0.00013090788,0.00022466609,0.00020695478,0.00006691069,0.00006692702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014611873,0.00012391854,0.00044132557,0.0008395062,0.000018919662,0.000034846114,0.00017937894,0.000022378603,0.0007595465],"category_scores_gemma":[0.00008490831,0.000082676146,0.00028503442,0.0009580073,0.000037420632,0.000058998277,0.000035162546,0.00040288703,0.000012528544],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6980626,0.001011672,0.004870521,0.0004956024,0.010080787,0.03960958,0.022188373,0.016044106,0.0022718578,0.0011965921,0.014115247,0.19005306],"study_design_scores_gemma":[0.2941115,0.009240675,0.10331325,0.0013578178,0.007918514,0.00039604196,0.010519794,0.006153521,0.00059085083,0.000020399986,0.5657739,0.00060374074],"about_ca_topic_score_codex":0.00008697051,"about_ca_topic_score_gemma":0.0004767404,"teacher_disagreement_score":0.55165863,"about_ca_system_score_codex":0.000192455,"about_ca_system_score_gemma":0.00014021434,"threshold_uncertainty_score":0.8316502},"labels":[],"label_agreement":null},{"id":"W4402604593","doi":"10.1016/j.ejca.2024.114313","title":"Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Outcome (game theory); Medicine; Clinical trial; Patient-reported outcome; Medical physics; Intensive care medicine; Internal medicine; Quality of life (healthcare); Mathematics; Nursing","score_opus":0.5593907242891036,"score_gpt":0.5386866630916815,"score_spread":0.020704061197422186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402604593","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36070365,0.59361136,0.011013551,0.02229641,0.006549884,0.0053861705,0.000072166506,0.000043502627,0.00032328605],"genre_scores_gemma":[0.9779811,0.017642213,0.00045881592,0.001713965,0.0019721026,0.00013616725,0.0000053419203,0.00005265942,0.000037644415],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9947888,0.0015927502,0.0029881094,0.00017987343,0.0002950807,0.00015536706],"domain_scores_gemma":[0.9962785,0.0012766653,0.0015733865,0.00019354973,0.00057388487,0.00010396737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013520455,0.00012946744,0.000854402,0.00010708206,0.00005654857,0.000037857215,0.00013819973,0.000027358736,0.0000428932],"category_scores_gemma":[0.0063443966,0.00007920687,0.00047992877,0.00031587062,0.000086202504,0.00009382372,0.000025087944,0.00038382201,5.193118e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033819948,0.0000949319,0.059327777,0.00705859,0.0005124284,0.000026553465,0.0012179976,0.00013126874,0.004446446,0.000084007566,0.0031145338,0.92060345],"study_design_scores_gemma":[0.08892225,0.00701513,0.16011265,0.65611464,0.0109368265,0.0002675411,0.0018404472,0.001420417,0.0044846684,0.00050599617,0.067059726,0.0013197461],"about_ca_topic_score_codex":0.00019918024,"about_ca_topic_score_gemma":0.00048693977,"teacher_disagreement_score":0.91928375,"about_ca_system_score_codex":0.00012259437,"about_ca_system_score_gemma":0.0009322715,"threshold_uncertainty_score":0.7595294},"labels":[],"label_agreement":null},{"id":"W4403563661","doi":"10.1016/j.ejca.2024.115078","title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Foundation Medicine; Chugai Pharmaceutical; Genentech; MacroGenics; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma; Eisai; Seagen; GlaxoSmithKline; UroGen Pharma; Advanced Accelerator Applications; Pfizer; Incyte; Ipsen; Clovis Oncology; Boston Scientific Corporation; AstraZeneca; Invitae; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Sanofi; Exelixis; Amgen; Myriad Genetics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Internal medicine; Cancer; Urology; Pathology","score_opus":0.055486289193787,"score_gpt":0.40743188139701186,"score_spread":0.35194559220322486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403563661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85573465,0.13276109,0.00017251444,0.0053621107,0.00071331795,0.0036375963,0.00020971324,0.000029788605,0.001379234],"genre_scores_gemma":[0.9866821,0.0089107575,0.000101511534,0.00016735312,0.00064205413,0.00019313804,0.000019480092,0.00006264145,0.0032209267],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950359,0.0017905241,0.0014968417,0.00034736708,0.000931884,0.00039747154],"domain_scores_gemma":[0.9977923,0.00091359415,0.000464566,0.00027495093,0.00033648204,0.00021807599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039473893,0.00033126978,0.0014249885,0.0002961075,0.00014888331,0.00021972206,0.00025598606,0.000019362351,0.0005610866],"category_scores_gemma":[0.00026721624,0.00016572284,0.00046324512,0.00055708166,0.00022073022,0.00025588126,0.000055059052,0.0007253647,0.00001515074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91794217,0.00066160545,0.0009717153,0.000104904626,0.0074825934,0.011534734,0.012654773,0.0043553202,0.009339742,0.000019991694,0.0022791969,0.032653246],"study_design_scores_gemma":[0.97345906,0.0014033554,0.002364937,0.0017308509,0.004822382,0.00007484552,0.004506913,0.0032332274,0.0016065293,0.000053997996,0.006461192,0.00028269624],"about_ca_topic_score_codex":0.0016748835,"about_ca_topic_score_gemma":0.0011952936,"teacher_disagreement_score":0.1309475,"about_ca_system_score_codex":0.00066124334,"about_ca_system_score_gemma":0.0016361674,"threshold_uncertainty_score":0.6757981},"labels":[],"label_agreement":null},{"id":"W4403763220","doi":"10.1016/j.ejca.2024.114974","title":"467 (PB455): IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER +/HER2- metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Breast cancer; Metastatic breast cancer; HER2 negative; Clinical trial; Cancer","score_opus":0.06766777546693979,"score_gpt":0.38378836128649385,"score_spread":0.31612058581955405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403763220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9145885,0.045107353,0.00017143947,0.024849797,0.007625398,0.0036197351,0.0017823051,0.000108021886,0.0021474601],"genre_scores_gemma":[0.9822699,0.0041523017,0.0011256414,0.0022414215,0.0067217937,0.0005409272,0.000021826256,0.00031169364,0.002614521],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939852,0.0006542857,0.002479883,0.0006031646,0.0012003321,0.0010771581],"domain_scores_gemma":[0.99651736,0.00031302145,0.00082126027,0.000459837,0.0005795292,0.0013090046],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003379093,0.0007191083,0.0018301287,0.0013473274,0.00013879254,0.00019166403,0.00038380484,0.000088197325,0.0032844888],"category_scores_gemma":[0.00033166495,0.0005069317,0.0006282374,0.0011461254,0.00013781739,0.0006072203,0.00005737267,0.00071974105,0.00006898477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.30751207,0.00045346704,0.00055885466,0.0005643858,0.00474327,0.0072028846,0.010499435,0.002082072,0.015879622,0.0001202907,0.008507892,0.64187574],"study_design_scores_gemma":[0.11683011,0.008699938,0.017033476,0.011033551,0.002710171,0.0011591639,0.0014018458,0.00012446646,0.0031482407,0.00009270063,0.83645546,0.0013108774],"about_ca_topic_score_codex":0.033526365,"about_ca_topic_score_gemma":0.1535233,"teacher_disagreement_score":0.82794756,"about_ca_system_score_codex":0.0081085265,"about_ca_system_score_gemma":0.008011457,"threshold_uncertainty_score":0.9997382},"labels":[],"label_agreement":null},{"id":"W4404406138","doi":"10.1016/j.ejca.2024.115122","title":"A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Oncology; Phase (matter); Internal medicine; Chemistry","score_opus":0.007978048884716541,"score_gpt":0.27065015428592937,"score_spread":0.26267210540121283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404406138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99820226,0.0010319018,0.00007207,0.000055190983,0.00018066238,0.00019796901,0.000005370761,0.0000029745586,0.00025160325],"genre_scores_gemma":[0.9996082,0.000050031205,0.000065830995,0.000021594067,0.00013332357,0.000003579947,0.00000615298,0.00002009544,0.00009117498],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99905246,0.00011217286,0.0004073881,0.00013487333,0.00019421238,0.00009887062],"domain_scores_gemma":[0.999552,0.00000434354,0.00017962111,0.00010130277,0.00012606134,0.000036657602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026119166,0.00009526897,0.00013345986,0.00013298375,0.000019179453,0.000017909197,0.00009693443,0.000017498456,0.000018402352],"category_scores_gemma":[0.000025276942,0.000073887146,0.000036674937,0.00016630323,0.000025707834,0.00001830721,0.000027010341,0.000107415464,8.1238363e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047572907,0.0045078513,0.4035422,0.0002695676,0.00030236272,0.00030954398,0.0042676507,0.0071793767,0.4595283,0.00003807837,0.002261951,0.11303584],"study_design_scores_gemma":[0.024116071,0.01408427,0.8274704,0.0015572523,0.000055950004,0.0000056983367,0.0006483213,0.00008835152,0.11022579,0.000013895943,0.021329183,0.00040478085],"about_ca_topic_score_codex":0.0000109975945,"about_ca_topic_score_gemma":0.0001352498,"teacher_disagreement_score":0.42392826,"about_ca_system_score_codex":0.000032864762,"about_ca_system_score_gemma":0.000052260868,"threshold_uncertainty_score":0.30130303},"labels":[],"label_agreement":null},{"id":"W4404406224","doi":"10.1016/j.ejca.2024.115119","title":"Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; Ono Pharmaceutical; National Cancer Institute; National Institute for Health and Care Research; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Internal medicine; Term (time); Immunotherapy; Cancer","score_opus":0.015403915778306266,"score_gpt":0.28854883820832294,"score_spread":0.2731449224300167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404406224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470824,0.0018836559,0.00007540584,0.0015348087,0.0008953712,0.00047141837,0.000032539865,0.00002410479,0.00037445527],"genre_scores_gemma":[0.9928438,0.0003825867,0.0000617878,0.0013908854,0.00023538774,0.000010167685,0.000006128627,0.00008465043,0.0049846284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973239,0.00029103569,0.0009965247,0.00032387587,0.00074902445,0.00031568678],"domain_scores_gemma":[0.99867594,0.00009461813,0.00038578454,0.000395681,0.00027862834,0.00016931912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094162795,0.00028459006,0.0006406541,0.0007292364,0.00010167829,0.00015569408,0.00039252936,0.00004657046,0.00072638487],"category_scores_gemma":[0.000098583114,0.0001661044,0.0004727735,0.0013774233,0.00010266041,0.00022017573,0.00006301316,0.00044376674,0.000034970544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015213763,0.00017317882,0.9414897,0.000060570634,0.0031065901,0.00033451343,0.005569398,0.00025248047,0.000028314555,0.0000013553991,0.0034848957,0.030285234],"study_design_scores_gemma":[0.009822411,0.0011886461,0.97990835,0.0009866321,0.0008677556,0.000005385634,0.00017796722,0.00012724611,0.000049368056,0.0000014519693,0.0066511305,0.0002136536],"about_ca_topic_score_codex":0.00022635015,"about_ca_topic_score_gemma":0.0026208714,"teacher_disagreement_score":0.038418647,"about_ca_system_score_codex":0.00074669055,"about_ca_system_score_gemma":0.0003057493,"threshold_uncertainty_score":0.7953405},"labels":[],"label_agreement":null},{"id":"W4404876468","doi":"10.1016/j.ejca.2024.115161","title":"Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; UZH Foundation; Schweizerische Akademie der Medizinischen Wissenschaften","keywords":"GNAQ; Metastatic melanoma; Medicine; Melanoma; Immune checkpoint; Cancer research; Sequence (biology); Oncology; Immune system; Immunotherapy; Mutation; Immunology; Biology; Genetics","score_opus":0.015192751424838143,"score_gpt":0.2734800818463288,"score_spread":0.25828733042149066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404876468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889323,0.009671917,0.000023207276,0.0005108724,0.00010253712,0.00036688827,0.00001805834,0.0000116090305,0.00036260538],"genre_scores_gemma":[0.99819845,0.00041573003,0.0010674939,0.000050339706,0.000042958076,0.0000080684595,0.000006637608,0.000044602042,0.00016572957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853575,0.0002227575,0.00049135246,0.00023584113,0.00029150624,0.00022279186],"domain_scores_gemma":[0.9993361,0.00005578323,0.00022180812,0.00011896838,0.00008478054,0.00018251706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030302745,0.00025044888,0.0005241703,0.00022363098,0.000047471625,0.000039489514,0.000046818153,0.000012799718,0.000042982905],"category_scores_gemma":[0.000017560013,0.00013650545,0.00006136367,0.0001972396,0.00016747764,0.00017636403,0.000022257113,0.00022729606,0.000005808026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006362502,0.0013116876,0.7341906,0.0005989275,0.0058539645,0.06985783,0.005804619,0.00012985068,0.0018568583,0.000081490034,0.000024444576,0.17392726],"study_design_scores_gemma":[0.03451027,0.028243938,0.91506493,0.004312682,0.0043099658,0.005026093,0.0008449529,0.00020592645,0.005391735,0.000055382923,0.0015887509,0.0004453772],"about_ca_topic_score_codex":0.00006814797,"about_ca_topic_score_gemma":0.000059954655,"teacher_disagreement_score":0.18087435,"about_ca_system_score_codex":0.0003567545,"about_ca_system_score_gemma":0.00028875758,"threshold_uncertainty_score":0.556653},"labels":[],"label_agreement":null},{"id":"W4406238848","doi":"10.1016/j.ejca.2024.115146","title":"Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Regeneron Pharmaceuticals","keywords":"Cervical cancer; Medicine; Phase (matter); Oncology; Internal medicine; Cancer; Physics","score_opus":0.05234366053193121,"score_gpt":0.38672200060934253,"score_spread":0.3343783400774113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406238848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747874,0.009234169,0.00008626429,0.0052633653,0.0014083266,0.0005091686,0.000076734264,0.000008655498,0.008625897],"genre_scores_gemma":[0.9953163,0.002584707,0.000047226196,0.0009176081,0.0007654861,0.000023934945,0.000014971066,0.00002264892,0.00030710062],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99559295,0.0009993828,0.0016834356,0.00033854638,0.00097550004,0.00041019736],"domain_scores_gemma":[0.99813133,0.00042036767,0.0006033783,0.0003576913,0.00030136327,0.00018585491],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020162032,0.0002948859,0.0013705587,0.0010706402,0.000049797567,0.0000336747,0.0005007907,0.00007124612,0.0013025724],"category_scores_gemma":[0.00025753953,0.00018920805,0.0006851358,0.0029846332,0.00010264605,0.00010423117,0.00009210709,0.00086710835,0.000003939807],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4630492,0.009998897,0.1316804,0.0003532862,0.0071280994,0.002120463,0.0035457928,0.0013761092,0.00068658363,0.00055408373,0.0037723298,0.37573475],"study_design_scores_gemma":[0.415967,0.005391573,0.52766377,0.0012644884,0.0059147016,0.00001729999,0.0005489892,0.00045654294,0.0003512429,0.00011682802,0.041916825,0.000390733],"about_ca_topic_score_codex":0.00077692815,"about_ca_topic_score_gemma":0.0012897981,"teacher_disagreement_score":0.39598337,"about_ca_system_score_codex":0.0005291603,"about_ca_system_score_gemma":0.0005772612,"threshold_uncertainty_score":0.99961036},"labels":[],"label_agreement":null},{"id":"W4406309524","doi":"10.1016/j.ejca.2025.115230","title":"Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","year":2025,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Great Ormond Street Institute of Child Health; Uppsala Universitet; Hospital for Sick Children; Gentofte Hospital; Andrew McDonough B+ Foundation; Morgan Adams Foundation; Royal Marsden NHS Foundation Trust; McGill University; Musella Foundation For Brain Tumor Research and Information; Universität Wien; Cure Starts Now Foundation; Augsburg University; AstraZeneca; Eli Lilly and Company","keywords":"Agency (philosophy); Food and drug administration; Product (mathematics); Business; Medicine; Drug; Pharmacology; Sociology","score_opus":0.021658511116672267,"score_gpt":0.3095409496236267,"score_spread":0.28788243850695444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406309524","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34699303,0.65028876,0.000004539899,0.0011912555,0.000043836768,0.0014386921,0.000011733468,0.000001616143,0.000026505468],"genre_scores_gemma":[0.64781725,0.35192603,0.000037322534,0.000034277273,0.00010569745,0.000038141465,0.000012790118,0.000019414492,0.000009083608],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99789035,0.00059580494,0.0008361877,0.00021732152,0.00030043075,0.00015992283],"domain_scores_gemma":[0.9987013,0.00006135681,0.00083444966,0.00013543006,0.00020629306,0.00006120392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00106017,0.00023729472,0.0006469094,0.00032373777,0.000043116517,0.000025727251,0.00010821302,0.000019868898,0.0000013208627],"category_scores_gemma":[0.00008797328,0.00010601594,0.000039948893,0.0007464105,0.00006673547,0.00007874307,0.000027861539,0.00022671842,7.6919356e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038683775,0.000498576,0.10803635,0.0027270068,0.00018532961,0.00008920531,0.0009011232,0.000030328398,0.0000045901443,0.000004254416,0.00021075134,0.88692564],"study_design_scores_gemma":[0.010029574,0.0014489071,0.94410586,0.035773687,0.0012290261,0.00010668106,0.00019976326,0.000004687962,0.000096592696,0.000001883191,0.006831396,0.0001719429],"about_ca_topic_score_codex":0.000009606942,"about_ca_topic_score_gemma":0.0016532568,"teacher_disagreement_score":0.88675374,"about_ca_system_score_codex":0.00010173299,"about_ca_system_score_gemma":0.00079048786,"threshold_uncertainty_score":0.43232045},"labels":[],"label_agreement":null},{"id":"W4407064625","doi":"10.1016/j.ejca.2025.115277","title":"Response to letter to the editor on “Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma”","year":2025,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Adrenocortical carcinoma; Germline; Medicine; Oncology; Internal medicine; Cancer research; Biology; Genetics; Gene","score_opus":0.006635666349259249,"score_gpt":0.24349376938378053,"score_spread":0.2368581030345213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407064625","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37373742,0.00011865565,0.000106567684,0.623758,0.0015605298,0.0003764709,0.0000911331,0.000008889657,0.00024230714],"genre_scores_gemma":[0.26741743,0.000003992584,0.00015119142,0.7022907,0.025057707,0.000009344766,0.000048132122,0.000063324085,0.004958133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964336,0.0007854036,0.0008666633,0.00037165594,0.0011190183,0.0004236648],"domain_scores_gemma":[0.9979092,0.00020087905,0.00042144003,0.00048393183,0.000714058,0.0002704888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007787266,0.00037124217,0.0008433453,0.001233971,0.000053681648,0.000033753255,0.00042924032,0.000099308105,0.00035228697],"category_scores_gemma":[0.00040565408,0.00020361818,0.00032697854,0.0015065302,0.000057344652,0.000040015846,0.00006461085,0.0022829878,0.00007884586],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011458205,0.00007115854,0.012676448,0.000030097459,0.00052097853,0.017346255,0.00036350687,0.0005130699,0.0000051204497,2.7632632e-7,0.9560594,0.0009555166],"study_design_scores_gemma":[0.0018107102,0.0012712554,0.36672232,0.0007286478,0.0009211966,0.00003839974,0.00000911557,0.0000058703877,0.000024531337,2.839429e-7,0.62828445,0.0001832159],"about_ca_topic_score_codex":0.000041364165,"about_ca_topic_score_gemma":0.000038433434,"teacher_disagreement_score":0.35404587,"about_ca_system_score_codex":0.00030211292,"about_ca_system_score_gemma":0.0003581992,"threshold_uncertainty_score":0.99185735},"labels":[],"label_agreement":null},{"id":"W4407636125","doi":"10.1016/j.ejca.2025.115306","title":"Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"EMD Serono; Genentech; PharmaMar; Swedish Orphan Biovitrum; Seagen; Mersana Therapeutics; Clovis Oncology; AstraZeneca; Novocure; Eisai; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Tarveda Therapeutics; Ludwig Institute for Cancer Research; Pfizer; Incyte; MSD Italia; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Intuitive Surgical; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ovarian cancer; Oncology; Medicine; Internal medicine; Randomized controlled trial; Phase (matter); Cancer; Physics","score_opus":0.01890757481348089,"score_gpt":0.3472415377581165,"score_spread":0.3283339629446356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407636125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932099,0.0013396937,0.0010636058,0.00063358265,0.00046074146,0.00040354105,0.000031370044,0.000002719665,0.002854877],"genre_scores_gemma":[0.99763125,0.00027386856,0.0006147676,0.0003432589,0.0002650282,0.000008884802,0.0000020103942,0.000019084608,0.0008418224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99686146,0.0016613363,0.000975983,0.00018776604,0.00016365499,0.00014981585],"domain_scores_gemma":[0.9984434,0.00010707943,0.0008497708,0.00026796813,0.00030078326,0.000030982097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002697707,0.00015545571,0.00041728158,0.00010686121,0.00006311015,0.000023599721,0.00033895535,0.000032488337,0.000044143133],"category_scores_gemma":[0.00070590613,0.00010219953,0.0001503056,0.00032030657,0.00007961302,0.000007788812,0.000074039825,0.000267616,1.7496683e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06070708,0.00028831253,0.0009066407,0.00001387738,0.00032843876,0.000023646777,0.000887123,0.0006191323,0.8980381,0.000030036741,0.0013022384,0.036855374],"study_design_scores_gemma":[0.24686864,0.0010803296,0.008581851,0.0003914752,0.000094431925,0.000007606538,0.0005204079,0.000056298482,0.72876513,0.0000357275,0.013381075,0.00021703987],"about_ca_topic_score_codex":0.0002640508,"about_ca_topic_score_gemma":0.00019360425,"teacher_disagreement_score":0.18616156,"about_ca_system_score_codex":0.00004719318,"about_ca_system_score_gemma":0.00028561454,"threshold_uncertainty_score":0.41675758},"labels":[],"label_agreement":null},{"id":"W4408224904","doi":"10.1016/j.ejca.2025.115357","title":"Guidance for discussants of randomized cancer trials at major meetings","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University; Queen's University","funders":"","keywords":"Randomized controlled trial; Cancer; Medicine; Family medicine; Internal medicine","score_opus":0.35179899169766626,"score_gpt":0.5962169971509585,"score_spread":0.2444180054532923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408224904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5001501,0.16927058,0.010464714,0.19281223,0.007860285,0.0052374266,0.00027288965,0.000047833866,0.11388392],"genre_scores_gemma":[0.87103546,0.024452206,0.006330259,0.0029142299,0.0021062477,0.000070958304,0.0000017348551,0.00008126048,0.09300767],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941995,0.0017709798,0.0026167776,0.00020691201,0.0009404032,0.0002654308],"domain_scores_gemma":[0.9812789,0.014469036,0.0016320291,0.00027382153,0.0021780694,0.00016813815],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04814385,0.0001401212,0.0017828346,0.00017613693,0.000068585374,0.000017928378,0.00036792387,0.00006906032,0.0006014671],"category_scores_gemma":[0.09079141,0.00008328439,0.0008965255,0.00020783697,0.00038667256,0.00005167561,0.0001303441,0.00071982073,0.0000044757553],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65147775,0.0003728038,0.013664128,0.0035106868,0.005567718,0.00017559624,0.0012401972,0.0001731135,0.07616322,0.0050863023,0.15053618,0.09203229],"study_design_scores_gemma":[0.6247227,0.0009879137,0.010525401,0.022432132,0.0037290512,0.000018743629,0.0001820559,0.00014620341,0.110513955,0.008249367,0.21814756,0.00034492402],"about_ca_topic_score_codex":0.000029816749,"about_ca_topic_score_gemma":0.00007659446,"teacher_disagreement_score":0.3708853,"about_ca_system_score_codex":0.00019130032,"about_ca_system_score_gemma":0.0009460067,"threshold_uncertainty_score":0.9801362},"labels":[],"label_agreement":null},{"id":"W4408283748","doi":"10.1016/j.ejca.2025.115343","title":"Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; McGill University; University of Ottawa; University of Calgary; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; Western University; University of Toronto; Centre Hospitalier de l’Université de Montréal; University of British Columbia; Sunnybrook Health Science Centre","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; De-escalation; Oncology; Randomized controlled trial; Internal medicine","score_opus":0.021238406405859434,"score_gpt":0.3149272005034317,"score_spread":0.29368879409757226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408283748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817805,0.010516062,0.00066226383,0.0037049744,0.00097576634,0.00089802046,0.000025914838,0.0000069885887,0.0014294812],"genre_scores_gemma":[0.9946786,0.004319291,0.00007657095,0.0003411816,0.00019237527,0.000029543218,0.000007385676,0.000013367238,0.000341687],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978974,0.0006734739,0.0009499483,0.00011562583,0.00021215445,0.00015140153],"domain_scores_gemma":[0.9987043,0.00042248098,0.00050104316,0.00011258239,0.00020753671,0.000052040592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019143365,0.00012359275,0.00130061,0.000400446,0.000048592272,0.000008633688,0.00006686423,0.00003052516,0.00005486919],"category_scores_gemma":[0.00023594001,0.00007489841,0.0007634891,0.000838772,0.00007344764,0.00006771405,0.0000067080487,0.00009961311,1.4250125e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7363209,0.00023426735,0.030099934,0.00010869002,0.0065346896,0.000024916928,0.002349748,0.0030965286,0.0006939078,0.000020976277,0.0024605382,0.21805492],"study_design_scores_gemma":[0.67227113,0.0006294646,0.3086373,0.0004749931,0.008183861,0.0000020445416,0.00006566724,0.0016813712,0.0010168741,0.000017931081,0.0069109877,0.0001083757],"about_ca_topic_score_codex":0.00017140461,"about_ca_topic_score_gemma":0.000196289,"teacher_disagreement_score":0.27853736,"about_ca_system_score_codex":0.0008902984,"about_ca_system_score_gemma":0.0011777142,"threshold_uncertainty_score":0.30542687},"labels":[],"label_agreement":null},{"id":"W4408514756","doi":"10.1016/j.ejca.2025.115368","title":"Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"PharmaMar","keywords":"Medicine","score_opus":0.1213412756104598,"score_gpt":0.36374994080209744,"score_spread":0.24240866519163762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408514756","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11927326,0.13153742,0.00011930818,0.22031279,0.0025497652,0.00086914183,0.000009524013,0.000033231852,0.52529556],"genre_scores_gemma":[0.95526314,0.04080091,0.00020551248,0.0027851213,0.00021114592,0.000016804,8.9685653e-7,0.000017568558,0.00069888943],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987604,0.00016449614,0.00034858374,0.00020471399,0.0003398235,0.00018197116],"domain_scores_gemma":[0.99925965,0.00012561673,0.0001427604,0.00025987424,0.00010501356,0.000107058346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034835283,0.00016132228,0.0002989838,0.00035248717,0.00003641167,0.000023428718,0.00016160904,0.000017424632,0.00026177522],"category_scores_gemma":[0.000039361737,0.000117429096,0.0001256975,0.0001606582,0.000032493204,0.000052005475,0.00003102651,0.00023627999,0.00004793202],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016891735,0.002285476,0.012397481,0.00020071772,0.00054902013,0.008452114,0.0006104266,0.0003720877,0.00020199896,0.010938956,0.03748685,0.9248157],"study_design_scores_gemma":[0.008160443,0.0022952107,0.848916,0.028446164,0.00016474664,0.000021075648,0.00057875086,0.00009234663,0.0031103985,0.00014872575,0.10785493,0.00021120427],"about_ca_topic_score_codex":0.00001176317,"about_ca_topic_score_gemma":0.000021361071,"teacher_disagreement_score":0.9246045,"about_ca_system_score_codex":0.00026112978,"about_ca_system_score_gemma":0.00013265428,"threshold_uncertainty_score":0.47886193},"labels":[],"label_agreement":null},{"id":"W4409052291","doi":"10.1016/j.ejca.2025.115397","title":"Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Memorial Sloan-Kettering Cancer Center; Genentech Foundation","keywords":"Fulvestrant; Metastatic breast cancer; Letrozole; HER2 negative; Oncology; Medicine; Breast cancer; Internal medicine; Maximum tolerated dose; Cancer; Estrogen receptor; Aromatase","score_opus":0.03895608083333525,"score_gpt":0.3902829151311198,"score_spread":0.35132683429778455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409052291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884858,0.005826779,0.0011645337,0.0015461489,0.0004776749,0.0021309978,0.00016569169,0.00004066489,0.00016169046],"genre_scores_gemma":[0.98926157,0.002930547,0.005905657,0.0007144107,0.0002577132,0.00007285651,0.000014507064,0.00011502833,0.0007277378],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958992,0.0009978906,0.0012920422,0.0006257738,0.00065362296,0.00053147366],"domain_scores_gemma":[0.99733233,0.0002157296,0.0008804614,0.00036906503,0.0008086516,0.00039376886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093545107,0.0005263833,0.0011186139,0.000478926,0.00019469946,0.00014042619,0.00042493726,0.00004690721,0.00025692707],"category_scores_gemma":[0.00015904556,0.00037149122,0.000060659222,0.0010753867,0.00021933201,0.0014877614,0.00016629942,0.00074936973,0.000004445503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18596832,0.009060872,0.0031361326,0.00021001433,0.0012553068,0.0023019523,0.01297304,0.004803582,0.04534095,0.000009364003,0.00024547763,0.73469496],"study_design_scores_gemma":[0.42417368,0.021997212,0.50361973,0.008113428,0.0017603067,0.00076400704,0.026689027,0.004064446,0.0047521144,0.000040094797,0.002773617,0.0012523269],"about_ca_topic_score_codex":0.0007552356,"about_ca_topic_score_gemma":0.0015079551,"teacher_disagreement_score":0.73344266,"about_ca_system_score_codex":0.0010157404,"about_ca_system_score_gemma":0.0010587983,"threshold_uncertainty_score":0.9998737},"labels":[],"label_agreement":null},{"id":"W4409202065","doi":"10.1016/j.ejca.2025.115395","title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Head and neck; Chemotherapy; Oncology; Basal cell; Internal medicine; Surgery; Cancer; Immunotherapy","score_opus":0.0300769779812097,"score_gpt":0.33640756087233453,"score_spread":0.3063305828911248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409202065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801606,0.014315513,0.000118028205,0.0021134135,0.00042348023,0.0011700533,0.000011222467,0.000010877749,0.0016768143],"genre_scores_gemma":[0.9947066,0.0015427568,0.0002743568,0.00097638735,0.00024777546,0.00002724153,0.0000010481383,0.000042529748,0.0021813079],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99757844,0.00074805366,0.0007653016,0.00025751579,0.00039340204,0.00025730155],"domain_scores_gemma":[0.9986648,0.00039278684,0.0003609215,0.00024472823,0.00020659654,0.00013019946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011010064,0.0002732014,0.0013638065,0.00013001118,0.00010743392,0.00004223176,0.00017237407,0.0000147140445,0.00018171807],"category_scores_gemma":[0.00016552756,0.000121833786,0.00013168587,0.0003149749,0.00014152256,0.00007525674,0.000045092074,0.0004387513,0.0000020641776],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91419303,0.0010897436,0.03648828,0.00010039498,0.0007210923,0.0010183047,0.017016862,0.00000618819,0.00014086715,0.0000026151479,0.0040942193,0.025128422],"study_design_scores_gemma":[0.9371245,0.006805714,0.04084796,0.0008904587,0.0013646556,0.000044890025,0.0045372625,0.000091465845,0.0002387838,0.0000058173746,0.007854253,0.00019424442],"about_ca_topic_score_codex":0.00035360054,"about_ca_topic_score_gemma":0.001443688,"teacher_disagreement_score":0.024934176,"about_ca_system_score_codex":0.00012257771,"about_ca_system_score_gemma":0.0005625278,"threshold_uncertainty_score":0.49682376},"labels":[],"label_agreement":null},{"id":"W4409429162","doi":"10.1016/j.ejca.2025.115434","title":"Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"European Society for Medical Oncology; Associazione Italiana per la Ricerca sul Cancro; Gilead Research Scholars; Gilead Sciences","keywords":"Obstetrics; Medicine; Cohort; Gynecology; Pregnancy; Breast cancer; Oncology; Cohort study; Cancer; Assisted reproductive technology; Internal medicine; Infertility; Biology; Genetics","score_opus":0.008600352306390042,"score_gpt":0.3048366797089288,"score_spread":0.29623632740253875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409429162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910355,0.0022714937,0.000035969086,0.0024027224,0.0009861852,0.0004052788,0.000026477439,0.000022118862,0.0028142445],"genre_scores_gemma":[0.99755067,0.0006291428,0.0000768667,0.000100991216,0.0003234277,0.000038740298,0.0000012390526,0.000028954206,0.0012499926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858993,0.00011680146,0.00045077616,0.0003225341,0.00034085644,0.00017910816],"domain_scores_gemma":[0.99877626,0.0000062456047,0.0002865223,0.00030514196,0.0005362058,0.00008964963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003700747,0.00015478912,0.00037047756,0.0004961276,0.00003185181,0.00002703063,0.00020529517,0.000026876362,0.0001909513],"category_scores_gemma":[0.00003446868,0.000113836606,0.00005806542,0.0005246285,0.00010709219,0.00020334113,0.00004583065,0.00045815198,0.0000011185361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00204821,0.000254575,0.94225943,0.00001392455,0.0005747367,0.0008729297,0.0011376907,0.000053428943,0.00019242507,0.0000045973247,0.00014537839,0.052442655],"study_design_scores_gemma":[0.0031413462,0.0005409318,0.99135613,0.0012881053,0.00025251327,0.00031462422,0.00085818407,0.0000056941035,0.00006663416,0.0000045423412,0.0020612683,0.000110005196],"about_ca_topic_score_codex":0.00063182396,"about_ca_topic_score_gemma":0.0026695107,"teacher_disagreement_score":0.05233265,"about_ca_system_score_codex":0.0005862054,"about_ca_system_score_gemma":0.0004452291,"threshold_uncertainty_score":0.4642122},"labels":[],"label_agreement":null},{"id":"W4409787176","doi":"10.1016/j.ejca.2025.115476","title":"Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials","year":2025,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Meta-analysis; Medicine; Oncology; Colorectal cancer; Randomized controlled trial; Chemotherapy; Internal medicine; Cancer","score_opus":0.12594839645342923,"score_gpt":0.45048315142826983,"score_spread":0.32453475497484063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409787176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.590176e-7,0.9801462,0.00009106845,0.001022506,0.00021527888,0.017662527,0.00036899725,0.0000078940575,0.0004846149],"genre_scores_gemma":[0.000012153692,0.9921683,0.00015758583,0.00079939613,0.00013615677,0.0025994843,0.0000130462,0.00006063205,0.004053256],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9825602,0.008516233,0.0077444124,0.00033510115,0.00062707433,0.00021697389],"domain_scores_gemma":[0.9768222,0.008816261,0.012663809,0.00039553686,0.0011113118,0.00019087021],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.020872215,0.000653805,0.09984214,0.00077361765,0.000034289274,0.00003106593,0.0002689974,0.00008258509,0.0009009675],"category_scores_gemma":[0.007701999,0.00028781348,0.029554673,0.00087173143,0.00009975105,0.000038852497,0.000035171342,0.00029417468,8.258681e-7],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019660715,0.00004834685,1.1697114e-7,0.4245712,0.5353533,0.000031486634,0.000020179947,0.000001428283,1.3946988e-7,0.0000046932923,0.0004110257,0.019897385],"study_design_scores_gemma":[0.101568624,0.00021577506,2.117954e-7,0.16231298,0.6891304,0.000018581282,0.0000019008411,0.0000032563828,7.0206886e-7,0.0000018305565,0.046619065,0.0001266206],"about_ca_topic_score_codex":0.000015334417,"about_ca_topic_score_gemma":0.000007543108,"teacher_disagreement_score":0.26225817,"about_ca_system_score_codex":0.00029423842,"about_ca_system_score_gemma":0.00093409873,"threshold_uncertainty_score":0.9999574},"labels":[],"label_agreement":null},{"id":"W4410001221","doi":"10.1016/j.ejca.2025.115474","title":"Impact and safety of pregnancy on desmoid fibromatosis management in the era of active surveillance. An international multicenter retrospective observational study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Observational study; Medicine; Pregnancy; Fibromatosis; Multicenter study; Retrospective cohort study; General surgery; Surgery; Internal medicine","score_opus":0.03747367533999535,"score_gpt":0.36269763795402116,"score_spread":0.3252239626140258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410001221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449027,0.0007207697,0.000015625585,0.00062932866,0.00015488401,0.00035106664,0.000029683984,0.000002591404,0.0036057595],"genre_scores_gemma":[0.998998,0.00061716523,0.00018010878,0.000074016396,0.00005585527,0.000004029522,0.000001752948,0.000008879576,0.000060226037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987386,0.000267626,0.0004289612,0.000113999835,0.00037152588,0.00007928682],"domain_scores_gemma":[0.9990703,0.00010964201,0.00032773628,0.00013672523,0.00033082225,0.000024782052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005207089,0.00009778013,0.0002732486,0.00012754527,0.000026240517,0.00000700057,0.00013515328,0.00000688258,0.000044346463],"category_scores_gemma":[0.00013670922,0.00006248673,0.000066102526,0.00018002823,0.000062784886,0.00009919191,0.000048193313,0.00019195449,3.0563442e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025089085,0.00052966474,0.97458583,0.000037518766,0.00091043394,0.00015723398,0.003944197,0.000062552936,0.00014432649,0.000053034342,0.00012774947,0.01693853],"study_design_scores_gemma":[0.0039164647,0.0011194848,0.9914662,0.0010959968,0.000086438966,0.000010042278,0.001992805,0.000015379634,0.0001452145,0.000014696518,0.000095658674,0.000041572097],"about_ca_topic_score_codex":0.000025745956,"about_ca_topic_score_gemma":0.000030158271,"teacher_disagreement_score":0.016896958,"about_ca_system_score_codex":0.0001525926,"about_ca_system_score_gemma":0.000040928095,"threshold_uncertainty_score":0.2548135},"labels":[],"label_agreement":null},{"id":"W4410199840","doi":"10.1016/j.ejca.2025.115489","title":"Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Breast cancer; Body mass index; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.006099843926916355,"score_gpt":0.25028780475853785,"score_spread":0.2441879608316215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410199840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969101,0.0007524047,0.000020965857,0.001290944,0.00027522392,0.00022569741,0.00010971103,0.0000025185275,0.00041245975],"genre_scores_gemma":[0.99883157,0.0006226753,0.000005099425,0.00023356052,0.00016427167,0.0000028471884,0.0000011675888,0.000013011412,0.00012578399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988666,0.00019368861,0.00033758243,0.0001264806,0.00034556646,0.00013006893],"domain_scores_gemma":[0.99903554,0.000033068285,0.0004175268,0.00013985165,0.000299519,0.00007449845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031394817,0.00011879011,0.00045828547,0.00031732893,0.0000355208,0.000015982983,0.000111876594,0.00002155503,0.00006468054],"category_scores_gemma":[0.000016737706,0.00006708363,0.00012702082,0.0007441837,0.00010128138,0.00005898123,0.00003278021,0.00028938244,1.2912824e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019282553,0.000099809295,0.9659765,0.000018074568,0.0014368119,0.00001455188,0.00042910664,0.000042005147,0.00010180255,0.0000024142514,0.00013618979,0.012460194],"study_design_scores_gemma":[0.018487228,0.0004703151,0.97808504,0.0004366094,0.0016564521,0.0000014942343,0.000039539667,0.000015060835,0.00018413586,0.0000023284022,0.0005560499,0.00006572387],"about_ca_topic_score_codex":0.0010315736,"about_ca_topic_score_gemma":0.0021686833,"teacher_disagreement_score":0.01239447,"about_ca_system_score_codex":0.00015072786,"about_ca_system_score_gemma":0.00018994861,"threshold_uncertainty_score":0.27355912},"labels":[],"label_agreement":null},{"id":"W4410632992","doi":"10.1016/j.ejca.2025.115445","title":"Conditional survival of children, adolescents and young adults (0–24 years) diagnosed with leukaemia during 2000–2014 world-wide: (CONCORD-3)","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Nova Scotia Cancer Centre; Ontario Institute for Cancer Research; Cancer Care Nova Scotia","funders":"Centers for Disease Control and Prevention; Rossy Foundation; National Cancer Institute; Institut National Du Cancer; Krebsliga Schweiz; Swiss Cancer Foundation; Ligue Contre le Cancer; Swiss Re; CHILDREN with CANCER UK; American Cancer Society","keywords":"Medicine; Demography; Population; Pediatrics; Survival analysis; Internal medicine; Environmental health","score_opus":0.007363733969480404,"score_gpt":0.26185849397220123,"score_spread":0.2544947600027208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410632992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953737,0.0017140438,0.00021612368,0.00028446413,0.00031839262,0.00018768385,0.000032222804,0.000010863793,0.0018624587],"genre_scores_gemma":[0.9962882,0.000561477,0.00017069648,0.00020448555,0.0004164531,0.0000019506008,0.0000061816263,0.000037932004,0.0023126416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823135,0.00017747235,0.0004990951,0.00019644438,0.00064098905,0.0002546361],"domain_scores_gemma":[0.99877816,0.00009327388,0.0003253766,0.00017453321,0.0004242105,0.00020443667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004082612,0.00016104574,0.00039391796,0.00032726626,0.000050322025,0.000023664239,0.0001802041,0.000025080493,0.00019482682],"category_scores_gemma":[0.00016931831,0.00012639134,0.00008232622,0.0002864081,0.00021381144,0.00011589672,0.00008296126,0.00042974838,0.000012195679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034455748,0.00010479859,0.9793708,0.00022360127,0.00041488232,0.0012171634,0.00031074963,0.000069182504,0.00096636027,0.000014286113,0.0098491395,0.004013513],"study_design_scores_gemma":[0.013879305,0.00027036463,0.9801226,0.0031799371,0.00015595663,0.0002157881,0.00008516091,0.000026134023,0.0009916996,0.0000035081928,0.0009613733,0.00010815797],"about_ca_topic_score_codex":0.00008516191,"about_ca_topic_score_gemma":0.0001239101,"teacher_disagreement_score":0.010433731,"about_ca_system_score_codex":0.0004194485,"about_ca_system_score_gemma":0.00092807633,"threshold_uncertainty_score":0.51540893},"labels":[],"label_agreement":null},{"id":"W4411373157","doi":"10.1016/j.ejca.2025.115584","title":"Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Clovis Oncology","keywords":"Placebo; Medicine; Oncology; Internal medicine; Ovarian carcinoma; Ovarian cancer; Cancer; Pathology; Alternative medicine","score_opus":0.04079906210408889,"score_gpt":0.3484937278941718,"score_spread":0.3076946657900829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411373157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.915264,0.009137619,0.014755249,0.014211417,0.007961934,0.009591692,0.0008102372,0.000021331029,0.02824651],"genre_scores_gemma":[0.99452585,0.0005517964,0.00076848886,0.00024301332,0.00086617924,0.00007466283,0.000005584323,0.000024859954,0.0029395863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965576,0.00087098294,0.0017874425,0.00019554723,0.00037395867,0.00021449785],"domain_scores_gemma":[0.9958856,0.00087781966,0.0019807387,0.0003165256,0.000853505,0.00008580154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020709985,0.00022227073,0.0014678838,0.00017083494,0.00007202221,0.000011634999,0.00016244201,0.00003790583,0.00004435319],"category_scores_gemma":[0.0009770832,0.0001267048,0.000969249,0.00020148235,0.00028166804,0.000048037,0.000017864782,0.00019684414,6.32961e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96829104,0.00062512973,0.000024361096,0.000051742973,0.00097163965,0.00003644041,0.00091849366,0.0001465937,0.002763266,0.00035706745,0.007342096,0.018472143],"study_design_scores_gemma":[0.94967145,0.0035625182,0.00020900671,0.0010733092,0.0010622779,0.000031477277,0.00010741396,0.00033818773,0.023264546,0.00011553052,0.020471795,0.00009251451],"about_ca_topic_score_codex":0.000028317729,"about_ca_topic_score_gemma":0.00001066315,"teacher_disagreement_score":0.07926182,"about_ca_system_score_codex":0.000309907,"about_ca_system_score_gemma":0.0008634136,"threshold_uncertainty_score":0.5166872},"labels":[],"label_agreement":null},{"id":"W4412056379","doi":"10.1016/j.ejca.2025.115600","title":"Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group","year":2025,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"National Cancer Institute; National Institutes of Health; National Cancer Center; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Rhabdomyosarcoma; Medicine; Soft tissue; Pediatric oncology; Soft tissue sarcoma; Prioritization; Oncology; Sarcoma; Internal medicine; Pathology; Cancer","score_opus":0.051034808724501154,"score_gpt":0.3709626629336062,"score_spread":0.319927854209105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412056379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018713035,0.99417263,0.0006484098,0.0007344208,0.00062206795,0.0015555315,0.00012057155,0.0000062238737,0.0002688228],"genre_scores_gemma":[0.0025667115,0.9930941,0.0019885467,0.00025268013,0.0016285594,0.00007911249,0.00019103878,0.00006832393,0.00013096897],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971338,0.00037988691,0.0016608054,0.00028247212,0.00035406422,0.00018899082],"domain_scores_gemma":[0.9964153,0.0006349861,0.0022410913,0.00032218394,0.00028546512,0.00010098464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009997739,0.0003026067,0.0014453271,0.00031738888,0.000038990227,0.000018194112,0.00026736263,0.00010570705,0.00003482338],"category_scores_gemma":[0.00043651907,0.00019210881,0.00044668865,0.00040105786,0.000054209613,0.00006377568,0.00006212007,0.00038028808,0.0000026861917],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059630074,0.000459037,0.04815345,0.0016733186,0.00046782868,0.0003980047,0.00027115858,0.000004289856,0.000003328779,0.0000066673647,0.0037764863,0.9447268],"study_design_scores_gemma":[0.0046398593,0.0005328616,0.25733095,0.017713837,0.005279454,0.00041924394,0.000023153412,0.0000038661424,0.000008259009,0.000018146768,0.7138303,0.00020008614],"about_ca_topic_score_codex":0.000091035,"about_ca_topic_score_gemma":0.00006178979,"teacher_disagreement_score":0.94452673,"about_ca_system_score_codex":0.00038853227,"about_ca_system_score_gemma":0.0010610207,"threshold_uncertainty_score":0.783397},"labels":[],"label_agreement":null},{"id":"W4412431011","doi":"10.1016/j.ejca.2025.115624","title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Research and Development; Johnson and Johnson; Cilag; Novocure","keywords":"Refractory (planetary science); Medicine; Oncology; Lung cancer; Internal medicine; Lung; Cancer; Cancer research; Biology","score_opus":0.013184561142536626,"score_gpt":0.29179966001687424,"score_spread":0.2786150988743376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412431011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99314344,0.0028633224,0.000070185684,0.0010017543,0.00030109787,0.00067366206,0.0000394374,0.000009928822,0.0018971906],"genre_scores_gemma":[0.99847233,0.0010829322,0.000046993046,0.00014998234,0.00006678254,0.000012502179,0.000012676842,0.000024070583,0.00013170141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985247,0.00031899274,0.00055232027,0.0002096451,0.00024304524,0.00015126496],"domain_scores_gemma":[0.9990156,0.00020261672,0.00041115342,0.00015374403,0.00015974639,0.00005710228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027434586,0.00014617795,0.00023675797,0.00016867937,0.00007621156,0.00003232826,0.000057793208,0.000024506042,0.000012531732],"category_scores_gemma":[0.000052713585,0.00009202146,0.000026126685,0.0003018679,0.000037647256,0.000084580686,0.000020762178,0.00025772952,4.8248063e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021934764,0.00094471447,0.6109515,0.000053236396,0.0005434079,0.0015404073,0.029062482,0.002198737,0.001410043,0.000005305385,0.00076474814,0.33059067],"study_design_scores_gemma":[0.024701703,0.0024344155,0.96525633,0.0010749316,0.00044348062,0.000012486424,0.0038386357,0.00019115343,0.00031234196,0.0000046694977,0.0016260741,0.00010377842],"about_ca_topic_score_codex":0.002147418,"about_ca_topic_score_gemma":0.0061991047,"teacher_disagreement_score":0.35430485,"about_ca_system_score_codex":0.0006568235,"about_ca_system_score_gemma":0.000310132,"threshold_uncertainty_score":0.37525263},"labels":[],"label_agreement":null},{"id":"W4412431037","doi":"10.1016/j.ejca.2025.115629","title":"Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration","year":2025,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Loxo Oncology; National Institutes of Health; Cambridge University Hospitals; Solving Kids' Cancer; College ter Beoordeling van Geneesmiddelen; G1 Therapeutics; Institut Gustave-Roussy; Amsterdam University Medical Centers; Deutsches Krebsforschungszentrum; B-IT Foundation; Uniwersytet Jagielloński Collegium Medicum; Bundesinstitut für Arzneimittel und Medizinprodukte; National Cancer Center Japan; Karolinska Institutet; University of Minnesota; Memorial Sloan-Kettering Cancer Center; Centre Léon Bérard; Eli Lilly and Company; AstraZeneca; University of Cambridge; Children's Hospital of Philadelphia; Royal Marsden NHS Foundation Trust; Children's Hospital Colorado; Hospital for Sick Children; Pfizer","keywords":"Food and drug administration; Agency (philosophy); Product (mathematics); Drug; Medicine; Business; Regulatory agency; Pharmacology; Political science","score_opus":0.018511681054757822,"score_gpt":0.3160960032715867,"score_spread":0.2975843222168289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412431037","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10141324,0.89585805,0.0001022249,0.00071737607,0.00010316126,0.0017414934,0.000024396066,0.0000029407872,0.00003714152],"genre_scores_gemma":[0.7157965,0.28369784,0.0001484336,0.000034350604,0.00023478804,0.000026611368,0.000008395994,0.000032682754,0.000020401143],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975616,0.0005930587,0.0010479436,0.00022464375,0.00041219115,0.00016056688],"domain_scores_gemma":[0.99779665,0.000055268472,0.0015651135,0.00016058929,0.0003608687,0.00006151405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001332319,0.0002514475,0.0007167674,0.00023550715,0.000052307172,0.000014962433,0.00014570194,0.000021872416,0.0000016364088],"category_scores_gemma":[0.000083734805,0.00012112658,0.000047222096,0.0005463928,0.00013644093,0.00011561653,0.000036344023,0.00030627698,4.4306066e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059023214,0.00008867286,0.010760467,0.0034059815,0.0001593818,0.000010311905,0.0012112135,0.00006527953,0.000023732146,0.0000023170533,0.00003469818,0.9836477],"study_design_scores_gemma":[0.018303378,0.004593009,0.7864893,0.15452182,0.003999596,0.00029991602,0.002372658,0.000006908388,0.0017417221,0.000017014985,0.026943127,0.00071153825],"about_ca_topic_score_codex":0.0000045115935,"about_ca_topic_score_gemma":0.00047224967,"teacher_disagreement_score":0.9829362,"about_ca_system_score_codex":0.00011047503,"about_ca_system_score_gemma":0.0013866782,"threshold_uncertainty_score":0.49393985},"labels":[],"label_agreement":null},{"id":"W4412431079","doi":"10.1016/j.ejca.2025.115622","title":"TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Hazard ratio; Oncology; Internal medicine; Stage (stratigraphy); Cohort; Proportional hazards model; Adenocarcinoma; Confidence interval; Cancer; Biology","score_opus":0.012496538016717088,"score_gpt":0.3558904715178846,"score_spread":0.34339393350116754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412431079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96319604,0.012076782,0.00062210934,0.0007628278,0.0003004292,0.00025011747,0.0001334495,0.000010185503,0.02264803],"genre_scores_gemma":[0.9962016,0.0010450786,0.00052904495,0.00016941044,0.00007693651,0.000004834128,0.000013206823,0.000017018512,0.0019428739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986251,0.000273653,0.0006028032,0.00012685088,0.0002254613,0.00014613495],"domain_scores_gemma":[0.9988104,0.00009019967,0.0004659758,0.00016028703,0.0003613229,0.00011179276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004524993,0.000115490264,0.00029458434,0.00034585636,0.000051282943,0.00001380107,0.00011259408,0.000017764934,0.00022327107],"category_scores_gemma":[0.00021124133,0.00009259997,0.00010658572,0.00044242342,0.000075290525,0.00011545973,0.000018534918,0.0002797066,0.0000057595753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060786126,0.00023929495,0.9591118,0.00015883465,0.0007508976,0.0006838951,0.0019226292,0.0011327012,0.00094280567,0.0001524056,0.0047474355,0.02954943],"study_design_scores_gemma":[0.005013428,0.00028147522,0.98407334,0.0010524638,0.0009133827,0.000025760279,0.0004915545,0.00019617252,0.0014294651,0.000040307477,0.0063948045,0.00008782517],"about_ca_topic_score_codex":0.000270026,"about_ca_topic_score_gemma":0.000058593978,"teacher_disagreement_score":0.03300553,"about_ca_system_score_codex":0.0002855026,"about_ca_system_score_gemma":0.0007288268,"threshold_uncertainty_score":0.37761173},"labels":[],"label_agreement":null},{"id":"W4412893617","doi":"10.1016/j.ejca.2025.115665","title":"Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; China Scholarship Council; University of Alberta","keywords":"Discontinuation; Emulation; Medicine; Oncology; Breast cancer; Endocrine system; Adjuvant; Internal medicine; Adjuvant therapy; Cancer; Psychology; Hormone","score_opus":0.014160976719778388,"score_gpt":0.326653820000401,"score_spread":0.3124928432806226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412893617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522877,0.0032824604,0.00008301691,0.00038527662,0.00036087065,0.00013539765,0.00010174096,0.0000013174486,0.0004211692],"genre_scores_gemma":[0.9975588,0.0019649686,0.000035559984,0.00002196446,0.0003293675,0.0000047088315,0.0000067281485,0.000013357494,0.000064566004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896,0.00021240121,0.00043660548,0.00011799335,0.00016027053,0.0001127385],"domain_scores_gemma":[0.9991483,0.000017052897,0.0004507354,0.00011972491,0.000238292,0.000025893123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024254115,0.00012032648,0.00028701412,0.00010615873,0.000016313663,0.0000058787355,0.00011320768,0.000016565973,0.00003243047],"category_scores_gemma":[0.000023362594,0.0000873047,0.00017190122,0.0001277264,0.000043623913,0.000008691635,0.000025576293,0.000074538446,2.2190561e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07253083,0.0005668573,0.7384009,0.000016259162,0.0009860529,0.00001155293,0.000428386,0.0048292982,0.075717695,0.000021129628,0.00054698973,0.10594408],"study_design_scores_gemma":[0.019816034,0.0011671846,0.96615934,0.00016612174,0.000032824733,0.0000019314193,0.00001891686,0.000007490853,0.012244763,0.000010136917,0.00030789967,0.000067355904],"about_ca_topic_score_codex":0.0005142397,"about_ca_topic_score_gemma":0.00008760314,"teacher_disagreement_score":0.22775848,"about_ca_system_score_codex":0.00007374048,"about_ca_system_score_gemma":0.00020837049,"threshold_uncertainty_score":0.35601825},"labels":[],"label_agreement":null},{"id":"W4413048580","doi":"10.1016/j.ejca.2025.115669","title":"Comparison of hypofractionation and conventional fractionation in postmastectomy radiotherapy after immediate breast reconstruction: A systematic review and meta-analysis of complications","year":2025,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Breast Implant and Reconstruction","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Capsular contracture; Breast cancer; Radiation therapy; Mastectomy; Breast reconstruction; Regimen; Meta-analysis; Dose fractionation; Randomized controlled trial; Surgery; Odds ratio; Confidence interval; Internal medicine; Oncology; Cancer","score_opus":0.059048180019346135,"score_gpt":0.38423384296611574,"score_spread":0.3251856629467696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413048580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011840124,0.99782544,0.00030462645,0.0005226932,0.00015632782,0.00073862687,0.00023157663,0.0000034219763,0.00009887353],"genre_scores_gemma":[0.0021968246,0.99698913,0.0004949229,0.000042909607,0.000055564928,0.000041937186,0.00004909535,0.0000151782915,0.000114460134],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99670696,0.00065188773,0.0020900974,0.00017649187,0.00030081064,0.00007376914],"domain_scores_gemma":[0.9955532,0.00026535877,0.0033063476,0.00014728212,0.000665838,0.00006198666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088659086,0.00020979597,0.0040408554,0.0012563445,0.000027138849,0.0000117435775,0.00006647933,0.00006796939,0.00025675265],"category_scores_gemma":[0.000045696146,0.00014806712,0.00087226176,0.00076389726,0.00010579515,0.00014923337,0.000013690531,0.00031888945,5.2952277e-7],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010405124,0.00015001866,0.00073200837,0.5253748,0.102504395,0.000006746743,0.000067300716,0.000010201008,0.0000032240384,0.000050106963,0.00007058348,0.37092653],"study_design_scores_gemma":[0.0008636137,0.00008425925,0.01159146,0.10897909,0.8591637,0.014939949,0.000053559303,0.000046191886,0.0000011308721,0.0000074402265,0.0040784976,0.00019111107],"about_ca_topic_score_codex":0.00000809219,"about_ca_topic_score_gemma":0.000008207803,"teacher_disagreement_score":0.7566593,"about_ca_system_score_codex":0.00011524735,"about_ca_system_score_gemma":0.00022012593,"threshold_uncertainty_score":0.6038002},"labels":[],"label_agreement":null},{"id":"W4413444771","doi":"10.1016/j.ejca.2025.115737","title":"Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of British Columbia","funders":"National Cancer Institute; Prostate Cancer Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Metastasis; Oncology; Distant metastasis; Internal medicine; Cancer; Radiation therapy; Radiology","score_opus":0.012709324857289372,"score_gpt":0.3018028231276723,"score_spread":0.28909349827038294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413444771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950804,0.0018121317,0.00069289363,0.0007874789,0.00010243613,0.001104891,0.000107418746,0.000025665151,0.0002866742],"genre_scores_gemma":[0.9943166,0.00016117841,0.004839427,0.0002822696,0.00002841974,0.000037086244,0.00007403375,0.000057118577,0.00020391468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966805,0.0006351771,0.00093941344,0.00031155327,0.0011551586,0.00027817415],"domain_scores_gemma":[0.9966611,0.00013752254,0.0011596673,0.00026445172,0.0015965675,0.00018065468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008313483,0.0003166467,0.0007374772,0.00077779987,0.000057552716,0.000045367124,0.00018447317,0.000018731525,0.00039971696],"category_scores_gemma":[0.00036785813,0.00020528867,0.0001245986,0.0010873815,0.00012914166,0.00029934023,0.00003415828,0.0002647086,0.0000015498483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025582716,0.0025859778,0.8886005,0.0010486693,0.004380456,0.0005302458,0.00068336166,0.0006066772,0.00086911244,0.000031995023,0.00029708826,0.07478319],"study_design_scores_gemma":[0.017285617,0.0022664666,0.97110444,0.0033327432,0.0027831327,0.000009630033,0.00016461787,0.00029345142,0.0020714384,0.000007765274,0.00046835482,0.00021233737],"about_ca_topic_score_codex":0.00010195902,"about_ca_topic_score_gemma":0.00002936399,"teacher_disagreement_score":0.08250394,"about_ca_system_score_codex":0.0003155851,"about_ca_system_score_gemma":0.0005675667,"threshold_uncertainty_score":0.8371429},"labels":[],"label_agreement":null},{"id":"W4414341356","doi":"10.1016/j.ejca.2025.115781","title":"Response to Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Discontinuation; Adjuvant; Emulation; Endocrine system; Clinical trial","score_opus":0.009826731838597634,"score_gpt":0.3134897694974399,"score_spread":0.3036630376588423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414341356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964565,0.001446191,0.0000951372,0.0013071653,0.00032578484,0.00017627375,0.000029790592,0.0000011820426,0.00016197955],"genre_scores_gemma":[0.9989448,0.00046671476,0.00003766209,0.0001153909,0.00025747312,0.0000025340244,0.0000034277246,0.000013730387,0.00015823258],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986496,0.000590944,0.0003946996,0.00010676641,0.00014750523,0.00011051208],"domain_scores_gemma":[0.9993737,0.00002622004,0.00029030023,0.00012108488,0.00014710658,0.000041611733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006789168,0.00009883408,0.00021400278,0.00013891111,0.000012948349,0.000007375929,0.000114081275,0.000027644883,0.000021585727],"category_scores_gemma":[0.000053470845,0.000070644885,0.00015249585,0.00014684573,0.000023464563,0.0000069407897,0.000020804178,0.00012234747,5.258198e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15365769,0.00012305201,0.019529188,0.0000044995813,0.00018502695,0.000016505712,0.0001707284,0.005172792,0.80438733,0.0000022994736,0.0015055496,0.01524532],"study_design_scores_gemma":[0.02367825,0.0053022928,0.76194584,0.00031961125,0.000029816427,0.0000043500086,0.00001266923,0.000029083296,0.20610979,0.0000047758867,0.0024389348,0.00012460368],"about_ca_topic_score_codex":0.000096748605,"about_ca_topic_score_gemma":0.000009357498,"teacher_disagreement_score":0.7424166,"about_ca_system_score_codex":0.000044229866,"about_ca_system_score_gemma":0.00017861045,"threshold_uncertainty_score":0.28808147},"labels":[],"label_agreement":null},{"id":"W4414446662","doi":"10.1016/j.ejca.2025.115807","title":"First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Gastroesophageal Junction; Chemotherapy; Interim analysis; Quality of life (healthcare); Interim","score_opus":0.04052856120843663,"score_gpt":0.3508443201991515,"score_spread":0.3103157589907149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414446662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88982314,0.015630476,0.057591334,0.028416488,0.0032715749,0.0046192654,0.00008323102,0.000048451657,0.0005160429],"genre_scores_gemma":[0.9901141,0.002330512,0.0013415829,0.0023882135,0.0011950145,0.00004494222,0.000018163288,0.0000448165,0.0025226492],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957335,0.0009098714,0.002240457,0.00027417555,0.0005175628,0.00032442473],"domain_scores_gemma":[0.9955197,0.0011800854,0.0023430523,0.0003070819,0.00046939123,0.00018068228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028299363,0.00028830726,0.0017695754,0.00021608667,0.00015918534,0.000029543735,0.00028515683,0.000038903996,0.00041432955],"category_scores_gemma":[0.0014087483,0.00017225005,0.000698196,0.000517336,0.00017464237,0.00012707147,0.00004507997,0.00040858658,0.0000016730902],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9529711,0.00026295416,0.0004725347,0.00014183068,0.0014336095,0.000021032618,0.0010225149,0.00077077054,0.000033193028,0.000030212117,0.008526203,0.034314033],"study_design_scores_gemma":[0.9739175,0.0029179058,0.018218705,0.0004692061,0.0007518659,0.0000061479473,0.0004251918,0.00047642802,0.000095644995,0.00010286088,0.0025051257,0.00011342952],"about_ca_topic_score_codex":0.00049852236,"about_ca_topic_score_gemma":0.00012213006,"teacher_disagreement_score":0.10029097,"about_ca_system_score_codex":0.0004177477,"about_ca_system_score_gemma":0.0009694966,"threshold_uncertainty_score":0.7024153},"labels":[],"label_agreement":null},{"id":"W4414801262","doi":"10.1016/j.ejca.2025.116041","title":"Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Kingston General Hospital; Queen's University; Cancer Care Ontario","funders":"","keywords":"Cancer; Clinical trial; Phase (matter); MEDLINE; Randomized controlled trial; Phases of clinical research","score_opus":0.4304948794959303,"score_gpt":0.6173364079889998,"score_spread":0.1868415284930695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414801262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8138965,0.010676932,0.001920696,0.08328584,0.0027799762,0.0025582917,0.00013795501,0.00003235352,0.08471148],"genre_scores_gemma":[0.9721829,0.005000254,0.0014021978,0.003936465,0.00067742803,0.000023198972,0.0000030629012,0.000042894993,0.016731549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926312,0.0029386808,0.0027199977,0.00028562185,0.0010951527,0.00032936092],"domain_scores_gemma":[0.98726785,0.007897794,0.0013880726,0.00043736192,0.0025639676,0.00044496052],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.02862728,0.00017359605,0.0015086718,0.00028695218,0.000058328074,0.000046956524,0.00049379695,0.00011560365,0.0013552728],"category_scores_gemma":[0.05326612,0.00011883325,0.00035987401,0.00048722205,0.000310841,0.00009872723,0.00016851498,0.001741516,0.000010085911],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14991793,0.0020842478,0.0033824982,0.000907899,0.002000064,0.0010144033,0.0014070186,0.00017186208,0.2723233,0.001437152,0.23106031,0.3342933],"study_design_scores_gemma":[0.21895352,0.010612565,0.002968702,0.0062645623,0.0009978542,0.000038570415,0.00033109574,0.00007741799,0.16732384,0.0010886163,0.591022,0.00032123618],"about_ca_topic_score_codex":0.000083616374,"about_ca_topic_score_gemma":0.00016432302,"teacher_disagreement_score":0.35996172,"about_ca_system_score_codex":0.00032133117,"about_ca_system_score_gemma":0.0037698387,"threshold_uncertainty_score":0.9995576},"labels":[],"label_agreement":null},{"id":"W4414801326","doi":"10.1016/j.ejca.2025.116037","title":"Response to Letter Re: TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma","year":2025,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Adenocarcinoma; Lung; Stage (stratigraphy); Adenocarcinoma of the lung","score_opus":0.017281973019050885,"score_gpt":0.3447939960168734,"score_spread":0.3275120229978225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414801326","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24141817,0.009343467,0.00054436346,0.734003,0.0015443785,0.0014314372,0.002323425,0.000036738977,0.009354994],"genre_scores_gemma":[0.37613922,0.001653552,0.0026522905,0.5753041,0.004060749,0.00008234882,0.0004294867,0.00027730974,0.039400965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99572957,0.0016105054,0.0012487465,0.00036453098,0.00068412925,0.00036253085],"domain_scores_gemma":[0.9970285,0.00045002208,0.0011474439,0.00047276597,0.0006979392,0.00020328845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001240853,0.00036157545,0.0007979087,0.0011027122,0.00007749592,0.00004045571,0.00032636992,0.0001206532,0.0005085273],"category_scores_gemma":[0.00072879484,0.00030197663,0.00028442717,0.0006873578,0.00010435283,0.00013315523,0.00005657295,0.0017837803,0.000024780627],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027778174,0.00008425219,0.029545723,0.00028382093,0.00091693,0.008400666,0.0017759438,0.0003557656,0.0003143686,0.0000011746029,0.9519615,0.0035820245],"study_design_scores_gemma":[0.0047864933,0.0007459738,0.16971147,0.0037678406,0.0019692343,0.00007452885,0.00013638473,0.00001900489,0.00037397654,0.000006567878,0.81810975,0.00029879907],"about_ca_topic_score_codex":0.00031662223,"about_ca_topic_score_gemma":0.00004417035,"teacher_disagreement_score":0.15869893,"about_ca_system_score_codex":0.00091601355,"about_ca_system_score_gemma":0.001698885,"threshold_uncertainty_score":0.99994326},"labels":[],"label_agreement":null},{"id":"W4415532668","doi":"10.1016/j.ejca.2025.116069","title":"Bridging the gap in lung cancer: A comprehensive global strategy for change","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bridging (networking); Global strategy; Sustainable development; Focus (optics); Lung; Global challenges","score_opus":0.062150033747664785,"score_gpt":0.38739588595120383,"score_spread":0.3252458522035391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415532668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6725126,0.24568664,0.00063195033,0.06577654,0.0023359791,0.0015416488,0.00010709542,0.000021264508,0.011386294],"genre_scores_gemma":[0.9891746,0.006058028,0.00006175895,0.0034063924,0.00096115546,0.000058890873,0.0000012728996,0.000014192241,0.00026370573],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990956,0.00009438985,0.0003243881,0.00012373285,0.00016606688,0.00019577493],"domain_scores_gemma":[0.9993153,0.00004776009,0.00019585459,0.00012241967,0.0002526308,0.00006602694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022485579,0.00011838449,0.00027599014,0.000060478687,0.000054777378,0.00002889621,0.00011847544,0.000013238224,0.000046996225],"category_scores_gemma":[0.000015556212,0.00007348271,0.00013854103,0.00020836871,0.000036781963,0.00006290227,0.000026046466,0.00014523305,0.0000010683941],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011253724,0.00023841306,0.37494868,0.0005278162,0.0011147901,0.00053111865,0.0008370565,0.0012105135,0.00010495858,0.0007023851,0.07077121,0.5478877],"study_design_scores_gemma":[0.007183485,0.00040401312,0.88561016,0.003365244,0.0006647688,0.000042389584,0.00023190898,0.0007324519,0.00024188409,0.00004996598,0.10135615,0.00011756786],"about_ca_topic_score_codex":0.00032277312,"about_ca_topic_score_gemma":0.00035693255,"teacher_disagreement_score":0.54777014,"about_ca_system_score_codex":0.0006908665,"about_ca_system_score_gemma":0.00030652923,"threshold_uncertainty_score":0.29965383},"labels":[],"label_agreement":null},{"id":"W4415769284","doi":"10.1016/j.ejca.2025.116092","title":"Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Colorectal cancer; Chemotherapy; Patient data; Systemic therapy; Complete response","score_opus":0.15029921483284128,"score_gpt":0.3338978763095091,"score_spread":0.18359866147666784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415769284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743988,0.021808252,0.00043145,0.0004507655,0.00015079949,0.0011041153,0.0014415652,0.000020039059,0.00019424272],"genre_scores_gemma":[0.9957159,0.00056325836,0.0021168026,0.00043408055,0.00014321266,0.000067189074,0.00035379332,0.00005047018,0.0005552831],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99743956,0.00058180484,0.0006725381,0.00038485485,0.00063187204,0.0002893683],"domain_scores_gemma":[0.9975497,0.00013329163,0.00057393545,0.0005171113,0.0010255448,0.00020040065],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009514678,0.0002651265,0.0010796468,0.00043503442,0.000117851356,0.00008042791,0.00042571453,0.000035170262,0.0009315211],"category_scores_gemma":[0.000093466464,0.0001468333,0.00046040397,0.00090166536,0.000055221964,0.00029799418,0.00008059098,0.00020443306,0.0000018027516],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01823102,0.0012115652,0.48616603,0.00027637463,0.44077653,0.0005406916,0.0014351162,0.000110502806,0.000348073,0.0000058623414,0.014741857,0.036156375],"study_design_scores_gemma":[0.01825287,0.011064759,0.121045016,0.0003848416,0.79304653,0.000043895114,0.00043796745,0.0013185272,0.006124327,0.00000270458,0.047713764,0.0005647809],"about_ca_topic_score_codex":0.00016312023,"about_ca_topic_score_gemma":0.00034651463,"teacher_disagreement_score":0.365121,"about_ca_system_score_codex":0.00013900366,"about_ca_system_score_gemma":0.00053795107,"threshold_uncertainty_score":0.99998176},"labels":[],"label_agreement":null},{"id":"W4415939209","doi":"10.1016/j.ejca.2025.116100","title":"Incidence, prevalence and treatment of patients with Epithelioid Haemangioendothelioma (EHE) in Canada: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) and Multi-pronged Canadian Research in Epithelioid Haemangioendothelioma (PRO_CARE EHE) study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Hôpital Maisonneuve-Rosemont; Centre hospitalier de l'Université Laval; University of Calgary; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Université Laval","funders":"","keywords":"Systemic therapy; Epithelioid sarcoma; Sarcoma; Epithelioid hemangioendothelioma; Prospective cohort study; Clinical research","score_opus":0.05803868499414491,"score_gpt":0.37877507251284914,"score_spread":0.32073638751870426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98139274,0.014563045,0.000001266798,0.0019937113,0.00009848524,0.0016494938,0.00012889376,0.0000025327374,0.00016980684],"genre_scores_gemma":[0.9969017,0.002512429,0.00016708323,0.00008167435,0.000063196334,0.000028656616,0.0000057682287,0.000041038005,0.00019848392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954122,0.0016705517,0.0009535293,0.00048404848,0.00078563695,0.00069404003],"domain_scores_gemma":[0.9970873,0.00026417826,0.00020469728,0.0003519474,0.0013922316,0.0006996422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031017396,0.0002542723,0.0007272323,0.002627391,0.00019931619,0.000065868044,0.00022121817,0.00004834728,0.000024790554],"category_scores_gemma":[0.00027429397,0.0001950846,0.000054789314,0.0017264459,0.0003909232,0.00015826215,0.00007156243,0.0005474244,7.0697564e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069370505,0.00035381375,0.9686101,0.00014426796,0.0001830133,0.0031483413,0.0020575258,0.000007240512,0.000054375727,0.0000084902285,0.00013279173,0.024606328],"study_design_scores_gemma":[0.010151539,0.0033311443,0.9796237,0.0015138052,0.00009766295,0.000060620474,0.0038807443,0.000077605815,0.00013124343,0.000008593152,0.0009672837,0.00015610544],"about_ca_topic_score_codex":0.9701048,"about_ca_topic_score_gemma":0.9994098,"teacher_disagreement_score":0.029304987,"about_ca_system_score_codex":0.0020870138,"about_ca_system_score_gemma":0.009276923,"threshold_uncertainty_score":0.99633956},"labels":[],"label_agreement":null},{"id":"W4415939211","doi":"10.1016/j.ejca.2025.116093","title":"Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer","year":2025,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"U.S. Food and Drug Administration; Andrew McDonough B+ Foundation","keywords":"Neuroblastoma; Chimeric antigen receptor; Monoclonal antibody; Cancer; Ganglioside; Antibody; Antibody therapy","score_opus":0.027648420189135763,"score_gpt":0.3479686014046495,"score_spread":0.32032018121551376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939211","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003889488,0.9944983,0.000019760955,0.00007466087,0.0001312175,0.0012469433,0.000048721264,0.0000044964227,0.000086421096],"genre_scores_gemma":[0.019045154,0.97973156,0.00043863928,0.00004034736,0.00038485328,0.000036464564,0.00001601197,0.000064527936,0.00024242148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975491,0.00023015172,0.0009899316,0.00030839708,0.0005348633,0.00038755056],"domain_scores_gemma":[0.99841714,0.000038820177,0.00087155885,0.00013378718,0.00030991336,0.00022879678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005820785,0.00033260847,0.0012426864,0.00057452195,0.00005070292,0.00001597632,0.00018769536,0.00003281017,0.000022504968],"category_scores_gemma":[0.00012437254,0.00020805647,0.00016424005,0.0004158732,0.00005591714,0.0000670058,0.00006975383,0.00047296807,0.0000010858439],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037153554,0.00015013585,0.013861268,0.012142778,0.0006763308,0.00030306037,0.000056713066,0.0000041108747,0.0000038054914,2.5619948e-7,0.0015601724,0.97086984],"study_design_scores_gemma":[0.0219055,0.0036962295,0.17942332,0.39079088,0.006393307,0.0008518826,0.000106992215,0.000003542991,0.00036214426,0.0000036819024,0.3955612,0.0009013417],"about_ca_topic_score_codex":0.000015739442,"about_ca_topic_score_gemma":0.00002991709,"teacher_disagreement_score":0.9699685,"about_ca_system_score_codex":0.00023400376,"about_ca_system_score_gemma":0.0024048225,"threshold_uncertainty_score":0.8484297},"labels":[],"label_agreement":null},{"id":"W4416265857","doi":"10.1016/j.ejca.2025.116106","title":"Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078]","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Incidence (geometry); Prostate cancer; Cancer; Population; Regret","score_opus":0.056180627005350245,"score_gpt":0.40335257158238547,"score_spread":0.3471719445770352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416265857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8944521,0.078852564,0.00040122136,0.011247805,0.0031958115,0.0075777834,0.00051644404,0.000033585304,0.0037227042],"genre_scores_gemma":[0.95763946,0.009798274,0.00015964711,0.0010352378,0.00059220864,0.0006862401,0.00002218474,0.000075349126,0.029991386],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99354583,0.00201353,0.0020886336,0.0005570561,0.0011180897,0.00067687914],"domain_scores_gemma":[0.99680346,0.00061284384,0.0008795514,0.0004854149,0.0008288975,0.00038985116],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033490069,0.00052631315,0.0021741292,0.0005187562,0.000292671,0.00018746738,0.00048624398,0.0000364466,0.0010964237],"category_scores_gemma":[0.0004939206,0.000298698,0.0005125458,0.0011387694,0.00023611722,0.00023297005,0.00013491198,0.00087127666,0.000015613912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90295345,0.0009109413,0.005308216,0.000103275575,0.0074078334,0.0030990886,0.0078068343,0.009881759,0.00851188,0.000015242458,0.022032233,0.031969234],"study_design_scores_gemma":[0.94786245,0.0012497011,0.011087339,0.0022342307,0.0055191754,0.000024977198,0.005479485,0.0014079545,0.0028185886,0.00004419352,0.021802139,0.00046975125],"about_ca_topic_score_codex":0.0074968874,"about_ca_topic_score_gemma":0.012354109,"teacher_disagreement_score":0.06905429,"about_ca_system_score_codex":0.0013655804,"about_ca_system_score_gemma":0.0029296952,"threshold_uncertainty_score":0.99994653},"labels":[],"label_agreement":null},{"id":"W4416380369","doi":"10.1016/j.ejca.2025.116110","title":"Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Astellas Pharma; Astellas Pharma US; Pfizer","keywords":"Enzalutamide; Post-hoc analysis; Post hoc; Subgroup analysis; Recurrent prostate cancer","score_opus":0.007018902896745158,"score_gpt":0.2850381728637095,"score_spread":0.27801926996696436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416380369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897385,0.0076180794,0.000040171548,0.0012540042,0.00011334552,0.0005514372,0.00017316364,0.000015526151,0.0004957664],"genre_scores_gemma":[0.9904386,0.004738806,0.00051128917,0.00033873008,0.000097395685,0.000025874302,0.00005520548,0.00005032458,0.0037438078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976632,0.00025454472,0.00059308036,0.00034761813,0.0007142019,0.0004273792],"domain_scores_gemma":[0.9982255,0.000039830615,0.0004883044,0.00027116798,0.0007170402,0.00025816276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045187204,0.00028744282,0.00071635784,0.0005450068,0.0000769135,0.00005951293,0.00022229846,0.000031793923,0.00012236011],"category_scores_gemma":[0.000047448986,0.00015315409,0.000120321536,0.0013613146,0.00017008254,0.00013671117,0.000052352363,0.0005993592,0.0000027150277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047223765,0.00039207004,0.89777803,0.00011201463,0.002801212,0.00061087095,0.00057093403,0.00017713397,0.0009556368,8.605447e-7,0.002677853,0.046699587],"study_design_scores_gemma":[0.03330456,0.008805663,0.9310141,0.0029729418,0.0037913276,0.000009977219,0.00023839713,0.000031585576,0.007971393,0.0000043951213,0.011441186,0.0004144384],"about_ca_topic_score_codex":0.00035561394,"about_ca_topic_score_gemma":0.0008269303,"teacher_disagreement_score":0.04628515,"about_ca_system_score_codex":0.0005706306,"about_ca_system_score_gemma":0.0008173637,"threshold_uncertainty_score":0.62454426},"labels":[],"label_agreement":null},{"id":"W4416408555","doi":"10.1016/j.ejca.2025.116113","title":"Response to letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; China Scholarship Council","keywords":"Discontinuation; Adjuvant; Emulation; Endocrine system; Clinical trial","score_opus":0.015063135892727057,"score_gpt":0.3279724163698583,"score_spread":0.31290928047713124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416408555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942366,0.0012546006,0.00010681466,0.0036055222,0.00035558446,0.00018153344,0.00010665121,0.0000014455052,0.00015124324],"genre_scores_gemma":[0.9988092,0.00044792352,0.0000604023,0.00019025146,0.000355066,0.000007438879,0.0000040736427,0.000015824007,0.00010979491],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9986448,0.00045695936,0.00044995372,0.00013969163,0.00018081098,0.00012778165],"domain_scores_gemma":[0.9991996,0.000033378183,0.00035301762,0.00015107707,0.00022739427,0.000035489506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005027432,0.00012855564,0.00028592494,0.00014722394,0.000017883156,0.0000074909917,0.00012543952,0.000017346192,0.000033782937],"category_scores_gemma":[0.00005553847,0.000094941206,0.00015674898,0.00016216944,0.00003436794,0.000008856306,0.000033548957,0.000077508055,4.4182283e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38810277,0.00037623494,0.22197884,0.000010705616,0.0007023844,0.00002190933,0.00078153634,0.0059694843,0.33260202,0.0000047601893,0.0038827471,0.045566592],"study_design_scores_gemma":[0.017864544,0.0016948017,0.9513106,0.00019418912,0.000025756604,0.0000017596724,0.00001992892,0.0000034515133,0.026806759,0.00000425083,0.0019930222,0.00008098114],"about_ca_topic_score_codex":0.00034770038,"about_ca_topic_score_gemma":0.00008771158,"teacher_disagreement_score":0.72933173,"about_ca_system_score_codex":0.00010257062,"about_ca_system_score_gemma":0.00020211974,"threshold_uncertainty_score":0.38715902},"labels":[],"label_agreement":null},{"id":"W4417451585","doi":"10.1016/j.ejca.2025.116190","title":"Ambient air pollution and survival in SCLC/LCNEC: Analysis of a single centre retrospective cohort","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Retrospective cohort study; Air pollution; Cohort; Pollution; Cohort study; Risk factor","score_opus":0.014090027745508923,"score_gpt":0.31947163993190025,"score_spread":0.3053816121863913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417451585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98140424,0.004825056,0.00010758968,0.0044835904,0.00020034054,0.00013613973,0.000016435792,0.0000048898023,0.008821713],"genre_scores_gemma":[0.9975661,0.001118583,0.000067562854,0.00017425818,0.00008733234,7.5245185e-7,9.408188e-7,0.0000087291555,0.0009757472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986347,0.00022268776,0.00040100224,0.00013909813,0.0004410563,0.00016143499],"domain_scores_gemma":[0.99907684,0.000032403685,0.00021757947,0.00011912497,0.00047846505,0.00007556652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093445345,0.00008807003,0.0005056613,0.0006020916,0.000030097279,0.000008436136,0.000072239185,0.000012633725,0.00005222145],"category_scores_gemma":[0.00028211655,0.000068890986,0.00012558035,0.0010430086,0.00011963836,0.000059618378,0.00006545758,0.00020884718,5.3626957e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052325963,0.00010973704,0.98490715,0.00005609606,0.0024815155,0.00011593291,0.0007026661,0.00031557505,0.0052894484,0.000053815245,0.0016588215,0.0037859993],"study_design_scores_gemma":[0.0014805469,0.00023115196,0.9927338,0.00045641258,0.0010012105,0.000002237489,0.00033979822,0.000057182402,0.0011313503,0.000010043936,0.0025081786,0.000048116886],"about_ca_topic_score_codex":0.00014889782,"about_ca_topic_score_gemma":0.0005078792,"teacher_disagreement_score":0.016161848,"about_ca_system_score_codex":0.0006205283,"about_ca_system_score_gemma":0.0001515977,"threshold_uncertainty_score":0.2809293},"labels":[],"label_agreement":null},{"id":"W69550992","doi":"10.1016/j.ejca.2003.07.002","title":"In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity","year":2003,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Squalene; Cisplatin; Pharmacology; Toxicity; Bone marrow; Chemistry; Carboplatin; Glutathione; Biology; Biochemistry; Chemotherapy; Immunology","score_opus":0.01961397300110962,"score_gpt":0.26454827207970794,"score_spread":0.24493429907859832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W69550992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649984,0.00016926033,0.0017750864,0.000045459987,0.00016488512,0.00009061332,0.000023818307,0.0000010498499,0.0012299679],"genre_scores_gemma":[0.9990065,0.00013888923,0.00061551406,0.00007237231,0.00006952156,0.0000013742283,5.949845e-7,0.000023206874,0.00007201865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989178,0.00028663743,0.0003435773,0.00015042625,0.00015961438,0.00014195323],"domain_scores_gemma":[0.99911654,0.000016298969,0.00047377523,0.00018104388,0.00015730537,0.00005504289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039929393,0.00012599096,0.00024612807,0.000082802646,0.00001782844,0.0000037696086,0.00013280081,0.000044114528,0.000009405926],"category_scores_gemma":[0.00013241997,0.000117059295,0.00012980218,0.00008625891,0.000041440348,0.000008209412,0.0000341344,0.00020341769,5.957848e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033100625,0.00014834733,0.000032417698,0.00001933869,0.000050465398,0.000015699317,0.00007695041,0.0034420793,0.99038285,0.000011814629,0.000035996844,0.0024739765],"study_design_scores_gemma":[0.0020157013,0.0011683035,0.00060170173,0.00004536078,0.000020958696,0.000010765907,0.00001529148,0.0002703538,0.99553907,0.0000093629915,0.00020340222,0.000099705576],"about_ca_topic_score_codex":0.000007896801,"about_ca_topic_score_gemma":0.000020107824,"teacher_disagreement_score":0.005156241,"about_ca_system_score_codex":0.000034225875,"about_ca_system_score_gemma":0.00012850025,"threshold_uncertainty_score":0.47735393},"labels":[],"label_agreement":null}]}